<SEC-DOCUMENT>0001628280-22-014095.txt : 20220512
<SEC-HEADER>0001628280-22-014095.hdr.sgml : 20220512
<ACCEPTANCE-DATETIME>20220512162517
ACCESSION NUMBER:		0001628280-22-014095
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220512
DATE AS OF CHANGE:		20220512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			X4 Pharmaceuticals, Inc
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38295
		FILM NUMBER:		22918219

	BUSINESS ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134
		BUSINESS PHONE:		857-529-8300

	MAIL ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsanis, Inc.
		DATE OF NAME CHANGE:	20100920
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>xfor-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:15224e09-2b4e-4653-a05c-4094a1da55b0,g:b51d9744-e75b-48fa-9941-02b626145304,d:092653cc5b8c43bdad358095e593d81b--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xfor="http://www.x4pharma.com/20220331" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xfor-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80L2ZyYWc6NTZlZmZlMTkyYzYzNGU3N2E2N2U0ZmM3Yzc0YzM0ODQvdGFibGU6MGY1MDZlZjViMTYzNDg5MzgxYjczNThlN2EzNDE3ZGUvdGFibGVyYW5nZTowZjUwNmVmNWIxNjM0ODkzODFiNzM1OGU3YTM0MTdkZV8wLTEtMS0xLTM0NDEx_9516f096-8d26-4681-997a-329eff22bd1f">false</ix:nonNumeric><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80L2ZyYWc6NTZlZmZlMTkyYzYzNGU3N2E2N2U0ZmM3Yzc0YzM0ODQvdGFibGU6MGY1MDZlZjViMTYzNDg5MzgxYjczNThlN2EzNDE3ZGUvdGFibGVyYW5nZTowZjUwNmVmNWIxNjM0ODkzODFiNzM1OGU3YTM0MTdkZV8xLTEtMS0xLTM0NDEx_7d73f596-2dcd-4fa5-a3ec-b78af29f64ee">2022</ix:nonNumeric><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80L2ZyYWc6NTZlZmZlMTkyYzYzNGU3N2E2N2U0ZmM3Yzc0YzM0ODQvdGFibGU6MGY1MDZlZjViMTYzNDg5MzgxYjczNThlN2EzNDE3ZGUvdGFibGVyYW5nZTowZjUwNmVmNWIxNjM0ODkzODFiNzM1OGU3YTM0MTdkZV8yLTEtMS0xLTM0NDEx_795231df-674a-4e68-be4b-ffea673b0a1c">Q1</ix:nonNumeric><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80L2ZyYWc6NTZlZmZlMTkyYzYzNGU3N2E2N2U0ZmM3Yzc0YzM0ODQvdGFibGU6MGY1MDZlZjViMTYzNDg5MzgxYjczNThlN2EzNDE3ZGUvdGFibGVyYW5nZTowZjUwNmVmNWIxNjM0ODkzODFiNzM1OGU3YTM0MTdkZV8zLTEtMS0xLTM0NDEx_15c9473f-5b84-45d6-8326-8b924bb6e2f9">0001501697</ix:nonNumeric><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80L2ZyYWc6NTZlZmZlMTkyYzYzNGU3N2E2N2U0ZmM3Yzc0YzM0ODQvdGFibGU6MGY1MDZlZjViMTYzNDg5MzgxYjczNThlN2EzNDE3ZGUvdGFibGVyYW5nZTowZjUwNmVmNWIxNjM0ODkzODFiNzM1OGU3YTM0MTdkZV80LTEtMS0xLTM0NDEx_42fac757-ba7e-4c19-8653-612f2e3f2fb3">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xfor-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24b035d294594e2eb13e2c7695f6e295_I20220509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i551b03b35a354b9c82567e2c1278da6f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ied3aba39e79f4b429586d34201372693_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2425a0da056146c48327ec0587899d61_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib471740b6fdd47e8af8050737b18ccdb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i854c77af00bd4ce9a4dfdb9a27239dce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60e626d1eb1f4f26b74d82ff06b61afd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6895f9ac9ea474583d9fff78ede70b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01d79d96f4a7455f94d5d1c06a5e5b1b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8de9ba4633443dbaddd152d4d468a43_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22eddc0d4a54868be305ee81dbe30b5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54a6aa4f5e554082b147ea3e13218602_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i047748a25ba140d9bf8ddde9f403b7c3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4df9455becee450483e383bda2635fb6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ec92573d25494d9ec868ce6d803b1f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86f8f316e485428cbd4027d61748adf8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7e2cf99863b4fb88048889aa87cf96f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5d7e807d2ef42dda0ab3c941f8caf6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f4ba6165a6d4e068a782de9870bba11_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c210c0dd8634743ac3fe20cd14d7221_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c88a11b199434aace5aef0bbc9f5ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb5a551d13c443f58e2de92a4c349fb4_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a536b78307a42ecbcb3238de82af6f7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if552410f512d4f14be1678c6b554dbef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2328bc9fe2404a29a05fe278a1035750_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6216409af0d8456fa56993e3fe6c83f0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c30ad47284440ecb1152f67b75b14bf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6490c404c2e943b29d2afa3f5b15a0ed_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa75eebec540404b9087007bb78de87d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa18918dfe8b4eb99398f5469d0f1f20_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53f51ae8287e4f2a9dc20c9692a90f3b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if34f27299a434668885ee2416dec75fa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7257e82e68c041908175389a8f7bdea1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica1cbeac75bb4931b6a264bbff4cb6ac_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9911b058cb814046a3c2b033f5239f56_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b8c9dbcf0c44ed99f42775671ed3b03_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideaca6ba9ebd4d459db86e8fec1e7f54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6a9e053963b4b5e8c0525ef05558e5c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fa190798a8f407db1aaf3fc492af313_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae98b37b4074b55b43d5b52c0da2b4e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i094278dbb6a548fd9082e115e09bdaf0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d672047c5424b409a161bd8c9acbfed_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4117ae9064c4a1eb42d624dc7250d94_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia42b7fcbe59440f2b41270d5bb32ea91_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia33efcad84ff4ab29dfe84a9f90b41b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife03ea1a6e3647c89acdff544fec694a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21d0f0aac3d548fbaf98b28d241b82e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1742801c50374deb91009bf46a82591f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3a80995916b45c199871913d2744c21_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i639b8d3e3f0d47f8a1670e543de3ddbb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96c436bc6e3549aaba4b6f5738544b57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02cddbe3e2e94249a26572dd230f54ab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd20f5ab879a4c7899f8376d38a509b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if06a3031bf214f0badb0fe08c193a7db_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdfa75b4c35d44a391617d28994286e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc17d505855a43e499fd5dbfc1919a1e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcc1bd21f38c467083120b5c7e8f04d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c7c501dd906429f8cddfe0fb9905586_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ab87fe587c64027a76fcc9c708f7361_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dc0bdf32a5146e0adcea6db6de6615d_D20181001-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37a902dab0bd4e4f9e87b18693f5f331_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic37a10f994534a07ba477a27d2a2bf64_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic4206af27e2d487f9f31e058fa7b8c0a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icce6cbe45cc4447fbfe3ebb0b1f74930_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55063b32fb884c81895bd748e6ed4f41_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26533fb9b8ff4cf98e7fe29b5121aa6d_D20240701-20240701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic45fa2c1cc904680a9c790308256e60f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">xfor:MinCashTestDate1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia692d84b888a4845bbc1ea6a9ee0dfbd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">xfor:MinCashTestDate2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7e48af44af640d5b517c67d3ad4d1f0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc53f4cff48d40168111b64915f524d7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaAustriaLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqm"><xbrli:measure>utr:sqm</xbrli:measure></xbrli:unit><xbrli:context id="i38936b88ef624fe69a0b0bfe09334734_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaAustriaLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f343631aa5f432096c5e6330be2f6e1_D20191111-20191111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-11</xbrli:startDate><xbrli:endDate>2019-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i1fdd127e11e14968982b457103d38af9_I20191111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i829185b9e0084c7584f58e45342583f9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3e0d04f60ed4d21934cf225abe43d0a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i975809049d0a45c497bb1ac01a475dac_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:IndemnificationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65cb0a8a766640df9a3c2d91519beec5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:IndemnificationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9987285e8b814bf3a75efbc5d0f415b7_I20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fd283910b0c46c7b76b73ec9c937efa_D20210323-20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7640c5cc7cdf4a798762f93ad58a800d_D20191129-20191129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-29</xbrli:startDate><xbrli:endDate>2019-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33b0d388662f46dc8e3e78c78b30a392_I20191129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c1e0a3da76d47a8892dbba813618c07_D20191126-20191126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-26</xbrli:startDate><xbrli:endDate>2019-11-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib952420c74dc41d0b56c0d7c1ae747af_I20190416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcbf7212a2a648e0bdba60353fb0018f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if11478b9d8ef48469399603eb4700067_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53cd7e343ca1417fabb4bb23d6a34e59_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i374920f0a8c246a18acce80fd3f3f518_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3719e7acfe4d42d793a973477e301657_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2a6dbe35ef24ffeb2d308772056da96_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if852079aba5d4e9ba7bdcc9ca39a389a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82c001a5dabd46658a607c7940a5a634_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberNineteenTwoThousandEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7762054b7322478e9a88838854405b2f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberNineteenTwoThousandEighteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if43e448bd5894bd2863d446143e0ff04_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarchThirteenTwoThousandNineteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3270dde03c414860922ae7af87624181_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarchThirteenTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1993d79bf6244d0b392f8df783ee312_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassAWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnAprilSixteenTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d8975a741104b5296f718b358811082_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnAprilSixteenTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1674d766cfaa4621a97b51e4f672d1aa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfbe308a558a41579f92a9d56f820980_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16d2edf8cc33443ea0ffbd013f4b66e0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85b541bd25654094be49307558799aae_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b51e9aec2ca4554a1cb58776b67a06a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch232021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12273bd7f6f844c29aa5394dbc198547_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch232021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31185213cb1d401ab6f9bfaf3eca7163_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberNineTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaadf734ea7f34c549783db6da7a96a56_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch32022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74b9f718ca0e4c5d9b871296a1e02de1_I20191129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c46977bdcd44c5fbb626a2c7adad70d_I20191129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a34589fe1b04db8902c62e32428ecf2_I20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i055ed4cd017b4077b80b39c7e53429d5_I20211109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie946fb34148e40778aa24e30c0fb5174_I20211109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96523b616e2c4aaaa42b757f1dead895_I20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb651aa4d13d4e91881e98c2a66705b2_I20220303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5abc6425ebed4d1098137ddae6cf173b_I20220303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1087c98fdfeb43a5b2b61cf5a5a18780_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3f763b38edd403fb65281fd8c0d1e6b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia64d3337ee204135be6803aad57e0f54_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia735dbcc36df42bd8741cce45232e31a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5ce63ce89fc4d53b2de1b932c6c5971_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34f00a49e9164c6f8f5d5aea7638c86e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f08fbd1d62147b7a24653057a24170f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe626170d10b4caa80d237bf4ea1bace_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ce083cdddd2478e9589bcc5c51fb670_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2610f6c62e848928bf100bd21dc705c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ed061951224fe2b05f82e41a77c8d4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1925ffb8b98e470a8755be697908ef08_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i289ea1ad164e40f3bd8d98acc9dd5ec5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c82af5f1bd54ac38a12ea61c79ef148_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4403e830d3884aac9399f56efc81108c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e78ac2b2f9c400db2a88a3ac72a5ab8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc1e4f78fe354943a530e1e6507b73ea_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i092653cc5b8c43bdad358095e593d81b_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzU2_606d20a1-fcc4-48b6-bb7e-8c923f021731">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ODNkN2U4NDc0ZjIyNGIwNWFiODJlOTUxZWJmMWYzZjcvdGFibGVyYW5nZTo4M2Q3ZTg0NzRmMjI0YjA1YWI4MmU5NTFlYmYxZjNmN18wLTAtMS0xLTM0NDEx_35dcc57b-722f-4d49-9ffc-291d65d1908a">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8zMDQ_53853b39-b50e-479e-b75d-6f1f68475917">March 31, 2022</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6MTQ0YjM3NTM5Y2I2NDNiMGExYmQ1M2U1MGM0ZTlmNTcvdGFibGVyYW5nZToxNDRiMzc1MzljYjY0M2IwYTFiZDUzZTUwYzRlOWY1N18wLTAtMS0xLTM0NDEx_80a7c632-7a75-455b-acf7-360d841065da">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from __________ to __________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8zOTI_3e1aae12-06d1-4d75-9b67-414c2d09c51e">001-38295</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzYw_4761e810-a53b-4c03-ada8-a797680c21e1">X4 PHARMACEUTICALS, INC</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ZGM2MzU4MDFjMGVmNGYyMGIzNzQ1ZTIwZGY5Mzk3ZWUvdGFibGVyYW5nZTpkYzYzNTgwMWMwZWY0ZjIwYjM3NDVlMjBkZjkzOTdlZV8wLTAtMS0xLTM0NDExL3RleHRyZWdpb246NzkyMTc5MWQzMmM4NDU2MTk2YWE1NWQ2OWYyOGI2NWZfNQ_c58d0bd6-73a8-4327-be1d-e71f7e900618">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ZGM2MzU4MDFjMGVmNGYyMGIzNzQ1ZTIwZGY5Mzk3ZWUvdGFibGVyYW5nZTpkYzYzNTgwMWMwZWY0ZjIwYjM3NDVlMjBkZjkzOTdlZV8wLTEtMS0xLTM0NDExL3RleHRyZWdpb246MTdiMWQ5OGFlNGM4NDk5ZmJkMzFmOWYxOTY4MzFjNTJfNQ_36d3d10a-b09d-451d-8bcc-9bccad88ba44">27-3181608</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ZGM2MzU4MDFjMGVmNGYyMGIzNzQ1ZTIwZGY5Mzk3ZWUvdGFibGVyYW5nZTpkYzYzNTgwMWMwZWY0ZjIwYjM3NDVlMjBkZjkzOTdlZV8yLTAtMS0xLTM0NDExL3RleHRyZWdpb246YmQyZTk5NzdkZmVmNGQ5MWI5MmQyNTA3ODE2NWE0NTlfNQ_312623fd-d5b8-4380-9dec-a3b7696084c4">61 North Beacon Street</ix:nonNumeric>, <ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ZGM2MzU4MDFjMGVmNGYyMGIzNzQ1ZTIwZGY5Mzk3ZWUvdGFibGVyYW5nZTpkYzYzNTgwMWMwZWY0ZjIwYjM3NDVlMjBkZjkzOTdlZV8yLTAtMS0xLTM0NDExL3RleHRyZWdpb246YmQyZTk5NzdkZmVmNGQ5MWI5MmQyNTA3ODE2NWE0NTlfOQ_bc297c76-c24f-407b-a111-f7d78a523f55">4th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ZGM2MzU4MDFjMGVmNGYyMGIzNzQ1ZTIwZGY5Mzk3ZWUvdGFibGVyYW5nZTpkYzYzNTgwMWMwZWY0ZjIwYjM3NDVlMjBkZjkzOTdlZV8yLTAtMS0xLTM0NDExL3RleHRyZWdpb246YmQyZTk5NzdkZmVmNGQ5MWI5MmQyNTA3ODE2NWE0NTlfMTI_2d202f41-49da-4f38-bff9-148730bb4aae">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ZGM2MzU4MDFjMGVmNGYyMGIzNzQ1ZTIwZGY5Mzk3ZWUvdGFibGVyYW5nZTpkYzYzNTgwMWMwZWY0ZjIwYjM3NDVlMjBkZjkzOTdlZV8yLTAtMS0xLTM0NDExL3RleHRyZWdpb246YmQyZTk5NzdkZmVmNGQ5MWI5MmQyNTA3ODE2NWE0NTlfMTY_ca9b76c9-96b9-411b-8732-2c18010162c2">Massachusetts</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ZGM2MzU4MDFjMGVmNGYyMGIzNzQ1ZTIwZGY5Mzk3ZWUvdGFibGVyYW5nZTpkYzYzNTgwMWMwZWY0ZjIwYjM3NDVlMjBkZjkzOTdlZV8yLTEtMS0xLTM0NDExL3RleHRyZWdpb246ZjJiODM5NjRmZjdjNGU1MDgyNjI2OTAzZWQwYThjYzZfNQ_aa5c2c04-b7f9-4efb-8282-fc349f631333">02134</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzYx_bc391b1c-9e53-4956-92a3-6cc3e0691de3">857</ix:nonNumeric>) <ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzU3_5347d68f-d36f-43d1-a618-ac45273b1d74">529-8300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">____________________________________________________________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6MDIwYzA0ZWEwNjZlNGZmZTkzMzI1ZDRkYWVhODU1OTUvdGFibGVyYW5nZTowMjBjMDRlYTA2NmU0ZmZlOTMzMjVkNGRhZWE4NTU5NV8xLTAtMS0xLTM0NDEx_47ad4a1a-3259-47b2-a8c2-257e6437da5b">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6MDIwYzA0ZWEwNjZlNGZmZTkzMzI1ZDRkYWVhODU1OTUvdGFibGVyYW5nZTowMjBjMDRlYTA2NmU0ZmZlOTMzMjVkNGRhZWE4NTU5NV8xLTItMS0xLTM0NDEx_cb6bb97d-4e09-45e0-a98e-170bd34da70c">XFOR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6MDIwYzA0ZWEwNjZlNGZmZTkzMzI1ZDRkYWVhODU1OTUvdGFibGVyYW5nZTowMjBjMDRlYTA2NmU0ZmZlOTMzMjVkNGRhZWE4NTU5NV8xLTQtMS0xLTM0NDEx_50f4efd6-8345-4a02-978f-77d6b6bd1520">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzU4_91d516da-ffcf-4a5c-acbf-81443311eed1">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzU5_6aa7bfef-216c-43f6-b7c1-96dffb3b38d0">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:24.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6NmJmNTMyYjhmOGQxNDg0YmI5NDhkODUyNmM3NjNlZTUvdGFibGVyYW5nZTo2YmY1MzJiOGY4ZDE0ODRiYjk0OGQ4NTI2Yzc2M2VlNV8xLTAtMS0xLTM0NDEx_521d9526-eeb8-4bd9-bb20-e7c4c1d78d8c">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6NmJmNTMyYjhmOGQxNDg0YmI5NDhkODUyNmM3NjNlZTUvdGFibGVyYW5nZTo2YmY1MzJiOGY4ZDE0ODRiYjk0OGQ4NTI2Yzc2M2VlNV8xLTQtMS0xLTM0NDEx_093113a0-7ed7-4b27-b164-4dce9d1b31db">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6NmJmNTMyYjhmOGQxNDg0YmI5NDhkODUyNmM3NjNlZTUvdGFibGVyYW5nZTo2YmY1MzJiOGY4ZDE0ODRiYjk0OGQ4NTI2Yzc2M2VlNV8yLTQtMS0xLTM0NDEx_f19c420d-9ffb-42b3-811e-8613d0eda24e">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzYy_4737e95e-ae79-4fce-adcd-742f9bdebf30">&#9746;</ix:nonNumeric></span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzU1_eb491d30-9dfa-4397-a86a-7edbfdcf2814">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of May&#160;9, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i24b035d294594e2eb13e2c7695f6e295_I20220509" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzE3_37cffef5-291d-4bc3-88d5-2d06da0e955e">30,823,573</ix:nonFraction> shares of common stock outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:38.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i092653cc5b8c43bdad358095e593d81b_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.660%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_16">PART I: FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_19">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_19">FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_22">Condensed Consolidated Balance Sheets (unaudited) as of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_22"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_22">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_22"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_22">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_22">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_22">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_22">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_22"> and December&#160;31, 20</a>21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_22">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_25">Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) for the Three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_25"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_25">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_25">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_25"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_25">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_25">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_25">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_25"> and 20</a>21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_25">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_28">Condensed Consolidated Statements of Redeemable Common Stock and Stockholders&#8217; Equity (unaudited) for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_28">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_28">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_28"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_28">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_28">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_28">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_28"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_28"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_28">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_28">21</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_28">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_31">Condensed Consolidated Statements of Cash Flows (unaudited) for the</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_31"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_31">Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_31">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_31">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_31"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_31">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_31">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_31">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_31">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_31">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_31"> and 20</a>21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_31">11</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_34">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_34">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_82">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_82">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_82">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_106">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_106">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_106">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_109">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_109">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_109">32</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_112">PART II: OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_115">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_115">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_115">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_118">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_118">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_118">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_121">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_121">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_121">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_124">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_124">DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_124">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_127">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_127">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_127">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_130">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_130">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_130">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_133">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_133">EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_133">72</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i092653cc5b8c43bdad358095e593d81b_136">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i092653cc5b8c43bdad358095e593d81b_136">74</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i092653cc5b8c43bdad358095e593d81b_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the (&#8220;Exchange Act&#8221;), that relate to future events or to our future operations or financial performance. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. These statements may be identified by such forward-looking terminology as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this report, regarding, among other things</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing, progress and reporting of results of our current trials of mavorixafor, including our global Phase 3 clinical trial in patients with Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#8220;WHIM&#8221;), syndrome, our Phase 1b clinical trial in combination with ibrutinib in patients with Waldenstr&#246;m&#8217;s macroglobulinemia, and our Phase 1b clinical trial as monotherapy in patients with Severe Congenital Neutropenia (&#8220;SCN&#8221;) and chronic neutropenia disorders;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the initiation, timing, design, progress and results of our current and future preclinical studies and clinical trials of X4P-002 and X4P-003 or any of our other product candidates or our research and development programs that we pursue;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of the ongoing COVID-19 pandemic on our business, operations, strategy, goals and anticipated timelines; </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the diversion of healthcare resources away from the conduct of clinical trials as a result of the ongoing COVID-19 pandemic and its variants, including the diversion of hospitals serving as our clinical trial sites and of hospital staff or independent physicians supporting the conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others in connection with the ongoing COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential benefits, including clinical utility, that may be derived from any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing of and our ability to obtain and maintain regulatory approval of our existing product candidates or any product candidates that we may develop in the future, and any related restrictions, limitations, or warnings in the label of any approved product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to research, develop, manufacture and commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing of our regulatory filings for our product candidates, along with regulatory developments in the United States and other foreign countries;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the size and growth potential of the markets for our product candidates, if approved, and the rate and degree of market acceptance of our product candidates, including reimbursement that may be received from payors; </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the benefits of U.S. Food and Drug Administration and European Commission designations, including, without limitation, Fast Track, Orphan Drug and Breakthrough Therapy; </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract and retain qualified employees and key personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">our competitive position and the development of and projections relating to our competitors or our industry;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations regarding our ability to obtain and maintain intellectual property protection;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our estimates and expectations regarding future operations, financial position, revenues, costs, expenses, uses of cash, capital requirements or our need for additional financing;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to in-license, acquire, develop and commercialize additional product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of laws and regulations;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to identify additional product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to raise additional capital; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our strategies, prospects, plans, expectations or objectives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should refer to the section titled &#8220;Risk Factors" in this Quarterly Report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i092653cc5b8c43bdad358095e593d81b_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:90%">SUMMARY OF SELECTED RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business faces significant risks and uncertainties. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. You should carefully review and consider the full discussion of our risk factors in the section titled &#8220;Risk Factors&#8221; in Part I, Item 1A of this Quarterly Report. Some of the more significant risks include the following:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses and have not generated revenue from product sales since our inception. We expect to continue to incur losses for the foreseeable future, and we may never achieve or maintain profitability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate any product development programs or commercialization efforts.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to our investors, restrict our operations or require us to relinquish rights to our technologies or product candidates. Future debt obligations may expose us to risks that could adversely affect our business, operating results and financial condition and may result in further dilution to our stockholders.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend almost entirely on the success of our lead product candidate, mavorixafor, which we are developing initially for the treatment of WHIM syndrome, for the treatment of SCN and chronic neutropenia disorders, for the treatment of Waldenstr&#246;m&#8217;s, and contingent on a potential strategic partner, for the treatment of clear cell renal cell carcinoma (&#8220;ccRCC&#8221;). We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, mavorixafor or any other product candidate.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to develop mavorixafor, and potentially future product candidates, in combination with other therapies, which exposes us to additional risks.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory review and approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, including mavorixafor, our business will be substantially harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on license agreements with Genzyme, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Georgetown University to permit us to use patents and patent applications. Termination of these rights or the failure to comply with obligations under these agreements could materially harm our business and prevent us from developing or commercializing our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of clinical trials may not support our product candidate claims.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may fail to enroll a sufficient number of patients in our clinical trials in a timely manner, which could delay or prevent clinical trials of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the commercial opportunity in WHIM syndrome, SCN or Waldenstr&#246;m&#8217;s is smaller than we anticipate, our potential future revenue from mavorixafor for the treatment of any of the diseases may be adversely affected and our business may suffer.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization of our product candidates, or our entry into licensing, collaboration or similar arrangements, could be delayed or prevented.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A breakthrough therapy designation or Fast Track designation by the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and neither of these designations increases the likelihood that our product candidates will receive marketing approval.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including marketing withdrawal.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval for our product candidates outside of the United States, which would limit our market opportunities and could harm our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we are able to commercialize mavorixafor or any other product candidate that we develop, the product may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have minimal experience manufacturing our product candidates on a large clinical or commercial scale and have no manufacturing facility. We are currently dependent on a single third party manufacturer for the manufacture of mavorixafor, the active pharmaceutical ingredient (&#8220;API&#8221;) and a single manufacturer of mavorixafor finished drug product capsules. If we experience problems with these third parties, the manufacturing of mavorixafor could be delayed, which could harm our results of operations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third-party clinical research organizations (&#8220;CROs&#8221;) to conduct our preclinical studies and clinical trials. If these CROs do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disruptions in our supply chain could delay the commercial launch of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may depend on such collaborations for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may engage in future acquisitions or in-licenses of technology that could disrupt our business, cause dilution to our stockholders and harm our financial condition and operating results.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect our intellectual property rights, our competitive position could be harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The global COVID-19 pandemic is adversely affecting, and is expected to continue to adversely affect, our business, including our clinical trials and preclinical studies. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends on our ability to retain executives and to attract, retain and motivate key personnel in a competitive environment for skilled biotechnology personnel.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price is expected to continue to be volatile.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are an &#8220;emerging growth company,&#8221; and a &#8220;smaller reporting company&#8221; and as a result of the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i092653cc5b8c43bdad358095e593d81b_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I  FINANCIAL INFORMATION</span></div><div id="i092653cc5b8c43bdad358095e593d81b_19"></div><div><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMy0xLTEtMS0zNDQxMQ_fde82a9b-c462-4ad9-ad5b-99a4ed93cfe6">66,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMy0zLTEtMS0zNDQxMQ_036d6899-216c-4693-8b4c-475b84ad0089">81,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development incentive receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="xfor:ResearchAndDevelopmentIncentiveReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNC0xLTEtMS0zNDQxMQ_455c1f2b-8c0b-4d9c-b4a8-4fdd86a25c8d">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="xfor:ResearchAndDevelopmentIncentiveReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNC0zLTEtMS0zNDQxMQ_b56ab6fc-9e2f-41a9-9431-2509426c05a3">747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNS0xLTEtMS0zNDQxMQ_479091a1-ffb0-450b-bb3d-c6724c829dfa">3,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNS0zLTEtMS0zNDQxMQ_62abc03c-87ae-4754-9de9-d26c43e61d1c">5,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNi0xLTEtMS0zNDQxMQ_5449c14b-4998-473d-b754-89c19d9bab00">70,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNi0zLTEtMS0zNDQxMQ_17d46484-2c2d-4e84-8f5c-ddb3f0ad2962">87,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNy0xLTEtMS0zNDQxMQ_fecb528c-64fa-46f2-a47f-e6cf2d40667d">1,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNy0zLTEtMS0zNDQxMQ_562a3160-9a92-45b3-b868-602b7ce391e7">1,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfOC0xLTEtMS0zNDQxMQ_69f35318-a300-446b-88cb-5420ebc3b1e7">17,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfOC0zLTEtMS0zNDQxMQ_e0efe09c-8211-45d3-82c4-beeb0f0f2b32">17,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfOS0xLTEtMS0zNDQxMQ_db7548d4-0fa4-47bb-9845-192a5049215f">8,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfOS0zLTEtMS0zNDQxMQ_91e52372-26f0-44a1-8b55-2d9fdfcc8f59">8,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTAtMS0xLTEtMzQ0MTE_dc00a2ba-070c-43a0-8889-438a0ecbdc5a">1,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTAtMy0xLTEtMzQ0MTE_b92024ea-9401-4962-8fbd-f72d45dce0bc">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTEtMS0xLTEtMzQ0MTE_958af311-7087-4a87-8aa1-38fa8d4cd684">99,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTEtMy0xLTEtMzQ0MTE_4e93cdac-edbd-4558-8760-cc8df95ca606">117,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTQtMS0xLTEtMzQ0MTE_60f7f7f8-edc4-48c4-95d5-8753e93e36bd">3,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTQtMy0xLTEtMzQ0MTE_241a9ae8-2df6-4ed8-8267-0710e4dde87c">4,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTUtMS0xLTEtMzQ0MTE_6e89dd26-c58f-4590-b9ef-83b30e20e2de">6,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTUtMy0xLTEtMzQ0MTE_20d574f9-54a0-4b87-b9d2-50e36fecd70f">7,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTYtMS0xLTEtMzQ0MTE_0c9180b8-0a54-41fa-b00f-006b7405e85a">1,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTYtMy0xLTEtMzQ0MTE_68457ea1-4e7a-431e-8127-aa39c0f81d71">1,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTctMS0xLTEtMzQ0MTE_d294df21-f06d-43a6-91b5-4f486d01757a">3,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTctMy0xLTEtMzQ0MTE_4f548d1e-a82f-4125-a891-0982eddb30af">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTgtMS0xLTEtMzQ0MTE_a4dd8802-e321-4dff-8ebb-0a1fbe933c3c">14,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTgtMy0xLTEtMzQ0MTE_4a98cdce-d585-4ef7-8ddc-b347e5b18ff7">14,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net of discount and current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="xfor:LongTermDebtNonCurrentIncludingAccretion" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTktMS0xLTEtMzQ0MTE_7dd1611f-7cfd-4557-9e12-29f95b67c382">29,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="xfor:LongTermDebtNonCurrentIncludingAccretion" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTktMy0xLTEtMzQ0MTE_0beaee4f-0fdb-462e-9808-11fc90cec263">33,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjAtMS0xLTEtMzQ0MTE_76a72002-4d56-4bab-93ff-9ac090d6f354">4,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjAtMy0xLTEtMzQ0MTE_4efc6331-2c4e-4bf3-b56d-ca3c3ead83b8">4,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjEtMS0xLTEtMzQ0MTE_d53df466-fc93-4912-b794-44214524c171">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjEtMy0xLTEtMzQ0MTE_65da535d-6c9b-4bff-bf3f-c83ad1115d23">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjItMS0xLTEtMzQ0MTE_e3cb5059-bd17-41fc-882a-cc8213545fa3">49,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjItMy0xLTEtMzQ0MTE_104e4852-ea45-45a8-a1ad-ad0dc52e34ff">52,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjMtMS0xLTEtMzQ0MTE_2fa36de4-7470-43a6-b2bb-d5b863cd0046"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjMtMy0xLTEtMzQ0MTE_733c8b80-87e6-471b-89b0-91c8899554fc"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMC0xLTEtMzQ0MTEvdGV4dHJlZ2lvbjozMGY5MGViMGZjZjQ0YzFmODY0MmE5Njg5ODZkYTEyN18xOQ_6bc07d9d-666a-4a7c-bc21-da61e9738da1"><ix:nonFraction unitRef="usdPerShare" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMC0xLTEtMzQ0MTEvdGV4dHJlZ2lvbjozMGY5MGViMGZjZjQ0YzFmODY0MmE5Njg5ODZkYTEyN18xOQ_b97e7f37-67ac-4c53-9adc-c39a73b9e619">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMC0xLTEtMzQ0MTEvdGV4dHJlZ2lvbjozMGY5MGViMGZjZjQ0YzFmODY0MmE5Njg5ODZkYTEyN18zMw_37f5119f-41eb-4409-925c-af48199031a7">125,000,000</ix:nonFraction> shares authorized as of each of March 31, 2022 and December 31, 2021; <ix:nonFraction unitRef="shares" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMC0xLTEtMzQ0MTEvdGV4dHJlZ2lvbjozMGY5MGViMGZjZjQ0YzFmODY0MmE5Njg5ODZkYTEyN18xMTA_028035f5-50e5-421f-a684-e73efa4448b5"><ix:nonFraction unitRef="shares" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMC0xLTEtMzQ0MTEvdGV4dHJlZ2lvbjozMGY5MGViMGZjZjQ0YzFmODY0MmE5Njg5ODZkYTEyN18xMTA_e2ea39d1-17e6-4f09-843e-88e48af07215">30,809,476</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMC0xLTEtMzQ0MTEvdGV4dHJlZ2lvbjozMGY5MGViMGZjZjQ0YzFmODY0MmE5Njg5ODZkYTEyN18xMTc_ae5728cd-d611-4f46-89fb-cb881c1815b3"><ix:nonFraction unitRef="shares" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMC0xLTEtMzQ0MTEvdGV4dHJlZ2lvbjozMGY5MGViMGZjZjQ0YzFmODY0MmE5Njg5ODZkYTEyN18xMTc_b4fe1fe5-b831-4fa6-ba41-b98bfef55771">28,127,657</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMS0xLTEtMzQ0MTE_67fd6a88-1eaa-4ef3-9dac-1b79eb6e61c4">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMy0xLTEtMzQ0MTE_089fb4a6-d8e9-47f6-a39c-545c39de47ab">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjYtMS0xLTEtMzQ0MTE_0d661b49-db6c-4e16-bafd-a7ef0119082c">354,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjYtMy0xLTEtMzQ0MTE_d8f4871f-65e5-4873-bac2-4d87b33bbea7">347,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjctMS0xLTEtMzQ0MTE_8df756b5-a721-40b4-989a-6f932221f22a">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjctMy0xLTEtMzQ0MTE_1b56aa45-2dc4-47ef-9905-4393f5ea889d">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjgtMS0xLTEtMzQ0MTE_0080f628-0bca-4548-a9ec-edbb2d2e4700">304,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjgtMy0xLTEtMzQ0MTE_e9883455-f9ae-4ae9-875e-b7589cd12838">282,871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjktMS0xLTEtMzQ0MTE_6f08348f-ea63-47d0-ae6e-813263434316">49,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjktMy0xLTEtMzQ0MTE_a9d3731c-a12d-479a-86b6-07025a357153">64,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMzAtMS0xLTEtMzQ0MTE_f617e66d-e565-4a8d-856e-72af20b61fb2">99,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMzAtMy0xLTEtMzQ0MTE_780795bf-7b7d-4988-9921-2bfc0009843f">117,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i092653cc5b8c43bdad358095e593d81b_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.458%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNC0xLTEtMS0zNDQxMQ_b520ce6e-646d-42f3-b7b8-6cec3a17a2ea">14,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNC0zLTEtMS0zNDQxMQ_007f76e3-06aa-49b8-afb8-3d508c5493f5">12,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNS0xLTEtMS0zNDQxMQ_ccc4a2da-acf2-4ded-ac58-6a6fcf527745">7,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNS0zLTEtMS0zNDQxMQ_c3d49f7a-f063-4010-bbe3-64d4682f8af1">5,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of non-financial asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNi0xLTEtMS0zODc5NA_18c9d18b-432c-45da-87ca-f84c49074041">509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNi0zLTEtMS0zOTY1NA_daa03654-8562-4394-93bc-60b254586e2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNi0xLTEtMS0zNDQxMQ_6d82fd05-f083-4a36-b3d3-8c452750ff23">21,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNi0zLTEtMS0zNDQxMQ_ce4e243b-46a3-40f9-ba43-da0229c9462e">17,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNy0xLTEtMS0zNDQxMQ_f918fc1c-b3ca-4eca-af05-556045056745">21,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNy0zLTEtMS0zNDQxMQ_fad2a4ea-bb23-44c3-9365-bab885c8dc61">17,936</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfOS0xLTEtMS0zNDQxMQ_b5fd3f43-2254-47b1-afa9-fc34df760944">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfOS0zLTEtMS0zNDQxMQ_44ccaeae-9f7a-4173-a272-2debee4b52bf">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTAtMS0xLTEtMzQ0MTE_ca102fec-dfd1-4e54-af63-5f566d237715">913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTAtMy0xLTEtMzQ0MTE_797c042e-df82-499f-aff6-659a75d8ee9f">891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTEtMS0xLTEtMzQ0MTE_23d16b96-1248-49b5-a52b-2129c5689f7c">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTEtMy0xLTEtMzQ0MTE_c3fdd2f7-99a5-4d6c-81c8-434531fef16d">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTItMS0xLTEtMzQ0MTE_e11eae8b-efab-4a2c-8009-5f9e7c50dd3d">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTItMy0xLTEtMzQ0MTE_d171e344-5983-4ca4-b6b5-de3c9f41de6d">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTQtMS0xLTEtMzQ0MTE_b6b18611-563b-44d6-8201-0b7731cb5ece">674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTQtMy0xLTEtMzQ0MTE_4d95f560-3843-4a27-aeaf-923328db0879">734</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTUtMS0xLTEtMzQ0MTE_0b943eac-e033-47fb-8d4d-506b2e31daeb">21,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTUtMy0xLTEtMzQ0MTE_541815ac-3fb8-48ed-8d64-6abd958743ab">18,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTYtMS0xLTEtMzQ0MTE_4087e002-3386-48d7-934b-29e7af98c978">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTYtMy0xLTEtMzQ0MTE_ad0504ec-1e55-42a3-bc09-3f4a3a55096d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTctMS0xLTEtMzQ0MTE_13756b9d-bb45-4009-8513-df0c8e8a112d">21,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2425a0da056146c48327ec0587899d61_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTctMy0xLTEtMzQ0MTE_4c3b0477-959b-40a3-aeef-cb02ce3d3134">18,676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend on Class B Warrant price reset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTgtMS0xLTEtMzQ0MTE_a7576fff-0027-4bb1-89ec-ef1f49493c0d">2,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTgtMy0xLTEtMzQ0MTE_4d1536b0-5181-4237-b8d8-6d23bccc7206">8,239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTktMS0xLTEtMzQ0MTE_700955f7-83aa-44c2-9a69-2a51dc98f10e">24,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTktMy0xLTEtMzQ0MTE_4380b22a-58ee-4fdf-ad65-c795e17d01c0">26,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMjAtMS0xLTEtMzQ0MTE_b435a167-2643-4da4-a3aa-1469bb093c7e">0.72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMjAtMy0xLTEtMzQ0MTE_b33dcda5-45c2-4c45-8d8b-9379a200576d">1.30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;basic and diluted</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMjEtMS0xLTEtMzQ0MTE_709e532c-1f0d-4669-ad08-b3a439303562">33,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMjEtMy0xLTEtMzQ0MTE_bee75ff4-7b8b-48e1-b19c-9e881372ebe3">20,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i092653cc5b8c43bdad358095e593d81b_28"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF REDEEMABLE COMMON STOCK AND STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.878%"><tr><td style="width:1.0%"></td><td style="width:43.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.259%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.281%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib471740b6fdd47e8af8050737b18ccdb_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMi0xLTEtMS0zNDQxMQ_539634a4-1c2e-43ae-82e5-11da9599c8e0">28,127,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib471740b6fdd47e8af8050737b18ccdb_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMi0zLTEtMS0zNDQxMQ_79d8e708-8a23-448a-b40d-fab2ee1c06e2">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i854c77af00bd4ce9a4dfdb9a27239dce_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMi01LTEtMS0zNDQxMQ_ea8cf5a1-9f06-4b44-83f9-632bc19cd75b">347,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60e626d1eb1f4f26b74d82ff06b61afd_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMi03LTEtMS0zNDQxMQ_c79823c3-8b3c-4a76-af1c-dadf1b9dc941">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6895f9ac9ea474583d9fff78ede70b3_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMi05LTEtMS0zNDQxMQ_304cc1b0-d926-470c-a008-b5dce3331d77">282,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMi0xMS0xLTEtMzQ0MTE_fafb7a20-869d-4221-8029-dc957c7b1b04">64,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $174</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01d79d96f4a7455f94d5d1c06a5e5b1b_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMy0xLTEtMS0zNjM5MQ_51db5e3c-0508-4d82-b656-b1ae177dc5f0">2,512,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d79d96f4a7455f94d5d1c06a5e5b1b_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMy0zLTEtMS0zNjM5MQ_44498c30-56c9-47eb-8fb5-09323d34b1aa">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8de9ba4633443dbaddd152d4d468a43_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMy01LTEtMS0zNjM5MQ_89c9a1b0-05b1-4d9a-85c3-9532b5bd1618">5,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMy0xMS0xLTEtMzYzOTE_e9638c86-d685-4304-8a1e-a5add0f4c5bd">5,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01d79d96f4a7455f94d5d1c06a5e5b1b_D20220101-20220331" decimals="INF" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMy0xLTEtMS0zNDQxMQ_440a4de7-07be-4597-9a77-9df48213e6cc">168,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8de9ba4633443dbaddd152d4d468a43_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMy01LTEtMS0zNDQxMQ_57dda43d-a6c2-4763-bee6-aba27f6ea93f">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMy0xMS0xLTEtMzQ0MTE_b3a47669-9f4a-42d5-a7cb-c45b1311f86a">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01d79d96f4a7455f94d5d1c06a5e5b1b_D20220101-20220331" decimals="INF" name="xfor:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNS0xLTEtMS0zOTAwMw_edaaebb4-f52f-4005-951e-c9a28fe568c8">100</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8de9ba4633443dbaddd152d4d468a43_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNC01LTEtMS0zNDQxMQ_bb6542f2-e7e5-4e36-b5eb-2f5bfca398a1">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNC0xMS0xLTEtMzQ0MTE_f8657460-cb8a-433c-906d-88d53de83cb0">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia22eddc0d4a54868be305ee81dbe30b5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNS05LTEtMS0zNDQxMQ_800e22c6-839c-4cd5-a613-971da27382a9">21,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNS0xMS0xLTEtMzQ0MTE_5dd7b07b-1533-4989-acfb-b235d007869c">21,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54a6aa4f5e554082b147ea3e13218602_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNi0xLTEtMS0zNDQxMQ_807e28d2-a474-4a29-a085-c4fc5c4b61af">30,809,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a6aa4f5e554082b147ea3e13218602_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNi0zLTEtMS0zNDQxMQ_b0afb1c6-3476-4201-9316-37bccd39b62f">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047748a25ba140d9bf8ddde9f403b7c3_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNi01LTEtMS0zNDQxMQ_f8f03458-8811-479d-96de-a6b4414608a0">354,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4df9455becee450483e383bda2635fb6_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNi03LTEtMS0zNDQxMQ_b16f0e3b-867a-4434-85f5-372d57426477">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0ec92573d25494d9ec868ce6d803b1f_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNi05LTEtMS0zNDQxMQ_768b2084-4edd-480a-a758-2b777134f20f">304,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNi0xMS0xLTEtMzQ0MTE_4f2ecd2a-5ff2-4ce6-894d-5f9bc126e760">49,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF REDEEMABLE COMMON STOCK AND STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.393%"><tr><td style="width:1.0%"></td><td style="width:28.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.503%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86f8f316e485428cbd4027d61748adf8_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi0xLTEtMS0zNDQxMQ_aeead976-17dc-45b1-b386-74dc4372f1bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86f8f316e485428cbd4027d61748adf8_I20201231" decimals="-3" name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi0zLTEtMS0zNDQxMQ_03f4b43d-766e-4155-bcca-1f4ddad5daaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7e2cf99863b4fb88048889aa87cf96f_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi01LTEtMS0zNDQxMQ_deed65ae-1ce1-48ae-b930-adcb1142d694">16,305,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7e2cf99863b4fb88048889aa87cf96f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi03LTEtMS0zNDQxMQ_6b1e3fbf-83de-4f7c-aa94-342a06c030b4">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d7e807d2ef42dda0ab3c941f8caf6f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi05LTEtMS0zNDQxMQ_c401a01d-f142-4b20-8c48-efbb70eb0017">267,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f4ba6165a6d4e068a782de9870bba11_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi0xMS0xLTEtMzQ0MTE_b172cad9-efa8-4743-868e-f5b16cf9954f">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c210c0dd8634743ac3fe20cd14d7221_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi0xMy0xLTEtMzQ0MTE_584ff457-7dad-4de6-ae89-fef0828751a4">194,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c88a11b199434aace5aef0bbc9f5ea_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi0xNS0xLTEtMzQ0MTE_74274dd2-90d6-4eac-b1cf-815ecda6bf56">72,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, redeemable common stock  and pre-funded warrants for the purchase of common stock, net of issuance costs <ix:nonFraction unitRef="usd" contextRef="icb5a551d13c443f58e2de92a4c349fb4_D20211001-20211231" xsi:nil="true" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMy0wLTEtMS0zNDQxMS90ZXh0cmVnaW9uOmNjZjJhOTU2MzYzYTQ3NmY5ODhiMDBmMTUzYzhmYzMxXzEzOA_c2750e2c-0a45-4b5f-9d38-91d7d0015c03"></ix:nonFraction> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a536b78307a42ecbcb3238de82af6f7_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMy0xLTEtMS0zNDQxMQ_8f1f190c-db0a-4873-b1ec-ddcd9b66ff95">229,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a536b78307a42ecbcb3238de82af6f7_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMy0zLTEtMS0zNDQxMQ_11077447-890d-47ab-ba61-04cf922047e0">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if552410f512d4f14be1678c6b554dbef_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMy01LTEtMS0zNDQxMQ_e0359f63-a630-4644-b525-d8ae9b3d71f7">6,041,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if552410f512d4f14be1678c6b554dbef_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMy03LTEtMS0zNDQxMQ_99751623-5957-4faa-9f4f-5c3ef3b88fb1">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2328bc9fe2404a29a05fe278a1035750_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMy05LTEtMS0zNDQxMQ_0e27a450-4322-497d-83d4-f49aae19ba4b">49,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMy0xNS0xLTEtMzQ0MTE_bcab4c92-994d-44ae-b9d3-4689e27859dd">49,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if552410f512d4f14be1678c6b554dbef_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNC01LTEtMS0zNDQxMQ_775bdfb6-46dd-45ce-9075-fa64fa929202">5,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2328bc9fe2404a29a05fe278a1035750_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNC05LTEtMS0zNDQxMQ_746f40e2-35a5-461e-8e7f-1af58d645fb4">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNC0xNS0xLTEtMzQ0MTE_8c90268f-3564-494b-96b4-d21dc3828ab7">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of pre-funded warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if552410f512d4f14be1678c6b554dbef_D20210101-20210331" decimals="INF" name="xfor:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNS01LTEtMS0zNDQxMQ_5088479f-1680-4f2c-9d49-402357507add">1,072,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if552410f512d4f14be1678c6b554dbef_D20210101-20210331" decimals="-3" name="xfor:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNS03LTEtMS0zNDQxMQ_57818886-72a7-4b1f-9407-1e6fe0db91c0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="xfor:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNS0xNS0xLTEtMzQ0MTE_2a1b3359-a3f6-40c9-8a85-fa1d28ce26db">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2328bc9fe2404a29a05fe278a1035750_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNi05LTEtMS0zNDQxMQ_9f909efa-dab5-43e9-96b0-044d1d82ffab">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNi0xNS0xLTEtMzQ0MTE_68e34078-4602-48eb-952b-8593848db897">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2425a0da056146c48327ec0587899d61_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNy0xMy0xLTEtMzQ0MTE_e85fb62e-98f8-4ce5-bc60-85b45ae433e6">18,676</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNy0xNS0xLTEtMzQ0MTE_73c8ea78-ed27-4696-84ba-0ec1b344b63c">18,676</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6216409af0d8456fa56993e3fe6c83f0_I20210331" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC0xLTEtMS0zNDQxMQ_5cbbac21-19e3-4723-ad22-c744eb3c7957">229,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6216409af0d8456fa56993e3fe6c83f0_I20210331" decimals="-3" name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC0zLTEtMS0zNDQxMQ_42d7d7ed-97fa-401b-a7a2-be56b3cdf89a">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c30ad47284440ecb1152f67b75b14bf_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC01LTEtMS0zNDQxMQ_d297dd20-ec77-4b0d-9fbe-9f8cf97cf21c">23,426,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c30ad47284440ecb1152f67b75b14bf_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC03LTEtMS0zNDQxMQ_617f08f7-eda7-483e-9c13-d6bb54b3a57e">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6490c404c2e943b29d2afa3f5b15a0ed_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC05LTEtMS0zNDQxMQ_aa8fc9b4-2965-4fa5-a254-b52cf3c70820">318,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa75eebec540404b9087007bb78de87d_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC0xMS0xLTEtMzQ0MTE_f85c3bab-27ae-4c5d-9e2b-697d7eafc0d9">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa18918dfe8b4eb99398f5469d0f1f20_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC0xMy0xLTEtMzQ0MTE_2409a23a-c33b-4e0e-b4f9-a43956a77b5f">212,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f51ae8287e4f2a9dc20c9692a90f3b_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC0xNS0xLTEtMzQ0MTE_ad30d92c-ea56-4d01-8e49-d5c95088195f">105,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i092653cc5b8c43bdad358095e593d81b_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMy0xLTEtMS0zNDQxMQ_6373c428-1948-42de-92e1-6982f15b32d2">21,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMy0zLTEtMS0zNDQxMQ_204d7152-bc22-4f0a-9d17-ad58d6213112">18,676</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfNS0xLTEtMS0zNDQxMQ_1dd1389a-3084-435d-a8f5-9c4cb0d476f7">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfNS0zLTEtMS0zNDQxMQ_b6a63cba-99fc-4e82-b93c-56e448a46b4d">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfNi0xLTEtMS0zNDQxMQ_7c6188ba-ecb6-4936-b78a-bed3a8b16433">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfNi0zLTEtMS0zNDQxMQ_c2080a99-b39f-4d8a-b56e-21c14b240aca">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="xfor:NonCashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfNy0xLTEtMS0zNDQxMQ_b7243937-5c4f-4251-b1ec-b82e3f9325f0">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="xfor:NonCashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfNy0zLTEtMS0zNDQxMQ_35481d01-9ecc-4197-87f9-907b68dc0a64">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="xfor:NonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfOC0xLTEtMS0zNDQxMQ_db298da7-9357-4422-b913-4254e832c2d7">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="xfor:NonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfOC0zLTEtMS0zNDQxMQ_1dac44e7-0542-44bd-a626-b6d83ad20c2b">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTAtMS0xLTEtMzQ0MTE_59b85549-2f34-4955-bf9c-0be4f15ccb88">120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTAtMy0xLTEtMzQ0MTE_eaaf024c-91ce-422a-94c0-997672d0bd15">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets and research and development incentive receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTItMS0xLTEtMzQ0MTE_d69b6540-7431-423d-850e-0a67b708b956">1,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTItMy0xLTEtMzQ0MTE_53971767-b8ab-44c6-8530-141a9bffbe32">711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTMtMS0xLTEtMzQ0MTE_25af890d-aacc-4d50-a56d-31609db32a2e">713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTMtMy0xLTEtMzQ0MTE_1dafcee1-45de-43e6-982d-2f8d7ba3b951">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTQtMS0xLTEtMzQ0MTE_6b815a36-4501-4e71-a7c9-be1d54a7f7de">984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTQtMy0xLTEtMzQ0MTE_6f1d4a18-45d5-40bf-997b-708d0419a2e3">786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="xfor:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTUtMS0xLTEtMzQ0MTE_409df25b-e060-4bd4-bcb4-4ed8efccf52d">236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="xfor:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTUtMy0xLTEtMzQ0MTE_4204ab24-285e-4bef-9eae-ca9f6aae46c7">160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset, net of non-cash portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTYtMS0xLTEtMzQ0MTE_906b71cc-4b98-4362-b8b4-effa46bb5e5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTYtMy0xLTEtMzQ0MTE_c804141c-fcab-4c08-b157-935eb69b7b8e">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTctMS0xLTEtMzQ0MTE_4b738dcb-f4db-4ae9-9b17-519d57ef2e02">20,229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTctMy0xLTEtMzQ0MTE_8106aca5-07c2-4e05-b516-450b7363e0a2">18,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of property, equipment and intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTktMS0xLTEtMzQ0MTE_9ab06298-df11-46b3-a138-0320fec06f9d">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTktMy0xLTEtMzQ0MTE_cb63fc87-d0c4-43ef-b3e3-2d4277f195d1">496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjAtMS0xLTEtMzQ0MTE_00cdaaae-719d-4715-b179-00781a8f7891">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjAtMy0xLTEtMzQ0MTE_4614b5b5-91ca-4f7e-9322-e1c4ea16ffc7">496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options and pre-funded warrants and issuance of shares of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="xfor:ProceedsFromExerciseOfStockOptionsAndWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjItMS0xLTEtMzQ0MTE_6c6c964d-2251-422f-9cba-6af51cd0b844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="xfor:ProceedsFromExerciseOfStockOptionsAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjItMy0xLTEtMzQ0MTE_777bb14a-3ce4-4b91-9981-9f0bfe296a0a">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee taxes paid related to net share settlement of vested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjMtMS0xLTEtMzQ0MTE_2e0492c7-907f-4bde-ad59-bca452b03c23">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjMtMy0xLTEtMzQ0MTE_3c49b3cf-45ac-4ce4-afa0-3cb45d0a5865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from borrowings under loan and security agreements, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="xfor:ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjQtMS0xLTEtMzQ0MTE_51245234-9d0f-4cd5-80ee-7f2af0df7b15">114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="xfor:ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjQtMy0xLTEtMzQ0MTE_c1676bd3-8867-4051-8699-8e73211da966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of borrowings under loan and security agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjUtMS0xLTEtMzkwMzM_03fabc9a-b35f-419f-9c04-d2071b28c501">795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-5" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjUtMy0xLTEtMzk3MDY_924750a3-382e-4fd8-96dc-a7c0da8179c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of shares of common stock, redeemable common stock and pre-funded warrants, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjUtMS0xLTEtMzQ0MTE_04072499-180e-4568-ad41-ba0a6cac179f">5,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjUtMy0xLTEtMzQ0MTE_b73a22de-432d-4752-b7df-b708b567875a">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjctMS0xLTEtMzQ0MTE_6bf59adc-7dbb-4d7e-be5b-9255ebb8ff9c">4,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjctMy0xLTEtMzQ0MTE_cc8d9e85-58ca-411d-8522-50ef8cb8d132">55,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjgtMS0xLTEtMzQ0MTE_abd431ff-b854-4c2c-8bb2-aaf25429860c">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjgtMy0xLTEtMzQ0MTE_fa9bbbf1-eba0-407e-be77-145d6bbb056a">143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjktMS0xLTEtMzQ0MTE_0b458d60-c0c2-4ac8-aac4-e86717ad155b">15,364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjktMy0xLTEtMzQ0MTE_bd831557-8804-4673-b4a3-c2c205116b31">35,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzAtMS0xLTEtMzQ0MTE_e441fb6e-030b-434b-99ba-872b0fc5c92c">83,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c88a11b199434aace5aef0bbc9f5ea_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzAtMy0xLTEtMzQ0MTE_f0d18994-cccd-454c-9839-3bb4e114c755">80,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzEtMS0xLTEtMzQ0MTE_9d51a938-61b0-4492-932a-9d6fdfa43a26">67,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f51ae8287e4f2a9dc20c9692a90f3b_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzEtMy0xLTEtMzQ0MTE_b381e065-c27f-47ec-8515-b1c83a420220">116,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of property, equipment and right-of-use assets included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzQtMS0xLTEtMzQ0MTE_6a0f6621-c30a-443f-921f-ef1591b3ab93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzQtMy0xLTEtMzQ0MTE_7fcec14a-9759-45b8-8383-e469dcbbde7d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of right-of-use asset financed by lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:CapitalLeaseObligationsIncurred" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzUtMS0xLTEtMzQ0MTE_b8f2e8d9-3853-4623-ae0d-4475a0e987cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:CapitalLeaseObligationsIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzUtMy0xLTEtMzQ0MTE_508bea07-0aee-46e2-8c35-a63def936340">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance costs not yet paid related to sale of shares of common stock, redeemable common stock and pre-funded warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzYtMS0xLTEtMzQ0MTE_7f0817ac-1945-4e00-a05e-e2657ef6741e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzYtMy0xLTEtMzQ0MTE_9e16efcf-eb5d-4cda-bb77-8c6dd35ac14a">3,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i092653cc5b8c43bdad358095e593d81b_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_37"></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zNy9mcmFnOjRhOWY0NDNiNGVlOTRiMzc5NTExM2I4MTAxZTcxZWQ1L3RleHRyZWdpb246NGE5ZjQ0M2I0ZWU5NGIzNzk1MTEzYjgxMDFlNzFlZDVfNDM5Mw_9097313d-45e4-4ee9-b8a3-7955eb539d4c" continuedAt="i6cbe5c8b99d1426685fa3bc90a51d722" escape="true">NATURE OF THE BUSINESS AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i6cbe5c8b99d1426685fa3bc90a51d722"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X4 Pharmaceuticals, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a late-stage clinical biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases. The Company&#8217;s lead product candidate, mavorixafor, is a potential first-in-class, once-daily, oral inhibitor of CXCR4 and is currently in a Phase 3 clinical trial for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#8220;WHIM&#8221;) syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. The Company is also conducting a 14-day, proof-of-concept Phase 1b clinical trial of mavorixafor in patients with Severe Congenital Neutropenia (&#8220;SCN&#8221;) and chronic neutropenia disorders, and a Phase 1b clinical trial of mavorixafor in combination with ibrutinib in Waldenstr&#246;m&#8217;s macroglobulinemia (&#8220;Waldenstr&#246;m&#8217;s&#8221;). The Company is headquartered in Boston, Massachusetts and has an additional facility in Vienna, Austria. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern Assessment&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. As of March 31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zNy9mcmFnOjRhOWY0NDNiNGVlOTRiMzc5NTExM2I4MTAxZTcxZWQ1L3RleHRyZWdpb246NGE5ZjQ0M2I0ZWU5NGIzNzk1MTEzYjgxMDFlNzFlZDVfMTM0Mg_346f4f81-70fb-4131-be85-fba9bebc110d">66.4</ix:nonFraction> million of cash and cash equivalents. Based on its current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expense and capital expenditure requirements into the fourth quarter of 2022. However, as further discussed in Note 7, the Company has a covenant under its loan agreement with Hercules Capital Inc. (&#8220;Hercules&#8221;) that requires that the Company maintain a minimum level of cash, as defined, beginning on September 1, 2022. Based on its current financial projections, the Company believes it would be in violation of this covenant in the third quarter of 2022. If the Company is in violation of this covenant, Hercules could require the repayment of all outstanding debt. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the Company believes that, in the aggregate, these conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. Nevertheless, the accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. In order to fund its operations beyond the fourth quarter of 2022, the Company is seeking to raise funds potentially through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations and strategic alliances. If the Company is unable to obtain future funding when needed, the Company may be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or pre-commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. There is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in late 2019 and continuing into 2022, the outbreak of COVID-19 has resulted in the declaration of a global pandemic and adversely affected economic activity across virtually all sectors and industries on a local, national and global scale. Impacts to the Company&#8217;s business have included temporary closures or postponements of activation of its clinical trial sites or facilities, disruptions or restrictions on its employees&#8217; ability to travel, disruptions to or delays in ongoing clinical trials, including patient enrollment at a slower pace than initially projected and the diversion of healthcare resources away from the conduct of the Company&#8217;s clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as the Company&#8217;s clinical trial sites and hospital staff supporting the conduct of the Company&#8217;s clinical trials. While global vaccination efforts are underway and certain jurisdictions, including Massachusetts, where the Company is headquartered, have reopened businesses and governmental agencies, there remain limitations on the physical operations of businesses and prohibitions on certain non-essential gatherings, and the Company is unable to accurately predict the full impact that COVID-19 will have due to numerous uncertainties, including the duration of the outbreak, the result of vaccination efforts, resurgence of the virus, actions that may be taken by governmental authorities, the impact on the Company&#8217;s business including its clinical programs and timelines, and the impact to the business of its service providers and partners.</span></div></ix:continuation><div><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_40"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNTE_d38a702b-569f-48bd-8863-7a4fb2c93061" continuedAt="i75f61dd178ae4b8bb55451375a282a62" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="i75f61dd178ae4b8bb55451375a282a62" continuedAt="ic149ccd38029448fb51a3cbf66e26c1c"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 17, 2022 (the &#8220;2021 Annual Report&#8221;). Since the </span></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ic149ccd38029448fb51a3cbf66e26c1c" continuedAt="iaff87e55d3ba4451baa6ccbc014afe86"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date of those consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of the ongoing COVID-19 pandemic has been and, notwithstanding vaccination efforts, is expected to continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. Impacts to the Company&#8217;s business have included temporary closures or postponements of activation of its clinical trial sites or facilities, disruptions or restrictions on its employees&#8217; ability to travel, disruptions to or delays in ongoing clinical trials, including patient enrollment at a slower pace than initially projected and the diversion of healthcare resources away from the conduct of the Company&#8217;s clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as the Company&#8217;s clinical trial sites and hospital staff supporting the conduct of the Company&#8217;s clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biotechnology industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and the challenges of complying with applicable regulatory requirements. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it is expected also to have the effect of heightening many of the other risks and uncertainties discussed above.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNDc_fd5d73e4-b411-4910-b89f-8e05ca37a4c4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including X4 Pharmaceuticals (Austria) GmbH, which is incorporated in Vienna, Austria (&#8220;X4 Austria&#8221;), and X4 Therapeutics, Inc. All significant intercompany accounts and transactions have been eliminated.</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNTQ_b0e0dfe7-60d0-4c1c-acdc-be6e69d70a0f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet at December 31, 2021 that is presented in these interim condensed consolidated financial statements was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed consolidated financial statements are unaudited. The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC for interim financial statements. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s&#160;audited financial statements and the notes thereto for the year ended December&#160;31, 2021 included in the 2021 Annual Report. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&#8217;s condensed financial position, condensed results of its operations and cash flows have been made. The results of operations for the three months ended March&#160;31, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December&#160;31, 2022.</span></ix:nonNumeric></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNTU_94ca7773-784e-4cb7-a39d-6c3ad9f7acad" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and the constraint of variable consideration from contracts with customers. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The COVID-19 pandemic has impacted and is expected to continue to impact the clinical development timelines for certain of the Company's clinical programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of issuance of these condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s condensed consolidated financial statements.</span></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="iaff87e55d3ba4451baa6ccbc014afe86" continuedAt="ia43aae6929bc4dd5a4a715a72bd80005"><div style="margin-top:12pt"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNDg_a0919d8b-ccd9-46a2-bf08-77cdab6db0aa" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of March&#160;31, 2022 and December&#160;31, 2021.</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:ScheduleOfCompensatingBalancesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNTc_460f91c9-e3c6-4c2b-9cb5-3a58b312b981" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:60.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Waltham lease</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34f27299a434668885ee2416dec75fa_I20220331" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfMi0xLTEtMS0zNDQxMQ_109e8089-a91c-454c-8d67-1822628fccd3">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7257e82e68c041908175389a8f7bdea1_I20211231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfMi0zLTEtMS0zNDQxMQ_85e28268-7ae7-4619-be54-376d41116102">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Vienna Austria lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1cbeac75bb4931b6a264bbff4cb6ac_I20220331" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfMy0xLTEtMS0zNDQxMQ_9843e9cc-178c-40e1-aeb3-377000ba238d">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9911b058cb814046a3c2b033f5239f56_I20211231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfMy0zLTEtMS0zNDQxMQ_4dfffa9d-bcaa-4fec-8fb4-0d478ab1dd23">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Boston lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b8c9dbcf0c44ed99f42775671ed3b03_I20220331" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfNC0xLTEtMS0zNDQxMQ_1313ad08-a591-4048-8308-d4d359165db0">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideaca6ba9ebd4d459db86e8fec1e7f54_I20211231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfNC0zLTEtMS0zNDQxMQ_8f02f0bd-6d34-4900-a33d-31ab435b1560">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfNy0xLTEtMS0zNDQxMQ_990bfd7c-423c-4200-932b-f9fbdaf745f5">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfNy0zLTEtMS0zNDQxMQ_01e297f8-49b7-48a6-9d45-3cd961998604">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s lease agreements for its facilities in Massachusetts and Austria, the Company maintains letters of credit, which are secured by restricted cash, for the benefit of the respective landlord. </span></div><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="xfor:ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNTk_f5269b17-45f5-4105-aa2a-e2edee613315" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the sum of the total of amounts shown in the Company&#8217;s condensed consolidated statements of cash flows as of March&#160;31, 2022 and December&#160;31, 2021:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:62.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.758%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmVhNGE3OTJiMTA1NjRmMjRiYWQyNjljYjdiOGM2ODlmL3RhYmxlcmFuZ2U6ZWE0YTc5MmIxMDU2NGYyNGJhZDI2OWNiN2I4YzY4OWZfMS0xLTEtMS0zNDQxMQ_bf932a8d-9f35-415f-8b0f-b7e3272d0593">66,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmVhNGE3OTJiMTA1NjRmMjRiYWQyNjljYjdiOGM2ODlmL3RhYmxlcmFuZ2U6ZWE0YTc5MmIxMDU2NGYyNGJhZDI2OWNiN2I4YzY4OWZfMS0zLTEtMS0zNDQxMQ_9471f3bb-b735-4c2f-8331-6e4fa7e7c49b">81,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmVhNGE3OTJiMTA1NjRmMjRiYWQyNjljYjdiOGM2ODlmL3RhYmxlcmFuZ2U6ZWE0YTc5MmIxMDU2NGYyNGJhZDI2OWNiN2I4YzY4OWZfMy0xLTEtMS0zNDQxMQ_d2092c33-6063-4f66-bba5-bd20d2cafcbd">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmVhNGE3OTJiMTA1NjRmMjRiYWQyNjljYjdiOGM2ODlmL3RhYmxlcmFuZ2U6ZWE0YTc5MmIxMDU2NGYyNGJhZDI2OWNiN2I4YzY4OWZfMy0zLTEtMS0zNDQxMQ_2d9493c9-2304-4cde-85de-03a7efae46e7">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmVhNGE3OTJiMTA1NjRmMjRiYWQyNjljYjdiOGM2ODlmL3RhYmxlcmFuZ2U6ZWE0YTc5MmIxMDU2NGYyNGJhZDI2OWNiN2I4YzY4OWZfNC0xLTEtMS0zNDQxMQ_863f1c9d-5372-44a4-8c87-a070819cbb0a">67,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmVhNGE3OTJiMTA1NjRmMjRiYWQyNjljYjdiOGM2ODlmL3RhYmxlcmFuZ2U6ZWE0YTc5MmIxMDU2NGYyNGJhZDI2OWNiN2I4YzY4OWZfNC0zLTEtMS0zNDQxMQ_9d9dfb54-5c84-4bf9-b5b7-d1767910ab17">83,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNjA_cc98caa7-eaf3-4151-b7d7-993a3a7f4d2a" continuedAt="i918d65af2022458abd44ef5ff78a64e1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" xsi:nil="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNDY_9a3954e4-134b-4f00-8337-3f7bdc494e57" escape="true"></ix:nonNumeric>Goodwill&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.</span></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i918d65af2022458abd44ef5ff78a64e1">The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform an interim quantitative impairment test, whereby the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than its carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. There were no triggering events during the three months ended March 31, 2022 that necessitated an interim impairment test of goodwill.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNjE_226d32e5-7c78-4be7-9a8c-04954cae08d9" continuedAt="i48babccb5dac4290bc9743f23ef3bf18" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASU 2021-04 was issued to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants for the purchase of common shares) that remain classified as equity following the modification or exchange. ASU 2021-04 is effective January 1, 2022 for the Company. The adoption of this standard did not have an impact on the Company&#8217;s consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13"), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. In accordance with ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326), Derivative and Hedging (Topic 815), and Leases (Topic 842)- Effective </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="ia43aae6929bc4dd5a4a715a72bd80005" continuedAt="iee0b8768e0714c2ba58ab1c3c4fdb116"><ix:continuation id="i48babccb5dac4290bc9743f23ef3bf18" continuedAt="if36c9ff68441496aadff1107063f580b">Dates, </ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iee0b8768e0714c2ba58ab1c3c4fdb116"><ix:continuation id="if36c9ff68441496aadff1107063f580b">as the Company meets the definition of a &#8220;smaller reporting company&#8221;, the Company has elected to defer the adoption of ASU 2016-13 until January 1, 2023. The Company expects that the adoption of ASU 2016-13 may accelerate the timing and could increase the level of credit loss expense in the consolidated statement of operations and will likely require an increased level of disclosure in the notes to the consolidated financial statements.</ix:continuation></ix:continuation> </span></div><div style="margin-top:12pt"><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_43"></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80My9mcmFnOjhlZjY2OTYzY2M3NDQ5Yzc4YWM5MWNhY2Q1Mjk4NjdmL3RleHRyZWdpb246OGVmNjY5NjNjYzc0NDljNzhhYzkxY2FjZDUyOTg2N2ZfOTY3_51bf309c-b07f-4a11-9e03-22dd707936de" continuedAt="i96a14f8e22cb4016b5acdcd67419fda2" escape="true">LICENSE, COLLABORATION AND FUNDING AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="i96a14f8e22cb4016b5acdcd67419fda2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Incentive Program</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses and capital expenditures incurred by the Company&#8217;s subsidiary in Austria. As of March&#160;31, 2022, the amount due under the program is $<ix:nonFraction unitRef="usd" contextRef="ia6a9e053963b4b5e8c0525ef05558e5c_I20220331" decimals="-3" name="xfor:GrantAndIncentiveReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80My9mcmFnOjhlZjY2OTYzY2M3NDQ5Yzc4YWM5MWNhY2Q1Mjk4NjdmL3RleHRyZWdpb246OGVmNjY5NjNjYzc0NDljNzhhYzkxY2FjZDUyOTg2N2ZfNDY4_fccf8198-2a16-4369-a76a-d7a7d79134b9">0.9</ix:nonFraction> million, which amount was included in research and development incentive receivable in the condensed consolidated balance sheet. During the three months ended March&#160;31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i6fa190798a8f407db1aaf3fc492af313_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80My9mcmFnOjhlZjY2OTYzY2M3NDQ5Yzc4YWM5MWNhY2Q1Mjk4NjdmL3RleHRyZWdpb246OGVmNjY5NjNjYzc0NDljNzhhYzkxY2FjZDUyOTg2N2ZfNjU1_52736589-abf8-44ed-b07b-1620fe4dbfa7"><ix:nonFraction unitRef="usd" contextRef="i6fa190798a8f407db1aaf3fc492af313_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80My9mcmFnOjhlZjY2OTYzY2M3NDQ5Yzc4YWM5MWNhY2Q1Mjk4NjdmL3RleHRyZWdpb246OGVmNjY5NjNjYzc0NDljNzhhYzkxY2FjZDUyOTg2N2ZfNjU1_f2e7d968-9e16-43ed-bb8e-1b87bcb6169c">0.1</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0ae98b37b4074b55b43d5b52c0da2b4e_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80My9mcmFnOjhlZjY2OTYzY2M3NDQ5Yzc4YWM5MWNhY2Q1Mjk4NjdmL3RleHRyZWdpb246OGVmNjY5NjNjYzc0NDljNzhhYzkxY2FjZDUyOTg2N2ZfNjYy_8c43daed-d669-4170-8261-8e39ae462a5b"><ix:nonFraction unitRef="usd" contextRef="i0ae98b37b4074b55b43d5b52c0da2b4e_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80My9mcmFnOjhlZjY2OTYzY2M3NDQ5Yzc4YWM5MWNhY2Q1Mjk4NjdmL3RleHRyZWdpb246OGVmNjY5NjNjYzc0NDljNzhhYzkxY2FjZDUyOTg2N2ZfNjYy_dcf653ea-6915-4bb2-8173-23dcd9a2560b">0.3</ix:nonFraction></ix:nonFraction> million, respectively, of income related to the program within the condensed consolidated statements of operations as other income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, a third party, who had previously acquired rights to certain intellectual property from the Company, terminated the arrangement and transferred these rights back to the Company. Also during the three months ended March 31, 2022, the Company transferred these rights to another third party in return for $<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80My9mcmFnOjhlZjY2OTYzY2M3NDQ5Yzc4YWM5MWNhY2Q1Mjk4NjdmL3RleHRyZWdpb246OGVmNjY5NjNjYzc0NDljNzhhYzkxY2FjZDUyOTg2N2ZfMTA5OTUxMTYzNDEzOA_4c95f2e0-6ffb-4e66-901e-b39ca606a7c5">0.5</ix:nonFraction> million. The Company has no continuing involvement in any ongoing research and development activities associated with the intellectual property. The Company concluded that these third parties are "non-customers" as the underlying intellectual property transferred to and from these third parties supports potential drug candidates that are not aligned with the Company's strategic focus and, therefore, are not an output of the Company's ordinary activities. Accordingly, the Company accounted for the sale of the intellectual property as the sale of a non-financial asset under ASC Topic 610-20,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Gains and Losses from the Derecognition of Nonfinancial Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 610-20"), and included the gain as part of gain on sale of non-financial asset for the period ended March 31, 2022. </span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material modifications of the Company&#8217;s license or collaboration agreements during the three months ended March 31, 2022.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_46"></div><div style="margin-top:12pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RleHRyZWdpb246NWVhMzc1MzRmOWVjNGFkMGI2MjRkMGQ2ZTRlMjgzMWVfMTc0OA_662364d7-832a-45e8-93fd-2a246dea4fab" continuedAt="i02fe26523761419186215ccd39a33944" escape="true">FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES </ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i02fe26523761419186215ccd39a33944" continuedAt="ic747538848d0481186be2e41c17555a1"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RleHRyZWdpb246NWVhMzc1MzRmOWVjNGFkMGI2MjRkMGQ2ZTRlMjgzMWVfMTc0NQ_091f6fcc-7b3f-4173-8cfc-d6639a494ba6" continuedAt="ia33682d90e0d469599741d6a263ce9ef" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of March 31, 2022 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094278dbb6a548fd9082e115e09bdaf0_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfMy0xLTEtMS0zNDQxMQ_224d9de2-fe3b-4e91-aa51-46aeddf500a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d672047c5424b409a161bd8c9acbfed_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfMy0zLTEtMS0zNDQxMQ_414df9be-985a-41e6-9689-80affaab78c3">2,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4117ae9064c4a1eb42d624dc7250d94_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfMy01LTEtMS0zNDQxMQ_33447499-efe5-4283-a396-c2b3c9c62d48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42b7fcbe59440f2b41270d5bb32ea91_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfMy03LTEtMS0zNDQxMQ_fbb8f728-8ca1-44f4-bb95-7fc00101091d">2,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094278dbb6a548fd9082e115e09bdaf0_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNC0xLTEtMS0zNDQxMQ_69603111-769d-4e42-80ee-457b81941a1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d672047c5424b409a161bd8c9acbfed_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNC0zLTEtMS0zNDQxMQ_1450951c-3d79-40dc-8a50-dbf231ba71c7">2,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4117ae9064c4a1eb42d624dc7250d94_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNC01LTEtMS0zNDQxMQ_e76bb412-9c6f-414f-97c2-0f357e5f3a3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42b7fcbe59440f2b41270d5bb32ea91_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNC03LTEtMS0zNDQxMQ_208ed843-2c32-4a85-8a38-a21b98137cec">2,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094278dbb6a548fd9082e115e09bdaf0_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNi0xLTEtMS0zNDQxMQ_02aefad9-602e-43a8-97f9-a729c7435806">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d672047c5424b409a161bd8c9acbfed_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNi0zLTEtMS0zNDQxMQ_4859a5b1-6d98-417d-ae87-cd65f6112a27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4117ae9064c4a1eb42d624dc7250d94_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNi01LTEtMS0zNDQxMQ_e2cb1e15-6459-4f46-a2a5-a790d1daf871">645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42b7fcbe59440f2b41270d5bb32ea91_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNi03LTEtMS0zNDQxMQ_0645f634-bdfb-4fa5-aa80-508566e53777">645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094278dbb6a548fd9082e115e09bdaf0_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNy0xLTEtMS0zNDQxMQ_8d23bda0-177d-4f8f-9988-26fd6012bee6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d672047c5424b409a161bd8c9acbfed_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNy0zLTEtMS0zNDQxMQ_cbae9ba2-2013-4fd2-99b2-eb7bf8b054a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4117ae9064c4a1eb42d624dc7250d94_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNy01LTEtMS0zNDQxMQ_5c8d1292-3d1e-4590-a811-bcf9e759933c">645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42b7fcbe59440f2b41270d5bb32ea91_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNy03LTEtMS0zNDQxMQ_1adb89d7-dd74-4090-8231-45fa0f573e8d">645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ic747538848d0481186be2e41c17555a1" continuedAt="i2934930ea35f483c86c367833f0ba5d7"><div><ix:continuation id="ia33682d90e0d469599741d6a263ce9ef"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2021 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia33efcad84ff4ab29dfe84a9f90b41b3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfMy0xLTEtMS0zNDQxMQ_97c57d0b-241a-4950-83aa-bc22f600bedc">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife03ea1a6e3647c89acdff544fec694a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfMy0zLTEtMS0zNDQxMQ_144089ab-b1e9-49c3-abcf-f62f9afa932f">27,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d0f0aac3d548fbaf98b28d241b82e0_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfMy01LTEtMS0zNDQxMQ_cbeb80a2-fea8-4de8-8efc-3aa134ce30e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1742801c50374deb91009bf46a82591f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfMy03LTEtMS0zNDQxMQ_e935b73a-8a81-44b3-b261-5836e7e046e3">47,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia33efcad84ff4ab29dfe84a9f90b41b3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNC0xLTEtMS0zNDQxMQ_48d1fc1b-d112-489a-a71e-194b7a8df501">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife03ea1a6e3647c89acdff544fec694a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNC0zLTEtMS0zNDQxMQ_842311f1-912e-4da9-b0f4-dbaf19cf0287">27,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d0f0aac3d548fbaf98b28d241b82e0_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNC01LTEtMS0zNDQxMQ_de7c6182-31c4-4cf2-9286-7ca3f03a4d4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1742801c50374deb91009bf46a82591f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNC03LTEtMS0zNDQxMQ_a0dad8de-ccf4-4138-a540-f14d50f8d10e">47,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities: </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia33efcad84ff4ab29dfe84a9f90b41b3_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNi0xLTEtMS0zNDQxMQ_8b878783-bd2d-4ff8-8ade-ca8392e8b598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife03ea1a6e3647c89acdff544fec694a_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNi0zLTEtMS0zNDQxMQ_7beeb558-f0ae-4aae-924a-4ded23d95b57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d0f0aac3d548fbaf98b28d241b82e0_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNi01LTEtMS0zNDQxMQ_1821cd90-c001-41dc-bcd1-4561eb862961">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1742801c50374deb91009bf46a82591f_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNi03LTEtMS0zNDQxMQ_72ce5ae0-54b7-413e-a445-b687c1b08b63">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia33efcad84ff4ab29dfe84a9f90b41b3_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNy0xLTEtMS0zNDQxMQ_5e8eb970-2d38-4b64-bb5b-bcef04d98ae1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife03ea1a6e3647c89acdff544fec694a_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNy0zLTEtMS0zNDQxMQ_3713cae9-2082-426e-8a94-9417ed912f2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d0f0aac3d548fbaf98b28d241b82e0_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNy01LTEtMS0zNDQxMQ_2eb508bc-3aef-486e-a791-dda7c8e2c7bc">821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1742801c50374deb91009bf46a82591f_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNy03LTEtMS0zNDQxMQ_3345e174-0451-4d5f-89cc-19d7aa45e7ac">821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash equivalents consisted of money market funds invested in U.S. Treasury securities. The money market funds were valued based on reported market pricing for the identical assets, which represents a Level 1 measurement, or by using inputs observable in active markets for similar securities, which represents a Level&#160;2 measurement.</span></div><div style="margin-top:2pt"><span><br/></span></div><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RleHRyZWdpb246NWVhMzc1MzRmOWVjNGFkMGI2MjRkMGQ2ZTRlMjgzMWVfMTc0Ng_3f5658ab-80c6-44f7-a1ca-5567d6148a4d" escape="true"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll-forward of the aggregate fair values financial instruments for which fair values are determined using Level 3 inputs:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:80.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.217%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Embedded Derivative Liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOjZjMzE4NzllZjg2NTQxZjJiYjdkNGFkM2Y0NDlmZjU5L3RhYmxlcmFuZ2U6NmMzMTg3OWVmODY1NDFmMmJiN2Q0YWQzZjQ0OWZmNTlfMS0xLTEtMS0zNDQxMQ_913ce308-66b6-4996-b044-a48e55d30783">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOjZjMzE4NzllZjg2NTQxZjJiYjdkNGFkM2Y0NDlmZjU5L3RhYmxlcmFuZ2U6NmMzMTg3OWVmODY1NDFmMmJiN2Q0YWQzZjQ0OWZmNTlfMi0xLTEtMS0zNDQxMQ_334159fb-3269-4641-a64b-82ac384098db">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOjZjMzE4NzllZjg2NTQxZjJiYjdkNGFkM2Y0NDlmZjU5L3RhYmxlcmFuZ2U6NmMzMTg3OWVmODY1NDFmMmJiN2Q0YWQzZjQ0OWZmNTlfMy0xLTEtMS0zNDQxMQ_3c3b499a-b271-4072-a6d2-3d0cc75617c3">645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><ix:continuation id="i2934930ea35f483c86c367833f0ba5d7" continuedAt="i030af58ccc7142a3a5dab84081422a65"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Embedded Derivative Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i030af58ccc7142a3a5dab84081422a65"> The fair value of the embedded derivative liability recognized in connection with the Company&#8217;s loan agreement with Hercules (Note 7), which is associated with additional fees due to Hercules upon events of default, was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of this embedded derivative liability, which is reported within other non-current liabilities on the condensed consolidated balance sheets, is estimated by the Company at each reporting date based, in part, on the results of third party valuations, which are prepared based on a discounted cash flow model that considers the timing and probability of occurrence of a redemption upon an event of default, the potential amount of prepayment fees or contingent interest upon an event of default and the Company&#8217;s risk-adjusted discount rate of <ix:nonFraction unitRef="usd" contextRef="id3a80995916b45c199871913d2744c21_I20220331" decimals="2" name="us-gaap:DerivativeLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RleHRyZWdpb246NWVhMzc1MzRmOWVjNGFkMGI2MjRkMGQ2ZTRlMjgzMWVfMTczOQ_d585e9c8-3b81-4bce-b2cd-e5c1f268578f">14</ix:nonFraction>%.</ix:continuation> </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RleHRyZWdpb246Yjc5OTcxNTRjYWY0NDJkZWFiM2NhMjMyYTE1Zjg3NmZfMjI5_ff9829fa-99a9-4b0d-9507-fdaf6d92146f" continuedAt="i8de4d36d2ed841c1b6ab97ab64c90adb" escape="true">PROPERTY AND EQUIPMENT, NET</ix:nonNumeric></span></div><ix:continuation id="i8de4d36d2ed841c1b6ab97ab64c90adb"><div style="margin-top:6pt"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RleHRyZWdpb246Yjc5OTcxNTRjYWY0NDJkZWFiM2NhMjMyYTE1Zjg3NmZfMjMw_a9e48487-4610-4830-8f8e-bf1743a6196e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:58.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.635%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639b8d3e3f0d47f8a1670e543de3ddbb_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfMS0xLTEtMS0zNDQxMQ_fdb90482-f075-4fac-a940-df8a5329f674">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c436bc6e3549aaba4b6f5738544b57_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfMS0zLTEtMS0zNDQxMQ_4c71a0b0-4c39-4ef2-ae8d-6f1ce48f3baf">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02cddbe3e2e94249a26572dd230f54ab_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfMi0xLTEtMS0zNDQxMQ_2701e8c8-d39b-4427-a794-e094ef76aa7d">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd20f5ab879a4c7899f8376d38a509b2_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfMi0zLTEtMS0zNDQxMQ_cbbe0110-5a56-475a-86cb-364a2c78074a">1,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06a3031bf214f0badb0fe08c193a7db_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfMy0xLTEtMS0zNDQxMQ_d88dbc95-089b-485d-ba34-8de2457d4dbe">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdfa75b4c35d44a391617d28994286e0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfMy0zLTEtMS0zNDQxMQ_253f9acb-7d09-46ad-868d-cae8cba90904">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc17d505855a43e499fd5dbfc1919a1e_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNC0xLTEtMS0zNDQxMQ_8434e9b1-db37-4d02-8de0-b36605df51d4">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc1bd21f38c467083120b5c7e8f04d0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNC0zLTEtMS0zNDQxMQ_bb1cdcce-06ba-491b-a5cd-ae6df93986b3">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7c501dd906429f8cddfe0fb9905586_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNS0xLTEtMS0zNDQxMQ_c67cdacb-7023-42e8-9b21-4996d13826c9">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab87fe587c64027a76fcc9c708f7361_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNS0zLTEtMS0zNDQxMQ_faa3cd75-dac4-4f1a-9204-1944c8dbbb51">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNi0xLTEtMS0zNDQxMQ_04df10e4-d183-4cb3-a102-1af0f576a021">2,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNi0zLTEtMS0zNDQxMQ_2d765c99-43ca-403e-a2fc-dc7329033219">2,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNy0xLTEtMS0zNDQxMQ_38a94a5a-461e-412b-9bad-78d7b40b3cc5">857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNy0zLTEtMS0zNDQxMQ_7d3e8e20-0cd2-443d-b14d-fab831b9dae7">724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfOC0xLTEtMS0zNDQxMQ_729deec2-8216-4a78-a7a1-7706f7611f80">1,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfOC0zLTEtMS0zNDQxMQ_578dde36-ccdc-45dc-88bc-7308c7dd5c80">1,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RleHRyZWdpb246Yjc5OTcxNTRjYWY0NDJkZWFiM2NhMjMyYTE1Zjg3NmZfMTY5_88861ea7-b88c-4337-82a7-df20757afc72">133</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RleHRyZWdpb246Yjc5OTcxNTRjYWY0NDJkZWFiM2NhMjMyYTE1Zjg3NmZfMTc2_e0a9e02d-dcdd-4866-b1c2-5173da690e81">106</ix:nonFraction> thousand for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="xfor:AccruedExpensesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RleHRyZWdpb246NDg1ZjVkM2U1OWM3NDQ5N2EzMDU0ZDA1YjMwNmE1YzVfNzA_c05abca8-277a-4809-b17b-d68be26af403" continuedAt="i57b4b10daa2246d893d0e2be69e08aad" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span><br/></span></div><div style="margin-top:6pt"><ix:continuation id="i57b4b10daa2246d893d0e2be69e08aad"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RleHRyZWdpb246NDg1ZjVkM2U1OWM3NDQ5N2EzMDU0ZDA1YjMwNmE1YzVfNzE_fc846a82-82dd-4e65-9413-1b512aa51427" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfMS0xLTEtMS0zNDQxMQ_f14cfd32-1602-4e78-b4c8-acfb44de2a5a">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfMS0zLTEtMS0zNDQxMQ_ed08ac24-7bbf-481c-abeb-49161dc15e6c">5,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="xfor:AccruedExternalResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfMi0xLTEtMS0zNDQxMQ_c184af1f-45bd-48d8-981f-e747d418c699">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="xfor:AccruedExternalResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfMi0zLTEtMS0zNDQxMQ_765ef03e-573d-4606-a78b-fd804f902f2f">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfMy0xLTEtMS0zNDQxMQ_28be4989-9c61-4870-840d-6b0468dce9ff">762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfMy0zLTEtMS0zNDQxMQ_fd7f5537-d588-411d-970c-fa3ccad5a0c7">632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfNS0xLTEtMS0zNDQxMQ_d290c3f5-2e31-48d1-894d-1e78130b8765">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfNS0zLTEtMS0zNDQxMQ_171c41c7-d02f-4357-8daa-6966d00e7eff">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfNi0xLTEtMS0zNDQxMQ_c0fea8d7-0517-4102-b7b3-a73d07926c4c">6,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfNi0zLTEtMS0zNDQxMQ_53a37e9f-a2cb-46a1-a9d8-fe80d9005fc1">7,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;LONG-TERM DEBT</span></div><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzkzOQ_c363ee43-486c-489c-8ae4-ef4ee096f7b4" continuedAt="i82e7b9eac60f43df96cdce2f8fdb07b8" escape="true"><div style="margin-top:6pt"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzk0MA_9e9b15db-6072-4d0f-b66b-9fa2cb855ffa" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:58.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.635%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfMS0xLTEtMS0zNDQxMQ_1ae5d688-1852-4885-956e-3a664c896f79">32,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfMS0zLTEtMS0zNDQxMQ_94b5e359-e7b4-4a41-9c21-3d983f8c935e">32,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfMi0xLTEtMS0zNDQxMQ_3dfc7633-4ef1-42c4-9b56-77355c47c005">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfMi0zLTEtMS0zNDQxMQ_b446d568-be1f-4236-954b-d2fb4101fc97">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative accretion of end of term payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" sign="-" name="xfor:AccretionOnLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfMy0xLTEtMS0zNDQxMQ_991e68a3-9b2e-493e-a1be-f85a8e8257ab">597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" sign="-" name="xfor:AccretionOnLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfMy0zLTEtMS0zNDQxMQ_e5fe6f0c-1cc0-441d-9375-2c765e8cd1f2">1,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="xfor:LongTermDebtIncludingAccretion" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfNC0xLTEtMS0zNDQxMQ_24607adc-db8a-49f8-a2c8-4ae69c48334a">33,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="xfor:LongTermDebtIncludingAccretion" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfNC0zLTEtMS0zNDQxMQ_da3065a1-50a7-43fc-be16-1f7981a6cb74">33,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfNS0xLTEtMS0zNDQxMQ_e5c468fd-baae-439e-b959-966058fe7124">3,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfNS0zLTEtMS0zNDQxMQ_0e541a4a-8946-4b7c-819c-a24883ac1fc9">795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfNi0xLTEtMS0zNDQxMQ_bde32bc1-f520-4708-8949-a9f1108a1929">29,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfNi0zLTEtMS0zNDQxMQ_3c14e864-7369-4ac0-a08d-1509f49b027e">33,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hercules Loan Agreement, As Amended</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into a Loan and Security Agreement (the &#8220;Hercules Loan Agreement&#8221;), as amended in December 2018, June 2019, March 2020, December 2020 and February 2022, with Hercules, under which the Company has borrowed an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i1dc0bdf32a5146e0adcea6db6de6615d_D20181001-20210331" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzQ2_3cb50d87-966e-45bc-bed7-1a3f42a020c9">32.5</ix:nonFraction> million of term loans to date. The Hercules Loan Agreement provides for maximum borrowings of up to $<ix:nonFraction unitRef="usd" contextRef="i37a902dab0bd4e4f9e87b18693f5f331_I20220331" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfNDQx_19c4d6b4-5bba-4942-be9c-318c4bd722e5">50.0</ix:nonFraction>&#160;million, which include, subject to Hercules investment committee&#8217;s sole discretion, a right of the Company to request that Hercules make additional term loan advances in an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="i37a902dab0bd4e4f9e87b18693f5f331_I20220331" decimals="-5" name="xfor:LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfODY0_710e6d71-b099-413a-aa81-be19a94ca10c">17.5</ix:nonFraction> million through December 31, 2022.  Borrowings under the Hercules Loan Agreement accrues interest at a variable rate equal to the greater of (i)&#160;<ix:nonFraction unitRef="number" contextRef="ic37a10f994534a07ba477a27d2a2bf64_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTAwNA_befed8c8-5618-4e01-a9b1-550d9de6e007">8.75</ix:nonFraction>% or (ii)&#160;<ix:nonFraction unitRef="number" contextRef="ic37a10f994534a07ba477a27d2a2bf64_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTAxNQ_befed8c8-5618-4e01-a9b1-550d9de6e007">8.75</ix:nonFraction>% plus </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;prime rate minus <ix:nonFraction unitRef="number" contextRef="ic4206af27e2d487f9f31e058fa7b8c0a_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTA2NA_cd6beb81-8c17-4ce9-b317-c96198832344">6.0</ix:nonFraction>%.&#160;In an event of default and until such event is no longer continuing, the interest rate applicable to borrowings would be increased by <ix:nonFraction unitRef="number" contextRef="ic37a10f994534a07ba477a27d2a2bf64_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTIwMg_4102c088-77ba-457c-8a2b-4584319d24aa">4.0</ix:nonFraction>%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Hercules Loan Agreement are repayable in monthly interest-only payments through January 1, 2023, and in equal monthly payments of principal and accrued interest from February 1, 2023 until the maturity date of the loan, which is July 1, 2024. The Company may prepay all, but not less than all, of the outstanding borrowings, subject to a prepayment premium of up to <ix:nonFraction unitRef="number" contextRef="icce6cbe45cc4447fbfe3ebb0b1f74930_I20220331" decimals="INF" name="xfor:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTU5OQ_911034df-7b24-48e3-82a8-c9c2a7c51417">1.0</ix:nonFraction>% of the principal amount outstanding as of the date of repayment. In addition, the Hercules Loan Agreement provides for payments of $<ix:nonFraction unitRef="usd" contextRef="i55063b32fb884c81895bd748e6ed4f41_D20220701-20220701" decimals="-5" name="us-gaap:LineOfCreditFacilityPeriodicPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTc5OA_ebe54f4f-d160-48db-9d95-74e0c2ad0ce5">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i26533fb9b8ff4cf98e7fe29b5121aa6d_D20240701-20240701" decimals="-5" name="us-gaap:LineOfCreditFacilityPeriodicPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTgwNg_0ee43ef6-8cf2-42dd-bae5-b7268ac6bd44">0.8</ix:nonFraction> million payable on July 1, 2023 and July 1, 2024, respectively, which payments are accelerated upon the prepayment of the borrowings upon the Company&#8217;s election on upon default of the loan. Borrowings under the Hercules Loan Agreement are collateralized by substantially all of the Company&#8217;s personal property and other assets except for their intellectual property (but including rights to payment and proceeds from the sale, licensing or disposition of the intellectual property). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, on February 9, 2022, the Company entered into Amendment No. 3 the Hercules Loan Agreement. The amendment primarily added a financial milestone that if met by June 30, 2022 would modify the minimum cash covenant contained in the Hercules Loan Agreement, which is effective beginning September 1, 2022, as further described below. The Company concluded that the amendment represented a modification to the debt.  Accordingly, fees paid to third parties directly related to the amended debt were expensed as incurred and fees paid to Hercules in conjunction with the amendment were deferred and will be amortized to interest expense over the life of the debt arrangement using the effective interest method.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i82e7b9eac60f43df96cdce2f8fdb07b8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Hercules Loan Agreement, effective as of the earlier of (a) certain specified events impacting the Company&#8217;s Phase III trial of mavorixafor for the treatment of WHIM syndrome and (b) September 1, 2022, the Company at all times thereafter must maintain cash in an account or accounts in which Hercules has a first priority security interest, in an aggregate amount greater than or equal to the greater of (i) $<ix:nonFraction unitRef="usd" contextRef="ic45fa2c1cc904680a9c790308256e60f_I20220331" decimals="-3" name="xfor:LineOfCreditCovenantMinimumCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMjgzMA_a3ca95fb-5947-42a9-be82-fea93c5b5b1b">30.0</ix:nonFraction> million or (ii) 6 multiplied by a metric based on prior months&#8217; cash expenditures;  provided, however, that from and after the Company&#8217;s achievement of certain financing milestones through June 30, 2022, the Company must maintain cash in an account or accounts in which Hercules has a first priority security interest in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="ic45fa2c1cc904680a9c790308256e60f_I20220331" decimals="-3" name="xfor:LineOfCreditCovenantMinimumCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTA5OTUxMTYzMjY3NQ_a3ca95fb-5947-42a9-be82-fea93c5b5b1b">30.0</ix:nonFraction> million. Following the achievement of certain operational performance milestones, the required level shall be reduced to the greater of $<ix:nonFraction unitRef="usd" contextRef="ia692d84b888a4845bbc1ea6a9ee0dfbd_I20220331" decimals="-3" name="xfor:LineOfCreditCovenantMinimumCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzA2Nw_45976f3a-f835-435a-a8bc-e614243aaa3f">20.0</ix:nonFraction>&#160;million, or, if the Company had not met the financing milestones noted above, 3 multiplied by the current cash expenditures metric; and provided further, that subject to the achievement of certain milestones, this covenant will be extinguished. The Hercules Loan Agreement also restricts the Company&#8217;s ability to incur additional indebtedness, pay dividends, encumber its intellectual property, or engage in certain fundamental business transactions, such as mergers or acquisitions of other businesses, with certain exceptions. </span></div><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzk0MQ_7d081c20-6c75-4b39-b22e-e3b446527a1a" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized interest expense under the Hercules Loan Agreement as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months ended March  31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37a10f994534a07ba477a27d2a2bf64_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOmY2ZjkyZWI4MzVhMDRmYzQ4ZWRjYWVkMDExZjgyYTFjL3RhYmxlcmFuZ2U6ZjZmOTJlYjgzNWEwNGZjNDhlZGNhZWQwMTFmODJhMWNfMi0xLTEtMS0zNDQxMQ_aaea7b4d-d503-4f5e-8911-dd9d420fcfb8">909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e48af44af640d5b517c67d3ad4d1f0_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOmY2ZjkyZWI4MzVhMDRmYzQ4ZWRjYWVkMDExZjgyYTFjL3RhYmxlcmFuZ2U6ZjZmOTJlYjgzNWEwNGZjNDhlZGNhZWQwMTFmODJhMWNfMi0zLTEtMS0zNDQxMQ_fb03928f-40c7-4596-b020-1993bd449214">890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37a10f994534a07ba477a27d2a2bf64_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOmY2ZjkyZWI4MzVhMDRmYzQ4ZWRjYWVkMDExZjgyYTFjL3RhYmxlcmFuZ2U6ZjZmOTJlYjgzNWEwNGZjNDhlZGNhZWQwMTFmODJhMWNfMy0xLTEtMS0zNDQxMQ_8e282f00-2e1d-459b-8123-affa19f9096d">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e48af44af640d5b517c67d3ad4d1f0_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOmY2ZjkyZWI4MzVhMDRmYzQ4ZWRjYWVkMDExZjgyYTFjL3RhYmxlcmFuZ2U6ZjZmOTJlYjgzNWEwNGZjNDhlZGNhZWQwMTFmODJhMWNfMy0zLTEtMS0zNDQxMQ_60d5d400-1a63-4619-929c-a41cd57e91ac">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual effective interest rate of the Hercules Loan Agreement as of March 31, 2022 is <ix:nonFraction unitRef="number" contextRef="i37a902dab0bd4e4f9e87b18693f5f331_I20220331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzcxMw_0959810a-1013-4224-97b6-7f37ed3abb3f">10.7</ix:nonFraction>%. There were <ix:nonFraction unitRef="usd" contextRef="ic37a10f994534a07ba477a27d2a2bf64_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzcyOA_a85a5af8-2641-4065-b5f7-63fe1d24d9f2">no</ix:nonFraction> principal payments due or paid under the Hercules Loan Agreement during the three months ended March&#160;31, 2022. An end-of-term payment of $<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTA5OTUxMTYzMzExNg_ad7b76f6-46f1-4e08-85ed-4f864f46cb6b">0.8</ix:nonFraction> million was paid during the three months ended March 31, 2022 in accordance with the Hercules Loan Agreement. </span></div><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzkzNg_f911e494-b53a-4f28-b15b-41b061fe440e" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future principal and end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands): </span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:83.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjEwNzA1ZDJhZDIzZTQwYjk5NDllMmRkZTI0YWJhOThlL3RhYmxlcmFuZ2U6MTA3MDVkMmFkMjNlNDBiOTk0OWUyZGRlMjRhYmE5OGVfMS0xLTEtMS0zNDQxMQ_e1394ae8-69fa-4843-a092-71baba37700d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjEwNzA1ZDJhZDIzZTQwYjk5NDllMmRkZTI0YWJhOThlL3RhYmxlcmFuZ2U6MTA3MDVkMmFkMjNlNDBiOTk0OWUyZGRlMjRhYmE5OGVfMy0xLTEtMS0zNDQxMQ_d59d8c85-8342-45e5-9555-5c63324190a9">19,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjEwNzA1ZDJhZDIzZTQwYjk5NDllMmRkZTI0YWJhOThlL3RhYmxlcmFuZ2U6MTA3MDVkMmFkMjNlNDBiOTk0OWUyZGRlMjRhYmE5OGVfNC0xLTEtMS0zNDQxMQ_472aedec-b792-4c40-bac1-cf8ecfc667de">13,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="xfor:LongTermDebtAndEOTPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjEwNzA1ZDJhZDIzZTQwYjk5NDllMmRkZTI0YWJhOThlL3RhYmxlcmFuZ2U6MTA3MDVkMmFkMjNlNDBiOTk0OWUyZGRlMjRhYmE5OGVfNi0xLTEtMS0zNDQxMQ_3a6860e9-d6a1-4c37-bdaf-f79fd2ae41af">33,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:18pt"><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_58"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMzI5MQ_592de9fa-d5a7-480b-84af-75fa1edaa720" continuedAt="i297afe1521354c6194e9fa14b9d3e749" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i297afe1521354c6194e9fa14b9d3e749" continuedAt="i713aefc7dba5469792e07c035a101eaf"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements for its facilities in Boston, Massachusetts, which is the Company&#8217;s principal executive office; Vienna, Austria, which is the Company&#8217;s research and development center; and Waltham, Massachusetts, which the Company has sublet to a third party. There are no restrictions or financial covenants associated with any of the lease agreements. </span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Vienna Austria Leases&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for approximately <ix:nonFraction unitRef="sqm" contextRef="icc53f4cff48d40168111b64915f524d7_D20220101-20220331" decimals="0" name="xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfNzg3_2c0bacf2-0b5f-42e2-84fc-b8fd43fb14a4">1,200</ix:nonFraction> square meters of laboratory and office space in Vienna, Austria (&#8220;Vienna Lease&#8221;), which commenced in February 2021 for a term of <ix:nonNumeric contextRef="i38936b88ef624fe69a0b0bfe09334734_I20220331" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfOTcz_8a3ef474-3156-457c-b10c-d48653dc2f78">7</ix:nonNumeric> years. The annual base rent for the Vienna Lease is approximately $<ix:nonFraction unitRef="usd" contextRef="i38936b88ef624fe69a0b0bfe09334734_I20220331" decimals="-3" name="xfor:LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMTMzMQ_32fa8b5b-6f58-45cb-8262-0d49637534e5">300</ix:nonFraction> thousand.</span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Boston Lease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i9f343631aa5f432096c5e6330be2f6e1_D20191111-20191111" decimals="0" name="xfor:CurrentOfficeSpaceUnderLeaseAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMTM4Mg_0c9f6e74-829f-4096-a761-216054ad95df">28,000</ix:nonFraction> square feet of office space in Boston, Massachusetts (&#8220;Boston Lease&#8221;), which serves as the Company&#8217;s headquarters. Base rental payments are approximately $<ix:nonFraction unitRef="usd" contextRef="i9f343631aa5f432096c5e6330be2f6e1_D20191111-20191111" decimals="-3" name="xfor:LesseeOperatingLeaseLeaseNotYetCommencedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMTUzOQ_eb5d9943-994a-4ee0-ab19-57e289849715">1.0</ix:nonFraction> million annually, plus certain operating expenses. The term of the Boston Lease will continue until November 2026, unless earlier terminated. The Company has the right to sublease the premises, subject to landlord consent and also has the right to renew the Boston Lease for an additional <ix:nonNumeric contextRef="i1fdd127e11e14968982b457103d38af9_I20191111" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMTgyMw_b7b64e5e-ead7-4548-814a-f4ec8b6ac6a6">five years</ix:nonNumeric> at the then prevailing effective market rental rate. The </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i713aefc7dba5469792e07c035a101eaf"><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company is required to maintain a security deposit in the form of a letter of credit for $0.9&#160;million for the benefit of the landlord. </span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Waltham Lease&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i829185b9e0084c7584f58e45342583f9_D20220101-20220331" decimals="0" name="xfor:CurrentOfficeSpaceUnderLeaseAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMjA1OA_c5d60f1e-ead1-46c6-827a-6a8738cba1ad">6,000</ix:nonFraction> square feet of office space in Waltham, Massachusetts (&#8220;Waltham Lease&#8221;). The Waltham Lease, as amended, commenced on January&#160;1, 2019, and expires approximately <ix:nonNumeric contextRef="i829185b9e0084c7584f58e45342583f9_D20220101-20220331" name="xfor:OperatingLeaseExpiration" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMjIwOA_5e1f5126-dc21-4570-baef-74d26178a41e">five years</ix:nonNumeric> from the commencement date. The base rent is approximately $<ix:nonFraction unitRef="usd" contextRef="i829185b9e0084c7584f58e45342583f9_D20220101-20220331" decimals="-3" name="xfor:AggregateBaseRent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMjI3MA_58f35eea-cce9-4505-8ec5-c14ae7aca86a">0.3</ix:nonFraction> million annually. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#8217; right-of-use assets or lease liabilities. The Company is subleasing the space to a third party for the duration of the lease. The right-of-use asset is being amortized to rent expense over the <ix:nonNumeric contextRef="ie3e0d04f60ed4d21934cf225abe43d0a_I20220331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMzI5Mg_e52a48ca-777a-4a94-87b6-82d83ac0fa08">five-year</ix:nonNumeric> term of the lease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the Company&#8217;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMzI5Mw_3b785cb7-1284-455e-8ce8-729ad220b6c5" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three months ended March&#160;31, 2022 and 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:67.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March  31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfMi0xLTEtMS0zNDQxMQ_69437ee5-f398-4c38-8b4e-c7e800104d26">530</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfMi0zLTEtMS0zNDQxMQ_330dfb95-76d0-4e08-b090-b8fc7ad9b961">476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfMy0xLTEtMS0zNDQxMQ_0857435c-4d5f-4adb-9386-a4fc8fec93a2">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfMy0zLTEtMS0zNDQxMQ_25ea0679-fcd5-4319-a058-633e933f8964">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfNC0xLTEtMS0zNDQxMQ_74073172-6efa-4ed9-8830-87bfdadc0182">530</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfNC0zLTEtMS0zNDQxMQ_5e537367-3b4b-4f3b-ac2c-6378cbf6113d">518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use asset obtained in exchange for operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfNi0xLTEtMS0zNDQxMQ_35cee4d9-d033-447e-a709-4192e6f76de0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfNi0zLTEtMS0zNDQxMQ_8e8e50f8-3537-4a3e-8db1-e8f11e95ea7a">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfNy0xLTEtMS0zNDQxMQ_c0d36dc7-ca0e-4161-986d-d6784c453c6e">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfNy0zLTEtMS0zNDQxMQ_23d15dbc-3143-45ca-b9ca-3b9ea210e942">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublease income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfOC0xLTEtMS0zNDQxMQ_b70b7f16-4e86-45bd-b62b-d1571c232b24">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfOC0zLTEtMS0zNDQxMQ_2118d1ca-0cef-4880-8fb0-fa117b8fc346">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfOS0xLTEtMS0zNDQxMQ_7cdc0ba7-cd1c-4c92-b63f-c7fa36034aca">4.7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfMTAtMS0xLTEtMzQ0MTE_643a7994-2471-40fd-9641-3889204e2d5b">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMzI4OQ_7c23b1f0-919f-472c-aebe-087673bbd29b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities due under lease agreements that have commenced as of March&#160;31, 2022 are as follows (in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:78.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfMS0xLTEtMS0zNDQxMQ_b9c9e82e-217a-4f2d-aa69-ed9502e89c45">1,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfMi0xLTEtMS0zNDQxMQ_89f3ef10-5274-4724-a181-238759339fa7">1,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfMy0xLTEtMS0zNDQxMQ_1828069c-4cd7-42b1-9b68-72d065a8bf08">1,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfNC0xLTEtMS0zNDQxMQ_c563740f-566b-4d02-9d68-b9600cd0ccf3">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfNS0xLTEtMS0zNDQxMQ_39ab8e0d-51b4-4ff7-bbaf-519ae84f3614">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfNi0xLTEtMS0zNDQxMQ_9dc3c725-41d3-4c4f-9ad0-64439aeee956">363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfNy0xLTEtMS0zNDQxMQ_95a3d030-50fc-4022-be9a-0aa9ce054429">7,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfOC0xLTEtMS0zNDQxMQ_ef8f09d0-486d-4caf-bfef-e70aec1b8e53">1,699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfOS0xLTEtMS0zNDQxMQ_7f003983-aea8-4dcb-b065-4a4ac17945b5">5,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_61"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82MS9mcmFnOmYzMTljODQyZWU1ZTQzOTY4NGUyN2RkYWQ5MWQ2M2E0L3RleHRyZWdpb246ZjMxOWM4NDJlZTVlNDM5Njg0ZTI3ZGRhZDkxZDYzYTRfMjI5OA_e1dd285a-f73f-4458-85b9-cab8b4286351" continuedAt="i415674ae9de04f8fb05e501b21fe4594" escape="true">COMMITMENTS AND CONTINGENCIES </ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i415674ae9de04f8fb05e501b21fe4594" continuedAt="ie051404087f04c2aad3a8bdc6b69eae4">The Company has agreements with Contract Research Organizations (&#8220;CROs&#8221;) pursuant to which the Company and the CROs are conducting clinical trials of mavorixafor&#160;for the treatment of WHIM syndrome, Waldenstr&#246;m&#8217;s and SCN and chronic </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ie051404087f04c2aad3a8bdc6b69eae4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">neutropenia disorders. The Company may terminate these agreements by providing notice pursuant to the contractual provisions of such agreements and would incur early termination fees. The Company also has agreements with contract manufacturing organizations (&#8220;CMOs&#8221;) for the production of mavorixafor for use in clinical trials.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company to, among other things, indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not currently aware of any indemnification claims and has <ix:nonFraction unitRef="usd" contextRef="i975809049d0a45c497bb1ac01a475dac_I20220331" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82MS9mcmFnOmYzMTljODQyZWU1ZTQzOTY4NGUyN2RkYWQ5MWQ2M2E0L3RleHRyZWdpb246ZjMxOWM4NDJlZTVlNDM5Njg0ZTI3ZGRhZDkxZDYzYTRfMTYxNg_465ec98c-b2ab-4735-8723-697f44056949"><ix:nonFraction unitRef="usd" contextRef="i65cb0a8a766640df9a3c2d91519beec5_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82MS9mcmFnOmYzMTljODQyZWU1ZTQzOTY4NGUyN2RkYWQ5MWQ2M2E0L3RleHRyZWdpb246ZjMxOWM4NDJlZTVlNDM5Njg0ZTI3ZGRhZDkxZDYzYTRfMTYxNg_fa10300b-24b8-4da3-aff6-b00c7b0ddd2a">no</ix:nonFraction></ix:nonFraction>t accrued any liabilities related to such obligations in its condensed consolidated financial statements as of March&#160;31, 2022 or December&#160;31, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to any legal proceedings.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_64"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMjgxMg_bed4c37e-28a5-446d-9201-4784c03bd729" continuedAt="i42c7d387e78749788e2a86b1af4dee9d" escape="true">COMMON STOCK AND COMMON STOCK WARRANTS</ix:nonNumeric></span></div><ix:continuation id="i42c7d387e78749788e2a86b1af4dee9d" continuedAt="i9e1ed2de1d9b4f53a2ab090b15f06d61"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December 31, 2021, the Company&#8217;s Restated Certificate of Incorporation authorized the Company to issue <ix:nonFraction unitRef="shares" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0ODc2Nw_fc4131bd-c941-4569-8a17-5a101e4026dd">125,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0ODgwNQ_823550c1-247b-4a03-a96c-deb6ad0ade91"><ix:nonFraction unitRef="usdPerShare" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0ODgwNQ_87093510-f55e-4f70-a05a-598cc2292937">0.001</ix:nonFraction></ix:nonFraction> per share. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of the holders of any preferred stock that may be issued. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. <ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="INF" name="us-gaap:DividendsCommonStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0OTE0Nw_65009448-d33c-4bd3-8cf1-55f4a3198ba4">No</ix:nonFraction> cash dividends have been declared or paid to date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2022, the Company entered into a securities purchase agreement pursuant to which it agreed to issue and sell to an investor (the &#8220;Investor&#8221;), in a private placement (the &#8220;Q1 2022 Private Placement&#8221;), <ix:nonFraction unitRef="shares" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0ODYzMw_807a74a0-7f08-4d1f-86e0-40bb7bde5261">900,000</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9987285e8b814bf3a75efbc5d0f415b7_I20210323" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0OTg0Mg_5a18b738-b1dd-4d4e-b435-798ec977e93e">1.80</ix:nonFraction> per share, which represents the volume weighted average price per share of the Company&#8217;s common stock as quoted on the Nasdaq Stock Market for the thirty (30) consecutive-day trading day period ending on March 2, 2022, and pre-funded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0ODY0NA_75cfe9f6-756d-4dfa-969e-f1f7884e0be9">766,666</ix:nonFraction> shares of common stock at a purchase price of $1.79 per pre-funded warrant (representing the price of  $<ix:nonFraction unitRef="usdPerShare" contextRef="i9987285e8b814bf3a75efbc5d0f415b7_I20210323" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0OTIzMg_5a18b738-b1dd-4d4e-b435-798ec977e93e">1.80</ix:nonFraction> per share minus the $<ix:nonFraction unitRef="usdPerShare" contextRef="i9987285e8b814bf3a75efbc5d0f415b7_I20210323" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0OTI0MQ_d0ea78dd-6af7-4e13-a5e2-508e855118e8">0.01</ix:nonFraction> per share exercise price of each such prefunded warrant). The pre-funded warrants are exercisable at any time after their original issuance date and will have no expiration date. The Q1 2022 Private Placement closed on March 7, 2022 and the Company received gross proceeds of <ix:nonFraction unitRef="usd" contextRef="i5fd283910b0c46c7b76b73ec9c937efa_D20210323-20210323" decimals="-5" name="xfor:ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0OTI1Ng_fb458331-8599-4b62-a250-aa20d040f076">3.0</ix:nonFraction> million, before deducting offering expenses payable by the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on March 3, 2022, the Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Investor, pursuant to which the Company agreed to register for resale the shares of common stock purchased by the Investor and the shares of common stock underlying the pre-funded warrants held by the Investor (the &#8220;Registrable Securities&#8221;). Pursuant to the Registration Rights Agreement, the Company filed a registration statement covering the resale of the Registrable Securities on April 22, 2022.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its issuance of common stock in a public offering that closed on November 29, 2019, the Company issued <ix:nonFraction unitRef="shares" contextRef="i7640c5cc7cdf4a798762f93ad58a800d_D20191129-20191129" decimals="INF" name="xfor:ClassOfWarrantOrRightIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMjUw_32218f9b-32ae-49fd-a220-238667d053c9">5,416,667</ix:nonFraction> Class B warrants, which are exercisable for shares of the Company&#8217;s common stock or pre-funded warrants to purchase shares of the Company's common stock. The Class B warrants were immediately exercisable upon issuance, had an initial exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i33b0d388662f46dc8e3e78c78b30a392_I20191129" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfNjI1_8c10a180-cfa8-4649-91d2-5d38578b0892">15.00</ix:nonFraction> per share and expire on a date that is the earlier of (a) the date that is <ix:nonNumeric contextRef="i1c1e0a3da76d47a8892dbba813618c07_D20191126-20191126" name="xfor:ClassOfWarrantOrRightWarrantsExpirationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfNzAz_4967130d-d639-4028-9f97-b0e1f40c95a9">30</ix:nonNumeric> calendar days from the date on which the Company issues a press release announcing top-line data from its Phase 3 clinical trial of mavorixafor for the treatment of patients with WHIM syndrome (or, if such date is not a business day, the next business day) and (b) November 28, 2024. The Class B warrants have a contingent price adjustment feature pursuant to which the exercise price of the Class B warrants is adjusted to the lowest weighted average offering price at which the Company sells its common stock or certain securities convertible into or exercisable for the Company's common stock in one or more subsequent offerings, if the weighted </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i9e1ed2de1d9b4f53a2ab090b15f06d61"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">average offering price for such offering is below $<ix:nonFraction unitRef="usdPerShare" contextRef="i33b0d388662f46dc8e3e78c78b30a392_I20191129" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTQwNQ_8c10a180-cfa8-4649-91d2-5d38578b0892">15.00</ix:nonFraction>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2022, the exercise price of the Class B warrants was adjusted to $<ix:nonFraction unitRef="usdPerShare" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="2" name="xfor:ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0ODAzMA_e97ba1ca-d668-4627-a841-9179fcc34123">1.80</ix:nonFraction> as a result of the Q1 2022 Private Placement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with previous equity offerings, the Company has issued pre-funded warrants, which are exercisable into <ix:nonFraction unitRef="shares" contextRef="ib952420c74dc41d0b56c0d7c1ae747af_I20190416" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTk0Ng_fdd4a06b-d0ae-4a78-9919-c2e0120a9f32">one</ix:nonFraction> share of the Company's common stock, are immediately exercisable upon issuance, and for which the remaining exercise price  is equal to or less than $<ix:nonFraction unitRef="usdPerShare" contextRef="i9987285e8b814bf3a75efbc5d0f415b7_I20210323" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMjE5Mg_d0ea78dd-6af7-4e13-a5e2-508e855118e8">0.01</ix:nonFraction> per share.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMjgwOQ_07c04780-bf75-4dab-bc3f-7c7877220bc1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a roll forward of outstanding warrants for the three month period ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Contractual Term (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable warrants to purchase common shares as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfMS0yLTEtMS0zNDQxMQ_92fee893-6fef-4b83-b4b3-f56b35d9a577">13,257,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="2" name="xfor:ClassOfWarrantOrRightWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfMS00LTEtMS0zNDQxMQ_203a4a66-c849-4082-a6f8-7481f4d378fd">7.96</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idcbf7212a2a648e0bdba60353fb0018f_D20210101-20211231" name="xfor:ClassOfWarrantOrRightWeightedAverageContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfMS02LTEtMS0zNDQxMQ_37a34a82-9b3c-44ae-a578-952193e4700c">2.72</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="INF" name="xfor:ClassOfWarrantOrRightIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfMi0yLTEtMS0zNDQxMQ_1d10e30d-a1fc-4c6a-85e2-4cdec0bb7935">766,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="2" name="xfor:ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfMi00LTEtMS0zNTE3OQ_f2fd10f4-1b1e-4087-8069-07f5701f9e98">1.80</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="INF" name="xfor:ClassOfWarrantOrRightExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfMy0yLTEtMS0zNDQxMQ_6f990a28-0e3d-4bee-b27f-1d21c96f0851">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable warrants to purchase common shares as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfNS0yLTEtMS0zNDQxMQ_1c1da325-dcd2-4f10-b0e9-474b1c65e6fc">14,023,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="2" name="xfor:ClassOfWarrantOrRightWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfNS00LTEtMS0zNDQxMQ_4a590a24-a460-469c-a119-163bda7c2bc7">6.91</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="xfor:ClassOfWarrantOrRightWeightedAverageContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfNS02LTEtMS0zNDQxMQ_4e1027af-c6de-4036-ab33-fefc32764eba">2.47</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company&#8217;s outstanding warrants to purchase shares of common stock consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares of<br/>Common<br/>Stock Issuable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 25, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if11478b9d8ef48469399603eb4700067_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMS0yLTEtMS0zNDQxMQ_a343b8d1-aa7f-4787-af2c-a4e1caf29b0b">5,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i53cd7e343ca1417fabb4bb23d6a34e59_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMS00LTEtMS0zNDQxMQ_0376e1e0-0d17-4ae5-801c-2db0b3c9b6c5">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 24, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 28, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i374920f0a8c246a18acce80fd3f3f518_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMi0yLTEtMS0zNDQxMQ_7da159b4-ab39-440c-a123-91c437cdf693">115,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3719e7acfe4d42d793a973477e301657_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMi00LTEtMS0zNDQxMQ_5cb80e1c-7cde-42e5-95cd-5ae55960a5c3">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 28, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 12, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2a6dbe35ef24ffeb2d308772056da96_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMy0yLTEtMS0zNDQxMQ_03c1430f-5987-433d-a587-915e329eef4f">20,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if852079aba5d4e9ba7bdcc9ca39a389a_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMy00LTEtMS0zNDQxMQ_ecb2983f-4d85-46bd-a25c-218edccccbd9">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 12, 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 19, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82c001a5dabd46658a607c7940a5a634_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNC0yLTEtMS0zNDQxMQ_aff02ce6-65d6-4acc-b121-1d8b22f79aca">20,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7762054b7322478e9a88838854405b2f_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNC00LTEtMS0zNDQxMQ_4572866a-0783-4fd8-be97-3851e285c007">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 19, 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 13, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if43e448bd5894bd2863d446143e0ff04_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNS0yLTEtMS0zNDQxMQ_6164d91e-c17b-4925-a291-7bb6964f6be0">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3270dde03c414860922ae7af87624181_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNS00LTEtMS0zNDQxMQ_f80934d1-170f-46fd-a0ee-cde75e95a45c">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 12, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 16, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1993d79bf6244d0b392f8df783ee312_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNi0yLTEtMS0zNDQxMQ_c86d160c-f3a2-43fc-8826-c8478cd6073e">3,866,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4d8975a741104b5296f718b358811082_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNi00LTEtMS0zNDQxMQ_b36feded-b389-46c4-9f07-25c7dd7f13c0">13.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 15, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1674d766cfaa4621a97b51e4f672d1aa_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNy0yLTEtMS0zNDQxMQ_136a33f5-53a9-45bd-b061-13d99e138407">5,416,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfbe308a558a41579f92a9d56f820980_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNy00LTEtMS0zNDQxMQ_848b10af-3f21-48ca-a36d-3533ba7d17aa">1.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 28, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16d2edf8cc33443ea0ffbd013f4b66e0_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfOC0yLTEtMS0zNDQxMQ_91a6e832-0abc-4733-9df0-4b761431cc6f">1,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i85b541bd25654094be49307558799aae_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfOC00LTEtMS0zNDQxMQ_1d5db741-6875-4b14-84c7-16cca46086f5">12.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 23, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b51e9aec2ca4554a1cb58776b67a06a_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfOS0yLTEtMS0zNDQxMQ_fb4398e4-2681-442d-96e6-aa901dbccee6">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12273bd7f6f844c29aa5394dbc198547_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfOS00LTEtMS0zNDQxMQ_e5008ed7-daec-4709-a8e4-df15b451330c">8.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 9, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31185213cb1d401ab6f9bfaf3eca7163_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMTAtMi0xLTEtMzUwOTQ_bce31ee4-fa5e-4e98-bb3a-6512e9f4c36b">2,008,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i31185213cb1d401ab6f9bfaf3eca7163_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMTAtNC0xLTEtMzUwOTQ_b9435e91-4d3c-4af3-a923-979b0869a13b">4.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaadf734ea7f34c549783db6da7a96a56_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMTEtMi0xLTEtMzUwOTQ_17538243-2bb6-4d73-ad36-628d96912ec3">766,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaadf734ea7f34c549783db6da7a96a56_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMTEtNC0xLTEtMzUwOTQ_dd22b6b0-0ac5-45c2-a6b6-a6779c761e8c">1.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMTAtMi0xLTEtMzQ0MTE_736116c0-0721-4b0e-8692-8e50e4deffec">14,023,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) In November 2019, the Company received $<ix:nonFraction unitRef="usdPerShare" contextRef="i74b9f718ca0e4c5d9b871296a1e02de1_I20191129" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjE3Mw_42bbc9d4-ca9f-4f04-a747-d2c892766f13">11.999</ix:nonFraction> per pre-funded warrant, or $<ix:nonFraction unitRef="usd" contextRef="i0c46977bdcd44c5fbb626a2c7adad70d_I20191129" decimals="-5" name="xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjE3Nw_a9be15c0-03fe-4df2-97c2-f61e7a8e688a">21.0</ix:nonFraction> million in aggregate proceeds. Each pre-funded</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">warrant may be exercised for an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="i0c46977bdcd44c5fbb626a2c7adad70d_I20191129" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjIyMw_737ce72f-7aa8-47f5-a8d7-460fad71da07">0.001</ix:nonFraction> per pre-funded warrant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) In March 2021, the Company received $<ix:nonFraction unitRef="usdPerShare" contextRef="i7a34589fe1b04db8902c62e32428ecf2_I20210323" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjIzMg_09855051-43ed-4729-98d4-7618b54a043a">8.69</ix:nonFraction> per pre-funded warrant, or $<ix:nonFraction unitRef="usd" contextRef="i9987285e8b814bf3a75efbc5d0f415b7_I20210323" decimals="-3" name="xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMjY5NA_c0febe68-a2d3-46d8-b493-a3395535a976">435</ix:nonFraction> thousand in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="i9987285e8b814bf3a75efbc5d0f415b7_I20210323" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMjc3OQ_d0ea78dd-6af7-4e13-a5e2-508e855118e8">0.01</ix:nonFraction> per pre-funded warrant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) In November 2021, the Company received $<ix:nonFraction unitRef="usdPerShare" contextRef="i055ed4cd017b4077b80b39c7e53429d5_I20211109" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjE5MA_11b82ab2-43a8-445d-8224-7409280db330">4.97</ix:nonFraction> per pre-funded warrant, or $<ix:nonFraction unitRef="usd" contextRef="ie946fb34148e40778aa24e30c0fb5174_I20211109" decimals="-3" name="xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjIwNw_35db27d2-505e-455f-bd74-7e6d52310398">10.0</ix:nonFraction>&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="i96523b616e2c4aaaa42b757f1dead895_I20201102" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjIxOA_1be798ca-b0aa-43c7-953c-9dc821c1147f">0.01</ix:nonFraction> per pre-funded warrant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) In March 2022, the Company received $<ix:nonFraction unitRef="usdPerShare" contextRef="idb651aa4d13d4e91881e98c2a66705b2_I20220303" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjI0Mg_8acd6475-9dc5-42b0-bf19-aa19287ffddb">1.79</ix:nonFraction> per pre-funded warrant, or $<ix:nonFraction unitRef="usd" contextRef="i5abc6425ebed4d1098137ddae6cf173b_I20220303" decimals="-3" name="xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjI2MA_34ddadbf-7cd1-4d6c-80af-d0216885a9bf">3.0</ix:nonFraction>&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i092653cc5b8c43bdad358095e593d81b_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMzg1NQ_38dcb507-5c9f-4fb1-ab8e-06475d982f35" continuedAt="ia02a218561a74b13ac983297f37ded99" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="ia02a218561a74b13ac983297f37ded99" continuedAt="i6684072716ff4b519220ab00a2da86f3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Plans&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following equity incentive plans:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The X4 Pharmaceuticals Inc. 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#8220;2015 Plan&#8221;);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The X4 Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;); and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The X4 Pharmaceuticals Inc. 2019 Inducement Equity Incentive Plan (the &#8220;2019 Plan&#8221;)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company also has the following employee stock purchase plan:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The X4 Pharmaceutical Inc. 2017 Employee Stock Purchase Plan (the &#8220;2017 ESPP&#8221;)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These plans are administered by the Board of Directors or by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of the stock option may not be greater than ten years. Incentive stock options granted to employees and restricted stock awards granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over four years. Non-statutory options granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over three or four years. Shares that are expired, terminated, surrendered or canceled under the Plans without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there are an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="i1087c98fdfeb43a5b2b61cf5a5a18780_I20220331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMTc4NA_e4aeb9f6-301b-4c69-a677-8ffe7c901c55">550,000</ix:nonFraction> shares of common stock available for issuance under the Company&#8217;s equity incentive plans. Approximately <ix:nonFraction unitRef="shares" contextRef="id3f763b38edd403fb65281fd8c0d1e6b_I20220331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMTg5OA_d3d5b391-b19a-46aa-99f0-a20ce7ada5d4">270,000</ix:nonFraction> shares of common stock remain available for issuance under the 2017 ESPP.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Valuation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMzg1Ng_d974c1bc-6c2e-4ee0-aa9b-2678315dc1b3" continuedAt="i47c94dd97a894add817952658821ab57" escape="true">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees, directors and non-employees.</ix:nonNumeric></span></div><div style="margin-top:18pt"><ix:continuation id="i47c94dd97a894add817952658821ab57"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:51.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.979%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfMi0xLTEtMS0zNDQxMQ_a99f6164-eb98-4ffd-bf5a-5f0454a3715d">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfMi0zLTEtMS0zNDQxMQ_ddcd6693-13ca-4c44-8ea2-9bebbe47a134">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfMy0xLTEtMS0zNDQxMQ_473e60d2-7f32-4647-938d-197d454e2c6f">6.1</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfMy0zLTEtMS0zNDQxMQ_b59d3c50-1d58-4b32-ba43-c6b5ee871f40">6.0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfNC0xLTEtMS0zNDQxMQ_8d4087ea-d9cd-4007-a5a1-724581039830">94.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfNC0zLTEtMS0zNDQxMQ_8d35246b-2a9c-42d9-8d64-41980d00855b">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfNS0xLTEtMS0zNDQxMQ_dfa3738c-6e81-477f-8f34-2d02d90cb1a2">0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfNS0zLTEtMS0zNDQxMQ_34027dfb-e241-4c60-85d4-28c02cfd9304">0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMzg1MQ_447f7572-a31e-4834-9f81-3a158738002e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity for the three months ended March&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfMS0xLTEtMS0zNDQxMQ_c50d6d28-999c-4380-a7be-aa4139630bd7">1,916,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfMS0zLTEtMS0zNDQxMQ_8ebc2974-562c-4345-960f-1a19e5ce9f8c">10.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia64d3337ee204135be6803aad57e0f54_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfMS01LTEtMS0zNDQxMQ_e9abd500-efa4-41fe-8ebb-8bf78b5deadb">7.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3aba39e79f4b429586d34201372693_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfMS03LTEtMS0zNDQxMQ_0fe58058-2bf1-44ad-a7bc-7e8d6c410602">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfMi0xLTEtMS0zNDQxMQ_70ed6a43-e5c7-4d2c-8337-5c6392c71bce">232,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfMi0zLTEtMS0zNDQxMQ_0a120928-3335-4cbd-a5e4-9c720d4a56ff">1.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNC0xLTEtMS0zNDQxMQ_be23db5f-3dc8-4348-9357-404efff6bd72">99,743</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNC0zLTEtMS0zNDQxMQ_f0978d29-6b63-4abc-963f-7bd4563719f1">23.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNS0xLTEtMS0zNDQxMQ_afd90f96-fec6-433e-b727-1a721ffd86dc">2,049,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNS0zLTEtMS0zNDQxMQ_c1957f2f-f9f5-4a38-abd1-2f5a842f635a">8.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNS01LTEtMS0zNDQxMQ_2b981eca-a967-407f-a679-5a59df2b7c90">7.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNS03LTEtMS0zNDQxMQ_f0e415f3-bbf8-45b1-aba6-9b1a47550ed5">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNi0xLTEtMS0zNDQxMQ_7a18cdf3-fe13-4e65-921c-c8ddba12db65">1,029,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNi0zLTEtMS0zNDQxMQ_4dfe6f49-7623-4af8-a151-45ef7201744c">10.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNi01LTEtMS0zNDQxMQ_496d1185-db3a-434e-b524-61537c357c00">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNi03LTEtMS0zNDQxMQ_b54bc6ab-2023-43c0-9588-3bd3d38612a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNy0xLTEtMS0zNDQxMQ_238bace1-540e-4164-abad-da9280994c39">1,798,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNy0zLTEtMS0zNDQxMQ_f23c3ffc-4ba1-46a5-9725-160a9fdf2a18">8.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNy01LTEtMS0zNDQxMQ_2d384f98-421d-42df-9239-07e35d00e983">7.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNy03LTEtMS0zNDQxMQ_0253af9f-71d5-4364-aff2-2f393fb877f7">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no stock options exercised in the three months ended March 31, 2022. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMjQ0Ng_5014b585-b584-46f8-989b-77ab3772e55e">13</ix:nonFraction> thousand. The weighted average grant-date fair value per share of stock options granted during the three months ended March&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="2" name="xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMjU5Mg_11407a85-f4fc-44b4-a0a9-386f8e8b3fdb">1.42</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="2" name="xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMjU5OQ_dae8be71-88da-4a5d-9043-19fe644c990d">6.52</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:6pt"><span><br/></span></div><ix:continuation id="i6684072716ff4b519220ab00a2da86f3"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMzg1Mg_ab0cae24-1497-4831-a919-b8c959bed7b3" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes the Company's restricted stock unit activity for the three months ended March 31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:78.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia735dbcc36df42bd8741cce45232e31a_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjM3Y2E0YTlhZDVkNDQ0YzI4MDgwNGQwMjNhZTg4MjViL3RhYmxlcmFuZ2U6MzdjYTRhOWFkNWQ0NDRjMjgwODA0ZDAyM2FlODgyNWJfMS0xLTEtMS0zNDQxMQ_7da31d1f-3316-4822-8089-689e2325afc7">925,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjM3Y2E0YTlhZDVkNDQ0YzI4MDgwNGQwMjNhZTg4MjViL3RhYmxlcmFuZ2U6MzdjYTRhOWFkNWQ0NDRjMjgwODA0ZDAyM2FlODgyNWJfMi0xLTEtMS0zNDQxMQ_9d7d216b-ec65-46b8-b664-a009d4e528cb">1,242,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjM3Y2E0YTlhZDVkNDQ0YzI4MDgwNGQwMjNhZTg4MjViL3RhYmxlcmFuZ2U6MzdjYTRhOWFkNWQ0NDRjMjgwODA0ZDAyM2FlODgyNWJfMy0xLTEtMS0zNDQxMQ_88511d77-911a-4281-93d5-6c62c5c8a4ea">192,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjM3Y2E0YTlhZDVkNDQ0YzI4MDgwNGQwMjNhZTg4MjViL3RhYmxlcmFuZ2U6MzdjYTRhOWFkNWQ0NDRjMjgwODA0ZDAyM2FlODgyNWJfNC0xLTEtMS0zNDQxMQ_d3211786-4df2-4eee-bd9d-c0d247d63d98">34,814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjM3Y2E0YTlhZDVkNDQ0YzI4MDgwNGQwMjNhZTg4MjViL3RhYmxlcmFuZ2U6MzdjYTRhOWFkNWQ0NDRjMjgwODA0ZDAyM2FlODgyNWJfNS0xLTEtMS0zNDQxMQ_0b1c48b0-9177-417b-a4f9-b8f1db8214f0">1,940,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company granted time-based restricted stock units to employees. These restricted stock units vest annually over a two or three year period. Stock-based compensation expense is being recognized for these time-based awards ratably based on the intrinsic value of the awards as of the date of grant, less estimated forfeitures. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, total unrecognized compensation expense related to unvested stock options and restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="if5ce63ce89fc4d53b2de1b932c6c5971_I20220331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMzY1OA_1b6a82da-daa3-48e4-ac79-73bb9707a8b6">8.5</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i34f00a49e9164c6f8f5d5aea7638c86e_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMzczMQ_1afda0e6-fecd-4d44-8544-0541a3e58d05">2.0</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMzg1Mw_e6cc4e20-6aaa-4b67-a365-1e9a4f21991d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:58.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.330%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f08fbd1d62147b7a24653057a24170f_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjUzZDAzNjI1ZDkwMTQyYTU4N2Q1NzU5NTg4NThmZjM5L3RhYmxlcmFuZ2U6NTNkMDM2MjVkOTAxNDJhNTg3ZDU3NTk1ODg1OGZmMzlfMi0xLTEtMS0zNDQxMQ_f883eb5b-5349-4ad4-bb72-8ce96bee5beb">704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe626170d10b4caa80d237bf4ea1bace_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjUzZDAzNjI1ZDkwMTQyYTU4N2Q1NzU5NTg4NThmZjM5L3RhYmxlcmFuZ2U6NTNkMDM2MjVkOTAxNDJhNTg3ZDU3NTk1ODg1OGZmMzlfMi0zLTEtMS0zNDQxMQ_3dafc6af-60ae-4170-8abe-9a652b0d7f5e">577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce083cdddd2478e9589bcc5c51fb670_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjUzZDAzNjI1ZDkwMTQyYTU4N2Q1NzU5NTg4NThmZjM5L3RhYmxlcmFuZ2U6NTNkMDM2MjVkOTAxNDJhNTg3ZDU3NTk1ODg1OGZmMzlfMy0xLTEtMS0zNDQxMQ_1c648595-a90e-455b-a59d-00b1642574d3">755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2610f6c62e848928bf100bd21dc705c_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjUzZDAzNjI1ZDkwMTQyYTU4N2Q1NzU5NTg4NThmZjM5L3RhYmxlcmFuZ2U6NTNkMDM2MjVkOTAxNDJhNTg3ZDU3NTk1ODg1OGZmMzlfMy0zLTEtMS0zNDQxMQ_fcaa34e8-ffe6-4d05-ac0d-6ebc6daf8318">681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjUzZDAzNjI1ZDkwMTQyYTU4N2Q1NzU5NTg4NThmZjM5L3RhYmxlcmFuZ2U6NTNkMDM2MjVkOTAxNDJhNTg3ZDU3NTk1ODg1OGZmMzlfNC0xLTEtMS0zNDQxMQ_bbdbd58e-6acd-4f98-a240-2fe0482d9a9d">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjUzZDAzNjI1ZDkwMTQyYTU4N2Q1NzU5NTg4NThmZjM5L3RhYmxlcmFuZ2U6NTNkMDM2MjVkOTAxNDJhNTg3ZDU3NTk1ODg1OGZmMzlfNC0zLTEtMS0zNDQxMQ_b0f5ab6d-2154-497a-a700-56c884cda253">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_76"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83Ni9mcmFnOjk1NTYwZTcyMDkzODQ2NDE5NzcwZDIyNzhiMjY3MTA0L3RleHRyZWdpb246OTU1NjBlNzIwOTM4NDY0MTk3NzBkMjI3OGIyNjcxMDRfNDI3_55af8806-736d-4292-b1a9-6cc7e05faa7e" continuedAt="ib083c46adea34641abb97cbefd475564" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib083c46adea34641abb97cbefd475564">The Company did <ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83Ni9mcmFnOjk1NTYwZTcyMDkzODQ2NDE5NzcwZDIyNzhiMjY3MTA0L3RleHRyZWdpb246OTU1NjBlNzIwOTM4NDY0MTk3NzBkMjI3OGIyNjcxMDRfMzg_9cc60e69-3d27-4903-ba79-a0e14faa0fea"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83Ni9mcmFnOjk1NTYwZTcyMDkzODQ2NDE5NzcwZDIyNzhiMjY3MTA0L3RleHRyZWdpb246OTU1NjBlNzIwOTM4NDY0MTk3NzBkMjI3OGIyNjcxMDRfMzg_a5cd5c6f-5d39-4ca6-ae5f-45c03ec4f467"><ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83Ni9mcmFnOjk1NTYwZTcyMDkzODQ2NDE5NzcwZDIyNzhiMjY3MTA0L3RleHRyZWdpb246OTU1NjBlNzIwOTM4NDY0MTk3NzBkMjI3OGIyNjcxMDRfMzg_a63305fa-2ccd-4caa-b6e1-829828b765db"><ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83Ni9mcmFnOjk1NTYwZTcyMDkzODQ2NDE5NzcwZDIyNzhiMjY3MTA0L3RleHRyZWdpb246OTU1NjBlNzIwOTM4NDY0MTk3NzBkMjI3OGIyNjcxMDRfMzg_b53779b2-8a6e-447a-ba66-f6e353a42198">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t record a U.S. federal or state income tax benefit for its losses for the three months ended March&#160;31, 2022 and 2021, due to the conclusion that a full valuation allowance is required against the Company&#8217;s U.S. federal and state deferred tax assets. For the three months ended March 31, 2022 and March 31, 2021, the Company recorded an immaterial income tax provision related to its Austrian subsidiary.</ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RleHRyZWdpb246YzVmODcyYWY3Nzc2NGU0ZmJmYjgxY2JmNTk0YWJkMTNfMTY3Mg_2a0c76c5-9258-49f0-8892-0883eb1314d1" continuedAt="i47c2411e158c4b6dad5e027663800567" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i47c2411e158c4b6dad5e027663800567" continuedAt="ia0c5a8a4b77a44f9bf0cd6a1904f21d4"><ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RleHRyZWdpb246YzVmODcyYWY3Nzc2NGU0ZmJmYjgxY2JmNTk0YWJkMTNfMTY3Mw_b8eac8f4-db04-4d03-a920-46f49adcf3d9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common stockholders was calculated as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfMy0xLTEtMS0zNDQxMQ_8d19c9b8-f386-4530-9105-b5210ac5017e">21,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfMy0zLTEtMS0zNDQxMQ_ead8cafe-70e1-4688-892d-405e7c4462e5">18,676</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend as a result of Class B warrant price reset (Note 10)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" name="us-gaap:DividendsPaidinkind" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfNC0xLTEtMS0zNDQxMQ_80e76c4b-d1be-4878-bb88-8e8a3a49ab1d">2,259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" name="us-gaap:DividendsPaidinkind" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfNC0zLTEtMS0zNDQxMQ_89d0a6a0-1f3d-49da-9edb-a176562d1cdc">8,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfNS0xLTEtMS0zNDQxMQ_1c13f24c-7563-4176-95cc-c85c1e431ecc">24,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfNS0zLTEtMS0zNDQxMQ_bbc3efd3-3892-4df3-b0a4-ee09866aff4c">26,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfNy0xLTEtMS0zNDQxMQ_a38a4990-c996-4377-8924-047e26ff2237">33,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfNy0zLTEtMS0zNDQxMQ_0a43d355-8647-4595-b547-0069679c3e55">20,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders&#8212; basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfOC0xLTEtMS0zNDQxMQ_fb0e8ddf-e3f5-4d6d-ad1d-5527da4f82a0">0.72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfOC0zLTEtMS0zNDQxMQ_cd63abfc-8b5c-4849-ac9c-731263cb6b6c">1.30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="margin-top:2pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ia0c5a8a4b77a44f9bf0cd6a1904f21d4"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted weighted average shares of common stock outstanding for the three months ended March&#160;31, 2022 and March&#160;31, 2021 include the weighted average effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price is $<ix:nonFraction unitRef="usdPerShare" contextRef="ia0ed061951224fe2b05f82e41a77c8d4_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RleHRyZWdpb246YzVmODcyYWY3Nzc2NGU0ZmJmYjgxY2JmNTk0YWJkMTNfNzM3_7148c239-e708-448a-a7a4-5b0a28ed62b9">0.01</ix:nonFraction> or less per share. During the quarters ended March 31, 2022 and March 31, 2021, in accordance with the Class B Warrant agreement, the exercise price of each outstanding Class B Warrant was adjusted to the price of shares of the Company&#8217;s common stock sold in public or private offerings to the extent such price is lower than the previous Class B warrant price. These price adjustments are accounted for as a deemed dividend that adjusts net loss available to common shareholders for purposes of basic earnings per share. The deemed dividend is calculated using the Black-Scholes pricing model, taking into account historical volatility of the Company&#8217;s common stock and the estimated remaining life of the outstanding Class B Warrants.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities include outstanding stock options, unvested restricted stock units and warrants to purchase shares of common stock for the three months ended March 31, 2022 and 2021. All potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered &#8220;anti-dilutive.&#8221; Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. <ix:nonNumeric contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RleHRyZWdpb246YzVmODcyYWY3Nzc2NGU0ZmJmYjgxY2JmNTk0YWJkMTNfMTY3NA_e4676408-fa89-410b-8371-dc1fe7a6f725" continuedAt="i63ddb78d0e30495b965928c4e9f39568" escape="true">The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="i63ddb78d0e30495b965928c4e9f39568"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:70.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.659%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase shares of common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1925ffb8b98e470a8755be697908ef08_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfMi0xLTEtMS0zNDQxMQ_e4109aed-fd5b-4dba-9907-842346e4905a">2,049,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i289ea1ad164e40f3bd8d98acc9dd5ec5_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfMi0zLTEtMS0zNDQxMQ_00ccf9e2-3137-44df-aa21-dc342c1b4e3e">1,858,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c82af5f1bd54ac38a12ea61c79ef148_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfMy0xLTEtMS0zNDQxMQ_3cbca46d-7033-4e7a-93ff-9ac96c034b71">1,940,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4403e830d3884aac9399f56efc81108c_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfMy0zLTEtMS0zNDQxMQ_5e24f6dc-70dd-4511-819f-0363fe2efefc">1,135,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase shares of common stock (excluding prefunded warrants, which are included in basic shares outstanding)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e78ac2b2f9c400db2a88a3ac72a5ab8_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfNC0xLTEtMS0zNDQxMQ_11786537-0858-4607-a8f8-d0385aacf66a">9,449,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc1e4f78fe354943a530e1e6507b73ea_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfNC0zLTEtMS0zNDQxMQ_fae393d4-0692-4b34-abd6-aa4efb4a26c2">9,474,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfNS0xLTEtMS0zNDQxMQ_6c564e2f-4d67-42f0-9a3a-fc0f224cf85b">13,438,974</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfNS0zLTEtMS0zNDQxMQ_6f0f6040-a439-40bf-813d-610f23a903f5">12,467,976</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i092653cc5b8c43bdad358095e593d81b_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The following information should be read in conjunction with our unaudited condensed consolidated financial statements and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;), on March 17, 2022, the (&#8220;Annual Report&#8221;). This discussion and analysis contains forward-looking statements that involve significant risks and uncertainties. Our actual results, performance or experience could differ materially from what is indicated by any forward-looking statement due to various important factors, risks and uncertainties, including, but not limited to, those set forth under &#8220;Risk Factors&#8221; included elsewhere in this Quarterly Report on Form 10-Q.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Such factors may be amplified by the ongoing COVID-19 pandemic and its potential impact on our business and the overall global economy.</span></div><div id="i092653cc5b8c43bdad358095e593d81b_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases, with an initial focus on people with immune system dysfunction. Our lead product candidate, mavorixafor, is a first-in-class, small molecule inhibitor of the chemokine receptor CXCR4 and is being developed as a once-daily oral therapy. Due to mavorixafor&#8217;s demonstrated ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells, we believe that mavorixafor has the potential to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies (&#8220;PIDs&#8221;) and certain types of cancer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently studying the safety and efficacy of mavorixafor in a global Phase 3 clinical trial of mavorixafor for the treatment of patients with Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#8220;WHIM&#8221;) syndrome, a rare, inherited PID, caused by genetic mutations in the CXCR4 receptor gene. We are also conducting a Phase 1b clinical trial of mavorixafor in people with a range of chronic neutropenia disorders, both with and without CXCR4 mutations, and a Phase 1b clinical trial of mavorixafor in combination with the Bruton tyrosine kinase inhibitor (&#8220;BTKi&#8221;) ibrutinib in people with Waldenstr&#246;m&#8217;s macroglobulinemia (&#8220;Waldenstr&#246;m&#8217;s&#8221;), a rare B-cell lymphoproliferative disorder, and confirmed mutations to both the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CXCR4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MYD88</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed enrollment of our global Phase 3 clinical trial of mavorixafor, which we refer to as the 4WHIM trial, in the third quarter of 2021, with 31 patients enrolled, and currently expect to report top-line data from the trial in the fourth quarter of 2022. We have completed enrollment with 16 patients in the Waldenstr&#246;m&#8217;s trial and are continuing to enroll patients in the chronic neutropenia trial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Food and Drug Administration (&#8220;FDA&#8221;) has granted certain special designations to mavorixafor, including Breakthrough Therapy Designation for the treatment of adults with WHIM syndrome, Fast Track Designation for adults with WHIM syndrome, and Rare Pediatric Designation for the treatment of people aged 12 to 18 with WHIM syndrome, which could result in accelerated review and approval by the agency. We have begun building our commercial team in anticipation of a possible New Drug Application (&#8220;NDA&#8221;) submission to the FDA in the second half of 2023, with the goal of obtaining approval for mavorixafor for the treatment of people in the United States, aged 12 and older with WHIM syndrome, should the final Phase 3 data support the filing of an NDA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We announced positive preliminary data from both of the ongoing Phase 1b clinical trials of mavorixafor during 2021, and we are continuing patient enrollment in the chronic neutropenia trial. Additional data are expected from the Phase 1b clinical trial in chronic neutropenia by the end of the third quarter of 2022 and from the Phase 1b clinical trial in Waldenstr&#246;m&#8217;s in the second half of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to mavorixafor, we are advancing earlier-stage product candidates to further expand our pipeline. We have advanced a lead optimization program: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling broader opportunities in CXCR4 disorders and primary immunodeficiencies. A second program, X4P-002, which is a CXCR4 antagonist designed to cross the blood-brain barrier and provide appropriate therapeutic exposures to potentially treat brain cancers in combination therapy, is in Investigational New Drug-enabling studies. We are also continuing to leverage our insights into CXCR4 biology and our research capabilities to identify other targets and develop additional product candidates. We anticipate filing an Investigational NDA of X4P-002 with the FDA in the fourth quarter of 2022 to enable its advancement into clinical development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated revenue from product sales and do not expect to generate significant revenue from the sale of our products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline</span></div><div style="margin-top:6pt"><img src="xfor-20220331_g1.jpg" alt="xfor-20220331_g1.jpg" style="height:259px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 1. X</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4 Pharmaceuticals, Data on File.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Phase 2 open label extension (OLE) trial for WHIM ongoing  2. Company market research. Qessential market research,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> 2019 and IPM . ai artificial intellegence study, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  3. Estimate using Andersen et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> J Intern Med. 2016 Jun: 279(6):566-75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">WM Epidemiology Analysis Nemetz Group.  &#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">COVID-19 Business Update </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of the ongoing COVID-19 pandemic, we have implemented business continuity measures designed to address and mitigate the impact of the COVID-19 pandemic on our employees, our business, including our clinical trials, supply chains and third-party providers. We continue to closely monitor the COVID-19 pandemic as we evolve our business continuity plans and response strategy. Following easing of governmental restrictions, in the fourth quarter of 2020, we opened our new corporate headquarters in Boston, Massachusetts under a return-to-work plan with a limited phased approach that is principles-based and  local in design, with a focus on employee safety and optimal work environment. While we are currently operating under a &#8220;hybrid&#8221; model where full-time in-person attendance in the office is optional, all employees who have been fully vaccinated have returned to the office. While we are experiencing limited financial impacts at this time, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the COVID-19 pandemic and continued uncertainty, our business, financial condition, results of operations and growth prospects could be materially adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to clinical development, we continue to implement risk-based approaches in accordance with FDA and European Medicines Agency (&#8220;EMA&#8221;) COVID-19 guidance, which includes virtual and remote patient visits and monitoring where possible, while prioritizing patient safety, maintaining trial continuity and preserving data integrity. We have experienced, and expect to continue to experience, a disruption or delay in our ability to initiate trial sites and/or enroll and assess patients in several of our clinical programs as a result of the ongoing COVID-19 pandemic, notwithstanding substantial vaccination efforts. While not currently impacted, there could be an impact on our ability to supply study drug, report trial results, or interact with regulators, ethics committees or other important agencies due to limitations in regulatory authority employee resources or otherwise. In addition, we rely on contract research organizations (&#8220;CROs&#8221;) or other third parties to assist us with clinical trials, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the ongoing COVID-19 pandemic. If the COVID-19 pandemic continues and persists for an extended period of time, we could experience further disruptions to our clinical development timelines, which would adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Supply Chain</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work closely with our third-party manufacturers, distributors and other partners to manage our supply chain activities and mitigate potential disruptions to our clinical supply as a result of the ongoing COVID-19 pandemic. We have business continuity plans in place and have manufacturing plans that will meet our global supply demands going forward. To best support our patients, we continue to work with our vendors to provide the option for direct-to-patient drug shipments from </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical sites. If the ongoing COVID-19 pandemic impacts essential distribution systems we could experience disruptions to our supply chain and operations, which could adversely impact our ability to carry out our clinical trials.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Activities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we could experience delays in the timing of review and/or our interactions with the FDA or the European Commission (&#8220;EC&#8221;) due to, for example, inability to conduct planned physical inspections related to regulatory approval, or the diversion of efforts of the FDA or EC and attention to approval of other therapeutics or other activities related to COVID-19, which could delay approval decisions with respect to the preparation and submission to the FDA of a new drug application (&#8220;NDA&#8221;), or the preparation and submission to the EC of a Marketing Authorization Application (&#8220;MAA&#8221;), and otherwise delay or limit our ability to make planned regulatory submissions or obtain new product approvals.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Impact</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing COVID-19 pandemic continues to evolve and has already resulted in a significant disruption of global financial markets. If the disruption persists and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our operations.</span></div><div id="i092653cc5b8c43bdad358095e593d81b_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March 31, 2022 and 2021</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the three months ended March 31, 2022 and 2021: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:67.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.741%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain of sale of non-financial asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates, including employee salaries and related expenses, preclinical and clinical development expenses for our product candidates; internal and third-party costs of manufacturing our drug products for use in our preclinical studies and clinical trials; facility, depreciation and other expenses; costs related to compliance with regulatory requirements; and payments made under third-party licensing agreements. We expense research and development costs as incurred. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.140%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Direct research and development expenses by product candidate:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mavorixafor </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X4P-002</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X4P-003</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Unallocated expense</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in research and development expenses in each period was primarily due to an increase in head count within our manufacturing, regulatory and clinical operations functions, resulting in higher compensation expenses, including stock-based compensation.  In addition, unallocated research and development expense increased due to additional facility costs associated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with our leased facilities, which are allocated to research and development departments based on head count. Research and development expenses also increased due to additional non-clinical costs related to advancing our XP-002 oncology program. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in sale and marketing, executive, finance and administrative functions. Selling, general and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor and public relations, accounting, and audit services. Selling, general and administrative expenses were higher as compared to the prior year primarily due to an increase in stock-based compensation costs, higher recruiting costs and an increase in facility costs. Head count in selling, general and administrative functions was relatively consistent with the prior period. We expect selling, general and administrative expenses will grow in the future as we continue to build out our selling, general and administrative functions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Sale of Non-Financial Asset</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, a third party, who had previously acquired rights to certain intellectual property from us, terminated the arrangement and transferred these rights back us. Also during the current period, we transferred these rights to another third party in return for $0.5 million. We have no continuing involvement in any ongoing research and development activities associated with the intellectual property. We concluded that these third parties are "non-customers" as the underlying intellectual property transferred to and from these third parties supports potential drug candidates that are not aligned with our strategic focus and, therefore, are not an output of our ordinary activities. Accordingly, we classified this transaction as a Gain on Sale of Non-Financial Asset for the period ended March 31, 2022. There was no such transaction in the same period of the prior year. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expenses, Net</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:66.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses, net, for the three months ended March 31, 2022 were consistent with same period in the prior year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not record a U.S. federal or state income tax benefit for our losses for the three months ended March&#160;31, 2022 and 2021, due to our conclusion that a full valuation allowance is required against our U.S. federal and state deferred tax assets. For the three months ended March 31, 2022 and 2021, we recorded an immaterial amount of income tax expense related to our Austrian subsidiary. </span></div><div><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have primarily funded our operations with proceeds from sales of common stock, warrants and pre-funded warrants for the purchase of our preferred stock and common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements, such as our existing loan and security agreement with Hercules Capital, Inc. (the &#8220;Hercules Loan Agreement&#8221;) as more fully described in the notes to our condensed consolidated financial statements included herein. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into a Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement, (the &#8220;ATM Sales Agreement&#8221;), with B. Riley Securities, Inc., Cantor Fitzgerald &amp; Co. and Stifel, Nicolaus &amp; Company, Incorporated, (collectively, the &#8220;Sales Agents&#8221;), pursuant to which we may offer and sell, at our sole discretion through one or more of the Sales Agents, shares of our common stock having an aggregate offering price of up to $50.0 million. We are currently subject to General Instruction I.B.6 to Form S-3 (the &#8220;Baby Shelf Rule&#8221;), and the amount of funds we can raise through primary public offerings of securities in any twelve-month period using our existing registration statement on Form S-3 is limited to one-third of the aggregate market </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value of the voting and non-voting common equity held by non-affiliates. We will be limited by the Baby Shelf Rule until such time as our public float exceeds $75.0 million. As a result of the Baby Shelf Rule, we currently may offer and sell shares of our common stock having an aggregate offering price of up to $23.3 million from time to time through the Sales Agents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we entered into a securities purchase agreement with several institutional and accredited investors pursuant to which we sold shares of common stock and, in lieu of common stock, pre-funded warrants to purchase shares of common stock for gross proceeds of $53.0 million, before deducting offering expenses payable by us. In November 2021, we raised approximately $10.0 million through the sale of pre-funded warrants to an investor. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC (&#8220;Lincoln Park&#8221;) pursuant to which Lincoln Park has committed to purchase, at our request from time to time over a 36-month period, shares of our common stock having an aggregate offering price of up to $50.0 million, subject to certain limitations. In March 2022, we raised $3.0 million for the sale of shares of our common stock and pre-funded warrants for the purchase of shares of common stock in a private placement.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have borrowed $32.5 million through our Hercules Loan Agreement. Under this facility we may borrow additional $17.5 million in term loans through December 2022 at the lender&#8217;s sole discretion. Principal payments under the Hercules Loan Agreement commence in February 2023, and the agreement matures in July 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any products and we do not expect to generate revenue from sales of any products for several years, if at all. As of March 31, 2022, our cash and cash equivalents were $66.4 million, and our restricted cash balance was $1.3 million. We expect that our research and development and selling, general and administrative expenses will continue to increase as we focus on completing the necessary development, obtaining regulatory approval and preparing for potential commercialization of our product candidates. Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further discussed in Note 7 to our condensed consolidated financial statements, our Hercules Loan Agreement has a covenant that would require us to maintain a minimum level of cash beginning on September 1, 2022, which date is extended if we meet certain financial milestones related to third-party funding. Based on our current financial projections, we believe we would be in violation of this covenant in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the third quarter of 2022. If we are in violation of this covenant, Hercules could require the repayment of all outstanding debt. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we believe that, in aggregate, these conditions raise substantial doubt about our ability to continue as a going concern for the one-year period following the issuance of these condensed consolidated financial statements for the quarterly period ended March 31, 2022. Unless and until we reach profitability in the future, we will require additional capital to fund our operations, which we may raise through a combination of equity offerings, debt financings, other third party funding, marketing and distribution arrangements and collaborations and strategic alliances. If we are unable to obtain funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion or pre-commercialization efforts, which would adversely affect our business prospects, or we may be unable to continue operations.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activities for each of the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,965)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,676)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,723)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,229)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,444)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,364)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,958&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,660&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;During the three months ended March 31, 2022, net cash used in operating activities was $20.2 million, primarily resulting from our net loss of $22.0 million, adjusted for noncash expenses of $2.0 million and changes in our operating assets and liabilities of $0.3 million. Non-cash expenses primarily includes stock-based compensation expense, non-cash lease expense and non-cash interest expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March 31, 2021 was $18.4 million, primarily resulting from our net losses of $18.7 million, adjusted for noncash expenses of $2.0 million and changes in our operating assets and liabilities of $1.7 million. Net cash used in changes in our operating assets and liabilities primarily consisted of a decrease in</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued expenses primarily due to the annual payment of accrued bonuses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three months ended March 31, 2022 and 2021, cash used in investing activities of less than $0.1 million and $0.5 million, respectively, related primarily to purchases of equipment for our facility in Boston during the three months ended March 31, 2022, and for furniture and laboratory equipment purchases related to our leased facility in Vienna, Austria during the three months ended March 31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;During the three months ended March 31, 2022, net cash provided by financing activities was $5.0 million, consisting primarily of $5.9 million of proceeds from a private placement equity offering that closed during the period and the sale of shares of our common stock to Lincoln Park, partially offset by $0.8 million of end-of-term payments made pursuant to our Hercules Loan Agreement.  During the three months ended March 31, 2021, net cash provided by financing activities was $55.0 million, consisting of gross proceeds on our private placement sale of shares of our common stock before offering costs and redeemable common stock repayments. </span></div><div id="i092653cc5b8c43bdad358095e593d81b_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Hercules Loan Agreement contains a minimum cash covenant that is effective on September 1, 2022 (which date is extended if we meet certain financial milestones related to third party funding). Based on our current operating cash flow projections and with no additional funding, we would be in violation of this minimum cash required to satisfy this covenant in the third quarter of 2022. To fund our operations, we are required to raise additional capital, which may be through a combination of equity offerings, such as through our ATM Sales Agreement or through our common stock purchase agreement with Lincoln Capital, debt financings, including refinancing of our Hercules Loan Agreement or entering into new debt arrangements with other third-parties, marketing and distribution arrangements and collaborations and strategic alliances. Our ability to raise such funds cannot be assured. During 2022 and beyond, we expect our expenses to continue to increase in connection with our ongoing activities, particularly as we advance the current and anticipated clinical trials of our product candidates in development. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our funding requirements. Our short-term and long-term funding requirements will depend on and could increase significantly as a result of many factors, including:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope, number, initiation, progress, timing, costs, design, duration, any potential delays, and results of clinical trials and nonclinical studies for our current or future product candidates, particularly our Phase 3 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pivotal clinical trial of mavorixafor for the treatment of patients with WHIM syndrome, our Phase 1b clinical trial of mavorixafor in SCN and chronic neutropenia disorders, and our Phase 1b clinical trial of mavorixafor in Waldenstr&#246;m&#8217;s;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the continued global impact of the ongoing COVID-19 pandemic and its effect on our ongoing clinical trials, our supply chain and the financial markets in general; </span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies for our product candidates than those that we currently expect;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to obtain marketing approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights covering our product candidates, including any such patent claims and intellectual property rights that we have licensed from Genzyme pursuant to the terms of our license agreement with Genzyme;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost and timing of completion of commercial-scale outsourced manufacturing activities with respect to our product candidates;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to establish and maintain licensing, collaboration or similar arrangements on favorable terms and whether and to what extent we retain development or commercialization responsibilities under any new licensing, collaboration or similar arrangement;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success of any other business, product or technology that we acquire or in which we invest;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of acquiring, licensing or investing in businesses, product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our need and ability to hire additional management and scientific and medical personnel;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs to continue to operate as a public company, including the need to implement additional financial and reporting systems and other internal systems and infrastructure for our business;</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">market acceptance of our product candidates, to the extent any are approved for commercial sale; and</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the effect of competing technological and market developments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, reduce or eliminate our product development efforts or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Hercules Loan Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 7 to the notes to our condensed consolidated financial statements for a full description of our Hercules Loan Agreement.</span></div><div id="i092653cc5b8c43bdad358095e593d81b_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, there were no material changes to our critical accounting policies as reported for the year ended December 31, 2021 as part of our Annual Report.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, see Note 2 of these condensed consolidated financial statements under the heading &#8220;Recently Adopted Accounting Pronouncements&#8221; for new accounting pronouncements or changes to the accounting pronouncements during the three months ended March&#160;31, 2022.</span></div><div id="i092653cc5b8c43bdad358095e593d81b_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company and Smaller Reporting Company Status</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). The JOBS Act permits an EGC to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to &#8220;opt out&#8221; of this provision and, as a result, we will comply with new or revised accounting standards when they are required to be adopted by public companies that are not EGCs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></div><div id="i092653cc5b8c43bdad358095e593d81b_106"></div><div style="margin-top:18pt;padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are not required to provide the information requested by this Item.</span></div><div id="i092653cc5b8c43bdad358095e593d81b_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March&#160;31, 2022, and have concluded that, based on such evaluation, our disclosure controls and procedures were effective as of March&#160;31, 2022 at the reasonable assurance level. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the three months ended March&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i092653cc5b8c43bdad358095e593d81b_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II: OTHER INFORMATION</span></div><div id="i092653cc5b8c43bdad358095e593d81b_115"></div><div style="margin-top:18pt;padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition.</span></div><div id="i092653cc5b8c43bdad358095e593d81b_118"></div><div style="margin-top:18pt;padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">An investment in our securities involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and related notes hereto, before deciding to invest in our common stock. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In these circumstances, the market price of our common stock could decline and you may lose all or part of your investment. We cannot assure you that any of the events discussed below will not occur.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception. We expect to continue to incur losses for the foreseeable future and we may never achieve or maintain profitability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical biopharmaceutical company with a limited operating history.</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses. Our net losses were $88.7 million, $62.1 million and $52.8 million for the years ended December 31, 2021, 2020 and 2019 respectively, and were $22.0 million for the quarter ended March 31, 2022. As of March 31, 2022, we had an accumulated deficit of $304.8 million. We have funded our operations to date primarily with proceeds from sales of common stock, warrants and prefunded warrants for the purchase of our preferred stock and our common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for at least the next few years as we conduct additional clinical trials for our product candidates; continue to discover and develop additional product candidates; acquire or in-license other product candidates and technologies; maintain, expand and protect our intellectual property portfolio; hire additional clinical, scientific and commercial personnel; establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval; seek regulatory approvals for any product candidates that successfully complete clinical trials; establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval; and add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. For example, we experienced delays in clinical trial site activation and slower patient enrollment in some of our clinical trials as a result of the COVID-19 pandemic, which have delayed our expectations regarding our ability to report data from those trials, and we may encounter additional delays, disruptions and other direct and indirect negative effects of the ongoing COVID-19 pandemic on our clinical trials. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. The net losses we incur may fluctuate significantly from quarter to quarter and year to year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate profits from operations and thereafter to remain profitable depends heavily on:</span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, number, progress, duration, endpoints, cost, results and timing of clinical trials and nonclinical studies of our current or potential future product candidates, including in particular the scope, progress, duration, endpoints, cost, results and timing for completion of our Phase 3 trial of mavorixafor for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#8220;WHIM&#8221;) syndrome, our Phase 1b clinical trial of mavorixafor for the treatment of Severe Congenital Neutropenia (&#8220;SCN&#8221;) and other chronic neutropenia disorders, and our Phase 1b clinical trial of mavorixafor for the treatment of Waldenstr&#246;m&#8217;s macroglobulinemia (&#8220;Waldenstr&#246;m&#8217;s&#8221;);&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise sufficient funds to support the development and potential commercialization of our product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes and timing of regulatory reviews, approvals or other actions;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain marketing approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain licensing, collaboration or similar arrangements on favorable terms and whether and to what extent we retain development or commercialization responsibilities under any new licensing, collaboration or similar arrangement;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of any other business, product or technology that we acquire or in which we invest;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture any approved products on commercially reasonable terms;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish a sales and marketing organization or suitable third-party alternatives for any approved product; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of product candidates and programs that we pursue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current plans, we do not expect to generate significant revenue from product sales unless and until we (or a potential future licensee or collaborator) obtain marketing approval for, and commercialize, one or more of our current or potential future product candidates. Neither we nor a licensee may ever succeed in obtaining marketing approval for, or commercializing, our product candidates and, even if we do, we may never generate revenues that are significant enough to generate profits from operations. Even if we do generate profits from operations, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to generate profits from operations and remain profitable would decrease our value and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or continue our operations. A decline in our value could also cause you to lose all or part of your investment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors that may alter or delay our plans. Assuming that we complete the development of and obtain marketing approval for any of our product candidates, we will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays, and may not be successful in such a transition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate any product development programs or commercialization efforts.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed a large amount of cash since inception. We expect our research and development expenses to increase in future periods as we continue to advance the clinical development of our product candidates and prepare for the launch and commercialization of any product candidates for which we receive regulatory approval, including potentially building our own commercial organization to address the United States and certain other markets. In addition, if we obtain marketing approval for any of our product candidates that are not then subject to licensing, collaboration or similar arrangements with third parties, we expect to incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing. Furthermore, we expect to incur additional costs associated with operating as a public company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we have cash and cash equivalents of $66.4 million. We have a covenant under our Hercules Loan Agreement that requires that we maintain a minimum level of cash, as defined, beginning on September 1, 2022. Based on our current cash flow projections and with no additional funding, we believe we may not be able to maintain the minimum cash required to satisfy this covenant. In such event, Hercules could require the repayment of all outstanding debt. We expect to seek additional funding to sustain our future operations and to satisfy certain covenants under our debt facility with Hercules, which may include raising funds through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. While we have successfully raised capital in the past, our ability to raise capital in future periods is not assured. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, adequate additional financing may not be available to us on acceptable terms, or at all. Under General Instruction I.B.6 to Form S-3 (the &#8220;Baby Shelf Rule&#8221;), the amount of funds we can raise through primary public offerings of securities in any twelve-month period using our registration statement on Form S-3 is limited to one-third of the aggregate market value of the voting and non-voting common equity held by non-affiliates. As of March 22, 2022, the aggregate market value of our common stock held by non-affiliates was $69,999,467, which was calculated based on 30,567,453 shares of our common stock outstanding held by non-affiliates as of that time, and at a price of $2.29 per share, the closing price of our common stock on March 9, 2022. We therefore are limited by the Baby Shelf Rule as of the filing of our Annual Report on Form 10-K for the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fiscal year ended December 31, 2021, until such time as our public float exceeds $75.0 million. As a result of the Baby Shelf Rule, we currently may offer and sell shares of our common stock having an aggregate offering price of up to $23.3 million from time to time.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require substantial additional funding to carry out our business plans, including the clinical development of mavorixafor. Further, even if and when we believe we have sufficient capital for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. We cannot be certain that additional funding will be available on acceptable terms, or at all. The ongoing COVID-19 pandemic has already resulted in a significant disruption of global financial markets. If the disruption continues or future variants of COVID-19 emerge globally, we could experience an inability to access additional capital when and if needed. If we are unable to raise additional capital when needed or in sufficient amounts or on terms acceptable to us, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts of one or more of our product candidates or one or more of our other research and development initiatives. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also could be required to:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seek new or additional collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">relinquish or license on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope, number, initiation, progress, timing, costs, design, duration, any potential delays, and results of clinical trials and nonclinical studies for our current or future product candidates, particularly our Phase 3 trial of mavorixafor for the treatment of WHIM syndrome, our Phase 1b clinical trial of mavorixafor for the treatment of SCN and chronic neutropenia disorders, and our Phase 1b clinical trial of mavorixafor for the treatment of Waldenstr&#246;m&#8217;s;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the clinical development plans that we establish for these product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number and characteristics of product candidates and programs that we develop or may in-license;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies for our product candidates than those that we currently expect;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to obtain marketing approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights covering our product candidates, including any such patent claims and intellectual property rights that we have licensed from Genzyme pursuant to the terms of our license agreement with Genzyme or from other third parties;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost and timing of completion of commercial-scale outsourced manufacturing activities with respect to our product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to establish and maintain licensing, collaboration or similar arrangements on favorable terms and whether and to what extent we retain development or commercialization responsibilities under any new licensing, collaboration or similar arrangement;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the success of any other business, product or technology that we acquire or in which we invest;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs of acquiring, licensing or investing in businesses, product candidates and technologies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our need and ability to hire additional management and scientific and medical personnel;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs to operate as a public company, including the need to implement additional financial and reporting systems and other internal systems and infrastructure for our business;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">market acceptance of our product candidates, to the extent any are approved for commercial sale;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the effect of competing technological and market developments; and,</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">business interruptions resulting from pandemics and public health emergencies, including those related to the ongoing COVID-19 pandemic, geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not raise additional capital in sufficient amounts, or on terms acceptable to us, we may be prevented from pursuing discovery, development and commercialization efforts, which will harm our business, operating results and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our investors, restrict our operations or require us to relinquish rights to our technologies or product candidates. Future debt obligations may expose us to risks that could adversely affect our business, operating results and financial condition and may result in further dilution to our stockholders.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. The ongoing COVID-19 pandemic has already resulted in a significant disruption of global financial markets. If the disruption persists or if future variants of COVID-19 emerge globally, we could experience an inability to access additional capital. Other than our common stock purchase agreement with Lincoln Park Capital Fund LLC (&#8220;Lincoln Park&#8221;), pursuant to which Lincoln Park is obligated, subject to certain limitations, to purchase up to $50.0 million in the aggregate of shares of our common stock, subject to certain limitations and conditions, we do not have any committed external sources of funds and may seek to raise additional capital at any time. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends or other distributions, acquiring or licensing intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business and may result in liens being placed on our assets and intellectual property. For example, our debt facility with Hercules contains a minimum cash &#160;&#160;&#160;&#160;financial covenant that we project we would be in violation of in the third quarter of 2022 based on our current cash flow projections, assuming we do not raise additional funding. If we default on such indebtedness, with Hercules or a future lender, we could lose such assets and intellectual property.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through licensing, collaboration or similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research and development programs or product candidates or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financings or through licensing, collaboration or similar arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not generated revenues from any product sales since inception and may never become profitable.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated revenues from any product sales. Our ability to generate revenue and become profitable depends upon our ability to successfully obtain marketing approval and commercialize our product candidates, including mavorixafor, X4P-002, X4P-003 or other product candidates that we may develop, in-license or acquire in the future. Even if we are able to successfully achieve regulatory approval for these product candidates, we are unable to predict the extent of any future losses and do not know when any of these product candidates will generate revenue for us, if at all. Our ability to generate revenue from mavorixafor or any of our current or future product candidates also depends on a number of additional factors, including our ability to:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successfully complete development activities, including all necessary nonclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">complete and submit New Drug Applications (&#8220;NDAs&#8221;), to the FDA and obtain regulatory approval for indications for which there is a commercial market;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">complete and submit marketing applications to, and obtain regulatory approval from, foreign regulatory authorities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">set and obtain a commercially viable price for our products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtain commercial quantities of our products at acceptable cost levels;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">develop a commercial organization capable of sales, marketing and distribution for the products we intend to sell ourselves in the markets in which we have retained commercialization rights;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">find suitable collaborators to help us market, sell and distribute our approved products in other markets; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtain coverage and adequate reimbursement from third-party, including government, payors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because of the numerous risks and uncertainties associated with product development, including the possibility that our product candidates may not advance through development or demonstrate safety and efficacy for their intended uses, the FDA or any other regulatory agency may require additional clinical trials or nonclinical studies. We are unable to predict the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability, and such expense could increase beyond our expectations if the FDA or any other regulatory agency requires such additional clinical trials or nonclinical studies as part of the application and approval process or post-approval process if we are successful at achieving regulatory approval. Even if we are able to successfully complete the development and regulatory reviews described above, we anticipate incurring significant costs associated with commercializing these products, if they are approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to generate revenues from the sale of our product candidates, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our discovery and preclinical development efforts, expand our business or continue our operations and may require us to raise additional capital that may dilute your ownership interest. A decline in our value could also cause you to lose all or part of your investment.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Development of Our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend almost entirely on the success of our lead product candidate, mavorixafor, which we are developing initially for the treatment of WHIM syndrome, for the treatment of SCN and chronic neutropenia disorders, for the treatment of Waldenstr&#246;m&#8217;s, and with a potential strategic partner, for the treatment of ccRCC. We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, mavorixafor or any other product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends almost entirely on the successful clinical development, regulatory approval and commercialization of mavorixafor. We currently have no products for sale and may never be able to develop marketable drug products. We are conducting a global Phase 3 pivotal clinical trial of our lead product candidate, mavorixafor, and may be required to complete additional nonclinical studies and clinical trials before we can seek regulatory approval. We are also conducting a Phase 1b clinical trial of mavorixafor for the treatment of SCN and chronic neutropenia disorders and for Waldenstr&#246;m&#8217;s. While we have investigated mavorixafor for the treatment of ccRCC, we do not intend to develop mavorixafor for this indication on our own. Our other programs, including X4P-002 and X4P-003, are still in the preclinical development stage. The clinical trials of our product candidates are, and the manufacturing and marketing of our product candidates will be, subject to extensive and rigorous review and regulation by government authorities in the United States and in other countries where we intend to test and, if approved, market any product candidate. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must successfully meet a number of critical developmental milestones, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developing dosages that will be well-tolerated, safe and effective;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">completing the development and scale-up to permit manufacture of our product candidates in commercial quantities and at acceptable costs;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">demonstrating through pivotal clinical trials that each product candidate is safe and effective in patients for the intended indication;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The time necessary to achieve these developmental milestones for any individual product candidate is long and uncertain, and we may not successfully complete these milestones for mavorixafor or any other product candidates that we may develop. We have not yet completed development of any product candidate. We also may not be able to finalize the design or formulation for our other programs, X4P-002 and X4P-003.  a next generation molecule for the treatment of rare diseases linked to defects in CXCR4 trafficking.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to test and develop our product candidates and may explore possible design or formulation changes to address safety, efficacy, manufacturing efficiency and performance issues to the extent any arise. We may not be able to complete development of any product candidates that demonstrate safety and efficacy and that will have a commercially reasonable treatment and storage period. If we are unable to complete development of mavorixafor or any other product candidates that we may develop, we will not be able to commercialize and earn revenue from them.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to develop mavorixafor, and potentially future product candidates, in combination with other therapies, which exposes us to additional risks.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to develop mavorixafor, and may develop future product candidates, in combination with one or more currently approved cancer therapies. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also evaluate mavorixafor or any other future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. We will not be able to market and sell mavorixafor or any product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the drugs that we choose to evaluate in combination with mavorixafor or any product candidate we develop, we may be unable to obtain approval of or market mavorixafor or any product candidate we develop.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory review and approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, including mavorixafor, our business will be substantially harmed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of drugs in development in the United States, only a small percentage receive FDA regulatory approval and are commercialized in the United States. We are not permitted to market mavorixafor or any other product candidate in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from such countries or jurisdictions, such as the marketing authorization application (&#8220;MAA&#8221;) in the European Union from the European Medicines Agency (&#8220;EMA&#8221;). Prior to submitting an NDA to the FDA for approval of mavorixafor for the treatment of WHIM syndrome, we will need to successfully complete our current Phase 3 pivotal clinical trial of mavorixafor in patients with WHIM syndrome, and we may be required by the FDA to conduct additional clinical trials and/or nonclinical studies to support potential approval. Successfully completing clinical trials and obtaining approval of an NDA is a complex, lengthy, expensive and uncertain process, and the FDA, or a comparable foreign regulatory authority, may delay, limit or deny approval of mavorixafor for the treatment of WHIM syndrome or other indications for many reasons, including, among others:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">disagreement with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">disagreement with the sufficiency of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure to demonstrate the safety and efficacy of mavorixafor or any other product candidate for its proposed indications;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure to demonstrate that any clinical and other benefits of mavorixafor or any other product candidate outweigh its safety risks;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a negative interpretation of the data from our nonclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">deficiencies in the manufacturing or control processes or failure of third-party manufacturing facilities with which we contract for clinical and commercial supplies to comply with current Good Manufacturing Practice requirements, or cGMPs;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">insufficient data collected from clinical trials of mavorixafor or changes in the approval requirements that render its nonclinical and clinical data insufficient to support the filing of an NDA or to obtain regulatory approval; or</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in clinical practice in or approved products available for the treatment of the target patient population that could have an impact on the indications that we are pursuing for mavorixafor or our other product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or a comparable foreign regulatory authority may also require more information, including additional nonclinical or clinical data to support approval, which may delay or prevent approval of our commercialization plans, or cause us to abandon the development program. Even if we obtain regulatory approval, our product candidates may be approved for fewer or more limited indications than we request, such approval may be contingent on the performance of costly post-marketing clinical trials, or we may not be allowed to include the labeling claims necessary or desirable for the successful commercialization of such product candidate. For instance, it is possible that mavorixafor could be approved for an indication but fail to be used for treating patients in that indication due to the availability of other available treatments or then-accepted clinical practice.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on license agreements with Genzyme, Beth Israel Deaconess Medical Center, Georgetown University and Dana-Farber Cancer Institute to permit us to use patents and patent applications. Termination of these rights or the failure to comply with obligations under these agreements could materially harm our business and prevent us from developing or commercializing our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to license agreements with Genzyme, Beth Israel Deaconess Medical Center, Georgetown University and Dana-Farber Cancer Institute under which we were granted rights to patents and patent applications that are important to our business. We rely on these license agreements in order to be able to use various proprietary technologies that are material to our business, including certain patents and patent applications that cover our product candidates, including mavorixafor. Our rights to use these patents and patent applications and employ the inventions claimed in these licensed patents are subject to the continuation of and our compliance with the terms of our license agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our license agreement with Genzyme imposes upon us various diligence, payment and other obligations, including the following:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our obligation to pay Genzyme milestone payments in the aggregate amount of up to $25.0 million, contingent upon our achievement of certain late-stage regulatory and sales milestones with respect to licensed products.</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our obligation to pay Genzyme tiered royalties based on net sales of licensed products that we commercialize under the agreement.</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our obligation to pay Genzyme a certain percentage of cash payments received by us or our affiliates in consideration for the grant of a sublicense under the license granted to us by Genzyme.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with any of our obligations under the Genzyme license agreement, or we are subject to a bankruptcy, Genzyme may have the right to terminate the license agreement, in which event we would not be able to market any product candidates covered by the license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to July 2014, we did not control the prosecution, maintenance, or filing of the patents and patent applications that are licensed to us under the Genzyme license agreement, or the enforcement of these patents and patent applications against infringement by third parties. Thus, these patents and patent applications were not drafted by us or our attorneys, and we did not control or have any input into the prosecution of these patents and patent applications prior to our execution of the Genzyme license agreement in July 2014. Under the terms of the license agreement with Genzyme, since July 2014, we have controlled the right to control the prosecution, maintenance, and filing of the patents and patent applications that are licensed to us, and the enforcement of these patents and patent applications against infringement by third parties. However, we cannot be certain that the same level of attention was given to the drafting and prosecution of these patents and patent applications as we may have used if we had control over the drafting and prosecution of such patents and patent applications. We also cannot be certain that drafting or prosecution of the patents and patent applications licensed to us has been conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our license agreement with Beth Israel Deaconess Medical Center, we paid an upfront, one-time fee for the rights granted by the license agreement. This license agreement imposes upon us various obligations, including the requirement to provide Beth Israel Deaconess Medical Center with progress reports at regular intervals and to maintain specified levels of insurance. Beth Israel Deaconess Medical Center may terminate the agreement for our non-payment, insolvency or default of material obligations. We have the right to terminate the agreement for any reason upon 90 days&#8217; advance written notice.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our license agreement with Georgetown imposes upon us various diligence, payment and other obligations, including our obligations to pay Georgetown milestone payments in the aggregate amount of up to $0.8 million, contingent upon our achievement of certain sales milestones with respect to licensed products, to deliver reports upon certain events and at regular intervals and to maintain customary levels of insurance. Georgetown may terminate the agreement for our non-payment, insolvency, failure to maintain insurance or default of material obligations. We have the right to terminate the agreement for any reason upon 60 days advance written notice.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our license agreement with the Dana-Farber Cancer Institute (&#8220;DFCI&#8221;) imposes upon us various diligence, payment and other obligations, including our obligations to pay DFCI milestone payments in the aggregate amount of up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $32.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, contingent upon our achievement of certain regulatory and sales milestones with respect to licensed products, to deliver reports at regular intervals and to maintain certain minimum levels of insurance.  DFCI may terminate the agreement if (i) we cease to carry on our business with respect to the licensed products, (ii) we default on diligence, insurance, payment or any other material obligations, (iii) one of our officers or that of a sublicensee is convicted of a felony relating to the manufacture, use, sale or importation of one or more licensed product, (iv) we become insolvent, (v) we grant a sublicense without notifying DFCI or on terms inconsistent with the terms required of sublicenses under the agreement or (vi) we bring a patent challenge against the licensed products. We have the right to terminate the agreement for any reason upon 90 days advance written notice.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise under any of our license agreements with Genzyme, Beth Israel Deaconess Medical Center, Georgetown University and/or Dana-Farber Cancer Institute regarding the intellectual property that is subject to such license agreement, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope of rights granted under the applicable license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">whether and the extent to which our technology and processes infringe on intellectual property that is not subject to the applicable license agreement;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our diligence obligations with respect to the use of the licensed technology under the applicable license agreement to develop and commercialize products and technologies, including the level of effort and specific activities that will satisfy those diligence obligations; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us and our collaborators.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain any of our license agreements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates and technologies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, certain of the above risks and uncertainties may be amplified as a result of the impact of the ongoing COVID-19 notwithstanding the commencement of vaccination efforts. The extent to which COVID-19 may impact our license agreements with Genzyme, Beth Israel Deaconess Medical Center, Georgetown University and/or Dana-Farber Cancer Institute, or any other third-party partner, will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19, including virus variants, and the actions to contain COVID-19, treat its impact or develop herd immunity, among others. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of clinical trials may not support our product candidate claims.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our clinical trials are completed as planned, we cannot be certain that their results will support the proposed product candidates, that the FDA or foreign government authorities will agree with our conclusions regarding such results, or that the FDA or foreign governmental authorities will not require additional clinical trials. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful and the results of later clinical trials often do not replicate the results of prior clinical trials and preclinical testing. The clinical trial results may fail to demonstrate that our product candidates are safe for humans and effective for the intended indications. This failure could cause us to abandon a product candidate and may delay development of other product candidates. Any delay in, or termination of, our clinical trials will delay or prevent the submission of our marketing applications (NDA and/or MAA) and, ultimately, our ability to obtain approval and commercialize our product candidates and generate product revenues. Information about certain clinical trials, including results (positive or negative) will be made public according to each country&#8217;s clinical trial register policies. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in our clinical trials may lead to a delay in the submission of our marketing approval application and jeopardize our ability to potentially receive approvals and generate revenues from the sale of our products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience delays in our current or future clinical trials, including our Phase 3 trial of mavorixafor for the treatment of WHIM syndrome, our Phase 1b clinical trial of mavorixafor for the treatment of SCN and chronic neutropenia disorders, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Phase 1b clinical trial of mavorixafor for the treatment of Waldenstr&#246;m&#8217;s. As a result of the ongoing COVID-19 pandemic, we have experienced delays in clinical trial site activation and slower patient enrollment in our clinical trials of mavorixafor for the treatment of WHIM syndrome, Waldenstr&#246;m&#8217;s and SCN and chronic neutropenia disorders. In addition, currently there is a conflict involving Russia and Ukraine, and our Phase 3 trial of mavorixafor for the treatment of WHIM syndrome includes a trial site located in Russia, where three of the patients enrolled are located. While we have secured alternative arrangements for the affected patients, we still might have to close this site in light of the conflict. While we do not currently believe our clinical trial timelines are significantly impacted, we cannot be certain what the overall impact of this conflict will be on our ability to conduct and complete clinical trials on schedule. Clinical trials may be delayed, suspended or terminated for a variety of reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">irect and indirect effects of the ongoing COVID-19 pandemic on various aspects and stages of the clinical development process, including the potential impact to expected site activation, enrollment and participation in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the diversion of healthcare resources away from the conduct of clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others in connection with the ongoing COVID-19 pandemic, or unforeseen events such as the armed conflict between Russia and Ukraine;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a trial design that we are able to execute;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in obtaining authorization to commence a trial or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inability, delay or failure in identifying and maintaining a sufficient number of trial sites, many of which may already be engaged in competing clinical trial programs;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in recruiting and enrolling suitable subjects to participate in a trial;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in having subjects complete a trial or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">clinical sites and investigators deviating from trial protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in reaching agreement on acceptable terms with prospective clinical research organizations (&#8220;CRO&#8221;), and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in obtaining institutional review board approval to conduct a clinical trial at each site;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays resulting from negative or equivocal findings of the Data Safety Monitoring Board (&#8220;DSMB&#8221;) if any;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">ambiguous or negative results;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">decision by the FDA, a comparable foreign regulatory authority, or recommendation by a DSMB to suspend or terminate clinical trials at any time for safety issues or for any other reason;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inadequate drug product for use in nonclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">lack of adequate funding to continue the product development program; or</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in governmental regulations or requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to enroll a sufficient number of patients in our clinical trials in a timely manner, which could delay or prevent clinical trials of our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on the rate at which we can recruit and enroll patients in testing our product candidates, and we have made certain assumptions about the rate at which we can enroll patients in our clinical trials. The timing of our clinical trials depends in part on the speed at which we can recruit patients to participate in testing mavorixafor and any other current or future product candidates that we may develop as well as completion of required follow-up periods. For example, as a result of the ongoing COVID-19 pandemic, we have experienced, and expect to continue to experience, enrollment at a slower pace at certain of our clinical trial sites than initially expected. In addition, certain of our clinical trial sites have suspended enrollment due to facility closures, quarantine, travel restrictions and other governmental restrictions. As a result, our original expectations regarding the timing of results from our clinical trials of mavorixafor for the treatment of WHIM syndrome, SCN and chronic neutropenia disorders and Waldenstr&#246;m&#8217;s were delayed, which we expect will have a material adverse impact on our clinical trial plans and timelines.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot identify patients to participate in our clinical trials, whether due to COVID-19 or otherwise, or if patients are unwilling to participate in our clinical trials for any reason, including if patients choose to enroll in competitive clinical trials for similar patient populations, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of mavorixafor and any other current or future product candidates that we may develop may be delayed. These delays could result in increased costs, delays in advancing our current or future product candidates, including mavorixafor, X4P-002 or X4P-003, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a trial, to complete our clinical trials in a timely manner. In particular, we are currently evaluating mavorixafor for the treatment of WHIM syndrome, SCN and chronic neutropenia disorders and Waldenstr&#246;m&#8217;s, rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials will further limit the pool of available trial participants.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment, a significant factor in the duration of clinical trials, is also affected by many factors, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays or difficulties in clinical site activation, including difficulties in training clinical site investigators and clinical site staff; </span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">diversion or prioritization of healthcare resources away from the conduct of our clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials, particularly for clinical trials that require in-patient monitoring following administration of the product candidate;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19, being forced to quarantine, or being unable to visit clinical trial locations;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the severity of the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the size and nature of the patient population (particularly with respect to orphan drugs which, by definition, are intended for a relatively small patient population);</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the eligibility criteria for the clinical trial in question;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the design of the clinical trial;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability to obtain and maintain patient consents;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the risk that enrolled subjects will drop out before completion (including due to unforeseen events such as the armed conflict between Russia and Ukraine);</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drug that may be approved or for which clinical trials are initiated for the indications that we are investigating;</span></div><div style="padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our CROs and our trial sites&#8217; efforts to facilitate timely screening and enrollment in clinical trials and</span></div><div style="padding-left:85.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">while we will have agreements governing their activities, we have limited control over their actual performance;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">patient referral practices of physicians; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to monitor patients adequately during and after treatment, which may be affected by COVID-19. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may be forced to delay, limit or terminate ongoing or planned clinical trials of our product candidates, which would delay our ability to obtain approvals and generate product revenues from any of these product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the commercial opportunity in WHIM syndrome, SCN and chronic neutropenia disorders or Waldenstr&#246;m&#8217;s is smaller than we anticipate, our potential future revenue from mavorixafor for the treatment of any of the diseases may be adversely affected and our business may suffer.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the size of the commercial opportunities in any of our target indications is smaller than we anticipate, we may not be able to achieve profitability and growth. We are developing mavorixafor initially as a treatment for patients with WHIM syndrome and also as a treatment for other rare diseases, including primary immunodeficiencies such as SCN and chronic neutropenia disorders and cancer such as Waldenstr&#246;m&#8217;s. WHIM syndrome, SCN and chronic neutropenia disorders and Waldenstr&#246;m&#8217;s each have a limited patient population.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we are aware of only a few small available patient registries for WHIM syndrome, and we rely on various estimates and assumptions to estimate the addressable WHIM syndrome population. Based on a broad online survey of physicians to validate current prevalence estimates and additional research using artificial intelligence, which interrogated a database of more than 300 million anonymized patient records that spanned 10 years of insurance claims, we estimate there are up to 3,700 diagnosed and undiagnosed WHIM patients in the United States, many of whom were previously undiagnosed. If the commercial opportunity in WHIM syndrome is smaller than we anticipate, whether because our estimates of the addressable patient population prove to be incorrect or for other reasons, our potential future revenue from mavorixafor may be adversely affected and our business may suffer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is critical to our ability to grow and become profitable that we successfully identify patients with WHIM syndrome, chronic neutropenia and Waldenstr&#246;m&#8217;s. Our projections of the number of people who have WHIM syndrome (or its other potential primary immunodeficiencies), SCN and chronic neutropenia disorders or Waldenstr&#246;m&#8217;s are based on a variety of sources, including third-party estimates and analyses in the scientific literature, and may prove to be incorrect. Further, new information may emerge that changes our estimate of the prevalence of these diseases or the number of patient candidates for each disease. The effort to identify patients for treatment is at an early stage, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the addressable patient population for our indications may be limited or may not be amenable to treatment with mavorixafor, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization of our product candidates, or our entry into licensing, collaboration or similar arrangements, could be delayed or prevented.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">diversion or prioritization of healthcare resources away from the conduct of clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others in connection with the ongoing COVID-19 pandemic or unforeseen events such as the armed conflict between Russia and Ukraine;;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate (including due to unforeseen events such as the armed conflict between Russia and Ukraine);</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulators, institutional review boards or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may experience delays in reaching, or we may fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks or undesirable side effects;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulators, institutional review boards or independent ethics committees may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, institutional review boards or independent ethics committees to suspend or terminate the clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will increase if we experience delays in testing or marketing approvals. We have experienced delays in clinical trial site activation and slower patient enrollment in our Phase 3 clinical trial of mavorixafor in patients with WHIM syndrome and our Phase 1b clinical trial of mavorixafor in patients with Waldenstr&#246;m&#8217;s and SCN and chronic neutropenia disorders as a result of the ongoing COVID-19 pandemic. Significant preclinical study or clinical trial delays, including as a result of COVID-19, also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, if they are approved, or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm our business and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, unforeseen global events such as the armed conflict between Russia and Ukraine could adversely affect the conduct of our clinical trials and harm our business and results of operations. In late February 2022, Russian military forces launched significant military action against Ukraine. Around the same time, the United States, the United Kingdom, the European Union, and several other nations announced a broad array of new or expanded sanctions, export controls, and other measures against Russia and others supporting Russia&#8217;s economy or military efforts. This armed conflict between Russia and Ukraine, including any resulting sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries, have created global security concerns that could result in a regional conflict and otherwise have a lasting impact on regional and global economies, any or all of which could disrupt our supply chain and adversely affect our ability to conduct ongoing and future clinical trials of our product candidates, including our Phase 3 trial of mavorixafor for the treatment of WHIM syndrome, which currently includes a trial site in Russia, where three of the patients enrolled are located. While we have secured alternative arrangements for affected patients, we still might have to close this site in light of the conflict. While we do not currently believe our clinical trial timelines are significantly impacted, we cannot be certain what the overall impact of this conflict will be on our ability to conduct clinical trials and our business in general.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim top-line or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Preliminary or top-line data may include, for example, data regarding a small percentage of the patients enrolled in a clinical trial, and such preliminary data should not be viewed as an indication, belief or guarantee that other patients enrolled in such clinical trial will achieve similar results or that the preliminary results from such patients will be maintained. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Marketing and Commercialization of Our Product Candidates</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakthrough therapy designation or Fast Track designation by the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and neither of these designations increases the likelihood that our product candidates will receive marketing approval.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained both breakthrough therapy and Fast Track designations for mavorixafor for the treatment of adult patients with WHIM and we may pursue those designations for other product candidates as well. A breakthrough therapy is defined as a product that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. A breakthrough therapy designation affords the possibility of rolling review, enabling the FDA to review portions of our marketing application before submission of a complete application, and possibly, priority review. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a drug or biologic candidate is intended for the treatment of a serious or life-threatening condition or disease and the drug demonstrates the potential to address unmet medical needs for the condition, the sponsor may apply for Fast Track designation. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designation as a breakthrough therapy and Fast Track designation are within the discretion of the FDA. Accordingly, even if we believe that our product candidates meet the criteria for designation as a breakthrough therapy or Fast Track designation, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of either or both of a breakthrough therapy designation or Fast Track designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies or for Fast Track designation, the FDA may later decide that the products no longer meet the conditions for qualification.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is possible that we may not be able to obtain or maintain orphan drug designation or exclusivity for our drug candidates, which could limit the potential profitability of our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for the treatment or prevention of rare diseases or conditions with relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the (&#8220;Orphan Drug Act&#8221;), the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is defined as a patient population of fewer than 200,000 individuals in the United States. We received orphan drug designation from the FDA for mavorixafor for the treatment of WHIM syndrome in October 2018, and from the EMA in July 2019. If a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same indication during that time period with some exceptions. A similar provision in the European Union allows 10 years of exclusivity in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that marketing exclusivity is no longer justified. Orphan drug exclusivity may be lost in both the United States and Europe under certain situations, such as the inability of the holder of the orphan drug designation to produce sufficient quantities of the drug to meet the needs of patients with the rare disease or condition or for certain other reasons.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales and marketing capabilities to market and sell our product candidates, we may be unable to generate any revenue.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are ultimately successful in obtaining regulatory approval of mavorixafor for the treatment of WHIM syndrome or another indication, in order to market and sell mavorixafor and our other product candidates in development, we currently intend to build and develop our own sales, marketing and distribution operations. Although our management team has previous experience with such efforts, there can be no assurance that we will be successful in building these operations. If we are unable to establish adequate sales, marketing and distribution capabilities, we may not be able to generate product revenue and may not become profitable. We will also be competing with many companies that currently have extensive and well-funded sales and marketing operations. If any of our product candidates are approved, we may be unable to compete successfully against these more established companies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among hospitals, physicians, patients and healthcare payors.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the product may not gain market acceptance among hospitals, physicians, health care payors, patients and the medical community. Market acceptance of any of our product candidates for which we receive approval depends on a number of factors, including:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the efficacy and safety of such product candidates as demonstrated in clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the clinical indications for which the product candidate is approved;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">acceptance by major operators of hospitals, physicians and patients of the product candidate as a safe and effective treatment, particularly the ability of mavorixafor and our other product candidates to establish themselves as a new standard of care in the treatment paradigm for the indications that we are pursuing;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the potential and perceived advantages of our product candidates over alternative treatments as compared to the relative costs of the product candidates and alternative treatments;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the prevalence and severity of any side effects with respect to our product candidates, including mavorixafor;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to offer any approved products for sale at competitive prices;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the timing of market introduction of our products as well as competitive products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our pricing, and the availability of coverage and adequate reimbursement by third party payors and government authorities;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">relative convenience and ease of administration; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the effectiveness of our sales and marketing efforts and those of our potential future collaborators.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be delays in getting our product candidates, if approved, on hospital or insurance formularies or limitations on coverages that may be available in the early stages of commercialization for newly approved drugs. If any of our product candidates are approved but fail to achieve market acceptance among hospitals, physicians, patients or health care payors, we will not be able to generate significant revenues, which would have a material adverse effect on our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including marketing withdrawal.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by any of our product candidates that we may develop or acquire could cause us or the FDA or other regulatory authorities to interrupt, delay or halt our clinical trials and could result in more restrictive labels or the delay or denial of marketing approval by the FDA or other regulatory authorities of such product candidates. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. In addition, any drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. If our product candidates receive marketing approval and we or others identify undesirable side effects caused by such product candidates (or any other similar drugs) after such approval, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may withdraw or limit their approval of such product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;boxed&#8221; warning or a contraindication;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be required to change the way such product candidates are distributed or administered, conduct additional clinical trials or change the labeling of the product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may require a Risk Evaluation and Mitigation Strategy plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be subject to regulatory investigations and government enforcement actions;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may decide to remove such product candidates from the marketplace after they are approved;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we could be sued and held liable for injury caused to individuals exposed to or taking our product candidates; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our reputation may suffer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates and could substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our product candidates and generate revenues.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties and any approved products will be subject to extensive post-approval regulatory requirements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain regulatory approval for a product candidate, it would be subject to extensive ongoing requirements by the FDA and comparable foreign regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-market information. The safety profile and efficacy of any product will continue to be closely monitored by the FDA and comparable foreign regulatory authorities after approval. If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, these regulatory authorities may require labeling changes or the FDA may require establishment of a Risk Evaluation Mitigation Strategy or similar strategy, impose significant restrictions on a product&#8217;s indicated uses or marketing, impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. Progress reports are required at quarterly intervals, every six months and at annual intervals depending upon the country, and more frequently if serious adverse events occur.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, manufacturers of drugs and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations. If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with cGMPs and other applicable regulatory requirements, the FDA may, among other things:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">issue warning letters;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">request modifications to promotional materials or require us to provide corrective information to healthcare practitioners;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend or withdraw regulatory approval;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend any ongoing clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">refuse to approve pending applications or supplements to applications filed by us;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our products and generate revenue.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product candidate for which we obtain marketing approval could be subject to marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we obtain marketing approval will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements, quality assurance and corresponding maintenance of records and documents and requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine. The FDA closely regulates the post-approval marketing and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promotion of drugs to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">restrictions on such products, manufacturers or manufacturing processes;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">restrictions on the labeling, marketing, distribution or use of a product;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">requirements to conduct post-approval clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">warning or untitled letters;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">withdrawal of the products from the market;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">recall of products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">fines, restitution or disgorgement of profits or revenue;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">refusal to permit the import or export of our products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">product seizure; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">injunctions or the imposition of civil or criminal penalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to other third parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell some of our product candidates if and when they are approved.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are risks involved both with establishing our own sales and marketing capabilities and with entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing any future products; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of these product revenue to us may be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of cancer, such as ccRCC. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, mavorixafor, is in clinical development for the treatment of WHIM syndrome, chronic neutropenia  and Waldenstr&#246;m&#8217;s, respectively. We are aware of other companies that are developing CXCR4 inhibitors that are in a similar stage of development as mavorixafor, including BioLineRx, Noxxon, Upsher-Smith, Polyphor and Glycomimetics. To our knowledge, there do not appear to be any competitors with programs in development for WHIM syndrome or chronic neutropenia disorders. With respect to chronic neutropenia, filgrastim injections (human granulocyte colony-stimulating factor (G-CSF)) and two biosimilars (Zarxio and Nivestym ) are FDA-approved to reduce the incidence and duration of after-affects of severe neutropenia (e.g.&#8218; fever&#8218; infections&#8218; oropharyngeal ulcers) in symptomatic patients with congenital neutropenia&#8218; cyclic neutropenia&#8218; or idiopathic neutropenia. In Waldenstr&#246;m&#8217;s, there are several treatment approaches currently being developed, including targeted therapies and immunotherapies (as monotherapies and combination therapies), chemotherapy, stem cell transplantation, and cancer vaccines. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well-established therapies and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic products. This may make it difficult for us to achieve our business strategy of using our product candidates in combination with existing therapies or replacing existing therapies with our product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may develop products that are more effective, have a better safety profile, are more convenient or less costly than any that we are developing or that would render our product candidates obsolete or non-competitive. Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products sooner than we may obtain approval for our product candidates, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties may compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval for our product candidates outside of the United States, which would limit our market opportunities and could harm our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. If regulatory approval is obtained, sales of any future product candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a product candidate, comparable foreign regulatory authorities also must approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for any product candidates, if approved, is also subject to approval. Obtaining approval for any future product candidates in the European Union from the European Commission following the opinion of the European Medicines Agency, if we choose to submit a marketing authorization application there, would be a lengthy and expensive process. Even if a product candidate is approved, the FDA or the European Commission, as the case may be, may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limit the indications for which the drug may be marketed, require extensive warnings on the drug labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of any future product candidates in certain countries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for our product candidates may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects could be harmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we seek approval to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could harm our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we seek approval of our product candidates outside of the United States, we expect that we will be subject to additional risks in commercialization including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">different regulatory requirements for approval of therapies in foreign countries;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">reduced protection for intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">foreign reimbursement, pricing and insurance regimes;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters and public health epidemics, such as the ongoing COVID-19 pandemic.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by many of the individual countries in and outside of Europe with which we will need to comply. Many biopharmaceutical companies have found the process of marketing their own products in foreign countries to be very challenging.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize mavorixafor or any other product candidate that we develop, the product may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws and regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted and, in some markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize mavorixafor or any other product candidate successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. and E.U. healthcare industries and elsewhere is cost containment. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage and reimbursement will be available for mavorixafor or any other product that we commercialize and, if coverage and reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for mavorixafor may be particularly difficult because of the higher prices typically associated with drugs directed at smaller populations of patients. In addition, third-party payors are likely to impose strict requirements for reimbursement of a higher priced drug, and any launch of a competitive product is likely to create downward pressure on the price initially charged. If reimbursement is not available or is available only to a limited degree, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the applicable regulatory authority. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacturing, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs, and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. In the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. In the European Union, reference pricing systems and other measures may lead to cost containment and reduced prices. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to develop product candidates and commercialize products and our overall financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit the commercialization of any product candidates we may develop.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk with respect to commercial sales of any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">reduced resources of our management to pursue our business strategy;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">decreased demand for any products that we may develop;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">significant costs to defend any related litigation;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">increased insurance costs; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability to commercialize any products that we may develop.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain clinical trial insurance coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we continue clinical trials or begin commercialization of any products. Insurance coverage is increasingly expensive. We may not be able to obtain or maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to significant penalties, including administrative, civil and criminal penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any drugs on the market, we are, and once we begin commercializing our product candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in the jurisdictions in which we conduct our business. Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, as well as market, sell and distribute any products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid; a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal false claims laws impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; in addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal physician payment transparency requirements, sometimes referred to as the &#8220;Sunshine Act&#8221; under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the &#8220;ACA&#8221;), require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information related to payments and other transfers of value to physicians, (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners and teaching hospitals and the ownership and investment interests of physicians and their immediate family members in such manufacturers; </span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, and their subcontractors that use, disclose, or otherwise process individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, drug pricing or marketing expenditures;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">state and local laws that require the registration of pharmaceutical sales representatives; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">state and foreign laws also govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict post-approval activities and affect our ability to sell profitably any product candidates for which we obtain marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Medicare covers certain drug purchases by the elderly and eligible disabled people and introduced a reimbursement methodology based on average sales prices for physician-administered drugs. In addition, Medicare may limit the number of drugs that will be covered in any therapeutic class. Ongoing cost reduction initiatives and future laws could decrease the coverage and price that we will receive for any approved products. While Medicare beneficiaries are limited to most elderly and certain disabled individual, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the ACA became law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our product candidates are the following:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">extension of manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expansion of eligibility criteria for Medicaid programs;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expansion of the entities eligible for discounts under the Public Health Service Act&#8217;s pharmaceutical pricing program;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">new requirements to report to CMS financial arrangements with physicians, as defined by such law, and teaching hospitals;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a new requirement to annually report to FDA drug samples that manufacturers and distributors provide to physicians; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been challenges to certain aspects of the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several presidential executive orders, Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. It is unclear whether these or similar policy initiatives will be implemented in the future. Further, Congress is considering additional health reform measures.  At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot predict what healthcare reform initiatives may be adopted in the future. However, we expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we will receive for any approved product. These new laws may result in additional reductions in Medicare and other healthcare funding. Any reduction in payments from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our product candidates may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing conditions and other requirements. Further, it is possible that additional governmental action will be taken in response to the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect its business, results of operations and financial condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and other anti-corruption laws that apply in countries where we do business and may do business in the future. The FCPA and these other laws generally prohibit us, our officers and employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential FCPA violations, and may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which its international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the U.S. government and authorities in the European Union or the United Kingdom, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, which we collectively refer to as Trade Control Laws.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, including Trade Control Laws. If we are not in compliance with the FCPA and other anti-corruption laws or Trade Control Laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the FCPA, other anti-corruption laws or Trade Control Laws by U.S. or other authorities could also have an adverse impact on our reputation, business, results of operations and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have minimal experience manufacturing our product candidates on a large clinical or commercial scale and have no manufacturing facility. We are currently dependent on a single third party manufacturer for the manufacture of mavorixafor, the active pharmaceutical ingredient (&#8220;API&#8221;), and a single manufacturer of mavorixafor finished drug product capsules. If we experience problems with these third parties, the manufacturing of mavorixafor could be delayed, which could harm our results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate facilities for the manufacture of mavorixafor or any other product candidate. We currently have no plans to build our own clinical or commercial scale manufacturing capabilities. We currently work exclusively with one manufacturer for the production of mavorixafor, the API, and a single manufacturer of mavorixafor finished drug product capsules. We cannot guarantee that these third parties will continue to perform their contractual duties in a timely and satisfactory manner as a result of the ongoing COVID-19 pandemic, which could negatively impact our supply chain activities and our clinical supply. While we believe we have adequate supply in 2022, this projection may be proven incorrect. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet our projected needs for clinical supplies to support our activities through regulatory approval and commercial manufacturing, the manufacturer with whom we currently work will need to increase its frequency and/or scale of production or we will need to find additional or alternative manufacturers. We have not yet secured alternate suppliers in the event the current manufacturer we utilize is unable to meet demand, or if otherwise we experience any problems with them. If such problems arise and we are unable to arrange for alternative third-party manufacturing sources, we are unable to find an alternative third party capable of reproducing the existing manufacturing method or we are unable to do so on commercially reasonable terms or in a timely manner, we may not be able to complete development of our product candidates, or market or distribute them.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured our product candidates ourselves, including reliance on the third party for regulatory compliance and quality assurance, the possibility of breach of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing agreement by the third party because of factors beyond our control (including a failure to synthesize and manufacture our product candidates or any products that we may eventually commercialize in accordance with our specifications), and the possibility of termination or nonrenewal of the agreement by the third party, based on its own business priorities, at a time that is costly or damaging to us. In addition, the FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP and similar foreign standards. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and some state agencies, and are subject to periodic unannounced inspections for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA or other regulatory authority approval before being implemented. FDA requirements also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, the manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain cGMP compliance. Any failure by our third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates or products if they are approved in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates. In addition, such failure could be the basis for the FDA to issue a warning letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including recall or seizure, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention of product, refusal to permit the import or export of products, injunction, or imposing civil and criminal penalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current manufacturer and any future manufacturers may not be able to manufacture our product candidates at a cost or in quantities or in a timely manner necessary to make commercially successful products. If we successfully commercialize any of our product candidates, we may be required to establish large-scale commercial manufacturing capabilities. In addition, as our drug development pipeline increases and matures, we will have a greater need for clinical study and commercial manufacturing capacity. We have no experience manufacturing pharmaceutical products on a commercial scale and some of these manufacturers will need to increase their scale of production to meet our projected needs for commercial manufacturing, the satisfaction of which may not be met on a timely basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party CROs to conduct our preclinical studies and clinical trials. If these CROs do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon third-party contract research organizations, or CROs, and clinical data management organizations to monitor and manage data for our ongoing preclinical and clinical programs. Although we control only certain aspects of their activities, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We also rely on third parties to conduct our preclinical studies in accordance with Good Laboratory Practice, or GLP, requirements and the Laboratory Animal Welfare Act of 1966 requirements. We, our CROs and our clinical trial sites are required to comply with regulations and current Good Clinical Practices, or GCP, and comparable foreign requirements to ensure that the health, safety and rights of patients are protected in clinical trials, and that data integrity is assured. Regulatory authorities ensure compliance with GCP requirements through periodic inspections of trial sponsors and trial sites. If we, any of our CROs or our clinical trial sites fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials or a specific site may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and preclinical programs. If CROs do not successfully carry out their contractual obligations or meet expected timelines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs may also fail to meet expected timelines as a result of circumstances beyond their control, including the ongoing COVID-19 pandemic. As a result of the ongoing COVID-19 pandemic, we have experienced delays in clinical trial site activation and slower patient enrollment in our clinical trials of mavorixafor in patients with WHIM, Waldenstr&#246;m&#8217;s and SCN, which could delay our ability to obtain regulatory approval for or successfully commercialize our product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions in our supply chain could delay the commercial launch of our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any significant disruption in our supplier relationships could harm our business. We currently rely on a single source supplier of mavorixafor, as well a single supplier for the finished product capsules for mavorixafor. If either of these single source suppliers suffers a major natural or man-made disaster at its manufacturing facility, we would not be able to manufacture mavorixafor on a commercial scale until a qualified alternative supplier is identified. Although alternative sources of supply exist, the number of third party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for alternative suppliers. Any significant delay in the supply of a product candidate or its key materials for an ongoing clinical study could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our product candidates. If we or our manufacturers are unable to purchase these key materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed, which would impair our ability to generate revenues from the sale of our product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, if the ongoing COVID-19 pandemic continues to persist for an extended period of time an impacts essential distribution systems such as FedEx and postal delivery, or if the armed conflict involving Russia and Ukraine, including any resulting sanctions, continues or escalates, we could experience disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of our products, which would adversely impact our ability to deliver products to clinical trial sites or to generate sales of and revenues from our approved products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, to provide accurate information to the FDA or comparable foreign regulatory authorities, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee or third party misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and, particularly in light of the work-from-home policies we have implemented in response to the ongoing COVID-19 pandemic and applicable stay-at-home orders or similar restrictions, the precautions we take to detect and prevent this activity, such as employee training, may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have established, and may seek to selectively establish in the future, collaborations, and, if we are unable to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may depend on such collaborations for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have, and may selectively seek in the future, third-party collaborators for the development and commercialization of our product candidates. Our likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our product candidates pose many risks to us, including that:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates or products if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators with marketing and distribution rights to one or more product candidates or products may not commit sufficient resources to the marketing and distribution of such drugs;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or products or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may lose certain valuable rights under circumstances identified in our collaborations if we undergo a change of control;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. In addition, if a future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in future acquisitions or in-licenses of technology that could disrupt our business, cause dilution to our stockholders and harm our financial condition and operating results.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we currently have no specific plans to acquire any other businesses or in-license any additional products or technology, we may, in the future, make acquisitions or licenses of, or investments in, companies, products or technologies that we believe are a strategic or commercial fit with our current product candidates and business or otherwise offer opportunities for us. In connection with these acquisitions or investments, we may:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue stock that would dilute our stockholders&#8217; percentage of ownership;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expend cash;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur debt and assume liabilities; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur amortization expenses related to intangible assets or incur large and immediate write-offs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may be unable to find suitable acquisition or license candidates and we may not be able to complete acquisitions or licenses on favorable terms, if at all. If we do complete an acquisition or license, we cannot assure you that it will ultimately strengthen our competitive position or that it will not be viewed negatively by customers, financial markets or investors. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Merger poses, and future acquisitions or licenses could also pose, numerous additional risks to our operations, including:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">problems integrating the purchased or licensed business, products or technologies;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases to our expenses</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure to have discovered undisclosed liabilities of the acquired or licensed asset or company;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management&#8217;s attention from their day-to-day responsibilities;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">harm to our operating results or financial condition;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> entrance into markets in which we have limited or no prior experience; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential loss of key employees, particularly those of the acquired entity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to complete one or more acquisitions or effectively integrate the operations, products or personnel gained through any such acquisition without a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent laws and rulings by U.S. courts make it difficult to predict how patents will be issued or enforced in our industry.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may have a significant impact on our ability to protect our technology and enforce our intellectual property rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been numerous recent changes to the patent laws and to the rules of the United States Patent and Trademark Office, or USPTO, which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, the Leahy-Smith America Invents Act, or AIA, which was signed into law in 2011, includes a transition from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, and changes the way issued patents are challenged. Certain changes, such as the institution of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review proceedings, that allow third parties to challenge newly issued patents, came into effect on September 16, 2012. The burden of proof required for challenging a patent in these proceedings is lower than in district court litigation, and patents in the biologics and pharmaceuticals industry have been successfully challenged using these new post-grant challenges. In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in specified circumstances or weakening the rights of patent owners in specified situations. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, these substantive changes to patent law associated with the AIA may further weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future, all of which could harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the patent positions of companies engaged in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Two cases involving diagnostic method claims and &#8220;gene patents&#8221; have recently been decided by the Supreme Court. On March 20, 2012, the Supreme Court issued a decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mayo Collaborative Services v. Prometheus Laboratories, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or Prometheus, a case involving patent claims directed to measuring a metabolic product in a patient to optimize a drug dosage amount for the patient. According to the Supreme Court, the addition of well-understood, routine or conventional activity such as &#8220;administering&#8221; or &#8220;determining&#8221; steps was not enough to transform an otherwise patent ineligible natural phenomenon into patent eligible subject matter. On July 3, 2012, the USPTO issued guidance indicating that process claims directed to a law of nature, a natural phenomenon or an abstract idea that do not include additional elements or steps that integrate the natural principle into the claimed invention such that the natural principle is practically applied and the claim amounts to significantly more than the natural principle itself should be rejected as directed to non-statutory subject matter. On June 13, 2013, the Supreme Court issued its decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Association for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or Myriad, a case involving patent claims held by Myriad Genetics, Inc. relating to the breast cancer susceptibility genes BRCA1 and BRCA2. Myriad held that isolated segments of naturally occurring DNA, such as the DNA constituting the BRCA1 and BRCA2 genes, is not patent eligible subject matter, but that complementary DNA, which is an artificial construct that may be created from RNA transcripts of genes, may be patent eligible.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that our efforts to seek patent protection for our technology and products will not be negatively impacted by the changes described above, future rulings in district court cases or changes in guidance or procedures issued by the USPTO. We cannot fully predict what impact the Supreme Court&#8217;s decisions may have on the ability of life science companies to obtain or enforce patents relating to their products and technologies in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, although the Supreme Court has held in Myriad that isolated segments of naturally occurring DNA are not patent-eligible subject matter, certain third parties could allege that activities that we may undertake infringe other gene-related patent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims, and we may deem it necessary to defend ourselves against these claims by asserting non-infringement and/or invalidity positions, or pay to obtain a license to these claims. In any of the foregoing or in other situations involving third-party intellectual property rights, if we are unsuccessful in defending against claims of patent infringement, we could be forced to pay damages or be subjected to an injunction that would prevent us from utilizing the patented subject matter. Such outcomes could harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property rights, our competitive position could be harmed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our ability to protect our proprietary technology. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary technology and products. Where we have the right to do so under our license agreements, we seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and products that are important to our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patents, including those patent rights licensed to us by third parties, are highly uncertain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The steps we have taken to police and protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside the United States. The rights already granted under any of our currently issued patents and those that may be granted under future issued patents may not provide us with the proprietary protection or competitive advantages that we are seeking. If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology and products similar or superior to ours, and our ability to successfully commercialize our technology and products may be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to patent rights, we do not know whether any of the pending patent applications for any of our product candidates will result in the issuance of patents that protect our technology or products, or which will effectively prevent others from commercializing competitive technologies and products. Our pending applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Further, the examination process may require us or our licensors to narrow the claims, which may limit the scope of patent protection that may be obtained. Although our license agreement with Genzyme includes a number of issued patents that are exclusively licensed to us, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we own or have licensed from third parties may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in the loss of patent protection, the narrowing of claims in such patents, or the invalidity or unenforceability of such patents, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection for our technology and products. Protecting against the unauthorized use of our patented technology, trademarks and other intellectual property rights is expensive, difficult and may, in some cases, not be possible. In some cases, it may be difficult or impossible to detect third party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be required to incur significant expenses to obtain our intellectual property rights, and we cannot ensure that we will obtain meaningful patent protection for our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, it is also possible that we will fail to identify patentable aspects of further inventions made in the course of our development and commercialization activities before they are publicly disclosed, making it too late to obtain patent protection on them. Further, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms where these are available in any countries where we are prosecuting patents. This includes in the United States under the Drug Price Competition and Patent Term Restoration Act of 1984, which permits a patent term extension of up to five years beyond the expiration of a patent that covers an approved product where the permission for the commercial marketing or use of the product is the first permitted commercial marketing or use, and as long as the remaining term of the patent does not exceed 14 years. However, the applicable authorities, including the FDA in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earlier than might otherwise be the case. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States, and these foreign laws may also be subject to change. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2013, the United States transitioned to a &#8220;first to file&#8221; system in which the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit prior art prior to the issuance of a patent by the USPTO and may become involved in post-grant review or derivation proceedings for applications filed on or after March 16, 2013, interference proceedings for applications filed before March 16, 2013, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reexamination, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, which could adversely affect our competitive position with respect to third parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO, and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other requirements during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the possibility of litigation relating to infringement claims asserted against it, we may become a party to other patent litigation and other proceedings, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review proceedings, post-grant review proceedings, derivation proceedings declared by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect to our current or future technologies or product candidates or products. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe or otherwise violate our intellectual property, including patents that may issue to or be licensed by us. As a result, we may be required to file claims in an effort to stop third-party infringement or unauthorized use. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. This can be prohibitively expensive, particularly for a company of our size, and time-consuming, and even if we are successful, any award of monetary damages or other remedy we may receive may not be commercially valuable. In addition, in an infringement proceeding, a court may decide that our asserted intellectual property is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our intellectual </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property does not cover its technology. An adverse determination in any litigation or defense proceedings could put our intellectual property at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the breadth or strength of our patent or other intellectual property rights is compromised or threatened, it could allow third parties to commercialize our technology or products or result in our inability to commercialize our technology and products without infringing third-party intellectual property rights. Further, third parties may be dissuaded from collaborating with us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference or derivation proceedings brought by the USPTO or its foreign counterparts may be necessary to determine the priority of inventions with respect to our patent applications, and we may also become involved in other proceedings, such as re-examination proceedings, before the USPTO or its foreign counterparts. Due to the substantial competition in the pharmaceutical space, the number of such proceedings may increase. This could delay the prosecution of our pending patent applications or impact the validity and enforceability of any future patents that we may obtain. In addition, any such litigation, submission or proceeding may be resolved adversely to us and, even if successful, may result in substantial costs and distraction to our management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Moreover, intellectual property law relating to the fields in which we operate is still evolving and, consequently, patent and other intellectual property positions in our industry are subject to change and are often uncertain. We may not prevail in any of these suits or other efforts to protect our technology, and the damages or other remedies awarded, if any, may not be commercially valuable. During the course of this type of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the market price for our common stock could be significantly harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to several license agreements and may need to obtain additional licenses from others to advance our research and development activities or allow the commercialization of our current product candidates and any that we may identify and pursue in the future. Our currently license agreements impose, and we expect that future license agreements will impose, various development, diligence, commercialization, and other obligations on us. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">From time to time, we may need to rely on licenses to proprietary technologies, which may be difficult or expensive to obtain or we may lose certain licenses which may be difficult to replace.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain licenses to patents and other proprietary rights held by third parties to develop, manufacture and market our product candidates. If we are unable to timely obtain these licenses on commercially reasonable terms and maintain these licenses, our ability to commercially market our product candidates may be inhibited or prevented, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates, and to use our proprietary technologies without infringing the proprietary rights of third parties. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference and various post grant proceedings before the USPTO, non-U.S. opposition proceedings, and German nullity proceedings. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of any such infringement claims, or to avoid potential claims, we may choose or be compelled to seek intellectual property licenses from third parties. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us likely would be nonexclusive, which would mean that our competitors also could obtain licenses to the same intellectual property. Ultimately, we could be prevented from commercializing a product candidate or technology or be forced to cease some aspect of our business operations if, as a result of actual or threatened infringement claims, we are unable to enter into licenses of the relevant intellectual property on acceptable terms. Further, if we attempt to modify a product candidate or technology or to develop alternative methods or products in response to infringement claims or to avoid potential claims, we could incur substantial costs, encounter delays in product introductions or interruptions in sales. Ultimately, such efforts could be unsuccessful.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock and negatively impact our ability to raise additional funds. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our trade secrets are difficult to protect and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technologies and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality, non-competition, non-solicitation, and invention assignment agreements with our employees and consultants that obligate them to assign to us any inventions developed in the course of their work for us. However, we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets or that the agreements we have executed will provide adequate protection. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. As a result, we may be forced to bring claims against third parties, or defend claims that they bring against us, to determine ownership of what we regard as our intellectual property. Monitoring unauthorized disclosure is difficult and we do not know whether the procedures that we have followed to prevent such disclosure are or will be adequate. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States may be less willing or unwilling to protect trade secrets. If any of the technology or information that we protect as trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor, our competitive position would be harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees, including members of our senior management, were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. All such individuals, including each member of our senior management, executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. We are not aware of any threatened or pending claims related to these matters or concerning the agreements with our senior management, but in the future litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive. In general, we have sought patent protection of our intellectual property in the following jurisdictions: US, Canada, China, Japan and in countries within Europe via the European Patent Office. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The global COVID-19 pandemic is adversely affecting, and is expected to continue to adversely affect, our business, including our clinical trials and preclinical studies. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by public health crises such as pandemics or similar outbreaks in regions where we have concentrations of clinical trial sites or other business operations, which could cause significant disruption in the operations of third party manufacturers and CROs upon whom we rely. The ongoing COVID-19 pandemic initially  resulted in a variety of restrictions in order to reduce the spread of the disease, including state and local orders across the United States and other countries worldwide, which, among other things, have directed individuals to stay at their places of residence, directed businesses and governmental agencies to limit non-essential operations at physical locations, prohibited certain non-essential gatherings, and ordered restrictions on travel. While many such restrictions have been lifted and vaccination efforts are ongoing, governmental restrictions may be re-imposed in light of rising incidence of COVID-19 cases and the discovery of variants of the virus. While fully vaccinated employees have returned to our Boston headquarters, work-from-home arrangements will persist to some degree. The effects of our work-from-home policies, as well as any government restrictions on in-office work that may be implemented or re-implemented in the future, including occupancy limits and social distancing requirements, may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions the speed of vaccination efforts, the efficacy of vaccines against current and future variants of the SARS-CoV-2 virus and other limitations on our ability to conduct our business in the ordinary course. In addition, because of the challenging immune profile of both immunodeficient patients and cancer patients, COVID-19 may impact our clinical trial patients more significantly than clinical trials with patients who are not immunocompromised. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarantines, stay-at-home and similar government orders related to COVID-19, if instituted in new jurisdictions or re-imposed in jurisdictions where they were previously lifted,  may adversely impact our business operations and the business operations of our CROs conducting our clinical trials and our third-party manufacturing facilities in the United States and other countries. Although vaccination efforts are on-going, many businesses continue to operate remotely, with limited personnel or with other impacts as a result of the ongoing pandemic. We cannot guarantee that these third parties will continue to perform their contractual duties in a timely and satisfactory manner as a result of the COVID-19 pandemic, which could negatively impact our supply chain activities and our clinical supply. Early in the pandemic, we experienced challenges in providing trial drugs to patients enrolled in our clinical trials and where necessary and practical have implemented direct-to-patient shipments from clinical sites. If the COVID-19 pandemic persists or if future variants of COVID-19 emerge globally and impacts the distribution system on which we rely or essential distribution systems such as FedEx and postal delivery, we could experience disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of our product candidates, which would adversely impact our ability to carry out our clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the ongoing COVID-19 pandemic, we are experiencing disruptions that could severely impact our business, clinical trials and preclinical studies, including:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in enrolling patients in our clinical trials, including travel restrictions on patients and constraints on the capacity of our clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in clinical site activation, including difficulties in training clinical site investigators and clinical site staff;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion or prioritization of healthcare resources away from the conduct of clinical trials and towards the COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials, particularly for clinical trials that require in-patient monitoring following administration of the product candidate;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or disruptions in the availability of clinical site staff, who, as healthcare providers, may have heightened exposure to COVID-19 or whose services may be diverted to the care of COVID-19 patients or to vaccination efforts, would adversely impact our clinical trial operations;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of our key clinical trial activities, such as clinical assessments at pre-specified time points during the trial and clinical trial site data monitoring, due to limitations on travel imposed or recommended by governmental entities, employers and others or interruption of clinical trial subject visits and study procedures (particularly any procedures that may be deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families, the desire of employees to avoid contact with large groups of people, an increased reliance on working from home or mass transit disruptions; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced ability to engage with the medical and investor communities due to the cancellation of conferences scheduled throughout the year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors arising from the ongoing COVID-19 pandemic could worsen in countries that are already experiencing high levels of COVID-19, could continue to spread to additional countries, or could, particularly as new variants of the virus are discovered, return to countries where the pandemic has been partially contained, whether through vaccination, herd immunity or otherwise, each of which could continue to adversely impact our ability to conduct clinical trials and our business generally, and could have a material adverse impact on our operations and financial condition and results. These and other factors may also arise from future pandemics.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The continued spread of COVID-19, including the spread of new variants of the SARS-CoV-2 virus, which has caused a broad impact globally, may materially affect us economically. While the ultimate economic impact brought by, and the duration of, COVID-19 is difficult to assess or predict, a sustained pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a sustained or deepened recession or market correction resulting from the spread of COVID-19 and the impacts of an enduring pandemic could materially affect our business and the value of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic continues to evolve. The extent to which the ongoing COVID-19 pandemic will continue to impact our business, our clinical development and regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions, social distancing requirements, business closures in the United States and other countries, and the timing of the roll-out of coronavirus vaccines and the efficacy of those vaccines against current and future variants of the coronavirus and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global economy as a whole.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain executives and to attract, retain and motivate key personnel in a competitive environment for skilled biotechnology personnel.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. We are highly dependent upon members of our current management team, including Paula Ragan, Ph.D., our Chief Executive Officer, the loss of whose services may adversely impact the achievement of our objectives. Although we have an employment agreement with Dr. Ragan, this agreement is at-will and does not prevent her from terminating her employment with us at any time by providing the requisite advance notice. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend on our ability to retain our management team and other key employees, and to attract and retain qualified personnel in the future. The loss of the services of certain members of our senior management or key employees could prevent or delay the implementation and completion of our strategic objectives, or divert management&#8217;s attention to seeking qualified replacements. The competition for qualified personnel in the pharmaceutical field is intense and we cannot guarantee that we will be able to retain our current personnel or attract and retain new qualified personnel necessary for the development of our business or to recruit suitable replacement personnel.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, we had approximately 100 full-time employees. As our development and commercialization plans and strategies develop, or as a result of any future acquisitions, we will need additional managerial, operational, development, sales, marketing, financial and other resources. Our management, personnel and systems currently in place will not be adequate to support this future growth. Future growth would impose significant added responsibilities on our employees, including:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our clinical trials effectively;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, recruiting, maintaining, motivating and integrating additional employees;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our internal development efforts effectively while complying with our contractual obligations to licensors, contractors and other third parties;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improving our managerial, development, operational and finance systems; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanding our facilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our operations expand, we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional management, administrative, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research and development, and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing the company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The pharmaceutical industry is highly competitive and is subject to rapid and significant technological change, which could render our technologies and products obsolete or uncompetitive.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is highly competitive and is subject to rapid and significant technological change, which could render certain of our products obsolete or uncompetitive. This is particularly true in the development of therapeutics for oncology indications where new products and combinations of products are rapidly being developed that change the treatment paradigm for patients. There is no assurance that our product candidates will be the best, have the best safety profile, be the first to market, or be the most economical to make or use. The introduction of competitive therapies as alternatives to our product candidates could dramatically reduce the value of those development projects or chances of successfully commercializing those product candidates, which could have a material adverse effect on our long-term financial success.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will compete with companies in the United States and internationally, including major pharmaceutical and chemical companies, specialized CROs, research and development firms, universities and other research institutions. Many of our competitors have greater financial resources and selling and marketing capabilities, greater experience in clinical testing and human clinical trials of pharmaceutical products and greater experience in obtaining FDA and other regulatory approvals than we do. In addition, some of our competitors may have lower development and manufacturing costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology or loss of data, including any cyber security incidents, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability which could harm our ability to operate our business effectively and adversely affect our business and reputation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we, our contract research organizations and other third parties on which we rely collect and store sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing on-site systems. These applications and data encompass a wide variety of business-critical information including research and development information and business and financial information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy. Because of the work-from-home policies we implemented due to COVID-19, information that is normally protected, including company confidential information, may be less secure. Additionally, despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, breaches, unauthorized access, interruptions due to employee error or malfeasance or other disruptions, or damage from natural disasters, terrorism, war and telecommunication and electrical failures. In addition, due to the COVID-19 pandemic, we have enabled substantially all of our employees to work remotely, which may make us more vulnerable to cyberattacks. Any such event could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. We have measures in place that are designed to detect and respond to such security incidents and breaches of privacy and security mandates. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, government enforcement actions and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to conduct research, development and commercialization activities, process and prepare company financial information, manage various general and administrative aspects of our business and damage our reputation, in addition to possibly requiring substantial expenditures of resources to remedy, any of which could adversely affect our business. The loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, there can be no assurance that we will promptly detect any such disruption or security breach, if at all. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our research, development and commercialization efforts could be delayed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenues and financial condition and increase our costs and expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics (including but not limited to the COVID-19 pandemic) and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on a single third-party manufacturer to provide the active pharmaceutical ingredient for mavorixafor and a single third-party manufacturer to provide fill and finish services for the final drug product formulation of mavorixafor for use in clinical trials. Our ability to obtain clinical supplies of product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net operating loss, or NOL, carryforwards could expire unused and be unavailable to offset future tax liabilities because of their limited duration or because of restrictions under U.S. tax law. As of December 31, 2021, we had U.S. federal and state NOLs of $315.0 million and $308.2 million, respectively. Our NOLs generated in tax years ending on or prior to December 31, 2017 are only permitted to be carried forward for 20 years under applicable U.S. tax law. Under the Tax Act, as modified by the CARES Act, our federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely, but the deductibility of federal NOLs, particularly for tax years beginning after December 31, 2020, may be limited. It is uncertain if and to what extent various states will conform to the Tax Act and the CARES Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 382 of the Internal Revenue Code of 1986, as amended, or Section 382, contains rules that limit the ability of a company that undergoes an ownership change to utilize its net operating losses, or NOLs, and tax credits existing as of the date of such ownership change. Under the rules, such an ownership change is generally any change in ownership of more than 50% of a company&#8217;s stock within a rolling three-year period. The rules generally operate by focusing on changes in ownership among stockholders considered by the rules as owning, directly or indirectly, 5% or more of the stock of a company and any change in ownership arising from new issuances of stock by the company. We have experienced multiple ownership changes since our inception and are conducting a study to assess whether an ownership change has occurred and whether these ownership changes will limit the future use of our NOL carryforwards. Future ownership changes as defined by Section 382 may further limit the amount of NOL carryforwards that could be utilized annually to offset future taxable income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our term loan contains restrictions that limit our flexibility in operating our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a loan and security agreement, as most recently amended in February 2022, with Hercules, secured by a lien on substantially all of our assets, including intellectual property. This loan contains various covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other things:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sell, transfer, lease or dispose of certain assets;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur indebtedness;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">encumber or permit liens on certain assets;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make certain investments;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make certain restricted payments, including paying dividends on, or repurchasing or making distributions with respect to, our common stock; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into certain transactions with affiliates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The covenants also include a requirement that, from and after an initial test date of September 1, 2022, we maintain cash in an aggregate amount greater than or equal to the greater of (i) $30.0 million, or (ii) six multiplied by a metric based on prior months&#8217; cash expenditures; provided, however, that from and after our achievement of certain financing milestones through June 30, 2022, we must maintain cash in an account or accounts in which Hercules has a first priority security interest in an aggregate amount of $30.0 million. Following the achievement of certain operational performance milestones, the required level shall be reduced to the greater of $20.0 million, or if we had not met the financing milestones noted above, three multiplied by the current cash expenditures metric; and provided further, that subject to the achievement of additional operational milestones, this covenant will be extinguished. Based on our current cash and cash equivalents and our current operating plan, we believe that if we fail to raise additional capital by June 30, 2022, we would be in violation of the minimum cash described above in the third quarter of 2022. A breach of any of the covenants under the loan and security agreement could result in a default under the loan. Upon the occurrence of an event of default under the loan, the lenders could elect to declare all amounts outstanding, if any, to be immediately due and payable and terminate all commitments to extend further credit. If there are any amounts outstanding that we are unable to repay, the lenders could proceed against the collateral granted to them to secure such indebtedness.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price is expected to continue to be volatile.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock could continue to be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or the ability of our collaborators to develop product candidates and conduct clinical trials that demonstrate such product candidates are safe and effective;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or the ability of our collaborators to obtain regulatory approvals for product candidates, and delays or failures to obtain such approvals;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any our product candidates to demonstrate safety and efficacy, receive regulatory approval and achieve commercial success;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain our existing third-party license, manufacturing and supply agreements;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by us or our licensors to prosecute, maintain or enforce our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our current or future product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any inability to obtain adequate supply of product candidates or the inability to do so at acceptable prices;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse decisions by regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new or competing products by our competitors;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial and development projections that we may provide to the public;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain intellectual property protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including intellectual property or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us of material developments in our business, financial condition and/or operations;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if securities or industry analysts do not publish research or reports about us, or if they issue an adverse or misleading opinions regarding our business and stock;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market or macroeconomic conditions;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock or our stockholders in the future;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity relating to our markets generally, including with respect to other products and potential products in such markets;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of health care payment systems; </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry, political and market conditions, including, but not limited to the ongoing impact of the COVID-19 pandemic.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, companies trading in the stock market in general, and Nasdaq in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including recently in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to the ongoing COVID-19 pandemic, may negatively affect the market price of our common stock, regardless of our actual operating performance.Similarly, the current conflict between Ukraine and Russia has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our business, financial condition, results of operations and reputation.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company,&#8221; and a &#8220;smaller reporting company&#8221; and as a result of the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act of 2012, (the &#8220;JOBS Act&#8221;), and may remain an emerging growth company until December 31, 2022. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure obligations regarding executive compensation; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors may find our common stock less attractive as a result of our reliance on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even following the termination of our status as an emerging growth company, we will be able to take advantage of the reduced disclosure requirements applicable to smaller reporting companies (as that term is defined in Rule 12b-2 of the Exchange Act) and, in particular, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. To the extent that we are no longer eligible to use exemptions from various reporting requirements, we may be unable to realize our anticipated cost savings from these exemptions, which could have a material adverse impact on our operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced, in part, on the research and reports that industry or financial analysts publish about us or our business. Equity research analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current expectation is that we will retain our future earnings to fund the development and growth of our business. In addition, the terms of our debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future. We are prohibited from declaring or paying any cash dividends under our existing loan and security agreement with Hercules Capital, Inc.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to decline.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales, particularly sales by our directors, executive officers, and significant stockholders, may have on the prevailing market price of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have filed registration statements on Form S-8 registering the issuance of shares of common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. Shares registered under these registration statements are available for sale in the public market subject to vesting arrangements and exercise of options, as well as Rule 144 in the case of our affiliates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002 and the rules and regulations of The Nasdaq Global Market. Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting in this Quarterly Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us, as and when required, conducted in connection with Section 404 of the Sarbanes-Oxley Act, or Section 404, or any subsequent testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal control over financial reporting that are deemed to be significant deficiencies or material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an EGC, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. When we cease to be an emerging growth company and we no longer qualify as a non-accelerated filer, we will be required to incur substantial additional professional fees and internal costs to expand our accounting and finance functions in order to include such attestation report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our consolidated financial statements. Our internal control over financial reporting will not prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. If we identify one or more material weaknesses in our internal controls, investors could lose confidence in the reliability of our consolidated financial statements, the market price of our stock could decline and we could be subject to sanctions or investigations by The Nasdaq Global Market, the SEC or other regulatory authorities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in securities class action litigation or shareholder derivative litigation that could divert management&#8217;s attention and harm our business and insurance coverage may not be sufficient to cover all costs and damages.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action or shareholder derivative litigation has often followed certain significant business transactions, such as the sale of a business division or announcement of a merger. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. We may become involved in this type of litigation in the future, including litigation, if any, that may result in connection with the Merger. Litigation often is expensive and diverts management&#8217;s attention and resources, which could adversely affect our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and by-laws may discourage, delay or prevent a merger, acquisition or other change in control of our Company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors such that not all members of the board are elected at one time;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of the board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the manner in which stockholders can remove directors from the board;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to the board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize the board of directors to issue preferred stock without stockholder approval, which could be used to institute a shareholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the board of directors; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or by-laws.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with the Company for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between the Company and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the Company or our directors, officers, employees or stockholders.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on the Company&#8217;s behalf, any action asserting a breach of fiduciary duty owed by our directors, officers, other employees or stockholders to the Company or our stockholders, any action asserting a claim against the Company arising pursuant to the Delaware General Corporation Law or as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware, or any action asserting a claim arising pursuant to our certificate of incorporation or by-laws or governed by the internal affairs doctrine. This provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or our directors, officers, employees or stockholders, which may discourage such lawsuits against the Company and our directors, officers, employees or stockholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alternatively, if a court were to find this provision in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_121"></div><div style="margin-top:18pt;padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="i092653cc5b8c43bdad358095e593d81b_124"></div><div style="margin-top:18pt;padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i092653cc5b8c43bdad358095e593d81b_127"></div><div style="margin-top:18pt;padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i092653cc5b8c43bdad358095e593d81b_130"></div><div style="margin-top:18pt;padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i092653cc5b8c43bdad358095e593d81b_133"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;EXHIBITS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Incorporated by Reference to:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit Description</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828020009266/ex31amendedcharter.htm">Restated Certificate of Incorporation, as amended, as of June 10, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/10/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38295</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000119312517348213/d495338dex32.htm">Amended and Restated By-laws of the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/20/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38295</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/d702482dex41.htm">Form of Common Stock Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000162828022000967/ex_101purchaseagreement.htm">Purchase Agreement, dated as of January 14, 2022, by and between X4 Pharmaceuticals Inc. and Lincoln Park Capital Fund, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">1/14/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000162828022000967/ex_102registrationrights.htm">Registration Rights Agreement, dated as of January 14, 2022, by and between X4 Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">1/14/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-311q12022.htm">Certification of Principal Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-312q12022.htm">Certification of Principal Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-321q12022.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">* Filed herewith</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">** The certification attached as Exhibit 32.1 accompanying this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i092653cc5b8c43bdad358095e593d81b_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.555%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 12, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paula Ragan, Ph.D.&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paula Ragan, Ph.D.<br/>President and Chief Executive Officer</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.555%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 12, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Adam S. Mostafa&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam S. Mostafa<br/>Chief Financial Officer and Treasurer</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex-311q12022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib1a3768a135d400da0c2eef4f201571c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paula Ragan, Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of X4 Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 12, 2022</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Paula Ragan, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paula Ragan, Ph.D.<br>President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex-312q12022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1831612df50543ecaffa1eb5079ea457_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Adam S. Mostafa, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of X4 Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 12, 2022</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Adam S. Mostafa</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam S. Mostafa<br>Chief Financial Officer and Treasurer<br>(Principal Financial Officer)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex-321q12022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i385ecdbf5c23458ea8452e2d5480d3f2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 906</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and Section 1350 of  Chapter 63 of Title 18 of the United States Code(18 U.S.C. &#167;1350), Paula Ragan, Ph.D., Chief Executive Officer of X4 Pharmaceuticals, Inc. (the &#8220;Company&#8221;) and Adam S. Mostafa, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge&#58;</font></div><div><font><br></font></div><div style="padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2022, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and</font></div><div style="padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the undersigned have set their hands hereto as of the 12th day of May 2022. </font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; May 12, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Paula Ragan, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Paula Ragan, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; May 12, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Adam S. Mostafa</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Adam S. Mostafa</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of X4 Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>xfor-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:15224e09-2b4e-4653-a05c-4094a1da55b0,g:b51d9744-e75b-48fa-9941-02b626145304-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xfor="http://www.x4pharma.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.x4pharma.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.x4pharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical">
        <link:definition>1405401 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusinessandBasisofPresentation" roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail">
        <link:definition>2402402 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail">
        <link:definition>2406403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Compensating Balance Arrangements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail">
        <link:definition>2407404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandFundingAgreements" roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements">
        <link:definition>2108103 - Disclosure - License, Collaboration, and Funding Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandFundingAgreementsAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail">
        <link:definition>2409405 - Disclosure - License, Collaboration, and Funding Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilities" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities">
        <link:definition>2110104 - Disclosure - Fair Value of Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesTables" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables">
        <link:definition>2311302 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail">
        <link:definition>2412406 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesDetails" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails">
        <link:definition>2413407 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNet">
        <link:definition>2114105 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetTables">
        <link:definition>2315303 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail" roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail">
        <link:definition>2416408 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetAdditionalInformationDetail">
        <link:definition>2417409 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.x4pharma.com/role/AccruedExpenses">
        <link:definition>2118106 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.x4pharma.com/role/AccruedExpensesTables">
        <link:definition>2319304 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesScheduleofAccruedExpensesDetail" roleURI="http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail">
        <link:definition>2420410 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.x4pharma.com/role/LongTermDebt">
        <link:definition>2121107 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.x4pharma.com/role/LongTermDebtTables">
        <link:definition>2322305 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtSummaryofLongTermDebtDetail" roleURI="http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail">
        <link:definition>2423411 - Disclosure - Long-Term Debt - Summary of Long Term Debt (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtHerculesLoanAgreementAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail">
        <link:definition>2424412 - Disclosure - Long Term Debt - Hercules Loan Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail" roleURI="http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail">
        <link:definition>2425413 - Disclosure - Long-Term Debt - Schedule of Future Principal Payments and the Final Payments Due (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.x4pharma.com/role/Leases">
        <link:definition>2126108 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.x4pharma.com/role/LeasesTables">
        <link:definition>2327306 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/LeasesAdditionalInformationDetail">
        <link:definition>2428414 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofComponentsofLeaseExpenseDetail" roleURI="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail">
        <link:definition>2429415 - Disclosure - Leases - Schedule of Components of Lease Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail">
        <link:definition>2430416 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1">
        <link:definition>2430416 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.x4pharma.com/role/CommitmentandContingencies">
        <link:definition>2131109 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail">
        <link:definition>2432417 - Disclosure - Commitment and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockWarrants" roleURI="http://www.x4pharma.com/role/CommonStockWarrants">
        <link:definition>2133110 - Disclosure - Common Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockWarrantsTables" roleURI="http://www.x4pharma.com/role/CommonStockWarrantsTables">
        <link:definition>2334307 - Disclosure - Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockWarrantsAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail">
        <link:definition>2435418 - Disclosure - Common Stock Warrants - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockWarrantsScheduleofOutstandingWarrantsDetail" roleURI="http://www.x4pharma.com/role/CommonStockWarrantsScheduleofOutstandingWarrantsDetail">
        <link:definition>2436419 - Disclosure - Common Stock Warrants - Schedule of Outstanding Warrants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail" roleURI="http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail">
        <link:definition>2437420 - Disclosure - Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.x4pharma.com/role/StockBasedCompensation">
        <link:definition>2138111 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.x4pharma.com/role/StockBasedCompensationTables">
        <link:definition>2339308 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2440421 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail" roleURI="http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail">
        <link:definition>2441422 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-date Fair Value of Stock Options Granted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetail" roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail">
        <link:definition>2442423 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationDetails" roleURI="http://www.x4pharma.com/role/StockBasedCompensationDetails">
        <link:definition>2443424 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails">
        <link:definition>2444425 - Disclosure - Stock-Based Compensation Summary of Stock-Based Compensation Expense Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.x4pharma.com/role/IncomeTaxes">
        <link:definition>2145112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>2446426 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.x4pharma.com/role/NetLossperShare">
        <link:definition>2147113 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.x4pharma.com/role/NetLossperShareTables">
        <link:definition>2348309 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail" roleURI="http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail">
        <link:definition>2449427 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail">
        <link:definition>2450428 - Disclosure - Net Loss per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail" roleURI="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail">
        <link:definition>2451429 - Disclosure - Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="xfor_TwoThousandSeventeenEquityIncentivePlanMember" abstract="true" name="TwoThousandSeventeenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="xfor_AggregateBaseRent" abstract="false" name="AggregateBaseRent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ResearchAndDevelopmentIncentiveReceivable" abstract="false" name="ResearchAndDevelopmentIncentiveReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ContingenciesAndCommitmentsLineItems" abstract="true" name="ContingenciesAndCommitmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_ClassAWarrantMember" abstract="true" name="ClassAWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" abstract="true" name="IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_AllstonLeaseAgreementMember" abstract="true" name="AllstonLeaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_RedeemableCommonStockMember" abstract="true" name="RedeemableCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" abstract="true" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="xfor_AllstonLeaseMember" abstract="true" name="AllstonLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_WarrantsRollForward" abstract="true" name="WarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_HerculesSecondAmendedLoanAgreementMember" abstract="true" name="HerculesSecondAmendedLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" abstract="false" name="ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" abstract="true" name="IssuanceOnNovemberNineTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_MinCashTestDate2Member" abstract="true" name="MinCashTestDate2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightIssued" abstract="false" name="ClassOfWarrantOrRightIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm" abstract="false" name="ClassOfWarrantOrRightWeightedAverageContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xfor_LongTermDebtIncludingAccretion" abstract="false" name="LongTermDebtIncludingAccretion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ProceedsFromExerciseOfStockOptionsAndWarrants" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" abstract="false" name="ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" abstract="false" name="ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_AccretionOnLongTermDebt" abstract="false" name="AccretionOnLongTermDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ScheduleOfLongTermDebtTable" abstract="true" name="ScheduleOfLongTermDebtTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" abstract="true" name="IssuanceOnOctoberNineteenTwoThousandEighteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_CurrentOfficeSpaceUnderLeaseAgreement" abstract="false" name="CurrentOfficeSpaceUnderLeaseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="xfor_LongTermDebtNonCurrentIncludingAccretion" abstract="false" name="LongTermDebtNonCurrentIncludingAccretion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ContingenciesAndCommitmentsTable" abstract="true" name="ContingenciesAndCommitmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_LongTermDebtAndEOTPayment" abstract="false" name="LongTermDebtAndEOTPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts" abstract="false" name="ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ViennaAustriaLeaseMember" abstract="true" name="ViennaAustriaLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightExercised" abstract="false" name="ClassOfWarrantOrRightExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xfor_DebtInstrumentPrepaymentPremiumPercentage" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" abstract="true" name="IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod" abstract="false" name="ClassOfWarrantOrRightWarrantsExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_OperatingLeaseExpiration" abstract="false" name="OperatingLeaseExpiration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xfor_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" abstract="true" name="IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ClassBWarrantsMember" abstract="true" name="ClassBWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_CollaborationLicenseAndFundingArrangementsLineItems" abstract="true" name="CollaborationLicenseAndFundingArrangementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_PrefundedWarrantsAxis" abstract="true" name="PrefundedWarrantsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="xfor_IndemnificationAgreementsMember" abstract="true" name="IndemnificationAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_SoftwareMember" abstract="true" name="SoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_LegacyWarrantsMember" abstract="true" name="LegacyWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_LineOfCreditCovenantMinimumCash" abstract="false" name="LineOfCreditCovenantMinimumCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ScheduleOfAccountingPoliciesTable" abstract="true" name="ScheduleOfAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" abstract="true" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_ResearchAndDevelopmentIncentiveProgramMember" abstract="true" name="ResearchAndDevelopmentIncentiveProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_HerculesLoanAgreementMember" abstract="true" name="HerculesLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ViennaLeaseAgreementMember" abstract="true" name="ViennaLeaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IncreaseDecreaseInLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_GrantAndIncentiveReceivables" abstract="false" name="GrantAndIncentiveReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" abstract="true" name="IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_AccruedExternalResearchAndDevelopmentExpenses" abstract="false" name="AccruedExternalResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xfor_FundedMember" abstract="true" name="FundedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_PrefundedWarrantsDomain" abstract="true" name="PrefundedWarrantsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IssuanceOnMarch32022Member" abstract="true" name="IssuanceOnMarch32022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_AccruedExpensesTextBlock" abstract="false" name="AccruedExpensesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="xfor_PreFundedWarrantMember" abstract="true" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" abstract="false" name="LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_MinCashTestDate1Member" abstract="true" name="MinCashTestDate1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_TwoThousandNineteenEquityIncentivePlanMember" abstract="true" name="TwoThousandNineteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" abstract="true" name="IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" abstract="true" name="IssuanceOnMarchThirteenTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_WalthamLeaseMember" abstract="true" name="WalthamLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" abstract="true" name="IssuanceOnAprilSixteenTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_CollaborationLicenseAndFundingArrangementsTable" abstract="true" name="CollaborationLicenseAndFundingArrangementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="xfor_IssuanceOnMarch232021Member" abstract="true" name="IssuanceOnMarch232021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" abstract="false" name="ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="xfor_ScheduleOfLongTermDebtLineItems" abstract="true" name="ScheduleOfLongTermDebtLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_WarrantsWeightedAverageExercisePriceRollForward" abstract="true" name="WarrantsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>xfor-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:15224e09-2b4e-4653-a05c-4094a1da55b0,g:b51d9744-e75b-48fa-9941-02b626145304-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="xfor-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7d04331c-4ead-4279-be14-642190d41fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a8ce5c9c-45e9-4d1f-b87f-e210f4bb6d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7d04331c-4ead-4279-be14-642190d41fc3" xlink:to="loc_us-gaap_LiabilitiesCurrent_a8ce5c9c-45e9-4d1f-b87f-e210f4bb6d7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtNonCurrentIncludingAccretion_17d1430c-9c6a-480d-be24-a01c0691d1d2" xlink:href="xfor-20220331.xsd#xfor_LongTermDebtNonCurrentIncludingAccretion"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7d04331c-4ead-4279-be14-642190d41fc3" xlink:to="loc_xfor_LongTermDebtNonCurrentIncludingAccretion_17d1430c-9c6a-480d-be24-a01c0691d1d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ab9732f3-0f73-46a1-958f-30d052c9e015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7d04331c-4ead-4279-be14-642190d41fc3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ab9732f3-0f73-46a1-958f-30d052c9e015" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ca022718-e165-46d9-a36f-36addd00c265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7d04331c-4ead-4279-be14-642190d41fc3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ca022718-e165-46d9-a36f-36addd00c265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ce4ddce5-66d9-4878-b352-89a9c7e5aa23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d7550f43-db9d-43f3-8711-c60ac81d2409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ce4ddce5-66d9-4878-b352-89a9c7e5aa23" xlink:to="loc_us-gaap_AccountsPayableCurrent_d7550f43-db9d-43f3-8711-c60ac81d2409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c82135b0-4113-4c76-b7a9-c2136acf93f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ce4ddce5-66d9-4878-b352-89a9c7e5aa23" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c82135b0-4113-4c76-b7a9-c2136acf93f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0eb07504-01e0-405b-afd5-9438e444a3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ce4ddce5-66d9-4878-b352-89a9c7e5aa23" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0eb07504-01e0-405b-afd5-9438e444a3c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_2f237b5b-84a7-4ca7-ba30-89bd22d4fdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ce4ddce5-66d9-4878-b352-89a9c7e5aa23" xlink:to="loc_us-gaap_LongTermDebtCurrent_2f237b5b-84a7-4ca7-ba30-89bd22d4fdfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ebd506f9-fa4e-4bfc-b265-7d461787188d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0e720205-30e8-457c-b94b-64f5dd87b4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ebd506f9-fa4e-4bfc-b265-7d461787188d" xlink:to="loc_us-gaap_CommonStockValue_0e720205-30e8-457c-b94b-64f5dd87b4d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e2a08889-8b57-401d-9099-22b69615ec7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ebd506f9-fa4e-4bfc-b265-7d461787188d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e2a08889-8b57-401d-9099-22b69615ec7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_236dde0a-e184-43b4-9e75-8adffe37a27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ebd506f9-fa4e-4bfc-b265-7d461787188d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_236dde0a-e184-43b4-9e75-8adffe37a27d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b3443644-ebd6-425b-bd83-0f63c77bf525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ebd506f9-fa4e-4bfc-b265-7d461787188d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b3443644-ebd6-425b-bd83-0f63c77bf525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f76a3974-9900-4e0d-8623-09391575c2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7fc820c8-907a-48d1-a489-4ac17b1df33e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f76a3974-9900-4e0d-8623-09391575c2d1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7fc820c8-907a-48d1-a489-4ac17b1df33e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveReceivable_958d7344-0570-47b2-a1f5-f2b27a151b08" xlink:href="xfor-20220331.xsd#xfor_ResearchAndDevelopmentIncentiveReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f76a3974-9900-4e0d-8623-09391575c2d1" xlink:to="loc_xfor_ResearchAndDevelopmentIncentiveReceivable_958d7344-0570-47b2-a1f5-f2b27a151b08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8baaa17f-49d0-4f5c-b2c0-fa0c447ef1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f76a3974-9900-4e0d-8623-09391575c2d1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8baaa17f-49d0-4f5c-b2c0-fa0c447ef1df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_68007170-81f9-4022-9b81-4510e4201650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_eda5a5ba-a1e1-495c-8ba4-c444c129b256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68007170-81f9-4022-9b81-4510e4201650" xlink:to="loc_us-gaap_AssetsCurrent_eda5a5ba-a1e1-495c-8ba4-c444c129b256" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_06a7f6c3-05ce-434a-9d34-2f411493213e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68007170-81f9-4022-9b81-4510e4201650" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_06a7f6c3-05ce-434a-9d34-2f411493213e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3a0080c7-b54a-44a7-a65a-69c0e214e1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68007170-81f9-4022-9b81-4510e4201650" xlink:to="loc_us-gaap_Goodwill_3a0080c7-b54a-44a7-a65a-69c0e214e1fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_71f70c39-ebdc-455b-bb3e-2964cdb25051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68007170-81f9-4022-9b81-4510e4201650" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_71f70c39-ebdc-455b-bb3e-2964cdb25051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2883fbc7-c26f-490e-98be-0e83262dee5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_68007170-81f9-4022-9b81-4510e4201650" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2883fbc7-c26f-490e-98be-0e83262dee5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fe7e2722-b32e-4668-86cf-0fecc0850f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_33e7295f-6f35-46eb-b37d-61469386ef1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fe7e2722-b32e-4668-86cf-0fecc0850f56" xlink:to="loc_us-gaap_Liabilities_33e7295f-6f35-46eb-b37d-61469386ef1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e5a11cf2-19d2-4452-9b5a-b7ad3d80c54d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fe7e2722-b32e-4668-86cf-0fecc0850f56" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e5a11cf2-19d2-4452-9b5a-b7ad3d80c54d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e4dc1163-fbd1-426e-befa-05058ece68e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fe7e2722-b32e-4668-86cf-0fecc0850f56" xlink:to="loc_us-gaap_StockholdersEquity_e4dc1163-fbd1-426e-befa-05058ece68e6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="xfor-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_62487307-1098-4024-bb96-6daeb3c24b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_d1ddc6ea-ef88-4cf6-a34f-8465fb41f87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_62487307-1098-4024-bb96-6daeb3c24b2b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_d1ddc6ea-ef88-4cf6-a34f-8465fb41f87e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_13412411-94ed-459b-b14d-6720a5ae3a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_62487307-1098-4024-bb96-6daeb3c24b2b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_13412411-94ed-459b-b14d-6720a5ae3a00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_462c83ae-b510-471d-85af-34c88063e2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_62487307-1098-4024-bb96-6daeb3c24b2b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_462c83ae-b510-471d-85af-34c88063e2db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_27afbb64-0728-4cd5-ab8f-c3077d05ca88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_62487307-1098-4024-bb96-6daeb3c24b2b" xlink:to="loc_us-gaap_InterestExpense_27afbb64-0728-4cd5-ab8f-c3077d05ca88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b8bde3d2-8178-4485-adae-85a4226a158b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fb89aeb8-8c4b-4590-8acb-8bdfb5eeb551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b8bde3d2-8178-4485-adae-85a4226a158b" xlink:to="loc_us-gaap_OperatingExpenses_fb89aeb8-8c4b-4590-8acb-8bdfb5eeb551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9d5ca248-6e1d-4445-82ed-c51f9d0d0b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_93134772-03d3-4b0b-a018-92fbd265a84a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9d5ca248-6e1d-4445-82ed-c51f9d0d0b17" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_93134772-03d3-4b0b-a018-92fbd265a84a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_08f28fce-70b1-4cf4-9e2a-35af2097df1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9d5ca248-6e1d-4445-82ed-c51f9d0d0b17" xlink:to="loc_us-gaap_OperatingIncomeLoss_08f28fce-70b1-4cf4-9e2a-35af2097df1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d9909b31-603d-4576-bdbf-6c9955a88d49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d0448d87-04e7-4d48-9d6b-b989f1edf8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d9909b31-603d-4576-bdbf-6c9955a88d49" xlink:to="loc_us-gaap_NetIncomeLoss_d0448d87-04e7-4d48-9d6b-b989f1edf8bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_caa6e533-76b3-475c-8077-333a6485bc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d9909b31-603d-4576-bdbf-6c9955a88d49" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_caa6e533-76b3-475c-8077-333a6485bc0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6cfd7373-c6af-4a5b-9e08-1deb78dc796c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f65bd3a7-3340-4ea3-81d1-c6e5cd19849f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6cfd7373-c6af-4a5b-9e08-1deb78dc796c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f65bd3a7-3340-4ea3-81d1-c6e5cd19849f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0ccd314a-4ce6-4f82-8c5f-fa899ca3b67a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6cfd7373-c6af-4a5b-9e08-1deb78dc796c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0ccd314a-4ce6-4f82-8c5f-fa899ca3b67a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2dc7fa08-f7b5-4261-9b32-e3bb53204c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_91f4e4a8-528c-4572-85ac-77f21f8fdc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2dc7fa08-f7b5-4261-9b32-e3bb53204c12" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_91f4e4a8-528c-4572-85ac-77f21f8fdc0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d64343b1-3c04-420c-a29b-45a21f032eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2dc7fa08-f7b5-4261-9b32-e3bb53204c12" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d64343b1-3c04-420c-a29b-45a21f032eb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_75e5889e-b522-4bf0-bcac-f75008c50d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2dc7fa08-f7b5-4261-9b32-e3bb53204c12" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_75e5889e-b522-4bf0-bcac-f75008c50d1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="xfor-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_40418484-a529-40e8-9d61-785a8f4dc672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f7968b53-322b-4e71-a80c-5fcbe37dfc54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_40418484-a529-40e8-9d61-785a8f4dc672" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f7968b53-322b-4e71-a80c-5fcbe37dfc54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_869703d3-0097-44ba-acac-b53d98841f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_40418484-a529-40e8-9d61-785a8f4dc672" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_869703d3-0097-44ba-acac-b53d98841f46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_14ce9feb-786f-49ba-bf8c-158e28d02215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_40418484-a529-40e8-9d61-785a8f4dc672" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_14ce9feb-786f-49ba-bf8c-158e28d02215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4a8cefa7-d834-4dd1-9def-aa07c47a2f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_40418484-a529-40e8-9d61-785a8f4dc672" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4a8cefa7-d834-4dd1-9def-aa07c47a2f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_880262c2-f618-46b0-86f5-438f66803a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_99326d71-5258-4897-8efc-4a09231f4d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_880262c2-f618-46b0-86f5-438f66803a37" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_99326d71-5258-4897-8efc-4a09231f4d23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40ef4660-271f-4044-80bc-f70da9e26b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts_73941806-6c6b-4ec2-82ca-97fd40d81ae9" xlink:href="xfor-20220331.xsd#xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40ef4660-271f-4044-80bc-f70da9e26b95" xlink:to="loc_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts_73941806-6c6b-4ec2-82ca-97fd40d81ae9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_df0bb3a5-93a1-469b-90a7-38e5893632fe" xlink:href="xfor-20220331.xsd#xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40ef4660-271f-4044-80bc-f70da9e26b95" xlink:to="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_df0bb3a5-93a1-469b-90a7-38e5893632fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_d8071b39-111a-4f41-b877-71efafe691ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40ef4660-271f-4044-80bc-f70da9e26b95" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_d8071b39-111a-4f41-b877-71efafe691ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2c0b8671-65e6-4303-b040-6cd4bf9c812b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40ef4660-271f-4044-80bc-f70da9e26b95" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2c0b8671-65e6-4303-b040-6cd4bf9c812b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_b58f936c-e6f9-4360-b9a5-0ed7b32aa7c8" xlink:href="xfor-20220331.xsd#xfor_ProceedsFromExerciseOfStockOptionsAndWarrants"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40ef4660-271f-4044-80bc-f70da9e26b95" xlink:to="loc_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_b58f936c-e6f9-4360-b9a5-0ed7b32aa7c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5997933a-161d-4f9d-8d40-cb4390bffd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_868cb67f-d505-43ad-a12b-52b2d8e151dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5997933a-161d-4f9d-8d40-cb4390bffd41" xlink:to="loc_us-gaap_NetIncomeLoss_868cb67f-d505-43ad-a12b-52b2d8e151dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_63a040d9-b9d4-452b-b2ed-3e0540cf0183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5997933a-161d-4f9d-8d40-cb4390bffd41" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_63a040d9-b9d4-452b-b2ed-3e0540cf0183" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashLeaseExpense_b1ea38d0-d814-4787-aea1-105a54269252" xlink:href="xfor-20220331.xsd#xfor_NonCashLeaseExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5997933a-161d-4f9d-8d40-cb4390bffd41" xlink:to="loc_xfor_NonCashLeaseExpense_b1ea38d0-d814-4787-aea1-105a54269252" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashInterestExpense_1240cdfe-b1d3-48d6-9159-d8f2b64c912d" xlink:href="xfor-20220331.xsd#xfor_NonCashInterestExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5997933a-161d-4f9d-8d40-cb4390bffd41" xlink:to="loc_xfor_NonCashInterestExpense_1240cdfe-b1d3-48d6-9159-d8f2b64c912d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_831b5a9a-0f5a-46f6-8ed9-12d1ef0027b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5997933a-161d-4f9d-8d40-cb4390bffd41" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_831b5a9a-0f5a-46f6-8ed9-12d1ef0027b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4fd2501f-d869-46d1-b673-2292572b4916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5997933a-161d-4f9d-8d40-cb4390bffd41" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4fd2501f-d869-46d1-b673-2292572b4916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_010a4728-f6fc-4b6f-81b3-478cfe6dab93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5997933a-161d-4f9d-8d40-cb4390bffd41" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_010a4728-f6fc-4b6f-81b3-478cfe6dab93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f43bf3e6-782c-498f-a815-6264fa305ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5997933a-161d-4f9d-8d40-cb4390bffd41" xlink:to="loc_us-gaap_ShareBasedCompensation_f43bf3e6-782c-498f-a815-6264fa305ecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInLeaseLiabilities_23ee37c3-d873-4d8f-9ac8-8b99812c8b0a" xlink:href="xfor-20220331.xsd#xfor_IncreaseDecreaseInLeaseLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5997933a-161d-4f9d-8d40-cb4390bffd41" xlink:to="loc_xfor_IncreaseDecreaseInLeaseLiabilities_23ee37c3-d873-4d8f-9ac8-8b99812c8b0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_36656491-8faa-49f7-ae81-461321174bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5997933a-161d-4f9d-8d40-cb4390bffd41" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_36656491-8faa-49f7-ae81-461321174bae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_c124eded-0fb8-4a4d-b30b-2ad2c995d26b" xlink:href="xfor-20220331.xsd#xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5997933a-161d-4f9d-8d40-cb4390bffd41" xlink:to="loc_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_c124eded-0fb8-4a4d-b30b-2ad2c995d26b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d980e8f-a257-48c5-9776-09ca2bc6150d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d961ec59-a26c-4f00-a5b9-24dbbc16cb15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d980e8f-a257-48c5-9776-09ca2bc6150d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d961ec59-a26c-4f00-a5b9-24dbbc16cb15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_fe52b57f-e74e-4909-980c-48e145077eed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d980e8f-a257-48c5-9776-09ca2bc6150d" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_fe52b57f-e74e-4909-980c-48e145077eed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_409e73d4-afa0-4255-82ff-a3190ec81b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_47ce64b7-d063-4588-8a36-7117f69f7a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_409e73d4-afa0-4255-82ff-a3190ec81b51" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_47ce64b7-d063-4588-8a36-7117f69f7a7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3fb38fa8-f0a6-40ce-92ca-09d9159d7fae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_409e73d4-afa0-4255-82ff-a3190ec81b51" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3fb38fa8-f0a6-40ce-92ca-09d9159d7fae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#AccruedExpensesScheduleofAccruedExpensesDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4ce54a5d-1a1d-4971-b386-a8b77f76c9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1920e5e8-34c7-4a27-91e5-1f0cbd3b19cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ce54a5d-1a1d-4971-b386-a8b77f76c9ed" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1920e5e8-34c7-4a27-91e5-1f0cbd3b19cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_14a7756e-6a40-4aaf-bba9-c7e1a58e99a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ce54a5d-1a1d-4971-b386-a8b77f76c9ed" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_14a7756e-6a40-4aaf-bba9-c7e1a58e99a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_b97c9eb1-4f00-439c-b9e8-20751194d158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ce54a5d-1a1d-4971-b386-a8b77f76c9ed" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_b97c9eb1-4f00-439c-b9e8-20751194d158" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses_066dc835-86f0-4a3d-8b35-ddbf0c06d5f4" xlink:href="xfor-20220331.xsd#xfor_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ce54a5d-1a1d-4971-b386-a8b77f76c9ed" xlink:to="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses_066dc835-86f0-4a3d-8b35-ddbf0c06d5f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#LongTermDebtSummaryofLongTermDebtDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtIncludingAccretion_98fcd45d-0315-4cf6-bada-8e79ff903735" xlink:href="xfor-20220331.xsd#xfor_LongTermDebtIncludingAccretion"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_7398c5b4-5edf-445c-88ee-6e4361ab1485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtIncludingAccretion_98fcd45d-0315-4cf6-bada-8e79ff903735" xlink:to="loc_us-gaap_LongTermDebt_7398c5b4-5edf-445c-88ee-6e4361ab1485" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccretionOnLongTermDebt_a4cd3694-a0d3-4ad9-b452-364bdc048b99" xlink:href="xfor-20220331.xsd#xfor_AccretionOnLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtIncludingAccretion_98fcd45d-0315-4cf6-bada-8e79ff903735" xlink:to="loc_xfor_AccretionOnLongTermDebt_a4cd3694-a0d3-4ad9-b452-364bdc048b99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_93f0bfc8-68fb-4144-8d11-a310ad820eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtIncludingAccretion_98fcd45d-0315-4cf6-bada-8e79ff903735" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_93f0bfc8-68fb-4144-8d11-a310ad820eac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtAndEOTPayment_26dd58bb-06aa-4033-b4f4-b552018ca645" xlink:href="xfor-20220331.xsd#xfor_LongTermDebtAndEOTPayment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d4fc49af-55aa-49e4-8878-85f7f17630d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtAndEOTPayment_26dd58bb-06aa-4033-b4f4-b552018ca645" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d4fc49af-55aa-49e4-8878-85f7f17630d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d3128107-1aed-4f25-b294-929a8f3eed9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtAndEOTPayment_26dd58bb-06aa-4033-b4f4-b552018ca645" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d3128107-1aed-4f25-b294-929a8f3eed9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6dabc7af-81db-4f94-b93b-0d03e8bc5806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtAndEOTPayment_26dd58bb-06aa-4033-b4f4-b552018ca645" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6dabc7af-81db-4f94-b93b-0d03e8bc5806" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#LeasesScheduleofComponentsofLeaseExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_3584bb14-3ed9-4984-9771-9ec75ba56ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d5b5a405-d9d4-4b46-b18f-179415e7426f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_3584bb14-3ed9-4984-9771-9ec75ba56ddc" xlink:to="loc_us-gaap_OperatingLeaseCost_d5b5a405-d9d4-4b46-b18f-179415e7426f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_3b885e0c-0d94-4cfe-8565-3f821cdf43a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_3584bb14-3ed9-4984-9771-9ec75ba56ddc" xlink:to="loc_us-gaap_ShortTermLeaseCost_3b885e0c-0d94-4cfe-8565-3f821cdf43a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70faf6b1-059b-4218-a076-18190971fe5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8cdce4e4-dd8c-4e1a-9856-0dc1bbf81d28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70faf6b1-059b-4218-a076-18190971fe5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8cdce4e4-dd8c-4e1a-9856-0dc1bbf81d28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c456606f-9a59-4305-8ad7-43d01eb1efcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70faf6b1-059b-4218-a076-18190971fe5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c456606f-9a59-4305-8ad7-43d01eb1efcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_478e71b8-b6e7-44c9-8e90-29d55fe52f69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70faf6b1-059b-4218-a076-18190971fe5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_478e71b8-b6e7-44c9-8e90-29d55fe52f69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c977e730-0ba5-418f-91b6-0971b09a1fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70faf6b1-059b-4218-a076-18190971fe5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c977e730-0ba5-418f-91b6-0971b09a1fbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6e0fa3bd-865f-4d55-8dfe-aee04d8388f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70faf6b1-059b-4218-a076-18190971fe5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6e0fa3bd-865f-4d55-8dfe-aee04d8388f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_77e4efa8-ab73-4137-8302-607bc8756440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70faf6b1-059b-4218-a076-18190971fe5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_77e4efa8-ab73-4137-8302-607bc8756440" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" xlink:type="simple" xlink:href="xfor-20220331.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_038ef483-249e-48e7-8ea5-6d6a77f68b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5a10755b-9bb1-4f85-bcb6-f805081e6d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_038ef483-249e-48e7-8ea5-6d6a77f68b7f" xlink:to="loc_us-gaap_OperatingLeaseLiability_5a10755b-9bb1-4f85-bcb6-f805081e6d02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_75387dc5-b696-449f-bf35-045a3a0fea97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_038ef483-249e-48e7-8ea5-6d6a77f68b7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_75387dc5-b696-449f-bf35-045a3a0fea97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7eebb339-9ac0-4eaf-96d4-9e92670c3a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_80d924a1-76be-4bd3-8761-29d6f003b947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7eebb339-9ac0-4eaf-96d4-9e92670c3a4d" xlink:to="loc_us-gaap_NetIncomeLoss_80d924a1-76be-4bd3-8761-29d6f003b947" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPaidinkind_436ef7b9-5c8b-4317-a45e-af866a0da302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPaidinkind"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7eebb339-9ac0-4eaf-96d4-9e92670c3a4d" xlink:to="loc_us-gaap_DividendsPaidinkind_436ef7b9-5c8b-4317-a45e-af866a0da302" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>xfor-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:15224e09-2b4e-4653-a05c-4094a1da55b0,g:b51d9744-e75b-48fa-9941-02b626145304-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="xfor-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i3c966ebb61734befacb67391b107df51_CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a4327ae9-aa7c-4a71-bf2b-576996ca3df4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_23e0756e-279f-42c3-ac3a-d76019ad6ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4327ae9-aa7c-4a71-bf2b-576996ca3df4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_23e0756e-279f-42c3-ac3a-d76019ad6ba5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c5c69bf3-1004-407a-a723-cc5eac914be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4327ae9-aa7c-4a71-bf2b-576996ca3df4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c5c69bf3-1004-407a-a723-cc5eac914be4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2982a874-ce93-4d25-88bb-cde6a9083e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4327ae9-aa7c-4a71-bf2b-576996ca3df4" xlink:to="loc_us-gaap_CommonStockSharesIssued_2982a874-ce93-4d25-88bb-cde6a9083e12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_febc090c-8011-4b10-8724-28453981113d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4327ae9-aa7c-4a71-bf2b-576996ca3df4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_febc090c-8011-4b10-8724-28453981113d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d0dd1652-4eee-48f9-b034-2195e4c9a94a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a4327ae9-aa7c-4a71-bf2b-576996ca3df4" xlink:to="loc_us-gaap_StatementTable_d0dd1652-4eee-48f9-b034-2195e4c9a94a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bd92b4f1-65c7-41d0-8bf8-8eedaffbefbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d0dd1652-4eee-48f9-b034-2195e4c9a94a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bd92b4f1-65c7-41d0-8bf8-8eedaffbefbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bd92b4f1-65c7-41d0-8bf8-8eedaffbefbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bd92b4f1-65c7-41d0-8bf8-8eedaffbefbb" xlink:to="loc_us-gaap_ClassOfStockDomain_bd92b4f1-65c7-41d0-8bf8-8eedaffbefbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a9b4ed9e-8451-45e0-a05b-ad185ea26701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bd92b4f1-65c7-41d0-8bf8-8eedaffbefbb" xlink:to="loc_us-gaap_ClassOfStockDomain_a9b4ed9e-8451-45e0-a05b-ad185ea26701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember_25107b72-27c7-4f74-ad13-e0e903331b1e" xlink:href="xfor-20220331.xsd#xfor_RedeemableCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a9b4ed9e-8451-45e0-a05b-ad185ea26701" xlink:to="loc_xfor_RedeemableCommonStockMember_25107b72-27c7-4f74-ad13-e0e903331b1e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="xfor-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended" id="if36057e266dc4a2e9a9b72956985172a_CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_04d09b50-d881-40ce-b637-0a09382d75fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0f1a1b82-0d68-45e9-87a4-eccdd38b08e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_04d09b50-d881-40ce-b637-0a09382d75fb" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0f1a1b82-0d68-45e9-87a4-eccdd38b08e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_bd1346fc-e481-49de-be82-4ec8cf9efa64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0f1a1b82-0d68-45e9-87a4-eccdd38b08e3" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_bd1346fc-e481-49de-be82-4ec8cf9efa64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_c9e2d547-80b2-4293-906f-aad75043c66a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0f1a1b82-0d68-45e9-87a4-eccdd38b08e3" xlink:to="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_c9e2d547-80b2-4293-906f-aad75043c66a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_787da771-e79f-45b6-92bd-8422418d8521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_04d09b50-d881-40ce-b637-0a09382d75fb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ba8a7f6f-d5f3-443f-b281-d1253f357f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_SharesOutstanding_ba8a7f6f-d5f3-443f-b281-d1253f357f19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a5e544f0-a8ab-4552-99ee-8a03783c9859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_StockholdersEquity_a5e544f0-a8ab-4552-99ee-8a03783c9859" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_283dd654-eab5-4a6c-914a-61422901a7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_283dd654-eab5-4a6c-914a-61422901a7a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f895e3b8-a0c1-4ea1-869b-347b7fa3b4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f895e3b8-a0c1-4ea1-869b-347b7fa3b4fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_29d461c0-8301-451e-a2d2-ebc3521c741c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_29d461c0-8301-451e-a2d2-ebc3521c741c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_e50f7871-1b91-491c-92d2-152353103cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_e50f7871-1b91-491c-92d2-152353103cd4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_b569c2e1-19b0-4a64-9592-6e1a06bdfdda" xlink:href="xfor-20220331.xsd#xfor_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_b569c2e1-19b0-4a64-9592-6e1a06bdfdda" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodValueWarrantsExercised_d78a2bcf-db09-4f50-86fc-b8939a7ec8c7" xlink:href="xfor-20220331.xsd#xfor_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_xfor_StockIssuedDuringPeriodValueWarrantsExercised_d78a2bcf-db09-4f50-86fc-b8939a7ec8c7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2c149899-dfff-41b9-a5a1-f2b9101f4596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2c149899-dfff-41b9-a5a1-f2b9101f4596" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dd0cafb2-046f-4cbb-970f-d0143b19ae9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dd0cafb2-046f-4cbb-970f-d0143b19ae9f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_99552c4d-6770-4a4c-9c15-c63125e345c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_99552c4d-6770-4a4c-9c15-c63125e345c0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_36db8f89-e3d3-41ef-bee7-a59b7e283733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_NetIncomeLoss_36db8f89-e3d3-41ef-bee7-a59b7e283733" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0e0d63f6-08dd-4077-818f-a5a18bb9d2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a132b95b-7c40-4984-9723-f7c6632a37ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f24f0fec-8e27-4fbf-8c28-bd51dac359a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_04d09b50-d881-40ce-b637-0a09382d75fb" xlink:to="loc_us-gaap_StatementTable_f24f0fec-8e27-4fbf-8c28-bd51dac359a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fa5b28c4-4ffe-43c6-87eb-0725517eeb61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f24f0fec-8e27-4fbf-8c28-bd51dac359a1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fa5b28c4-4ffe-43c6-87eb-0725517eeb61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fa5b28c4-4ffe-43c6-87eb-0725517eeb61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa5b28c4-4ffe-43c6-87eb-0725517eeb61" xlink:to="loc_us-gaap_EquityComponentDomain_fa5b28c4-4ffe-43c6-87eb-0725517eeb61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_64096cb1-3817-46a2-bf47-0a0fa53266a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa5b28c4-4ffe-43c6-87eb-0725517eeb61" xlink:to="loc_us-gaap_EquityComponentDomain_64096cb1-3817-46a2-bf47-0a0fa53266a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0b21f354-1624-4eb6-bada-4bba18d75031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64096cb1-3817-46a2-bf47-0a0fa53266a7" xlink:to="loc_us-gaap_CommonStockMember_0b21f354-1624-4eb6-bada-4bba18d75031" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e19725e1-ac19-4ead-aac3-68546165b248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64096cb1-3817-46a2-bf47-0a0fa53266a7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e19725e1-ac19-4ead-aac3-68546165b248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_91ead567-5298-4087-b3bc-5db622609381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64096cb1-3817-46a2-bf47-0a0fa53266a7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_91ead567-5298-4087-b3bc-5db622609381" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_76df89a1-e448-4890-b3fd-f3dcde071283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64096cb1-3817-46a2-bf47-0a0fa53266a7" xlink:to="loc_us-gaap_RetainedEarningsMember_76df89a1-e448-4890-b3fd-f3dcde071283" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember_ddf9efb6-c981-406f-827e-73dcbd9c42fd" xlink:href="xfor-20220331.xsd#xfor_RedeemableCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64096cb1-3817-46a2-bf47-0a0fa53266a7" xlink:to="loc_xfor_RedeemableCommonStockMember_ddf9efb6-c981-406f-827e-73dcbd9c42fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_90b2f5eb-a78e-44d0-89b0-5d41a0103175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f24f0fec-8e27-4fbf-8c28-bd51dac359a1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_90b2f5eb-a78e-44d0-89b0-5d41a0103175" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_90b2f5eb-a78e-44d0-89b0-5d41a0103175_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_90b2f5eb-a78e-44d0-89b0-5d41a0103175" xlink:to="loc_us-gaap_ClassOfStockDomain_90b2f5eb-a78e-44d0-89b0-5d41a0103175_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4ecac29d-d4b7-43c9-8d26-e1ab8798db70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_90b2f5eb-a78e-44d0-89b0-5d41a0103175" xlink:to="loc_us-gaap_ClassOfStockDomain_4ecac29d-d4b7-43c9-8d26-e1ab8798db70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember_450babbc-ff27-4235-b130-8ddc1f02b5c8" xlink:href="xfor-20220331.xsd#xfor_RedeemableCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4ecac29d-d4b7-43c9-8d26-e1ab8798db70" xlink:to="loc_xfor_RedeemableCommonStockMember_450babbc-ff27-4235-b130-8ddc1f02b5c8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail" xlink:type="extended" id="ied35a9bfef6d4253a1044127e2fc09c5_NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cf57b691-dbfa-45d4-98fb-fada49b857c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_59ae9d15-c4fc-4e25-8588-58a40ad0bed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cf57b691-dbfa-45d4-98fb-fada49b857c7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_59ae9d15-c4fc-4e25-8588-58a40ad0bed3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7bf850ab-4289-4198-aa30-d770ff092c40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cf57b691-dbfa-45d4-98fb-fada49b857c7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7bf850ab-4289-4198-aa30-d770ff092c40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfAccountingPoliciesTable_44953ff1-0862-49b4-83fb-643d75cf7b07" xlink:href="xfor-20220331.xsd#xfor_ScheduleOfAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cf57b691-dbfa-45d4-98fb-fada49b857c7" xlink:to="loc_xfor_ScheduleOfAccountingPoliciesTable_44953ff1-0862-49b4-83fb-643d75cf7b07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f19f9613-9f80-4939-b252-e60406f2604a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_ScheduleOfAccountingPoliciesTable_44953ff1-0862-49b4-83fb-643d75cf7b07" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f19f9613-9f80-4939-b252-e60406f2604a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f19f9613-9f80-4939-b252-e60406f2604a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f19f9613-9f80-4939-b252-e60406f2604a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f19f9613-9f80-4939-b252-e60406f2604a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f31c4e25-59b1-4cfd-800c-162ec29ebad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f19f9613-9f80-4939-b252-e60406f2604a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f31c4e25-59b1-4cfd-800c-162ec29ebad7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail" xlink:type="extended" id="i27f566efd9ef4083bc800ba496c2c4cb_SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_1ad58e35-9199-4455-9e16-32ea1ab11e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_657a3bec-d736-4dcd-8650-4ec3ddab72e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1ad58e35-9199-4455-9e16-32ea1ab11e16" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_657a3bec-d736-4dcd-8650-4ec3ddab72e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_7b5cb707-30a0-4c98-a4e0-39a3f04316f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1ad58e35-9199-4455-9e16-32ea1ab11e16" xlink:to="loc_us-gaap_RestrictedCash_7b5cb707-30a0-4c98-a4e0-39a3f04316f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_25e93623-2615-4277-9dda-5d0a31a99550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1ad58e35-9199-4455-9e16-32ea1ab11e16" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_25e93623-2615-4277-9dda-5d0a31a99550" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8579d74b-39d7-4f6d-bc69-078db71c83bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_25e93623-2615-4277-9dda-5d0a31a99550" xlink:to="loc_us-gaap_CreditFacilityAxis_8579d74b-39d7-4f6d-bc69-078db71c83bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8579d74b-39d7-4f6d-bc69-078db71c83bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_8579d74b-39d7-4f6d-bc69-078db71c83bc" xlink:to="loc_us-gaap_CreditFacilityDomain_8579d74b-39d7-4f6d-bc69-078db71c83bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5f613560-f9b2-466a-b86b-fedb7c8c797a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_8579d74b-39d7-4f6d-bc69-078db71c83bc" xlink:to="loc_us-gaap_CreditFacilityDomain_5f613560-f9b2-466a-b86b-fedb7c8c797a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_a8b21694-e93f-4447-bc9b-24e94b3353fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5f613560-f9b2-466a-b86b-fedb7c8c797a" xlink:to="loc_us-gaap_LetterOfCreditMember_a8b21694-e93f-4447-bc9b-24e94b3353fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4562fc10-2c9e-4b82-aaf3-e1831f8e033b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_25e93623-2615-4277-9dda-5d0a31a99550" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4562fc10-2c9e-4b82-aaf3-e1831f8e033b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_4562fc10-2c9e-4b82-aaf3-e1831f8e033b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4562fc10-2c9e-4b82-aaf3-e1831f8e033b" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_4562fc10-2c9e-4b82-aaf3-e1831f8e033b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b054be02-4f67-4515-a072-bd334bc725a4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4562fc10-2c9e-4b82-aaf3-e1831f8e033b" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b054be02-4f67-4515-a072-bd334bc725a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember_bfdc7f9c-2db4-4d6d-a81f-b5a7fe1ae478" xlink:href="xfor-20220331.xsd#xfor_WalthamLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b054be02-4f67-4515-a072-bd334bc725a4" xlink:to="loc_xfor_WalthamLeaseMember_bfdc7f9c-2db4-4d6d-a81f-b5a7fe1ae478" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaLeaseAgreementMember_7df14a64-7d4c-458f-8bf8-ddc4b85fb061" xlink:href="xfor-20220331.xsd#xfor_ViennaLeaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b054be02-4f67-4515-a072-bd334bc725a4" xlink:to="loc_xfor_ViennaLeaseAgreementMember_7df14a64-7d4c-458f-8bf8-ddc4b85fb061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseAgreementMember_89497979-4ee0-437f-b633-903a3626fbc4" xlink:href="xfor-20220331.xsd#xfor_AllstonLeaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b054be02-4f67-4515-a072-bd334bc725a4" xlink:to="loc_xfor_AllstonLeaseAgreementMember_89497979-4ee0-437f-b633-903a3626fbc4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail" xlink:type="extended" id="i0a83ede41e724cb69956dd4eabfbe30d_LicenseCollaborationandFundingAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_38e54de6-9a9e-4afe-9fd5-919ed416e5d6" xlink:href="xfor-20220331.xsd#xfor_CollaborationLicenseAndFundingArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GrantAndIncentiveReceivables_ab0d9a17-5805-4fc9-a648-5bc51492977c" xlink:href="xfor-20220331.xsd#xfor_GrantAndIncentiveReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_38e54de6-9a9e-4afe-9fd5-919ed416e5d6" xlink:to="loc_xfor_GrantAndIncentiveReceivables_ab0d9a17-5805-4fc9-a648-5bc51492977c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bf321523-b9d0-43f2-a18a-9c0cf2e42d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_38e54de6-9a9e-4afe-9fd5-919ed416e5d6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bf321523-b9d0-43f2-a18a-9c0cf2e42d9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_a66227e6-a143-4357-90d5-b02ea1d9ae39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_38e54de6-9a9e-4afe-9fd5-919ed416e5d6" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_a66227e6-a143-4357-90d5-b02ea1d9ae39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborationLicenseAndFundingArrangementsTable_eab1f9a3-5855-46ff-bae2-cac4abdebdaf" xlink:href="xfor-20220331.xsd#xfor_CollaborationLicenseAndFundingArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_38e54de6-9a9e-4afe-9fd5-919ed416e5d6" xlink:to="loc_xfor_CollaborationLicenseAndFundingArrangementsTable_eab1f9a3-5855-46ff-bae2-cac4abdebdaf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_da9cf04c-123e-4ce5-9757-3d051fc41b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsTable_eab1f9a3-5855-46ff-bae2-cac4abdebdaf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_da9cf04c-123e-4ce5-9757-3d051fc41b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_da9cf04c-123e-4ce5-9757-3d051fc41b37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_da9cf04c-123e-4ce5-9757-3d051fc41b37" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_da9cf04c-123e-4ce5-9757-3d051fc41b37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4de38bc0-d14d-46fa-ab6d-06d5e90ba2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_da9cf04c-123e-4ce5-9757-3d051fc41b37" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4de38bc0-d14d-46fa-ab6d-06d5e90ba2cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember_418a9270-c763-4347-a937-844723b51495" xlink:href="xfor-20220331.xsd#xfor_ResearchAndDevelopmentIncentiveProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4de38bc0-d14d-46fa-ab6d-06d5e90ba2cf" xlink:to="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember_418a9270-c763-4347-a937-844723b51495" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail" xlink:type="extended" id="i4a4bd8ef9ef74a96bb8b0b4239cbf5e4_FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_de2d032b-c2b4-4106-8bbc-e4360f9227c2" xlink:href="xfor-20220331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c6e82704-92ba-4644-868b-dd7d0014ec85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_de2d032b-c2b4-4106-8bbc-e4360f9227c2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c6e82704-92ba-4644-868b-dd7d0014ec85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_287208b0-bf94-4954-8a48-0f3c061d9ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_de2d032b-c2b4-4106-8bbc-e4360f9227c2" xlink:to="loc_us-gaap_DerivativeLiabilities_287208b0-bf94-4954-8a48-0f3c061d9ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_52feab28-56d7-4e7c-9d39-4858819182db" xlink:href="xfor-20220331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_de2d032b-c2b4-4106-8bbc-e4360f9227c2" xlink:to="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_52feab28-56d7-4e7c-9d39-4858819182db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_bc72254f-5b03-4e5b-9cb3-e6114fb9cadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_52feab28-56d7-4e7c-9d39-4858819182db" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_bc72254f-5b03-4e5b-9cb3-e6114fb9cadd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_bc72254f-5b03-4e5b-9cb3-e6114fb9cadd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_bc72254f-5b03-4e5b-9cb3-e6114fb9cadd" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_bc72254f-5b03-4e5b-9cb3-e6114fb9cadd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8ebc389d-a038-4a0e-bf89-c5182a1aa302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_bc72254f-5b03-4e5b-9cb3-e6114fb9cadd" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8ebc389d-a038-4a0e-bf89-c5182a1aa302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_4fae71b0-80bd-4cc4-86de-ae664bb5044b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8ebc389d-a038-4a0e-bf89-c5182a1aa302" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_4fae71b0-80bd-4cc4-86de-ae664bb5044b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1c655d2-f57d-4754-8022-818cdd20fa20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_52feab28-56d7-4e7c-9d39-4858819182db" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1c655d2-f57d-4754-8022-818cdd20fa20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1c655d2-f57d-4754-8022-818cdd20fa20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1c655d2-f57d-4754-8022-818cdd20fa20" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1c655d2-f57d-4754-8022-818cdd20fa20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c62ca4de-6928-43c1-b2f6-8a315ea631cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1c655d2-f57d-4754-8022-818cdd20fa20" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c62ca4de-6928-43c1-b2f6-8a315ea631cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_802aa215-f3ef-4e7d-b84d-6f3dddfc4b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c62ca4de-6928-43c1-b2f6-8a315ea631cc" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_802aa215-f3ef-4e7d-b84d-6f3dddfc4b3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_47c5e532-7b3b-4eaa-a09f-389051985c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_52feab28-56d7-4e7c-9d39-4858819182db" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_47c5e532-7b3b-4eaa-a09f-389051985c44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_47c5e532-7b3b-4eaa-a09f-389051985c44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_47c5e532-7b3b-4eaa-a09f-389051985c44" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_47c5e532-7b3b-4eaa-a09f-389051985c44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4d8b2d9-1b94-4f1d-ad6f-25d0531f09fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_47c5e532-7b3b-4eaa-a09f-389051985c44" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4d8b2d9-1b94-4f1d-ad6f-25d0531f09fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d63af673-f29f-441a-80b4-ad72e007c0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4d8b2d9-1b94-4f1d-ad6f-25d0531f09fd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d63af673-f29f-441a-80b4-ad72e007c0b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5d1c0561-ae3d-4262-ace9-fa3c75eff9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4d8b2d9-1b94-4f1d-ad6f-25d0531f09fd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5d1c0561-ae3d-4262-ace9-fa3c75eff9e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b4ee17e8-8b17-4021-b315-4bfbf307a36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4d8b2d9-1b94-4f1d-ad6f-25d0531f09fd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b4ee17e8-8b17-4021-b315-4bfbf307a36f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail" xlink:type="extended" id="id7e884aa1ba8469f97f6299353c526d7_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c163cb-d4e3-41e9-b2af-13363bef9d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8dd2a2b2-1e85-425b-94f3-7f9931623f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c163cb-d4e3-41e9-b2af-13363bef9d68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8dd2a2b2-1e85-425b-94f3-7f9931623f01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6ba196a8-0609-421e-967f-70be7d57bfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c163cb-d4e3-41e9-b2af-13363bef9d68" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6ba196a8-0609-421e-967f-70be7d57bfb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_434c941f-b2a0-4844-9856-78fb7cb539b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c163cb-d4e3-41e9-b2af-13363bef9d68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_434c941f-b2a0-4844-9856-78fb7cb539b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f462f3b2-4c6d-417f-94b9-e1ded08b29d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c163cb-d4e3-41e9-b2af-13363bef9d68" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f462f3b2-4c6d-417f-94b9-e1ded08b29d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3c4859b-87d7-484a-b9c9-7a86067e15a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f462f3b2-4c6d-417f-94b9-e1ded08b29d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3c4859b-87d7-484a-b9c9-7a86067e15a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d3c4859b-87d7-484a-b9c9-7a86067e15a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3c4859b-87d7-484a-b9c9-7a86067e15a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d3c4859b-87d7-484a-b9c9-7a86067e15a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf93ee11-1f40-4b9f-8afc-a943fe90758f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3c4859b-87d7-484a-b9c9-7a86067e15a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf93ee11-1f40-4b9f-8afc-a943fe90758f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1b901499-346d-452e-956d-e57ed678f832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf93ee11-1f40-4b9f-8afc-a943fe90758f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1b901499-346d-452e-956d-e57ed678f832" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2f96766c-73f4-4af1-aee3-4c6f943aecc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf93ee11-1f40-4b9f-8afc-a943fe90758f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2f96766c-73f4-4af1-aee3-4c6f943aecc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_cfff4999-563f-47a9-8b48-9947e1984cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf93ee11-1f40-4b9f-8afc-a943fe90758f" xlink:to="loc_us-gaap_ComputerEquipmentMember_cfff4999-563f-47a9-8b48-9947e1984cf4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SoftwareMember_05276596-2902-4d75-b528-654f01eabc12" xlink:href="xfor-20220331.xsd#xfor_SoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf93ee11-1f40-4b9f-8afc-a943fe90758f" xlink:to="loc_xfor_SoftwareMember_05276596-2902-4d75-b528-654f01eabc12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LabEquipmentMember_42a296a8-b3f3-4c6c-b83d-5e494acb8670" xlink:href="xfor-20220331.xsd#xfor_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf93ee11-1f40-4b9f-8afc-a943fe90758f" xlink:to="loc_xfor_LabEquipmentMember_42a296a8-b3f3-4c6c-b83d-5e494acb8670" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail" xlink:type="extended" id="i9d50c3a9b3734611a0681681ba45451d_LongTermDebtHerculesLoanAgreementAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:href="xfor-20220331.xsd#xfor_ScheduleOfLongTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_e32e271a-de80-42ce-a4dd-52f039fcbb12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_e32e271a-de80-42ce-a4dd-52f039fcbb12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_74e3ac70-5087-4bbd-99de-82ec068f3a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_74e3ac70-5087-4bbd-99de-82ec068f3a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5ba2d6c2-6007-4d26-b529-300a3cdc6373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5ba2d6c2-6007-4d26-b529-300a3cdc6373" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_e731ee94-988a-4447-a25f-061091ab4701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_e731ee94-988a-4447-a25f-061091ab4701" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree_5b498c39-17f9-4d48-a082-7326efcdc087" xlink:href="xfor-20220331.xsd#xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree_5b498c39-17f9-4d48-a082-7326efcdc087" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentPrepaymentPremiumPercentage_4288d176-0ea9-40b0-943c-f1771b64df6f" xlink:href="xfor-20220331.xsd#xfor_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_xfor_DebtInstrumentPrepaymentPremiumPercentage_4288d176-0ea9-40b0-943c-f1771b64df6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_c4359296-4efa-49d0-bbb3-e9b9e6e3fe5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_c4359296-4efa-49d0-bbb3-e9b9e6e3fe5a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1c339aaa-569d-4a8f-86e8-f527dfe62c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_InterestExpenseDebt_1c339aaa-569d-4a8f-86e8-f527dfe62c12" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6f7b9a4e-0c4a-4b5e-850e-3bde0a250371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_6f7b9a4e-0c4a-4b5e-850e-3bde0a250371" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1d4e8815-4b59-49fd-8db2-f953c6a0eccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1d4e8815-4b59-49fd-8db2-f953c6a0eccc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_7b425110-911a-4716-bef8-e9a58d0d9949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_7b425110-911a-4716-bef8-e9a58d0d9949" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditCovenantMinimumCash_c4aacfe8-018a-42fa-a220-8d3b72175d5c" xlink:href="xfor-20220331.xsd#xfor_LineOfCreditCovenantMinimumCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_xfor_LineOfCreditCovenantMinimumCash_c4aacfe8-018a-42fa-a220-8d3b72175d5c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:href="xfor-20220331.xsd#xfor_ScheduleOfLongTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3016a00d-c3a5-447e-b51d-6d15b73a8516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:to="loc_us-gaap_DebtInstrumentAxis_3016a00d-c3a5-447e-b51d-6d15b73a8516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3016a00d-c3a5-447e-b51d-6d15b73a8516_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3016a00d-c3a5-447e-b51d-6d15b73a8516" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3016a00d-c3a5-447e-b51d-6d15b73a8516_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8637f2c8-df36-41f7-a5a1-2a1e43f86b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3016a00d-c3a5-447e-b51d-6d15b73a8516" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8637f2c8-df36-41f7-a5a1-2a1e43f86b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesLoanAgreementMember_5fbf2c79-9df0-4a53-b962-54c77d541ce7" xlink:href="xfor-20220331.xsd#xfor_HerculesLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8637f2c8-df36-41f7-a5a1-2a1e43f86b79" xlink:to="loc_xfor_HerculesLoanAgreementMember_5fbf2c79-9df0-4a53-b962-54c77d541ce7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesSecondAmendedLoanAgreementMember_ef3e3a04-5aa5-4005-8e2d-1f954dc92a6b" xlink:href="xfor-20220331.xsd#xfor_HerculesSecondAmendedLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8637f2c8-df36-41f7-a5a1-2a1e43f86b79" xlink:to="loc_xfor_HerculesSecondAmendedLoanAgreementMember_ef3e3a04-5aa5-4005-8e2d-1f954dc92a6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2ca8d2c4-7e81-419e-947d-b54559b8b3af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:to="loc_srt_RangeAxis_2ca8d2c4-7e81-419e-947d-b54559b8b3af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2ca8d2c4-7e81-419e-947d-b54559b8b3af_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2ca8d2c4-7e81-419e-947d-b54559b8b3af" xlink:to="loc_srt_RangeMember_2ca8d2c4-7e81-419e-947d-b54559b8b3af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_81e026fe-0d58-40ee-98d1-0de75c3ccf33" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2ca8d2c4-7e81-419e-947d-b54559b8b3af" xlink:to="loc_srt_RangeMember_81e026fe-0d58-40ee-98d1-0de75c3ccf33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e71a09ef-34e2-4cbf-8a07-aa3a5b502736" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_81e026fe-0d58-40ee-98d1-0de75c3ccf33" xlink:to="loc_srt_MaximumMember_e71a09ef-34e2-4cbf-8a07-aa3a5b502736" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_386639be-f2bf-444c-a783-e8238689b029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:to="loc_us-gaap_VariableRateAxis_386639be-f2bf-444c-a783-e8238689b029" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_386639be-f2bf-444c-a783-e8238689b029_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_386639be-f2bf-444c-a783-e8238689b029" xlink:to="loc_us-gaap_VariableRateDomain_386639be-f2bf-444c-a783-e8238689b029_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_47f79419-3ea4-4f70-86d3-a8b5800c9834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_386639be-f2bf-444c-a783-e8238689b029" xlink:to="loc_us-gaap_VariableRateDomain_47f79419-3ea4-4f70-86d3-a8b5800c9834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_3ed624be-c1bc-47bf-82b1-5dcb7d782378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_47f79419-3ea4-4f70-86d3-a8b5800c9834" xlink:to="loc_us-gaap_PrimeRateMember_3ed624be-c1bc-47bf-82b1-5dcb7d782378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_819d6a98-f498-4bb8-8c40-c3139fba0f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_819d6a98-f498-4bb8-8c40-c3139fba0f49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_819d6a98-f498-4bb8-8c40-c3139fba0f49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_819d6a98-f498-4bb8-8c40-c3139fba0f49" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_819d6a98-f498-4bb8-8c40-c3139fba0f49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f8f909a-0f27-4b82-a031-3c1227e1384a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_819d6a98-f498-4bb8-8c40-c3139fba0f49" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f8f909a-0f27-4b82-a031-3c1227e1384a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_ab40f8cd-abf3-4a26-8759-740842647245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f8f909a-0f27-4b82-a031-3c1227e1384a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_ab40f8cd-abf3-4a26-8759-740842647245" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d8054175-e802-4f94-9bf0-ce75875a1c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d8054175-e802-4f94-9bf0-ce75875a1c54" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d8054175-e802-4f94-9bf0-ce75875a1c54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d8054175-e802-4f94-9bf0-ce75875a1c54" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d8054175-e802-4f94-9bf0-ce75875a1c54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b850d99a-cc4a-488f-9a3c-ec5d78ec0ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d8054175-e802-4f94-9bf0-ce75875a1c54" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b850d99a-cc4a-488f-9a3c-ec5d78ec0ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_96a88702-8d1d-4ac1-a3da-682709dcb699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b850d99a-cc4a-488f-9a3c-ec5d78ec0ce1" xlink:to="loc_us-gaap_SubsequentEventMember_96a88702-8d1d-4ac1-a3da-682709dcb699" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_01e9f5a4-0e0d-4ebd-8e73-e4b0764a2a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:to="loc_us-gaap_CreditFacilityAxis_01e9f5a4-0e0d-4ebd-8e73-e4b0764a2a95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_01e9f5a4-0e0d-4ebd-8e73-e4b0764a2a95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_01e9f5a4-0e0d-4ebd-8e73-e4b0764a2a95" xlink:to="loc_us-gaap_CreditFacilityDomain_01e9f5a4-0e0d-4ebd-8e73-e4b0764a2a95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b40f20b7-d481-4a0d-a48a-a024bd8410ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_01e9f5a4-0e0d-4ebd-8e73-e4b0764a2a95" xlink:to="loc_us-gaap_CreditFacilityDomain_b40f20b7-d481-4a0d-a48a-a024bd8410ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate2Member_eb7026ce-9cd7-4dad-984c-ce50010e02ca" xlink:href="xfor-20220331.xsd#xfor_MinCashTestDate2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b40f20b7-d481-4a0d-a48a-a024bd8410ef" xlink:to="loc_xfor_MinCashTestDate2Member_eb7026ce-9cd7-4dad-984c-ce50010e02ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate1Member_f0e0f500-e88d-4f99-905d-063dbd4c6424" xlink:href="xfor-20220331.xsd#xfor_MinCashTestDate1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b40f20b7-d481-4a0d-a48a-a024bd8410ef" xlink:to="loc_xfor_MinCashTestDate1Member_f0e0f500-e88d-4f99-905d-063dbd4c6424" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#LeasesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LeasesAdditionalInformationDetail" xlink:type="extended" id="i809c06a953dd479f97cd99167cefc5d6_LeasesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement_1c19145b-0072-4d35-b38d-a3f5ca097292" xlink:href="xfor-20220331.xsd#xfor_CurrentOfficeSpaceUnderLeaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement_1c19145b-0072-4d35-b38d-a3f5ca097292" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_OperatingLeaseExpiration_72f131ec-ad8b-4005-b7b9-f4fe033162dc" xlink:href="xfor-20220331.xsd#xfor_OperatingLeaseExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_xfor_OperatingLeaseExpiration_72f131ec-ad8b-4005-b7b9-f4fe033162dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AggregateBaseRent_ce5f569c-334d-4fd6-bc31-47ffab164b4e" xlink:href="xfor-20220331.xsd#xfor_AggregateBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_xfor_AggregateBaseRent_ce5f569c-334d-4fd6-bc31-47ffab164b4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_35e58b84-5bcd-4046-847d-22de7c516065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_35e58b84-5bcd-4046-847d-22de7c516065" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_9a38b81b-25b2-40bd-9c8b-3ffc302238a1" xlink:href="xfor-20220331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_9a38b81b-25b2-40bd-9c8b-3ffc302238a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_2e95d331-b05f-4f6a-adfe-41513c9cf34d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_2e95d331-b05f-4f6a-adfe-41513c9cf34d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent_d6140c58-ea1e-4184-b51d-7394fa6234f2" xlink:href="xfor-20220331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent_d6140c58-ea1e-4184-b51d-7394fa6234f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_baf196fe-7cff-4376-8da4-01de155164d8" xlink:href="xfor-20220331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_baf196fe-7cff-4376-8da4-01de155164d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2640ee99-5b97-469f-a30f-5792edb822b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2640ee99-5b97-469f-a30f-5792edb822b7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_71c6d410-0f98-4b3c-9efc-54be033223d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_us-gaap_OperatingLeaseLiability_71c6d410-0f98-4b3c-9efc-54be033223d4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3294a077-78b9-46be-9ef2-d039ccd0701c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3294a077-78b9-46be-9ef2-d039ccd0701c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_77b92cd0-1f2a-4fed-b1dc-fa838d785438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_77b92cd0-1f2a-4fed-b1dc-fa838d785438" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a644cc1c-50b6-4a03-bbbd-4bc9ef74964c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_77b92cd0-1f2a-4fed-b1dc-fa838d785438" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a644cc1c-50b6-4a03-bbbd-4bc9ef74964c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_a644cc1c-50b6-4a03-bbbd-4bc9ef74964c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a644cc1c-50b6-4a03-bbbd-4bc9ef74964c" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_a644cc1c-50b6-4a03-bbbd-4bc9ef74964c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c38d0c42-d39b-4180-a36c-84310c1d0fd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a644cc1c-50b6-4a03-bbbd-4bc9ef74964c" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c38d0c42-d39b-4180-a36c-84310c1d0fd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember_1623d359-5145-4f49-9c86-e7b4d4ce74e1" xlink:href="xfor-20220331.xsd#xfor_WalthamLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c38d0c42-d39b-4180-a36c-84310c1d0fd3" xlink:to="loc_xfor_WalthamLeaseMember_1623d359-5145-4f49-9c86-e7b4d4ce74e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaAustriaLeaseMember_4027e6fe-5f23-49da-9b5f-4af140e04f29" xlink:href="xfor-20220331.xsd#xfor_ViennaAustriaLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c38d0c42-d39b-4180-a36c-84310c1d0fd3" xlink:to="loc_xfor_ViennaAustriaLeaseMember_4027e6fe-5f23-49da-9b5f-4af140e04f29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseMember_565a9590-af9b-4cc0-9ce1-6101f6e33696" xlink:href="xfor-20220331.xsd#xfor_AllstonLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c38d0c42-d39b-4180-a36c-84310c1d0fd3" xlink:to="loc_xfor_AllstonLeaseMember_565a9590-af9b-4cc0-9ce1-6101f6e33696" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#CommitmentandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail" xlink:type="extended" id="id655ec9716814b688b7547a27cf7a70f_CommitmentandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ContingenciesAndCommitmentsLineItems_ab46759d-9a21-4cb4-9c19-dfa57e0af9d5" xlink:href="xfor-20220331.xsd#xfor_ContingenciesAndCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_5a8d4188-0544-49e0-b1a1-24134bf3dc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_ContingenciesAndCommitmentsLineItems_ab46759d-9a21-4cb4-9c19-dfa57e0af9d5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_5a8d4188-0544-49e0-b1a1-24134bf3dc8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ContingenciesAndCommitmentsTable_05536710-e9ab-498d-bbfa-6cf75db06296" xlink:href="xfor-20220331.xsd#xfor_ContingenciesAndCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_xfor_ContingenciesAndCommitmentsLineItems_ab46759d-9a21-4cb4-9c19-dfa57e0af9d5" xlink:to="loc_xfor_ContingenciesAndCommitmentsTable_05536710-e9ab-498d-bbfa-6cf75db06296" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_986250e2-42ed-4265-99be-5002418ed1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_ContingenciesAndCommitmentsTable_05536710-e9ab-498d-bbfa-6cf75db06296" xlink:to="loc_us-gaap_TypeOfArrangementAxis_986250e2-42ed-4265-99be-5002418ed1ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_986250e2-42ed-4265-99be-5002418ed1ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_986250e2-42ed-4265-99be-5002418ed1ac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_986250e2-42ed-4265-99be-5002418ed1ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49e852e9-049f-47ac-8e92-3de6f58cba8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_986250e2-42ed-4265-99be-5002418ed1ac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49e852e9-049f-47ac-8e92-3de6f58cba8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IndemnificationAgreementsMember_c28f4da8-97ef-40f2-9adf-681700fd4581" xlink:href="xfor-20220331.xsd#xfor_IndemnificationAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49e852e9-049f-47ac-8e92-3de6f58cba8d" xlink:to="loc_xfor_IndemnificationAgreementsMember_c28f4da8-97ef-40f2-9adf-681700fd4581" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#CommonStockWarrantsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail" xlink:type="extended" id="i171f15edcb9c45318242fd106ea243d0_CommonStockWarrantsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightIssued_a5e4e564-7538-4f32-a0c3-c10e19d67dc4" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_xfor_ClassOfWarrantOrRightIssued_a5e4e564-7538-4f32-a0c3-c10e19d67dc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_01dcd45e-d35f-4645-aa81-ebffce5454c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_01dcd45e-d35f-4645-aa81-ebffce5454c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_d6306ec4-6ea9-42f9-8eda-c77ae12a66cc" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_d6306ec4-6ea9-42f9-8eda-c77ae12a66cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_02e26058-e272-40f4-98a0-78bbb7bb2534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_02e26058-e272-40f4-98a0-78bbb7bb2534" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_620c1397-8ead-471b-9792-34e4c2736987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_620c1397-8ead-471b-9792-34e4c2736987" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4857702c-aabc-44cb-803a-6511dea35f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4857702c-aabc-44cb-803a-6511dea35f80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_013ce893-7499-4d28-921c-244bedd4937d" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_013ce893-7499-4d28-921c-244bedd4937d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_1366e60e-6de0-4ca0-9766-ff1f7f7abe52" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_1366e60e-6de0-4ca0-9766-ff1f7f7abe52" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_68e9b3b1-68b4-4d9b-8749-a53728b55b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_68e9b3b1-68b4-4d9b-8749-a53728b55b2d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_e0d315a8-8033-4207-8b39-2886b656a911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_DividendsCommonStock_e0d315a8-8033-4207-8b39-2886b656a911" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_39234639-9b67-4bb0-8a91-1d85dde60dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_39234639-9b67-4bb0-8a91-1d85dde60dc4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d0a4be02-39b7-44eb-a395-f5c37919a5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d0a4be02-39b7-44eb-a395-f5c37919a5a9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0ef05845-de40-48d6-b2d9-9e5bfd1a323d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0ef05845-de40-48d6-b2d9-9e5bfd1a323d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_45d2c813-8ef3-4e61-bff2-92db04450753" xlink:href="xfor-20220331.xsd#xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_45d2c813-8ef3-4e61-bff2-92db04450753" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_115bcf1d-15ae-4f01-bf3c-0d74b0f60126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_115bcf1d-15ae-4f01-bf3c-0d74b0f60126" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_960e98d4-0162-47b3-8fc9-21808ea8d67e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_115bcf1d-15ae-4f01-bf3c-0d74b0f60126" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_960e98d4-0162-47b3-8fc9-21808ea8d67e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_960e98d4-0162-47b3-8fc9-21808ea8d67e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_960e98d4-0162-47b3-8fc9-21808ea8d67e" xlink:to="loc_us-gaap_EquityComponentDomain_960e98d4-0162-47b3-8fc9-21808ea8d67e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b26775c-9c93-43dd-91b5-b3749cc401b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_960e98d4-0162-47b3-8fc9-21808ea8d67e" xlink:to="loc_us-gaap_EquityComponentDomain_3b26775c-9c93-43dd-91b5-b3749cc401b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassAWarrantMember_038612ef-98fc-4d16-9bd3-586445363844" xlink:href="xfor-20220331.xsd#xfor_ClassAWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b26775c-9c93-43dd-91b5-b3749cc401b6" xlink:to="loc_xfor_ClassAWarrantMember_038612ef-98fc-4d16-9bd3-586445363844" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassBWarrantsMember_7932109e-bc32-444f-a5cb-8d3b6da7606a" xlink:href="xfor-20220331.xsd#xfor_ClassBWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b26775c-9c93-43dd-91b5-b3749cc401b6" xlink:to="loc_xfor_ClassBWarrantsMember_7932109e-bc32-444f-a5cb-8d3b6da7606a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_2e5a7d04-0c6e-4d2b-b272-da9ef7512b7c" xlink:href="xfor-20220331.xsd#xfor_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b26775c-9c93-43dd-91b5-b3749cc401b6" xlink:to="loc_xfor_PreFundedWarrantMember_2e5a7d04-0c6e-4d2b-b272-da9ef7512b7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsAxis_e0eb602c-a35a-4524-b98f-11c8bae939d0" xlink:href="xfor-20220331.xsd#xfor_PrefundedWarrantsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_115bcf1d-15ae-4f01-bf3c-0d74b0f60126" xlink:to="loc_xfor_PrefundedWarrantsAxis_e0eb602c-a35a-4524-b98f-11c8bae939d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain_e0eb602c-a35a-4524-b98f-11c8bae939d0_default" xlink:href="xfor-20220331.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xfor_PrefundedWarrantsAxis_e0eb602c-a35a-4524-b98f-11c8bae939d0" xlink:to="loc_xfor_PrefundedWarrantsDomain_e0eb602c-a35a-4524-b98f-11c8bae939d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain_2292a13b-ad16-4117-971f-ec3463360924" xlink:href="xfor-20220331.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xfor_PrefundedWarrantsAxis_e0eb602c-a35a-4524-b98f-11c8bae939d0" xlink:to="loc_xfor_PrefundedWarrantsDomain_2292a13b-ad16-4117-971f-ec3463360924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FundedMember_3cdbb591-192d-4e80-9b15-374ca054945d" xlink:href="xfor-20220331.xsd#xfor_FundedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_PrefundedWarrantsDomain_2292a13b-ad16-4117-971f-ec3463360924" xlink:to="loc_xfor_FundedMember_3cdbb591-192d-4e80-9b15-374ca054945d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail" xlink:type="extended" id="ia7d1277b2d42486f8acc4ae6b805a683_CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6e62d5f2-4a81-40c9-b12a-b2bff270f58c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_cdc71bb9-30ce-4b7e-81e2-163a09e709e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6e62d5f2-4a81-40c9-b12a-b2bff270f58c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_cdc71bb9-30ce-4b7e-81e2-163a09e709e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47bf5abf-ab8f-4daa-9bb2-401c3cb5df76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6e62d5f2-4a81-40c9-b12a-b2bff270f58c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47bf5abf-ab8f-4daa-9bb2-401c3cb5df76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_c5ba47ab-f676-4647-bc31-49dabf1269e9" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6e62d5f2-4a81-40c9-b12a-b2bff270f58c" xlink:to="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_c5ba47ab-f676-4647-bc31-49dabf1269e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_bd41a916-25b9-4976-b308-9718f72fa2d8" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6e62d5f2-4a81-40c9-b12a-b2bff270f58c" xlink:to="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_bd41a916-25b9-4976-b308-9718f72fa2d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_4ea76059-a203-4566-9057-842a662c8968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6e62d5f2-4a81-40c9-b12a-b2bff270f58c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_4ea76059-a203-4566-9057-842a662c8968" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_efc2c485-ee04-4fe7-bade-f66afbf35d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4ea76059-a203-4566-9057-842a662c8968" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_efc2c485-ee04-4fe7-bade-f66afbf35d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_efc2c485-ee04-4fe7-bade-f66afbf35d1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_efc2c485-ee04-4fe7-bade-f66afbf35d1e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_efc2c485-ee04-4fe7-bade-f66afbf35d1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_efc2c485-ee04-4fe7-bade-f66afbf35d1e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_18c958a9-6506-49dd-aa56-e008d05bc6f2" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_18c958a9-6506-49dd-aa56-e008d05bc6f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_f3df4584-c9f7-4a23-97e7-7a4fbfd9d702" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_f3df4584-c9f7-4a23-97e7-7a4fbfd9d702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_b2cb13e7-300d-414e-918e-0c117de322ea" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_b2cb13e7-300d-414e-918e-0c117de322ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_daff8a53-4927-4dca-8f7c-74d9be5b6ed3" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_daff8a53-4927-4dca-8f7c-74d9be5b6ed3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_f35351b8-94ea-4a9e-bb7e-e520825825de" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_f35351b8-94ea-4a9e-bb7e-e520825825de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_10c2da3f-8b8b-4d47-9d88-2255a0f941cf" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_10c2da3f-8b8b-4d47-9d88-2255a0f941cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_b3859733-5d51-4b99-9354-379af4741429" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_b3859733-5d51-4b99-9354-379af4741429" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_007d32a0-7742-4e4d-80b4-ec2970561dc1" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_007d32a0-7742-4e4d-80b4-ec2970561dc1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch232021Member_9dcc1445-4a67-4171-87f4-5074d3bcd499" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnMarch232021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnMarch232021Member_9dcc1445-4a67-4171-87f4-5074d3bcd499" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_05392704-20c8-42f3-859b-ba618f5a6f76" xlink:href="xfor-20220331.xsd#xfor_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_PreFundedWarrantMember_05392704-20c8-42f3-859b-ba618f5a6f76" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_39e13336-2559-4668-b413-615cb9a460b8" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_39e13336-2559-4668-b413-615cb9a460b8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch32022Member_6b75937c-20bd-4566-80fa-d4e6c95b8a7c" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnMarch32022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnMarch32022Member_6b75937c-20bd-4566-80fa-d4e6c95b8a7c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f44f850d-08cd-406d-8e5d-f789d313946b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4ea76059-a203-4566-9057-842a662c8968" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f44f850d-08cd-406d-8e5d-f789d313946b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f44f850d-08cd-406d-8e5d-f789d313946b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f44f850d-08cd-406d-8e5d-f789d313946b" xlink:to="loc_us-gaap_EquityComponentDomain_f44f850d-08cd-406d-8e5d-f789d313946b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a21d8e1d-fc3e-473b-a4df-b87f14513327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f44f850d-08cd-406d-8e5d-f789d313946b" xlink:to="loc_us-gaap_EquityComponentDomain_a21d8e1d-fc3e-473b-a4df-b87f14513327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_5604ddd2-5cb6-4470-875b-1f4b4ace2a6f" xlink:href="xfor-20220331.xsd#xfor_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a21d8e1d-fc3e-473b-a4df-b87f14513327" xlink:to="loc_xfor_PreFundedWarrantMember_5604ddd2-5cb6-4470-875b-1f4b4ace2a6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassBWarrantsMember_d6bc51da-e602-4ff2-96b0-4a5a750cbd8a" xlink:href="xfor-20220331.xsd#xfor_ClassBWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a21d8e1d-fc3e-473b-a4df-b87f14513327" xlink:to="loc_xfor_ClassBWarrantsMember_d6bc51da-e602-4ff2-96b0-4a5a750cbd8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassAWarrantMember_1185db41-4557-4b5e-a6ee-d027eb497a52" xlink:href="xfor-20220331.xsd#xfor_ClassAWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a21d8e1d-fc3e-473b-a4df-b87f14513327" xlink:to="loc_xfor_ClassAWarrantMember_1185db41-4557-4b5e-a6ee-d027eb497a52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LegacyWarrantsMember_2535ea6d-9f60-4cb4-b081-bb5b7390b942" xlink:href="xfor-20220331.xsd#xfor_LegacyWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a21d8e1d-fc3e-473b-a4df-b87f14513327" xlink:to="loc_xfor_LegacyWarrantsMember_2535ea6d-9f60-4cb4-b081-bb5b7390b942" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_0a5ab9be-05d2-4f5a-a7b6-ee8412ccd0b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4ea76059-a203-4566-9057-842a662c8968" xlink:to="loc_srt_TitleOfIndividualAxis_0a5ab9be-05d2-4f5a-a7b6-ee8412ccd0b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0a5ab9be-05d2-4f5a-a7b6-ee8412ccd0b5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_0a5ab9be-05d2-4f5a-a7b6-ee8412ccd0b5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0a5ab9be-05d2-4f5a-a7b6-ee8412ccd0b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0aeb9b07-eab5-4563-b5c7-8848d11ee529" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_0a5ab9be-05d2-4f5a-a7b6-ee8412ccd0b5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0aeb9b07-eab5-4563-b5c7-8848d11ee529" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsAxis_52c73553-ace9-47a2-9965-32fc4fd2b6f2" xlink:href="xfor-20220331.xsd#xfor_PrefundedWarrantsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4ea76059-a203-4566-9057-842a662c8968" xlink:to="loc_xfor_PrefundedWarrantsAxis_52c73553-ace9-47a2-9965-32fc4fd2b6f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain_52c73553-ace9-47a2-9965-32fc4fd2b6f2_default" xlink:href="xfor-20220331.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xfor_PrefundedWarrantsAxis_52c73553-ace9-47a2-9965-32fc4fd2b6f2" xlink:to="loc_xfor_PrefundedWarrantsDomain_52c73553-ace9-47a2-9965-32fc4fd2b6f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain_82dfa760-a9ce-438d-adea-3f7530e2d415" xlink:href="xfor-20220331.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xfor_PrefundedWarrantsAxis_52c73553-ace9-47a2-9965-32fc4fd2b6f2" xlink:to="loc_xfor_PrefundedWarrantsDomain_82dfa760-a9ce-438d-adea-3f7530e2d415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FundedMember_97982f41-73ed-494b-abc9-b1c8b860d063" xlink:href="xfor-20220331.xsd#xfor_FundedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_PrefundedWarrantsDomain_82dfa760-a9ce-438d-adea-3f7530e2d415" xlink:to="loc_xfor_FundedMember_97982f41-73ed-494b-abc9-b1c8b860d063" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="i979754cf755f424cb6bb745d7fdbd0b7_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f115289-9cad-4cd5-9324-72c422f111fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_431161f2-4e75-46f5-b72c-2a3e3ec2d551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f115289-9cad-4cd5-9324-72c422f111fa" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_431161f2-4e75-46f5-b72c-2a3e3ec2d551" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dd064284-73a0-4a86-b49f-db42ece34282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f115289-9cad-4cd5-9324-72c422f111fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dd064284-73a0-4a86-b49f-db42ece34282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_d50ac1a4-dfa5-466e-af52-1e560d5f3b39" xlink:href="xfor-20220331.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f115289-9cad-4cd5-9324-72c422f111fa" xlink:to="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_d50ac1a4-dfa5-466e-af52-1e560d5f3b39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_870cbdb3-7a11-4133-a7b7-fcb9a5de94cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f115289-9cad-4cd5-9324-72c422f111fa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_870cbdb3-7a11-4133-a7b7-fcb9a5de94cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e0aa6ea5-1ffb-46c3-ac03-a70f382f259e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f115289-9cad-4cd5-9324-72c422f111fa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e0aa6ea5-1ffb-46c3-ac03-a70f382f259e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b24e502d-50a2-4c89-91b1-a274537f0927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f115289-9cad-4cd5-9324-72c422f111fa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b24e502d-50a2-4c89-91b1-a274537f0927" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_59194d29-71cb-4750-b508-867d3d455b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b24e502d-50a2-4c89-91b1-a274537f0927" xlink:to="loc_us-gaap_PlanNameAxis_59194d29-71cb-4750-b508-867d3d455b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_59194d29-71cb-4750-b508-867d3d455b5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_59194d29-71cb-4750-b508-867d3d455b5b" xlink:to="loc_us-gaap_PlanNameDomain_59194d29-71cb-4750-b508-867d3d455b5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_10b992a4-6751-4e00-b242-da98b1fc1965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_59194d29-71cb-4750-b508-867d3d455b5b" xlink:to="loc_us-gaap_PlanNameDomain_10b992a4-6751-4e00-b242-da98b1fc1965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember_1c249593-1035-43c3-947f-6388533f6524" xlink:href="xfor-20220331.xsd#xfor_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_10b992a4-6751-4e00-b242-da98b1fc1965" xlink:to="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember_1c249593-1035-43c3-947f-6388533f6524" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember_02e36b4f-38ac-4d0f-8e3f-283c879836a4" xlink:href="xfor-20220331.xsd#xfor_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_10b992a4-6751-4e00-b242-da98b1fc1965" xlink:to="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember_02e36b4f-38ac-4d0f-8e3f-283c879836a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_71a94f17-84fb-408b-b1f4-f7434fa30505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b24e502d-50a2-4c89-91b1-a274537f0927" xlink:to="loc_us-gaap_AwardTypeAxis_71a94f17-84fb-408b-b1f4-f7434fa30505" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71a94f17-84fb-408b-b1f4-f7434fa30505_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_71a94f17-84fb-408b-b1f4-f7434fa30505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71a94f17-84fb-408b-b1f4-f7434fa30505_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_606663a9-dd37-46d1-9c8c-63fd0e65c797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_71a94f17-84fb-408b-b1f4-f7434fa30505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_606663a9-dd37-46d1-9c8c-63fd0e65c797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69b02943-5088-4d27-af6a-666ecfcb28ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_606663a9-dd37-46d1-9c8c-63fd0e65c797" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_69b02943-5088-4d27-af6a-666ecfcb28ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="xfor-20220331.xsd#StockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationDetails" xlink:type="extended" id="i5419251e6e5140b3a3b038713946de8b_StockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fed7457-83a4-4553-bc40-7358d11a231b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_78a8240d-0233-471a-8ca9-2c74340f8d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fed7457-83a4-4553-bc40-7358d11a231b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_78a8240d-0233-471a-8ca9-2c74340f8d11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2f9827bc-b9af-4c88-ae1b-97069cbe5eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_78a8240d-0233-471a-8ca9-2c74340f8d11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2f9827bc-b9af-4c88-ae1b-97069cbe5eef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ccfdaa6a-63c1-481f-91f9-26669363ae55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_78a8240d-0233-471a-8ca9-2c74340f8d11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ccfdaa6a-63c1-481f-91f9-26669363ae55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8aee4f5b-92a0-4d4a-9ea2-2ebce988963c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_78a8240d-0233-471a-8ca9-2c74340f8d11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8aee4f5b-92a0-4d4a-9ea2-2ebce988963c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c331fed1-adf1-4d1f-8ae8-aa57a6249edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_78a8240d-0233-471a-8ca9-2c74340f8d11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c331fed1-adf1-4d1f-8ae8-aa57a6249edb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3a7c13a0-7f91-495a-8da0-d26d8a352102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aec4772-4652-4deb-adf6-d7251add67b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fed7457-83a4-4553-bc40-7358d11a231b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aec4772-4652-4deb-adf6-d7251add67b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2d63846e-1c38-4a8c-8ad9-e5acc42e1ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aec4772-4652-4deb-adf6-d7251add67b1" xlink:to="loc_us-gaap_AwardTypeAxis_2d63846e-1c38-4a8c-8ad9-e5acc42e1ea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d63846e-1c38-4a8c-8ad9-e5acc42e1ea8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2d63846e-1c38-4a8c-8ad9-e5acc42e1ea8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d63846e-1c38-4a8c-8ad9-e5acc42e1ea8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24ed14e8-ac9e-4f71-81a1-863d64848e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2d63846e-1c38-4a8c-8ad9-e5acc42e1ea8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24ed14e8-ac9e-4f71-81a1-863d64848e3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8693a792-e0c3-491a-b24d-b4bc105fb2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24ed14e8-ac9e-4f71-81a1-863d64848e3e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8693a792-e0c3-491a-b24d-b4bc105fb2eb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" xlink:type="simple" xlink:href="xfor-20220331.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" xlink:type="extended" id="i5a81fc15c6cb468c8a07b473d7452309_StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa0df835-5f7d-4100-8378-299b910f9747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_38b09427-c375-48f7-8984-b51ba9764b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa0df835-5f7d-4100-8378-299b910f9747" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_38b09427-c375-48f7-8984-b51ba9764b8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_472f2c94-90ec-40eb-9359-82121e76a9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa0df835-5f7d-4100-8378-299b910f9747" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_472f2c94-90ec-40eb-9359-82121e76a9f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_281b4dfe-3b3e-410c-85b0-39ddc6ff7afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_472f2c94-90ec-40eb-9359-82121e76a9f5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_281b4dfe-3b3e-410c-85b0-39ddc6ff7afc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_281b4dfe-3b3e-410c-85b0-39ddc6ff7afc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_281b4dfe-3b3e-410c-85b0-39ddc6ff7afc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_281b4dfe-3b3e-410c-85b0-39ddc6ff7afc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9d0f83d0-b1d3-4b31-a285-6e48fec471c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_281b4dfe-3b3e-410c-85b0-39ddc6ff7afc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9d0f83d0-b1d3-4b31-a285-6e48fec471c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_529b0888-e19f-4cc3-9507-93ed55166d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d0f83d0-b1d3-4b31-a285-6e48fec471c5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_529b0888-e19f-4cc3-9507-93ed55166d9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c5775006-75d5-45be-945a-9176c15de90b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d0f83d0-b1d3-4b31-a285-6e48fec471c5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c5775006-75d5-45be-945a-9176c15de90b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#NetLossperShareAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail" xlink:type="extended" id="i2690fbbd767f4c38b2727dcaeea3522b_NetLossperShareAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_968568cd-4296-46af-b8af-d049dc73c549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e27cc31f-5a12-4053-bd69-5969fbb98187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_968568cd-4296-46af-b8af-d049dc73c549" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e27cc31f-5a12-4053-bd69-5969fbb98187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41f70a28-b8c2-443f-bb40-029d99f52770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_968568cd-4296-46af-b8af-d049dc73c549" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41f70a28-b8c2-443f-bb40-029d99f52770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1008baab-bf93-4647-8573-32a5cfcecb92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_968568cd-4296-46af-b8af-d049dc73c549" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1008baab-bf93-4647-8573-32a5cfcecb92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bf1d5d44-33d5-459c-84c4-a8ec266d2b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1008baab-bf93-4647-8573-32a5cfcecb92" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bf1d5d44-33d5-459c-84c4-a8ec266d2b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bf1d5d44-33d5-459c-84c4-a8ec266d2b40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bf1d5d44-33d5-459c-84c4-a8ec266d2b40" xlink:to="loc_us-gaap_ClassOfStockDomain_bf1d5d44-33d5-459c-84c4-a8ec266d2b40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_edbab4f6-159e-45af-b632-9452e786a8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bf1d5d44-33d5-459c-84c4-a8ec266d2b40" xlink:to="loc_us-gaap_ClassOfStockDomain_edbab4f6-159e-45af-b632-9452e786a8d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember_d7699eef-5284-4b19-b042-226c228ffd06" xlink:href="xfor-20220331.xsd#xfor_RedeemableCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_edbab4f6-159e-45af-b632-9452e786a8d3" xlink:to="loc_xfor_RedeemableCommonStockMember_d7699eef-5284-4b19-b042-226c228ffd06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_270d7f88-f0ff-44f4-9351-2ddc831f3d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1008baab-bf93-4647-8573-32a5cfcecb92" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_270d7f88-f0ff-44f4-9351-2ddc831f3d3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_270d7f88-f0ff-44f4-9351-2ddc831f3d3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_270d7f88-f0ff-44f4-9351-2ddc831f3d3e" xlink:to="loc_us-gaap_EquityComponentDomain_270d7f88-f0ff-44f4-9351-2ddc831f3d3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_310fd5dc-dfce-4f3e-859d-4b549b09b04f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_270d7f88-f0ff-44f4-9351-2ddc831f3d3e" xlink:to="loc_us-gaap_EquityComponentDomain_310fd5dc-dfce-4f3e-859d-4b549b09b04f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_7c9105b9-e9c1-4c97-87e7-c80cb7f93d53" xlink:href="xfor-20220331.xsd#xfor_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_310fd5dc-dfce-4f3e-859d-4b549b09b04f" xlink:to="loc_xfor_PreFundedWarrantMember_7c9105b9-e9c1-4c97-87e7-c80cb7f93d53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_39e6b9b5-9a9f-4bd0-8de1-ed01f03becd0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1008baab-bf93-4647-8573-32a5cfcecb92" xlink:to="loc_srt_RangeAxis_39e6b9b5-9a9f-4bd0-8de1-ed01f03becd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39e6b9b5-9a9f-4bd0-8de1-ed01f03becd0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_39e6b9b5-9a9f-4bd0-8de1-ed01f03becd0" xlink:to="loc_srt_RangeMember_39e6b9b5-9a9f-4bd0-8de1-ed01f03becd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_810645bf-0350-44a3-9ea7-6a415ac5fc9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_39e6b9b5-9a9f-4bd0-8de1-ed01f03becd0" xlink:to="loc_srt_RangeMember_810645bf-0350-44a3-9ea7-6a415ac5fc9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e95bc78c-6648-40f9-85ca-72cf3bbf230a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_810645bf-0350-44a3-9ea7-6a415ac5fc9d" xlink:to="loc_srt_MaximumMember_e95bc78c-6648-40f9-85ca-72cf3bbf230a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail" xlink:type="extended" id="i7bcd097358a14bc9b51abc5f7c93b6b7_NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f9a3a2d8-5cee-46f0-bb62-0e53ee7d94c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8ae170a5-79c6-44de-a214-8cd09191f62d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f9a3a2d8-5cee-46f0-bb62-0e53ee7d94c2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8ae170a5-79c6-44de-a214-8cd09191f62d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cf25454c-737c-4f89-b234-294141ec9fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f9a3a2d8-5cee-46f0-bb62-0e53ee7d94c2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cf25454c-737c-4f89-b234-294141ec9fcf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_572e5571-c7ea-40d3-81b6-63f359b4e431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cf25454c-737c-4f89-b234-294141ec9fcf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_572e5571-c7ea-40d3-81b6-63f359b4e431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_572e5571-c7ea-40d3-81b6-63f359b4e431_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_572e5571-c7ea-40d3-81b6-63f359b4e431" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_572e5571-c7ea-40d3-81b6-63f359b4e431_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2161819c-5107-4472-8c58-34275f956af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_572e5571-c7ea-40d3-81b6-63f359b4e431" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2161819c-5107-4472-8c58-34275f956af8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9b092bc4-1360-469d-ba89-225bde06b1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2161819c-5107-4472-8c58-34275f956af8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9b092bc4-1360-469d-ba89-225bde06b1e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_571a1b49-6683-4b83-a523-0f4dc5775502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2161819c-5107-4472-8c58-34275f956af8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_571a1b49-6683-4b83-a523-0f4dc5775502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b1206eea-d441-41b8-8b7c-4e4097fb8217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2161819c-5107-4472-8c58-34275f956af8" xlink:to="loc_us-gaap_WarrantMember_b1206eea-d441-41b8-8b7c-4e4097fb8217" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>xfor-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:15224e09-2b4e-4653-a05c-4094a1da55b0,g:b51d9744-e75b-48fa-9941-02b626145304-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_xfor_LongTermDebtIncludingAccretion_e3c13feb-3a5b-48e2-bb08-30ad00898c55_totalLabel_en-US" xlink:label="lab_xfor_LongTermDebtIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_xfor_LongTermDebtIncludingAccretion_label_en-US" xlink:label="lab_xfor_LongTermDebtIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Including Accretion</link:label>
    <link:label id="lab_xfor_LongTermDebtIncludingAccretion_documentation_en-US" xlink:label="lab_xfor_LongTermDebtIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Including Accretion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtIncludingAccretion" xlink:href="xfor-20220331.xsd#xfor_LongTermDebtIncludingAccretion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LongTermDebtIncludingAccretion" xlink:to="lab_xfor_LongTermDebtIncludingAccretion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_90b5da9c-5da2-4329-862b-3ee8394781bb_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8903dff8-1cce-4387-9bb5-ad54466bcada_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax benefit</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_54de4a4a-f81c-4b07-83a7-e9206e302109_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_9712209c-6cc9-45db-9ec5-03b881661410_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aeaaea8e-cbe4-48e9-9437-b3f0f8bd663b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_08ede38b-9971-45d7-865e-1d845ab613cb_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4e8a5dbd-c3a1-4904-8a50-1eaed84f014e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e68d36ee-4d62-4552-90d0-bda9db5ca153_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7471d984-f807-46e3-8275-1a2022e6b4a3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3889e46e-c386-4dfe-9c6d-fe973bd1a473_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a14edf95-4858-4352-bad2-77c702036174_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_e7feb164-7eea-49ce-a854-c314235b8b6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Principal Payments and the Final Payments Due</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AccruedExpensesTextBlock_695c6a0b-03e7-4d68-acd9-f65b81f5d8a1_terseLabel_en-US" xlink:label="lab_xfor_AccruedExpensesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_xfor_AccruedExpensesTextBlock_label_en-US" xlink:label="lab_xfor_AccruedExpensesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses [Text Block]</link:label>
    <link:label id="lab_xfor_AccruedExpensesTextBlock_documentation_en-US" xlink:label="lab_xfor_AccruedExpensesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExpensesTextBlock" xlink:href="xfor-20220331.xsd#xfor_AccruedExpensesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AccruedExpensesTextBlock" xlink:to="lab_xfor_AccruedExpensesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_e2a6634d-c2a8-403b-9cde-e33fa844d9da_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b8690d48-bfaf-4806-8c08-7982160949d8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_79ee9f5c-52a8-43ae-8737-fb5a44bbc8ec_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_86ba9c4b-5a93-4f38-b425-2b2b035d2e2c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e8981923-b8fb-44b7-b797-60b4e42a4d62_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ebea97db-8ea7-47d2-89f6-560e6dbac0c2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term-operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_2d3d2e08-e003-435a-828d-2c9f4a2d44e8_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable common shares, beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_90309cfa-2427-4765-b00e-0950f038eca0_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred shares, ending balance, shares</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e9432fb6-8132-4f03-9329-819595f3954d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f83c53a8-c676-4804-baad-b71b4d66c2d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ba5b7686-29e6-4147-af09-28fd404b8893_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield (in percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent_491a4148-d302-4dbe-bd5a-529131883741_terseLabel_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual base rent</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent_label_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rent</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent_documentation_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" xlink:href="xfor-20220331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" xlink:to="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f11f34cd-af68-4acd-9ad9-4827971382c6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_65994701-e57b-4dac-9121-0b047dcdca83_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e8336d6e-b5fd-46e9-b98d-fb3049a1d741_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (in percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_38509cec-595b-481e-9f5f-55706cbe6117_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_69250713-32dc-49c5-aefc-a76e0878cec1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPaidinkind_3492dd81-b7ba-4445-b7a1-33d08c9bd4e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsPaidinkind" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Paid-in-kind</link:label>
    <link:label id="lab_us-gaap_DividendsPaidinkind_label_en-US" xlink:label="lab_us-gaap_DividendsPaidinkind" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Paid-in-kind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPaidinkind" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPaidinkind"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPaidinkind" xlink:to="lab_us-gaap_DividendsPaidinkind" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ebaff6c5-0ab9-4d17-bb6f-62756a82d50b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_82588a66-0f6e-449a-a8ea-83866ac5c202_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_27284c80-bc42-40c0-84f8-a518b941d6e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_871b5f9e-f9e0-4dc6-a779-b62585b7a96a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_DebtInstrumentPrepaymentPremiumPercentage_9ab78f65-9306-493d-aee5-80d84a8bdd0e_terseLabel_en-US" xlink:label="lab_xfor_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument prepayment premium, percentage</link:label>
    <link:label id="lab_xfor_DebtInstrumentPrepaymentPremiumPercentage_label_en-US" xlink:label="lab_xfor_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Premium, Percentage</link:label>
    <link:label id="lab_xfor_DebtInstrumentPrepaymentPremiumPercentage_documentation_en-US" xlink:label="lab_xfor_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Premium, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentPrepaymentPremiumPercentage" xlink:href="xfor-20220331.xsd#xfor_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_DebtInstrumentPrepaymentPremiumPercentage" xlink:to="lab_xfor_DebtInstrumentPrepaymentPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_e8c32ec1-e30a-482d-9c60-2c75583d3a06_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_e3b89fab-e979-4b01-b28e-dfb3966f616f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94e66717-8727-40a5-8c8b-afc1edd3dfcb_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_b4da775f-f02b-45bb-866e-05a1cdd72922_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On October 25, 2016</link:label>
    <link:label id="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_label_en-US" xlink:label="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On October Twenty Five Two Thousand Sixteen [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on october twenty five two thousand sixteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:to="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LabEquipmentMember_19de27fe-782e-47de-a77c-77978b2165f0_terseLabel_en-US" xlink:label="lab_xfor_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_xfor_LabEquipmentMember_label_en-US" xlink:label="lab_xfor_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_xfor_LabEquipmentMember_documentation_en-US" xlink:label="lab_xfor_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LabEquipmentMember" xlink:href="xfor-20220331.xsd#xfor_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LabEquipmentMember" xlink:to="lab_xfor_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1021b76f-5b47-464a-a4fa-ad175cbcc144_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_43e314f4-6994-4e32-8cba-cae31322bf11_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate-operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_01100bcb-b9b4-44e6-a963-5d9a7d6a6662_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember_1753de94-6e48-4d6c-a4d4-7e3b83f139f0_terseLabel_en-US" xlink:label="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan</link:label>
    <link:label id="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember_label_en-US" xlink:label="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:href="xfor-20220331.xsd#xfor_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_338d1c65-80e0-4470-9431-0160ea2497f1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_e9156e64-b229-4fab-9f7f-650f5240e4be_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c71cb9e-b336-4011-8277-62e30d21f714_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_502b9f2d-5c10-4b04-bcda-cbb299283694_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_ad949861-eef6-40be-a884-016bf3b7ad67_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7dd90a75-bbf6-4dc3-bf4a-21eb30a8bc7f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_b3e5482f-2857-46bb-92c2-361b6c461900_terseLabel_en-US" xlink:label="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label id="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_label_en-US" xlink:label="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label id="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_documentation_en-US" xlink:label="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:href="xfor-20220331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_20e74125-d05d-4fdc-b3cd-60ac26eb3112_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_c0687ff1-6c35-492a-b1c6-07e656993ab4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4394124a-58c6-4692-85b5-7e0c3125991f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6667c1fe-09f9-441c-a881-8f00981aad4f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_974c9d92-89e3-48c5-bbc3-583dba287541_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_52325b35-bfe7-4947-a125-3fa7b273ea0c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2ae87ad9-bc87-42b6-b2a2-44d4c6e5f660_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_948c628f-b687-4dcb-ac50-d9e78824202f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses, other current assets and research and development incentive receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_954e586a-5beb-4399-875b-59ddb3b176b5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease not yet commenced, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b96f187e-d6d9-4c6e-ab40-7bb06b1513d9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6785ef55-6a4f-4713-a7f3-85f36835503c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b21d011c-a553-4c42-8969-61df7b66227a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property, equipment and right-of-use assets included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_5644bc36-8313-425b-8e34-e3694b4eab53_terseLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:to="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LegacyWarrantsMember_2d7553dc-811e-42e7-98e7-c4a750363bb4_terseLabel_en-US" xlink:label="lab_xfor_LegacyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Warrants</link:label>
    <link:label id="lab_xfor_LegacyWarrantsMember_label_en-US" xlink:label="lab_xfor_LegacyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Warrants [Member]</link:label>
    <link:label id="lab_xfor_LegacyWarrantsMember_documentation_en-US" xlink:label="lab_xfor_LegacyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LegacyWarrantsMember" xlink:href="xfor-20220331.xsd#xfor_LegacyWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LegacyWarrantsMember" xlink:to="lab_xfor_LegacyWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_29751732-37f0-45c7-96de-c85f1b07c1d5_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ee242e9b-19c4-42ed-9a46-7459e18faaf0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f27ca943-76e1-4bb8-8237-1bc7f156a4d6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_78d76748-fd14-45e0-bd33-a622532b8815_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_MinCashTestDate1Member_a1e42e58-2e88-4605-ba1b-1c76a1825c3b_terseLabel_en-US" xlink:label="lab_xfor_MinCashTestDate1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 1</link:label>
    <link:label id="lab_xfor_MinCashTestDate1Member_label_en-US" xlink:label="lab_xfor_MinCashTestDate1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 1 [Member]</link:label>
    <link:label id="lab_xfor_MinCashTestDate1Member_documentation_en-US" xlink:label="lab_xfor_MinCashTestDate1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate1Member" xlink:href="xfor-20220331.xsd#xfor_MinCashTestDate1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_MinCashTestDate1Member" xlink:to="lab_xfor_MinCashTestDate1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bfe22b8c-73c8-401a-a3b4-3c3f7b2d37f2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_6b6f0d0c-fe5a-45ed-9750-e1a83bf033e9_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cdd3249e-0fd7-499b-af36-2205c190fa1c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dbca2c94-7d37-47ce-9e94-f91ac322710b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4be88e1f-a23f-475d-86e3-c8e9188b797b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0e80c837-a774-4ffe-a14e-b44386607e4c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ScheduleOfLongTermDebtLineItems_5ca7bcc7-d478-4b97-a6b4-51b36d717486_terseLabel_en-US" xlink:label="lab_xfor_ScheduleOfLongTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Long Term Debt [Line Items]</link:label>
    <link:label id="lab_xfor_ScheduleOfLongTermDebtLineItems_label_en-US" xlink:label="lab_xfor_ScheduleOfLongTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Long Term Debt [Line Items]</link:label>
    <link:label id="lab_xfor_ScheduleOfLongTermDebtLineItems_documentation_en-US" xlink:label="lab_xfor_ScheduleOfLongTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Long Term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfLongTermDebtLineItems" xlink:href="xfor-20220331.xsd#xfor_ScheduleOfLongTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems" xlink:to="lab_xfor_ScheduleOfLongTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AllstonLeaseMember_e1129862-50b9-4566-9f91-b243f65fe526_terseLabel_en-US" xlink:label="lab_xfor_AllstonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allston Lease</link:label>
    <link:label id="lab_xfor_AllstonLeaseMember_label_en-US" xlink:label="lab_xfor_AllstonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allston Lease [Member]</link:label>
    <link:label id="lab_xfor_AllstonLeaseMember_documentation_en-US" xlink:label="lab_xfor_AllstonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allston Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseMember" xlink:href="xfor-20220331.xsd#xfor_AllstonLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AllstonLeaseMember" xlink:to="lab_xfor_AllstonLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_6bc46afc-727d-491b-a3fe-50e5b1efc9ab_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_10360714-9e24-479d-9850-3cc555b90e36_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend on Class B Warrant price reset</link:label>
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_label_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:to="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1593599d-fb19-490e-9943-c0cb389fab6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_348e0e89-2135-4b96-90f3-d20cd31bb753_terseLabel_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_label_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Office Space</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_documentation_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:href="xfor-20220331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:to="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_1d794fed-6fa7-4f61-bf31-3592ee096523_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_f967f452-d173-4e82-a651-6ec21f2209cd_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_9513796d-2103-4a43-be8c-5360cb4a5b33_terseLabel_en-US" xlink:label="lab_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and pre-funded warrants and issuance of shares of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_label_en-US" xlink:label="lab_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Exercise Of Stock Options And Warrants</link:label>
    <link:label id="lab_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_documentation_en-US" xlink:label="lab_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:href="xfor-20220331.xsd#xfor_ProceedsFromExerciseOfStockOptionsAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:to="lab_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_ce1d81f9-02b6-4ffb-b614-189af660ca30_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement_0d10df02-5fdf-4a1a-9704-1b76fe3c1b8b_terseLabel_en-US" xlink:label="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current office space under lease agreement</link:label>
    <link:label id="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement_label_en-US" xlink:label="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Office Space Under Lease Agreement</link:label>
    <link:label id="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement_documentation_en-US" xlink:label="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current office space under lease agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:href="xfor-20220331.xsd#xfor_CurrentOfficeSpaceUnderLeaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:to="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5ce9f200-5af9-4018-b952-641ac85a5a19_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_4aa91a2a-180b-4108-a055-845cc38ba121_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_056abc92-e162-482e-9946-723aecc4e774_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e15a3da4-4563-46cb-925f-477102fd8a15_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c66070e-daf0-43f0-9a65-96b1cf9a464b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_747801f6-125a-4071-8320-648ca1d981b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d31f6048-442d-4746-8b36-c3b16cdd1a23_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_HerculesSecondAmendedLoanAgreementMember_3e6f266e-39b8-421c-a157-a1b554798618_terseLabel_en-US" xlink:label="lab_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Second Amended Loan Agreement</link:label>
    <link:label id="lab_xfor_HerculesSecondAmendedLoanAgreementMember_label_en-US" xlink:label="lab_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Second Amended Loan Agreement [Member]</link:label>
    <link:label id="lab_xfor_HerculesSecondAmendedLoanAgreementMember_documentation_en-US" xlink:label="lab_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Second Amended Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:href="xfor-20220331.xsd#xfor_HerculesSecondAmendedLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:to="lab_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8d88ab98-f05b-48ee-a8b6-0bc7c2d73c0a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8dfb160e-ee78-47b2-a640-3925d20fa30d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_27ba5f6d-29e9-4958-b02c-cc1bb91b7632_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_8806b98d-d207-4243-b519-c28b04f1da21_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ViennaLeaseAgreementMember_06f108db-5c61-4ca2-98e6-cf3b3ca4ccb1_terseLabel_en-US" xlink:label="lab_xfor_ViennaLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vienna Austria Lease</link:label>
    <link:label id="lab_xfor_ViennaLeaseAgreementMember_label_en-US" xlink:label="lab_xfor_ViennaLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vienna Lease Agreement [Member]</link:label>
    <link:label id="lab_xfor_ViennaLeaseAgreementMember_documentation_en-US" xlink:label="lab_xfor_ViennaLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vienna lease agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaLeaseAgreementMember" xlink:href="xfor-20220331.xsd#xfor_ViennaLeaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ViennaLeaseAgreementMember" xlink:to="lab_xfor_ViennaLeaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_41788e07-2a20-407b-ba82-7e9150443d52_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f48b5d37-2f7e-44cf-88a9-df6e2c6ce64c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9a58ff61-f82d-4535-bcd5-73f3e819cbc5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_103f9157-d1ae-4512-9c21-37c089a878a1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of the Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_WarrantsRollForward_b49edf96-aee2-4012-81b9-b29f35121e74_terseLabel_en-US" xlink:label="lab_xfor_WarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Roll Forward]</link:label>
    <link:label id="lab_xfor_WarrantsRollForward_label_en-US" xlink:label="lab_xfor_WarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Roll Forward]</link:label>
    <link:label id="lab_xfor_WarrantsRollForward_documentation_en-US" xlink:label="lab_xfor_WarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WarrantsRollForward" xlink:href="xfor-20220331.xsd#xfor_WarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_WarrantsRollForward" xlink:to="lab_xfor_WarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_583d0480-729d-4626-b710-d5a7225740f2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_26a1138e-a492-44fc-91ac-08883c2354a6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d2e82cba-f61e-4561-a333-5f5d3cb37b1f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightExercised_9cbbcc5d-7d1b-41ff-ab95-c2200f82f667_negatedLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightExercised_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Exercised</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightExercised_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightExercised" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightExercised" xlink:to="lab_xfor_ClassOfWarrantOrRightExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_HerculesLoanAgreementMember_6ce9ff86-b9d7-44ec-8560-8dc677cb6ab2_terseLabel_en-US" xlink:label="lab_xfor_HerculesLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Loan Agreement</link:label>
    <link:label id="lab_xfor_HerculesLoanAgreementMember_label_en-US" xlink:label="lab_xfor_HerculesLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Loan Agreement [Member]</link:label>
    <link:label id="lab_xfor_HerculesLoanAgreementMember_documentation_en-US" xlink:label="lab_xfor_HerculesLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesLoanAgreementMember" xlink:href="xfor-20220331.xsd#xfor_HerculesLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_HerculesLoanAgreementMember" xlink:to="lab_xfor_HerculesLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_edf018b5-a6da-4b04-8305-5a502e897678_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_74c7953a-4ff4-4fe1-92a0-4630cb34f6ec_terseLabel_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, weighted average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Awards Grant In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Awards Grant in Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:href="xfor-20220331.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnMarch32022Member_d1ac090a-d9f8-4e35-890a-c3d38a7cb425_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnMarch32022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on March 3 2022</link:label>
    <link:label id="lab_xfor_IssuanceOnMarch32022Member_label_en-US" xlink:label="lab_xfor_IssuanceOnMarch32022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on March 3 2022 [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnMarch32022Member_documentation_en-US" xlink:label="lab_xfor_IssuanceOnMarch32022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on March 3 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch32022Member" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnMarch32022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnMarch32022Member" xlink:to="lab_xfor_IssuanceOnMarch32022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ba8db31d-bc4a-4fd0-8ea7-16dac6280f32_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_499a54bc-ca9c-493a-ae9d-66a206e82bc7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_34c11c77-abe4-4fd7-85f2-a6f7b5a0dbf8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_27f77f4a-135e-41c6-8e98-b5f0fdc7827b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_60df91ad-c4e5-4dd7-9def-36cfc55c22eb_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses_6b07e944-73c5-439c-81ce-cddc6bff8ba8_terseLabel_en-US" xlink:label="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued external research and development expenses</link:label>
    <link:label id="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued External Research And Development Expenses</link:label>
    <link:label id="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued external research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:href="xfor-20220331.xsd#xfor_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:to="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts_f6e993f3-5397-4c24-a5b5-21013a95615e_negatedTerseLabel_en-US" xlink:label="lab_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under loan and security agreements, net of issuance costs</link:label>
    <link:label id="lab_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts_label_en-US" xlink:label="lab_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under loan and security agreements, net of issuance costs</link:label>
    <link:label id="lab_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under loan and security agreements, net of issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts" xlink:href="xfor-20220331.xsd#xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts" xlink:to="lab_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7e8ba243-23f2-461a-b503-7775dc4cbdd5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveReceivable_542e82e8-8240-4394-bee6-8189c588e3dd_terseLabel_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development incentive receivable</link:label>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveReceivable_label_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Incentive Receivable</link:label>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveReceivable_documentation_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development incentive receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:href="xfor-20220331.xsd#xfor_ResearchAndDevelopmentIncentiveReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:to="lab_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ScheduleOfAccountingPoliciesTable_6fbdf949-62ba-47e7-bc6c-5fdb71eade88_terseLabel_en-US" xlink:label="lab_xfor_ScheduleOfAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounting Policies [Table]</link:label>
    <link:label id="lab_xfor_ScheduleOfAccountingPoliciesTable_label_en-US" xlink:label="lab_xfor_ScheduleOfAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounting Policies [Table]</link:label>
    <link:label id="lab_xfor_ScheduleOfAccountingPoliciesTable_documentation_en-US" xlink:label="lab_xfor_ScheduleOfAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfAccountingPoliciesTable" xlink:href="xfor-20220331.xsd#xfor_ScheduleOfAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ScheduleOfAccountingPoliciesTable" xlink:to="lab_xfor_ScheduleOfAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_cf27a242-1d70-431e-a9f6-f411b3100c68_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_37d5dd36-9963-4c5e-8e67-9618b6c4ac4c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_225eb9a7-38fe-476e-bd21-6d3ad3beed7d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a8bbe43b-ec94-4399-829d-57a8198025ac_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock_77332d8b-66ec-43c3-9c7b-fd746e4d8627_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Compensating Balances [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensatingBalancesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_e2dc0a06-32bc-4f86-8d22-2e1acd7aaa90_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_a76f6f61-3dd3-4bef-ae58-849cc23a2b0a_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b2f42654-0fc8-4cff-9369-e431bdb8cc71_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, Exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a7feb632-d51a-4198-9dfb-893f80e3fb0f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_DenominatorAbstract_cf5d4748-2c04-450e-8941-6a4f917c3f82_terseLabel_en-US" xlink:label="lab_xfor_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_xfor_DenominatorAbstract_label_en-US" xlink:label="lab_xfor_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_xfor_DenominatorAbstract_documentation_en-US" xlink:label="lab_xfor_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DenominatorAbstract" xlink:href="xfor-20220331.xsd#xfor_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_DenominatorAbstract" xlink:to="lab_xfor_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3f2bf5d8-473e-441d-ba49-aa5f6fc7c37e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AggregateBaseRent_09534950-7bfe-49f3-ac0d-6b26b1e9182b_terseLabel_en-US" xlink:label="lab_xfor_AggregateBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current base rent</link:label>
    <link:label id="lab_xfor_AggregateBaseRent_label_en-US" xlink:label="lab_xfor_AggregateBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Base Rent</link:label>
    <link:label id="lab_xfor_AggregateBaseRent_documentation_en-US" xlink:label="lab_xfor_AggregateBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate base rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AggregateBaseRent" xlink:href="xfor-20220331.xsd#xfor_AggregateBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AggregateBaseRent" xlink:to="lab_xfor_AggregateBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ff615447-af52-42a4-97f8-0ec169cd8910_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_208b7771-8597-48a9-b895-3e1936c6ed70_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs not yet paid related to sale of shares of common stock, redeemable common stock and pre-funded warrants</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_06a09d85-5beb-445f-9d21-1810ac84dd3b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average contractual term outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a26b7620-c772-47e5-9afe-d8b761cabfdf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_992a07c9-e3dd-4379-950f-18bb83433209_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_ebc1aa4d-56e9-424e-a175-4e6d5a47f08b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax benefit</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f7f8762d-0547-410a-8d4b-082aaa7a2eb8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a820646b-9b57-4592-b59e-ee8b33c11327_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_ab010b52-f213-4bb6-bda1-132ffc48212c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_22f7ad26-01a6-41ca-a1df-99abcfd2dbb4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 125,000,000 shares authorized as of each of March 31, 2022 and December 31, 2021; 30,809,476 and 28,127,657 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_581aa68b-c4da-41bc-a88a-49bc9f69c05a_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0325318f-0e7a-43df-b8a3-e0bdd3df865c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost of stock based awards, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b0c48ca1-2a9b-4c12-b672-d44b3a1a5827_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Financial Statements</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_eebe47cf-93d3-4935-8220-6f47fc77de30_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_3becfa89-67c8-4e18-83ab-c0b7204420ff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_642e7f9a-4775-412d-98cc-532d7eaa9b49_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c7f6d10e-0907-4392-93af-ea4f57b49c45_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_52afb96f-0b34-462f-b59d-8040da3fae34_terseLabel_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease not yet commenced</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_label_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_documentation_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:href="xfor-20220331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:to="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember_d0a3cbc7-a0fc-4b38-95cc-6c35dcfd19b1_terseLabel_en-US" xlink:label="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan</link:label>
    <link:label id="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:href="xfor-20220331.xsd#xfor_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9d49b4ad-8a28-486a-8b25-f9fd16401eb5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_bcec221a-9a64-47f9-85d0-57ed064a2318_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On December 28, 2017 One</link:label>
    <link:label id="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_label_en-US" xlink:label="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On December Twenty Eight Two Thousand Seventeen One [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on december twenty eight two thousand seventeen one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:to="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_aba35b9c-cf36-4b11-a18b-57acd8773a66_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March 13, 2019</link:label>
    <link:label id="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_label_en-US" xlink:label="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March Thirteen Two Thousand Nineteen [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on march thirteen two thousand nineteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:to="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember_337f79f3-9fd4-4dd8-b8a2-84d7a88facd3_terseLabel_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Incentive</link:label>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember_label_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Incentive Program [Member]</link:label>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember_documentation_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development incentive program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:href="xfor-20220331.xsd#xfor_ResearchAndDevelopmentIncentiveProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:to="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_30056521-5e01-40e8-bc86-c2597c8c080e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_c18e361c-2cc4-432b-9754-56da4e4fd4a7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_6a6e1ab5-9438-4028-8746-1dec780b9573_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_402fc8de-c1bc-4280-af89-39cd20c70781_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_bfa9d35f-8628-4ed2-a519-b0a16b8849c4_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_fd81e695-0da9-46cd-aa05-da239da84ded_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares of Common Stock Issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6a729f6d-d695-477b-989f-090165417618_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and exercisable warrants to purchase common shares as of December 31, 2021</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_02b8d8a4-4fb5-43b4-9db8-8a4f088e4be6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants, Outstanding and exercisable warrants, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6cb41a33-7eb7-48a0-a71e-8a02358dfb51_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_7481eddc-1373-4fca-a138-0859164da699_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property, equipment and intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_99131b4f-92e5-4433-a6f0-2ea64d164d43_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_93db7654-9fd1-49cd-8066-ba558626c084_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b56252ab-bf78-450a-8fce-517fd1a6fff1_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_a7560daa-71aa-44b8-a3d7-956ca2667cf0_terseLabel_en-US" xlink:label="lab_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_label_en-US" xlink:label="lab_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Reconciliation Of Cash And Cash Equivalents And Restricted Cash To Cash Flows [Table Text Block]</link:label>
    <link:label id="lab_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_documentation_en-US" xlink:label="lab_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of cash and cash equivalents and restricted cash to cashflows.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:href="xfor-20220331.xsd#xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:to="lab_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_94cc6197-cf0f-47ed-a9cb-874de3d78edd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants for purchase of convertible preferred shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_30000558-b3a5-484a-b826-4d49a5b7a9dd_terseLabel_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:label id="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:label id="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="xfor-20220331.xsd#xfor_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_00361baa-689a-4524-8bb4-c4046a1c2fd5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPayment_609b63ef-829a-4236-9d47-cd40b9008244_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility periodic payment</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPayment_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Periodic Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_29e218f3-d915-4791-9395-c621fac90305_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_c3197955-5583-44f7-b17a-82d5b2475fbd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_60d9f223-c681-475d-a7f5-72c72f5b75ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_ac0befea-e0e7-4466-9770-cbc413f5f3d4_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_0f115368-1855-4e8e-bfb1-dc1b41f6eb96_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3cdb3e7b-ac5e-4b09-8ddc-6d8dd8e9d960_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_22809886-e802-42f4-acbb-b02324b87bcf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_4e132335-4562-4b8e-9b5e-85e2edad005d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_1b386edb-e1b3-431b-aac7-372cf240ab02_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On April 16, 2019</link:label>
    <link:label id="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_label_en-US" xlink:label="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On April Sixteen Two Thousand Nineteen [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on april sixteen two thousand nineteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:to="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d983180c-99af-48fc-81f4-e7e178bb5ecd_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52548499-4312-467d-ae7a-efb5209ce2bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_9b07299a-3599-4491-83fb-473c70037cc7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Including Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_91adb27a-de61-454f-9ee8-a16f0bda5db1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2a8a9bb0-98f7-4fdd-bf4f-eec0ca99f518_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Collaboration, and Funding Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_22efbc18-d7b0-4afa-8d30-520dc1323f3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95cbbcc5-1e48-4f23-8291-14b9a0de0f2e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_342b61e4-ae39-4093-81c0-cd117a6dd86f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_5ff32bf7-4278-4be1-9055-53518d48cf76_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b5d2efb4-0fd5-4d68-91d7-f9881071c466_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_a4de19a2-76e9-4280-8348-f90feb2b69ae_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_76a2915d-e4e3-407a-9b56-9d50f1a178f0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8d0e9a5a-f4f5-4869-b6e5-cc11c2bbd9e5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5082c846-6a17-4118-9a26-d9bb124e9972_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa6ce8b0-4088-49a8-92a5-b77198e00b94_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_63bbbd55-f021-46e6-8b41-c3ae03568602_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, warrants to purchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_175d2ff8-a758-4f59-aa6a-bff0c16ea4d6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from lines of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_53f1c01c-3b0c-4607-bfd7-0620d06eeb3f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_GrantAndIncentiveReceivables_f0ce5f6d-8d6d-445e-9514-8b576a7512f8_terseLabel_en-US" xlink:label="lab_xfor_GrantAndIncentiveReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant receivable</link:label>
    <link:label id="lab_xfor_GrantAndIncentiveReceivables_label_en-US" xlink:label="lab_xfor_GrantAndIncentiveReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant And Incentive Receivables</link:label>
    <link:label id="lab_xfor_GrantAndIncentiveReceivables_documentation_en-US" xlink:label="lab_xfor_GrantAndIncentiveReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant and incentive receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GrantAndIncentiveReceivables" xlink:href="xfor-20220331.xsd#xfor_GrantAndIncentiveReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_GrantAndIncentiveReceivables" xlink:to="lab_xfor_GrantAndIncentiveReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_05d8e46c-df1a-41a7-95a0-3de123f14bc7_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f9c30562-40c0-44be-bd38-d12cb1b4bf94_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9c6755af-c4af-470d-a87c-15bce57d7782_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree_eafb25b0-3d21-4182-9f73-7ea9677c5030_terseLabel_en-US" xlink:label="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent additional term loan advances, tranche three</link:label>
    <link:label id="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree_label_en-US" xlink:label="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Three</link:label>
    <link:label id="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree_documentation_en-US" xlink:label="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" xlink:href="xfor-20220331.xsd#xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" xlink:to="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0d8de34c-d07d-49ae-a9c9-ad8e32d1c25d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b87c17e5-2535-4425-9133-1f648e2a3b7a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2c20bc25-fb59-49ea-be88-adf038f0eaae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6960adaf-38ef-479b-8f98-f56dd6072666_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ff42c085-c9a9-4e63-813f-ed7576ea3193_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_05312ebf-8a3b-4947-8786-5257d797f85a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_34cbe2cb-2e6d-494b-8a2c-556c416db140_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, Vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a49b1dff-1375-45c9-aa05-2f6503e4786c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_6a972d5d-c2bd-4f8d-ba01-f03771ed7c55_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_617b49f6-1cec-4222-82c6-dd6025954b0e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0074fc60-59a9-4b8c-8cfd-fe69b35c46c0_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_bb9e58fb-2563-4b4c-80db-db6764886cd7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4c668ad0-7648-4e52-a1e5-37159e0af6c3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c8864924-446c-4b72-9443-73403720b299_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f0e96f05-b8a4-4109-afe5-b459fd7753a2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice_686e4b4a-325b-40ee-b47a-2e0eee4f356e_terseLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued, Weighted Average Exercise Price</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued, Weighted Average Exercise Price</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:to="lab_xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnMarch232021Member_3c1db288-134c-46d7-b50a-ae6e61257226_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnMarch232021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March 23, 2021</link:label>
    <link:label id="lab_xfor_IssuanceOnMarch232021Member_label_en-US" xlink:label="lab_xfor_IssuanceOnMarch232021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March 23, 2021 [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnMarch232021Member_documentation_en-US" xlink:label="lab_xfor_IssuanceOnMarch232021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March 23, 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch232021Member" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnMarch232021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnMarch232021Member" xlink:to="lab_xfor_IssuanceOnMarch232021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_29b9da01-f632-4502-b408-2a3055dacb26_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6eb16600-fbd8-4d9b-ac98-bc376c92f9f6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_065cdcfa-4106-47f3-86a9-fd48b7c93018_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On October 19, 2018</link:label>
    <link:label id="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_label_en-US" xlink:label="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On October Nineteen Two Thousand Eighteen [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on october nineteen two thousand eighteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:to="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_df0a20f1-d461-4e10-81fd-5a2913c63958_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_be88db5f-c68e-4f28-ba3b-e8874c39f276_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_6f7079f6-d944-4e93-be5c-a5ae1a479b87_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24cc7f6f-d10b-4d04-bcba-59e884d0527e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate of loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_aafebcc4-7ec5-406f-927c-7665485d1c25_terseLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:to="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IncreaseDecreaseInLeaseLiabilities_c0cc611e-4689-4e06-b944-7a30f9d5455a_terseLabel_en-US" xlink:label="lab_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_xfor_IncreaseDecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Lease Liabilities</link:label>
    <link:label id="lab_xfor_IncreaseDecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:href="xfor-20220331.xsd#xfor_IncreaseDecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d6a41bee-e261-489c-981f-e8db0dd753d1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_b3c4bfd9-848f-402d-98eb-5ed814491bdc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, term of contract (years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_StockIssuedDuringPeriodValueWarrantsExercised_58a2df25-1db4-473a-9e12-8450355af0de_terseLabel_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</link:label>
    <link:label id="lab_xfor_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</link:label>
    <link:label id="lab_xfor_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="xfor-20220331.xsd#xfor_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_xfor_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a99562a9-30fa-4620-9e12-c06c8f2a64d3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_cd03634b-688f-4996-87a1-729e70d2b2f5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_56020322-1216-4393-a915-bcbb2cf971fe_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_e67710f9-10be-4097-8bbe-1b718de3ca5c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30ecfe38-c835-4e6a-913f-b9d8e3acf978_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (in percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b5131520-38d1-4567-a956-7b9546676952_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b592bbcd-3d48-4cc7-a482-cf6fd38c010d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c37b16f4-95d4-4f3a-bdf3-d89d36672f2d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Aggregate Fair Values of Warrant Liability and Derivative Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_00870a19-07a5-4288-8e8c-31a330d05a72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_78cffa34-bdcd-436f-9b99-9adc916171c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_926aa7d6-f4e3-499a-866c-181c025cd824_terseLabel_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of shares of common stock, redeemable common stock and pre-funded warrants, net of issuance costs</link:label>
    <link:label id="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_label_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Net of Issuance Costs</link:label>
    <link:label id="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:href="xfor-20220331.xsd#xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:to="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8546129a-a45a-4a37-ba35-f67a857ff5fe_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c5149ac0-2407-464b-9d1c-1a55fc201af2_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5b6e8917-f000-406d-85eb-29ca166c37e5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_85915913-3a61-4ae8-be85-edec0a0c59da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f3b6d600-1b68-4245-98fc-05ecc2e1b890_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e96181c6-e6bc-4054-b375-90962896d57d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b0c7ff37-e237-4743-8797-997687f235dd_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_49bce7b8-cd5d-49c9-9b07-141553c00421_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2c2c0ec4-7328-45ac-85f7-eb63cc333a46_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_747fcc3c-02da-4e33-bf75-f949dc0f0367_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On November 29, 2019 One</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_label_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Twenty Nine Two Thousand Nineteen One [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Twenty Nine Two Thousand Nineteen One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:to="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_a23ea2f3-4ddb-4759-9e67-43174b665cfb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_1051f0ca-c00e-45be-865f-480ead95eac8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate increase percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5fba2787-951f-4489-9354-b046e184c96f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_9ba04d8e-d4f2-4370-9017-6e8d1c38b869_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Common Shares, Value</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="lab_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_add24be8-cfaf-4f32-880e-86d9fa9c053c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_6c2506e0-0043-41d8-82bb-7993c0fdf5da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_d976a63e-969d-42bb-ba3b-bcad071ab2fe_periodStartLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Outstanding and exercisable warrants, Beginning Balance (in usd per share)</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_d29a98ff-ac4f-490a-93d0-01d1e847a51f_periodEndLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Outstanding and exercisable warrants, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Weighted Average Exercise Price</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right weighted average exercise price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:to="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_88b38ff4-0b39-4f80-b823-1deba60b64c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_fe29eb3e-c7e5-44cf-84ca-7b0dfab7e9da_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9b4b0a26-7719-40a3-b228-4b2d386d4582_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_8357d4f2-cf3c-4624-9ef6-e054a8961ff2_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease costs</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c6aec6f3-2179-4b9e-b2d4-c30e9a58d7a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_3b6464ec-6dac-4e34-9069-909e82acea5e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_32fe60a2-eb94-433a-b5fd-95e3c4058361_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_PrefundedWarrantsAxis_a55ad078-34df-4d29-a68d-ce3734d1dc85_terseLabel_en-US" xlink:label="lab_xfor_PrefundedWarrantsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants [Axis]</link:label>
    <link:label id="lab_xfor_PrefundedWarrantsAxis_label_en-US" xlink:label="lab_xfor_PrefundedWarrantsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants [Axis]</link:label>
    <link:label id="lab_xfor_PrefundedWarrantsAxis_documentation_en-US" xlink:label="lab_xfor_PrefundedWarrantsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsAxis" xlink:href="xfor-20220331.xsd#xfor_PrefundedWarrantsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_PrefundedWarrantsAxis" xlink:to="lab_xfor_PrefundedWarrantsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_4310f88b-0735-48bb-a2fe-1439d8353c0e_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_60483260-dd14-4dce-bbb0-483f9d4b2d56_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_51f95690-ff07-41ec-9081-efb5da520105_terseLabel_en-US" xlink:label="lab_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset, net of non-cash portion</link:label>
    <link:label id="lab_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_label_en-US" xlink:label="lab_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset, Non-cash Potion</link:label>
    <link:label id="lab_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_documentation_en-US" xlink:label="lab_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset, Net Of Non-cash Potion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" xlink:href="xfor-20220331.xsd#xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" xlink:to="lab_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ec255dbc-9886-40ad-92fe-09c4e1c8905f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_f966a6ee-91d0-46aa-9a34-e2c3819c625f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders&#8212;basic and diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ViennaAustriaLeaseMember_cec624b2-33b1-4bcc-9df3-e105ca61eb74_terseLabel_en-US" xlink:label="lab_xfor_ViennaAustriaLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vienna Lease</link:label>
    <link:label id="lab_xfor_ViennaAustriaLeaseMember_label_en-US" xlink:label="lab_xfor_ViennaAustriaLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vienna Austria Lease [Member]</link:label>
    <link:label id="lab_xfor_ViennaAustriaLeaseMember_documentation_en-US" xlink:label="lab_xfor_ViennaAustriaLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vienna Austria Lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaAustriaLeaseMember" xlink:href="xfor-20220331.xsd#xfor_ViennaAustriaLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ViennaAustriaLeaseMember" xlink:to="lab_xfor_ViennaAustriaLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_7b3e4758-42d1-45e1-beb8-b15d85d38810_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-Based Compensation Expense Classification</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_c83eaec9-e8eb-4f82-a3fd-f2addec29f29_terseLabel_en-US" xlink:label="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label id="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_label_en-US" xlink:label="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label id="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_documentation_en-US" xlink:label="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:href="xfor-20220331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1a0e6d9f-63e5-4079-84d4-3685892023cd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_0286d52f-ac68-4f7c-8a96-29ee7ed297a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CollaborationLicenseAndFundingArrangementsTable_1429befb-d820-4c2f-a656-4454e47c0900_terseLabel_en-US" xlink:label="lab_xfor_CollaborationLicenseAndFundingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration License And Funding Arrangements [Table]</link:label>
    <link:label id="lab_xfor_CollaborationLicenseAndFundingArrangementsTable_label_en-US" xlink:label="lab_xfor_CollaborationLicenseAndFundingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration License And Funding Arrangements [Table]</link:label>
    <link:label id="lab_xfor_CollaborationLicenseAndFundingArrangementsTable_documentation_en-US" xlink:label="lab_xfor_CollaborationLicenseAndFundingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration, license and funding arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborationLicenseAndFundingArrangementsTable" xlink:href="xfor-20220331.xsd#xfor_CollaborationLicenseAndFundingArrangementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsTable" xlink:to="lab_xfor_CollaborationLicenseAndFundingArrangementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e14fd966-99e6-4826-9501-c266b7865639_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_66dfa8d5-3596-4ae8-bb2a-41a184624f50_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IndemnificationAgreementsMember_9efcbc73-0bd0-4957-8dd5-b7103e47772d_terseLabel_en-US" xlink:label="lab_xfor_IndemnificationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreements</link:label>
    <link:label id="lab_xfor_IndemnificationAgreementsMember_label_en-US" xlink:label="lab_xfor_IndemnificationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreements [Member]</link:label>
    <link:label id="lab_xfor_IndemnificationAgreementsMember_documentation_en-US" xlink:label="lab_xfor_IndemnificationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreements Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IndemnificationAgreementsMember" xlink:href="xfor-20220331.xsd#xfor_IndemnificationAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IndemnificationAgreementsMember" xlink:to="lab_xfor_IndemnificationAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ad81ce59-db7e-4aa3-8054-db3e6ff8f787_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_adee524c-70a7-4887-90ec-d73a05019823_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_fc9fb262-2cd0-4967-bdc3-d8d77444ff46_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6a3ee9d5-89e9-48c6-bb1a-426a0e467e26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5933a8ce-4710-4a8d-bb99-133237efe7e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_711e8460-e5b5-43e6-a90c-32e762ff4ca7_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Nine Two Thousand Twenty One</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_label_en-US" xlink:label="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Nine Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Nine Two Thousand Twenty One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:to="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_7e85217f-5aeb-47e1-8658-b8d4945fc63b_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b69847a0-e7b4-4dae-8da9-5a6b3c4c5c18_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a68eff69-9bb0-4dcc-b636-19a804f099bc_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CollaborationLicenseAndFundingArrangementsLineItems_16b62bfb-8510-446d-82d1-d600ef909bde_terseLabel_en-US" xlink:label="lab_xfor_CollaborationLicenseAndFundingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration License And Funding Arrangements [Line Items]</link:label>
    <link:label id="lab_xfor_CollaborationLicenseAndFundingArrangementsLineItems_label_en-US" xlink:label="lab_xfor_CollaborationLicenseAndFundingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration License And Funding Arrangements [Line Items]</link:label>
    <link:label id="lab_xfor_CollaborationLicenseAndFundingArrangementsLineItems_documentation_en-US" xlink:label="lab_xfor_CollaborationLicenseAndFundingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration, license and funding arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems" xlink:href="xfor-20220331.xsd#xfor_CollaborationLicenseAndFundingArrangementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="lab_xfor_CollaborationLicenseAndFundingArrangementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_9f0af204-168f-4c53-a831-22d683a85a5d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_89c88289-fed1-40a2-814e-c0ea23d11d12_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_fa0ca888-d67b-41d6-860c-27ac8d2f501d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_e23a4fcc-3dd6-4a63-86c9-bca9880b097d_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c5c9be34-4555-4c0e-ae74-dbf944236b38_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_aad6a76d-0137-4ded-b33c-46a6d346aa78_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_fd500c4c-64be-452d-8cd6-3c5d1eb50013_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_e7ff3537-8356-4e24-9802-434c26f3e867_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_e66cea09-b58f-40ef-83d7-91477f63db34_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, renewal term of contract (years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3da0bc78-ec9e-451b-9be2-314d9376da65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AllstonLeaseAgreementMember_36d2a6cb-0bc4-40b9-84d8-121ba25cf7c7_terseLabel_en-US" xlink:label="lab_xfor_AllstonLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allston Lease Agreement</link:label>
    <link:label id="lab_xfor_AllstonLeaseAgreementMember_label_en-US" xlink:label="lab_xfor_AllstonLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allston Lease Agreement [Member]</link:label>
    <link:label id="lab_xfor_AllstonLeaseAgreementMember_documentation_en-US" xlink:label="lab_xfor_AllstonLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allston Lease Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseAgreementMember" xlink:href="xfor-20220331.xsd#xfor_AllstonLeaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AllstonLeaseAgreementMember" xlink:to="lab_xfor_AllstonLeaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_f6cc091d-3db6-495e-b4dd-97db07dc7299_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_fd771472-aea6-458e-a709-58f5a518fff5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5a50d70-3e01-4d31-8a44-287af57b407a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_74fbc295-c0b9-4c17-8b08-f11623d49d8e_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On September 12, 2018 One</link:label>
    <link:label id="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_label_en-US" xlink:label="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On September Twelve Two Thousand Eighteen One [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on september twelve two thousand eighteen one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:to="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_8cca1a05-011b-49f3-a863-5032366163c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Long Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_5b6db6c8-7476-4cdc-8b86-125af99237e4_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_556f9664-b567-4daa-9cfc-f788b9545df5_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_e15f88c9-a07f-4934-ac61-77ec794151ce_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_MinCashTestDate2Member_9995706f-f8b5-4792-81d2-cf8be286fa7a_terseLabel_en-US" xlink:label="lab_xfor_MinCashTestDate2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 2</link:label>
    <link:label id="lab_xfor_MinCashTestDate2Member_label_en-US" xlink:label="lab_xfor_MinCashTestDate2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 2 [Member]</link:label>
    <link:label id="lab_xfor_MinCashTestDate2Member_documentation_en-US" xlink:label="lab_xfor_MinCashTestDate2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate2Member" xlink:href="xfor-20220331.xsd#xfor_MinCashTestDate2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_MinCashTestDate2Member" xlink:to="lab_xfor_MinCashTestDate2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_c78fa825-f601-49cf-a0a4-2b0516105971_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ContingenciesAndCommitmentsTable_93cbb6a7-6dcd-41ac-9307-2d78252d8d7e_terseLabel_en-US" xlink:label="lab_xfor_ContingenciesAndCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies And Commitments [Table]</link:label>
    <link:label id="lab_xfor_ContingenciesAndCommitmentsTable_label_en-US" xlink:label="lab_xfor_ContingenciesAndCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies And Commitments [Table]</link:label>
    <link:label id="lab_xfor_ContingenciesAndCommitmentsTable_documentation_en-US" xlink:label="lab_xfor_ContingenciesAndCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies And Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ContingenciesAndCommitmentsTable" xlink:href="xfor-20220331.xsd#xfor_ContingenciesAndCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ContingenciesAndCommitmentsTable" xlink:to="lab_xfor_ContingenciesAndCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf52f2cf-2831-40c8-8c4e-828244b954a1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_NonCashInterestExpense_0ef9db9d-c8ff-4292-a46b-de8cfd24310f_terseLabel_en-US" xlink:label="lab_xfor_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of debt discount</link:label>
    <link:label id="lab_xfor_NonCashInterestExpense_label_en-US" xlink:label="lab_xfor_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense</link:label>
    <link:label id="lab_xfor_NonCashInterestExpense_documentation_en-US" xlink:label="lab_xfor_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashInterestExpense" xlink:href="xfor-20220331.xsd#xfor_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_NonCashInterestExpense" xlink:to="lab_xfor_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_7b16ff7a-30f7-4921-8203-67147a74a46a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_5ab7ef4b-a9d9-4d38-8159-fdb51a7692f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_bdc10b45-4b4e-4566-83d5-54cc79bae3d0_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_465c6b49-0b74-48e3-aec9-0e6bf2e84020_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2bd3fbda-1752-4f33-b47d-ff81388b617f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4e5d3bb6-c6e3-42fe-8c66-2a2d3f9e64f5_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_afdb9937-9a19-480b-a2c0-0558e7d98f23_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStock_4e133fa3-9f57-46e8-a529-e46201febf83_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on common stock declared or paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_14606b52-9b86-46e8-9541-535b1a5cfbc1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2addd04d-3931-48e9-8a78-923c609a63a6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_35b7cd4d-d902-4d41-89f7-b12526b8b032_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_23c162b5-616f-4f71-a9cd-91683632a834_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_NonCashLeaseExpense_3e4a19ac-2d30-4680-b2a5-4cc643b065a5_terseLabel_en-US" xlink:label="lab_xfor_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_xfor_NonCashLeaseExpense_label_en-US" xlink:label="lab_xfor_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Lease Expense</link:label>
    <link:label id="lab_xfor_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_xfor_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashLeaseExpense" xlink:href="xfor-20220331.xsd#xfor_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_NonCashLeaseExpense" xlink:to="lab_xfor_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_5b591cf0-ff6f-4c0a-ab38-3c7089ecb6d3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_WarrantsWeightedAverageExercisePriceRollForward_6c8c025d-4fb5-490f-a491-89159dc8cc17_terseLabel_en-US" xlink:label="lab_xfor_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_xfor_WarrantsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_xfor_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_xfor_WarrantsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_xfor_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WarrantsWeightedAverageExercisePriceRollForward" xlink:href="xfor-20220331.xsd#xfor_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_WarrantsWeightedAverageExercisePriceRollForward" xlink:to="lab_xfor_WarrantsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_88ec6205-0db9-40c5-8951-bc57acfb2e61_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6c060213-66f3-4182-a912-5f104b5d01b1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_128316a3-1253-40f5-a8b9-145eb2d1b098_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightIssued_9bdc6210-bbe1-46c1-9cfa-fe9ec3714a37_terseLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightIssued_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightIssued_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right issued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightIssued" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightIssued" xlink:to="lab_xfor_ClassOfWarrantOrRightIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7fb4f88d-1c2a-410e-aa13-46c15eb2b910_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_a8ab892c-7588-4a64-8f29-9910b1b75f6b_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_923e5bd9-1b66-436b-a1c1-a25384cfdf42_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_1e1df5b2-99e6-44d3-87f9-9cc44040878e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassAWarrantMember_ca566a9a-c376-4760-a8a0-8aadd5134e95_terseLabel_en-US" xlink:label="lab_xfor_ClassAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrant</link:label>
    <link:label id="lab_xfor_ClassAWarrantMember_label_en-US" xlink:label="lab_xfor_ClassAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrant [Member]</link:label>
    <link:label id="lab_xfor_ClassAWarrantMember_documentation_en-US" xlink:label="lab_xfor_ClassAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassAWarrantMember" xlink:href="xfor-20220331.xsd#xfor_ClassAWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassAWarrantMember" xlink:to="lab_xfor_ClassAWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b7888ef6-a4ca-4c76-aa51-9c379f6d2b20_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_da0593fa-4634-4add-b31d-3dc69e07fdde_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e5386c5b-8860-4b64-9fbb-ba12e39455ff_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a593cbc7-e367-4bac-86a5-ec6afdca9ce9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_e0062146-dcc3-4f1a-8922-a028b0f97d39_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_487bccf5-15f3-47ff-816c-201a44af1593_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_SoftwareMember_f51ba1f8-2769-4a68-bc1e-9ab05927bf01_terseLabel_en-US" xlink:label="lab_xfor_SoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_xfor_SoftwareMember_label_en-US" xlink:label="lab_xfor_SoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software [Member]</link:label>
    <link:label id="lab_xfor_SoftwareMember_documentation_en-US" xlink:label="lab_xfor_SoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SoftwareMember" xlink:href="xfor-20220331.xsd#xfor_SoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_SoftwareMember" xlink:to="lab_xfor_SoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_RedeemableCommonStockMember_6ba2bfdd-3c83-4add-94af-b06cb121491f_terseLabel_en-US" xlink:label="lab_xfor_RedeemableCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Common Stock</link:label>
    <link:label id="lab_xfor_RedeemableCommonStockMember_label_en-US" xlink:label="lab_xfor_RedeemableCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Common Stock [Member]</link:label>
    <link:label id="lab_xfor_RedeemableCommonStockMember_documentation_en-US" xlink:label="lab_xfor_RedeemableCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember" xlink:href="xfor-20220331.xsd#xfor_RedeemableCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_RedeemableCommonStockMember" xlink:to="lab_xfor_RedeemableCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8ed8927c-dca9-495e-8d37-457b416c2f44_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_08bb88ff-b985-4d67-96dd-3c847bd95bed_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_f44e32bb-ee4d-43bc-bb1b-fe85761ed6cd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_81b08e2f-11a0-4263-b68f-d97981884fcd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14438929-c072-4524-b83e-612204721cb8_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_b42c4156-12f1-4ca2-8a44-3580ee5173c0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares Options, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_68cced54-bfcb-4883-b9cf-7880cc8729a1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</link:label>
    <link:label id="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_label_en-US" xlink:label="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_3a032ae1-0972-4a18-aaa0-eea026b9a399_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fc8fc83b-4f6c-44c7-a223-c73ce632d7c5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cf4e4eed-30c4-41e9-b4bd-3fec3922eb3f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_bbf0b64e-4c33-4d40-87cb-b645488c5cff_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b1291e85-0b22-44ca-b44a-af4ca961a253_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average contractual term outstanding, Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassBWarrantsMember_a3a9f073-26a9-4ab2-9a1a-4eee504298ed_terseLabel_en-US" xlink:label="lab_xfor_ClassBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Warrants</link:label>
    <link:label id="lab_xfor_ClassBWarrantsMember_label_en-US" xlink:label="lab_xfor_ClassBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Warrants [Member]</link:label>
    <link:label id="lab_xfor_ClassBWarrantsMember_documentation_en-US" xlink:label="lab_xfor_ClassBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassBWarrantsMember" xlink:href="xfor-20220331.xsd#xfor_ClassBWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassBWarrantsMember" xlink:to="lab_xfor_ClassBWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b0f7ea2a-e88c-4d6e-b95b-707a51b343f6_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_5a3d47e1-73ab-4ede-beb5-1ea9bdb155ee_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_NumeratorAbstract_9471f7e2-8a39-4cd2-94d3-f5595ce20969_terseLabel_en-US" xlink:label="lab_xfor_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_xfor_NumeratorAbstract_label_en-US" xlink:label="lab_xfor_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_xfor_NumeratorAbstract_documentation_en-US" xlink:label="lab_xfor_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NumeratorAbstract" xlink:href="xfor-20220331.xsd#xfor_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_NumeratorAbstract" xlink:to="lab_xfor_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_PrefundedWarrantsDomain_9ca704e8-77a2-4228-b518-a5ce61180ce2_terseLabel_en-US" xlink:label="lab_xfor_PrefundedWarrantsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants [Domain]</link:label>
    <link:label id="lab_xfor_PrefundedWarrantsDomain_label_en-US" xlink:label="lab_xfor_PrefundedWarrantsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants [Domain]</link:label>
    <link:label id="lab_xfor_PrefundedWarrantsDomain_documentation_en-US" xlink:label="lab_xfor_PrefundedWarrantsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain" xlink:href="xfor-20220331.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_PrefundedWarrantsDomain" xlink:to="lab_xfor_PrefundedWarrantsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ContingenciesAndCommitmentsLineItems_67bd5664-d4b0-4f02-997b-035530a95007_terseLabel_en-US" xlink:label="lab_xfor_ContingenciesAndCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies And Commitments [Line Items]</link:label>
    <link:label id="lab_xfor_ContingenciesAndCommitmentsLineItems_label_en-US" xlink:label="lab_xfor_ContingenciesAndCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies And Commitments [Line Items]</link:label>
    <link:label id="lab_xfor_ContingenciesAndCommitmentsLineItems_documentation_en-US" xlink:label="lab_xfor_ContingenciesAndCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies And Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ContingenciesAndCommitmentsLineItems" xlink:href="xfor-20220331.xsd#xfor_ContingenciesAndCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ContingenciesAndCommitmentsLineItems" xlink:to="lab_xfor_ContingenciesAndCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_5a3fe939-2d03-4334-9432-06f6507ab311_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_6dfe7f4c-6e6e-414a-b774-1206d66ff071_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_OperatingLeaseExpiration_afdca308-e049-4e27-86a8-455ac82f3d18_terseLabel_en-US" xlink:label="lab_xfor_OperatingLeaseExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expiration (years)</link:label>
    <link:label id="lab_xfor_OperatingLeaseExpiration_label_en-US" xlink:label="lab_xfor_OperatingLeaseExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Expiration</link:label>
    <link:label id="lab_xfor_OperatingLeaseExpiration_documentation_en-US" xlink:label="lab_xfor_OperatingLeaseExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expiration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_OperatingLeaseExpiration" xlink:href="xfor-20220331.xsd#xfor_OperatingLeaseExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_OperatingLeaseExpiration" xlink:to="lab_xfor_OperatingLeaseExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa286dcc-9905-4a5a-9381-58a0557287a0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae0510a5-1149-4eff-af9a-216a6d52f286_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_71e9c18c-35ab-491d-a027-68227c03c178_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ed1b1fb2-c880-4bec-adaa-3f94903c2ac3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_b1b3ea16-443c-4275-b4fc-005ad126d2fd_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5355df5e-abdd-4cb6-be9e-f6d23aad5628_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ScheduleOfLongTermDebtTable_ad3b6e6f-4e36-49ab-a558-98e572fa6dd3_terseLabel_en-US" xlink:label="lab_xfor_ScheduleOfLongTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Long Term Debt [Table]</link:label>
    <link:label id="lab_xfor_ScheduleOfLongTermDebtTable_label_en-US" xlink:label="lab_xfor_ScheduleOfLongTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Long Term Debt [Table]</link:label>
    <link:label id="lab_xfor_ScheduleOfLongTermDebtTable_documentation_en-US" xlink:label="lab_xfor_ScheduleOfLongTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Long Term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfLongTermDebtTable" xlink:href="xfor-20220331.xsd#xfor_ScheduleOfLongTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ScheduleOfLongTermDebtTable" xlink:to="lab_xfor_ScheduleOfLongTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_14ba628f-9984-4f66-b299-9d0f5c74325d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_cd6602a8-4724-4315-bc97-0f68e3f44b1d_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_b692914a-0184-47d6-9061-d98b140c9dd1_terseLabel_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock before underwriting discounts commissions and other expenses</link:label>
    <link:label id="lab_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_label_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock Before Underwriting Discounts Commissions And Other Expenses</link:label>
    <link:label id="lab_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_documentation_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock Before Underwriting Discounts Commissions And Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" xlink:href="xfor-20220331.xsd#xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" xlink:to="lab_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_1304df51-96b5-4ce0-9186-9e1daf985e28_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</link:label>
    <link:label id="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_label_en-US" xlink:label="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fbad3f26-8d86-4a41-b290-6d6dd1a5e59c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_312658bc-8a15-4334-8a9a-6189365f2a3c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9dd7326e-bebc-4475-9de8-26330d66a0c5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8cbadc7f-9fc0-42c4-b1b5-f8c28abe32e9_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_ad2823ea-6cd4-4d16-b50f-d3c64e265ac7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_2aecb615-22e7-40da-a779-060305081ecb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_341bed93-01ea-4980-a23d-ede77111a419_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LongTermDebtAndEOTPayment_76f5b43f-23d8-4457-ab9d-07794970c676_totalLabel_en-US" xlink:label="lab_xfor_LongTermDebtAndEOTPayment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of long-term debt</link:label>
    <link:label id="lab_xfor_LongTermDebtAndEOTPayment_label_en-US" xlink:label="lab_xfor_LongTermDebtAndEOTPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt and EOT payment</link:label>
    <link:label id="lab_xfor_LongTermDebtAndEOTPayment_documentation_en-US" xlink:label="lab_xfor_LongTermDebtAndEOTPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt and end of term payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtAndEOTPayment" xlink:href="xfor-20220331.xsd#xfor_LongTermDebtAndEOTPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LongTermDebtAndEOTPayment" xlink:to="lab_xfor_LongTermDebtAndEOTPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d895e881-94fc-4cb8-86df-dc05367cba33_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument variable percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_FundedMember_aa247040-d0f6-4e6e-8a95-d314aec04260_terseLabel_en-US" xlink:label="lab_xfor_FundedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded</link:label>
    <link:label id="lab_xfor_FundedMember_label_en-US" xlink:label="lab_xfor_FundedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded [Member]</link:label>
    <link:label id="lab_xfor_FundedMember_documentation_en-US" xlink:label="lab_xfor_FundedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FundedMember" xlink:href="xfor-20220331.xsd#xfor_FundedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_FundedMember" xlink:to="lab_xfor_FundedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_cee95c3f-e0df-4f62-a410-2a09e322fba7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_dd1bc6c7-2938-4ef6-9c6b-1f6c21ec20cb_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding&#8212;basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_f8dbc547-75a1-4121-870b-0404e430c173_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_c35d2b48-0a35-4559-b3a7-a9a5048200f6_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4af81869-3162-46a7-ac65-7c2b4bb2c0c9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_91aa63c2-359e-489b-8c80-97c780353960_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_7446e25b-5921-43f8-97ee-663a7ceb0915_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e534bc00-6991-4186-83b4-537a571346d0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e87720ad-ff10-4328-8eff-194e2ea63598_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_214e9483-ce0d-4358-9483-c62ae14e31a8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa439f92-19da-4261-aa18-e29ab61c5c66_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AccretionOnLongTermDebt_98fa3b74-be83-41d3-82af-686aef0f36b2_negatedLabel_en-US" xlink:label="lab_xfor_AccretionOnLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative accretion of end of term payments</link:label>
    <link:label id="lab_xfor_AccretionOnLongTermDebt_label_en-US" xlink:label="lab_xfor_AccretionOnLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion On Long Term Debt</link:label>
    <link:label id="lab_xfor_AccretionOnLongTermDebt_documentation_en-US" xlink:label="lab_xfor_AccretionOnLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion on long term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccretionOnLongTermDebt" xlink:href="xfor-20220331.xsd#xfor_AccretionOnLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AccretionOnLongTermDebt" xlink:to="lab_xfor_AccretionOnLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_35205ee7-f7e4-48ef-951e-a1df84bfce07_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0fbe6ef3-50a4-4b31-a2ed-1d11b3e1265a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_4b7994e1-5142-4563-af8d-e57e3f74d85b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_aee15f43-7a7e-464b-b023-2db48e1d3d3b_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_601711e2-33ad-43ed-9e05-2e63c4265015_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5aa4ba69-e3bc-4a32-a246-e0f1b4d5d228_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d69c99e1-6b28-4b1a-8c92-3f184900fb3b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_26718ade-e9dd-4781-93b4-c8ff0f9d388c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee taxes paid related to net share settlement of vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_9b3a9f42-8b5a-47d0-96a5-7787d94dd99e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_eef8f73c-9055-48ef-8ce9-7c42bfef9401_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of right-of-use asset financed by lease liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Obligation Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:to="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e8586ffb-5530-471f-80a2-fe85897f8ab4_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_5c18bb05-d4ca-42a8-b0e3-77a52cf83aa6_terseLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrants or rights expiration period (in years)</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Warrants Expiration Period</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Warrants Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod" xlink:to="lab_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_73ab5b69-855b-4ef9-88fc-5f3b60dd00ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_PreFundedWarrantMember_a9849f1d-0350-47e4-be88-c4f4452a50c8_terseLabel_en-US" xlink:label="lab_xfor_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant</link:label>
    <link:label id="lab_xfor_PreFundedWarrantMember_label_en-US" xlink:label="lab_xfor_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant [Member]</link:label>
    <link:label id="lab_xfor_PreFundedWarrantMember_documentation_en-US" xlink:label="lab_xfor_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember" xlink:href="xfor-20220331.xsd#xfor_PreFundedWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_PreFundedWarrantMember" xlink:to="lab_xfor_PreFundedWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e8e9fa3e-e99f-41fb-8222-0b4093e6f0ee_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_dfff345c-4ec6-44b0-be8e-df11193f9238_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_65ce08d8-144f-4358-948f-7e7f77394f80_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm_ef4113a1-a530-4e0d-815d-40764efb473d_terseLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Contractual Term (Years)</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Weighted Average Contractual Term</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right weighted average contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm" xlink:to="lab_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3eff9d95-ea3d-4ffb-af90-9cf61142f7bc_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_d84086a4-d4ac-4db1-bcf4-7fbf12d355d7_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On November 29, 2019</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_label_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Twenty Nine Two Thousand Nineteen [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Twenty Nine Two Thousand Nineteen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" xlink:to="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6fb1bdee-f752-4e46-b7a2-169004cc5121_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost of stock based awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_dab3e552-977c-4e17-a74f-1e5895493673_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b0b6a837-1e7a-4716-a46b-84d45c675835_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_3cf9aca7-fc78-4eda-8ac1-1d0911b65591_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount, net of accretion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_7c78810c-8e2e-4424-8aba-8226aa23bce0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_ed291916-4cee-4c06-ae16-8381d7f287cd_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LongTermDebtNonCurrentIncludingAccretion_5bc53909-fba4-474e-a937-d96dad6d888d_terseLabel_en-US" xlink:label="lab_xfor_LongTermDebtNonCurrentIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of discount and current portion</link:label>
    <link:label id="lab_xfor_LongTermDebtNonCurrentIncludingAccretion_label_en-US" xlink:label="lab_xfor_LongTermDebtNonCurrentIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Non Current Including Accretion</link:label>
    <link:label id="lab_xfor_LongTermDebtNonCurrentIncludingAccretion_documentation_en-US" xlink:label="lab_xfor_LongTermDebtNonCurrentIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt non current including accretion.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtNonCurrentIncludingAccretion" xlink:href="xfor-20220331.xsd#xfor_LongTermDebtNonCurrentIncludingAccretion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LongTermDebtNonCurrentIncludingAccretion" xlink:to="lab_xfor_LongTermDebtNonCurrentIncludingAccretion" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_WalthamLeaseMember_36605db2-2db9-487e-b3d3-a07c1253c6dc_terseLabel_en-US" xlink:label="lab_xfor_WalthamLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waltham Lease</link:label>
    <link:label id="lab_xfor_WalthamLeaseMember_label_en-US" xlink:label="lab_xfor_WalthamLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waltham Lease [Member]</link:label>
    <link:label id="lab_xfor_WalthamLeaseMember_documentation_en-US" xlink:label="lab_xfor_WalthamLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waltham Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember" xlink:href="xfor-20220331.xsd#xfor_WalthamLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_WalthamLeaseMember" xlink:to="lab_xfor_WalthamLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7e819273-cae8-434a-a97a-cdf41d5c956e_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_af9f18d3-d99e-41f1-bc55-bfffb1bf7da3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_62a57d6d-d648-49b5-afc1-4e1417992c7d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_2d830217-3b4b-452b-9971-b04c5a451763_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_1b3d4427-8457-45ea-87ee-cfec7c076755_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_4e0443bf-ff4f-4aea-8452-9db8f45e4270_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_cbdb73db-b771-4437-993f-5a0104f86421_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Valuation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_209d7cca-725b-4fa6-958b-1ec13a20cb0d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LineOfCreditCovenantMinimumCash_630e9288-6efb-4cad-9a21-c7559f4e7fa4_terseLabel_en-US" xlink:label="lab_xfor_LineOfCreditCovenantMinimumCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Covenant, Minimum Cash</link:label>
    <link:label id="lab_xfor_LineOfCreditCovenantMinimumCash_label_en-US" xlink:label="lab_xfor_LineOfCreditCovenantMinimumCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Covenant, Minimum Cash</link:label>
    <link:label id="lab_xfor_LineOfCreditCovenantMinimumCash_documentation_en-US" xlink:label="lab_xfor_LineOfCreditCovenantMinimumCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Covenant, Minimum Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditCovenantMinimumCash" xlink:href="xfor-20220331.xsd#xfor_LineOfCreditCovenantMinimumCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LineOfCreditCovenantMinimumCash" xlink:to="lab_xfor_LineOfCreditCovenantMinimumCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2cf61665-91c4-4f2c-8aec-3a51b68f2c63_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average contractual term outstanding, Vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>xfor-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:15224e09-2b4e-4653-a05c-4094a1da55b0,g:b51d9744-e75b-48fa-9941-02b626145304-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/CoverPage" xlink:type="simple" xlink:href="xfor-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_88d56362-e022-4693-8626-8a19309510f5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_DocumentType_88d56362-e022-4693-8626-8a19309510f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c8f16456-6f00-4e9c-8cf6-425553a90b1d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_DocumentQuarterlyReport_c8f16456-6f00-4e9c-8cf6-425553a90b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0e821b0d-0da7-46e9-983c-c27a357fdee2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_DocumentPeriodEndDate_0e821b0d-0da7-46e9-983c-c27a357fdee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_dce38e31-5c1e-4ed7-a3a9-97197f79295e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_DocumentTransitionReport_dce38e31-5c1e-4ed7-a3a9-97197f79295e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_859b57f4-8e89-47b8-931f-61a22c7486a5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityFileNumber_859b57f4-8e89-47b8-931f-61a22c7486a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b7fbd14a-daf0-4a45-a945-674be81a5ed1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityRegistrantName_b7fbd14a-daf0-4a45-a945-674be81a5ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6857e0ee-c39f-4fda-8a86-ff335958a697" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6857e0ee-c39f-4fda-8a86-ff335958a697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_33aa0a33-d47c-484d-8662-928cd77b5eb1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityTaxIdentificationNumber_33aa0a33-d47c-484d-8662-928cd77b5eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4b119ae4-4ccd-483c-baf7-b7546e16666f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityAddressAddressLine1_4b119ae4-4ccd-483c-baf7-b7546e16666f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_ef03e628-8482-4eee-afc3-912470839266" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityAddressAddressLine2_ef03e628-8482-4eee-afc3-912470839266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_dd1c989c-b9d7-4b40-a374-e26d5edeb51e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityAddressCityOrTown_dd1c989c-b9d7-4b40-a374-e26d5edeb51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_29997697-fd3a-4059-ba77-d0b8b9cd20dc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityAddressStateOrProvince_29997697-fd3a-4059-ba77-d0b8b9cd20dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bf3352b2-20ed-42f2-8263-f1e3266e9c68" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityAddressPostalZipCode_bf3352b2-20ed-42f2-8263-f1e3266e9c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ec4bee26-7cf6-440d-a230-a1fb430168ed" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_CityAreaCode_ec4bee26-7cf6-440d-a230-a1fb430168ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1fa50c80-6952-4eb2-b192-21decfc48ecc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_LocalPhoneNumber_1fa50c80-6952-4eb2-b192-21decfc48ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7f034d1e-0280-4dcc-ae5a-628d0f6ace84" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_Security12bTitle_7f034d1e-0280-4dcc-ae5a-628d0f6ace84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_dd604330-841d-4570-a1ef-ea49bd535c31" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_TradingSymbol_dd604330-841d-4570-a1ef-ea49bd535c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_26d13ff6-f975-49ab-bcfd-7b7224155911" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_SecurityExchangeName_26d13ff6-f975-49ab-bcfd-7b7224155911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_681791f9-cc67-4e24-921e-df0fcb450afa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityCurrentReportingStatus_681791f9-cc67-4e24-921e-df0fcb450afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a898653b-fe0e-4313-9414-f68add15a5b8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityInteractiveDataCurrent_a898653b-fe0e-4313-9414-f68add15a5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_cfcc37ed-f0f4-42c4-81e1-a9d4fea5e881" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityFilerCategory_cfcc37ed-f0f4-42c4-81e1-a9d4fea5e881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b1f4ae20-bd0c-4452-8b1a-24a694e13174" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntitySmallBusiness_b1f4ae20-bd0c-4452-8b1a-24a694e13174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_97657b05-a7b1-4f48-a977-912786a05074" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityEmergingGrowthCompany_97657b05-a7b1-4f48-a977-912786a05074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_c6341a4e-ed86-449b-aa62-5f4fe417b957" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityExTransitionPeriod_c6341a4e-ed86-449b-aa62-5f4fe417b957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d577ecd1-4495-444b-bace-1f741ac93180" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityShellCompany_d577ecd1-4495-444b-bace-1f741ac93180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ee12cbf6-baf8-4947-924c-c0873abab100" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ee12cbf6-baf8-4947-924c-c0873abab100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_96f40c8d-45fb-47c1-80cd-61bc51ec4c56" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_AmendmentFlag_96f40c8d-45fb-47c1-80cd-61bc51ec4c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3ccdcb86-d1dc-4d11-808d-59885790bea6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_DocumentFiscalYearFocus_3ccdcb86-d1dc-4d11-808d-59885790bea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e4cc8176-caa6-4edf-a89c-492b6e67b152" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e4cc8176-caa6-4edf-a89c-492b6e67b152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_75751636-47f4-4076-80e2-3b992b92eb51" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_EntityCentralIndexKey_75751636-47f4-4076-80e2-3b992b92eb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a187863e-b494-483d-9311-800dba321ac2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a556c234-7ef7-4756-8aff-a55e29d04bb8" xlink:to="loc_dei_CurrentFiscalYearEndDate_a187863e-b494-483d-9311-800dba321ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="xfor-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f03b6716-bd69-4584-8f3e-143428e043d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d0ea0545-08ce-451b-82fc-010492d9dfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f03b6716-bd69-4584-8f3e-143428e043d8" xlink:to="loc_us-gaap_AssetsAbstract_d0ea0545-08ce-451b-82fc-010492d9dfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_13207bc4-818a-417c-8bb4-4ea0d376a4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d0ea0545-08ce-451b-82fc-010492d9dfb0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_13207bc4-818a-417c-8bb4-4ea0d376a4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83df3a28-493e-4be7-b652-d2303e52227d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13207bc4-818a-417c-8bb4-4ea0d376a4c8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83df3a28-493e-4be7-b652-d2303e52227d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveReceivable_e6c5f6b3-1391-4b70-8b01-f1e15de6d7c6" xlink:href="xfor-20220331.xsd#xfor_ResearchAndDevelopmentIncentiveReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13207bc4-818a-417c-8bb4-4ea0d376a4c8" xlink:to="loc_xfor_ResearchAndDevelopmentIncentiveReceivable_e6c5f6b3-1391-4b70-8b01-f1e15de6d7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_804f6edf-d0c6-472a-ab3a-abcb960b9913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13207bc4-818a-417c-8bb4-4ea0d376a4c8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_804f6edf-d0c6-472a-ab3a-abcb960b9913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_abc4fb86-186a-4e86-a7dc-f0a7e641ed37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13207bc4-818a-417c-8bb4-4ea0d376a4c8" xlink:to="loc_us-gaap_AssetsCurrent_abc4fb86-186a-4e86-a7dc-f0a7e641ed37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_75230dbe-6003-44cb-b4da-37d15a3a8cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d0ea0545-08ce-451b-82fc-010492d9dfb0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_75230dbe-6003-44cb-b4da-37d15a3a8cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e1111f5b-9cf1-481a-88bf-a81c9e472887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d0ea0545-08ce-451b-82fc-010492d9dfb0" xlink:to="loc_us-gaap_Goodwill_e1111f5b-9cf1-481a-88bf-a81c9e472887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bf6a7f5d-2c0b-4108-806c-72b9599e077c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d0ea0545-08ce-451b-82fc-010492d9dfb0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bf6a7f5d-2c0b-4108-806c-72b9599e077c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_be197176-ab22-4675-9450-a60b60344dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d0ea0545-08ce-451b-82fc-010492d9dfb0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_be197176-ab22-4675-9450-a60b60344dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_44012f89-41d4-45a9-8368-b30a70cddbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d0ea0545-08ce-451b-82fc-010492d9dfb0" xlink:to="loc_us-gaap_Assets_44012f89-41d4-45a9-8368-b30a70cddbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_221ee6f3-2048-437c-898d-babd17b5656f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f03b6716-bd69-4584-8f3e-143428e043d8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_221ee6f3-2048-437c-898d-babd17b5656f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9abf33b8-bdeb-4bd7-ba22-16d54d5d6e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_221ee6f3-2048-437c-898d-babd17b5656f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9abf33b8-bdeb-4bd7-ba22-16d54d5d6e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8db97cae-3a07-4e85-8920-ac7f6eda2b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9abf33b8-bdeb-4bd7-ba22-16d54d5d6e8a" xlink:to="loc_us-gaap_AccountsPayableCurrent_8db97cae-3a07-4e85-8920-ac7f6eda2b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0757bc9d-3337-491f-87e6-d866965b4069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9abf33b8-bdeb-4bd7-ba22-16d54d5d6e8a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0757bc9d-3337-491f-87e6-d866965b4069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5beca22-5294-42a6-958b-5e019480a5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9abf33b8-bdeb-4bd7-ba22-16d54d5d6e8a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5beca22-5294-42a6-958b-5e019480a5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_3291ec82-ba04-426b-a6cf-0819acf7d5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9abf33b8-bdeb-4bd7-ba22-16d54d5d6e8a" xlink:to="loc_us-gaap_LongTermDebtCurrent_3291ec82-ba04-426b-a6cf-0819acf7d5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2f369f4a-dc22-480b-b3e8-f7119d48078b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9abf33b8-bdeb-4bd7-ba22-16d54d5d6e8a" xlink:to="loc_us-gaap_LiabilitiesCurrent_2f369f4a-dc22-480b-b3e8-f7119d48078b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtNonCurrentIncludingAccretion_13fbf8e2-1af0-498e-b774-e0071d0f3388" xlink:href="xfor-20220331.xsd#xfor_LongTermDebtNonCurrentIncludingAccretion"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_221ee6f3-2048-437c-898d-babd17b5656f" xlink:to="loc_xfor_LongTermDebtNonCurrentIncludingAccretion_13fbf8e2-1af0-498e-b774-e0071d0f3388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_acd4ff41-a0bf-41c5-b585-84aca41a9cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_221ee6f3-2048-437c-898d-babd17b5656f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_acd4ff41-a0bf-41c5-b585-84aca41a9cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2425c651-afdd-4480-8728-5d7b07a8e5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_221ee6f3-2048-437c-898d-babd17b5656f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2425c651-afdd-4480-8728-5d7b07a8e5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7ad23cff-6ee3-4f33-89c2-d0514a4ef077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_221ee6f3-2048-437c-898d-babd17b5656f" xlink:to="loc_us-gaap_Liabilities_7ad23cff-6ee3-4f33-89c2-d0514a4ef077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a042127d-0df7-4eb3-9660-bdf17e9853a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_221ee6f3-2048-437c-898d-babd17b5656f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a042127d-0df7-4eb3-9660-bdf17e9853a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3ef91bb5-9059-4e79-a330-24b90f8efc63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_221ee6f3-2048-437c-898d-babd17b5656f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3ef91bb5-9059-4e79-a330-24b90f8efc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6254778a-6c3a-464f-a9e2-8c17240ca48c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ef91bb5-9059-4e79-a330-24b90f8efc63" xlink:to="loc_us-gaap_CommonStockValue_6254778a-6c3a-464f-a9e2-8c17240ca48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0b9df1ba-812c-473b-9902-80f973b586e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ef91bb5-9059-4e79-a330-24b90f8efc63" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0b9df1ba-812c-473b-9902-80f973b586e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a013e651-8037-4395-951b-5f784c00c88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ef91bb5-9059-4e79-a330-24b90f8efc63" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a013e651-8037-4395-951b-5f784c00c88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f53985d9-305e-4355-9998-cefb1b91ba19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ef91bb5-9059-4e79-a330-24b90f8efc63" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f53985d9-305e-4355-9998-cefb1b91ba19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a916aa0a-5373-4c24-8ff3-1d5992d25982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3ef91bb5-9059-4e79-a330-24b90f8efc63" xlink:to="loc_us-gaap_StockholdersEquity_a916aa0a-5373-4c24-8ff3-1d5992d25982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_53aab768-bcfc-41d7-b695-23ed0c945b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_221ee6f3-2048-437c-898d-babd17b5656f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_53aab768-bcfc-41d7-b695-23ed0c945b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="xfor-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6d021d06-1bba-41ee-ac13-0af1acfda551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d0dd1652-4eee-48f9-b034-2195e4c9a94a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6d021d06-1bba-41ee-ac13-0af1acfda551" xlink:to="loc_us-gaap_StatementTable_d0dd1652-4eee-48f9-b034-2195e4c9a94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bd92b4f1-65c7-41d0-8bf8-8eedaffbefbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d0dd1652-4eee-48f9-b034-2195e4c9a94a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bd92b4f1-65c7-41d0-8bf8-8eedaffbefbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a9b4ed9e-8451-45e0-a05b-ad185ea26701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bd92b4f1-65c7-41d0-8bf8-8eedaffbefbb" xlink:to="loc_us-gaap_ClassOfStockDomain_a9b4ed9e-8451-45e0-a05b-ad185ea26701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember_25107b72-27c7-4f74-ad13-e0e903331b1e" xlink:href="xfor-20220331.xsd#xfor_RedeemableCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a9b4ed9e-8451-45e0-a05b-ad185ea26701" xlink:to="loc_xfor_RedeemableCommonStockMember_25107b72-27c7-4f74-ad13-e0e903331b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a4327ae9-aa7c-4a71-bf2b-576996ca3df4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d0dd1652-4eee-48f9-b034-2195e4c9a94a" xlink:to="loc_us-gaap_StatementLineItems_a4327ae9-aa7c-4a71-bf2b-576996ca3df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_23e0756e-279f-42c3-ac3a-d76019ad6ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4327ae9-aa7c-4a71-bf2b-576996ca3df4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_23e0756e-279f-42c3-ac3a-d76019ad6ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c5c69bf3-1004-407a-a723-cc5eac914be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4327ae9-aa7c-4a71-bf2b-576996ca3df4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c5c69bf3-1004-407a-a723-cc5eac914be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2982a874-ce93-4d25-88bb-cde6a9083e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4327ae9-aa7c-4a71-bf2b-576996ca3df4" xlink:to="loc_us-gaap_CommonStockSharesIssued_2982a874-ce93-4d25-88bb-cde6a9083e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_febc090c-8011-4b10-8724-28453981113d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4327ae9-aa7c-4a71-bf2b-576996ca3df4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_febc090c-8011-4b10-8724-28453981113d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="xfor-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_76f6f6e7-ef7b-4f3f-b889-d7d57d925b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_76f6f6e7-ef7b-4f3f-b889-d7d57d925b0d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e215f9f4-9326-4977-99ca-a7b1143f19a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e215f9f4-9326-4977-99ca-a7b1143f19a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_64042e17-b352-4c56-84e1-89cd09e8fc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_64042e17-b352-4c56-84e1-89cd09e8fc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_ce4e5361-d01c-4a31-b57d-c6a446d66d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_ce4e5361-d01c-4a31-b57d-c6a446d66d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cac685ec-169a-4c52-ab7f-23c302ff28d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:to="loc_us-gaap_OperatingExpenses_cac685ec-169a-4c52-ab7f-23c302ff28d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d57ae54a-7617-42e5-a98d-139c5b948c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:to="loc_us-gaap_OperatingIncomeLoss_d57ae54a-7617-42e5-a98d-139c5b948c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6176eaa5-6c81-40a0-8f9e-064c466307ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6176eaa5-6c81-40a0-8f9e-064c466307ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b91e4e18-9056-4075-8d18-6dca6f00a001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6176eaa5-6c81-40a0-8f9e-064c466307ff" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b91e4e18-9056-4075-8d18-6dca6f00a001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ca39d5db-ade8-40a5-b244-d50285e3ef16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6176eaa5-6c81-40a0-8f9e-064c466307ff" xlink:to="loc_us-gaap_InterestExpense_ca39d5db-ade8-40a5-b244-d50285e3ef16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_a73b41f5-2cd2-42c8-aec0-2beacc280997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6176eaa5-6c81-40a0-8f9e-064c466307ff" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_a73b41f5-2cd2-42c8-aec0-2beacc280997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4b8bab25-8783-46b1-80d2-e80a8238cfce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6176eaa5-6c81-40a0-8f9e-064c466307ff" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4b8bab25-8783-46b1-80d2-e80a8238cfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_df52b0ef-9947-4c86-a870-3073f42bfba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6176eaa5-6c81-40a0-8f9e-064c466307ff" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_df52b0ef-9947-4c86-a870-3073f42bfba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_458d255a-ed9f-4e89-885f-4fbdca695ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_458d255a-ed9f-4e89-885f-4fbdca695ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_45f336ce-e73a-4ac7-9f2d-a22bd36cd4be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_45f336ce-e73a-4ac7-9f2d-a22bd36cd4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5f52e8bd-e526-4e83-bc69-0469ffc9364f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:to="loc_us-gaap_NetIncomeLoss_5f52e8bd-e526-4e83-bc69-0469ffc9364f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_75a6aa2d-42dc-4865-88e0-4ec310f08825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_75a6aa2d-42dc-4865-88e0-4ec310f08825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_89cea9b2-7371-4b5f-ad1e-f735e84987f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_89cea9b2-7371-4b5f-ad1e-f735e84987f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_a84cee01-0c7c-4245-a859-7ebc7fb3a2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_a84cee01-0c7c-4245-a859-7ebc7fb3a2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4f6cc0b0-3830-4d8b-9317-1d719b3200de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66bc5549-ec8c-4bb2-93ce-c765a496d11d" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4f6cc0b0-3830-4d8b-9317-1d719b3200de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="xfor-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_cd52dcd8-866f-4207-aeb3-51ac79024621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f24f0fec-8e27-4fbf-8c28-bd51dac359a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cd52dcd8-866f-4207-aeb3-51ac79024621" xlink:to="loc_us-gaap_StatementTable_f24f0fec-8e27-4fbf-8c28-bd51dac359a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fa5b28c4-4ffe-43c6-87eb-0725517eeb61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f24f0fec-8e27-4fbf-8c28-bd51dac359a1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fa5b28c4-4ffe-43c6-87eb-0725517eeb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_64096cb1-3817-46a2-bf47-0a0fa53266a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa5b28c4-4ffe-43c6-87eb-0725517eeb61" xlink:to="loc_us-gaap_EquityComponentDomain_64096cb1-3817-46a2-bf47-0a0fa53266a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0b21f354-1624-4eb6-bada-4bba18d75031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64096cb1-3817-46a2-bf47-0a0fa53266a7" xlink:to="loc_us-gaap_CommonStockMember_0b21f354-1624-4eb6-bada-4bba18d75031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e19725e1-ac19-4ead-aac3-68546165b248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64096cb1-3817-46a2-bf47-0a0fa53266a7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e19725e1-ac19-4ead-aac3-68546165b248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_91ead567-5298-4087-b3bc-5db622609381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64096cb1-3817-46a2-bf47-0a0fa53266a7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_91ead567-5298-4087-b3bc-5db622609381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_76df89a1-e448-4890-b3fd-f3dcde071283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64096cb1-3817-46a2-bf47-0a0fa53266a7" xlink:to="loc_us-gaap_RetainedEarningsMember_76df89a1-e448-4890-b3fd-f3dcde071283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember_ddf9efb6-c981-406f-827e-73dcbd9c42fd" xlink:href="xfor-20220331.xsd#xfor_RedeemableCommonStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64096cb1-3817-46a2-bf47-0a0fa53266a7" xlink:to="loc_xfor_RedeemableCommonStockMember_ddf9efb6-c981-406f-827e-73dcbd9c42fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_90b2f5eb-a78e-44d0-89b0-5d41a0103175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f24f0fec-8e27-4fbf-8c28-bd51dac359a1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_90b2f5eb-a78e-44d0-89b0-5d41a0103175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4ecac29d-d4b7-43c9-8d26-e1ab8798db70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_90b2f5eb-a78e-44d0-89b0-5d41a0103175" xlink:to="loc_us-gaap_ClassOfStockDomain_4ecac29d-d4b7-43c9-8d26-e1ab8798db70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember_450babbc-ff27-4235-b130-8ddc1f02b5c8" xlink:href="xfor-20220331.xsd#xfor_RedeemableCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4ecac29d-d4b7-43c9-8d26-e1ab8798db70" xlink:to="loc_xfor_RedeemableCommonStockMember_450babbc-ff27-4235-b130-8ddc1f02b5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_04d09b50-d881-40ce-b637-0a09382d75fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f24f0fec-8e27-4fbf-8c28-bd51dac359a1" xlink:to="loc_us-gaap_StatementLineItems_04d09b50-d881-40ce-b637-0a09382d75fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0f1a1b82-0d68-45e9-87a4-eccdd38b08e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_04d09b50-d881-40ce-b637-0a09382d75fb" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0f1a1b82-0d68-45e9-87a4-eccdd38b08e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_bd1346fc-e481-49de-be82-4ec8cf9efa64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0f1a1b82-0d68-45e9-87a4-eccdd38b08e3" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_bd1346fc-e481-49de-be82-4ec8cf9efa64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_c9e2d547-80b2-4293-906f-aad75043c66a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0f1a1b82-0d68-45e9-87a4-eccdd38b08e3" xlink:to="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_c9e2d547-80b2-4293-906f-aad75043c66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_787da771-e79f-45b6-92bd-8422418d8521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0f1a1b82-0d68-45e9-87a4-eccdd38b08e3" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_787da771-e79f-45b6-92bd-8422418d8521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_04d09b50-d881-40ce-b637-0a09382d75fb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ba8a7f6f-d5f3-443f-b281-d1253f357f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_SharesOutstanding_ba8a7f6f-d5f3-443f-b281-d1253f357f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a5e544f0-a8ab-4552-99ee-8a03783c9859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_StockholdersEquity_a5e544f0-a8ab-4552-99ee-8a03783c9859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_283dd654-eab5-4a6c-914a-61422901a7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_283dd654-eab5-4a6c-914a-61422901a7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f895e3b8-a0c1-4ea1-869b-347b7fa3b4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f895e3b8-a0c1-4ea1-869b-347b7fa3b4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_29d461c0-8301-451e-a2d2-ebc3521c741c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_29d461c0-8301-451e-a2d2-ebc3521c741c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_e50f7871-1b91-491c-92d2-152353103cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_e50f7871-1b91-491c-92d2-152353103cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_b569c2e1-19b0-4a64-9592-6e1a06bdfdda" xlink:href="xfor-20220331.xsd#xfor_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_b569c2e1-19b0-4a64-9592-6e1a06bdfdda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodValueWarrantsExercised_d78a2bcf-db09-4f50-86fc-b8939a7ec8c7" xlink:href="xfor-20220331.xsd#xfor_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_xfor_StockIssuedDuringPeriodValueWarrantsExercised_d78a2bcf-db09-4f50-86fc-b8939a7ec8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2c149899-dfff-41b9-a5a1-f2b9101f4596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2c149899-dfff-41b9-a5a1-f2b9101f4596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dd0cafb2-046f-4cbb-970f-d0143b19ae9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dd0cafb2-046f-4cbb-970f-d0143b19ae9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_99552c4d-6770-4a4c-9c15-c63125e345c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_99552c4d-6770-4a4c-9c15-c63125e345c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_36db8f89-e3d3-41ef-bee7-a59b7e283733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_NetIncomeLoss_36db8f89-e3d3-41ef-bee7-a59b7e283733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0e0d63f6-08dd-4077-818f-a5a18bb9d2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_SharesOutstanding_0e0d63f6-08dd-4077-818f-a5a18bb9d2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a132b95b-7c40-4984-9723-f7c6632a37ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9dccebd5-c718-4b5f-8608-aecf7ae256c5" xlink:to="loc_us-gaap_StockholdersEquity_a132b95b-7c40-4984-9723-f7c6632a37ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="simple" xlink:href="xfor-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_cde232ed-5ad1-460d-aae1-76745b72d3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c68583ff-f656-495a-977d-5bbeb66a2e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cde232ed-5ad1-460d-aae1-76745b72d3bc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c68583ff-f656-495a-977d-5bbeb66a2e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="xfor-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9d3bcefa-001a-4e93-a0fc-ebea1894b63e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae989c19-5737-42bf-a2de-b0f09d86bc87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d3bcefa-001a-4e93-a0fc-ebea1894b63e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae989c19-5737-42bf-a2de-b0f09d86bc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fdc890e1-c71c-4cd0-8e18-03a9fc7af17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae989c19-5737-42bf-a2de-b0f09d86bc87" xlink:to="loc_us-gaap_NetIncomeLoss_fdc890e1-c71c-4cd0-8e18-03a9fc7af17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa120430-d571-4045-8543-74980787ae1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae989c19-5737-42bf-a2de-b0f09d86bc87" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa120430-d571-4045-8543-74980787ae1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7198e5d2-018f-4ae4-afd7-bf10c69e6488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa120430-d571-4045-8543-74980787ae1e" xlink:to="loc_us-gaap_ShareBasedCompensation_7198e5d2-018f-4ae4-afd7-bf10c69e6488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_232ebc31-011a-442f-9697-9e806ae56c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa120430-d571-4045-8543-74980787ae1e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_232ebc31-011a-442f-9697-9e806ae56c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashLeaseExpense_0d2f0946-f282-4b8f-b705-6f5d79b49b8f" xlink:href="xfor-20220331.xsd#xfor_NonCashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa120430-d571-4045-8543-74980787ae1e" xlink:to="loc_xfor_NonCashLeaseExpense_0d2f0946-f282-4b8f-b705-6f5d79b49b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashInterestExpense_6058add7-c88e-4641-bacc-3233198557e2" xlink:href="xfor-20220331.xsd#xfor_NonCashInterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa120430-d571-4045-8543-74980787ae1e" xlink:to="loc_xfor_NonCashInterestExpense_6058add7-c88e-4641-bacc-3233198557e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_26fa1910-82a9-4eb5-884b-8b2b96f7d9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa120430-d571-4045-8543-74980787ae1e" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_26fa1910-82a9-4eb5-884b-8b2b96f7d9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9867aa50-c41c-4df3-b32d-55f058d6bccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa120430-d571-4045-8543-74980787ae1e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9867aa50-c41c-4df3-b32d-55f058d6bccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_61d4f037-2d4f-454e-bf75-c1466f79ccc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9867aa50-c41c-4df3-b32d-55f058d6bccf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_61d4f037-2d4f-454e-bf75-c1466f79ccc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1b1832fa-5691-41a0-9903-be00a8c3d040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9867aa50-c41c-4df3-b32d-55f058d6bccf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1b1832fa-5691-41a0-9903-be00a8c3d040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_bd2605e9-0e31-4a9e-99a8-dba4b8466580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9867aa50-c41c-4df3-b32d-55f058d6bccf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_bd2605e9-0e31-4a9e-99a8-dba4b8466580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInLeaseLiabilities_cb397449-c143-4ed1-900f-b4180755cc99" xlink:href="xfor-20220331.xsd#xfor_IncreaseDecreaseInLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9867aa50-c41c-4df3-b32d-55f058d6bccf" xlink:to="loc_xfor_IncreaseDecreaseInLeaseLiabilities_cb397449-c143-4ed1-900f-b4180755cc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_bb87be56-d3ca-48c7-b5b9-6ad3100ecf9c" xlink:href="xfor-20220331.xsd#xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9867aa50-c41c-4df3-b32d-55f058d6bccf" xlink:to="loc_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_bb87be56-d3ca-48c7-b5b9-6ad3100ecf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86aadac5-1dd8-45b0-ac2a-607be84e67fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ae989c19-5737-42bf-a2de-b0f09d86bc87" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86aadac5-1dd8-45b0-ac2a-607be84e67fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_619574eb-a61f-4ff0-a1c8-2cf6fab638df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d3bcefa-001a-4e93-a0fc-ebea1894b63e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_619574eb-a61f-4ff0-a1c8-2cf6fab638df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_af1a083e-4822-4819-ad41-d11e7e5cefad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_619574eb-a61f-4ff0-a1c8-2cf6fab638df" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_af1a083e-4822-4819-ad41-d11e7e5cefad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97e576e9-b804-4c31-a0a9-de3f50c5aa90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_619574eb-a61f-4ff0-a1c8-2cf6fab638df" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97e576e9-b804-4c31-a0a9-de3f50c5aa90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a816c8af-e7e2-43e4-b835-012a2e62ad1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d3bcefa-001a-4e93-a0fc-ebea1894b63e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a816c8af-e7e2-43e4-b835-012a2e62ad1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_ed164c67-20f6-4794-9f8e-2c1a5d6dc2da" xlink:href="xfor-20220331.xsd#xfor_ProceedsFromExerciseOfStockOptionsAndWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a816c8af-e7e2-43e4-b835-012a2e62ad1f" xlink:to="loc_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_ed164c67-20f6-4794-9f8e-2c1a5d6dc2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1a085da6-261a-45d9-a3f8-75124b50e684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a816c8af-e7e2-43e4-b835-012a2e62ad1f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1a085da6-261a-45d9-a3f8-75124b50e684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts_abc1c21e-c135-45fb-958e-f4b451719407" xlink:href="xfor-20220331.xsd#xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a816c8af-e7e2-43e4-b835-012a2e62ad1f" xlink:to="loc_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts_abc1c21e-c135-45fb-958e-f4b451719407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_b796d79a-52e5-4577-9c95-0d8b1cd6244a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a816c8af-e7e2-43e4-b835-012a2e62ad1f" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_b796d79a-52e5-4577-9c95-0d8b1cd6244a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_a91537c2-ed7d-416f-a7d0-7ef6e82dcd52" xlink:href="xfor-20220331.xsd#xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a816c8af-e7e2-43e4-b835-012a2e62ad1f" xlink:to="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_a91537c2-ed7d-416f-a7d0-7ef6e82dcd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_87b3b196-1afb-4019-abd5-200ae3965a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a816c8af-e7e2-43e4-b835-012a2e62ad1f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_87b3b196-1afb-4019-abd5-200ae3965a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84398273-3947-47ca-88ba-545e7964c2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d3bcefa-001a-4e93-a0fc-ebea1894b63e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84398273-3947-47ca-88ba-545e7964c2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aea582a0-b3da-4468-93e4-09cd6e83e360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d3bcefa-001a-4e93-a0fc-ebea1894b63e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aea582a0-b3da-4468-93e4-09cd6e83e360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_11e413d7-e2bf-4ec3-83bd-a4852cbaec78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d3bcefa-001a-4e93-a0fc-ebea1894b63e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_11e413d7-e2bf-4ec3-83bd-a4852cbaec78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9923a644-16e8-43a2-ada8-94405281a83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d3bcefa-001a-4e93-a0fc-ebea1894b63e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9923a644-16e8-43a2-ada8-94405281a83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2add1a45-47ac-44d7-8271-0c98a13513a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d3bcefa-001a-4e93-a0fc-ebea1894b63e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2add1a45-47ac-44d7-8271-0c98a13513a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_59b54ac9-76da-4f08-a150-8c9e3a8502ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2add1a45-47ac-44d7-8271-0c98a13513a0" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_59b54ac9-76da-4f08-a150-8c9e3a8502ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_e9392433-6a70-4bf9-abc8-37c970a60b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2add1a45-47ac-44d7-8271-0c98a13513a0" xlink:to="loc_us-gaap_CapitalLeaseObligationsIncurred_e9392433-6a70-4bf9-abc8-37c970a60b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_3da9d382-85c0-48d8-a379-815a05f02183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2add1a45-47ac-44d7-8271-0c98a13513a0" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_3da9d382-85c0-48d8-a379-815a05f02183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="simple" xlink:href="xfor-20220331.xsd#NatureoftheBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f9106f26-ea6c-4c93-85f5-9a5d8cd595fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_6a1f8adc-73c0-4734-ab81-aacf3db1cb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f9106f26-ea6c-4c93-85f5-9a5d8cd595fb" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_6a1f8adc-73c0-4734-ab81-aacf3db1cb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3fd56c87-2007-41f4-9994-308b7651a4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfAccountingPoliciesTable_44953ff1-0862-49b4-83fb-643d75cf7b07" xlink:href="xfor-20220331.xsd#xfor_ScheduleOfAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3fd56c87-2007-41f4-9994-308b7651a4f9" xlink:to="loc_xfor_ScheduleOfAccountingPoliciesTable_44953ff1-0862-49b4-83fb-643d75cf7b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f19f9613-9f80-4939-b252-e60406f2604a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfAccountingPoliciesTable_44953ff1-0862-49b4-83fb-643d75cf7b07" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f19f9613-9f80-4939-b252-e60406f2604a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f31c4e25-59b1-4cfd-800c-162ec29ebad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f19f9613-9f80-4939-b252-e60406f2604a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f31c4e25-59b1-4cfd-800c-162ec29ebad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cf57b691-dbfa-45d4-98fb-fada49b857c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfAccountingPoliciesTable_44953ff1-0862-49b4-83fb-643d75cf7b07" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_cf57b691-dbfa-45d4-98fb-fada49b857c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_59ae9d15-c4fc-4e25-8588-58a40ad0bed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cf57b691-dbfa-45d4-98fb-fada49b857c7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_59ae9d15-c4fc-4e25-8588-58a40ad0bed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7bf850ab-4289-4198-aa30-d770ff092c40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cf57b691-dbfa-45d4-98fb-fada49b857c7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7bf850ab-4289-4198-aa30-d770ff092c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="xfor-20220331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c2650474-61bc-41c9-9969-1abe94407d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9dc5f225-6fb2-4636-bb2b-7528df476713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c2650474-61bc-41c9-9969-1abe94407d7b" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9dc5f225-6fb2-4636-bb2b-7528df476713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="xfor-20220331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a75beca0-8716-448a-89a8-6855af2dec39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_f9c4f84d-1336-4bfa-a4bc-e3736ea88386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a75beca0-8716-448a-89a8-6855af2dec39" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_f9c4f84d-1336-4bfa-a4bc-e3736ea88386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e6ae5223-27dc-4d7a-921b-a4b617cd9de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a75beca0-8716-448a-89a8-6855af2dec39" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e6ae5223-27dc-4d7a-921b-a4b617cd9de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_3e270bf4-8771-430b-94ad-24efb82e3593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a75beca0-8716-448a-89a8-6855af2dec39" xlink:to="loc_us-gaap_UseOfEstimates_3e270bf4-8771-430b-94ad-24efb82e3593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9d0698e2-b11c-4060-ba49-fd5fdab22fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a75beca0-8716-448a-89a8-6855af2dec39" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9d0698e2-b11c-4060-ba49-fd5fdab22fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1d9b9ffe-4c77-40b2-98ff-339ffe79fbea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a75beca0-8716-448a-89a8-6855af2dec39" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1d9b9ffe-4c77-40b2-98ff-339ffe79fbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_171a8076-cb72-4ef4-bbc9-4a4f4f3b0aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a75beca0-8716-448a-89a8-6855af2dec39" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_171a8076-cb72-4ef4-bbc9-4a4f4f3b0aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_367a03ec-dcec-4c59-aa21-7d95f093921f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a75beca0-8716-448a-89a8-6855af2dec39" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_367a03ec-dcec-4c59-aa21-7d95f093921f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="xfor-20220331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_96cbc66c-3e6d-4efe-bd8e-8f9cb8155b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensatingBalancesTextBlock_053207f4-cc92-4dbf-a8f5-81fc192f7c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensatingBalancesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_96cbc66c-3e6d-4efe-bd8e-8f9cb8155b79" xlink:to="loc_us-gaap_ScheduleOfCompensatingBalancesTextBlock_053207f4-cc92-4dbf-a8f5-81fc192f7c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_176a1eda-d972-4316-b8e2-bb7b24ce0889" xlink:href="xfor-20220331.xsd#xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_96cbc66c-3e6d-4efe-bd8e-8f9cb8155b79" xlink:to="loc_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_176a1eda-d972-4316-b8e2-bb7b24ce0889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3f7da3a8-c455-4ab1-936b-62bc51d662ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_25e93623-2615-4277-9dda-5d0a31a99550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f7da3a8-c455-4ab1-936b-62bc51d662ca" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_25e93623-2615-4277-9dda-5d0a31a99550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8579d74b-39d7-4f6d-bc69-078db71c83bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_25e93623-2615-4277-9dda-5d0a31a99550" xlink:to="loc_us-gaap_CreditFacilityAxis_8579d74b-39d7-4f6d-bc69-078db71c83bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5f613560-f9b2-466a-b86b-fedb7c8c797a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_8579d74b-39d7-4f6d-bc69-078db71c83bc" xlink:to="loc_us-gaap_CreditFacilityDomain_5f613560-f9b2-466a-b86b-fedb7c8c797a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_a8b21694-e93f-4447-bc9b-24e94b3353fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5f613560-f9b2-466a-b86b-fedb7c8c797a" xlink:to="loc_us-gaap_LetterOfCreditMember_a8b21694-e93f-4447-bc9b-24e94b3353fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4562fc10-2c9e-4b82-aaf3-e1831f8e033b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_25e93623-2615-4277-9dda-5d0a31a99550" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4562fc10-2c9e-4b82-aaf3-e1831f8e033b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b054be02-4f67-4515-a072-bd334bc725a4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4562fc10-2c9e-4b82-aaf3-e1831f8e033b" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b054be02-4f67-4515-a072-bd334bc725a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember_bfdc7f9c-2db4-4d6d-a81f-b5a7fe1ae478" xlink:href="xfor-20220331.xsd#xfor_WalthamLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b054be02-4f67-4515-a072-bd334bc725a4" xlink:to="loc_xfor_WalthamLeaseMember_bfdc7f9c-2db4-4d6d-a81f-b5a7fe1ae478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaLeaseAgreementMember_7df14a64-7d4c-458f-8bf8-ddc4b85fb061" xlink:href="xfor-20220331.xsd#xfor_ViennaLeaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b054be02-4f67-4515-a072-bd334bc725a4" xlink:to="loc_xfor_ViennaLeaseAgreementMember_7df14a64-7d4c-458f-8bf8-ddc4b85fb061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseAgreementMember_89497979-4ee0-437f-b633-903a3626fbc4" xlink:href="xfor-20220331.xsd#xfor_AllstonLeaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b054be02-4f67-4515-a072-bd334bc725a4" xlink:to="loc_xfor_AllstonLeaseAgreementMember_89497979-4ee0-437f-b633-903a3626fbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_1ad58e35-9199-4455-9e16-32ea1ab11e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_25e93623-2615-4277-9dda-5d0a31a99550" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_1ad58e35-9199-4455-9e16-32ea1ab11e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_657a3bec-d736-4dcd-8650-4ec3ddab72e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1ad58e35-9199-4455-9e16-32ea1ab11e16" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_657a3bec-d736-4dcd-8650-4ec3ddab72e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_7b5cb707-30a0-4c98-a4e0-39a3f04316f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1ad58e35-9199-4455-9e16-32ea1ab11e16" xlink:to="loc_us-gaap_RestrictedCash_7b5cb707-30a0-4c98-a4e0-39a3f04316f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_96794bb7-98da-46a2-91c2-f815377b2d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37ca71a9-7335-4724-a013-917008f17998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_96794bb7-98da-46a2-91c2-f815377b2d92" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37ca71a9-7335-4724-a013-917008f17998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_727b2636-1a0e-4d45-9a65-0aad424dbdef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_96794bb7-98da-46a2-91c2-f815377b2d92" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_727b2636-1a0e-4d45-9a65-0aad424dbdef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40fddaf4-5d16-40f1-8a34-d5ea815e18be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_96794bb7-98da-46a2-91c2-f815377b2d92" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40fddaf4-5d16-40f1-8a34-d5ea815e18be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements" xlink:type="simple" xlink:href="xfor-20220331.xsd#LicenseCollaborationandFundingAgreements"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_99242bdd-98f3-4a82-a031-23099d2dc122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c6d4dbe6-a6e5-4665-bc07-0e6772ffe526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_99242bdd-98f3-4a82-a031-23099d2dc122" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c6d4dbe6-a6e5-4665-bc07-0e6772ffe526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fbaa22ec-0b4e-4f44-937c-9916366fc857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborationLicenseAndFundingArrangementsTable_eab1f9a3-5855-46ff-bae2-cac4abdebdaf" xlink:href="xfor-20220331.xsd#xfor_CollaborationLicenseAndFundingArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fbaa22ec-0b4e-4f44-937c-9916366fc857" xlink:to="loc_xfor_CollaborationLicenseAndFundingArrangementsTable_eab1f9a3-5855-46ff-bae2-cac4abdebdaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_da9cf04c-123e-4ce5-9757-3d051fc41b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsTable_eab1f9a3-5855-46ff-bae2-cac4abdebdaf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_da9cf04c-123e-4ce5-9757-3d051fc41b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4de38bc0-d14d-46fa-ab6d-06d5e90ba2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_da9cf04c-123e-4ce5-9757-3d051fc41b37" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4de38bc0-d14d-46fa-ab6d-06d5e90ba2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember_418a9270-c763-4347-a937-844723b51495" xlink:href="xfor-20220331.xsd#xfor_ResearchAndDevelopmentIncentiveProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4de38bc0-d14d-46fa-ab6d-06d5e90ba2cf" xlink:to="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember_418a9270-c763-4347-a937-844723b51495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_38e54de6-9a9e-4afe-9fd5-919ed416e5d6" xlink:href="xfor-20220331.xsd#xfor_CollaborationLicenseAndFundingArrangementsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsTable_eab1f9a3-5855-46ff-bae2-cac4abdebdaf" xlink:to="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_38e54de6-9a9e-4afe-9fd5-919ed416e5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GrantAndIncentiveReceivables_ab0d9a17-5805-4fc9-a648-5bc51492977c" xlink:href="xfor-20220331.xsd#xfor_GrantAndIncentiveReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_38e54de6-9a9e-4afe-9fd5-919ed416e5d6" xlink:to="loc_xfor_GrantAndIncentiveReceivables_ab0d9a17-5805-4fc9-a648-5bc51492977c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bf321523-b9d0-43f2-a18a-9c0cf2e42d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_38e54de6-9a9e-4afe-9fd5-919ed416e5d6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bf321523-b9d0-43f2-a18a-9c0cf2e42d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_a66227e6-a143-4357-90d5-b02ea1d9ae39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_38e54de6-9a9e-4afe-9fd5-919ed416e5d6" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_a66227e6-a143-4357-90d5-b02ea1d9ae39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities" xlink:type="simple" xlink:href="xfor-20220331.xsd#FairValueofFinancialAssetsandLiabilities"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1cf6863c-c57d-4e55-b7f5-867abaccd9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_56474e96-5e59-4903-a57c-78f4e63f2372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1cf6863c-c57d-4e55-b7f5-867abaccd9d4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_56474e96-5e59-4903-a57c-78f4e63f2372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" xlink:type="simple" xlink:href="xfor-20220331.xsd#FairValueofFinancialAssetsandLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1b4a2fa0-c418-49f5-bfc0-2f0185f4ec97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_84bfa20d-a932-42cd-803c-e18288753534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b4a2fa0-c418-49f5-bfc0-2f0185f4ec97" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_84bfa20d-a932-42cd-803c-e18288753534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f2f188ba-428c-4671-bdd7-594038a079ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b4a2fa0-c418-49f5-bfc0-2f0185f4ec97" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f2f188ba-428c-4671-bdd7-594038a079ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_faeb5682-40bb-49da-829f-e76b79a28f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_52feab28-56d7-4e7c-9d39-4858819182db" xlink:href="xfor-20220331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_faeb5682-40bb-49da-829f-e76b79a28f9d" xlink:to="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_52feab28-56d7-4e7c-9d39-4858819182db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_bc72254f-5b03-4e5b-9cb3-e6114fb9cadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_52feab28-56d7-4e7c-9d39-4858819182db" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_bc72254f-5b03-4e5b-9cb3-e6114fb9cadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8ebc389d-a038-4a0e-bf89-c5182a1aa302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_bc72254f-5b03-4e5b-9cb3-e6114fb9cadd" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8ebc389d-a038-4a0e-bf89-c5182a1aa302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_4fae71b0-80bd-4cc4-86de-ae664bb5044b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8ebc389d-a038-4a0e-bf89-c5182a1aa302" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_4fae71b0-80bd-4cc4-86de-ae664bb5044b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1c655d2-f57d-4754-8022-818cdd20fa20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_52feab28-56d7-4e7c-9d39-4858819182db" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1c655d2-f57d-4754-8022-818cdd20fa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c62ca4de-6928-43c1-b2f6-8a315ea631cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1c655d2-f57d-4754-8022-818cdd20fa20" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c62ca4de-6928-43c1-b2f6-8a315ea631cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_802aa215-f3ef-4e7d-b84d-6f3dddfc4b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c62ca4de-6928-43c1-b2f6-8a315ea631cc" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_802aa215-f3ef-4e7d-b84d-6f3dddfc4b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_47c5e532-7b3b-4eaa-a09f-389051985c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_52feab28-56d7-4e7c-9d39-4858819182db" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_47c5e532-7b3b-4eaa-a09f-389051985c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4d8b2d9-1b94-4f1d-ad6f-25d0531f09fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_47c5e532-7b3b-4eaa-a09f-389051985c44" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4d8b2d9-1b94-4f1d-ad6f-25d0531f09fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d63af673-f29f-441a-80b4-ad72e007c0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4d8b2d9-1b94-4f1d-ad6f-25d0531f09fd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d63af673-f29f-441a-80b4-ad72e007c0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5d1c0561-ae3d-4262-ace9-fa3c75eff9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4d8b2d9-1b94-4f1d-ad6f-25d0531f09fd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5d1c0561-ae3d-4262-ace9-fa3c75eff9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b4ee17e8-8b17-4021-b315-4bfbf307a36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4d8b2d9-1b94-4f1d-ad6f-25d0531f09fd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b4ee17e8-8b17-4021-b315-4bfbf307a36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_de2d032b-c2b4-4106-8bbc-e4360f9227c2" xlink:href="xfor-20220331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_52feab28-56d7-4e7c-9d39-4858819182db" xlink:to="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_de2d032b-c2b4-4106-8bbc-e4360f9227c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c6e82704-92ba-4644-868b-dd7d0014ec85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_de2d032b-c2b4-4106-8bbc-e4360f9227c2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c6e82704-92ba-4644-868b-dd7d0014ec85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_287208b0-bf94-4954-8a48-0f3c061d9ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_de2d032b-c2b4-4106-8bbc-e4360f9227c2" xlink:to="loc_us-gaap_DerivativeLiabilities_287208b0-bf94-4954-8a48-0f3c061d9ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="xfor-20220331.xsd#FairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_71ff5527-bdef-42aa-9848-6d88f5678cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6579d5ec-0e2e-4f8a-8088-d8729f0675c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_71ff5527-bdef-42aa-9848-6d88f5678cb4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6579d5ec-0e2e-4f8a-8088-d8729f0675c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e2dd035f-6bf1-4863-991b-1cf97689257d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_71ff5527-bdef-42aa-9848-6d88f5678cb4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e2dd035f-6bf1-4863-991b-1cf97689257d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="xfor-20220331.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a5c2ba6a-6820-43f4-b721-45e7358bb854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5b84db37-9b93-4624-ae6e-9173705f2a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a5c2ba6a-6820-43f4-b721-45e7358bb854" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5b84db37-9b93-4624-ae6e-9173705f2a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="xfor-20220331.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_21b412f0-76c1-46cb-95d3-c877b2cf5211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_fdcbd6ee-6439-4a73-a92a-8ec85cd6c108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_21b412f0-76c1-46cb-95d3-c877b2cf5211" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_fdcbd6ee-6439-4a73-a92a-8ec85cd6c108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eceb0108-dfea-4981-b7dd-6c6cd5a5273c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f462f3b2-4c6d-417f-94b9-e1ded08b29d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eceb0108-dfea-4981-b7dd-6c6cd5a5273c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f462f3b2-4c6d-417f-94b9-e1ded08b29d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3c4859b-87d7-484a-b9c9-7a86067e15a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f462f3b2-4c6d-417f-94b9-e1ded08b29d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3c4859b-87d7-484a-b9c9-7a86067e15a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf93ee11-1f40-4b9f-8afc-a943fe90758f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d3c4859b-87d7-484a-b9c9-7a86067e15a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf93ee11-1f40-4b9f-8afc-a943fe90758f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1b901499-346d-452e-956d-e57ed678f832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf93ee11-1f40-4b9f-8afc-a943fe90758f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1b901499-346d-452e-956d-e57ed678f832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2f96766c-73f4-4af1-aee3-4c6f943aecc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf93ee11-1f40-4b9f-8afc-a943fe90758f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2f96766c-73f4-4af1-aee3-4c6f943aecc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_cfff4999-563f-47a9-8b48-9947e1984cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf93ee11-1f40-4b9f-8afc-a943fe90758f" xlink:to="loc_us-gaap_ComputerEquipmentMember_cfff4999-563f-47a9-8b48-9947e1984cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SoftwareMember_05276596-2902-4d75-b528-654f01eabc12" xlink:href="xfor-20220331.xsd#xfor_SoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf93ee11-1f40-4b9f-8afc-a943fe90758f" xlink:to="loc_xfor_SoftwareMember_05276596-2902-4d75-b528-654f01eabc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LabEquipmentMember_42a296a8-b3f3-4c6c-b83d-5e494acb8670" xlink:href="xfor-20220331.xsd#xfor_LabEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf93ee11-1f40-4b9f-8afc-a943fe90758f" xlink:to="loc_xfor_LabEquipmentMember_42a296a8-b3f3-4c6c-b83d-5e494acb8670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c163cb-d4e3-41e9-b2af-13363bef9d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f462f3b2-4c6d-417f-94b9-e1ded08b29d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c163cb-d4e3-41e9-b2af-13363bef9d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8dd2a2b2-1e85-425b-94f3-7f9931623f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c163cb-d4e3-41e9-b2af-13363bef9d68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8dd2a2b2-1e85-425b-94f3-7f9931623f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6ba196a8-0609-421e-967f-70be7d57bfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c163cb-d4e3-41e9-b2af-13363bef9d68" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6ba196a8-0609-421e-967f-70be7d57bfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_434c941f-b2a0-4844-9856-78fb7cb539b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_18c163cb-d4e3-41e9-b2af-13363bef9d68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_434c941f-b2a0-4844-9856-78fb7cb539b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#PropertyandEquipmentNetAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6b9b97bf-fd77-4a95-951c-a073650ae979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_29fd94b1-ae1c-4d1f-89e9-254ec149ba54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6b9b97bf-fd77-4a95-951c-a073650ae979" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_29fd94b1-ae1c-4d1f-89e9-254ec149ba54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/AccruedExpenses" xlink:type="simple" xlink:href="xfor-20220331.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b997d118-68f7-453d-a460-f4820f7c73cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExpensesTextBlock_66917850-bd4f-43a9-921a-ac38d65bc0d8" xlink:href="xfor-20220331.xsd#xfor_AccruedExpensesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b997d118-68f7-453d-a460-f4820f7c73cb" xlink:to="loc_xfor_AccruedExpensesTextBlock_66917850-bd4f-43a9-921a-ac38d65bc0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="xfor-20220331.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_970feb3a-a8df-43e1-b0ef-ac1cb4951ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4164993f-6eb8-4768-a6a1-a44cb36186b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_970feb3a-a8df-43e1-b0ef-ac1cb4951ec6" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4164993f-6eb8-4768-a6a1-a44cb36186b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#AccruedExpensesScheduleofAccruedExpensesDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_247ef4e5-afee-4766-ab73-7960cf08441f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c1bcfe28-6a65-4ac3-aa03-12693a93b95e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_247ef4e5-afee-4766-ab73-7960cf08441f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c1bcfe28-6a65-4ac3-aa03-12693a93b95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses_6a071415-3329-46c0-ab4d-9038d444ea62" xlink:href="xfor-20220331.xsd#xfor_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_247ef4e5-afee-4766-ab73-7960cf08441f" xlink:to="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses_6a071415-3329-46c0-ab4d-9038d444ea62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_67f62dac-e3a6-4e5e-9a13-7cd664649f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_247ef4e5-afee-4766-ab73-7960cf08441f" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_67f62dac-e3a6-4e5e-9a13-7cd664649f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_56d9f939-108e-4489-9c4e-88ebfc5190e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_247ef4e5-afee-4766-ab73-7960cf08441f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_56d9f939-108e-4489-9c4e-88ebfc5190e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_56cfb4d9-0d6b-4a4c-87f8-05d9b151dce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_247ef4e5-afee-4766-ab73-7960cf08441f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_56cfb4d9-0d6b-4a4c-87f8-05d9b151dce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebt" xlink:type="simple" xlink:href="xfor-20220331.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3c767656-4e52-4b29-866d-4f901b529e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_046bf4c4-da5e-4c18-8a6c-395e83a849bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3c767656-4e52-4b29-866d-4f901b529e37" xlink:to="loc_us-gaap_LongTermDebtTextBlock_046bf4c4-da5e-4c18-8a6c-395e83a849bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="xfor-20220331.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5c8a84eb-5fb7-4f50-bee3-bec416cbc82b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_318a8cdd-ab72-47bc-85c3-0c5e95546c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5c8a84eb-5fb7-4f50-bee3-bec416cbc82b" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_318a8cdd-ab72-47bc-85c3-0c5e95546c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_4ece0ef4-c0b4-400b-9939-20fc8145308c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5c8a84eb-5fb7-4f50-bee3-bec416cbc82b" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_4ece0ef4-c0b4-400b-9939-20fc8145308c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_9233e9fb-ab9f-4328-957c-2078fa4561e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5c8a84eb-5fb7-4f50-bee3-bec416cbc82b" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_9233e9fb-ab9f-4328-957c-2078fa4561e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#LongTermDebtSummaryofLongTermDebtDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e18c6157-635b-4f2e-a651-440b8a4fce32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2c52624b-e508-4def-b20d-7418810fb1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e18c6157-635b-4f2e-a651-440b8a4fce32" xlink:to="loc_us-gaap_LongTermDebt_2c52624b-e508-4def-b20d-7418810fb1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_afda8218-1cb4-49da-a159-9a1943b116a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e18c6157-635b-4f2e-a651-440b8a4fce32" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_afda8218-1cb4-49da-a159-9a1943b116a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccretionOnLongTermDebt_99be1521-f603-4594-b2a1-b46034697394" xlink:href="xfor-20220331.xsd#xfor_AccretionOnLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e18c6157-635b-4f2e-a651-440b8a4fce32" xlink:to="loc_xfor_AccretionOnLongTermDebt_99be1521-f603-4594-b2a1-b46034697394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtIncludingAccretion_ea599747-e460-47d6-8292-2a06c26021e6" xlink:href="xfor-20220331.xsd#xfor_LongTermDebtIncludingAccretion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e18c6157-635b-4f2e-a651-440b8a4fce32" xlink:to="loc_xfor_LongTermDebtIncludingAccretion_ea599747-e460-47d6-8292-2a06c26021e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_3a8e5568-0c04-4b98-b169-d5ea515484d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e18c6157-635b-4f2e-a651-440b8a4fce32" xlink:to="loc_us-gaap_LongTermDebtCurrent_3a8e5568-0c04-4b98-b169-d5ea515484d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_80aeb741-e553-43f1-8258-5f978410d816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e18c6157-635b-4f2e-a651-440b8a4fce32" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_80aeb741-e553-43f1-8258-5f978410d816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditCovenantMinimumCash_c4984bbf-577d-4295-a26c-40d7fc8a848e" xlink:href="xfor-20220331.xsd#xfor_LineOfCreditCovenantMinimumCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e18c6157-635b-4f2e-a651-440b8a4fce32" xlink:to="loc_xfor_LineOfCreditCovenantMinimumCash_c4984bbf-577d-4295-a26c-40d7fc8a848e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_23de45f6-9ad2-474b-97a9-d7240c170ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:href="xfor-20220331.xsd#xfor_ScheduleOfLongTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_23de45f6-9ad2-474b-97a9-d7240c170ccd" xlink:to="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3016a00d-c3a5-447e-b51d-6d15b73a8516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:to="loc_us-gaap_DebtInstrumentAxis_3016a00d-c3a5-447e-b51d-6d15b73a8516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8637f2c8-df36-41f7-a5a1-2a1e43f86b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3016a00d-c3a5-447e-b51d-6d15b73a8516" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8637f2c8-df36-41f7-a5a1-2a1e43f86b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesLoanAgreementMember_5fbf2c79-9df0-4a53-b962-54c77d541ce7" xlink:href="xfor-20220331.xsd#xfor_HerculesLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8637f2c8-df36-41f7-a5a1-2a1e43f86b79" xlink:to="loc_xfor_HerculesLoanAgreementMember_5fbf2c79-9df0-4a53-b962-54c77d541ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesSecondAmendedLoanAgreementMember_ef3e3a04-5aa5-4005-8e2d-1f954dc92a6b" xlink:href="xfor-20220331.xsd#xfor_HerculesSecondAmendedLoanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8637f2c8-df36-41f7-a5a1-2a1e43f86b79" xlink:to="loc_xfor_HerculesSecondAmendedLoanAgreementMember_ef3e3a04-5aa5-4005-8e2d-1f954dc92a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2ca8d2c4-7e81-419e-947d-b54559b8b3af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:to="loc_srt_RangeAxis_2ca8d2c4-7e81-419e-947d-b54559b8b3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_81e026fe-0d58-40ee-98d1-0de75c3ccf33" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2ca8d2c4-7e81-419e-947d-b54559b8b3af" xlink:to="loc_srt_RangeMember_81e026fe-0d58-40ee-98d1-0de75c3ccf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e71a09ef-34e2-4cbf-8a07-aa3a5b502736" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_81e026fe-0d58-40ee-98d1-0de75c3ccf33" xlink:to="loc_srt_MaximumMember_e71a09ef-34e2-4cbf-8a07-aa3a5b502736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_386639be-f2bf-444c-a783-e8238689b029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:to="loc_us-gaap_VariableRateAxis_386639be-f2bf-444c-a783-e8238689b029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_47f79419-3ea4-4f70-86d3-a8b5800c9834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_386639be-f2bf-444c-a783-e8238689b029" xlink:to="loc_us-gaap_VariableRateDomain_47f79419-3ea4-4f70-86d3-a8b5800c9834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_3ed624be-c1bc-47bf-82b1-5dcb7d782378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_47f79419-3ea4-4f70-86d3-a8b5800c9834" xlink:to="loc_us-gaap_PrimeRateMember_3ed624be-c1bc-47bf-82b1-5dcb7d782378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_819d6a98-f498-4bb8-8c40-c3139fba0f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_819d6a98-f498-4bb8-8c40-c3139fba0f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f8f909a-0f27-4b82-a031-3c1227e1384a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_819d6a98-f498-4bb8-8c40-c3139fba0f49" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f8f909a-0f27-4b82-a031-3c1227e1384a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_ab40f8cd-abf3-4a26-8759-740842647245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0f8f909a-0f27-4b82-a031-3c1227e1384a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_ab40f8cd-abf3-4a26-8759-740842647245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d8054175-e802-4f94-9bf0-ce75875a1c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d8054175-e802-4f94-9bf0-ce75875a1c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b850d99a-cc4a-488f-9a3c-ec5d78ec0ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d8054175-e802-4f94-9bf0-ce75875a1c54" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b850d99a-cc4a-488f-9a3c-ec5d78ec0ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_96a88702-8d1d-4ac1-a3da-682709dcb699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b850d99a-cc4a-488f-9a3c-ec5d78ec0ce1" xlink:to="loc_us-gaap_SubsequentEventMember_96a88702-8d1d-4ac1-a3da-682709dcb699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_01e9f5a4-0e0d-4ebd-8e73-e4b0764a2a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:to="loc_us-gaap_CreditFacilityAxis_01e9f5a4-0e0d-4ebd-8e73-e4b0764a2a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b40f20b7-d481-4a0d-a48a-a024bd8410ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_01e9f5a4-0e0d-4ebd-8e73-e4b0764a2a95" xlink:to="loc_us-gaap_CreditFacilityDomain_b40f20b7-d481-4a0d-a48a-a024bd8410ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate2Member_eb7026ce-9cd7-4dad-984c-ce50010e02ca" xlink:href="xfor-20220331.xsd#xfor_MinCashTestDate2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b40f20b7-d481-4a0d-a48a-a024bd8410ef" xlink:to="loc_xfor_MinCashTestDate2Member_eb7026ce-9cd7-4dad-984c-ce50010e02ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate1Member_f0e0f500-e88d-4f99-905d-063dbd4c6424" xlink:href="xfor-20220331.xsd#xfor_MinCashTestDate1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b40f20b7-d481-4a0d-a48a-a024bd8410ef" xlink:to="loc_xfor_MinCashTestDate1Member_f0e0f500-e88d-4f99-905d-063dbd4c6424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:href="xfor-20220331.xsd#xfor_ScheduleOfLongTermDebtLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtTable_2053cfae-1421-49d4-8ade-f2e3e2760ee8" xlink:to="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_e32e271a-de80-42ce-a4dd-52f039fcbb12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_e32e271a-de80-42ce-a4dd-52f039fcbb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_74e3ac70-5087-4bbd-99de-82ec068f3a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_74e3ac70-5087-4bbd-99de-82ec068f3a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5ba2d6c2-6007-4d26-b529-300a3cdc6373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5ba2d6c2-6007-4d26-b529-300a3cdc6373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_e731ee94-988a-4447-a25f-061091ab4701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_e731ee94-988a-4447-a25f-061091ab4701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree_5b498c39-17f9-4d48-a082-7326efcdc087" xlink:href="xfor-20220331.xsd#xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree_5b498c39-17f9-4d48-a082-7326efcdc087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentPrepaymentPremiumPercentage_4288d176-0ea9-40b0-943c-f1771b64df6f" xlink:href="xfor-20220331.xsd#xfor_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_xfor_DebtInstrumentPrepaymentPremiumPercentage_4288d176-0ea9-40b0-943c-f1771b64df6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_c4359296-4efa-49d0-bbb3-e9b9e6e3fe5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_c4359296-4efa-49d0-bbb3-e9b9e6e3fe5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1c339aaa-569d-4a8f-86e8-f527dfe62c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_InterestExpenseDebt_1c339aaa-569d-4a8f-86e8-f527dfe62c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6f7b9a4e-0c4a-4b5e-850e-3bde0a250371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_6f7b9a4e-0c4a-4b5e-850e-3bde0a250371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1d4e8815-4b59-49fd-8db2-f953c6a0eccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1d4e8815-4b59-49fd-8db2-f953c6a0eccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_7b425110-911a-4716-bef8-e9a58d0d9949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_7b425110-911a-4716-bef8-e9a58d0d9949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditCovenantMinimumCash_c4aacfe8-018a-42fa-a220-8d3b72175d5c" xlink:href="xfor-20220331.xsd#xfor_LineOfCreditCovenantMinimumCash"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfLongTermDebtLineItems_8b7239dc-7ab8-4aef-b008-52e530f90b06" xlink:to="loc_xfor_LineOfCreditCovenantMinimumCash_c4aacfe8-018a-42fa-a220-8d3b72175d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bb23d70b-9814-47ec-bbea-c52d3746f433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d6a1252c-8f7e-4c9d-8a83-fa09f17607c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bb23d70b-9814-47ec-bbea-c52d3746f433" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d6a1252c-8f7e-4c9d-8a83-fa09f17607c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7fa03593-6c7c-4d77-80de-82231deb145c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bb23d70b-9814-47ec-bbea-c52d3746f433" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7fa03593-6c7c-4d77-80de-82231deb145c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_83cb80b5-abfc-45f5-9ac1-d05251b16bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bb23d70b-9814-47ec-bbea-c52d3746f433" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_83cb80b5-abfc-45f5-9ac1-d05251b16bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtAndEOTPayment_0342b0a6-68e9-47e8-b092-679bb5c88bf3" xlink:href="xfor-20220331.xsd#xfor_LongTermDebtAndEOTPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bb23d70b-9814-47ec-bbea-c52d3746f433" xlink:to="loc_xfor_LongTermDebtAndEOTPayment_0342b0a6-68e9-47e8-b092-679bb5c88bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/Leases" xlink:type="simple" xlink:href="xfor-20220331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a65109f4-8afc-4d1d-a3af-6cb3db8495dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_fb608a46-1f67-4393-ae4b-a5c6f6a755ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a65109f4-8afc-4d1d-a3af-6cb3db8495dc" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_fb608a46-1f67-4393-ae4b-a5c6f6a755ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesTables" xlink:type="simple" xlink:href="xfor-20220331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d178ad7b-d1af-420f-a9c2-a127d90592db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_1edf7ca8-b3c4-463c-8585-690d2d3e7689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d178ad7b-d1af-420f-a9c2-a127d90592db" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_1edf7ca8-b3c4-463c-8585-690d2d3e7689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1c95d95d-c453-43e1-80b8-01d4396f11e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d178ad7b-d1af-420f-a9c2-a127d90592db" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1c95d95d-c453-43e1-80b8-01d4396f11e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#LeasesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9026c5f2-4f77-4a83-b91c-9f4cc9297c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_77b92cd0-1f2a-4fed-b1dc-fa838d785438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9026c5f2-4f77-4a83-b91c-9f4cc9297c3a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_77b92cd0-1f2a-4fed-b1dc-fa838d785438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a644cc1c-50b6-4a03-bbbd-4bc9ef74964c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_77b92cd0-1f2a-4fed-b1dc-fa838d785438" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a644cc1c-50b6-4a03-bbbd-4bc9ef74964c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c38d0c42-d39b-4180-a36c-84310c1d0fd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a644cc1c-50b6-4a03-bbbd-4bc9ef74964c" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c38d0c42-d39b-4180-a36c-84310c1d0fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember_1623d359-5145-4f49-9c86-e7b4d4ce74e1" xlink:href="xfor-20220331.xsd#xfor_WalthamLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c38d0c42-d39b-4180-a36c-84310c1d0fd3" xlink:to="loc_xfor_WalthamLeaseMember_1623d359-5145-4f49-9c86-e7b4d4ce74e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaAustriaLeaseMember_4027e6fe-5f23-49da-9b5f-4af140e04f29" xlink:href="xfor-20220331.xsd#xfor_ViennaAustriaLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c38d0c42-d39b-4180-a36c-84310c1d0fd3" xlink:to="loc_xfor_ViennaAustriaLeaseMember_4027e6fe-5f23-49da-9b5f-4af140e04f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseMember_565a9590-af9b-4cc0-9ce1-6101f6e33696" xlink:href="xfor-20220331.xsd#xfor_AllstonLeaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c38d0c42-d39b-4180-a36c-84310c1d0fd3" xlink:to="loc_xfor_AllstonLeaseMember_565a9590-af9b-4cc0-9ce1-6101f6e33696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_77b92cd0-1f2a-4fed-b1dc-fa838d785438" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement_1c19145b-0072-4d35-b38d-a3f5ca097292" xlink:href="xfor-20220331.xsd#xfor_CurrentOfficeSpaceUnderLeaseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement_1c19145b-0072-4d35-b38d-a3f5ca097292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_OperatingLeaseExpiration_72f131ec-ad8b-4005-b7b9-f4fe033162dc" xlink:href="xfor-20220331.xsd#xfor_OperatingLeaseExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_xfor_OperatingLeaseExpiration_72f131ec-ad8b-4005-b7b9-f4fe033162dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AggregateBaseRent_ce5f569c-334d-4fd6-bc31-47ffab164b4e" xlink:href="xfor-20220331.xsd#xfor_AggregateBaseRent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_xfor_AggregateBaseRent_ce5f569c-334d-4fd6-bc31-47ffab164b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_35e58b84-5bcd-4046-847d-22de7c516065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_35e58b84-5bcd-4046-847d-22de7c516065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_9a38b81b-25b2-40bd-9c8b-3ffc302238a1" xlink:href="xfor-20220331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_9a38b81b-25b2-40bd-9c8b-3ffc302238a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_2e95d331-b05f-4f6a-adfe-41513c9cf34d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_2e95d331-b05f-4f6a-adfe-41513c9cf34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent_d6140c58-ea1e-4184-b51d-7394fa6234f2" xlink:href="xfor-20220331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent_d6140c58-ea1e-4184-b51d-7394fa6234f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_baf196fe-7cff-4376-8da4-01de155164d8" xlink:href="xfor-20220331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_baf196fe-7cff-4376-8da4-01de155164d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2640ee99-5b97-469f-a30f-5792edb822b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2640ee99-5b97-469f-a30f-5792edb822b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_71c6d410-0f98-4b3c-9efc-54be033223d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_us-gaap_OperatingLeaseLiability_71c6d410-0f98-4b3c-9efc-54be033223d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3294a077-78b9-46be-9ef2-d039ccd0701c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5f746f0b-f2c4-415f-802d-000afb6f8cbf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3294a077-78b9-46be-9ef2-d039ccd0701c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#LeasesScheduleofComponentsofLeaseExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ba6dee6f-b14c-424d-b5f8-118bf1ad40b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_185335e9-077d-47c0-ae02-a9c9e748b053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ba6dee6f-b14c-424d-b5f8-118bf1ad40b5" xlink:to="loc_us-gaap_OperatingLeaseCost_185335e9-077d-47c0-ae02-a9c9e748b053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_3e5ce16f-6409-40c6-b36b-dbe842afdd32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ba6dee6f-b14c-424d-b5f8-118bf1ad40b5" xlink:to="loc_us-gaap_ShortTermLeaseCost_3e5ce16f-6409-40c6-b36b-dbe842afdd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_61ff5b42-96b4-475d-8502-30a19d9ccb20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ba6dee6f-b14c-424d-b5f8-118bf1ad40b5" xlink:to="loc_us-gaap_LeaseCost_61ff5b42-96b4-475d-8502-30a19d9ccb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2d26aa53-3fcf-4f4c-a37f-ce20dccafbda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ba6dee6f-b14c-424d-b5f8-118bf1ad40b5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2d26aa53-3fcf-4f4c-a37f-ce20dccafbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_bb6f6d42-6261-4c14-b1e8-a630d3c0dd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ba6dee6f-b14c-424d-b5f8-118bf1ad40b5" xlink:to="loc_us-gaap_OperatingLeasePayments_bb6f6d42-6261-4c14-b1e8-a630d3c0dd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_8c32601c-dcdc-4629-abd1-95c90ca2f71b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ba6dee6f-b14c-424d-b5f8-118bf1ad40b5" xlink:to="loc_us-gaap_SubleaseIncome_8c32601c-dcdc-4629-abd1-95c90ca2f71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0e13d738-1630-47e8-9e3c-6c51ac41283f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ba6dee6f-b14c-424d-b5f8-118bf1ad40b5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0e13d738-1630-47e8-9e3c-6c51ac41283f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_eee68005-c46a-4eb7-b75a-9b4a90e0577c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ba6dee6f-b14c-424d-b5f8-118bf1ad40b5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_eee68005-c46a-4eb7-b75a-9b4a90e0577c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b07c7ff0-6cca-49e6-b6af-f65d05deca0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6dc55d78-24c9-4966-9b54-b2f973549ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b07c7ff0-6cca-49e6-b6af-f65d05deca0d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6dc55d78-24c9-4966-9b54-b2f973549ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3b397547-0a7d-4815-a88b-b9ff6099e893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b07c7ff0-6cca-49e6-b6af-f65d05deca0d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3b397547-0a7d-4815-a88b-b9ff6099e893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4090e2bf-e6de-4965-a448-5a2adab470be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b07c7ff0-6cca-49e6-b6af-f65d05deca0d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4090e2bf-e6de-4965-a448-5a2adab470be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bc186ed9-bc20-4a37-876a-3445404a7928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b07c7ff0-6cca-49e6-b6af-f65d05deca0d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bc186ed9-bc20-4a37-876a-3445404a7928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_23b0c431-314b-404a-a83d-52539eed6968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b07c7ff0-6cca-49e6-b6af-f65d05deca0d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_23b0c431-314b-404a-a83d-52539eed6968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6cce9b3e-feae-466a-ad1c-7b8731ac78e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b07c7ff0-6cca-49e6-b6af-f65d05deca0d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6cce9b3e-feae-466a-ad1c-7b8731ac78e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_76d1cfb0-cf93-4ec2-a9d7-9eec1966dccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b07c7ff0-6cca-49e6-b6af-f65d05deca0d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_76d1cfb0-cf93-4ec2-a9d7-9eec1966dccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2fd74ef4-3505-4601-8a81-2b737f79f4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b07c7ff0-6cca-49e6-b6af-f65d05deca0d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2fd74ef4-3505-4601-8a81-2b737f79f4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_77992bb8-544e-4de5-83d4-4424f8bdd1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b07c7ff0-6cca-49e6-b6af-f65d05deca0d" xlink:to="loc_us-gaap_OperatingLeaseLiability_77992bb8-544e-4de5-83d4-4424f8bdd1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" xlink:type="simple" xlink:href="xfor-20220331.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="xfor-20220331.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4c9b75e2-672f-4aae-baaf-44fd38e8631b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a4f64355-ba7f-41b2-a21d-27d63ddc32ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4c9b75e2-672f-4aae-baaf-44fd38e8631b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a4f64355-ba7f-41b2-a21d-27d63ddc32ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#CommitmentandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_912d73bf-0130-4fc9-a96f-9d0f0ca3a914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ContingenciesAndCommitmentsTable_05536710-e9ab-498d-bbfa-6cf75db06296" xlink:href="xfor-20220331.xsd#xfor_ContingenciesAndCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_912d73bf-0130-4fc9-a96f-9d0f0ca3a914" xlink:to="loc_xfor_ContingenciesAndCommitmentsTable_05536710-e9ab-498d-bbfa-6cf75db06296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_986250e2-42ed-4265-99be-5002418ed1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ContingenciesAndCommitmentsTable_05536710-e9ab-498d-bbfa-6cf75db06296" xlink:to="loc_us-gaap_TypeOfArrangementAxis_986250e2-42ed-4265-99be-5002418ed1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49e852e9-049f-47ac-8e92-3de6f58cba8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_986250e2-42ed-4265-99be-5002418ed1ac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49e852e9-049f-47ac-8e92-3de6f58cba8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IndemnificationAgreementsMember_c28f4da8-97ef-40f2-9adf-681700fd4581" xlink:href="xfor-20220331.xsd#xfor_IndemnificationAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49e852e9-049f-47ac-8e92-3de6f58cba8d" xlink:to="loc_xfor_IndemnificationAgreementsMember_c28f4da8-97ef-40f2-9adf-681700fd4581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ContingenciesAndCommitmentsLineItems_ab46759d-9a21-4cb4-9c19-dfa57e0af9d5" xlink:href="xfor-20220331.xsd#xfor_ContingenciesAndCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ContingenciesAndCommitmentsTable_05536710-e9ab-498d-bbfa-6cf75db06296" xlink:to="loc_xfor_ContingenciesAndCommitmentsLineItems_ab46759d-9a21-4cb4-9c19-dfa57e0af9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_5a8d4188-0544-49e0-b1a1-24134bf3dc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ContingenciesAndCommitmentsLineItems_ab46759d-9a21-4cb4-9c19-dfa57e0af9d5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_5a8d4188-0544-49e0-b1a1-24134bf3dc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockWarrants" xlink:type="simple" xlink:href="xfor-20220331.xsd#CommonStockWarrants"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommonStockWarrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_27b1bebb-1b9d-44f3-a764-0c6b6328fb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5bbf1a83-efea-4cc0-8524-a5f364f763c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27b1bebb-1b9d-44f3-a764-0c6b6328fb3d" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5bbf1a83-efea-4cc0-8524-a5f364f763c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockWarrantsTables" xlink:type="simple" xlink:href="xfor-20220331.xsd#CommonStockWarrantsTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommonStockWarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a8f45d8d-40ec-466c-a9b1-6350d14ba25d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_c7c8b465-a646-4362-a278-0a2000e00a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a8f45d8d-40ec-466c-a9b1-6350d14ba25d" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_c7c8b465-a646-4362-a278-0a2000e00a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#CommonStockWarrantsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5a1d505e-1638-4882-9782-41e37694189f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_115bcf1d-15ae-4f01-bf3c-0d74b0f60126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5a1d505e-1638-4882-9782-41e37694189f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_115bcf1d-15ae-4f01-bf3c-0d74b0f60126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_960e98d4-0162-47b3-8fc9-21808ea8d67e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_115bcf1d-15ae-4f01-bf3c-0d74b0f60126" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_960e98d4-0162-47b3-8fc9-21808ea8d67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b26775c-9c93-43dd-91b5-b3749cc401b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_960e98d4-0162-47b3-8fc9-21808ea8d67e" xlink:to="loc_us-gaap_EquityComponentDomain_3b26775c-9c93-43dd-91b5-b3749cc401b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassAWarrantMember_038612ef-98fc-4d16-9bd3-586445363844" xlink:href="xfor-20220331.xsd#xfor_ClassAWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b26775c-9c93-43dd-91b5-b3749cc401b6" xlink:to="loc_xfor_ClassAWarrantMember_038612ef-98fc-4d16-9bd3-586445363844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassBWarrantsMember_7932109e-bc32-444f-a5cb-8d3b6da7606a" xlink:href="xfor-20220331.xsd#xfor_ClassBWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b26775c-9c93-43dd-91b5-b3749cc401b6" xlink:to="loc_xfor_ClassBWarrantsMember_7932109e-bc32-444f-a5cb-8d3b6da7606a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_2e5a7d04-0c6e-4d2b-b272-da9ef7512b7c" xlink:href="xfor-20220331.xsd#xfor_PreFundedWarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b26775c-9c93-43dd-91b5-b3749cc401b6" xlink:to="loc_xfor_PreFundedWarrantMember_2e5a7d04-0c6e-4d2b-b272-da9ef7512b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsAxis_e0eb602c-a35a-4524-b98f-11c8bae939d0" xlink:href="xfor-20220331.xsd#xfor_PrefundedWarrantsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_115bcf1d-15ae-4f01-bf3c-0d74b0f60126" xlink:to="loc_xfor_PrefundedWarrantsAxis_e0eb602c-a35a-4524-b98f-11c8bae939d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain_2292a13b-ad16-4117-971f-ec3463360924" xlink:href="xfor-20220331.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_PrefundedWarrantsAxis_e0eb602c-a35a-4524-b98f-11c8bae939d0" xlink:to="loc_xfor_PrefundedWarrantsDomain_2292a13b-ad16-4117-971f-ec3463360924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FundedMember_3cdbb591-192d-4e80-9b15-374ca054945d" xlink:href="xfor-20220331.xsd#xfor_FundedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_PrefundedWarrantsDomain_2292a13b-ad16-4117-971f-ec3463360924" xlink:to="loc_xfor_FundedMember_3cdbb591-192d-4e80-9b15-374ca054945d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_115bcf1d-15ae-4f01-bf3c-0d74b0f60126" xlink:to="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightIssued_a5e4e564-7538-4f32-a0c3-c10e19d67dc4" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_xfor_ClassOfWarrantOrRightIssued_a5e4e564-7538-4f32-a0c3-c10e19d67dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_01dcd45e-d35f-4645-aa81-ebffce5454c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_01dcd45e-d35f-4645-aa81-ebffce5454c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_d6306ec4-6ea9-42f9-8eda-c77ae12a66cc" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_d6306ec4-6ea9-42f9-8eda-c77ae12a66cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_02e26058-e272-40f4-98a0-78bbb7bb2534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_02e26058-e272-40f4-98a0-78bbb7bb2534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_620c1397-8ead-471b-9792-34e4c2736987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_620c1397-8ead-471b-9792-34e4c2736987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4857702c-aabc-44cb-803a-6511dea35f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4857702c-aabc-44cb-803a-6511dea35f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_013ce893-7499-4d28-921c-244bedd4937d" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_013ce893-7499-4d28-921c-244bedd4937d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_1366e60e-6de0-4ca0-9766-ff1f7f7abe52" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_1366e60e-6de0-4ca0-9766-ff1f7f7abe52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_68e9b3b1-68b4-4d9b-8749-a53728b55b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_68e9b3b1-68b4-4d9b-8749-a53728b55b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_e0d315a8-8033-4207-8b39-2886b656a911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_DividendsCommonStock_e0d315a8-8033-4207-8b39-2886b656a911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_39234639-9b67-4bb0-8a91-1d85dde60dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_39234639-9b67-4bb0-8a91-1d85dde60dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d0a4be02-39b7-44eb-a395-f5c37919a5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d0a4be02-39b7-44eb-a395-f5c37919a5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0ef05845-de40-48d6-b2d9-9e5bfd1a323d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0ef05845-de40-48d6-b2d9-9e5bfd1a323d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_45d2c813-8ef3-4e61-bff2-92db04450753" xlink:href="xfor-20220331.xsd#xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ac7ae13a-be20-43e4-8fa9-8f14f034ba21" xlink:to="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_45d2c813-8ef3-4e61-bff2-92db04450753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockWarrantsScheduleofOutstandingWarrantsDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#CommonStockWarrantsScheduleofOutstandingWarrantsDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommonStockWarrantsScheduleofOutstandingWarrantsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a7cfea53-dbf1-4614-928d-9edc4c7372ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WarrantsRollForward_2ca02e65-a543-4167-a7d1-d5054a803604" xlink:href="xfor-20220331.xsd#xfor_WarrantsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a7cfea53-dbf1-4614-928d-9edc4c7372ab" xlink:to="loc_xfor_WarrantsRollForward_2ca02e65-a543-4167-a7d1-d5054a803604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_a07251ee-5022-4cf2-bfcc-990ef3c41426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_WarrantsRollForward_2ca02e65-a543-4167-a7d1-d5054a803604" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_a07251ee-5022-4cf2-bfcc-990ef3c41426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightIssued_e07d2485-9170-4627-968c-60906d10f15e" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_WarrantsRollForward_2ca02e65-a543-4167-a7d1-d5054a803604" xlink:to="loc_xfor_ClassOfWarrantOrRightIssued_e07d2485-9170-4627-968c-60906d10f15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightExercised_f87de634-375a-43fa-baf0-aa5833412ad3" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_WarrantsRollForward_2ca02e65-a543-4167-a7d1-d5054a803604" xlink:to="loc_xfor_ClassOfWarrantOrRightExercised_f87de634-375a-43fa-baf0-aa5833412ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8a764b1c-fff2-4e68-bb57-c59eb3e79604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_WarrantsRollForward_2ca02e65-a543-4167-a7d1-d5054a803604" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8a764b1c-fff2-4e68-bb57-c59eb3e79604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice_1d73b8cd-87ac-45a5-bdd8-1eeb12168459" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_WarrantsRollForward_2ca02e65-a543-4167-a7d1-d5054a803604" xlink:to="loc_xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice_1d73b8cd-87ac-45a5-bdd8-1eeb12168459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WarrantsWeightedAverageExercisePriceRollForward_46fa86bc-2c90-4540-90c3-96d86a1f6fc9" xlink:href="xfor-20220331.xsd#xfor_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a7cfea53-dbf1-4614-928d-9edc4c7372ab" xlink:to="loc_xfor_WarrantsWeightedAverageExercisePriceRollForward_46fa86bc-2c90-4540-90c3-96d86a1f6fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_d66d3663-ceea-49d6-92f0-50720b121951" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_WarrantsWeightedAverageExercisePriceRollForward_46fa86bc-2c90-4540-90c3-96d86a1f6fc9" xlink:to="loc_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_d66d3663-ceea-49d6-92f0-50720b121951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_3d9ec67c-1c5b-456e-a91a-8be7a2c9e90f" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_WarrantsWeightedAverageExercisePriceRollForward_46fa86bc-2c90-4540-90c3-96d86a1f6fc9" xlink:to="loc_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_3d9ec67c-1c5b-456e-a91a-8be7a2c9e90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm_36844f72-dfe0-49a3-8b3f-cdde60e5e8dc" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a7cfea53-dbf1-4614-928d-9edc4c7372ab" xlink:to="loc_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm_36844f72-dfe0-49a3-8b3f-cdde60e5e8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d692cacc-825b-4017-b8d6-9c29c81e7f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_4ea76059-a203-4566-9057-842a662c8968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d692cacc-825b-4017-b8d6-9c29c81e7f89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_4ea76059-a203-4566-9057-842a662c8968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_efc2c485-ee04-4fe7-bade-f66afbf35d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4ea76059-a203-4566-9057-842a662c8968" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_efc2c485-ee04-4fe7-bade-f66afbf35d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_efc2c485-ee04-4fe7-bade-f66afbf35d1e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_18c958a9-6506-49dd-aa56-e008d05bc6f2" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_18c958a9-6506-49dd-aa56-e008d05bc6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_f3df4584-c9f7-4a23-97e7-7a4fbfd9d702" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_f3df4584-c9f7-4a23-97e7-7a4fbfd9d702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_b2cb13e7-300d-414e-918e-0c117de322ea" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_b2cb13e7-300d-414e-918e-0c117de322ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_daff8a53-4927-4dca-8f7c-74d9be5b6ed3" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_daff8a53-4927-4dca-8f7c-74d9be5b6ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_f35351b8-94ea-4a9e-bb7e-e520825825de" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_f35351b8-94ea-4a9e-bb7e-e520825825de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_10c2da3f-8b8b-4d47-9d88-2255a0f941cf" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_10c2da3f-8b8b-4d47-9d88-2255a0f941cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_b3859733-5d51-4b99-9354-379af4741429" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_b3859733-5d51-4b99-9354-379af4741429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_007d32a0-7742-4e4d-80b4-ec2970561dc1" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_007d32a0-7742-4e4d-80b4-ec2970561dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch232021Member_9dcc1445-4a67-4171-87f4-5074d3bcd499" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnMarch232021Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnMarch232021Member_9dcc1445-4a67-4171-87f4-5074d3bcd499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_05392704-20c8-42f3-859b-ba618f5a6f76" xlink:href="xfor-20220331.xsd#xfor_PreFundedWarrantMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_PreFundedWarrantMember_05392704-20c8-42f3-859b-ba618f5a6f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_39e13336-2559-4668-b413-615cb9a460b8" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_39e13336-2559-4668-b413-615cb9a460b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch32022Member_6b75937c-20bd-4566-80fa-d4e6c95b8a7c" xlink:href="xfor-20220331.xsd#xfor_IssuanceOnMarch32022Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c7224bd-ebb1-4af4-944e-e6f0a168484d" xlink:to="loc_xfor_IssuanceOnMarch32022Member_6b75937c-20bd-4566-80fa-d4e6c95b8a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f44f850d-08cd-406d-8e5d-f789d313946b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4ea76059-a203-4566-9057-842a662c8968" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f44f850d-08cd-406d-8e5d-f789d313946b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a21d8e1d-fc3e-473b-a4df-b87f14513327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f44f850d-08cd-406d-8e5d-f789d313946b" xlink:to="loc_us-gaap_EquityComponentDomain_a21d8e1d-fc3e-473b-a4df-b87f14513327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_5604ddd2-5cb6-4470-875b-1f4b4ace2a6f" xlink:href="xfor-20220331.xsd#xfor_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a21d8e1d-fc3e-473b-a4df-b87f14513327" xlink:to="loc_xfor_PreFundedWarrantMember_5604ddd2-5cb6-4470-875b-1f4b4ace2a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassBWarrantsMember_d6bc51da-e602-4ff2-96b0-4a5a750cbd8a" xlink:href="xfor-20220331.xsd#xfor_ClassBWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a21d8e1d-fc3e-473b-a4df-b87f14513327" xlink:to="loc_xfor_ClassBWarrantsMember_d6bc51da-e602-4ff2-96b0-4a5a750cbd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassAWarrantMember_1185db41-4557-4b5e-a6ee-d027eb497a52" xlink:href="xfor-20220331.xsd#xfor_ClassAWarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a21d8e1d-fc3e-473b-a4df-b87f14513327" xlink:to="loc_xfor_ClassAWarrantMember_1185db41-4557-4b5e-a6ee-d027eb497a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LegacyWarrantsMember_2535ea6d-9f60-4cb4-b081-bb5b7390b942" xlink:href="xfor-20220331.xsd#xfor_LegacyWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a21d8e1d-fc3e-473b-a4df-b87f14513327" xlink:to="loc_xfor_LegacyWarrantsMember_2535ea6d-9f60-4cb4-b081-bb5b7390b942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_0a5ab9be-05d2-4f5a-a7b6-ee8412ccd0b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4ea76059-a203-4566-9057-842a662c8968" xlink:to="loc_srt_TitleOfIndividualAxis_0a5ab9be-05d2-4f5a-a7b6-ee8412ccd0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0aeb9b07-eab5-4563-b5c7-8848d11ee529" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_0a5ab9be-05d2-4f5a-a7b6-ee8412ccd0b5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0aeb9b07-eab5-4563-b5c7-8848d11ee529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsAxis_52c73553-ace9-47a2-9965-32fc4fd2b6f2" xlink:href="xfor-20220331.xsd#xfor_PrefundedWarrantsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4ea76059-a203-4566-9057-842a662c8968" xlink:to="loc_xfor_PrefundedWarrantsAxis_52c73553-ace9-47a2-9965-32fc4fd2b6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain_82dfa760-a9ce-438d-adea-3f7530e2d415" xlink:href="xfor-20220331.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_PrefundedWarrantsAxis_52c73553-ace9-47a2-9965-32fc4fd2b6f2" xlink:to="loc_xfor_PrefundedWarrantsDomain_82dfa760-a9ce-438d-adea-3f7530e2d415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FundedMember_97982f41-73ed-494b-abc9-b1c8b860d063" xlink:href="xfor-20220331.xsd#xfor_FundedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_PrefundedWarrantsDomain_82dfa760-a9ce-438d-adea-3f7530e2d415" xlink:to="loc_xfor_FundedMember_97982f41-73ed-494b-abc9-b1c8b860d063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6e62d5f2-4a81-40c9-b12a-b2bff270f58c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4ea76059-a203-4566-9057-842a662c8968" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_6e62d5f2-4a81-40c9-b12a-b2bff270f58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_cdc71bb9-30ce-4b7e-81e2-163a09e709e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6e62d5f2-4a81-40c9-b12a-b2bff270f58c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_cdc71bb9-30ce-4b7e-81e2-163a09e709e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47bf5abf-ab8f-4daa-9bb2-401c3cb5df76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6e62d5f2-4a81-40c9-b12a-b2bff270f58c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47bf5abf-ab8f-4daa-9bb2-401c3cb5df76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_c5ba47ab-f676-4647-bc31-49dabf1269e9" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6e62d5f2-4a81-40c9-b12a-b2bff270f58c" xlink:to="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_c5ba47ab-f676-4647-bc31-49dabf1269e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_bd41a916-25b9-4976-b308-9718f72fa2d8" xlink:href="xfor-20220331.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6e62d5f2-4a81-40c9-b12a-b2bff270f58c" xlink:to="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_bd41a916-25b9-4976-b308-9718f72fa2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="xfor-20220331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4ff239d-7b4f-45d4-a02c-c3ab9bccfe2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9d22d0e7-32c2-496c-b248-870ef6f7484b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4ff239d-7b4f-45d4-a02c-c3ab9bccfe2a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9d22d0e7-32c2-496c-b248-870ef6f7484b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="xfor-20220331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_378d42ff-302c-40c3-81e7-a45ba9d9048c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_fc3f8613-97b8-4c64-a790-de68ceb34c73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_378d42ff-302c-40c3-81e7-a45ba9d9048c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_fc3f8613-97b8-4c64-a790-de68ceb34c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5b865a65-efd5-4a6c-8640-3018101543c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_378d42ff-302c-40c3-81e7-a45ba9d9048c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5b865a65-efd5-4a6c-8640-3018101543c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_5d10b5d9-a1f6-48d9-882c-8e2913122b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_378d42ff-302c-40c3-81e7-a45ba9d9048c" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_5d10b5d9-a1f6-48d9-882c-8e2913122b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_f5425264-4fa8-4687-b323-6d3ed81df48f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_378d42ff-302c-40c3-81e7-a45ba9d9048c" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_f5425264-4fa8-4687-b323-6d3ed81df48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_365b5afa-3cbd-4494-9933-ccf52a2b1b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b24e502d-50a2-4c89-91b1-a274537f0927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_365b5afa-3cbd-4494-9933-ccf52a2b1b51" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b24e502d-50a2-4c89-91b1-a274537f0927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_59194d29-71cb-4750-b508-867d3d455b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b24e502d-50a2-4c89-91b1-a274537f0927" xlink:to="loc_us-gaap_PlanNameAxis_59194d29-71cb-4750-b508-867d3d455b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_10b992a4-6751-4e00-b242-da98b1fc1965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_59194d29-71cb-4750-b508-867d3d455b5b" xlink:to="loc_us-gaap_PlanNameDomain_10b992a4-6751-4e00-b242-da98b1fc1965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember_1c249593-1035-43c3-947f-6388533f6524" xlink:href="xfor-20220331.xsd#xfor_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_10b992a4-6751-4e00-b242-da98b1fc1965" xlink:to="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember_1c249593-1035-43c3-947f-6388533f6524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember_02e36b4f-38ac-4d0f-8e3f-283c879836a4" xlink:href="xfor-20220331.xsd#xfor_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_10b992a4-6751-4e00-b242-da98b1fc1965" xlink:to="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember_02e36b4f-38ac-4d0f-8e3f-283c879836a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_71a94f17-84fb-408b-b1f4-f7434fa30505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b24e502d-50a2-4c89-91b1-a274537f0927" xlink:to="loc_us-gaap_AwardTypeAxis_71a94f17-84fb-408b-b1f4-f7434fa30505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_606663a9-dd37-46d1-9c8c-63fd0e65c797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_71a94f17-84fb-408b-b1f4-f7434fa30505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_606663a9-dd37-46d1-9c8c-63fd0e65c797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69b02943-5088-4d27-af6a-666ecfcb28ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_606663a9-dd37-46d1-9c8c-63fd0e65c797" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_69b02943-5088-4d27-af6a-666ecfcb28ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f115289-9cad-4cd5-9324-72c422f111fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b24e502d-50a2-4c89-91b1-a274537f0927" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f115289-9cad-4cd5-9324-72c422f111fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_431161f2-4e75-46f5-b72c-2a3e3ec2d551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f115289-9cad-4cd5-9324-72c422f111fa" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_431161f2-4e75-46f5-b72c-2a3e3ec2d551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dd064284-73a0-4a86-b49f-db42ece34282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f115289-9cad-4cd5-9324-72c422f111fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dd064284-73a0-4a86-b49f-db42ece34282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_d50ac1a4-dfa5-466e-af52-1e560d5f3b39" xlink:href="xfor-20220331.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f115289-9cad-4cd5-9324-72c422f111fa" xlink:to="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_d50ac1a4-dfa5-466e-af52-1e560d5f3b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_870cbdb3-7a11-4133-a7b7-fcb9a5de94cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f115289-9cad-4cd5-9324-72c422f111fa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_870cbdb3-7a11-4133-a7b7-fcb9a5de94cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e0aa6ea5-1ffb-46c3-ac03-a70f382f259e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f115289-9cad-4cd5-9324-72c422f111fa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e0aa6ea5-1ffb-46c3-ac03-a70f382f259e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_770ecd39-e67f-46d2-b75c-380950a262dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bd9e6a0d-2bf0-4de3-8dda-64a0c0e2a83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_770ecd39-e67f-46d2-b75c-380950a262dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bd9e6a0d-2bf0-4de3-8dda-64a0c0e2a83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f90626ba-ffab-438d-ac5a-e38aae32d168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_770ecd39-e67f-46d2-b75c-380950a262dd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f90626ba-ffab-438d-ac5a-e38aae32d168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_362210bf-dad6-459b-968c-39cc28df0efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_770ecd39-e67f-46d2-b75c-380950a262dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_362210bf-dad6-459b-968c-39cc28df0efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_89d91ea3-7f75-419c-95dc-4870a068aa65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_770ecd39-e67f-46d2-b75c-380950a262dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_89d91ea3-7f75-419c-95dc-4870a068aa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#StockBasedCompensationSummaryofStockOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49f28c2d-85e2-4490-86e8-4086a4bd5223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571ca88-8658-4292-a05d-98671e5b7f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49f28c2d-85e2-4490-86e8-4086a4bd5223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571ca88-8658-4292-a05d-98671e5b7f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_810e224f-4f05-42b4-abfa-76a2e213777c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571ca88-8658-4292-a05d-98671e5b7f9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_810e224f-4f05-42b4-abfa-76a2e213777c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6861d482-e077-42bf-979d-d6b00f2f15fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571ca88-8658-4292-a05d-98671e5b7f9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6861d482-e077-42bf-979d-d6b00f2f15fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d10a5593-1237-4bb5-a0a3-f2a387cfccc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571ca88-8658-4292-a05d-98671e5b7f9b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d10a5593-1237-4bb5-a0a3-f2a387cfccc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_17a1a85d-ce03-4dfd-abab-b75b8c21ae2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571ca88-8658-4292-a05d-98671e5b7f9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_17a1a85d-ce03-4dfd-abab-b75b8c21ae2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_49368680-4d8a-4a04-aa3d-57a97781f8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9571ca88-8658-4292-a05d-98671e5b7f9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_49368680-4d8a-4a04-aa3d-57a97781f8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_91a7c610-3ca8-4934-8936-5ea3d877b609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49f28c2d-85e2-4490-86e8-4086a4bd5223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_91a7c610-3ca8-4934-8936-5ea3d877b609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4a1db24e-7535-4ad4-bc01-c58556b64e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49f28c2d-85e2-4490-86e8-4086a4bd5223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4a1db24e-7535-4ad4-bc01-c58556b64e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29a53ecf-324a-4412-8db0-2be43caf4bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49f28c2d-85e2-4490-86e8-4086a4bd5223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29a53ecf-324a-4412-8db0-2be43caf4bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b0c534b4-bf61-4a09-8d75-823b651bb003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29a53ecf-324a-4412-8db0-2be43caf4bb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b0c534b4-bf61-4a09-8d75-823b651bb003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2205de75-52fc-4607-8fa2-d51ab687b23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29a53ecf-324a-4412-8db0-2be43caf4bb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2205de75-52fc-4607-8fa2-d51ab687b23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_768486f2-11f0-4dd0-b4a0-c4770732c51b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29a53ecf-324a-4412-8db0-2be43caf4bb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_768486f2-11f0-4dd0-b4a0-c4770732c51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7d10e295-abd7-44de-b944-391c6885e2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29a53ecf-324a-4412-8db0-2be43caf4bb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7d10e295-abd7-44de-b944-391c6885e2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1eefc789-46c6-461f-b231-cc6f9ce7178c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49f28c2d-85e2-4490-86e8-4086a4bd5223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1eefc789-46c6-461f-b231-cc6f9ce7178c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_55e1e32f-fdfb-43db-81f3-4041708d1797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49f28c2d-85e2-4490-86e8-4086a4bd5223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_55e1e32f-fdfb-43db-81f3-4041708d1797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_66632e47-2a44-4e5c-a8b2-3af3d3b2fe04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49f28c2d-85e2-4490-86e8-4086a4bd5223" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_66632e47-2a44-4e5c-a8b2-3af3d3b2fe04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_43320a79-0725-4a0a-a642-6a28437a6965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49f28c2d-85e2-4490-86e8-4086a4bd5223" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_43320a79-0725-4a0a-a642-6a28437a6965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a82f0af5-421a-4734-b9c4-4ec102e65881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49f28c2d-85e2-4490-86e8-4086a4bd5223" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a82f0af5-421a-4734-b9c4-4ec102e65881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3bbd2f44-82c8-4968-89a7-5b20af0a6187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49f28c2d-85e2-4490-86e8-4086a4bd5223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3bbd2f44-82c8-4968-89a7-5b20af0a6187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6365ad37-c430-4b14-8b11-3fd640d3c3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49f28c2d-85e2-4490-86e8-4086a4bd5223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6365ad37-c430-4b14-8b11-3fd640d3c3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5913fade-e24c-4069-aab7-09c4ea4dc713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49f28c2d-85e2-4490-86e8-4086a4bd5223" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5913fade-e24c-4069-aab7-09c4ea4dc713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_28238799-7d5c-4635-941f-9c05a6b48605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49f28c2d-85e2-4490-86e8-4086a4bd5223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_28238799-7d5c-4635-941f-9c05a6b48605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="xfor-20220331.xsd#StockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3766c788-c3e2-4806-afef-79b77a2acf96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aec4772-4652-4deb-adf6-d7251add67b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3766c788-c3e2-4806-afef-79b77a2acf96" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aec4772-4652-4deb-adf6-d7251add67b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2d63846e-1c38-4a8c-8ad9-e5acc42e1ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aec4772-4652-4deb-adf6-d7251add67b1" xlink:to="loc_us-gaap_AwardTypeAxis_2d63846e-1c38-4a8c-8ad9-e5acc42e1ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24ed14e8-ac9e-4f71-81a1-863d64848e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2d63846e-1c38-4a8c-8ad9-e5acc42e1ea8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24ed14e8-ac9e-4f71-81a1-863d64848e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8693a792-e0c3-491a-b24d-b4bc105fb2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24ed14e8-ac9e-4f71-81a1-863d64848e3e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8693a792-e0c3-491a-b24d-b4bc105fb2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fed7457-83a4-4553-bc40-7358d11a231b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aec4772-4652-4deb-adf6-d7251add67b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fed7457-83a4-4553-bc40-7358d11a231b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_78a8240d-0233-471a-8ca9-2c74340f8d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fed7457-83a4-4553-bc40-7358d11a231b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_78a8240d-0233-471a-8ca9-2c74340f8d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2f9827bc-b9af-4c88-ae1b-97069cbe5eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_78a8240d-0233-471a-8ca9-2c74340f8d11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2f9827bc-b9af-4c88-ae1b-97069cbe5eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ccfdaa6a-63c1-481f-91f9-26669363ae55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_78a8240d-0233-471a-8ca9-2c74340f8d11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ccfdaa6a-63c1-481f-91f9-26669363ae55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8aee4f5b-92a0-4d4a-9ea2-2ebce988963c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_78a8240d-0233-471a-8ca9-2c74340f8d11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8aee4f5b-92a0-4d4a-9ea2-2ebce988963c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c331fed1-adf1-4d1f-8ae8-aa57a6249edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_78a8240d-0233-471a-8ca9-2c74340f8d11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c331fed1-adf1-4d1f-8ae8-aa57a6249edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3a7c13a0-7f91-495a-8da0-d26d8a352102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_78a8240d-0233-471a-8ca9-2c74340f8d11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3a7c13a0-7f91-495a-8da0-d26d8a352102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" xlink:type="simple" xlink:href="xfor-20220331.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba755d0c-1bdd-4a21-b858-e2a25fee39c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_472f2c94-90ec-40eb-9359-82121e76a9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba755d0c-1bdd-4a21-b858-e2a25fee39c5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_472f2c94-90ec-40eb-9359-82121e76a9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_281b4dfe-3b3e-410c-85b0-39ddc6ff7afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_472f2c94-90ec-40eb-9359-82121e76a9f5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_281b4dfe-3b3e-410c-85b0-39ddc6ff7afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9d0f83d0-b1d3-4b31-a285-6e48fec471c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_281b4dfe-3b3e-410c-85b0-39ddc6ff7afc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9d0f83d0-b1d3-4b31-a285-6e48fec471c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_529b0888-e19f-4cc3-9507-93ed55166d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d0f83d0-b1d3-4b31-a285-6e48fec471c5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_529b0888-e19f-4cc3-9507-93ed55166d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c5775006-75d5-45be-945a-9176c15de90b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d0f83d0-b1d3-4b31-a285-6e48fec471c5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c5775006-75d5-45be-945a-9176c15de90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa0df835-5f7d-4100-8378-299b910f9747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_472f2c94-90ec-40eb-9359-82121e76a9f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa0df835-5f7d-4100-8378-299b910f9747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_38b09427-c375-48f7-8984-b51ba9764b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa0df835-5f7d-4100-8378-299b910f9747" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_38b09427-c375-48f7-8984-b51ba9764b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="xfor-20220331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_32345000-45db-40b9-9401-b6ee524152c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4c7b2c05-dc91-4610-b4fd-a4705e63ef4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32345000-45db-40b9-9401-b6ee524152c5" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4c7b2c05-dc91-4610-b4fd-a4705e63ef4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4a7c8639-0ab0-4e44-9197-6bc8a75e5ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5716f727-66a2-43a4-89e1-cdbfb3db4f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4a7c8639-0ab0-4e44-9197-6bc8a75e5ccf" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5716f727-66a2-43a4-89e1-cdbfb3db4f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2986ce07-648b-48ce-86d4-1635e4bd392c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4a7c8639-0ab0-4e44-9197-6bc8a75e5ccf" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2986ce07-648b-48ce-86d4-1635e4bd392c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_680fd233-9ec1-4fab-88ac-e74a213fde45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4a7c8639-0ab0-4e44-9197-6bc8a75e5ccf" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_680fd233-9ec1-4fab-88ac-e74a213fde45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShare" xlink:type="simple" xlink:href="xfor-20220331.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0c7851b6-af11-4de3-bcd8-8d068f0724e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e282ddfe-ac04-4b7b-bffa-f6a3aaaae6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0c7851b6-af11-4de3-bcd8-8d068f0724e7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e282ddfe-ac04-4b7b-bffa-f6a3aaaae6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="xfor-20220331.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0a491cd5-34e1-42fa-85dc-3722913069c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_07999111-7833-48df-a270-295b68da9f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a491cd5-34e1-42fa-85dc-3722913069c7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_07999111-7833-48df-a270-295b68da9f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b9338d57-3aad-400c-89ea-bc25d63abcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a491cd5-34e1-42fa-85dc-3722913069c7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b9338d57-3aad-400c-89ea-bc25d63abcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4ff0a350-0a76-49ae-b1fc-cdc7b21775b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NumeratorAbstract_f0fb79c3-5965-4906-8c2e-edf447e0b316" xlink:href="xfor-20220331.xsd#xfor_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4ff0a350-0a76-49ae-b1fc-cdc7b21775b6" xlink:to="loc_xfor_NumeratorAbstract_f0fb79c3-5965-4906-8c2e-edf447e0b316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8c96174e-e2f1-4582-91c8-738bd2d81cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_NumeratorAbstract_f0fb79c3-5965-4906-8c2e-edf447e0b316" xlink:to="loc_us-gaap_NetIncomeLoss_8c96174e-e2f1-4582-91c8-738bd2d81cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPaidinkind_406dc624-40a9-46d4-8753-b5b95e48946a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPaidinkind"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_NumeratorAbstract_f0fb79c3-5965-4906-8c2e-edf447e0b316" xlink:to="loc_us-gaap_DividendsPaidinkind_406dc624-40a9-46d4-8753-b5b95e48946a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8056963b-1ad6-475b-ad10-efd58f4411cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_NumeratorAbstract_f0fb79c3-5965-4906-8c2e-edf447e0b316" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8056963b-1ad6-475b-ad10-efd58f4411cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DenominatorAbstract_e156b5e4-cd37-4de8-baeb-466fb4085409" xlink:href="xfor-20220331.xsd#xfor_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4ff0a350-0a76-49ae-b1fc-cdc7b21775b6" xlink:to="loc_xfor_DenominatorAbstract_e156b5e4-cd37-4de8-baeb-466fb4085409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_bf96abb2-33e9-49a4-8b83-708560709bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_DenominatorAbstract_e156b5e4-cd37-4de8-baeb-466fb4085409" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_bf96abb2-33e9-49a4-8b83-708560709bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_13ef0bb4-933e-4705-8faf-f4e1f0e36681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_DenominatorAbstract_e156b5e4-cd37-4de8-baeb-466fb4085409" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_13ef0bb4-933e-4705-8faf-f4e1f0e36681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#NetLossperShareAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_167eb86f-115a-4575-aad5-6ba0d43b4035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1008baab-bf93-4647-8573-32a5cfcecb92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_167eb86f-115a-4575-aad5-6ba0d43b4035" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1008baab-bf93-4647-8573-32a5cfcecb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bf1d5d44-33d5-459c-84c4-a8ec266d2b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1008baab-bf93-4647-8573-32a5cfcecb92" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bf1d5d44-33d5-459c-84c4-a8ec266d2b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_edbab4f6-159e-45af-b632-9452e786a8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bf1d5d44-33d5-459c-84c4-a8ec266d2b40" xlink:to="loc_us-gaap_ClassOfStockDomain_edbab4f6-159e-45af-b632-9452e786a8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember_d7699eef-5284-4b19-b042-226c228ffd06" xlink:href="xfor-20220331.xsd#xfor_RedeemableCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_edbab4f6-159e-45af-b632-9452e786a8d3" xlink:to="loc_xfor_RedeemableCommonStockMember_d7699eef-5284-4b19-b042-226c228ffd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_270d7f88-f0ff-44f4-9351-2ddc831f3d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1008baab-bf93-4647-8573-32a5cfcecb92" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_270d7f88-f0ff-44f4-9351-2ddc831f3d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_310fd5dc-dfce-4f3e-859d-4b549b09b04f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_270d7f88-f0ff-44f4-9351-2ddc831f3d3e" xlink:to="loc_us-gaap_EquityComponentDomain_310fd5dc-dfce-4f3e-859d-4b549b09b04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_7c9105b9-e9c1-4c97-87e7-c80cb7f93d53" xlink:href="xfor-20220331.xsd#xfor_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_310fd5dc-dfce-4f3e-859d-4b549b09b04f" xlink:to="loc_xfor_PreFundedWarrantMember_7c9105b9-e9c1-4c97-87e7-c80cb7f93d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_39e6b9b5-9a9f-4bd0-8de1-ed01f03becd0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1008baab-bf93-4647-8573-32a5cfcecb92" xlink:to="loc_srt_RangeAxis_39e6b9b5-9a9f-4bd0-8de1-ed01f03becd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_810645bf-0350-44a3-9ea7-6a415ac5fc9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_39e6b9b5-9a9f-4bd0-8de1-ed01f03becd0" xlink:to="loc_srt_RangeMember_810645bf-0350-44a3-9ea7-6a415ac5fc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e95bc78c-6648-40f9-85ca-72cf3bbf230a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_810645bf-0350-44a3-9ea7-6a415ac5fc9d" xlink:to="loc_srt_MaximumMember_e95bc78c-6648-40f9-85ca-72cf3bbf230a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_968568cd-4296-46af-b8af-d049dc73c549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1008baab-bf93-4647-8573-32a5cfcecb92" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_968568cd-4296-46af-b8af-d049dc73c549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e27cc31f-5a12-4053-bd69-5969fbb98187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_968568cd-4296-46af-b8af-d049dc73c549" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e27cc31f-5a12-4053-bd69-5969fbb98187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41f70a28-b8c2-443f-bb40-029d99f52770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_968568cd-4296-46af-b8af-d049dc73c549" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41f70a28-b8c2-443f-bb40-029d99f52770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail" xlink:type="simple" xlink:href="xfor-20220331.xsd#NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4765063c-982d-4af6-aff4-bcd8603e1625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cf25454c-737c-4f89-b234-294141ec9fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4765063c-982d-4af6-aff4-bcd8603e1625" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cf25454c-737c-4f89-b234-294141ec9fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_572e5571-c7ea-40d3-81b6-63f359b4e431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cf25454c-737c-4f89-b234-294141ec9fcf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_572e5571-c7ea-40d3-81b6-63f359b4e431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2161819c-5107-4472-8c58-34275f956af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_572e5571-c7ea-40d3-81b6-63f359b4e431" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2161819c-5107-4472-8c58-34275f956af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9b092bc4-1360-469d-ba89-225bde06b1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2161819c-5107-4472-8c58-34275f956af8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9b092bc4-1360-469d-ba89-225bde06b1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_571a1b49-6683-4b83-a523-0f4dc5775502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2161819c-5107-4472-8c58-34275f956af8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_571a1b49-6683-4b83-a523-0f4dc5775502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b1206eea-d441-41b8-8b7c-4e4097fb8217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2161819c-5107-4472-8c58-34275f956af8" xlink:to="loc_us-gaap_WarrantMember_b1206eea-d441-41b8-8b7c-4e4097fb8217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f9a3a2d8-5cee-46f0-bb62-0e53ee7d94c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cf25454c-737c-4f89-b234-294141ec9fcf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f9a3a2d8-5cee-46f0-bb62-0e53ee7d94c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8ae170a5-79c6-44de-a214-8cd09191f62d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f9a3a2d8-5cee-46f0-bb62-0e53ee7d94c2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8ae170a5-79c6-44de-a214-8cd09191f62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>xfor-20220331_g1.jpg
<TEXT>
begin 644 xfor-20220331_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *Q!Q@# 2(  A$! Q$!_\0
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ME HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X
MOXK_ /(NV_\ U]+_ .@/11\5_P#D7;?_ *^E_P#0'HKY',O]X?HCWL'_  CM
M****^N/!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9R@,G+_<YZ\5[M_P2_M?%47C[Q1J$$\=M\/X; KKC7G^H>3!,04DX#J-Y)/
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M $",?*G4@,23GT_]LB&VUC]A?P1J,WB./QY>6NHP1Q>)VA9'NN)D=AO);G:
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M)'.R3)@PD;@7 QN*XK[(_9#UJ[T7]LCXX^#K!H[3PU]INM0&GPPHJ+.+A$#
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M==3^TE^TU\-+7]G_ $[X+?"!;S4-!1T:YU2]B>,&-93*0HD"NTCR_,S%5 '
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M3[B6X:WFDO(+%FMY&5$N')#@E P"@;"O;(K:IC'"S2TT]=?R^9G'#\UTWW_
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MS),@8XQ\Q!)ZDDYKQ'7OCUX[\1?%2/XBW7B"X7Q=#*LL%]#A/("Y"QH@&T(
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MQQ6\FCQND2A-PY61WR&#L&!)!!(Q@FO6-8_X*=?&'5=!FTZ*'PYIEQ)'Y?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM#GU_P )I:W-IX7\R)[J\;[3&X5HS()(BGS%@4;@=NM?G-14QP<8J/*_AO\
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M_P#0'HKY',O]X?HCWL'_  C],O\ AU/_ -51_P#+?_\ NJC_ (=3_P#54?\
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MS/@+_AU/_P!51_\ +?\ _NJC_AU/_P!51_\ +?\ _NJOOVBC^T,3_/\ @O\
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M:*/[0Q/\_P""_P @^JT?Y?S/@+_AU/\ ]51_\M__ .ZJ/^'4_P#U5'_RW_\
M[JK[]HH_M#$_S_@O\@^JT?Y?S/@+_AU/_P!51_\ +?\ _NJC_AU/_P!51_\
M+?\ _NJOOVBC^T,3_/\ @O\ (/JM'^7\SX"_X=3_ /54?_+?_P#NJC_AU/\
M]51_\M__ .ZJ^_:*/[0Q/\_X+_(/JM'^7\SX"_X=3_\ 54?_ "W_ /[JH_X=
M3_\ 54?_ "W_ /[JK[]HH_M#$_S_ (+_ "#ZK1_E_,^ O^'4_P#U5'_RW_\
M[JH_X=3_ /54?_+?_P#NJOOVBC^T,3_/^"_R#ZK1_E_,^ O^'4__ %5'_P M
M_P#^ZJ/^'4__ %5'_P M_P#^ZJ^_:*/[0Q/\_P""_P @^JT?Y?S/@+_AU/\
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M]HH_M#$_S_@O\@^JT?Y?S/@+_AU/_P!51_\ +?\ _NJC_AU/_P!51_\ +?\
M_NJOOVBC^T,3_/\ @O\ (/JM'^7\SX"_X=3_ /54?_+?_P#NJC_AU/\ ]51_
M\M__ .ZJ^_:*/[0Q/\_X+_(/JM'^7\SX"_X=3_\ 54?_ "W_ /[JH_X=3_\
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M[0Q/\_X+_(/JM'^7\SX"_P"'4_\ U5'_ ,M__P"ZJ/\ AU/_ -51_P#+?_\
MNJOOVBC^T,3_ #_@O\@^JT?Y?S/@+_AU/_U5'_RW_P#[JH_X=3_]51_\M_\
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M6_\ _=5??M%']H8G^?\ !?Y!]5H_R_F? 7_#J?\ ZJC_ .6__P#=5'_#J?\
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MPQYJS1_:&)_F_!"^JT;OW?S/@+_AU/\ ]51_\M__ .ZJ/^'4_P#U5'_RW_\
M[JK[]HH_M#$_S_@O\A_5:/\ +^9\!?\ #J?_ *JC_P"6_P#_ '51_P .I_\
MJJ/_ );_ /\ =5??M%']H8G^?\%_D'U6C_+^9\!?\.I_^JH_^6__ /=5'_#J
M?_JJ/_EO_P#W57W[11_:&)_G_!?Y!]5H_P OYGP%_P .I_\ JJ/_ );_ /\
M=5'_  ZG_P"JH_\ EO\ _P!U5]^T4?VAB?Y_P7^0?5:/\OYGP%_PZG_ZJC_Y
M;_\ ]U4?\.I_^JH_^6__ /=5??M%']H8G^?\%_D'U6C_ "_F? 7_  ZG_P"J
MH_\ EO\ _P!U4?\ #J?_ *JC_P"6_P#_ '57W[11_:&)_G_!?Y!]5H_R_F?
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M\.I_^JH_^6__ /=5??M%']H8G^?\%_D'U6C_ "_F? 7_  ZG_P"JH_\ EO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.CQ_PD5Q\RY^RQ_+D9
M^^_.*T:X7X@?%+PQ\*9SJ?BK5?[+L9EAMD?RI)LR,9F V1[F&1&_S% /EQN)
MX'&_\-H?!O\ Z''_ ,IEY_\ &:J6YW8;+L;BH>TH4)2C=ZJ+:^](]LHKQ/\
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MG_PVA\&_^AQ_\IEY_P#&:/\ AM#X-_\ 0X_^4R\_^,T7#^QLS_Z!:G_@$O\
M(]LHKQ/_ (;0^#?_ $./_E,O/_C-'_#:'P;_ .AQ_P#*9>?_ !FBX?V-F?\
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M\-H?!O\ Z''_ ,IEY_\ &:+A_8V9_P#0+4_\ E_D>V45XG_PVA\&_P#H<?\
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M,_\ H%J?^ 2_R/;**\3_ .&T/@W_ -#C_P"4R\_^,T?\-H?!O_H<?_*9>?\
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MD<[6Q@GH>E>?6G[;'@[5O#L6L:1X:\8Z[;JKO>II>D"<Z:JLRYN6638F0A8
M,3M() S0!]!T5X;J7[87@F/38M0T'3?$GC6R\A;F[N/#>E-<QZ>K D"X8E1&
MP .5)R,<BN[B^-7@Z3X7K\0SK,<?A-H//^W.C9'S;-FS&[?O^7:!G/% ';T5
MX(W[97A2QGLY-:\+>-?#6B7CK'#X@UC0V@L'W#*D/N+8(Y!V].>E>@?%+XT>
M&_A'I-A=ZQ)<WESJ4ODZ=IFEP_:+N^DP#MBC!&[J.20/F49R1D [NBO%/#W[
M67A37O%VA>%9=&\2Z)XEU:X: :5K.G"UN+8!"ZR2JS_<8*<%-W3D"LSX5_\
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M4 %%%% !1110!]1?\$\/^2U:U_V+\_\ Z4VU?H=7YX_\$\/^2U:U_P!B_/\
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M@8''2K%06/\ Q[C_ %WWF_U_WOO']/3VQ3Z"ZD]%%%(84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P
M]_P6 MWF_95L'2XLX%B\26CNEWMWS#RIUV09!/F9(;*X/EI+S@L&*F_X*\?\
MFH0_\@W_ )&"S_X_O];]R7_CV_Z;>O\ TR\ZBJ>R(CN_ZZ'VW1114EA1110
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M'@X7?GYC\K<53^'OQ)^)7A#XS:3\-?B!?:!XI;4[*>[M]5T93%=0B,9#7,6
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MR!F^4X)&6ZY89S0!D_';6-%N/VHO@=IT,T$NO6UW>23QQD&2*%H?D#^@8AB
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M;JCDGDE@<YYKK_$OPR\+^+O!R>%-2T>%_#L?E>7I]LS6T:")@T87RBI4*5'
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M8?[3VM>'_B%_P4(_9L:\O;+7O ES9K<Z?<VUPD]I<7)FFVE75BK@R1VW3@X
MYZ5]P_%*X\+:]X*\8>&]>O;"6W?1+B74;"65#(EHT;@R-&3D+\K88\94\\4
M:_@+QYH7Q.\':3XI\,ZC%JNA:I MQ:W471E/8@\JP.5*G!4@@@$&O%_VKOVR
M]%_9ADT'1XO#VH>-O&NOD_V;X=TMMLDBA@NYV"N5#,=JA48L0<#@UY)_P1_O
M+^X_9:U**Z+M9V_B2ZCLMW_/,Q0,P'/ WL_XDU]/_%N\^&OP[T^3XF>/+'0[
M5O#\6^+7KZRCDNK?[P5(7*F3<2[*JH<DN0!S0!XS^S7^WA9_&[XC7?P[\6>
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MLDYY- 'KU%<)\<?B</@[\+==\6?9/MTMC&HAMR<!Y7=8T#'LNY@3[ UY]9^
M_CUJMG!J\OQ:T?3;V6,3?V';>&XI;)6(R(_/9O-*\XW=>.] 'OE%<#\%_&WB
M7QKX5G?Q?X<F\->(K"[DL;N$PR);W#)C$]N7&6B8'@@GH>3UJY\4/ L7Q"T6
MSTZ^U1M/T*&\2ZU6W PM_;(K$V[MN&V-FVENN0I!&": .RHKQ/\ 9_L;/_A*
MO'.J>%+ :5\.;R6V32H(8_*M;BXC5UN;FVC'RK$_[M0R@*Y0L/4^V4 %%%%
M!1110!\/?\%@+AX?V5;!$M[.=9?$EHCO=[=\(\J=M\&2#YF0%PN3Y;R\8#%2
MC_@L!I]Q>_LJV$L-E'=QVGB2TGGD=RIMD,4\8E7##<VZ1(\$,,2L=N0&4IOH
M3&UV?<-%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHK@/A'\5?^%IKXM/]E_V9_8.O7.B?\?'G>?Y(7][]U=N=WW>
M<8ZF@#OZ**X3XU?%BS^"_@.X\27=A/JC+-';6]E;D*TTTC81=QX4>IYX'0GB
M@#NZ*Y/X:^)/$_BGP^U[XK\('P7J/G%$T\ZE'?%H\ B3?& !DDC:>1MKK* "
MBBJ6M:O;>']'O]4O&9+2R@DN9F5=Q"(I9B!WX!H NT5PD'Q(OO$WPGM/&?@[
MPW-XANK^WCNK'1KB[BLY)5=@,-(VY$(4EN_3'>NXA9Y(8VD3RI&4%DSG:<<C
M/>@!]%%% !1110 4444 %%%% !1165XLUW_A%_"VL:SY'VG^S[.:[\G?L\SR
MT+;=V#C.,9P: -6BN7^%_C;_ (61\/?#_BC[%_9W]K6:7?V7S?-\K<,[=^U=
MV/7 KSOXJ?M/6'PG^*^B^#]2T.XN+/4+6"YEU>&=0MHLMP8 9$(^Z&VY8-_%
MTXY /;**CN+B.TMY9YG$<,:EW=C@*H&23^%>2_ ;]HBU^.]]XFBL]#N=(MM'
M:W\N6ZF#/<I,K.C[ /D!55(Y.=W;% 'KU%%% !117 >%?BK_ ,)-\6O&_@G^
MR_LW_"-16<GV[[1O^T^?'OQLVC9MZ?>.?:@#OZ**X/XX_%+_ (4S\,]5\7?V
M9_;'V%H5^Q_:/(W[Y5C^_M;&-V>AZ4 =Y138I/,B1\8W '%.H ***Y#PG\3M
M*\::AXML],CN"_AN];3[IYE"*\RH&8)R25&0,D#D'C&"0#KZ*X3X(?%#_A<G
MPSTKQ=_9G]C_ &YIE^Q^?Y^SRYGC^_M7.=F>@QG%=W0 4444 %%4=<N[VPT6
M_N=.L/[4U"&WDDMK'SEA^T2!25CWMPFXX&X\#.:C\-WVH:GH&GW>K:9_8NIS
M0))<Z=]H6?[-(1EH_,7Y7P>-PX- &E117&:3\2(KOXF:UX)O[(Z=J-I;17]C
M(TP=-0M6^5I$X!5DD!5EYQE3D[L  [.BBB@ HHHH **** "BLKQ9KO\ PB_A
M;6-9\C[3_9]G-=^3OV>9Y:%MN[!QG&,X-9GPO\;?\+(^'OA_Q1]B_L[^UK-+
MO[+YOF^5N&=N_:N['K@4 =11110 4444 %%%% !117DFF^/O&%Y^T(GAO4=-
MAT;PNVBWEU:0F5)KF[DBN((Q.Y4$1J0YV(&)P27P<*H!ZW1110 4444 ?)G_
M  4,Q_PK?3/E7/\ :UI\V!G_ %-YQFO@*OOW_@H8X_X5OIB[U)_M:T.S>,C]
MS><[=W'UVCIU.,#X"J9[G]!\#_\ (G7^*7YA1114'Z %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7W5\&?'6D?#G]AMM;UOPI9>,]/CUIXV
MTG4"@B<M*H#'?&XRIY^[^5?"M=:OQ8\5+\.6\!C5,>%&N/M1T_[/%_K-P;=Y
MFS?U XW8IH\+-\N>9TZ5+I&<9/5K17O9K6_;;U/5OC%^UQ)\0_A__P (1X8\
M&:9X!\,32B:ZL].96\XA@P VQQJHW ,<+DE1SC(/N_[2GQ.\5>"]6^!6FZ#K
MM[I%G=6UO+<Q6<IC$YS"N),??7!/RG(Y/%? M=KXN^,WC'QY=Z!<Z[K'VZ?0
M46/3F^RPQ^0JE2!A$&[E5^]GI1<\ZMD%!5*"P\$J<.=M.[;<HV3UO=^K/N+Q
M-X%O_$/[=5]=Z-K+^&YK/PY'?75Y:6<-Q<RK_JBL8E1T5RNT;MI( QWJ"+QI
MIWQ!_93^+=QI]MXIFTVWBEC2^\87S75Q<2JH+%5)*Q!#M^5. 3V(KXTNOVAO
MB'>?$.'QR_B69?%,4 MEOX;>&/,0S\C1J@1EYZ,I[>@K6UO]K#XK^)+35K34
M_%\U[9ZK:&RN[62TMS"\1# A4\O:A(8Y9 &/'/ P[GAOAO&M44Y0?(J:O=JW
M([O:/O)]+O3MU/I3PO\ %S1[GX6_#_PWXINO'WP9U/3;:.'3M2TZTFCL=38*
MH5RHC/GJV%8J5QES\Q!)K<^%WPYU;P[^V;JDWCK6;/Q;X@;PXVHZ;J4%G%:O
M)\ZPAC"H"K*$#KSG@YR>WR3X'_:E^*7PY\/P:)H'BV>TTN#B&WFMH+D1#^ZI
MEC8J/8'%<K>?%;Q??>.$\8S^(K]_$Z.'34_-(E3 QA<<!<$C:!MP2,8-*YN^
M'<2W7A"481FI+^9WD[]8J45_,N>29]D7OCC1?%'P+^+%LME\3?%&FQI(EU=>
M-9M.9-+O5!*",&9'&'V91 V,+A03AOC3X>_#/Q+\5M<DT?PKIAU74HX&N6@6
M:.(^6"H+9=E!Y8<9SS70?$3]HOXC?%;1XM)\4>*+C4M-C</]E6&*!&8="XB1
M=^.V[.#S7&>&/%.K^"]<M=9T+4;C2M4M6W175JY1U[$>X(X(/!!(.10>YEN7
M8G 8>LH\JG)W2U<5HEK\.]M;)?/K]=^";RZ^+W[)_P 0_#^M:/#X)M_!L:2P
MS:1"]G%>SQ1$O'=1EB))"8T+$_Q.AP"!GXOKTGXB?M'?$?XK:.FE>*/%%QJ.
MFJP<VL<,-O&Y!R"XB1=^#R-V<'FO-J1TY5@JV#55U;+GES<L6VEHD]6DW=Z[
M:!1110>\?47_  3P_P"2U:U_V+\__I3;5^AU?GC_ ,$\/^2U:U_V+\__ *4V
MU?H=5QV/YYXV_P"1O+_#$****H^"*]W+Y<EJ/.\G?+MV[-WF?*QV^W3.?;WJ
MQ5:[F$,EJ#<Q6_F2[ LF,R_*QV+R.>,]^%/%6:9*W9Q_Q6^$?A/XW^#9_"OC
M72?[:T">6.:2T^TS0;G1MR'?$ZL,'T-?&/QX_P""4O@OQ!JW@F3X5Z#I'AJP
MM-1\SQ%%JFL:B[7EINC_ '<63+AL"3H4^\.?3[^HI%'S)\??V#O!?Q:^%/A7
MPIX;N)_ NH^#3N\-:M:/)/)8C(8QL7?>ZE@K9W[E95(/4'Y1\??\$U/VB_C)
MX@BO_'7Q-\&ZA/;6;6<6JPPR+>W$87"1W#):QM*#@ M([E03C/0_J310!X!^
MQ#\.?&?PA^!MCX*\9^&M$\.W>BW$EM;OHEV9TU"/.XW4F?NN[,<Y.3C.U!A1
MY/\ MW?LF_&7]ISQMX6E\(^(?"FG^$= C6YBTW7IICYM]O):66$6TL4BA B@
M/D8,@(PQS]KT4 ?)GP!^&O[6_AGXE:3=?%'XG^$?$7@6&.5+K2])M(XYG/E,
M(MI6PBP%?:?OC@=^E>8^.OV!_C-X3\:>/!\$/BCIOA?P+X[GDGUC2-45EE@\
MPMO2$K!)Q^\D 93$VW:I)QNK] :* /C;X@_L7>,]$_8TTGX'?"?Q'I=C<22C
M^WM6UF::V^VQON><)Y,<A >0HNT_\LQM+'G/G7PQ_9?_ &U?A/X;T?PSX;^*
M_P /='\,Z;M2.PM;*/[F[+$L=,W,[<DLQ+$DDG)S7Z'44 ? _P"U)^QY^T'\
M9OVC++XA^%_%O@NPTS0%B3P[::R\LYM"%!>5H'M)8?,,F6W<_=C/!48]F_9F
M\"_M->%_&&I7/QK^(GAOQ?X=DL3':6FBVZ1RQW/F(0[%;.#Y=@<?>/)''<?2
M5% !1110 4444 %%%% !1110 4444 %06,GFVX;SO/\ F8;]NWHQ&,>W3\*G
MJO8S">W#BXCNAN8>9%C;PQ&.IY&,'W!I]!=2Q1112&%%%% !1110!X!\9O$/
MPA\3^(I-"U+PW+X[\:6A7_1/#5B\VI6I#<$W,97R I(SND7'!Q6M\#?#/Q.T
M74IY?$>HS6WA1HV%KHFN7R:KJD3;C@M=QH@"XQ\K-,<<;J]@L]+L]-:X:TM(
M+5KB4S3&&-4,LAZNV!RQ]3S5F@ KP+]L&-(? _@Q(T5%'C#2\*HP/]8QKWVN
M"^,7PK_X6UHNC:?_ &I_97]G:Q:ZMYGV?SO,\EB?+QN7&<_>R<>AH [VO OV
MBP;?XM? J]F_X\D\12V[$L0/-DAQ'^H->H?%G4+[2OAKXCO=,U=M"U"WLWE@
MOTM%NFC=1D;8FX<G&T+ZL*P/$'PQ_P"%Q_![1=$\9RW5MK7V:TO)+^T*Q7-I
M?HBDRQD#"L&+#@8P2!B@#COVWF63X%R6:H9;J\U?3[>VC5<L\AN%( ]\*U-\
M#J;+]LGXAQ7 Q+=>'-/GM\L?]6IV-@?[U7=!_9SUV]\6Z%K7Q"^(]]X^AT";
M[3I>G/IL-E!',!A990A/FNO4,<'/U(/1?%;X(MX]\0:3XIT#Q)>>"_&>EQ/;
MV^L6<"3J\+')BFA?B5,Y(!(P23S0!R'Q'Q>?M@?"6"!"\]KI.J7$Y4?<C9-B
MDGTW CZGWI_[%?[CX3ZI92<7EGXBU*WNAN)/F";)SGV(KJ?A5\#Y? OB;5?%
MGB/Q/=^-O&>I0+:2ZM=6Z6Z0VZG(BAA3(C4G!(!P2!TYSA^(OV=];M?%VMZ]
M\/?B)?> &UZ7S]5L5TZ&^MYI<8,L:R$>4[<DL,DD]J ,_P" )%U\=_CS>0(?
MLC:M96XDQA3)' 1(![@]?J/6C]LA_LWA?X?WK\6UGXUTR>>0D (@,@R2>V2/
MSKTOX1_"K3/@_P"$1HFG3W%]++/)>7NHWC;KB\N9#EY9#W)P!] .O4Z/Q#^'
M^C?%#P?J7AG7[=KC3+Y-KA&VNC @JZ'LRL 0?4<@CB@#HZ\ _8_?[5IGQ/O(
MQFVNO'.IR0R @AU_=C(([9%*O[/_ ,3([(:,GQXUA?#83R/LYT6V-]Y.,;?M
MF=^_'\>,UZAX)^&NF_#3X>P>$_"K/IEO;0.D%U*!-()6R3,^<!VW'<1P.V .
M* *WQBU?P9I_@J:Q\>NB>'=8E32Y!)#*Z,\N=@)C4F/D<.<!2 <@XKRN/]F'
MQEX%0+\-_C#K^C6<*;;?2==B34K6-1TC3=@1H.G"D@>IKT^Y^%O_  F'PL?P
M=\0-3'C)[B)DO-2^R)9M*V\LCK&A*QLORX([KGN:\^M?@!\3=%M4TO1?CQJ]
MMH,8\N.WO]$MKR[6//W?M+$-G' ../3M0!T7[/7Q1\0>/;/Q-HOB^SM+;Q5X
M7U$Z9?2Z>6-M<_*"LJ9'&><KVX.!G WOC%\.-1^*&@66D6FM6VEV27:7%[;7
MEB]W#?QIDB"14FB;86VD@-\VW!X)!=\//A%IOPL\'W^C^'KNZ74+YY;FYUJ_
M(N;JXNG',\I. Y!P<<#CW)KH/!>DZSH?AFRL?$&O?\)-K$083ZK]C2T\\EB0
M?*0E5P"!QUQGO0!7\'Z7XDTF.2'7-4T6_MD1$M8M'T>2P$(&1@[[F8$8P  %
MQCOVZ.BB@ HHHH **** /B3_ (*\67VO]E"&3^S?M_V7Q!9S>=Y_E_8ODE3S
MMO\ RTSO\K9_TVW?P45#_P %@%1OV5;#?IDFH,OB2T9)D9@+$^5.//8#@J03
M%AN,SJ<Y"@E4]D1'=_UT_KM^I]PT445)84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7R5\.=0NM)^"W[2-[8W,UE>V_B/7
MI8;BWD,<D3B%"&5@<@@\@BOK6OG+PO\ "7Q9IOPE^.>BW&E>7J7B75]7NM*@
M^TQ'[1'/$JQ-N#X3<0>'(([XH XFS^'/CO4/V=+3XCW?Q=\70^)K70!J]M;6
M]X%L?+2$2(DL6,S.57YG=CEF)(/0T_V@H[OXL?L[_##QM?ZYK%A?7D^FQ7%G
MI]UY-I)),PWS&/!_>*02C9^7/2O>+7P/K<?[+*>$&LL>(AX1_LLV?FI_Q\_9
M/+\O?NV??XSG'OBO/_$7P>\7WW[+_P ._"4&D;_$.DW>F2WMG]IA'E+$^9#O
M+[&P/[I.>V: .<^-GQ'C^#.I>$/A7<_$C7M TB:UEU'5/&&HF34-5DB:5]D$
M;I&2&+!AOV_*JKZ8/.>!_CYX<\$_%+PCIO@WXM>(OB1HFO7Z:;J.E^*(YYI[
M9I/EBN(9Y(H\ .0"@Z@GCNON/QI^&?BV3X@>&OB5\/Q8W?B31[>2PO-)U%_+
MCU&S<[O+63^!PQ)!.!SG/R[67PWJWQJ\>>+](FU;0++X7^&+&0RWUK_:$&JW
MFI<?+&K*FV*/U/#\<&@#D8+'Q+^T=\4O'EM_PG>N^#_"'A6]&D6EKX7NQ:W%
MQ<JN99)9=I) / 7I]""6VO$'PY\:+^SSXS\/^-/&%U>SV,5S/8:WHUTT%Y<V
MD<9:..YS&!DX*N 6W*?O9Y-;4/"OQ*^#/Q,\6Z[X%\,VGCWPYXJF2^FTN34H
M]/N+&\"[7</(-KHW!QUZ#C&6Z+P#\./'-Q\.?&Z>-=:%SXF\5?:F2R%S)+9:
M4DD;)'!%DG"KG)*CG/\ %C) /$[?3=2^&O[ MUKVC^*_$7]HW]A8744DNHM_
MQ+\SQ*8[4J%,49!(V@GK7IGQ2\5>*?%_Q*\%?"SPWX@G\+KJ&DMK.L:S;*&N
M_LZ_(L<+-]UF<'+=1P<\$-R=Q\._B;XA_9'UKX:7_@==.UO3;>SLM.>/5[:9
M-36.X1GD'S 185,X<\Y]>*[_ .*7PO\ %T/B_P (?$7P+'8W?B;1+!M-O='U
M"7RH[^U89V+(,A75R2,\'.<\88 YG5;;Q/\ LT_$'P*$\;:_XS\&>)M371;V
MT\3W N[FVN)!^YEBFV@@9!RO3 /4D%<ZUT#Q=\5?VDOBOX>_X6%XC\.>%-,7
M3V:VT>[\N8.]OE5A=@WDKD.S;!\QQGI70+X-^)'QP^(/A'5_'?AJQ\">%_"]
MY_:<6D)J2:A=7MVHQ$QDC 144Y/KU&#G*]9\,_ >N^'_ (\?%KQ%?V/V?1M=
M.F_V=<^=&WG^5 RR?*&++@D#Y@,]LT <C\#=<\5^%_B)\4_AS>Z]>^-$\.PV
MUYI%WK$@:Y;SHB_E2R]6Y*#<?0G@' \3\"^.K#Q>L@\;?'CQK\/?BF)I!/IE
M^YL]+LY QV!H&01%0I7*M(I/H*^B_"?PW\3:?^T)\6/$CPMIFDZ[I]C;Z9JB
MO#*?-CA",PCR2-K?WU ..XKAO$&G?&?7O#<GA+Q;\)_"_P 1+U5>"'Q;=:C;
M1VOS9"S-;%!(K*#SY>T\<4 ?2WAUII- TUKC48-7G-M&9-0MHQ'%<MM&954,
MP56/( ) SU->+_':#4+CQ=9+X@^*UO\ #/X?_8VVIINI)9:K>W6><2.G"*I'
M"$GU'((] ^"/P^N/A7\*?#?A6\O?[0N]-MO+FN%)VERQ9@N>=H+%1GL!P*\:
M^)OPO\7Z3\?-0\>:?\/-)^+&EZAI\%K!8ZC?06TNEO'U,9G!7:W)R 3ESTYR
M 87[/WQ,$'[1%YX'\/?$C4_B3X-FTA[T7.M2M<7%K<HX!03LJ[Q@YX^7Y@.H
M-+\)_!/B_P"-6M?$S^U?B?XMT70=-\57UG8VNBZAY,ZLK X,S!F$2J4"Q+A1
M\Q[UT/@?X8_$:']I#1_'GB+1-*L=)FT6?3OL6BSH8M)4-NBC<L5:5F.<LBX!
M;L!7=?LZ^ ]=\")\0QKEC]A.K>+;[4[/]]')YMM((]C_ ",=N=IX;!&.10!Y
M=X)^.GB3X?\ P+^+-QKNI/XFU?P+J]QI%EJ-TGSW'S)'"TN#EL.V22<D<9[T
MNO\ P7\>VOP9U;Q=<?%7Q%J'BR?19;N^TVZG1]'E1H2TL"6^T!/ERHD4C!YP
M,XK<\*?L]ZKKWAGXX^'/$UL=)M/%WB"ZO-.NA)'-F-B&AFVHQQAU4[6VGCM5
M*^A^/^K?#:]^'EQX0T>"X737T]_&$>KQO%=1B,I^[ML*ZRNO 9RJ@DD@#B@#
MT_\ 9?\ ^3>OA_\ ]@B#_P!!KQ_XZ>!T^)'[2&J^&V0227_PWN$@W=IA=EHF
M_!U4_A7NGP'\,ZGX+^#?@_0]9MOL>J:?IT4%S;^8K^6X'(W*2I^H)%<[=^ ]
M=D_:LL?&*V.?#D?A1]->]\Z/BX-R7";-V_[O.=N/>@#@=:^*.H>/_P!E7PG;
MVLSP^*/&3V_AEF4_.DY<Q7;G'(PD<S>V13O@WX2A;XG?'_PUIT\^E0!=-L+:
M>SE:*6W LBB,CJ05*\$$'M4GPY^!7BG0?VB-6U#4K>-/A]I=Y>ZQH.V5#NN[
MQ8Q*-@8LH0"4#*CEB1G-=S\*O >N^&_C-\7-=U&Q^S:5KMU8R:=<>=&WGK'
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M-YSC?C\=@Z?>/0? -??W_!0QO^+:Z8.?^0O:G[QQ_J;SMG%? -3/<_H/@?\
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M^:?074GHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%^W5X3UWQ=\/].M="T74=:N$U.VE:'3K22=PHBNP6(1"< LHZ_Q#@9Y^(O\
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MS_\ $5^O5%'*'_$0,5_SXC][/R%_X4?\1_\ HG_BC_P37/\ \11_PH_XC_\
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MFN?_ (BC_A1_Q'_Z)_XH_P#!-<__ !%?KE;P^7/=/Y$,7F.&\R,_-+\BC<_
MY&-O4\*.>PL4<H?\1 Q7_/B/WL_(7_A1_P 1_P#HG_BC_P $US_\11_PH_XC
M_P#1/_%'_@FN?_B*_7JBCE#_ (B!BO\ GQ'[V?D+_P */^(__1/_ !1_X)KG
M_P"(H_X4?\1_^B?^*/\ P37/_P 17Z]44<H?\1 Q7_/B/WL_(7_A1_Q'_P"B
M?^*/_!-<_P#Q%'_"C_B/_P!$_P#%'_@FN?\ XBOUZHHY0_XB!BO^?$?O9^0O
M_"C_ (C_ /1/_%'_ ()KG_XBC_A1_P 1_P#HG_BC_P $US_\17Z]44<H?\1
MQ7_/B/WL_(7_ (4?\1_^B?\ BC_P37/_ ,11_P */^(__1/_ !1_X)KG_P"(
MK]>J*.4/^(@8K_GQ'[V?D+_PH_XC_P#1/_%'_@FN?_B*/^%'_$?_ *)_XH_\
M$US_ /$5^O5%'*'_ !$#%?\ /B/WL_(7_A1_Q'_Z)_XH_P#!-<__ !%'_"C_
M (C_ /1/_%'_ ()KG_XBOUZHHY0_XB!BO^?$?O9^0O\ PH_XC_\ 1/\ Q1_X
M)KG_ .(H_P"%'_$?_HG_ (H_\$US_P#$5^O5%'*'_$0,5_SXC][/R%_X4?\
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MH_\ !-<__$4?\*/^(_\ T3_Q1_X)KG_XBOUZHHY0_P"(@8K_ )\1^]GY"_\
M"C_B/_T3_P 4?^":Y_\ B*/^%'_$?_HG_BC_ ,$US_\ $5^O5%'*'_$0,5_S
MXC][/R%_X4?\1_\ HG_BC_P37/\ \11_PH_XC_\ 1/\ Q1_X)KG_ .(K]>J*
M.4/^(@8K_GQ'[V?D+_PH_P"(_P#T3_Q1_P"":Y_^(H_X4?\ $?\ Z)_XH_\
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MH_\ !-<__$4?\*/^(_\ T3_Q1_X)KG_XBOUZHHY0_P"(@8K_ )\1^]GY"_\
M"C_B/_T3_P 4?^":Y_\ B*/^%'_$?_HG_BC_ ,$US_\ $5^O5%'*'_$0,5_S
MXC][/R%_X4?\1_\ HG_BC_P37/\ \11_PH_XC_\ 1/\ Q1_X)KG_ .(K]>J*
M.4/^(@8K_GQ'[V?D+_PH_P"(_P#T3_Q1_P"":Y_^(H_X4?\ $?\ Z)_XH_\
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M$499F. !ZFL/_A/_  O_ -#)I'_@=%_\55*+ELB)3C'XG8WJ*P?^$_\ "_\
MT,FD?^!T7_Q5'_"?^%_^ADTC_P #HO\ XJJ]G/LR/;4_YE]YO45@_P#"?^%_
M^ADTC_P.B_\ BJ/^$_\ "_\ T,FD?^!T7_Q5'LY]F'MJ?\R^\WJ*P?\ A/\
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M>SGV8>VI_P R^\WJ*P?^$_\ "_\ T,FD?^!T7_Q5'_"?^%_^ADTC_P #HO\
MXJCV<^S#VU/^9?>;U%8/_"?^%_\ H9-(_P# Z+_XJC_A/_"__0R:1_X'1?\
MQ5'LY]F'MJ?\R^\WJ*P?^$_\+_\ 0R:1_P"!T7_Q5'_"?^%_^ADTC_P.B_\
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M?^%_^ADTC_P.B_\ BJ/9S[,/;4_YE]YO45@_\)_X7_Z&32/_  .B_P#BJ/\
MA/\ PO\ ]#)I'_@=%_\ %4>SGV8>VI_S+[S>HK!_X3_PO_T,FD?^!T7_ ,51
M_P )_P"%_P#H9-(_\#HO_BJ/9S[,/;4_YE]YO45@_P#"?^%_^ADTC_P.B_\
MBJ/^$_\ "_\ T,FD?^!T7_Q5'LY]F'MJ?\R^\WJ*P?\ A/\ PO\ ]#)I'_@=
M%_\ %4?\)_X7_P"ADTC_ ,#HO_BJ/9S[,/;4_P"9?>;U%8/_  G_ (7_ .AD
MTC_P.B_^*H_X3_PO_P!#)I'_ ('1?_%4>SGV8>VI_P R^\WJ*P?^$_\ "_\
MT,FD?^!T7_Q5'_"?^%_^ADTC_P #HO\ XJCV<^S#VU/^9?>;U%8/_"?^%_\
MH9-(_P# Z+_XJC_A/_"__0R:1_X'1?\ Q5'LY]F'MJ?\R^\WJ*P?^$_\+_\
M0R:1_P"!T7_Q5'_"?^%_^ADTC_P.B_\ BJ/9S[,/;4_YE]Y=C"_\)%.<?-]E
MCYP.F]_;/ZX]JT:Y-/'7AO\ MN:3_A(-)$9MT42?;8L$AGR,[_<=N_7TO?\
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M\+_]#)I'_@=%_P#%4?\ "?\ A?\ Z&32/_ Z+_XJCV<^S#VU/^9?>;U%8/\
MPG_A?_H9-(_\#HO_ (JC_A/_  O_ -#)I'_@=%_\51[.?9A[:G_,OO-ZBL'_
M (3_ ,+_ /0R:1_X'1?_ !5'_"?^%_\ H9-(_P# Z+_XJCV<^S#VU/\ F7WF
M]16#_P )_P"%_P#H9-(_\#HO_BJ/^$_\+_\ 0R:1_P"!T7_Q5'LY]F'MJ?\
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MS[,/;4_YE]YO45@_\)_X7_Z&32/_  .B_P#BJ/\ A/\ PO\ ]#)I'_@=%_\
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M\51[.?9C]M3_ )E]YO45@_\ "?\ A?\ Z&32/_ Z+_XJC_A/_"__ $,FD?\
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M_P"ADTC_ ,#HO_BJ/^$_\+_]#)I'_@=%_P#%4>SGV8>VI_S+[SRKP_\ L._
MOPK\0(O&NE?#G3+/Q##.+J&99)C!#*""KQVY<PH00""J#!&1@U;^,7[&_P (
M/C[XIB\1^//"1U[68K9;-+@ZI>6X6%69E4)#,B]78YQGFO2O^$_\+_\ 0R:1
M_P"!T7_Q5'_"?^%_^ADTC_P.B_\ BJ/9S[,/;4_YE]YY/\+OV'?@E\%_&EEX
MM\&^"O['\06:R+!>?VK?3[ Z%'^269E.58CD=ZG^)'[$_P $OBYXP;Q5XK\
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M_%4>SGV8>VI_S+[S>HK!_P"$_P#"_P#T,FD?^!T7_P 51_PG_A?_ *&32/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/C8_\
M"03KN.W[+&=N_C[[\[=_Z[!_O'&%T*SXS_Q/YQN/_'K'\O./OOSUQ^GX^FA5
M2(CU"BBBI+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH KVZ[9[H^7,FYP=TDFY7^1>4&X[1VQ@<@G'.38JO;X\^ZP)@=XSY
MA.T_*OW/;Z=\U8IL2"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M_AJ7_J6/_)__ .U5X+11]1P_\OXO_,/[6QO\_P""_P CWK_AJ7_J6/\ R?\
M_M5'_#4O_4L?^3__ -JKP6BCZCA_Y?Q?^8?VMC?Y_P %_D>]?\-2_P#4L?\
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MAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?$G_  5X_P"34(?^0;_R,%G_ ,?W^M^Y+_Q[?]-O7_IE
MYU%4_P#@L.F[]EO2#Y-O+M\46K;IY=C1_P"CW(W1C<-[\[=N&^5G;;\NY"F^
MA$=V?<]%%%(L**\LT?\ :@^&6O>.QX-L?$ZR^)#=260LFLKE/WR%@R>8T83.
M5/\ %@]LY%=+\2OBQX4^#^BV^K>+M672+"XG%M%(8)9BTA5FVA8U9NBDYQCB
M@#KJ*YKX>_$CP[\5/#B:]X6U'^U-)>1X5N/(DARZG##;(JMQ]*Z6@ HHHH *
M*** "BBN,^('QB\(?"V\T6U\4:O_ &9<:S*T%BGV::;SG!4$9C1@O+K]['7Z
MT =G1110 444R::.WA>65UBBC4L[N0%4 9))/04 /HKS'P?^TQ\-/'_C%?"W
MA[Q1'JNMMYFV""UGV,$!+$2F/RR  >0V#VKTZ@ HHHH **** "BBB@ HHHH
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M/+F0IO'R2*P ;_ED?6D_:.^,_BRS^,7@#X9?#_6!I.L:M*)M2NUMHK@Q6['
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M$OBL:G+I7PKL9FMM.TMK2#==R;0!F0IY@ '[QL-PSJHR 17,_M<>,]4^,7Q
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MU.&>&#RR/,G#NTKKN0;8UZ,!Q]:];^)?Q^\'_";Q-X>T+Q#=W$5_KC%;=;6
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MXT\&:'\/_P!O_P"'5OX:TNUT*TNK-)I+;3XE@BW%+A&(10 ,JH!QUY]30!]
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MP;)_Z-BKZ8KYG_9G_P"1\O\ _L&R?^C8J^F*^8S#^.S[_)O]T7JPHHHKSCW
MHHHH CN'\NWD?S$BVJ3YDGW5XZGD<#ZBDM9/.M87\V.;<@;S(AA'R.J\G@_4
M_6G3,5A<JRHP4D,_W1QU/M26[,\$;,R.Q4$M']TG'4>U/H+J24444AA1110
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M) /:_P!H7X\7FG>$_@UXB^'7B2VFT?Q7XZTC2IKZT2*XBN[&=I!+&"ZMMR4
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MF?$^\C&;:Z\<ZG)#(""'7]V,@CMD4 >B?''XG#X._"W7?%GV3[=+8QJ(;<G
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M ?!CX'>%?@/X9N-&\+V]Q_IERU[?ZAJ%PUS>7]RV-TT\K<NQP/0>@%=_110
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M\9ZE MI+JUU;I;I#;J<B*&%,B-2<$@'!('3G.'XB_9WUNU\7:WKWP]^(E]X
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M%5R0,D#/3FO#/^$ \4?]"WJ__@#+_P#$U]-@I15%)L^!S6G.6*;BFS HK?\
M^$ \4?\ 0MZO_P" ,O\ \31_P@'BC_H6]7_\ 9?_ (FN_P!I#N>1[&I_*_N,
M"BM__A /%'_0MZO_ . ,O_Q-'_" >*/^A;U?_P  9?\ XFCVD.X>QJ?RO[C
MHK?_ .$ \4?]"WJ__@#+_P#$T?\ " >*/^A;U?\ \ 9?_B:/:0[A[&I_*_N,
M"BM__A /%'_0MZO_ . ,O_Q-'_" >*/^A;U?_P  9?\ XFCVD.X>QJ?RO[C
MHK?_ .$ \4?]"WJ__@#+_P#$T?\ " >*/^A;U?\ \ 9?_B:/:0[A[&I_*_N,
M"BM__A /%'_0MZO_ . ,O_Q-'_" >*/^A;U?_P  9?\ XFCVD.X>QJ?RO[C
MHK?_ .$ \4?]"WJ__@#+_P#$T?\ " >*/^A;U?\ \ 9?_B:/:0[A[&I_*_N,
M"BM__A /%'_0MZO_ . ,O_Q-'_" >*/^A;U?_P  9?\ XFCVD.X>QJ?RO[C
MHK?_ .$ \4?]"WJ__@#+_P#$T?\ " >*/^A;U?\ \ 9?_B:/:0[A[&I_*_N,
M"BM__A /%'_0MZO_ . ,O_Q-'_" >*/^A;U?_P  9?\ XFCVD.X>QJ?RO[C
MHK?_ .$ \4?]"WJ__@#+_P#$T?\ " >*/^A;U?\ \ 9?_B:/:0[A[&I_*_N,
M"BM__A /%'_0MZO_ . ,O_Q-'_" >*/^A;U?_P  9?\ XFCVD.X>QJ?RO[C
MHK?_ .$ \4?]"WJ__@#+_P#$T?\ " >*/^A;U?\ \ 9?_B:/:0[A[&I_*_N,
M"BM__A /%'_0MZO_ . ,O_Q-'_" >*/^A;U?_P  9?\ XFCVD.X>QJ?RO[C
MHK?_ .$ \4?]"WJ__@#+_P#$T?\ " >*/^A;U?\ \ 9?_B:/:0[A[&I_*_N,
M"BM__A /%'_0MZO_ . ,O_Q-'_" >*/^A;U?_P  9?\ XFCVD.X>QJ?RO[C
MHK?_ .$ \4?]"WJ__@#+_P#$T?\ " >*/^A;U?\ \ 9?_B:/:0[A[&I_*_N,
M"BM__A /%'_0MZO_ . ,O_Q-'_" >*/^A;U?_P  9?\ XFCVD.X>QJ?RO[C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\/?\
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M/^AA_P#))/\ &MZBCG?E]R#V4>[^]_YF#_8^N?\ 0P_^22?XT?V/KG_0P_\
MDDG^-;U%'._+[D'LH]W][_S,'^Q]<_Z&'_R23_&C^Q]<_P"AA_\ ))/\:WJ*
M.=^7W(/91[O[W_F8/]CZY_T,/_DDG^-']CZY_P!##_Y))_C6]11SOR^Y![*/
M=_>_\S!_L?7/^AA_\DD_QH_L?7/^AA_\DD_QK>HHYWY?<@]E'N_O?^9@_P!C
MZY_T,/\ Y))_C1_8^N?]##_Y))_C6]11SOR^Y![*/=_>_P#,P?['US_H8?\
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M91[O[W_F8/\ 8^N?]##_ .22?XT?V/KG_0P_^22?XUO44<[\ON0>RCW?WO\
MS,'^Q]<_Z&'_ ,DD_P :/['US_H8?_))/\:WJ*.=^7W(/91[O[W_ )F#_8^N
M?]##_P"22?XT?V/KG_0P_P#DDG^-;U%'._+[D'LH]W][_P S!_L?7/\ H8?_
M "23_&C^Q]<_Z&'_ ,DD_P :WJ*.=^7W(/91[O[W_F8/]CZY_P!##_Y))_C1
M_8^N?]##_P"22?XUO44<[\ON0>RCW?WO_,P?['US_H8?_))/\:/['US_ *&'
M_P DD_QK>HHYWY?<@]E'N_O?^9@_V/KG_0P_^22?XT?V/KG_ $,/_DDG^-;U
M%'._+[D'LH]W][_S,'^Q]<_Z&'_R23_&C^Q]<_Z&'_R23_&MZBCG?E]R#V4>
M[^]_YF#_ &/KG_0P_P#DDG^-']CZY_T,/_DDG^-;U%'._+[D'LH]W][_ ,S!
M_L?7/^AA_P#))/\ &C^Q]<_Z&'_R23_&MZBCG?E]R#V4>[^]_P"9@_V/KG_0
MP_\ DDG^-']CZY_T,/\ Y))_C6]11SOR^Y![*/=_>_\ ,YJ#2-;,US_Q/Y1A
MQ_K+)-I^4?=YZ?US4_\ 8^N?]##_ .22?XUK6[ W%T \S$. 5D0A5^5>$.!D
M=\@GDD9XP+%-S?\ 20E2CW?WO_,P?['US_H8?_))/\:/['US_H8?_))/\:WJ
M*7._+[D/V4>[^]_YF#_8^N?]##_Y))_C1_8^N?\ 0P_^22?XUO44<[\ON0>R
MCW?WO_,P?['US_H8?_))/\:/['US_H8?_))/\:WJ*.=^7W(/91[O[W_F8/\
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M^-']CZY_T,/_ )))_C6]11SOR^Y![*/=_>_\S!_L?7/^AA_\DD_QH_L?7/\
MH8?_ "23_&MZBCG?E]R#V4>[^]_YF#_8^N?]##_Y))_C1_8^N?\ 0P_^22?X
MUO44<[\ON0>RCW?WO_,P?['US_H8?_))/\:/['US_H8?_))/\:WJ*.=^7W(/
M91[O[W_F8/\ 8^N?]##_ .22?XT?V/KG_0P_^22?XUO44<[\ON0>RCW?WO\
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M]##_ .22?XUO44<[\ON0>RCW?WO_ #,'^Q]<_P"AA_\ ))/\:/['US_H8?\
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MBODFBC^S:7=_A_D']N8G^6/W/_,^MO\ A>G@?_H-_P#DI/\ _$4?\+T\#_\
M0;_\E)__ (BODFBC^S:7=_A_D']N8G^6/W/_ #/K;_A>G@?_ *#?_DI/_P#$
M4?\ "]/ _P#T&_\ R4G_ /B*^2:*/[-I=W^'^0?VYB?Y8_<_\SZV_P"%Z>!_
M^@W_ .2D_P#\11_PO3P/_P!!O_R4G_\ B*^2:*/[-I=W^'^0?VYB?Y8_<_\
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M@O\ %7]GF*7XG>*OB!X>O?'5HT\7C&\%[<V]ZL3X>"7:&2)D,F8SD JI!Y-
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MB?XM6%[X?U[5'_:4^)_C'XR6,-Q<2:;\,EN'\-6TR;F11$;=(Y+=0!NDWX8
MFOT-_9K\>:G\4/@#X \5ZTT;ZOJVC6]U=R1J%5Y2@W, .!DY.!P,T ;7Q$^*
M&E?#23PQ%J-O>7EQXBUJWT*Q@L41G\^4,V]MS*!&JH[,<D@+P"<"NPKP/QA(
M/''[8W@30@/,M/!>@7GB2YX!47-TPM+8'@X8(MTPY'7/->^4 %%%% !1110
M4444 %5[%@]N")I)QN8;Y4"M]X\8P.!T''0#KUJQ4%C)YMN&\[S_ )F&_;MZ
M,1C'MT_"GT%U)Z***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /A[_@L!I]Q>_LJV$L-E'=QVGB2T
MGGD=RIMD,4\8E7##<VZ1(\$,,2L=N0&4J;_@KQ9?:_V4(9/[-^W_ &7Q!9S>
M=Y_E_8ODE3SMO_+3._RMG_3;=_!15/9$1>K_ *Z?UV/MNBBBI+"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S_$,U_;Z#J4
MNEK$^IQVTC6JSH7C,H4E R@@D;L9 (/N*\6_91_:&U+XY?#W7-:\26MAINH:
M3>O#,M@CI$(A&KABKLQ!^^#S_#7O-?F=J?C(_L]^)OVC/!RNMN^KQ;=/CSL)
M\V;"A,=Q#=,W_ /:@#W/]F3]M+7?C5\7KKPMK6G:18:;-;3S:<]G'*L[,C J
MKEY&!_=[B<*.5]*[[1?V@?$/B/\ :RU7X96%CIK>&M)LS/=W;12?:MPB0G:W
MF;<>9*B_<SUKYW\5^!E_9MU3]G'QBR?9/)A2RUB1L($,C&23<<CG;<SCGL@S
M6O\ LYMI'BI/V@/B7XAUN[T/0]2GELQK5FP6XA@=W=Q&2K$-M:%1A<\@ 9Q@
M ^Q1\6_ S:T-''C/P\=6,OD_8/[5@\_S.FSR]^[=[8S7G_[6WQMUSX"_#6R\
M0^'[33[R]GU..R:/4HY'C"-'*Q(".ASE!W]>*^._BM#X&NOV<BO@'X5ZU#I%
MA<1G_A/-=MK>WFFS-M)$@^:<,25PN O' VXKT/\ :BO[G5/V&?A==7D\ES<R
MRZ:TDTK%G<_9)N23R3[F@#[-L_%]E:^"=/\ $.NWUEI%K+9PW%Q<W,RP01%T
M4GYG. ,G R:\/_:"_:DN_A_>?#M_!%QX?\1Z5XDOI;2XO-YND 1X5_=O%*%W
M#S&SG/(%>._M#0O\2/BM\"?AIJ=Y-:^&KO2[.YGC@?:7>3*'VW;8MJDYQO;'
M6N>_:L^ _A/X*_$;X82>$+>;3;+5+_$VGO=23QJ\<L.)%\PLP+!\'G'RC&.X
M!^@/B#Q-H_A+3C?ZYJUCHU@&"&ZU"Y2"(,>@W.0,FET#Q)I'BK3UO]$U6RUB
MQ8E1=:?<)/$2.H#(2*^#?VA=6M?'_P"V-)H/BS0/$WBWPQX>LD$.@>&;=IYY
M2T22,^U74JI:0;G4@X1!]-O]G/1=6\$?M/.?"'@3QQX5^&VMVKQW-KXBTR:*
M.WD6)G4EV+# =<*S,6_>%>] 'V%)\3_!T/\ :N_Q9H:?V2_EZANU*$?8VR1M
MF^;]V<JPPV.0?2M;0?$6E>*=-34-%U.SU>P<D)=6%PD\3$=0&4D'\Z^"?A#\
M%_#?QH_:J^,%GXK@FO\ 2=/U*[N!IZ7$D*2RFY=59BC*WR@MC!_B_ Z_[(6@
MZGHWBOX_^"?#6HS6HMEFM=->1_\ 53J\\44N>S#Y<D>@]!0!]B:G\6O VBZL
MVEZAXS\/V&IJP1K*ZU2".8,> "C.&S[8K)^-GQHT;X(_#^Z\3:ELO"NU+2QC
MN$CDNW8@!4W'G .XX!(4$X-? ^@ZYX9^$O@^[\!_&?X,WL-U/+,#XJMK>/[>
MY9B08I9% ;:>C)*5('0\Y]E^.VC_  Y\2_L0Q:AX+DFU+1M"EB.F2W-S,TUK
M*TZ)*CAFZ[9&&TC: 05&,&@#Z$^&'Q^\,>-OAA8>*]2\0Z#I;^1%)J47]I1"
M/3Y)"0L<K,WR,3P V"2.E==:_$CPE?:U;Z1;>*-%N-6N(UFAL(M0A:>6-EWJ
MZQAMQ4J0P(&"#GI7Q/XN^''AWP;_ ,$_6UG1].^QZEK]OI=SJ4WGR/Y\@G7#
M;68A?O-PH YKT#X"_!SPM\,_@#:?%I-).H>/(/#]UJJ:C>7$K8)A=E4(6V !
M,+G;G!//- 'H/BSQ1XL\+?$;QE%J?Q1\'Z%HVH:2T?AG2=2O+>"ZM;TH@260
M/%N9-^\_>?J/E/0=]\.[O7O!_P +;*Z^)GB72;W5K=));_6X9$ALRAD8QMNV
M1J $*#.T<^O4_)/[*?[-/A'X_?#G6_&OCTWFO>(=6U&XC^U?;)(WMR ,OA2
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M=/,)_P!)MSY>XX'RW'.-^/QV#I]X]!\[U]3@?X*/S[-_]Z84445WGBA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'K?[,__(^7_P#V#9/_ $;%7TQ7S/\
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MUGX;20QZ1JG@/QC_ ,)!\.]8OKQ)K>\ABF:6!)5C=G1?GD4A@"/,4@'::O\
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M=*?074GHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M./)7R]N,H?X^F*]!^&OP%\ _"&:XG\)>&K;2;J=?+DNM\D\Q0D$IYDC,P4D
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M&YM;CETF.'R6\(V_AV6;"^6#N$B*2>N[@$8[9YKY8UR.#1_%5\EAN-M:WCB
M3(RMM5SM#*P# X R#@U5&O[;[-OZ]"<5A%AK>_?5KIT]&_QL_([#2/@IJEYX
M U;Q3J$KZ5#:1&6WMY8,O<J!R?O#:.F#@Y_GG^&_AM_PD7P_U_Q/_:/V?^RF
MV_9?(W>;PI^]N&WKZ'I7I_AGQSK'CWX7_$B_UBY\Z1;=%CC0;8XEVMPJ]OYG
MN:J_!C4Y=&^"OC:^@MXKF:WE\Q(YXQ(F0BX)4]<=?PKF=:JE*^Z:7WV.Z.&P
M\I0Y4[.,GKW5]?\ @'@E%>[:YJ\_Q*^ -[KVO)#)K&EWRPP7PB5'D4L@(^4
M8_>$8''R@]:\)KMIU'43NK-.QY.(HJBX\KNI*ZZ!1116QRGK?[,__(^7_P#V
M#9/_ $;%7TQ7S/\ LS_\CY?_ /8-D_\ 1L5?3%?,9A_'9]_DW^Z+U84445YQ
M[@4444 ,G)6&0@J#M/\ K/N]._M26S%K>(DH24&3']WIV]J692T+A55V*D!7
M^Z>.A]J2W5D@C5E1&"@%8_N@XZ#VI]!=22BBBD,**** "BBB@ HHHH ****
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M!:^,?#&OZYH'BCQ+X.OHK6;7_"\RR6&JVTL>^"Y3:2JN=KJZ*<*R''H/HF@
MHHHH *@LV+09)B)W-_J?N_>/Z^OOFIZAM4>.':\<<3;F.V+[OWC@]!R>I]R:
M?074FHHHI#"BBB@ HHHH **\H\0>"_B3H'B#4=:\'^-+34K&ZE\Y_#GBJW+V
M\62"WDW,6)(A@8"E749S4?PI_:$LOB1XDO?#-SI$NF^(K%"]R+&ZBU.P !(P
M+J E5;C[L@1NV* /6F8(I9B%4#))Z"O"+_\ ;(\'PR7D^G>'_%_B'0+-V2Y\
M2:1HK3:;#M.')E+ X7N0I'<9KV_5--M]9TV[T^[0RVEU"\$R!BI9&4JPRI!'
M!/(.:\X\;^+/!G[,_P )X8%MEM=+M8C9Z7HT1:66[E.=L*!B6<L3R3GJ2: .
M\\,>)M+\9>'[#6]%O(]0TJ^B$UO<Q9VNI^O((.00>000>15/QYX^T+X9^%[S
MQ#XCOET_2K4#?*5+$L3A550"68D@  5PO[+'@+5?AS\$]"TG6X!9ZG(TUY-9
MKP+;S9&D$6.VT, 1V.:YC]IB-=9^)7P0T*Z.[3KGQ(UY-$S85W@CW1@^O+'C
MOF@#H/!7[4'AKQ=XJT_P]>:'XF\(:EJ89M-'B;2S9I?X&3Y+;F!XYYQG('4@
M5T7Q3^-OA[X2MIMKJ,6HZMK6IEA8:)HMHUU>W6W&XI&,# SU)'MFN _;8A^S
M_!VUUN$B/4M$UO3[ZSGV@M'*)U3(/;AS^51>$477/VTO&]Y=$22Z/X:LK2T5
MF_U:2MYCE1]<\^_O0!Z#\*_CCX?^+5QJ=C86^J:-KFEE?MVB:Y:&UO;<-]UF
M0DC!]B<<9QD9P_''[3GAOP=XIO?#MGHOB7QAJVGJKZC#X7TMKP6 (R#,VY0.
M/0G'?%<[X\C_ +%_;&^&=]:$12ZQHFI6-YM4#S8H@)4!/?#$'\*3]BN);KX;
M>(-=D/F:CK7B34+N[F+99G\S: ?3A>GO[T >N_#WXA:%\4O"EGXB\.7GVW3+
MG<%8J4=&4X9'4\JP/8_49!!JI\2/B=I?POM=#GU6WO+A-8U:WT> 6:(Q6:;=
MM9]S+A!M.2,GV->7_L[Q_P!C?&3XZ:';D)IL.M6U_% J@*DMQ 7E( ]2%_*G
M?M@?\@;X9_\ 8]:7_P"U* /?:Y#X=?$[2_B8OB$Z7;WD']AZO/HUS]L1%WS1
M;=S)M9LH=PP3@^PKKZ\"_9'_ -7\6?\ L?-3_E%0![?KNN:?X9T>\U;5;N*P
MTVSB::XN9CA(T49)->++^U]H%PHO++P1\0-2T C>-?M?#LC6)C_YZ!RP;;CG
M.WO7:_'_ .&ES\7OA'XA\*65VEE>7T2&"67/E^9'(LBJ^ 3M)0 D XSG!QBO
M,;']HOQY\.[.&R^('P;UVWBM(0DNJ^%=FH6K!1CS-BX\I,#.&<D#\J /=/!?
MC;0_B)X;M->\.ZC%JNDW0)BN(<CH<$$$ JP/!4@$=Q6CJVK6FA:7=ZEJ%Q':
M6-I$T\\\APL:*"68GT !KS[X WGP[U?PC>ZQ\-C&ND:I?R7EW$DDI\N[8*9
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M2@#A5G+$#_;/I7N5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\31_P@'A?_H6](_\ 8O_ (FMZBCVD^[#V-/^5?<8/_" >%_^A;TC_P  8O\
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M(V#F4$/T_B]Z?0GJ2T444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEX/U'1/A9X8U3PIH/A-8+86.H6D%NBB7S&7RQ%-)DY1BQ;!);)R237T;110
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M5O455X=G]_\ P"+5.Z^[_@F#_P )MI__ #[ZO_X)KS_XU1_PFVG_ //OJ_\
MX)KS_P"-5O447AV?W_\  "U3NON_X)@_\)MI_P#S[ZO_ .":\_\ C5'_  FV
MG_\ /OJ__@FO/_C5;U%%X=G]_P#P M4[K[O^"8/_  FVG_\ /OJ__@FO/_C5
M'_";:?\ \^^K_P#@FO/_ (U6]11>'9_?_P  +5.Z^[_@F#_PFVG_ //OJ_\
MX)KS_P"-4?\ ";:?_P ^^K_^":\_^-5O447AV?W_ / "U3NON_X)@_\ ";:?
M_P ^^K_^":\_^-4?\)MI_P#S[ZO_ .":\_\ C5;U%%X=G]__   M4[K[O^"8
M/_";:?\ \^^K_P#@FO/_ (U1_P )MI__ #[ZO_X)KS_XU6]11>'9_?\ \ +5
M.Z^[_@F#_P )MI__ #[ZO_X)KS_XU1_PFVG_ //OJ_\ X)KS_P"-5O447AV?
MW_\  "U3NON_X)@_\)MI_P#S[ZO_ .":\_\ C5'_  FVG_\ /OJ__@FO/_C5
M;U%%X=G]_P#P M4[K[O^"8/_  FVG_\ /OJ__@FO/_C5'_";:?\ \^^K_P#@
MFO/_ (U6]11>'9_?_P  +5.Z^[_@F#_PFVG_ //OJ_\ X)KS_P"-4?\ ";:?
M_P ^^K_^":\_^-5O447AV?W_ / "U3NON_X)@_\ ";:?_P ^^K_^":\_^-4?
M\)MI_P#S[ZO_ .":\_\ C5;U%%X=G]__   M4[K[O^"8/_";:?\ \^^K_P#@
MFO/_ (U1_P )MI__ #[ZO_X)KS_XU6]11>'9_?\ \ +5.Z^[_@F#_P )MI__
M #[ZO_X)KS_XU1_PFVG_ //OJ_\ X)KS_P"-5O447AV?W_\  "U3NON_X)@_
M\)MI_P#S[ZO_ .":\_\ C5'_  FVG_\ /OJ__@FO/_C5;U%%X=G]_P#P M4[
MK[O^"8/_  FVG_\ /OJ__@FO/_C5'_";:?\ \^^K_P#@FO/_ (U6]11>'9_?
M_P  +5.Z^[_@F#_PFVG_ //OJ_\ X)KS_P"-4?\ ";:?_P ^^K_^":\_^-5O
M447AV?W_ / "U3NON_X)@_\ ";:?_P ^^K_^":\_^-4?\)MI_P#S[ZO_ .":
M\_\ C5;U%%X=G]__   M4[K[O^"8/_";:?\ \^^K_P#@FO/_ (U1_P )MI__
M #[ZO_X)KS_XU6]11>'9_?\ \ +5.Z^[_@F#_P )MI__ #[ZO_X)KS_XU1_P
MFVG_ //OJ_\ X)KS_P"-5O447AV?W_\  "U3NON_X)@_\)MI_P#S[ZO_ .":
M\_\ C5'_  FVG_\ /OJ__@FO/_C5;U%%X=G]_P#P M4[K[O^"8/_  FVG_\
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M_P"-5O447AV?W_\  "U3NON_X)@_\)MI_P#S[ZO_ .":\_\ C5'_  FVG_\
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M_@F#_P )MI__ #[ZO_X)KS_XU1_PFVG_ //OJ_\ X)KS_P"-5O447AV?W_\
M "U3NON_X)@_\)MI_P#S[ZO_ .":\_\ C5'_  FVG_\ /OJ__@FO/_C5;U%%
MX=G]_P#P M4[K[O^"8/_  FVG_\ /OJ__@FO/_C5'_";:?\ \^^K_P#@FO/_
M (U6]11>'9_?_P  +5.Z^[_@F#_PFVG_ //OJ_\ X)KS_P"-4?\ ";:?_P ^
M^K_^":\_^-5O447AV?W_ / "U3NON_X)@_\ ";:?_P ^^K_^":\_^-4?\)MI
M_P#S[ZO_ .":\_\ C5;U%%X=G]__   M4[K[O^"8/_";:?\ \^^K_P#@FO/_
M (U1_P )MI__ #[ZO_X)KS_XU6]11>'9_?\ \ +5.Z^[_@F#_P )MI__ #[Z
MO_X)KS_XU1_PFVG_ //OJ_\ X)KS_P"-5O447AV?W_\  "U3NON_X)@_\)MI
M_P#S[ZO_ .":\_\ C5'_  FVG_\ /OJ__@FO/_C5;U%%X=G]_P#P M4[K[O^
M"8/_  FVG_\ /OJ__@FO/_C5'_";:?\ \^^K_P#@FO/_ (U6]11>'9_?_P
M+5.Z^[_@F#_PFVG_ //OJ_\ X)KS_P"-4?\ ";:?_P ^^K_^":\_^-5O447A
MV?W_ / "U3NON_X)@_\ ";:?_P ^^K_^":\_^-4?\)MI_P#S[ZO_ .":\_\
MC5;U%%X=G]__   M4[K[O^"8/_";:?\ \^^K_P#@FO/_ (U1_P )MI__ #[Z
MO_X)KS_XU6]11>'9_?\ \ +5.Z^[_@G*KXLLEU>6Y-KJGE- D8/]CW6[(9B?
M^7?..1_$1_LCDFY_PFVG_P#/OJ__ ()KS_XU5V-1_P )%.WRY^RQCMG[[^W]
M?P'4Z-.3AV_'_@$Q5375?=_P3!_X3;3_ /GWU?\ \$UY_P#&J/\ A-M/_P"?
M?5__  37G_QJMZBE>'9_?_P"K5.Z^[_@F#_PFVG_ //OJ_\ X)KS_P"-4?\
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M#3W0$S2[7 *%0!'\JG ..>N>_6K%%X=OQ_X DJG=?=_P3!_X3;3_ /GWU?\
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M)KS_ .-5O447AV?W_P# "U3NON_X)@_\)MI__/OJ_P#X)KS_ .-4?\)MI_\
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M=?=_P3!_X3;3_P#GWU?_ ,$UY_\ &J/^$VT__GWU?_P37G_QJMZBB\.S^_\
MX 6J=U]W_!,'_A-M/_Y]]7_\$UY_\:H_X3;3_P#GWU?_ ,$UY_\ &JWJ*+P[
M/[_^ %JG=?=_P3!_X3;3_P#GWU?_ ,$UY_\ &J/^$VT__GWU?_P37G_QJMZB
MB\.S^_\ X 6J=U]W_!,'_A-M/_Y]]7_\$UY_\:H_X3;3_P#GWU?_ ,$UY_\
M&JWJ*+P[/[_^ %JG=?=_P3!_X3;3_P#GWU?_ ,$UY_\ &J/^$VT__GWU?_P3
M7G_QJMZBB\.S^_\ X 6J=U]W_!,'_A-M/_Y]]7_\$UY_\:H_X3;3_P#GWU?_
M ,$UY_\ &JWJ*+P[/[_^ %JG=?=_P3!_X3;3_P#GWU?_ ,$UY_\ &J/^$VT_
M_GWU?_P37G_QJMZBB\.S^_\ X 6J=U]W_!,'_A-M/_Y]]7_\$UY_\:H_X3;3
M_P#GWU?_ ,$UY_\ &JWJ*+P[/[_^ %JG=?=_P3!_X3;3_P#GWU?_ ,$UY_\
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MBE*VEAPOKS/^OO9]MT445!J%%%% !1110 4444 %%%% !1110 4444 %%%%
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MU5X+11]1P_\ +^+_ ,P_M;&_S_@O\CWK_AJ7_J6/_)__ .U4?\-2_P#4L?\
MD_\ _:J\%HH^HX?^7\7_ )A_:V-_G_!?Y'O7_#4O_4L?^3__ -JH_P"&I?\
MJ6/_ "?_ /M5>"T4?4</_+^+_P P_M;&_P _X+_(]Z_X:E_ZEC_R?_\ M5'_
M  U+_P!2Q_Y/_P#VJO!:*/J.'_E_%_YA_:V-_G_!?Y'O7_#4O_4L?^3_ /\
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M5?M'?&/Q'HUYX>O_ (D65S-IVBWJD7$&G6]G+';&1?X7<,QV^@4C@U]0Z?\
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M&C7'AV30)=)L9-"DMS:/I;VR&U:$C:8C%C:4(XVXQB@#YGV+'_P3%0*H4?\
M"KE. ,==-!-'A.-8_P#@F/$$4*/^%8S'"C'73W)_6OI;_A$]#_X1C_A&_P"Q
MM/\ ^$=^R_8?[(^RI]D^S[=GD^3C9Y>WY=N,8XQ1%X3T.#PR/#<>C:?'X=^R
MFQ_LA;5!:?9RNTP^3C9Y>WY=N,8XQ0!^?WBK_DRC]D'_ +&_PW_Z#-6_X@^/
MGB3XD_'+XF>&=?\ C]I/[/NA>$M1_LZTT66ULX[[4X@NX7?VBZ;^+J%C'W67
M('5OM2;X;^$KC1-'T:7PMHLFD:--%<:9I[Z?";>QECSY;PQ[=L;)D[2H!&3B
MJGBCX/\ @/QQK%OJWB/P1X<\0:K;@"&^U32;>YGC .1M=T+#!]#0!\*?L,:M
MIEQ^T9^T'J%CK'B7XD:3+HMC/;:AKZ;]0UJ%4<$HL@0,C$%8P0J[2@X%<IH:
M_"7PUX#N_''P2_:<UKX*"'[1=GP#XDOH;M+:5<EH!IKN7+%AU_?DY.-W2OTL
MM_!OA^S\22>(8-#TV#7Y+9;)]5CM(UNFMU(*PF4#<4! (7.!CI6%JGP1^'6N
M>)O^$CU+P#X7U#Q#O63^UKK1K:6[WK]UO-9"^1V.: ,+]EWQYXF^)W[/_@?Q
M3XQL5L/$>J:>L]U&L?EA\DA)0G\/F(%?'0;^.*]2H'' X%% !1110!\/?\%@
M+."Z_95L9)H;V62V\26DT+6B!HXG,,Z;YR?NQ[7=<CGS'B'0FBI_^"O'_)I\
M/_(2_P"1@L_^/'_5?<F_X^?^F/I_TU\FBJ>R(CN_ZZ'VU1114EA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO=D1?*!V%>H:?X-\$_\ #.<6DFST\>#GT$2N0J^48_(#&;=_>_BWYSGG.>:
M,7]J3Q)J6AZ-\.YM'U2ZT_[9XQTVVFDL;AHO/@?S-T;%2-R-@94\' KT#XC?
M%SP?\)=/AO/%NOVNBQ3$B%)=SRRXQG9&@+MC(S@'&1GK7R5#>ZC?_LI_L^R:
MFTC3KXQT^*-I!@F%)KA8OP\L)CVQ7JWA>SM=<_;<\<R:Y#%<7NE:%9?V&MP
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MV>:&^7._..W>O*/VTM$T/^S_ (;:C-;V\>M0^*["WLY@H$OE%B9(QWV<*<=
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MG_AN/3<=?^$%DQ_X&&L_]B*PL[WX;Z]K5W!#+XJU#7;X:W<2 -.9A)_JW)Y
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M:X4445T'"%%%% 'K?[,__(^7_P#V#9/_ $;%7TQ7S/\ LS_\CY?_ /8-D_\
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MZ'DUR_AWXC>'[[P##X1\76%_-9VDYGM+S2V3SD)))4ASC^)N>>#TXS1)\2M
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MU#2[^![6ZM9UW)-$ZE61AZ$$BO/H_P!F7X:Q?!-OA&OAO'P];(.C_;KGO/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUIKVH>.O$/A+X1?"C5?BOJ/AR?[)K%\NJ6^E:=;7&,F!;B;(DD7G<H'!QU[
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MEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMM8,PN/-^[DQAPL>=N=@Z9XH [K]MO3[6^_9'^*L-RJ^2F@7$JC@ .B[X_\
MQY5KP3P%<2^)/VJ/V9)M6D:Z>V^%;7]O),"Y-S)$B2.#T#%#R>OZ5K>/-!_:
M7_:*\%1?"CQ;X!T/P-HM[)#;^(_&]KKT5VE]:HZM)]DM%7S(FDVC'F9')!VY
MR/1_V@O@7XI76OAIX^^$EOIK>*_A^LMG!H>HR^3;ZCILL0CDMA)CY' 1=C'
M&3DT 8/[; 6S^)'[-6I0R&'48_B#;6L;HV&\F6-A*OT(50?8^]?5,W^J?_=-
M?*7AOP#\6?V@/CEX+\;_ !5\%:?\-O"O@?SKO2_#<>L1:K=7FH2*$$\DL2A
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MW_\ B*.5?S?G_D'/+^1_A_F;U%8/]@ZM_P!#+=_^ UO_ /$4?V#JW_0RW?\
MX#6__P 11RK^;\_\@YY?R/\ #_,WJ*P?[!U;_H9;O_P&M_\ XBC^P=6_Z&6[
M_P# :W_^(HY5_-^?^0<\OY'^'^9O45@_V#JW_0RW?_@-;_\ Q%']@ZM_T,MW
M_P" UO\ _$4<J_F_/_(.>7\C_#_,WJ*P?[!U;_H9;O\ \!K?_P"(H_L'5O\
MH9;O_P !K?\ ^(HY5_-^?^0<\OY'^'^9O45@_P!@ZM_T,MW_ . UO_\ $4?V
M#JW_ $,MW_X#6_\ \11RK^;\_P#(.>7\C_#_ #-ZBL'^P=6_Z&6[_P# :W_^
M(H_L'5O^AEN__ :W_P#B*.5?S?G_ )!SR_D?X?YF]16#_8.K?]#+=_\ @-;_
M /Q%']@ZM_T,MW_X#6__ ,11RK^;\_\ (.>7\C_#_,WJ*P?[!U;_ *&6[_\
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M &#JW_0RW?\ X#6__P 11_8.K?\ 0RW?_@-;_P#Q%'*OYOS_ ,@YY?R/\/\
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MR_D?X?YF]16#_8.K?]#+=_\ @-;_ /Q%']@ZM_T,MW_X#6__ ,11RK^;\_\
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M5O\ H9;O_P !K?\ ^(HY5_-^?^0<\OY'^'^9O45@_P!@ZM_T,MW_ . UO_\
M$4?V#JW_ $,MW_X#6_\ \11RK^;\_P#(.>7\C_#_ #-ZBL'^P=6_Z&6[_P#
M:W_^(H_L'5O^AEN__ :W_P#B*.5?S?G_ )!SR_D?X?YF]16#_8.K?]#+=_\
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MJ_F_/_(.>7\C_#_,WJ*P?[!U;_H9;O\ \!K?_P"(H_L'5O\ H9;O_P !K?\
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M?_XBC^P=6_Z&6[_\!K?_ .(HY5_-^?\ D'/+^1_A_F;U%8/]@ZM_T,MW_P"
MUO\ _$4?V#JW_0RW?_@-;_\ Q%'*OYOS_P @YY?R/\/\S>HK!_L'5O\ H9;O
M_P !K?\ ^(H_L'5O^AEN_P#P&M__ (BCE7\WY_Y!SR_D?X?YF]16#_8.K?\
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M&6[_ / :W_\ B*/[!U;_ *&6[_\  :W_ /B*.5?S?G_D'/+^1_A_F;U%8/\
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M_P#H9-(_\#HO_BJ/9S[,/;4_YE]YO45@_P#"?^%_^ADTC_P.B_\ BJ/^$_\
M"_\ T,FD?^!T7_Q5'LY]F'MJ?\R^\WJ*P?\ A/\ PO\ ]#)I'_@=%_\ %4?\
M)_X7_P"ADTC_ ,#HO_BJ/9S[,/;4_P"9?>;U%8/_  G_ (7_ .ADTC_P.B_^
M*H_X3_PO_P!#)I'_ ('1?_%4>SGV8>VI_P R^\WJ*P?^$_\ "_\ T,FD?^!T
M7_Q5'_"?^%_^ADTC_P #HO\ XJCV<^S#VU/^9?>;U%8/_"?^%_\ H9-(_P#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFVG^S]$MOM-W+N<+\D>1NQNR>> ">U &Y13(9/.ACDV-'O4-M<889'0CUI]
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M3_?*GR_)!11178>4%%%% !1110 4444 %%%% !1110 4444 %%%% '>_ O\
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MT>Y.V,[3L?C=NRORJZ[OFVN5<_X*\?\ )J$/_(-_Y&"S_P"/[_6_<E_X]O\
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M_M"65QHFHP7FJ:UKLMA;R6DBR7:26X$;1*1EPQX!7.3TH ]6_9P_Y('\/O\
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MZ,;AO?G;MPWRL[;?EW(4WT(CNS[GHHHI%A1110 4444 %%%% !1110 4444
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MDKZVKYS,OXJ]/U9]SD?^[2_Q/\D%%%%>4?1!1110 4444 5[>0-/= 3-+M<
MH5 $?RJ< XYZY[]:L57MY!)/=*)UE*. 8P #%\JG:?7KG_@56*;$@HHHI#"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CN&VV\C%S& I.\#)7CK
MBDM6WVL+"0S H#YA&"W'7';-+<-LMY&\P184GS",A>.OX4EJ_F6L+B43!D!\
MP# ?CK^-/H3U):***104444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !5>YD"S6H,S1;I2 H4'S/D8[3QQTW9X^[COBK%5[F01S6JF=8=\I4(0#YOR
M,=H].F[_ (#30F6****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH KW
M<@CDM09VAW2[0JJ#YGRL=IXXZ9SQTJQ5>[E$<EJ#<+!OEVA6 /F_*QVCT/&?
M^ U8IDK=A1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ JO8R"2W#"9KCYF'F,H4\,1C  Z=/PJQ5>QD$UN&$ZW(W,/,4 #AB
M,<>G3\*?074L4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?$G_  5XL?M?[*$,G]F_;_LOB"SF
M\[S_ "_L64E3SMO_ "TSO\K9_P!-MW\%%'_!7BS^U?LH0R?V=]O^S>(+.;SO
MM'E_8ODE3SMO_+3._P K;_TVW?P453V1$=Y?UT7]=/U/MNBBBI+"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /GC]J"0'6M#3<,BWD.W(R,L.<
M;O;^Z.GWFQA?$Z^Q_$W@G1O&NN(FM69O8[:W4PKYTB!"S-N.%<==J]NPY/09
MW_"B_ __ $!/_)N?_P"+KW*&-IT:<823NCY+&957Q->56#5GWO\ Y'R317UM
M_P *+\#_ /0$_P#)N?\ ^+H_X47X'_Z G_DW/_\ %UO_ &E2[/\ #_,X_P"P
M\3_-'[W_ )'R317UM_PHOP/_ - 3_P FY_\ XNC_ (47X'_Z G_DW/\ _%T?
MVE2[/\/\P_L/$_S1^]_Y'R317UM_PHOP/_T!/_)N?_XNC_A1?@?_ * G_DW/
M_P#%T?VE2[/\/\P_L/$_S1^]_P"1\DT5];?\*+\#_P#0$_\ )N?_ .+H_P"%
M%^!_^@)_Y-S_ /Q=']I4NS_#_,/[#Q/\T?O?^1\DT5];?\*+\#_] 3_R;G_^
M+H_X47X'_P"@)_Y-S_\ Q=']I4NS_#_,/[#Q/\T?O?\ D?)-%?6W_"B_ _\
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M% !1110!7MYO,GND\^&7RW"^7&/FB^13M?D\G.[H.&''<V*AA=VFG#21NJN
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MX//..W!/-2_\/3/"O_0D:Q_X%14?4<3_ "?D)8BE=^\?;U%?$/\ P],\*_\
M0D:Q_P"!45'_  ],\*_]"1K'_@5%1]1Q/\@_K-+^8^WJ*^(?^'IGA7_H2-8_
M\"HJ/^'IGA7_ *$C6/\ P*BH^HXG^0/K-+^8^WJ*^(?^'IGA7_H2-8_\"HJ/
M^'IGA7_H2-8_\"HJ/J.)_D#ZS2_F/MZBOB'_ (>F>%?^A(UC_P "HJ/^'IGA
M7_H2-8_\"HJ/J.)_D#ZS2_F/MZBOB'_AZ9X5_P"A(UC_ ,"HJ/\ AZ9X5_Z$
MC6/_  *BH^HXG^0/K-+^8^WJ*^(?^'IGA7_H2-8_\"HJ/^'IGA7_ *$C6/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653087814424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">X4 PHARMACEUTICALS, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3181608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">61 North Beacon Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">529-8300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XFOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,823,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653087940024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 66,427<span></span>
</td>
<td class="nump">$ 81,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ResearchAndDevelopmentIncentiveReceivable', window );">Research and development incentive receivable</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,586<span></span>
</td>
<td class="nump">5,344<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">70,881<span></span>
</td>
<td class="nump">87,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">17,351<span></span>
</td>
<td class="nump">17,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">8,344<span></span>
</td>
<td class="nump">8,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,646<span></span>
</td>
<td class="nump">1,723<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">99,625<span></span>
</td>
<td class="nump">117,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,569<span></span>
</td>
<td class="nump">4,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">6,877<span></span>
</td>
<td class="nump">7,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">3,415<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,970<span></span>
</td>
<td class="nump">14,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LongTermDebtNonCurrentIncludingAccretion', window );">Long-term debt, net of discount and current portion</a></td>
<td class="nump">29,809<span></span>
</td>
<td class="nump">33,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">4,482<span></span>
</td>
<td class="nump">4,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">826<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">49,911<span></span>
</td>
<td class="nump">52,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 125,000,000 shares authorized as of each of March 31, 2022 and December 31, 2021; 30,809,476 and 28,127,657 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">354,638<span></span>
</td>
<td class="nump">347,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(304,836)<span></span>
</td>
<td class="num">(282,871)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">49,714<span></span>
</td>
<td class="nump">64,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 99,625<span></span>
</td>
<td class="nump">$ 117,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LongTermDebtNonCurrentIncludingAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt non current including accretion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LongTermDebtNonCurrentIncludingAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ResearchAndDevelopmentIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development incentive receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ResearchAndDevelopmentIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090818376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">30,809,476<span></span>
</td>
<td class="nump">28,127,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">30,809,476<span></span>
</td>
<td class="nump">28,127,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090379560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 14,113<span></span>
</td>
<td class="nump">$ 12,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">7,664<span></span>
</td>
<td class="nump">5,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (Loss) on Disposition of Assets</a></td>
<td class="num">(509)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">21,268<span></span>
</td>
<td class="nump">17,936<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(21,268)<span></span>
</td>
<td class="num">(17,936)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(913)<span></span>
</td>
<td class="num">(891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">176<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(674)<span></span>
</td>
<td class="num">(734)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(21,942)<span></span>
</td>
<td class="num">(18,670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(21,965)<span></span>
</td>
<td class="num">(18,676)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend on Class B Warrant price reset</a></td>
<td class="num">(2,259)<span></span>
</td>
<td class="num">(8,239)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (24,224)<span></span>
</td>
<td class="num">$ (26,915)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (1.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding&#8212;basic and diluted (in shares)</a></td>
<td class="nump">33,737,000<span></span>
</td>
<td class="nump">20,751,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL109261905-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12B<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL109261756-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653087405640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Redeemable Common Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Redeemable Common Shares, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable common shares, beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred shares, ending balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,305,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 72,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 267,077<span></span>
</td>
<td class="num">$ (119)<span></span>
</td>
<td class="num">$ (194,175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,885<span></span>
</td>
<td class="nump">6,041,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">49,640<span></span>
</td>
<td class="nump">$ 1,875<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">49,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period Shares Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,072,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_StockIssuedDuringPeriodValueWarrantsExercised', window );">Stock Issued During Period Value Warrants Exercised</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,676)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,426,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">105,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">318,008<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="num">(212,851)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Redeemable Common Shares, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,127,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 64,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">347,374<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="num">(282,871)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,512,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 5,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">5,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period Shares Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,965)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,809,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 49,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 354,638<span></span>
</td>
<td class="num">$ (119)<span></span>
</td>
<td class="num">$ (304,836)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090524984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (21,965)<span></span>
</td>
<td class="num">$ (18,676)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,459<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_NonCashInterestExpense', window );">Accretion of debt discount</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(120)<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets and research and development incentive receivable</a></td>
<td class="nump">1,633<span></span>
</td>
<td class="num">(711)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(713)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(984)<span></span>
</td>
<td class="num">(786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(236)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion', window );">Operating lease right-of-use asset, net of non-cash portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(20,229)<span></span>
</td>
<td class="num">(18,444)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisition of property, equipment and intangible assets</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(496)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants', window );">Proceeds from exercise of stock options and pre-funded warrants and issuance of shares of common stock under employee stock purchase plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee taxes paid related to net share settlement of vested restricted stock units</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts', window );">Proceeds from borrowings under loan and security agreements, net of issuance costs</a></td>
<td class="num">(114)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayments of Secured Debt</a></td>
<td class="num">(795)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts', window );">Proceeds from sale of shares of common stock, redeemable common stock and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">5,877<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,956<span></span>
</td>
<td class="nump">55,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(69)<span></span>
</td>
<td class="num">(143)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(15,364)<span></span>
</td>
<td class="nump">35,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">83,108<span></span>
</td>
<td class="nump">80,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">67,744<span></span>
</td>
<td class="nump">116,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Acquisition of property, equipment and right-of-use assets included in accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Acquisition of right-of-use asset financed by lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance costs not yet paid related to sale of shares of common stock, redeemable common stock and pre-funded warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset, Net Of Non-cash Potion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from borrowings under loan and security agreements, net of issuance costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of stock options and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ProceedsFromExerciseOfStockOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance or Sale of Equity, Net of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090595208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090569528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text">NATURE OF THE BUSINESS AND BASIS OF PRESENTATION<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X4 Pharmaceuticals, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a late-stage clinical biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases. The Company&#8217;s lead product candidate, mavorixafor, is a potential first-in-class, once-daily, oral inhibitor of CXCR4 and is currently in a Phase 3 clinical trial for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#8220;WHIM&#8221;) syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. The Company is also conducting a 14-day, proof-of-concept Phase 1b clinical trial of mavorixafor in patients with Severe Congenital Neutropenia (&#8220;SCN&#8221;) and chronic neutropenia disorders, and a Phase 1b clinical trial of mavorixafor in combination with ibrutinib in Waldenstr&#246;m&#8217;s macroglobulinemia (&#8220;Waldenstr&#246;m&#8217;s&#8221;). The Company is headquartered in Boston, Massachusetts and has an additional facility in Vienna, Austria. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern Assessment&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. As of March 31, 2022, the Company had $66.4 million of cash and cash equivalents. Based on its current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expense and capital expenditure requirements into the fourth quarter of 2022. However, as further discussed in Note 7, the Company has a covenant under its loan agreement with Hercules Capital Inc. (&#8220;Hercules&#8221;) that requires that the Company maintain a minimum level of cash, as defined, beginning on September 1, 2022. Based on its current financial projections, the Company believes it would be in violation of this covenant in the third quarter of 2022. If the Company is in violation of this covenant, Hercules could require the repayment of all outstanding debt. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the Company believes that, in the aggregate, these conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. Nevertheless, the accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. In order to fund its operations beyond the fourth quarter of 2022, the Company is seeking to raise funds potentially through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations and strategic alliances. If the Company is unable to obtain future funding when needed, the Company may be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or pre-commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. There is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in late 2019 and continuing into 2022, the outbreak of COVID-19 has resulted in the declaration of a global pandemic and adversely affected economic activity across virtually all sectors and industries on a local, national and global scale. Impacts to the Company&#8217;s business have included temporary closures or postponements of activation of its clinical trial sites or facilities, disruptions or restrictions on its employees&#8217; ability to travel, disruptions to or delays in ongoing clinical trials, including patient enrollment at a slower pace than initially projected and the diversion of healthcare resources away from the conduct of the Company&#8217;s clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as the Company&#8217;s clinical trial sites and hospital staff supporting the conduct of the Company&#8217;s clinical trials. While global vaccination efforts are underway and certain jurisdictions, including Massachusetts, where the Company is headquartered, have reopened businesses and governmental agencies, there remain limitations on the physical operations of businesses and prohibitions on certain non-essential gatherings, and the Company is unable to accurately predict the full impact that COVID-19 will have due to numerous uncertainties, including the duration of the outbreak, the result of vaccination efforts, resurgence of the virus, actions that may be taken by governmental authorities, the impact on the Company&#8217;s business including its clinical programs and timelines, and the impact to the business of its service providers and partners.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090238984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 17, 2022 (the &#8220;2021 Annual Report&#8221;). Since the </span><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date of those consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of the ongoing COVID-19 pandemic has been and, notwithstanding vaccination efforts, is expected to continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. Impacts to the Company&#8217;s business have included temporary closures or postponements of activation of its clinical trial sites or facilities, disruptions or restrictions on its employees&#8217; ability to travel, disruptions to or delays in ongoing clinical trials, including patient enrollment at a slower pace than initially projected and the diversion of healthcare resources away from the conduct of the Company&#8217;s clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as the Company&#8217;s clinical trial sites and hospital staff supporting the conduct of the Company&#8217;s clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biotechnology industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and the challenges of complying with applicable regulatory requirements. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it is expected also to have the effect of heightening many of the other risks and uncertainties discussed above.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including X4 Pharmaceuticals (Austria) GmbH, which is incorporated in Vienna, Austria (&#8220;X4 Austria&#8221;), and X4 Therapeutics, Inc. All significant intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet at December 31, 2021 that is presented in these interim condensed consolidated financial statements was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed consolidated financial statements are unaudited. The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC for interim financial statements. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s&#160;audited financial statements and the notes thereto for the year ended December&#160;31, 2021 included in the 2021 Annual Report. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&#8217;s condensed financial position, condensed results of its operations and cash flows have been made. The results of operations for the three months ended March&#160;31, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December&#160;31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and the constraint of variable consideration from contracts with customers. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The COVID-19 pandemic has impacted and is expected to continue to impact the clinical development timelines for certain of the Company's clinical programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of issuance of these condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of March&#160;31, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:60.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Waltham lease</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Vienna Austria lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Boston lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s lease agreements for its facilities in Massachusetts and Austria, the Company maintains letters of credit, which are secured by restricted cash, for the benefit of the respective landlord. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the sum of the total of amounts shown in the Company&#8217;s condensed consolidated statements of cash flows as of March&#160;31, 2022 and December&#160;31, 2021:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:62.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.758%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,744&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform an interim quantitative impairment test, whereby the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than its carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. There were no triggering events during the three months ended March 31, 2022 that necessitated an interim impairment test of goodwill. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASU 2021-04 was issued to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants for the purchase of common shares) that remain classified as equity following the modification or exchange. ASU 2021-04 is effective January 1, 2022 for the Company. The adoption of this standard did not have an impact on the Company&#8217;s consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13"), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. In accordance with ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326), Derivative and Hedging (Topic 815), and Leases (Topic 842)- Effective </span></div>Dates, as the Company meets the definition of a &#8220;smaller reporting company&#8221;, the Company has elected to defer the adoption of ASU 2016-13 until January 1, 2023. The Company expects that the adoption of ASU 2016-13 may accelerate the timing and could increase the level of credit loss expense in the consolidated statement of operations and will likely require an increased level of disclosure in the notes to the consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090275352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Funding Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License, Collaboration, and Funding Agreements</a></td>
<td class="text">LICENSE, COLLABORATION AND FUNDING AGREEMENTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Incentive Program</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses and capital expenditures incurred by the Company&#8217;s subsidiary in Austria. As of March&#160;31, 2022, the amount due under the program is $0.9 million, which amount was included in research and development incentive receivable in the condensed consolidated balance sheet. During the three months ended March&#160;31, 2022 and 2021, the Company recorded $0.1 million and $0.3 million, respectively, of income related to the program within the condensed consolidated statements of operations as other income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, a third party, who had previously acquired rights to certain intellectual property from the Company, terminated the arrangement and transferred these rights back to the Company. Also during the three months ended March 31, 2022, the Company transferred these rights to another third party in return for $0.5 million. The Company has no continuing involvement in any ongoing research and development activities associated with the intellectual property. The Company concluded that these third parties are "non-customers" as the underlying intellectual property transferred to and from these third parties supports potential drug candidates that are not aligned with the Company's strategic focus and, therefore, are not an output of the Company's ordinary activities. Accordingly, the Company accounted for the sale of the intellectual property as the sale of a non-financial asset under ASC Topic 610-20,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Gains and Losses from the Derecognition of Nonfinancial Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 610-20"), and included the gain as part of gain on sale of non-financial asset for the period ended March 31, 2022. </span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material modifications of the Company&#8217;s license or collaboration agreements during the three months ended March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653091530376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text">FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of March 31, 2022 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2021 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities: </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash equivalents consisted of money market funds invested in U.S. Treasury securities. The money market funds were valued based on reported market pricing for the identical assets, which represents a Level 1 measurement, or by using inputs observable in active markets for similar securities, which represents a Level&#160;2 measurement.</span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll-forward of the aggregate fair values financial instruments for which fair values are determined using Level 3 inputs:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:80.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.217%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Embedded Derivative Liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Embedded Derivative Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span> The fair value of the embedded derivative liability recognized in connection with the Company&#8217;s loan agreement with Hercules (Note 7), which is associated with additional fees due to Hercules upon events of default, was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of this embedded derivative liability, which is reported within other non-current liabilities on the condensed consolidated balance sheets, is estimated by the Company at each reporting date based, in part, on the results of third party valuations, which are prepared based on a discounted cash flow model that considers the timing and probability of occurrence of a redemption upon an event of default, the potential amount of prepayment fees or contingent interest upon an event of default and the Company&#8217;s risk-adjusted discount rate of 14%.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090567832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">PROPERTY AND EQUIPMENT, NET<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:58.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.635%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(857)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property and equipment was $133 thousand and $106 thousand for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090274392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_AccruedExpensesTextBlock', window );">Accrued Expenses</a></td>
<td class="text">ACCRUED EXPENSES<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,870&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AccruedExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AccruedExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653091468536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:58.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.635%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative accretion of end of term payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,415)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(795)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,809&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hercules Loan Agreement, As Amended</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into a Loan and Security Agreement (the &#8220;Hercules Loan Agreement&#8221;), as amended in December 2018, June 2019, March 2020, December 2020 and February 2022, with Hercules, under which the Company has borrowed an aggregate of $32.5 million of term loans to date. The Hercules Loan Agreement provides for maximum borrowings of up to $50.0&#160;million, which include, subject to Hercules investment committee&#8217;s sole discretion, a right of the Company to request that Hercules make additional term loan advances in an aggregate amount of up to $17.5 million through December 31, 2022.  Borrowings under the Hercules Loan Agreement accrues interest at a variable rate equal to the greater of (i)&#160;8.75% or (ii)&#160;8.75% plus </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;prime rate minus 6.0%.&#160;In an event of default and until such event is no longer continuing, the interest rate applicable to borrowings would be increased by 4.0%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Hercules Loan Agreement are repayable in monthly interest-only payments through January 1, 2023, and in equal monthly payments of principal and accrued interest from February 1, 2023 until the maturity date of the loan, which is July 1, 2024. The Company may prepay all, but not less than all, of the outstanding borrowings, subject to a prepayment premium of up to 1.0% of the principal amount outstanding as of the date of repayment. In addition, the Hercules Loan Agreement provides for payments of $1.3 million and $0.8 million payable on July 1, 2023 and July 1, 2024, respectively, which payments are accelerated upon the prepayment of the borrowings upon the Company&#8217;s election on upon default of the loan. Borrowings under the Hercules Loan Agreement are collateralized by substantially all of the Company&#8217;s personal property and other assets except for their intellectual property (but including rights to payment and proceeds from the sale, licensing or disposition of the intellectual property). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, on February 9, 2022, the Company entered into Amendment No. 3 the Hercules Loan Agreement. The amendment primarily added a financial milestone that if met by June 30, 2022 would modify the minimum cash covenant contained in the Hercules Loan Agreement, which is effective beginning September 1, 2022, as further described below. The Company concluded that the amendment represented a modification to the debt.  Accordingly, fees paid to third parties directly related to the amended debt were expensed as incurred and fees paid to Hercules in conjunction with the amendment were deferred and will be amortized to interest expense over the life of the debt arrangement using the effective interest method.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Hercules Loan Agreement, effective as of the earlier of (a) certain specified events impacting the Company&#8217;s Phase III trial of mavorixafor for the treatment of WHIM syndrome and (b) September 1, 2022, the Company at all times thereafter must maintain cash in an account or accounts in which Hercules has a first priority security interest, in an aggregate amount greater than or equal to the greater of (i) $30.0 million or (ii) 6 multiplied by a metric based on prior months&#8217; cash expenditures;  provided, however, that from and after the Company&#8217;s achievement of certain financing milestones through June 30, 2022, the Company must maintain cash in an account or accounts in which Hercules has a first priority security interest in an aggregate amount of $30.0 million. Following the achievement of certain operational performance milestones, the required level shall be reduced to the greater of $20.0&#160;million, or, if the Company had not met the financing milestones noted above, 3 multiplied by the current cash expenditures metric; and provided further, that subject to the achievement of certain milestones, this covenant will be extinguished. The Hercules Loan Agreement also restricts the Company&#8217;s ability to incur additional indebtedness, pay dividends, encumber its intellectual property, or engage in certain fundamental business transactions, such as mergers or acquisitions of other businesses, with certain exceptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized interest expense under the Hercules Loan Agreement as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months ended March  31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual effective interest rate of the Hercules Loan Agreement as of March 31, 2022 is 10.7%. There were no principal payments due or paid under the Hercules Loan Agreement during the three months ended March&#160;31, 2022. An end-of-term payment of $0.8 million was paid during the three months ended March 31, 2022 in accordance with the Hercules Loan Agreement. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future principal and end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands): </span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:83.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,097&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090250712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements for its facilities in Boston, Massachusetts, which is the Company&#8217;s principal executive office; Vienna, Austria, which is the Company&#8217;s research and development center; and Waltham, Massachusetts, which the Company has sublet to a third party. There are no restrictions or financial covenants associated with any of the lease agreements. </span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Vienna Austria Leases&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for approximately 1,200 square meters of laboratory and office space in Vienna, Austria (&#8220;Vienna Lease&#8221;), which commenced in February 2021 for a term of 7 years. The annual base rent for the Vienna Lease is approximately $300 thousand.</span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Boston Lease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company leases approximately 28,000 square feet of office space in Boston, Massachusetts (&#8220;Boston Lease&#8221;), which serves as the Company&#8217;s headquarters. Base rental payments are approximately $1.0 million annually, plus certain operating expenses. The term of the Boston Lease will continue until November 2026, unless earlier terminated. The Company has the right to sublease the premises, subject to landlord consent and also has the right to renew the Boston Lease for an additional five years at the then prevailing effective market rental rate. The </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company is required to maintain a security deposit in the form of a letter of credit for $0.9&#160;million for the benefit of the landlord. </span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Waltham Lease&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 6,000 square feet of office space in Waltham, Massachusetts (&#8220;Waltham Lease&#8221;). The Waltham Lease, as amended, commenced on January&#160;1, 2019, and expires approximately five years from the commencement date. The base rent is approximately $0.3 million annually. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#8217; right-of-use assets or lease liabilities. The Company is subleasing the space to a third party for the duration of the lease. The right-of-use asset is being amortized to rent expense over the five-year term of the lease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the Company&#8217;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three months ended March&#160;31, 2022 and 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:67.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March  31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use asset obtained in exchange for operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublease income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities due under lease agreements that have commenced as of March&#160;31, 2022 are as follows (in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:78.220%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,699)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090599688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES The Company has agreements with Contract Research Organizations (&#8220;CROs&#8221;) pursuant to which the Company and the CROs are conducting clinical trials of mavorixafor&#160;for the treatment of WHIM syndrome, Waldenstr&#246;m&#8217;s and SCN and chronic <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">neutropenia disorders. The Company may terminate these agreements by providing notice pursuant to the contractual provisions of such agreements and would incur early termination fees. The Company also has agreements with contract manufacturing organizations (&#8220;CMOs&#8221;) for the production of mavorixafor for use in clinical trials.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company to, among other things, indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of March&#160;31, 2022 or December&#160;31, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to any legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653091528216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Common Stock Warrants</a></td>
<td class="text">COMMON STOCK AND COMMON STOCK WARRANTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December 31, 2021, the Company&#8217;s Restated Certificate of Incorporation authorized the Company to issue 125,000,000 shares of common stock, par value $0.001 per share. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of the holders of any preferred stock that may be issued. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. No cash dividends have been declared or paid to date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2022, the Company entered into a securities purchase agreement pursuant to which it agreed to issue and sell to an investor (the &#8220;Investor&#8221;), in a private placement (the &#8220;Q1 2022 Private Placement&#8221;), 900,000 shares of common stock at a price of $1.80 per share, which represents the volume weighted average price per share of the Company&#8217;s common stock as quoted on the Nasdaq Stock Market for the thirty (30) consecutive-day trading day period ending on March 2, 2022, and pre-funded warrants to purchase 766,666 shares of common stock at a purchase price of $1.79 per pre-funded warrant (representing the price of  $1.80 per share minus the $0.01 per share exercise price of each such prefunded warrant). The pre-funded warrants are exercisable at any time after their original issuance date and will have no expiration date. The Q1 2022 Private Placement closed on March 7, 2022 and the Company received gross proceeds of 3.0 million, before deducting offering expenses payable by the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on March 3, 2022, the Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Investor, pursuant to which the Company agreed to register for resale the shares of common stock purchased by the Investor and the shares of common stock underlying the pre-funded warrants held by the Investor (the &#8220;Registrable Securities&#8221;). Pursuant to the Registration Rights Agreement, the Company filed a registration statement covering the resale of the Registrable Securities on April 22, 2022.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its issuance of common stock in a public offering that closed on November 29, 2019, the Company issued 5,416,667 Class B warrants, which are exercisable for shares of the Company&#8217;s common stock or pre-funded warrants to purchase shares of the Company's common stock. The Class B warrants were immediately exercisable upon issuance, had an initial exercise price of $15.00 per share and expire on a date that is the earlier of (a) the date that is 30 calendar days from the date on which the Company issues a press release announcing top-line data from its Phase 3 clinical trial of mavorixafor for the treatment of patients with WHIM syndrome (or, if such date is not a business day, the next business day) and (b) November 28, 2024. The Class B warrants have a contingent price adjustment feature pursuant to which the exercise price of the Class B warrants is adjusted to the lowest weighted average offering price at which the Company sells its common stock or certain securities convertible into or exercisable for the Company's common stock in one or more subsequent offerings, if the weighted </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">average offering price for such offering is below $15.00.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2022, the exercise price of the Class B warrants was adjusted to $1.80 as a result of the Q1 2022 Private Placement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with previous equity offerings, the Company has issued pre-funded warrants, which are exercisable into one share of the Company's common stock, are immediately exercisable upon issuance, and for which the remaining exercise price  is equal to or less than $0.01 per share.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a roll forward of outstanding warrants for the three month period ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Contractual Term (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable warrants to purchase common shares as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,257,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.96</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.80</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable warrants to purchase common shares as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,023,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47</span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company&#8217;s outstanding warrants to purchase shares of common stock consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares of<br/>Common<br/>Stock Issuable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 25, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 24, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 28, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 28, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 12, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 12, 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 19, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 19, 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 13, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 12, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 16, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,866,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 15, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,416,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 28, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 23, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 9, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,008,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">766,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,023,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) In November 2019, the Company received $11.999 per pre-funded warrant, or $21.0 million in aggregate proceeds. Each pre-funded</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">warrant may be exercised for an additional $0.001 per pre-funded warrant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) In March 2021, the Company received $8.69 per pre-funded warrant, or $435 thousand in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) In November 2021, the Company received $4.97 per pre-funded warrant, or $10.0&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) In March 2022, the Company received $1.79 per pre-funded warrant, or $3.0&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653091500632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Plans&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following equity incentive plans:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The X4 Pharmaceuticals Inc. 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#8220;2015 Plan&#8221;);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The X4 Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;); and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The X4 Pharmaceuticals Inc. 2019 Inducement Equity Incentive Plan (the &#8220;2019 Plan&#8221;)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company also has the following employee stock purchase plan:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The X4 Pharmaceutical Inc. 2017 Employee Stock Purchase Plan (the &#8220;2017 ESPP&#8221;)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These plans are administered by the Board of Directors or by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of the stock option may not be greater than ten years. Incentive stock options granted to employees and restricted stock awards granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over four years. Non-statutory options granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over three or four years. Shares that are expired, terminated, surrendered or canceled under the Plans without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there are an aggregate of approximately 550,000 shares of common stock available for issuance under the Company&#8217;s equity incentive plans. Approximately 270,000 shares of common stock remain available for issuance under the 2017 ESPP.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Valuation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees, directors and non-employees.</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:51.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.979%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity for the three months ended March&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,743)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049,158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029,146&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,798,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no stock options exercised in the three months ended March 31, 2022. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2021 was $13 thousand. The weighted average grant-date fair value per share of stock options granted during the three months ended March&#160;31, 2022 and 2021 was $1.42 and $6.52, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes the Company's restricted stock unit activity for the three months ended March 31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:78.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192,255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,940,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company granted time-based restricted stock units to employees. These restricted stock units vest annually over a two or three year period. Stock-based compensation expense is being recognized for these time-based awards ratably based on the intrinsic value of the awards as of the date of grant, less estimated forfeitures. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, total unrecognized compensation expense related to unvested stock options and restricted stock units was $8.5 million, which is expected to be recognized over a weighted average period of 2.0 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:58.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.327%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.330%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653091512856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXESThe Company did not record a U.S. federal or state income tax benefit for its losses for the three months ended March&#160;31, 2022 and 2021, due to the conclusion that a full valuation allowance is required against the Company&#8217;s U.S. federal and state deferred tax assets. For the three months ended March 31, 2022 and March 31, 2021, the Company recorded an immaterial income tax provision related to its Austrian subsidiary.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090304440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">NET LOSS PER SHARE<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common stockholders was calculated as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,676)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend as a result of Class B warrant price reset (Note 10)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,224)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,915)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders&#8212; basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.72)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted weighted average shares of common stock outstanding for the three months ended March&#160;31, 2022 and March&#160;31, 2021 include the weighted average effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price is $0.01 or less per share. During the quarters ended March 31, 2022 and March 31, 2021, in accordance with the Class B Warrant agreement, the exercise price of each outstanding Class B Warrant was adjusted to the price of shares of the Company&#8217;s common stock sold in public or private offerings to the extent such price is lower than the previous Class B warrant price. These price adjustments are accounted for as a deemed dividend that adjusts net loss available to common shareholders for purposes of basic earnings per share. The deemed dividend is calculated using the Black-Scholes pricing model, taking into account historical volatility of the Company&#8217;s common stock and the estimated remaining life of the outstanding Class B Warrants.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities include outstanding stock options, unvested restricted stock units and warrants to purchase shares of common stock for the three months ended March 31, 2022 and 2021. All potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered &#8220;anti-dilutive.&#8221; Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase shares of common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,940,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase shares of common stock (excluding prefunded warrants, which are included in basic shares outstanding)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,449,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,474,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,438,974&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,467,976&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090428360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including X4 Pharmaceuticals (Austria) GmbH, which is incorporated in Vienna, Austria (&#8220;X4 Austria&#8221;), and X4 Therapeutics, Inc. All significant intercompany accounts and transactions have been eliminated.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Unaudited Interim Financial Statements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet at December 31, 2021 that is presented in these interim condensed consolidated financial statements was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed consolidated financial statements are unaudited. The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC for interim financial statements. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s&#160;audited financial statements and the notes thereto for the year ended December&#160;31, 2021 included in the 2021 Annual Report. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&#8217;s condensed financial position, condensed results of its operations and cash flows have been made. The results of operations for the three months ended March&#160;31, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December&#160;31, 2022.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and the constraint of variable consideration from contracts with customers. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The COVID-19 pandemic has impacted and is expected to continue to impact the clinical development timelines for certain of the Company's clinical programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of issuance of these condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s condensed consolidated financial statements.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of March&#160;31, 2022 and December&#160;31, 2021.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.</span>The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform an interim quantitative impairment test, whereby the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than its carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. There were no triggering events during the three months ended March 31, 2022 that necessitated an interim impairment test of goodwill.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASU 2021-04 was issued to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants for the purchase of common shares) that remain classified as equity following the modification or exchange. ASU 2021-04 is effective January 1, 2022 for the Company. The adoption of this standard did not have an impact on the Company&#8217;s consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13"), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. In accordance with ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326), Derivative and Hedging (Topic 815), and Leases (Topic 842)- Effective </span></div>Dates, as the Company meets the definition of a &#8220;smaller reporting company&#8221;, the Company has elected to defer the adoption of ASU 2016-13 until January 1, 2023. The Company expects that the adoption of ASU 2016-13 may accelerate the timing and could increase the level of credit loss expense in the consolidated statement of operations and will likely require an increased level of disclosure in the notes to the consolidated financial statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653092413496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensatingBalancesTextBlock', window );">Schedule of Restricted Cash</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:60.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Waltham lease</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Vienna Austria lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Boston lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the sum of the total of amounts shown in the Company&#8217;s condensed consolidated statements of cash flows as of March&#160;31, 2022 and December&#160;31, 2021:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:62.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.758%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,744&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensatingBalancesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes disclosure of  these arrangements and the amount involved, if determinable, for the most recent audited balance sheet required and for any subsequent unaudited balance sheet required in the notes to the financial statements. Compensating balances that are maintained under an agreement to assure future credit availability are generally disclosed in the notes to the financial statements along with the amount and terms of such agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 6.H.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13728-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensatingBalancesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of reconciliation of cash and cash equivalents and restricted cash to cashflows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653091545288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of March 31, 2022 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2021 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities: </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Aggregate Fair Values of Warrant Liability and Derivative Liability</a></td>
<td class="text"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll-forward of the aggregate fair values financial instruments for which fair values are determined using Level 3 inputs:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:80.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.217%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Embedded Derivative Liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090293464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:58.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.635%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(857)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653091530376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,870&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653093632248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Long Term Debt</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:58.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.635%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative accretion of end of term payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,415)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(795)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,809&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Interest Income and Interest Expense Disclosure</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized interest expense under the Hercules Loan Agreement as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months ended March  31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Principal Payments and the Final Payments Due</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future principal and end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands): </span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:83.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,097&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090268200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three months ended March&#160;31, 2022 and 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:67.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March  31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use asset obtained in exchange for operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublease income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities due under lease agreements that have commenced as of March&#160;31, 2022 are as follows (in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:78.220%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,699)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090293464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a roll forward of outstanding warrants for the three month period ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Contractual Term (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable warrants to purchase common shares as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,257,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.96</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.80</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable warrants to purchase common shares as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,023,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47</span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company&#8217;s outstanding warrants to purchase shares of common stock consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares of<br/>Common<br/>Stock Issuable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 25, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 24, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 28, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 28, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 12, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 12, 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 19, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 19, 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 13, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 12, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 16, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,866,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 15, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,416,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 28, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 23, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 9, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,008,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">766,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,023,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) In November 2019, the Company received $11.999 per pre-funded warrant, or $21.0 million in aggregate proceeds. Each pre-funded</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">warrant may be exercised for an additional $0.001 per pre-funded warrant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) In March 2021, the Company received $8.69 per pre-funded warrant, or $435 thousand in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) In November 2021, the Company received $4.97 per pre-funded warrant, or $10.0&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) In March 2022, the Company received $1.79 per pre-funded warrant, or $3.0&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653088872648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Stock Option Valuation</a></td>
<td class="text">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees, directors and non-employees.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:51.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.979%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity for the three months ended March&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,743)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049,158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029,146&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,798,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes the Company's restricted stock unit activity for the three months ended March 31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:78.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192,255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,940,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-Based Compensation Expense Classification</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:58.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.327%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.330%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653091528216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common stockholders was calculated as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,676)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend as a result of Class B warrant price reset (Note 10)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,224)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,915)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders&#8212; basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.72)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text">The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase shares of common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,940,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase shares of common stock (excluding prefunded warrants, which are included in basic shares outstanding)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,449,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,474,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,438,974&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,467,976&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653093615768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 66,427<span></span>
</td>
<td class="nump">$ 81,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (304,836)<span></span>
</td>
<td class="num">$ (282,871)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090502072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Compensating Balance Arrangements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Total restricted cash</a></td>
<td class="nump">$ 1,317<span></span>
</td>
<td class="nump">$ 1,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Vienna Austria Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Allston Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653087900856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 66,427<span></span>
</td>
<td class="nump">$ 81,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 67,744<span></span>
</td>
<td class="nump">$ 83,108<span></span>
</td>
<td class="nump">$ 116,660<span></span>
</td>
<td class="nump">$ 80,702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653088922920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Funding Agreements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain (Loss) on Disposition of Other Assets</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xfor_ResearchAndDevelopmentIncentiveProgramMember', window );">Research and Development Incentive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_GrantAndIncentiveReceivables', window );">Grant receivable</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_CollaborationLicenseAndFundingArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration, license and funding arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_CollaborationLicenseAndFundingArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_GrantAndIncentiveReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant and incentive receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_GrantAndIncentiveReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xfor_ResearchAndDevelopmentIncentiveProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xfor_ResearchAndDevelopmentIncentiveProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653087157352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 2,626,000<span></span>
</td>
<td class="nump">$ 47,793,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">645,000<span></span>
</td>
<td class="nump">821,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,626,000<span></span>
</td>
<td class="nump">27,793,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">645,000<span></span>
</td>
<td class="nump">$ 821,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090745960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</a></td>
<td class="nump">$ 645<span></span>
</td>
<td class="nump">$ 821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</a></td>
<td class="num">$ (176)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653087202440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,260<span></span>
</td>
<td class="nump">$ 2,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(857)<span></span>
</td>
<td class="num">(724)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,254<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_SoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 576<span></span>
</td>
<td class="nump">$ 576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_SoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_SoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653091558264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653087338232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation and benefits</a></td>
<td class="nump">$ 3,784<span></span>
</td>
<td class="nump">$ 5,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_AccruedExternalResearchAndDevelopmentExpenses', window );">Accrued external research and development expenses</a></td>
<td class="nump">2,013<span></span>
</td>
<td class="nump">1,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">762<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 6,877<span></span>
</td>
<td class="nump">$ 7,870<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AccruedExternalResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued external research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AccruedExternalResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653088915592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Summary of Long Term Debt (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount of long-term debt</a></td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="nump">$ 32,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt discount, net of accretion</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_AccretionOnLongTermDebt', window );">Cumulative accretion of end of term payments</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">1,157<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LongTermDebtIncludingAccretion', window );">Long-term debt</a></td>
<td class="nump">33,224<span></span>
</td>
<td class="nump">33,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="num">(3,415)<span></span>
</td>
<td class="num">(795)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Long-term debt, net of current portion</a></td>
<td class="nump">$ 29,809<span></span>
</td>
<td class="nump">$ 33,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AccretionOnLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion on long term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AccretionOnLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LongTermDebtIncludingAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Including Accretion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LongTermDebtIncludingAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653085065512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt - Hercules Loan Agreement - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2024</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ScheduleOfLongTermDebtLineItems', window );"><strong>Schedule Of Long Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember', window );">Hercules Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ScheduleOfLongTermDebtLineItems', window );"><strong>Schedule Of Long Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument variable percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate increase percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree', window );">Contingent additional term loan advances, tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">909,000<span></span>
</td>
<td class="nump">$ 890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,000<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember', window );">Hercules Loan Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ScheduleOfLongTermDebtLineItems', window );"><strong>Schedule Of Long Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPayment', window );">Line of credit facility periodic payment</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember', window );">Hercules Loan Agreement | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ScheduleOfLongTermDebtLineItems', window );"><strong>Schedule Of Long Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument variable percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember', window );">Hercules Loan Agreement | Maximum | Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ScheduleOfLongTermDebtLineItems', window );"><strong>Schedule Of Long Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_DebtInstrumentPrepaymentPremiumPercentage', window );">Debt instrument prepayment premium, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesSecondAmendedLoanAgreementMember', window );">Hercules Second Amended Loan Agreement | Min Cash Test Date 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ScheduleOfLongTermDebtLineItems', window );"><strong>Schedule Of Long Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LineOfCreditCovenantMinimumCash', window );">Line of Credit, Covenant, Minimum Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesSecondAmendedLoanAgreementMember', window );">Hercules Second Amended Loan Agreement | Min Cash Test Date 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ScheduleOfLongTermDebtLineItems', window );"><strong>Schedule Of Long Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LineOfCreditCovenantMinimumCash', window );">Line of Credit, Covenant, Minimum Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments of both interest and principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_DebtInstrumentPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Prepayment Premium, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_DebtInstrumentPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LineOfCreditCovenantMinimumCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit, Covenant, Minimum Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LineOfCreditCovenantMinimumCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ScheduleOfLongTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Long Term Debt [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ScheduleOfLongTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xfor_HerculesSecondAmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xfor_HerculesSecondAmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=xfor_MinCashTestDate2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=xfor_MinCashTestDate2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=xfor_MinCashTestDate1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=xfor_MinCashTestDate1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653087827624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Future Principal Payments and the Final Payments Due (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">19,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">13,295<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LongTermDebtAndEOTPayment', window );">Principal amount of long-term debt</a></td>
<td class="nump">$ 33,097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LongTermDebtAndEOTPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term debt and end of term payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LongTermDebtAndEOTPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653087283352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 11, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>m&#178; </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,344<span></span>
</td>
<td class="nump">$ 8,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember', window );">Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_CurrentOfficeSpaceUnderLeaseAgreement', window );">Current office space under lease agreement | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_OperatingLeaseExpiration', window );">Operating lease expiration (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_AggregateBaseRent', window );">Current base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease, term of contract (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaAustriaLeaseMember', window );">Vienna Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace', window );">Office space | m&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease not yet commenced, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent', window );">Annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseMember', window );">Allston Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_CurrentOfficeSpaceUnderLeaseAgreement', window );">Current office space under lease agreement | ft&#178;</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount', window );">Lease not yet commenced</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease, renewal term of contract (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AggregateBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AggregateBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_CurrentOfficeSpaceUnderLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current office space under lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_CurrentOfficeSpaceUnderLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Office Space</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_OperatingLeaseExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_OperatingLeaseExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaAustriaLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaAustriaLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653088928920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed operating lease cost</a></td>
<td class="nump">$ 530<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term-operating leases (in years)</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate-operating leases</a></td>
<td class="nump">11.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653087399736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 1,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">1,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">1,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">7,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(1,699)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">$ 5,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653093627752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xfor_IndemnificationAgreementsMember', window );">Indemnification Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ContingenciesAndCommitmentsLineItems', window );"><strong>Contingencies And Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ContingenciesAndCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingencies And Commitments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ContingenciesAndCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xfor_IndemnificationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xfor_IndemnificationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653084835608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Nov. 29, 2019</div></th>
<th class="th"><div>Nov. 26, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 03, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 09, 2021</div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
<th class="th"><div>Apr. 16, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightIssued', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod', window );">Class of warrants or rights expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,023,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,257,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights', window );">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued', window );">Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</a></td>
<td class="nump">$ 435,000<span></span>
</td>
<td class="nump">$ 21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends on common stock declared or paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, warrants to purchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses', window );">Proceeds from issuance of common stock before underwriting discounts commissions and other expenses</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_PrefundedWarrantsAxis=xfor_FundedMember', window );">Funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (usd per share)</a></td>
<td class="nump">$ 8.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_ClassBWarrantsMember', window );">Class B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightIssued', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,416,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember', window );">Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants for purchase of convertible preferred shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Warrants Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock Before Underwriting Discounts Commissions And Other Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_PrefundedWarrantsAxis=xfor_FundedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_PrefundedWarrantsAxis=xfor_FundedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_ClassBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_ClassBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653087090232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants - Schedule of Outstanding Warrants (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_WarrantsRollForward', window );"><strong>Warrants [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding and exercisable warrants to purchase common shares as of December 31, 2021</a></td>
<td class="nump">13,257,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightIssued', window );">Issued</a></td>
<td class="nump">766,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants, Outstanding and exercisable warrants, Ending Balance (in shares)</a></td>
<td class="nump">14,023,726<span></span>
</td>
<td class="nump">13,257,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice', window );">Class Of Warrant Or Right Issued, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_WarrantsWeightedAverageExercisePriceRollForward', window );"><strong>Warrants, Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding and exercisable warrants, Beginning Balance (in usd per share)</a></td>
<td class="nump">7.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding and exercisable warrants, Ending Balance (in usd per share)</a></td>
<td class="nump">$ 6.91<span></span>
</td>
<td class="nump">$ 7.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm', window );">Weighted Average Contractual Term (Years)</a></td>
<td class="text">2 years 5 months 19 days<span></span>
</td>
<td class="text">2 years 8 months 19 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Issued, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right weighted average contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_WarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_WarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_WarrantsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_WarrantsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653083054856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 03, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 09, 2021</div></th>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
<th class="th"><div>Nov. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">14,023,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,257,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued', window );">Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights', window );">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_PrefundedWarrantsAxis=xfor_FundedMember', window );">Funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.97<span></span>
</td>
<td class="nump">$ 8.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember', window );">Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_ClassBWarrantsMember', window );">Class B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember', window );">Issuance On October 25, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember', window );">Issuance On October 25, 2016 | Legacy Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">5,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember', window );">Issuance On December 28, 2017 One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember', window );">Issuance On December 28, 2017 One | Legacy Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">115,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember', window );">Issuance On September 12, 2018 One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember', window );">Issuance On September 12, 2018 One | Legacy Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">20,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember', window );">Issuance On October 19, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember', window );">Issuance On October 19, 2018 | Legacy Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">20,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember', window );">Issuance On March 13, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember', window );">Issuance On March 13, 2019 | Legacy Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember', window );">Issuance On April 16, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember', window );">Issuance On April 16, 2019 | Class A Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">3,866,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember', window );">Issuance On November 29, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember', window );">Issuance On November 29, 2019 | Class B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">5,416,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember', window );">Issuance On November 29, 2019 One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember', window );">Issuance On November 29, 2019 One | Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member', window );">Issuance On March 23, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 8.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member', window );">Issuance On March 23, 2021 | Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember', window );">Issuance on November Nine Two Thousand Twenty One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">2,008,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 4.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch32022Member', window );">Issuance on March 3 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">766,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_PrefundedWarrantsAxis=xfor_FundedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_PrefundedWarrantsAxis=xfor_FundedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_ClassBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_ClassBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_LegacyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_LegacyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_ClassAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_ClassAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch32022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch32022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653088130088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, options exercised</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue', window );">Options granted, weighted average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 1.42<span></span>
</td>
<td class="nump">$ 6.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost of stock based awards</a></td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost of stock based awards, recognition period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xfor_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xfor_TwoThousandSeventeenEquityIncentivePlanMember', window );">Two Thousand Seventeen Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Awards Grant in Period Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xfor_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xfor_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xfor_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xfor_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653088989288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-date Fair Value of Stock Options Granted (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (in percentage)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (in percentage)</a></td>
<td class="nump">94.50%<span></span>
</td>
<td class="nump">101.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653090486312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">1,916,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">232,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(99,743)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">2,049,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares Options, Exercisable (in shares)</a></td>
<td class="nump">1,029,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares Options, Vested and expected to vest (in shares)</a></td>
<td class="nump">1,798,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in usd per share)</a></td>
<td class="nump">$ 10.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in usd per share)</a></td>
<td class="nump">23.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in usd per share)</a></td>
<td class="nump">8.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable (in usd per share)</a></td>
<td class="nump">10.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest (in usd per share)</a></td>
<td class="nump">$ 8.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual term outstanding (in years)</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term outstanding, Exercisable (in years)</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term outstanding, Vested and expected to vest (in years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Ending balance</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653092296664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,242,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(192,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(34,814)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested ending balance (in shares)</a></td>
<td class="nump">1,940,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested beginning balance (in shares)</a></td>
<td class="nump">925,101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653087114248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Summary of Stock-Based Compensation Expense Classification (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 1,459<span></span>
</td>
<td class="nump">$ 1,258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 755<span></span>
</td>
<td class="nump">$ 681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653087182920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653092284824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (21,965)<span></span>
</td>
<td class="num">$ (18,676)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPaidinkind', window );">Dividends, Paid-in-kind</a></td>
<td class="num">(2,259)<span></span>
</td>
<td class="num">(8,239)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (24,224)<span></span>
</td>
<td class="num">$ (26,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding&#8212;basic and diluted (in shares)</a></td>
<td class="nump">33,737,000<span></span>
</td>
<td class="nump">20,751,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (1.30)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPaidinkind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid paid-in-kind dividends (PIK) declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPaidinkind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653087365832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Nov. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding&#8212;basic and diluted (in shares)</a></td>
<td class="nump">33,737,000<span></span>
</td>
<td class="nump">20,751,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember', window );">Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember', window );">Pre Funded Warrant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140653083046424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">13,438,974<span></span>
</td>
<td class="nump">12,467,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">2,049,158<span></span>
</td>
<td class="nump">1,858,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">1,940,788<span></span>
</td>
<td class="nump">1,135,419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">9,449,028<span></span>
</td>
<td class="nump">9,474,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>xfor-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xfor="http://www.x4pharma.com/20220331"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="xfor-20220331.xsd" xlink:type="simple"/>
    <context id="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i24b035d294594e2eb13e2c7695f6e295_I20220509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2022-05-09</instant>
        </period>
    </context>
    <context id="i551b03b35a354b9c82567e2c1278da6f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ied3aba39e79f4b429586d34201372693_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib00aa6fecd42425ea68620951639c543_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2425a0da056146c48327ec0587899d61_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib471740b6fdd47e8af8050737b18ccdb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i854c77af00bd4ce9a4dfdb9a27239dce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60e626d1eb1f4f26b74d82ff06b61afd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6895f9ac9ea474583d9fff78ede70b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01d79d96f4a7455f94d5d1c06a5e5b1b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie8de9ba4633443dbaddd152d4d468a43_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia22eddc0d4a54868be305ee81dbe30b5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i54a6aa4f5e554082b147ea3e13218602_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i047748a25ba140d9bf8ddde9f403b7c3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4df9455becee450483e383bda2635fb6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie0ec92573d25494d9ec868ce6d803b1f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i86f8f316e485428cbd4027d61748adf8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7e2cf99863b4fb88048889aa87cf96f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5d7e807d2ef42dda0ab3c941f8caf6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f4ba6165a6d4e068a782de9870bba11_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c210c0dd8634743ac3fe20cd14d7221_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66c88a11b199434aace5aef0bbc9f5ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb5a551d13c443f58e2de92a4c349fb4_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0a536b78307a42ecbcb3238de82af6f7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if552410f512d4f14be1678c6b554dbef_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2328bc9fe2404a29a05fe278a1035750_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6216409af0d8456fa56993e3fe6c83f0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8c30ad47284440ecb1152f67b75b14bf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6490c404c2e943b29d2afa3f5b15a0ed_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifa75eebec540404b9087007bb78de87d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifa18918dfe8b4eb99398f5469d0f1f20_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i53f51ae8287e4f2a9dc20c9692a90f3b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if34f27299a434668885ee2416dec75fa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7257e82e68c041908175389a8f7bdea1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica1cbeac75bb4931b6a264bbff4cb6ac_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9911b058cb814046a3c2b033f5239f56_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b8c9dbcf0c44ed99f42775671ed3b03_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ideaca6ba9ebd4d459db86e8fec1e7f54_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6a9e053963b4b5e8c0525ef05558e5c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6fa190798a8f407db1aaf3fc492af313_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ae98b37b4074b55b43d5b52c0da2b4e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i094278dbb6a548fd9082e115e09bdaf0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2d672047c5424b409a161bd8c9acbfed_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie4117ae9064c4a1eb42d624dc7250d94_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia42b7fcbe59440f2b41270d5bb32ea91_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia33efcad84ff4ab29dfe84a9f90b41b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife03ea1a6e3647c89acdff544fec694a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21d0f0aac3d548fbaf98b28d241b82e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1742801c50374deb91009bf46a82591f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id3a80995916b45c199871913d2744c21_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i639b8d3e3f0d47f8a1670e543de3ddbb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i96c436bc6e3549aaba4b6f5738544b57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02cddbe3e2e94249a26572dd230f54ab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idd20f5ab879a4c7899f8376d38a509b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if06a3031bf214f0badb0fe08c193a7db_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibdfa75b4c35d44a391617d28994286e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc17d505855a43e499fd5dbfc1919a1e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifcc1bd21f38c467083120b5c7e8f04d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c7c501dd906429f8cddfe0fb9905586_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5ab87fe587c64027a76fcc9c708f7361_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1dc0bdf32a5146e0adcea6db6de6615d_D20181001-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i37a902dab0bd4e4f9e87b18693f5f331_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic37a10f994534a07ba477a27d2a2bf64_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic4206af27e2d487f9f31e058fa7b8c0a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icce6cbe45cc4447fbfe3ebb0b1f74930_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i55063b32fb884c81895bd748e6ed4f41_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i26533fb9b8ff4cf98e7fe29b5121aa6d_D20240701-20240701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="ic45fa2c1cc904680a9c790308256e60f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">xfor:MinCashTestDate1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia692d84b888a4845bbc1ea6a9ee0dfbd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">xfor:MinCashTestDate2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id7e48af44af640d5b517c67d3ad4d1f0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icc53f4cff48d40168111b64915f524d7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaAustriaLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i38936b88ef624fe69a0b0bfe09334734_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaAustriaLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9f343631aa5f432096c5e6330be2f6e1_D20191111-20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-11</startDate>
            <endDate>2019-11-11</endDate>
        </period>
    </context>
    <context id="i1fdd127e11e14968982b457103d38af9_I20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-11</instant>
        </period>
    </context>
    <context id="i829185b9e0084c7584f58e45342583f9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie3e0d04f60ed4d21934cf225abe43d0a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i975809049d0a45c497bb1ac01a475dac_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:IndemnificationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i65cb0a8a766640df9a3c2d91519beec5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:IndemnificationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9987285e8b814bf3a75efbc5d0f415b7_I20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2021-03-23</instant>
        </period>
    </context>
    <context id="i5fd283910b0c46c7b76b73ec9c937efa_D20210323-20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <context id="i7640c5cc7cdf4a798762f93ad58a800d_D20191129-20191129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-29</startDate>
            <endDate>2019-11-29</endDate>
        </period>
    </context>
    <context id="i33b0d388662f46dc8e3e78c78b30a392_I20191129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-29</instant>
        </period>
    </context>
    <context id="i1c1e0a3da76d47a8892dbba813618c07_D20191126-20191126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2019-11-26</startDate>
            <endDate>2019-11-26</endDate>
        </period>
    </context>
    <context id="ib952420c74dc41d0b56c0d7c1ae747af_I20190416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-16</instant>
        </period>
    </context>
    <context id="idcbf7212a2a648e0bdba60353fb0018f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if11478b9d8ef48469399603eb4700067_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i53cd7e343ca1417fabb4bb23d6a34e59_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i374920f0a8c246a18acce80fd3f3f518_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3719e7acfe4d42d793a973477e301657_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic2a6dbe35ef24ffeb2d308772056da96_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if852079aba5d4e9ba7bdcc9ca39a389a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i82c001a5dabd46658a607c7940a5a634_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberNineteenTwoThousandEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7762054b7322478e9a88838854405b2f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberNineteenTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if43e448bd5894bd2863d446143e0ff04_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarchThirteenTwoThousandNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3270dde03c414860922ae7af87624181_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarchThirteenTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib1993d79bf6244d0b392f8df783ee312_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnAprilSixteenTwoThousandNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4d8975a741104b5296f718b358811082_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnAprilSixteenTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1674d766cfaa4621a97b51e4f672d1aa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icfbe308a558a41579f92a9d56f820980_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i16d2edf8cc33443ea0ffbd013f4b66e0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i85b541bd25654094be49307558799aae_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0b51e9aec2ca4554a1cb58776b67a06a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch232021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i12273bd7f6f844c29aa5394dbc198547_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch232021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i31185213cb1d401ab6f9bfaf3eca7163_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberNineTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaadf734ea7f34c549783db6da7a96a56_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch32022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i74b9f718ca0e4c5d9b871296a1e02de1_I20191129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-29</instant>
        </period>
    </context>
    <context id="i0c46977bdcd44c5fbb626a2c7adad70d_I20191129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2019-11-29</instant>
        </period>
    </context>
    <context id="i7a34589fe1b04db8902c62e32428ecf2_I20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-23</instant>
        </period>
    </context>
    <context id="i055ed4cd017b4077b80b39c7e53429d5_I20211109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-09</instant>
        </period>
    </context>
    <context id="ie946fb34148e40778aa24e30c0fb5174_I20211109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2021-11-09</instant>
        </period>
    </context>
    <context id="i96523b616e2c4aaaa42b757f1dead895_I20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="idb651aa4d13d4e91881e98c2a66705b2_I20220303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-03</instant>
        </period>
    </context>
    <context id="i5abc6425ebed4d1098137ddae6cf173b_I20220303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2022-03-03</instant>
        </period>
    </context>
    <context id="i1087c98fdfeb43a5b2b61cf5a5a18780_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id3f763b38edd403fb65281fd8c0d1e6b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia64d3337ee204135be6803aad57e0f54_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia735dbcc36df42bd8741cce45232e31a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5ce63ce89fc4d53b2de1b932c6c5971_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i34f00a49e9164c6f8f5d5aea7638c86e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3f08fbd1d62147b7a24653057a24170f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibe626170d10b4caa80d237bf4ea1bace_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7ce083cdddd2478e9589bcc5c51fb670_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id2610f6c62e848928bf100bd21dc705c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia0ed061951224fe2b05f82e41a77c8d4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1925ffb8b98e470a8755be697908ef08_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i289ea1ad164e40f3bd8d98acc9dd5ec5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0c82af5f1bd54ac38a12ea61c79ef148_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4403e830d3884aac9399f56efc81108c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9e78ac2b2f9c400db2a88a3ac72a5ab8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifc1e4f78fe354943a530e1e6507b73ea_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqm">
        <measure>utr:sqm</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80L2ZyYWc6NTZlZmZlMTkyYzYzNGU3N2E2N2U0ZmM3Yzc0YzM0ODQvdGFibGU6MGY1MDZlZjViMTYzNDg5MzgxYjczNThlN2EzNDE3ZGUvdGFibGVyYW5nZTowZjUwNmVmNWIxNjM0ODkzODFiNzM1OGU3YTM0MTdkZV8wLTEtMS0xLTM0NDEx_9516f096-8d26-4681-997a-329eff22bd1f">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80L2ZyYWc6NTZlZmZlMTkyYzYzNGU3N2E2N2U0ZmM3Yzc0YzM0ODQvdGFibGU6MGY1MDZlZjViMTYzNDg5MzgxYjczNThlN2EzNDE3ZGUvdGFibGVyYW5nZTowZjUwNmVmNWIxNjM0ODkzODFiNzM1OGU3YTM0MTdkZV8xLTEtMS0xLTM0NDEx_7d73f596-2dcd-4fa5-a3ec-b78af29f64ee">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80L2ZyYWc6NTZlZmZlMTkyYzYzNGU3N2E2N2U0ZmM3Yzc0YzM0ODQvdGFibGU6MGY1MDZlZjViMTYzNDg5MzgxYjczNThlN2EzNDE3ZGUvdGFibGVyYW5nZTowZjUwNmVmNWIxNjM0ODkzODFiNzM1OGU3YTM0MTdkZV8yLTEtMS0xLTM0NDEx_795231df-674a-4e68-be4b-ffea673b0a1c">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80L2ZyYWc6NTZlZmZlMTkyYzYzNGU3N2E2N2U0ZmM3Yzc0YzM0ODQvdGFibGU6MGY1MDZlZjViMTYzNDg5MzgxYjczNThlN2EzNDE3ZGUvdGFibGVyYW5nZTowZjUwNmVmNWIxNjM0ODkzODFiNzM1OGU3YTM0MTdkZV8zLTEtMS0xLTM0NDEx_15c9473f-5b84-45d6-8326-8b924bb6e2f9">0001501697</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80L2ZyYWc6NTZlZmZlMTkyYzYzNGU3N2E2N2U0ZmM3Yzc0YzM0ODQvdGFibGU6MGY1MDZlZjViMTYzNDg5MzgxYjczNThlN2EzNDE3ZGUvdGFibGVyYW5nZTowZjUwNmVmNWIxNjM0ODkzODFiNzM1OGU3YTM0MTdkZV80LTEtMS0xLTM0NDEx_42fac757-ba7e-4c19-8653-612f2e3f2fb3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzU2_606d20a1-fcc4-48b6-bb7e-8c923f021731">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ODNkN2U4NDc0ZjIyNGIwNWFiODJlOTUxZWJmMWYzZjcvdGFibGVyYW5nZTo4M2Q3ZTg0NzRmMjI0YjA1YWI4MmU5NTFlYmYxZjNmN18wLTAtMS0xLTM0NDEx_35dcc57b-722f-4d49-9ffc-291d65d1908a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8zMDQ_53853b39-b50e-479e-b75d-6f1f68475917">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6MTQ0YjM3NTM5Y2I2NDNiMGExYmQ1M2U1MGM0ZTlmNTcvdGFibGVyYW5nZToxNDRiMzc1MzljYjY0M2IwYTFiZDUzZTUwYzRlOWY1N18wLTAtMS0xLTM0NDEx_80a7c632-7a75-455b-acf7-360d841065da">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8zOTI_3e1aae12-06d1-4d75-9b67-414c2d09c51e">001-38295</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzYw_4761e810-a53b-4c03-ada8-a797680c21e1">X4 PHARMACEUTICALS, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ZGM2MzU4MDFjMGVmNGYyMGIzNzQ1ZTIwZGY5Mzk3ZWUvdGFibGVyYW5nZTpkYzYzNTgwMWMwZWY0ZjIwYjM3NDVlMjBkZjkzOTdlZV8wLTAtMS0xLTM0NDExL3RleHRyZWdpb246NzkyMTc5MWQzMmM4NDU2MTk2YWE1NWQ2OWYyOGI2NWZfNQ_c58d0bd6-73a8-4327-be1d-e71f7e900618">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ZGM2MzU4MDFjMGVmNGYyMGIzNzQ1ZTIwZGY5Mzk3ZWUvdGFibGVyYW5nZTpkYzYzNTgwMWMwZWY0ZjIwYjM3NDVlMjBkZjkzOTdlZV8wLTEtMS0xLTM0NDExL3RleHRyZWdpb246MTdiMWQ5OGFlNGM4NDk5ZmJkMzFmOWYxOTY4MzFjNTJfNQ_36d3d10a-b09d-451d-8bcc-9bccad88ba44">27-3181608</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ZGM2MzU4MDFjMGVmNGYyMGIzNzQ1ZTIwZGY5Mzk3ZWUvdGFibGVyYW5nZTpkYzYzNTgwMWMwZWY0ZjIwYjM3NDVlMjBkZjkzOTdlZV8yLTAtMS0xLTM0NDExL3RleHRyZWdpb246YmQyZTk5NzdkZmVmNGQ5MWI5MmQyNTA3ODE2NWE0NTlfNQ_312623fd-d5b8-4380-9dec-a3b7696084c4">61 North Beacon Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ZGM2MzU4MDFjMGVmNGYyMGIzNzQ1ZTIwZGY5Mzk3ZWUvdGFibGVyYW5nZTpkYzYzNTgwMWMwZWY0ZjIwYjM3NDVlMjBkZjkzOTdlZV8yLTAtMS0xLTM0NDExL3RleHRyZWdpb246YmQyZTk5NzdkZmVmNGQ5MWI5MmQyNTA3ODE2NWE0NTlfOQ_bc297c76-c24f-407b-a111-f7d78a523f55">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ZGM2MzU4MDFjMGVmNGYyMGIzNzQ1ZTIwZGY5Mzk3ZWUvdGFibGVyYW5nZTpkYzYzNTgwMWMwZWY0ZjIwYjM3NDVlMjBkZjkzOTdlZV8yLTAtMS0xLTM0NDExL3RleHRyZWdpb246YmQyZTk5NzdkZmVmNGQ5MWI5MmQyNTA3ODE2NWE0NTlfMTI_2d202f41-49da-4f38-bff9-148730bb4aae">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ZGM2MzU4MDFjMGVmNGYyMGIzNzQ1ZTIwZGY5Mzk3ZWUvdGFibGVyYW5nZTpkYzYzNTgwMWMwZWY0ZjIwYjM3NDVlMjBkZjkzOTdlZV8yLTAtMS0xLTM0NDExL3RleHRyZWdpb246YmQyZTk5NzdkZmVmNGQ5MWI5MmQyNTA3ODE2NWE0NTlfMTY_ca9b76c9-96b9-411b-8732-2c18010162c2">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6ZGM2MzU4MDFjMGVmNGYyMGIzNzQ1ZTIwZGY5Mzk3ZWUvdGFibGVyYW5nZTpkYzYzNTgwMWMwZWY0ZjIwYjM3NDVlMjBkZjkzOTdlZV8yLTEtMS0xLTM0NDExL3RleHRyZWdpb246ZjJiODM5NjRmZjdjNGU1MDgyNjI2OTAzZWQwYThjYzZfNQ_aa5c2c04-b7f9-4efb-8282-fc349f631333">02134</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzYx_bc391b1c-9e53-4956-92a3-6cc3e0691de3">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzU3_5347d68f-d36f-43d1-a618-ac45273b1d74">529-8300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6MDIwYzA0ZWEwNjZlNGZmZTkzMzI1ZDRkYWVhODU1OTUvdGFibGVyYW5nZTowMjBjMDRlYTA2NmU0ZmZlOTMzMjVkNGRhZWE4NTU5NV8xLTAtMS0xLTM0NDEx_47ad4a1a-3259-47b2-a8c2-257e6437da5b">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6MDIwYzA0ZWEwNjZlNGZmZTkzMzI1ZDRkYWVhODU1OTUvdGFibGVyYW5nZTowMjBjMDRlYTA2NmU0ZmZlOTMzMjVkNGRhZWE4NTU5NV8xLTItMS0xLTM0NDEx_cb6bb97d-4e09-45e0-a98e-170bd34da70c">XFOR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6MDIwYzA0ZWEwNjZlNGZmZTkzMzI1ZDRkYWVhODU1OTUvdGFibGVyYW5nZTowMjBjMDRlYTA2NmU0ZmZlOTMzMjVkNGRhZWE4NTU5NV8xLTQtMS0xLTM0NDEx_50f4efd6-8345-4a02-978f-77d6b6bd1520">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzU4_91d516da-ffcf-4a5c-acbf-81443311eed1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzU5_6aa7bfef-216c-43f6-b7c1-96dffb3b38d0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6NmJmNTMyYjhmOGQxNDg0YmI5NDhkODUyNmM3NjNlZTUvdGFibGVyYW5nZTo2YmY1MzJiOGY4ZDE0ODRiYjk0OGQ4NTI2Yzc2M2VlNV8xLTAtMS0xLTM0NDEx_521d9526-eeb8-4bd9-bb20-e7c4c1d78d8c">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6NmJmNTMyYjhmOGQxNDg0YmI5NDhkODUyNmM3NjNlZTUvdGFibGVyYW5nZTo2YmY1MzJiOGY4ZDE0ODRiYjk0OGQ4NTI2Yzc2M2VlNV8xLTQtMS0xLTM0NDEx_093113a0-7ed7-4b27-b164-4dce9d1b31db">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGFibGU6NmJmNTMyYjhmOGQxNDg0YmI5NDhkODUyNmM3NjNlZTUvdGFibGVyYW5nZTo2YmY1MzJiOGY4ZDE0ODRiYjk0OGQ4NTI2Yzc2M2VlNV8yLTQtMS0xLTM0NDEx_f19c420d-9ffb-42b3-811e-8613d0eda24e">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzYy_4737e95e-ae79-4fce-adcd-742f9bdebf30">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzU1_eb491d30-9dfa-4397-a86a-7edbfdcf2814">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i24b035d294594e2eb13e2c7695f6e295_I20220509"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8xL2ZyYWc6YjhjNzNhOTlmZjk1NDg0NWFkM2Y0NTRmNTNlYTY3NzgvdGV4dHJlZ2lvbjpiOGM3M2E5OWZmOTU0ODQ1YWQzZjQ1NGY1M2VhNjc3OF8yMzE3_37cffef5-291d-4bc3-88d5-2d06da0e955e"
      unitRef="shares">30823573</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMy0xLTEtMS0zNDQxMQ_fde82a9b-c462-4ad9-ad5b-99a4ed93cfe6"
      unitRef="usd">66427000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMy0zLTEtMS0zNDQxMQ_036d6899-216c-4693-8b4c-475b84ad0089"
      unitRef="usd">81787000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <xfor:ResearchAndDevelopmentIncentiveReceivable
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNC0xLTEtMS0zNDQxMQ_455c1f2b-8c0b-4d9c-b4a8-4fdd86a25c8d"
      unitRef="usd">868000</xfor:ResearchAndDevelopmentIncentiveReceivable>
    <xfor:ResearchAndDevelopmentIncentiveReceivable
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNC0zLTEtMS0zNDQxMQ_b56ab6fc-9e2f-41a9-9431-2509426c05a3"
      unitRef="usd">747000</xfor:ResearchAndDevelopmentIncentiveReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNS0xLTEtMS0zNDQxMQ_479091a1-ffb0-450b-bb3d-c6724c829dfa"
      unitRef="usd">3586000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNS0zLTEtMS0zNDQxMQ_62abc03c-87ae-4754-9de9-d26c43e61d1c"
      unitRef="usd">5344000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNi0xLTEtMS0zNDQxMQ_5449c14b-4998-473d-b754-89c19d9bab00"
      unitRef="usd">70881000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNi0zLTEtMS0zNDQxMQ_17d46484-2c2d-4e84-8f5c-ddb3f0ad2962"
      unitRef="usd">87878000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNy0xLTEtMS0zNDQxMQ_fecb528c-64fa-46f2-a47f-e6cf2d40667d"
      unitRef="usd">1403000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfNy0zLTEtMS0zNDQxMQ_562a3160-9a92-45b3-b868-602b7ce391e7"
      unitRef="usd">1514000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfOC0xLTEtMS0zNDQxMQ_69f35318-a300-446b-88cb-5420ebc3b1e7"
      unitRef="usd">17351000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfOC0zLTEtMS0zNDQxMQ_e0efe09c-8211-45d3-82c4-beeb0f0f2b32"
      unitRef="usd">17351000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfOS0xLTEtMS0zNDQxMQ_db7548d4-0fa4-47bb-9845-192a5049215f"
      unitRef="usd">8344000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfOS0zLTEtMS0zNDQxMQ_91e52372-26f0-44a1-8b55-2d9fdfcc8f59"
      unitRef="usd">8710000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTAtMS0xLTEtMzQ0MTE_dc00a2ba-070c-43a0-8889-438a0ecbdc5a"
      unitRef="usd">1646000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTAtMy0xLTEtMzQ0MTE_b92024ea-9401-4962-8fbd-f72d45dce0bc"
      unitRef="usd">1723000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTEtMS0xLTEtMzQ0MTE_958af311-7087-4a87-8aa1-38fa8d4cd684"
      unitRef="usd">99625000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTEtMy0xLTEtMzQ0MTE_4e93cdac-edbd-4558-8760-cc8df95ca606"
      unitRef="usd">117176000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTQtMS0xLTEtMzQ0MTE_60f7f7f8-edc4-48c4-95d5-8753e93e36bd"
      unitRef="usd">3569000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTQtMy0xLTEtMzQ0MTE_241a9ae8-2df6-4ed8-8267-0710e4dde87c"
      unitRef="usd">4283000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTUtMS0xLTEtMzQ0MTE_6e89dd26-c58f-4590-b9ef-83b30e20e2de"
      unitRef="usd">6877000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTUtMy0xLTEtMzQ0MTE_20d574f9-54a0-4b87-b9d2-50e36fecd70f"
      unitRef="usd">7870000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTYtMS0xLTEtMzQ0MTE_0c9180b8-0a54-41fa-b00f-006b7405e85a"
      unitRef="usd">1109000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTYtMy0xLTEtMzQ0MTE_68457ea1-4e7a-431e-8127-aa39c0f81d71"
      unitRef="usd">1075000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTctMS0xLTEtMzQ0MTE_d294df21-f06d-43a6-91b5-4f486d01757a"
      unitRef="usd">3415000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTctMy0xLTEtMzQ0MTE_4f548d1e-a82f-4125-a891-0982eddb30af"
      unitRef="usd">795000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTgtMS0xLTEtMzQ0MTE_a4dd8802-e321-4dff-8ebb-0a1fbe933c3c"
      unitRef="usd">14970000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTgtMy0xLTEtMzQ0MTE_4a98cdce-d585-4ef7-8ddc-b347e5b18ff7"
      unitRef="usd">14023000</us-gaap:LiabilitiesCurrent>
    <xfor:LongTermDebtNonCurrentIncludingAccretion
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTktMS0xLTEtMzQ0MTE_7dd1611f-7cfd-4557-9e12-29f95b67c382"
      unitRef="usd">29809000</xfor:LongTermDebtNonCurrentIncludingAccretion>
    <xfor:LongTermDebtNonCurrentIncludingAccretion
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMTktMy0xLTEtMzQ0MTE_0beaee4f-0fdb-462e-9808-11fc90cec263"
      unitRef="usd">33139000</xfor:LongTermDebtNonCurrentIncludingAccretion>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjAtMS0xLTEtMzQ0MTE_76a72002-4d56-4bab-93ff-9ac090d6f354"
      unitRef="usd">4482000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjAtMy0xLTEtMzQ0MTE_4efc6331-2c4e-4bf3-b56d-ca3c3ead83b8"
      unitRef="usd">4776000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjEtMS0xLTEtMzQ0MTE_d53df466-fc93-4912-b794-44214524c171"
      unitRef="usd">650000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjEtMy0xLTEtMzQ0MTE_65da535d-6c9b-4bff-bf3f-c83ad1115d23"
      unitRef="usd">826000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjItMS0xLTEtMzQ0MTE_e3cb5059-bd17-41fc-882a-cc8213545fa3"
      unitRef="usd">49911000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjItMy0xLTEtMzQ0MTE_104e4852-ea45-45a8-a1ad-ad0dc52e34ff"
      unitRef="usd">52764000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjMtMS0xLTEtMzQ0MTE_2fa36de4-7470-43a6-b2bb-d5b863cd0046"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjMtMy0xLTEtMzQ0MTE_733c8b80-87e6-471b-89b0-91c8899554fc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMC0xLTEtMzQ0MTEvdGV4dHJlZ2lvbjozMGY5MGViMGZjZjQ0YzFmODY0MmE5Njg5ODZkYTEyN18xOQ_6bc07d9d-666a-4a7c-bc21-da61e9738da1"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMC0xLTEtMzQ0MTEvdGV4dHJlZ2lvbjozMGY5MGViMGZjZjQ0YzFmODY0MmE5Njg5ODZkYTEyN18xOQ_b97e7f37-67ac-4c53-9adc-c39a73b9e619"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMC0xLTEtMzQ0MTEvdGV4dHJlZ2lvbjozMGY5MGViMGZjZjQ0YzFmODY0MmE5Njg5ODZkYTEyN18zMw_37f5119f-41eb-4409-925c-af48199031a7"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMC0xLTEtMzQ0MTEvdGV4dHJlZ2lvbjozMGY5MGViMGZjZjQ0YzFmODY0MmE5Njg5ODZkYTEyN18xMTA_028035f5-50e5-421f-a684-e73efa4448b5"
      unitRef="shares">30809476</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMC0xLTEtMzQ0MTEvdGV4dHJlZ2lvbjozMGY5MGViMGZjZjQ0YzFmODY0MmE5Njg5ODZkYTEyN18xMTA_e2ea39d1-17e6-4f09-843e-88e48af07215"
      unitRef="shares">30809476</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMC0xLTEtMzQ0MTEvdGV4dHJlZ2lvbjozMGY5MGViMGZjZjQ0YzFmODY0MmE5Njg5ODZkYTEyN18xMTc_ae5728cd-d611-4f46-89fb-cb881c1815b3"
      unitRef="shares">28127657</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMC0xLTEtMzQ0MTEvdGV4dHJlZ2lvbjozMGY5MGViMGZjZjQ0YzFmODY0MmE5Njg5ODZkYTEyN18xMTc_b4fe1fe5-b831-4fa6-ba41-b98bfef55771"
      unitRef="shares">28127657</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMS0xLTEtMzQ0MTE_67fd6a88-1eaa-4ef3-9dac-1b79eb6e61c4"
      unitRef="usd">31000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjUtMy0xLTEtMzQ0MTE_089fb4a6-d8e9-47f6-a39c-545c39de47ab"
      unitRef="usd">28000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjYtMS0xLTEtMzQ0MTE_0d661b49-db6c-4e16-bafd-a7ef0119082c"
      unitRef="usd">354638000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjYtMy0xLTEtMzQ0MTE_d8f4871f-65e5-4873-bac2-4d87b33bbea7"
      unitRef="usd">347374000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjctMS0xLTEtMzQ0MTE_8df756b5-a721-40b4-989a-6f932221f22a"
      unitRef="usd">-119000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjctMy0xLTEtMzQ0MTE_1b56aa45-2dc4-47ef-9905-4393f5ea889d"
      unitRef="usd">-119000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjgtMS0xLTEtMzQ0MTE_0080f628-0bca-4548-a9ec-edbb2d2e4700"
      unitRef="usd">-304836000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjgtMy0xLTEtMzQ0MTE_e9883455-f9ae-4ae9-875e-b7589cd12838"
      unitRef="usd">-282871000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjktMS0xLTEtMzQ0MTE_6f08348f-ea63-47d0-ae6e-813263434316"
      unitRef="usd">49714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMjktMy0xLTEtMzQ0MTE_a9d3731c-a12d-479a-86b6-07025a357153"
      unitRef="usd">64412000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMzAtMS0xLTEtMzQ0MTE_f617e66d-e565-4a8d-856e-72af20b61fb2"
      unitRef="usd">99625000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yMi9mcmFnOjY5N2VmZTIzY2M0ODQ5YzJiYWNlNDkxOGIyN2VlMDJmL3RhYmxlOjRmYTJmODY1M2IzZjQ0YWM5YzMwMDQ1ZjVjNGVkNDU2L3RhYmxlcmFuZ2U6NGZhMmY4NjUzYjNmNDRhYzljMzAwNDVmNWM0ZWQ0NTZfMzAtMy0xLTEtMzQ0MTE_780795bf-7b7d-4988-9921-2bfc0009843f"
      unitRef="usd">117176000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNC0xLTEtMS0zNDQxMQ_b520ce6e-646d-42f3-b7b8-6cec3a17a2ea"
      unitRef="usd">14113000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNC0zLTEtMS0zNDQxMQ_007f76e3-06aa-49b8-afb8-3d508c5493f5"
      unitRef="usd">12104000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNS0xLTEtMS0zNDQxMQ_ccc4a2da-acf2-4ded-ac58-6a6fcf527745"
      unitRef="usd">7664000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNS0zLTEtMS0zNDQxMQ_c3d49f7a-f063-4010-bbe3-64d4682f8af1"
      unitRef="usd">5832000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNi0xLTEtMS0zODc5NA_18c9d18b-432c-45da-87ca-f84c49074041"
      unitRef="usd">509000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNi0zLTEtMS0zOTY1NA_daa03654-8562-4394-93bc-60b254586e2a"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:OperatingExpenses
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNi0xLTEtMS0zNDQxMQ_6d82fd05-f083-4a36-b3d3-8c452750ff23"
      unitRef="usd">21268000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNi0zLTEtMS0zNDQxMQ_ce4e243b-46a3-40f9-ba43-da0229c9462e"
      unitRef="usd">17936000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNy0xLTEtMS0zNDQxMQ_f918fc1c-b3ca-4eca-af05-556045056745"
      unitRef="usd">-21268000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfNy0zLTEtMS0zNDQxMQ_fad2a4ea-bb23-44c3-9365-bab885c8dc61"
      unitRef="usd">-17936000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfOS0xLTEtMS0zNDQxMQ_b5fd3f43-2254-47b1-afa9-fc34df760944"
      unitRef="usd">3000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfOS0zLTEtMS0zNDQxMQ_44ccaeae-9f7a-4173-a272-2debee4b52bf"
      unitRef="usd">2000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTAtMS0xLTEtMzQ0MTE_ca102fec-dfd1-4e54-af63-5f566d237715"
      unitRef="usd">913000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTAtMy0xLTEtMzQ0MTE_797c042e-df82-499f-aff6-659a75d8ee9f"
      unitRef="usd">891000</us-gaap:InterestExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTEtMS0xLTEtMzQ0MTE_23d16b96-1248-49b5-a52b-2129c5689f7c"
      unitRef="usd">176000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTEtMy0xLTEtMzQ0MTE_c3fdd2f7-99a5-4d6c-81c8-434531fef16d"
      unitRef="usd">-31000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTItMS0xLTEtMzQ0MTE_e11eae8b-efab-4a2c-8009-5f9e7c50dd3d"
      unitRef="usd">60000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTItMy0xLTEtMzQ0MTE_d171e344-5983-4ca4-b6b5-de3c9f41de6d"
      unitRef="usd">186000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTQtMS0xLTEtMzQ0MTE_b6b18611-563b-44d6-8201-0b7731cb5ece"
      unitRef="usd">-674000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTQtMy0xLTEtMzQ0MTE_4d95f560-3843-4a27-aeaf-923328db0879"
      unitRef="usd">-734000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTUtMS0xLTEtMzQ0MTE_0b943eac-e033-47fb-8d4d-506b2e31daeb"
      unitRef="usd">-21942000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTUtMy0xLTEtMzQ0MTE_541815ac-3fb8-48ed-8d64-6abd958743ab"
      unitRef="usd">-18670000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTYtMS0xLTEtMzQ0MTE_4087e002-3386-48d7-934b-29e7af98c978"
      unitRef="usd">23000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTYtMy0xLTEtMzQ0MTE_ad0504ec-1e55-42a3-bc09-3f4a3a55096d"
      unitRef="usd">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTctMS0xLTEtMzQ0MTE_13756b9d-bb45-4009-8513-df0c8e8a112d"
      unitRef="usd">-21965000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2425a0da056146c48327ec0587899d61_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTctMy0xLTEtMzQ0MTE_4c3b0477-959b-40a3-aeef-cb02ce3d3134"
      unitRef="usd">-18676000</us-gaap:NetIncomeLoss>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTgtMS0xLTEtMzQ0MTE_a7576fff-0027-4bb1-89ec-ef1f49493c0d"
      unitRef="usd">2259000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTgtMy0xLTEtMzQ0MTE_4d1536b0-5181-4237-b8d8-6d23bccc7206"
      unitRef="usd">8239000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTktMS0xLTEtMzQ0MTE_700955f7-83aa-44c2-9a69-2a51dc98f10e"
      unitRef="usd">-24224000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMTktMy0xLTEtMzQ0MTE_4380b22a-58ee-4fdf-ad65-c795e17d01c0"
      unitRef="usd">-26915000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMjAtMS0xLTEtMzQ0MTE_b435a167-2643-4da4-a3aa-1469bb093c7e"
      unitRef="usdPerShare">-0.72</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMjAtMy0xLTEtMzQ0MTE_b33dcda5-45c2-4c45-8d8b-9379a200576d"
      unitRef="usdPerShare">-1.30</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMjEtMS0xLTEtMzQ0MTE_709e532c-1f0d-4669-ad08-b3a439303562"
      unitRef="shares">33737000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yNS9mcmFnOjQzOWFkZjc2NDgyZTQzYzY5MjllNWQ1YmE2Y2Y0YWJmL3RhYmxlOjMxMTZmMDNiNDI3OTQyYWI5OGU0YTg0NGIzYjNjMDlhL3RhYmxlcmFuZ2U6MzExNmYwM2I0Mjc5NDJhYjk4ZTRhODQ0YjNiM2MwOWFfMjEtMy0xLTEtMzQ0MTE_bee75ff4-7b8b-48e1-b19c-9e881372ebe3"
      unitRef="shares">20751000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="ib471740b6fdd47e8af8050737b18ccdb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMi0xLTEtMS0zNDQxMQ_539634a4-1c2e-43ae-82e5-11da9599c8e0"
      unitRef="shares">28127657</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib471740b6fdd47e8af8050737b18ccdb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMi0zLTEtMS0zNDQxMQ_79d8e708-8a23-448a-b40d-fab2ee1c06e2"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i854c77af00bd4ce9a4dfdb9a27239dce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMi01LTEtMS0zNDQxMQ_ea8cf5a1-9f06-4b44-83f9-632bc19cd75b"
      unitRef="usd">347374000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60e626d1eb1f4f26b74d82ff06b61afd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMi03LTEtMS0zNDQxMQ_c79823c3-8b3c-4a76-af1c-dadf1b9dc941"
      unitRef="usd">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib6895f9ac9ea474583d9fff78ede70b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMi05LTEtMS0zNDQxMQ_304cc1b0-d926-470c-a008-b5dce3331d77"
      unitRef="usd">-282871000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMi0xMS0xLTEtMzQ0MTE_fafb7a20-869d-4221-8029-dc957c7b1b04"
      unitRef="usd">64412000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i01d79d96f4a7455f94d5d1c06a5e5b1b_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMy0xLTEtMS0zNjM5MQ_51db5e3c-0508-4d82-b656-b1ae177dc5f0"
      unitRef="shares">2512902</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i01d79d96f4a7455f94d5d1c06a5e5b1b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMy0zLTEtMS0zNjM5MQ_44498c30-56c9-47eb-8fb5-09323d34b1aa"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie8de9ba4633443dbaddd152d4d468a43_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMy01LTEtMS0zNjM5MQ_89c9a1b0-05b1-4d9a-85c3-9532b5bd1618"
      unitRef="usd">5817000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMy0xMS0xLTEtMzYzOTE_e9638c86-d685-4304-8a1e-a5add0f4c5bd"
      unitRef="usd">5820000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="i01d79d96f4a7455f94d5d1c06a5e5b1b_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMy0xLTEtMS0zNDQxMQ_440a4de7-07be-4597-9a77-9df48213e6cc"
      unitRef="shares">168817</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="ie8de9ba4633443dbaddd152d4d468a43_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMy01LTEtMS0zNDQxMQ_57dda43d-a6c2-4763-bee6-aba27f6ea93f"
      unitRef="usd">-12000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfMy0xMS0xLTEtMzQ0MTE_b3a47669-9f4a-42d5-a7cb-c45b1311f86a"
      unitRef="usd">-12000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <xfor:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i01d79d96f4a7455f94d5d1c06a5e5b1b_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNS0xLTEtMS0zOTAwMw_edaaebb4-f52f-4005-951e-c9a28fe568c8"
      unitRef="shares">100</xfor:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie8de9ba4633443dbaddd152d4d468a43_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNC01LTEtMS0zNDQxMQ_bb6542f2-e7e5-4e36-b5eb-2f5bfca398a1"
      unitRef="usd">1459000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNC0xMS0xLTEtMzQ0MTE_f8657460-cb8a-433c-906d-88d53de83cb0"
      unitRef="usd">1459000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ia22eddc0d4a54868be305ee81dbe30b5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNS05LTEtMS0zNDQxMQ_800e22c6-839c-4cd5-a613-971da27382a9"
      unitRef="usd">-21965000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNS0xMS0xLTEtMzQ0MTE_5dd7b07b-1533-4989-acfb-b235d007869c"
      unitRef="usd">-21965000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i54a6aa4f5e554082b147ea3e13218602_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNi0xLTEtMS0zNDQxMQ_807e28d2-a474-4a29-a085-c4fc5c4b61af"
      unitRef="shares">30809476</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i54a6aa4f5e554082b147ea3e13218602_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNi0zLTEtMS0zNDQxMQ_b0afb1c6-3476-4201-9316-37bccd39b62f"
      unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i047748a25ba140d9bf8ddde9f403b7c3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNi01LTEtMS0zNDQxMQ_f8f03458-8811-479d-96de-a6b4414608a0"
      unitRef="usd">354638000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4df9455becee450483e383bda2635fb6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNi03LTEtMS0zNDQxMQ_b16f0e3b-867a-4434-85f5-372d57426477"
      unitRef="usd">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0ec92573d25494d9ec868ce6d803b1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNi05LTEtMS0zNDQxMQ_768b2084-4edd-480a-a758-2b777134f20f"
      unitRef="usd">-304836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjRlNDNjY2RhZWViNTQwNzY4MzZmOTlmOTE0NTc4NzgwL3RhYmxlcmFuZ2U6NGU0M2NjZGFlZWI1NDA3NjgzNmY5OWY5MTQ1Nzg3ODBfNi0xMS0xLTEtMzQ0MTE_4f2ecd2a-5ff2-4ce6-894d-5f9bc126e760"
      unitRef="usd">49714000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i86f8f316e485428cbd4027d61748adf8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi0xLTEtMS0zNDQxMQ_aeead976-17dc-45b1-b386-74dc4372f1bf"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="i86f8f316e485428cbd4027d61748adf8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi0zLTEtMS0zNDQxMQ_03f4b43d-766e-4155-bcca-1f4ddad5daaa"
      unitRef="usd">0</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:SharesOutstanding
      contextRef="ic7e2cf99863b4fb88048889aa87cf96f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi01LTEtMS0zNDQxMQ_deed65ae-1ce1-48ae-b930-adcb1142d694"
      unitRef="shares">16305731</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic7e2cf99863b4fb88048889aa87cf96f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi03LTEtMS0zNDQxMQ_6b1e3fbf-83de-4f7c-aa94-342a06c030b4"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5d7e807d2ef42dda0ab3c941f8caf6f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi05LTEtMS0zNDQxMQ_c401a01d-f142-4b20-8c48-efbb70eb0017"
      unitRef="usd">267077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f4ba6165a6d4e068a782de9870bba11_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi0xMS0xLTEtMzQ0MTE_b172cad9-efa8-4743-868e-f5b16cf9954f"
      unitRef="usd">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c210c0dd8634743ac3fe20cd14d7221_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi0xMy0xLTEtMzQ0MTE_584ff457-7dad-4de6-ae89-fef0828751a4"
      unitRef="usd">-194175000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i66c88a11b199434aace5aef0bbc9f5ea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMi0xNS0xLTEtMzQ0MTE_74274dd2-90d6-4eac-b1cf-815ecda6bf56"
      unitRef="usd">72799000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="icb5a551d13c443f58e2de92a4c349fb4_D20211001-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMy0wLTEtMS0zNDQxMS90ZXh0cmVnaW9uOmNjZjJhOTU2MzYzYTQ3NmY5ODhiMDBmMTUzYzhmYzMxXzEzOA_c2750e2c-0a45-4b5f-9d38-91d7d0015c03"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0a536b78307a42ecbcb3238de82af6f7_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMy0xLTEtMS0zNDQxMQ_8f1f190c-db0a-4873-b1ec-ddcd9b66ff95"
      unitRef="shares">229885</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0a536b78307a42ecbcb3238de82af6f7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMy0zLTEtMS0zNDQxMQ_11077447-890d-47ab-ba61-04cf922047e0"
      unitRef="usd">1875000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if552410f512d4f14be1678c6b554dbef_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMy01LTEtMS0zNDQxMQ_e0359f63-a630-4644-b525-d8ae9b3d71f7"
      unitRef="shares">6041951</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if552410f512d4f14be1678c6b554dbef_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMy03LTEtMS0zNDQxMQ_99751623-5957-4faa-9f4f-5c3ef3b88fb1"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2328bc9fe2404a29a05fe278a1035750_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMy05LTEtMS0zNDQxMQ_0e27a450-4322-497d-83d4-f49aae19ba4b"
      unitRef="usd">49633000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfMy0xNS0xLTEtMzQ0MTE_bcab4c92-994d-44ae-b9d3-4689e27859dd"
      unitRef="usd">49640000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if552410f512d4f14be1678c6b554dbef_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNC01LTEtMS0zNDQxMQ_775bdfb6-46dd-45ce-9075-fa64fa929202"
      unitRef="shares">5860</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2328bc9fe2404a29a05fe278a1035750_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNC05LTEtMS0zNDQxMQ_746f40e2-35a5-461e-8e7f-1af58d645fb4"
      unitRef="usd">40000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNC0xNS0xLTEtMzQ0MTE_8c90268f-3564-494b-96b4-d21dc3828ab7"
      unitRef="usd">40000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <xfor:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="if552410f512d4f14be1678c6b554dbef_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNS01LTEtMS0zNDQxMQ_5088479f-1680-4f2c-9d49-402357507add"
      unitRef="shares">1072887</xfor:StockIssuedDuringPeriodSharesWarrantsExercised>
    <xfor:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="if552410f512d4f14be1678c6b554dbef_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNS03LTEtMS0zNDQxMQ_57818886-72a7-4b1f-9407-1e6fe0db91c0"
      unitRef="usd">1000</xfor:StockIssuedDuringPeriodValueWarrantsExercised>
    <xfor:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNS0xNS0xLTEtMzQ0MTE_2a1b3359-a3f6-40c9-8a85-fa1d28ce26db"
      unitRef="usd">1000</xfor:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2328bc9fe2404a29a05fe278a1035750_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNi05LTEtMS0zNDQxMQ_9f909efa-dab5-43e9-96b0-044d1d82ffab"
      unitRef="usd">1258000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNi0xNS0xLTEtMzQ0MTE_68e34078-4602-48eb-952b-8593848db897"
      unitRef="usd">1258000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i2425a0da056146c48327ec0587899d61_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNy0xMy0xLTEtMzQ0MTE_e85fb62e-98f8-4ce5-bc60-85b45ae433e6"
      unitRef="usd">-18676000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfNy0xNS0xLTEtMzQ0MTE_73c8ea78-ed27-4696-84ba-0ec1b344b63c"
      unitRef="usd">-18676000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i6216409af0d8456fa56993e3fe6c83f0_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC0xLTEtMS0zNDQxMQ_5cbbac21-19e3-4723-ad22-c744eb3c7957"
      unitRef="shares">229885</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="i6216409af0d8456fa56993e3fe6c83f0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC0zLTEtMS0zNDQxMQ_42d7d7ed-97fa-401b-a7a2-be56b3cdf89a"
      unitRef="usd">1875000</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:SharesOutstanding
      contextRef="i8c30ad47284440ecb1152f67b75b14bf_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC01LTEtMS0zNDQxMQ_d297dd20-ec77-4b0d-9fbe-9f8cf97cf21c"
      unitRef="shares">23426429</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8c30ad47284440ecb1152f67b75b14bf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC03LTEtMS0zNDQxMQ_617f08f7-eda7-483e-9c13-d6bb54b3a57e"
      unitRef="usd">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6490c404c2e943b29d2afa3f5b15a0ed_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC05LTEtMS0zNDQxMQ_aa8fc9b4-2965-4fa5-a254-b52cf3c70820"
      unitRef="usd">318008000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifa75eebec540404b9087007bb78de87d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC0xMS0xLTEtMzQ0MTE_f85c3bab-27ae-4c5d-9e2b-697d7eafc0d9"
      unitRef="usd">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifa18918dfe8b4eb99398f5469d0f1f20_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC0xMy0xLTEtMzQ0MTE_2409a23a-c33b-4e0e-b4f9-a43956a77b5f"
      unitRef="usd">-212851000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i53f51ae8287e4f2a9dc20c9692a90f3b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8yOC9mcmFnOjM1YzcwOWYyOGI3OTQzYjJiNTkxY2I3NzUzODhkODMxL3RhYmxlOjNhNTkzMjRlOTA5YzQyOTU5ODNmZDBlMzJjMGUxMTE1L3RhYmxlcmFuZ2U6M2E1OTMyNGU5MDljNDI5NTk4M2ZkMGUzMmMwZTExMTVfOC0xNS0xLTEtMzQ0MTE_ad30d92c-ea56-4d01-8e49-d5c95088195f"
      unitRef="usd">105062000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMy0xLTEtMS0zNDQxMQ_6373c428-1948-42de-92e1-6982f15b32d2"
      unitRef="usd">-21965000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMy0zLTEtMS0zNDQxMQ_204d7152-bc22-4f0a-9d17-ad58d6213112"
      unitRef="usd">-18676000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfNS0xLTEtMS0zNDQxMQ_1dd1389a-3084-435d-a8f5-9c4cb0d476f7"
      unitRef="usd">1459000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfNS0zLTEtMS0zNDQxMQ_b6a63cba-99fc-4e82-b93c-56e448a46b4d"
      unitRef="usd">1258000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfNi0xLTEtMS0zNDQxMQ_7c6188ba-ecb6-4936-b78a-bed3a8b16433"
      unitRef="usd">133000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfNi0zLTEtMS0zNDQxMQ_c2080a99-b39f-4d8a-b56e-21c14b240aca"
      unitRef="usd">106000</us-gaap:DepreciationDepletionAndAmortization>
    <xfor:NonCashLeaseExpense
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfNy0xLTEtMS0zNDQxMQ_b7243937-5c4f-4251-b1ec-b82e3f9325f0"
      unitRef="usd">366000</xfor:NonCashLeaseExpense>
    <xfor:NonCashLeaseExpense
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfNy0zLTEtMS0zNDQxMQ_35481d01-9ecc-4197-87f9-907b68dc0a64"
      unitRef="usd">314000</xfor:NonCashLeaseExpense>
    <xfor:NonCashInterestExpense
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfOC0xLTEtMS0zNDQxMQ_db298da7-9357-4422-b913-4254e832c2d7"
      unitRef="usd">198000</xfor:NonCashInterestExpense>
    <xfor:NonCashInterestExpense
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfOC0zLTEtMS0zNDQxMQ_1dac44e7-0542-44bd-a626-b6d83ad20c2b"
      unitRef="usd">178000</xfor:NonCashInterestExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTAtMS0xLTEtMzQ0MTE_59b85549-2f34-4955-bf9c-0be4f15ccb88"
      unitRef="usd">120000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTAtMy0xLTEtMzQ0MTE_eaaf024c-91ce-422a-94c0-997672d0bd15"
      unitRef="usd">-99000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTItMS0xLTEtMzQ0MTE_d69b6540-7431-423d-850e-0a67b708b956"
      unitRef="usd">-1633000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTItMy0xLTEtMzQ0MTE_53971767-b8ab-44c6-8530-141a9bffbe32"
      unitRef="usd">711000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTMtMS0xLTEtMzQ0MTE_25af890d-aacc-4d50-a56d-31609db32a2e"
      unitRef="usd">-713000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTMtMy0xLTEtMzQ0MTE_1dafcee1-45de-43e6-982d-2f8d7ba3b951"
      unitRef="usd">-23000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTQtMS0xLTEtMzQ0MTE_6b815a36-4501-4e71-a7c9-be1d54a7f7de"
      unitRef="usd">-984000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTQtMy0xLTEtMzQ0MTE_6f1d4a18-45d5-40bf-997b-708d0419a2e3"
      unitRef="usd">-786000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <xfor:IncreaseDecreaseInLeaseLiabilities
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTUtMS0xLTEtMzQ0MTE_409df25b-e060-4bd4-bcb4-4ed8efccf52d"
      unitRef="usd">-236000</xfor:IncreaseDecreaseInLeaseLiabilities>
    <xfor:IncreaseDecreaseInLeaseLiabilities
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTUtMy0xLTEtMzQ0MTE_4204ab24-285e-4bef-9eae-ca9f6aae46c7"
      unitRef="usd">-160000</xfor:IncreaseDecreaseInLeaseLiabilities>
    <xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTYtMS0xLTEtMzQ0MTE_906b71cc-4b98-4362-b8b4-effa46bb5e5f"
      unitRef="usd">0</xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion>
    <xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTYtMy0xLTEtMzQ0MTE_c804141c-fcab-4c08-b157-935eb69b7b8e"
      unitRef="usd">43000</xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTctMS0xLTEtMzQ0MTE_4b738dcb-f4db-4ae9-9b17-519d57ef2e02"
      unitRef="usd">-20229000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTctMy0xLTEtMzQ0MTE_8106aca5-07c2-4e05-b516-450b7363e0a2"
      unitRef="usd">-18444000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTktMS0xLTEtMzQ0MTE_9ab06298-df11-46b3-a138-0320fec06f9d"
      unitRef="usd">22000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMTktMy0xLTEtMzQ0MTE_cb63fc87-d0c4-43ef-b3e3-2d4277f195d1"
      unitRef="usd">496000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjAtMS0xLTEtMzQ0MTE_00cdaaae-719d-4715-b179-00781a8f7891"
      unitRef="usd">-22000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjAtMy0xLTEtMzQ0MTE_4614b5b5-91ca-4f7e-9322-e1c4ea16ffc7"
      unitRef="usd">-496000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <xfor:ProceedsFromExerciseOfStockOptionsAndWarrants
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjItMS0xLTEtMzQ0MTE_6c6c964d-2251-422f-9cba-6af51cd0b844"
      unitRef="usd">0</xfor:ProceedsFromExerciseOfStockOptionsAndWarrants>
    <xfor:ProceedsFromExerciseOfStockOptionsAndWarrants
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjItMy0xLTEtMzQ0MTE_777bb14a-3ce4-4b91-9981-9f0bfe296a0a"
      unitRef="usd">41000</xfor:ProceedsFromExerciseOfStockOptionsAndWarrants>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjMtMS0xLTEtMzQ0MTE_2e0492c7-907f-4bde-ad59-bca452b03c23"
      unitRef="usd">12000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjMtMy0xLTEtMzQ0MTE_3c49b3cf-45ac-4ce4-afa0-3cb45d0a5865"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <xfor:ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjQtMS0xLTEtMzQ0MTE_51245234-9d0f-4cd5-80ee-7f2af0df7b15"
      unitRef="usd">114000</xfor:ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts>
    <xfor:ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjQtMy0xLTEtMzQ0MTE_c1676bd3-8867-4051-8699-8e73211da966"
      unitRef="usd">0</xfor:ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjUtMS0xLTEtMzkwMzM_03fabc9a-b35f-419f-9c04-d2071b28c501"
      unitRef="usd">795000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjUtMy0xLTEtMzk3MDY_924750a3-382e-4fd8-96dc-a7c0da8179c0"
      unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
    <xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjUtMS0xLTEtMzQ0MTE_04072499-180e-4568-ad41-ba0a6cac179f"
      unitRef="usd">5877000</xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts>
    <xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjUtMy0xLTEtMzQ0MTE_b73a22de-432d-4752-b7df-b708b567875a"
      unitRef="usd">55000000</xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjctMS0xLTEtMzQ0MTE_6bf59adc-7dbb-4d7e-be5b-9255ebb8ff9c"
      unitRef="usd">4956000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjctMy0xLTEtMzQ0MTE_cc8d9e85-58ca-411d-8522-50ef8cb8d132"
      unitRef="usd">55041000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjgtMS0xLTEtMzQ0MTE_abd431ff-b854-4c2c-8bb2-aaf25429860c"
      unitRef="usd">-69000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjgtMy0xLTEtMzQ0MTE_fa9bbbf1-eba0-407e-be77-145d6bbb056a"
      unitRef="usd">-143000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjktMS0xLTEtMzQ0MTE_0b458d60-c0c2-4ac8-aac4-e86717ad155b"
      unitRef="usd">-15364000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMjktMy0xLTEtMzQ0MTE_bd831557-8804-4673-b4a3-c2c205116b31"
      unitRef="usd">35958000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzAtMS0xLTEtMzQ0MTE_e441fb6e-030b-434b-99ba-872b0fc5c92c"
      unitRef="usd">83108000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i66c88a11b199434aace5aef0bbc9f5ea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzAtMy0xLTEtMzQ0MTE_f0d18994-cccd-454c-9839-3bb4e114c755"
      unitRef="usd">80702000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzEtMS0xLTEtMzQ0MTE_9d51a938-61b0-4492-932a-9d6fdfa43a26"
      unitRef="usd">67744000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i53f51ae8287e4f2a9dc20c9692a90f3b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzEtMy0xLTEtMzQ0MTE_b381e065-c27f-47ec-8515-b1c83a420220"
      unitRef="usd">116660000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzQtMS0xLTEtMzQ0MTE_6a0f6621-c30a-443f-921f-ef1591b3ab93"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzQtMy0xLTEtMzQ0MTE_7fcec14a-9759-45b8-8383-e469dcbbde7d"
      unitRef="usd">17000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzUtMS0xLTEtMzQ0MTE_b8f2e8d9-3853-4623-ae0d-4475a0e987cd"
      unitRef="usd">0</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzUtMy0xLTEtMzQ0MTE_508bea07-0aee-46e2-8c35-a63def936340"
      unitRef="usd">1343000</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzYtMS0xLTEtMzQ0MTE_7f0817ac-1945-4e00-a05e-e2657ef6741e"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zMS9mcmFnOjE5NjlhYTEyM2ZjNzQ5MmZiNjkwMGY5YTM1NjUwNTJmL3RhYmxlOjI0OTU3ODM4MWZiZTRjZTRiZmM5YmU3NWI3ZmRhNWQ5L3RhYmxlcmFuZ2U6MjQ5NTc4MzgxZmJlNGNlNGJmYzliZTc1YjdmZGE1ZDlfMzYtMy0xLTEtMzQ0MTE_9e16efcf-eb5d-4cda-bb77-8c6dd35ac14a"
      unitRef="usd">3485000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zNy9mcmFnOjRhOWY0NDNiNGVlOTRiMzc5NTExM2I4MTAxZTcxZWQ1L3RleHRyZWdpb246NGE5ZjQ0M2I0ZWU5NGIzNzk1MTEzYjgxMDFlNzFlZDVfNDM5Mw_9097313d-45e4-4ee9-b8a3-7955eb539d4c">NATURE OF THE BUSINESS AND BASIS OF PRESENTATION&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;X4 Pharmaceuticals, Inc. (together with its subsidiaries, the &#x201c;Company&#x201d;) is a late-stage clinical biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases. The Company&#x2019;s lead product candidate, mavorixafor, is a potential first-in-class, once-daily, oral inhibitor of CXCR4 and is currently in a Phase 3 clinical trial for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#x201c;WHIM&#x201d;) syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. The Company is also conducting a 14-day, proof-of-concept Phase 1b clinical trial of mavorixafor in patients with Severe Congenital Neutropenia (&#x201c;SCN&#x201d;) and chronic neutropenia disorders, and a Phase 1b clinical trial of mavorixafor in combination with ibrutinib in Waldenstr&#xf6;m&#x2019;s macroglobulinemia (&#x201c;Waldenstr&#xf6;m&#x2019;s&#x201d;). The Company is headquartered in Boston, Massachusetts and has an additional facility in Vienna, Austria. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern Assessment&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. As of March 31, 2022, the Company had $66.4 million of cash and cash equivalents. Based on its current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expense and capital expenditure requirements into the fourth quarter of 2022. However, as further discussed in Note 7, the Company has a covenant under its loan agreement with Hercules Capital Inc. (&#x201c;Hercules&#x201d;) that requires that the Company maintain a minimum level of cash, as defined, beginning on September 1, 2022. Based on its current financial projections, the Company believes it would be in violation of this covenant in the third quarter of 2022. If the Company is in violation of this covenant, Hercules could require the repayment of all outstanding debt. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result, the Company believes that, in the aggregate, these conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. Nevertheless, the accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. In order to fund its operations beyond the fourth quarter of 2022, the Company is seeking to raise funds potentially through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations and strategic alliances. If the Company is unable to obtain future funding when needed, the Company may be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or pre-commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. There is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impact of the COVID-19 Pandemic&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in late 2019 and continuing into 2022, the outbreak of COVID-19 has resulted in the declaration of a global pandemic and adversely affected economic activity across virtually all sectors and industries on a local, national and global scale. Impacts to the Company&#x2019;s business have included temporary closures or postponements of activation of its clinical trial sites or facilities, disruptions or restrictions on its employees&#x2019; ability to travel, disruptions to or delays in ongoing clinical trials, including patient enrollment at a slower pace than initially projected and the diversion of healthcare resources away from the conduct of the Company&#x2019;s clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as the Company&#x2019;s clinical trial sites and hospital staff supporting the conduct of the Company&#x2019;s clinical trials. While global vaccination efforts are underway and certain jurisdictions, including Massachusetts, where the Company is headquartered, have reopened businesses and governmental agencies, there remain limitations on the physical operations of businesses and prohibitions on certain non-essential gatherings, and the Company is unable to accurately predict the full impact that COVID-19 will have due to numerous uncertainties, including the duration of the outbreak, the result of vaccination efforts, resurgence of the virus, actions that may be taken by governmental authorities, the impact on the Company&#x2019;s business including its clinical programs and timelines, and the impact to the business of its service providers and partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl8zNy9mcmFnOjRhOWY0NDNiNGVlOTRiMzc5NTExM2I4MTAxZTcxZWQ1L3RleHRyZWdpb246NGE5ZjQ0M2I0ZWU5NGIzNzk1MTEzYjgxMDFlNzFlZDVfMTM0Mg_346f4f81-70fb-4131-be85-fba9bebc110d"
      unitRef="usd">66400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNTE_d38a702b-569f-48bd-8863-7a4fb2c93061">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 17, 2022 (the &#x201c;2021 Annual Report&#x201d;). Since the &lt;/span&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;date of those consolidated financial statements, there have been no material changes to the Company&#x2019;s significant accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The impact of the ongoing COVID-19 pandemic has been and, notwithstanding vaccination efforts, is expected to continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. Impacts to the Company&#x2019;s business have included temporary closures or postponements of activation of its clinical trial sites or facilities, disruptions or restrictions on its employees&#x2019; ability to travel, disruptions to or delays in ongoing clinical trials, including patient enrollment at a slower pace than initially projected and the diversion of healthcare resources away from the conduct of the Company&#x2019;s clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as the Company&#x2019;s clinical trial sites and hospital staff supporting the conduct of the Company&#x2019;s clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biotechnology industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and the challenges of complying with applicable regulatory requirements. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#x2019;s business and results of operations, it is expected also to have the effect of heightening many of the other risks and uncertainties discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including X4 Pharmaceuticals (Austria) GmbH, which is incorporated in Vienna, Austria (&#x201c;X4 Austria&#x201d;), and X4 Therapeutics, Inc. All significant intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Condensed Consolidated Financial Statements&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheet at December 31, 2021 that is presented in these interim condensed consolidated financial statements was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying condensed consolidated financial statements are unaudited. The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC for interim financial statements. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s&#160;audited financial statements and the notes thereto for the year ended December&#160;31, 2021 included in the 2021 Annual Report. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&#x2019;s condensed financial position, condensed results of its operations and cash flows have been made. The results of operations for the three months ended March&#160;31, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and the constraint of variable consideration from contracts with customers. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The COVID-19 pandemic has impacted and is expected to continue to impact the clinical development timelines for certain of the Company's clinical programs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the date of issuance of these condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of March&#160;31, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letter of credit security: Waltham lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letter of credit security: Vienna Austria lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letter of credit security: Boston lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company&#x2019;s lease agreements for its facilities in Massachusetts and Austria, the Company maintains letters of credit, which are secured by restricted cash, for the benefit of the respective landlord. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the sum of the total of amounts shown in the Company&#x2019;s condensed consolidated statements of cash flows as of March&#160;31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform an interim quantitative impairment test, whereby the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than its carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. There were no triggering events during the three months ended March 31, 2022 that necessitated an interim impairment test of goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2021-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASU 2021-04 was issued to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants for the purchase of common shares) that remain classified as equity following the modification or exchange. ASU 2021-04 is effective January 1, 2022 for the Company. The adoption of this standard did not have an impact on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2016-13"), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. In accordance with ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326), Derivative and Hedging (Topic 815), and Leases (Topic 842)- Effective &lt;/span&gt;&lt;/div&gt;Dates, as the Company meets the definition of a &#x201c;smaller reporting company&#x201d;, the Company has elected to defer the adoption of ASU 2016-13 until January 1, 2023. The Company expects that the adoption of ASU 2016-13 may accelerate the timing and could increase the level of credit loss expense in the consolidated statement of operations and will likely require an increased level of disclosure in the notes to the consolidated financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNDc_fd5d73e4-b411-4910-b89f-8e05ca37a4c4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including X4 Pharmaceuticals (Austria) GmbH, which is incorporated in Vienna, Austria (&#x201c;X4 Austria&#x201d;), and X4 Therapeutics, Inc. All significant intercompany accounts and transactions have been eliminated.&lt;/span&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNTQ_b0e0dfe7-60d0-4c1c-acdc-be6e69d70a0f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Condensed Consolidated Financial Statements&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheet at December 31, 2021 that is presented in these interim condensed consolidated financial statements was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying condensed consolidated financial statements are unaudited. The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC for interim financial statements. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s&#160;audited financial statements and the notes thereto for the year ended December&#160;31, 2021 included in the 2021 Annual Report. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&#x2019;s condensed financial position, condensed results of its operations and cash flows have been made. The results of operations for the three months ended March&#160;31, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December&#160;31, 2022.&lt;/span&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNTU_94ca7773-784e-4cb7-a39d-6c3ad9f7acad">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and the constraint of variable consideration from contracts with customers. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The COVID-19 pandemic has impacted and is expected to continue to impact the clinical development timelines for certain of the Company's clinical programs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the date of issuance of these condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNDg_a0919d8b-ccd9-46a2-bf08-77cdab6db0aa">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of March&#160;31, 2022 and December&#160;31, 2021.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCompensatingBalancesTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNTc_460f91c9-e3c6-4c2b-9cb5-3a58b312b981">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letter of credit security: Waltham lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letter of credit security: Vienna Austria lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letter of credit security: Boston lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensatingBalancesTextBlock>
    <us-gaap:RestrictedCash
      contextRef="if34f27299a434668885ee2416dec75fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfMi0xLTEtMS0zNDQxMQ_109e8089-a91c-454c-8d67-1822628fccd3"
      unitRef="usd">250000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i7257e82e68c041908175389a8f7bdea1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfMi0zLTEtMS0zNDQxMQ_85e28268-7ae7-4619-be54-376d41116102"
      unitRef="usd">250000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ica1cbeac75bb4931b6a264bbff4cb6ac_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfMy0xLTEtMS0zNDQxMQ_9843e9cc-178c-40e1-aeb3-377000ba238d"
      unitRef="usd">212000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i9911b058cb814046a3c2b033f5239f56_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfMy0zLTEtMS0zNDQxMQ_4dfffa9d-bcaa-4fec-8fb4-0d478ab1dd23"
      unitRef="usd">216000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i8b8c9dbcf0c44ed99f42775671ed3b03_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfNC0xLTEtMS0zNDQxMQ_1313ad08-a591-4048-8308-d4d359165db0"
      unitRef="usd">855000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ideaca6ba9ebd4d459db86e8fec1e7f54_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfNC0zLTEtMS0zNDQxMQ_8f02f0bd-6d34-4900-a33d-31ab435b1560"
      unitRef="usd">855000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfNy0xLTEtMS0zNDQxMQ_990bfd7c-423c-4200-932b-f9fbdaf745f5"
      unitRef="usd">1317000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmMxODk2ZmFmYTIxZTRjOWU5YmIyMTg4ZTkxMzE3ZTc0L3RhYmxlcmFuZ2U6YzE4OTZmYWZhMjFlNGM5ZTliYjIxODhlOTEzMTdlNzRfNy0zLTEtMS0zNDQxMQ_01e297f8-49b7-48a6-9d45-3cd961998604"
      unitRef="usd">1321000</us-gaap:RestrictedCashNoncurrent>
    <xfor:ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNTk_f5269b17-45f5-4105-aa2a-e2edee613315">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the sum of the total of amounts shown in the Company&#x2019;s condensed consolidated statements of cash flows as of March&#160;31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</xfor:ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmVhNGE3OTJiMTA1NjRmMjRiYWQyNjljYjdiOGM2ODlmL3RhYmxlcmFuZ2U6ZWE0YTc5MmIxMDU2NGYyNGJhZDI2OWNiN2I4YzY4OWZfMS0xLTEtMS0zNDQxMQ_bf932a8d-9f35-415f-8b0f-b7e3272d0593"
      unitRef="usd">66427000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmVhNGE3OTJiMTA1NjRmMjRiYWQyNjljYjdiOGM2ODlmL3RhYmxlcmFuZ2U6ZWE0YTc5MmIxMDU2NGYyNGJhZDI2OWNiN2I4YzY4OWZfMS0zLTEtMS0zNDQxMQ_9471f3bb-b735-4c2f-8331-6e4fa7e7c49b"
      unitRef="usd">81787000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmVhNGE3OTJiMTA1NjRmMjRiYWQyNjljYjdiOGM2ODlmL3RhYmxlcmFuZ2U6ZWE0YTc5MmIxMDU2NGYyNGJhZDI2OWNiN2I4YzY4OWZfMy0xLTEtMS0zNDQxMQ_d2092c33-6063-4f66-bba5-bd20d2cafcbd"
      unitRef="usd">1317000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmVhNGE3OTJiMTA1NjRmMjRiYWQyNjljYjdiOGM2ODlmL3RhYmxlcmFuZ2U6ZWE0YTc5MmIxMDU2NGYyNGJhZDI2OWNiN2I4YzY4OWZfMy0zLTEtMS0zNDQxMQ_2d9493c9-2304-4cde-85de-03a7efae46e7"
      unitRef="usd">1321000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmVhNGE3OTJiMTA1NjRmMjRiYWQyNjljYjdiOGM2ODlmL3RhYmxlcmFuZ2U6ZWE0YTc5MmIxMDU2NGYyNGJhZDI2OWNiN2I4YzY4OWZfNC0xLTEtMS0zNDQxMQ_863f1c9d-5372-44a4-8c87-a070819cbb0a"
      unitRef="usd">67744000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RhYmxlOmVhNGE3OTJiMTA1NjRmMjRiYWQyNjljYjdiOGM2ODlmL3RhYmxlcmFuZ2U6ZWE0YTc5MmIxMDU2NGYyNGJhZDI2OWNiN2I4YzY4OWZfNC0zLTEtMS0zNDQxMQ_9d9dfb54-5c84-4bf9-b5b7-d1767910ab17"
      unitRef="usd">83108000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNjA_cc98caa7-eaf3-4151-b7d7-993a3a7f4d2a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.&lt;/span&gt;The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform an interim quantitative impairment test, whereby the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than its carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. There were no triggering events during the three months ended March 31, 2022 that necessitated an interim impairment test of goodwill.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNDY_9a3954e4-134b-4f00-8337-3f7bdc494e57"
      xsi:nil="true"/>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80MC9mcmFnOjE5YjNmNTQ1N2RkNTQ2YTM5YzM3OTI1NzE3ZjI5OWEwL3RleHRyZWdpb246MTliM2Y1NDU3ZGQ1NDZhMzljMzc5MjU3MTdmMjk5YTBfMTIwNjE_226d32e5-7c78-4be7-9a8c-04954cae08d9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2021-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASU 2021-04 was issued to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants for the purchase of common shares) that remain classified as equity following the modification or exchange. ASU 2021-04 is effective January 1, 2022 for the Company. The adoption of this standard did not have an impact on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2016-13"), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. In accordance with ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326), Derivative and Hedging (Topic 815), and Leases (Topic 842)- Effective &lt;/span&gt;&lt;/div&gt;Dates, as the Company meets the definition of a &#x201c;smaller reporting company&#x201d;, the Company has elected to defer the adoption of ASU 2016-13 until January 1, 2023. The Company expects that the adoption of ASU 2016-13 may accelerate the timing and could increase the level of credit loss expense in the consolidated statement of operations and will likely require an increased level of disclosure in the notes to the consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80My9mcmFnOjhlZjY2OTYzY2M3NDQ5Yzc4YWM5MWNhY2Q1Mjk4NjdmL3RleHRyZWdpb246OGVmNjY5NjNjYzc0NDljNzhhYzkxY2FjZDUyOTg2N2ZfOTY3_51bf309c-b07f-4a11-9e03-22dd707936de">LICENSE, COLLABORATION AND FUNDING AGREEMENTS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Incentive Program&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses and capital expenditures incurred by the Company&#x2019;s subsidiary in Austria. As of March&#160;31, 2022, the amount due under the program is $0.9 million, which amount was included in research and development incentive receivable in the condensed consolidated balance sheet. During the three months ended March&#160;31, 2022 and 2021, the Company recorded $0.1 million and $0.3 million, respectively, of income related to the program within the condensed consolidated statements of operations as other income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License and Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, a third party, who had previously acquired rights to certain intellectual property from the Company, terminated the arrangement and transferred these rights back to the Company. Also during the three months ended March 31, 2022, the Company transferred these rights to another third party in return for $0.5 million. The Company has no continuing involvement in any ongoing research and development activities associated with the intellectual property. The Company concluded that these third parties are "non-customers" as the underlying intellectual property transferred to and from these third parties supports potential drug candidates that are not aligned with the Company's strategic focus and, therefore, are not an output of the Company's ordinary activities. Accordingly, the Company accounted for the sale of the intellectual property as the sale of a non-financial asset under ASC Topic 610-20,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Gains and Losses from the Derecognition of Nonfinancial Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 610-20"), and included the gain as part of gain on sale of non-financial asset for the period ended March 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no material modifications of the Company&#x2019;s license or collaboration agreements during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <xfor:GrantAndIncentiveReceivables
      contextRef="ia6a9e053963b4b5e8c0525ef05558e5c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80My9mcmFnOjhlZjY2OTYzY2M3NDQ5Yzc4YWM5MWNhY2Q1Mjk4NjdmL3RleHRyZWdpb246OGVmNjY5NjNjYzc0NDljNzhhYzkxY2FjZDUyOTg2N2ZfNDY4_fccf8198-2a16-4369-a76a-d7a7d79134b9"
      unitRef="usd">900000</xfor:GrantAndIncentiveReceivables>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6fa190798a8f407db1aaf3fc492af313_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80My9mcmFnOjhlZjY2OTYzY2M3NDQ5Yzc4YWM5MWNhY2Q1Mjk4NjdmL3RleHRyZWdpb246OGVmNjY5NjNjYzc0NDljNzhhYzkxY2FjZDUyOTg2N2ZfNjU1_52736589-abf8-44ed-b07b-1620fe4dbfa7"
      unitRef="usd">100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6fa190798a8f407db1aaf3fc492af313_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80My9mcmFnOjhlZjY2OTYzY2M3NDQ5Yzc4YWM5MWNhY2Q1Mjk4NjdmL3RleHRyZWdpb246OGVmNjY5NjNjYzc0NDljNzhhYzkxY2FjZDUyOTg2N2ZfNjU1_f2e7d968-9e16-43ed-bb8e-1b87bcb6169c"
      unitRef="usd">100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0ae98b37b4074b55b43d5b52c0da2b4e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80My9mcmFnOjhlZjY2OTYzY2M3NDQ5Yzc4YWM5MWNhY2Q1Mjk4NjdmL3RleHRyZWdpb246OGVmNjY5NjNjYzc0NDljNzhhYzkxY2FjZDUyOTg2N2ZfNjYy_8c43daed-d669-4170-8261-8e39ae462a5b"
      unitRef="usd">300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0ae98b37b4074b55b43d5b52c0da2b4e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80My9mcmFnOjhlZjY2OTYzY2M3NDQ5Yzc4YWM5MWNhY2Q1Mjk4NjdmL3RleHRyZWdpb246OGVmNjY5NjNjYzc0NDljNzhhYzkxY2FjZDUyOTg2N2ZfNjYy_dcf653ea-6915-4bb2-8173-23dcd9a2560b"
      unitRef="usd">300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80My9mcmFnOjhlZjY2OTYzY2M3NDQ5Yzc4YWM5MWNhY2Q1Mjk4NjdmL3RleHRyZWdpb246OGVmNjY5NjNjYzc0NDljNzhhYzkxY2FjZDUyOTg2N2ZfMTA5OTUxMTYzNDEzOA_4c95f2e0-6ffb-4e66-901e-b39ca606a7c5"
      unitRef="usd">500000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RleHRyZWdpb246NWVhMzc1MzRmOWVjNGFkMGI2MjRkMGQ2ZTRlMjgzMWVfMTc0OA_662364d7-832a-45e8-93fd-2a246dea4fab">FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of March 31, 2022 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&#x2014;money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Embedded derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2021 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&#x2014;money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Embedded derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash equivalents consisted of money market funds invested in U.S. Treasury securities. The money market funds were valued based on reported market pricing for the identical assets, which represents a Level 1 measurement, or by using inputs observable in active markets for similar securities, which represents a Level&#160;2 measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll-forward of the aggregate fair values financial instruments for which fair values are determined using Level 3 inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.583%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Embedded Derivative Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Embedded Derivative Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt; The fair value of the embedded derivative liability recognized in connection with the Company&#x2019;s loan agreement with Hercules (Note 7), which is associated with additional fees due to Hercules upon events of default, was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of this embedded derivative liability, which is reported within other non-current liabilities on the condensed consolidated balance sheets, is estimated by the Company at each reporting date based, in part, on the results of third party valuations, which are prepared based on a discounted cash flow model that considers the timing and probability of occurrence of a redemption upon an event of default, the potential amount of prepayment fees or contingent interest upon an event of default and the Company&#x2019;s risk-adjusted discount rate of 14%.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RleHRyZWdpb246NWVhMzc1MzRmOWVjNGFkMGI2MjRkMGQ2ZTRlMjgzMWVfMTc0NQ_091f6fcc-7b3f-4173-8cfc-d6639a494ba6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of March 31, 2022 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&#x2014;money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Embedded derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2021 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&#x2014;money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Embedded derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i094278dbb6a548fd9082e115e09bdaf0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfMy0xLTEtMS0zNDQxMQ_224d9de2-fe3b-4e91-aa51-46aeddf500a7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2d672047c5424b409a161bd8c9acbfed_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfMy0zLTEtMS0zNDQxMQ_414df9be-985a-41e6-9689-80affaab78c3"
      unitRef="usd">2626000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie4117ae9064c4a1eb42d624dc7250d94_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfMy01LTEtMS0zNDQxMQ_33447499-efe5-4283-a396-c2b3c9c62d48"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia42b7fcbe59440f2b41270d5bb32ea91_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfMy03LTEtMS0zNDQxMQ_fbb8f728-8ca1-44f4-bb95-7fc00101091d"
      unitRef="usd">2626000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i094278dbb6a548fd9082e115e09bdaf0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNC0xLTEtMS0zNDQxMQ_69603111-769d-4e42-80ee-457b81941a1c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2d672047c5424b409a161bd8c9acbfed_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNC0zLTEtMS0zNDQxMQ_1450951c-3d79-40dc-8a50-dbf231ba71c7"
      unitRef="usd">2626000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie4117ae9064c4a1eb42d624dc7250d94_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNC01LTEtMS0zNDQxMQ_e76bb412-9c6f-414f-97c2-0f357e5f3a3e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia42b7fcbe59440f2b41270d5bb32ea91_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNC03LTEtMS0zNDQxMQ_208ed843-2c32-4a85-8a38-a21b98137cec"
      unitRef="usd">2626000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i094278dbb6a548fd9082e115e09bdaf0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNi0xLTEtMS0zNDQxMQ_02aefad9-602e-43a8-97f9-a729c7435806"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2d672047c5424b409a161bd8c9acbfed_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNi0zLTEtMS0zNDQxMQ_4859a5b1-6d98-417d-ae87-cd65f6112a27"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie4117ae9064c4a1eb42d624dc7250d94_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNi01LTEtMS0zNDQxMQ_e2cb1e15-6459-4f46-a2a5-a790d1daf871"
      unitRef="usd">645000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia42b7fcbe59440f2b41270d5bb32ea91_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNi03LTEtMS0zNDQxMQ_0645f634-bdfb-4fa5-aa80-508566e53777"
      unitRef="usd">645000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i094278dbb6a548fd9082e115e09bdaf0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNy0xLTEtMS0zNDQxMQ_8d23bda0-177d-4f8f-9988-26fd6012bee6"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2d672047c5424b409a161bd8c9acbfed_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNy0zLTEtMS0zNDQxMQ_cbae9ba2-2013-4fd2-99b2-eb7bf8b054a8"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie4117ae9064c4a1eb42d624dc7250d94_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNy01LTEtMS0zNDQxMQ_5c8d1292-3d1e-4590-a811-bcf9e759933c"
      unitRef="usd">645000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia42b7fcbe59440f2b41270d5bb32ea91_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmI4YWMyZDMxNjM0ODRmNTY5MmMwZTIxZjdjM2NhYjgwL3RhYmxlcmFuZ2U6YjhhYzJkMzE2MzQ4NGY1NjkyYzBlMjFmN2MzY2FiODBfNy03LTEtMS0zNDQxMQ_1adb89d7-dd74-4090-8231-45fa0f573e8d"
      unitRef="usd">645000</us-gaap:DerivativeLiabilities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia33efcad84ff4ab29dfe84a9f90b41b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfMy0xLTEtMS0zNDQxMQ_97c57d0b-241a-4950-83aa-bc22f600bedc"
      unitRef="usd">20000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ife03ea1a6e3647c89acdff544fec694a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfMy0zLTEtMS0zNDQxMQ_144089ab-b1e9-49c3-abcf-f62f9afa932f"
      unitRef="usd">27793000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i21d0f0aac3d548fbaf98b28d241b82e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfMy01LTEtMS0zNDQxMQ_cbeb80a2-fea8-4de8-8efc-3aa134ce30e6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1742801c50374deb91009bf46a82591f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfMy03LTEtMS0zNDQxMQ_e935b73a-8a81-44b3-b261-5836e7e046e3"
      unitRef="usd">47793000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia33efcad84ff4ab29dfe84a9f90b41b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNC0xLTEtMS0zNDQxMQ_48d1fc1b-d112-489a-a71e-194b7a8df501"
      unitRef="usd">20000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ife03ea1a6e3647c89acdff544fec694a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNC0zLTEtMS0zNDQxMQ_842311f1-912e-4da9-b0f4-dbaf19cf0287"
      unitRef="usd">27793000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i21d0f0aac3d548fbaf98b28d241b82e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNC01LTEtMS0zNDQxMQ_de7c6182-31c4-4cf2-9286-7ca3f03a4d4b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1742801c50374deb91009bf46a82591f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNC03LTEtMS0zNDQxMQ_a0dad8de-ccf4-4138-a540-f14d50f8d10e"
      unitRef="usd">47793000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ia33efcad84ff4ab29dfe84a9f90b41b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNi0xLTEtMS0zNDQxMQ_8b878783-bd2d-4ff8-8ade-ca8392e8b598"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ife03ea1a6e3647c89acdff544fec694a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNi0zLTEtMS0zNDQxMQ_7beeb558-f0ae-4aae-924a-4ded23d95b57"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i21d0f0aac3d548fbaf98b28d241b82e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNi01LTEtMS0zNDQxMQ_1821cd90-c001-41dc-bcd1-4561eb862961"
      unitRef="usd">821000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1742801c50374deb91009bf46a82591f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNi03LTEtMS0zNDQxMQ_72ce5ae0-54b7-413e-a445-b687c1b08b63"
      unitRef="usd">821000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia33efcad84ff4ab29dfe84a9f90b41b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNy0xLTEtMS0zNDQxMQ_5e8eb970-2d38-4b64-bb5b-bcef04d98ae1"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ife03ea1a6e3647c89acdff544fec694a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNy0zLTEtMS0zNDQxMQ_3713cae9-2082-426e-8a94-9417ed912f2d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i21d0f0aac3d548fbaf98b28d241b82e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNy01LTEtMS0zNDQxMQ_2eb508bc-3aef-486e-a791-dda7c8e2c7bc"
      unitRef="usd">821000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1742801c50374deb91009bf46a82591f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOmZhMWY1MGRmOWI2YzQzNTRiMzg5ODBlZGJhMmE3ODc3L3RhYmxlcmFuZ2U6ZmExZjUwZGY5YjZjNDM1NGIzODk4MGVkYmEyYTc4NzdfNy03LTEtMS0zNDQxMQ_3345e174-0451-4d5f-89cc-19d7aa45e7ac"
      unitRef="usd">821000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RleHRyZWdpb246NWVhMzc1MzRmOWVjNGFkMGI2MjRkMGQ2ZTRlMjgzMWVfMTc0Ng_3f5658ab-80c6-44f7-a1ca-5567d6148a4d">&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll-forward of the aggregate fair values financial instruments for which fair values are determined using Level 3 inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.583%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Embedded Derivative Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOjZjMzE4NzllZjg2NTQxZjJiYjdkNGFkM2Y0NDlmZjU5L3RhYmxlcmFuZ2U6NmMzMTg3OWVmODY1NDFmMmJiN2Q0YWQzZjQ0OWZmNTlfMS0xLTEtMS0zNDQxMQ_913ce308-66b6-4996-b044-a48e55d30783"
      unitRef="usd">821000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOjZjMzE4NzllZjg2NTQxZjJiYjdkNGFkM2Y0NDlmZjU5L3RhYmxlcmFuZ2U6NmMzMTg3OWVmODY1NDFmMmJiN2Q0YWQzZjQ0OWZmNTlfMi0xLTEtMS0zNDQxMQ_334159fb-3269-4641-a64b-82ac384098db"
      unitRef="usd">-176000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RhYmxlOjZjMzE4NzllZjg2NTQxZjJiYjdkNGFkM2Y0NDlmZjU5L3RhYmxlcmFuZ2U6NmMzMTg3OWVmODY1NDFmMmJiN2Q0YWQzZjQ0OWZmNTlfMy0xLTEtMS0zNDQxMQ_3c3b499a-b271-4072-a6d2-3d0cc75617c3"
      unitRef="usd">645000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DerivativeLiabilities
      contextRef="id3a80995916b45c199871913d2744c21_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80Ni9mcmFnOjVlYTM3NTM0ZjllYzRhZDBiNjI0ZDBkNmU0ZTI4MzFlL3RleHRyZWdpb246NWVhMzc1MzRmOWVjNGFkMGI2MjRkMGQ2ZTRlMjgzMWVfMTczOQ_d585e9c8-3b81-4bce-b2cd-e5c1f268578f"
      unitRef="usd">0.14</us-gaap:DerivativeLiabilities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RleHRyZWdpb246Yjc5OTcxNTRjYWY0NDJkZWFiM2NhMjMyYTE1Zjg3NmZfMjI5_ff9829fa-99a9-4b0d-9507-fdaf6d92146f">PROPERTY AND EQUIPMENT, NET&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(857)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense related to property and equipment was $133 thousand and $106 thousand for the three months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RleHRyZWdpb246Yjc5OTcxNTRjYWY0NDJkZWFiM2NhMjMyYTE1Zjg3NmZfMjMw_a9e48487-4610-4830-8f8e-bf1743a6196e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(857)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i639b8d3e3f0d47f8a1670e543de3ddbb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfMS0xLTEtMS0zNDQxMQ_fdb90482-f075-4fac-a940-df8a5329f674"
      unitRef="usd">228000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i96c436bc6e3549aaba4b6f5738544b57_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfMS0zLTEtMS0zNDQxMQ_4c71a0b0-4c39-4ef2-ae8d-6f1ce48f3baf"
      unitRef="usd">228000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i02cddbe3e2e94249a26572dd230f54ab_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfMi0xLTEtMS0zNDQxMQ_2701e8c8-d39b-4427-a794-e094ef76aa7d"
      unitRef="usd">1254000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idd20f5ab879a4c7899f8376d38a509b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfMi0zLTEtMS0zNDQxMQ_cbbe0110-5a56-475a-86cb-364a2c78074a"
      unitRef="usd">1251000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if06a3031bf214f0badb0fe08c193a7db_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfMy0xLTEtMS0zNDQxMQ_d88dbc95-089b-485d-ba34-8de2457d4dbe"
      unitRef="usd">169000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibdfa75b4c35d44a391617d28994286e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfMy0zLTEtMS0zNDQxMQ_253f9acb-7d09-46ad-868d-cae8cba90904"
      unitRef="usd">150000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icc17d505855a43e499fd5dbfc1919a1e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNC0xLTEtMS0zNDQxMQ_8434e9b1-db37-4d02-8de0-b36605df51d4"
      unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifcc1bd21f38c467083120b5c7e8f04d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNC0zLTEtMS0zNDQxMQ_bb1cdcce-06ba-491b-a5cd-ae6df93986b3"
      unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6c7c501dd906429f8cddfe0fb9905586_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNS0xLTEtMS0zNDQxMQ_c67cdacb-7023-42e8-9b21-4996d13826c9"
      unitRef="usd">576000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5ab87fe587c64027a76fcc9c708f7361_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNS0zLTEtMS0zNDQxMQ_faa3cd75-dac4-4f1a-9204-1944c8dbbb51"
      unitRef="usd">576000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNi0xLTEtMS0zNDQxMQ_04df10e4-d183-4cb3-a102-1af0f576a021"
      unitRef="usd">2260000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNi0zLTEtMS0zNDQxMQ_2d765c99-43ca-403e-a2fc-dc7329033219"
      unitRef="usd">2238000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNy0xLTEtMS0zNDQxMQ_38a94a5a-461e-412b-9bad-78d7b40b3cc5"
      unitRef="usd">857000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfNy0zLTEtMS0zNDQxMQ_7d3e8e20-0cd2-443d-b14d-fab831b9dae7"
      unitRef="usd">724000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfOC0xLTEtMS0zNDQxMQ_729deec2-8216-4a78-a7a1-7706f7611f80"
      unitRef="usd">1403000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RhYmxlOjM3OWUyNzZhMTAzYjQzOTI4ZWRhMTI4NWE4YmEwY2ZhL3RhYmxlcmFuZ2U6Mzc5ZTI3NmExMDNiNDM5MjhlZGExMjg1YThiYTBjZmFfOC0zLTEtMS0zNDQxMQ_578dde36-ccdc-45dc-88bc-7308c7dd5c80"
      unitRef="usd">1514000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RleHRyZWdpb246Yjc5OTcxNTRjYWY0NDJkZWFiM2NhMjMyYTE1Zjg3NmZfMTY5_88861ea7-b88c-4337-82a7-df20757afc72"
      unitRef="usd">133000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl80OS9mcmFnOmI3OTk3MTU0Y2FmNDQyZGVhYjNjYTIzMmExNWY4NzZmL3RleHRyZWdpb246Yjc5OTcxNTRjYWY0NDJkZWFiM2NhMjMyYTE1Zjg3NmZfMTc2_e0a9e02d-dcdd-4866-b1c2-5173da690e81"
      unitRef="usd">106000</us-gaap:DepreciationDepletionAndAmortization>
    <xfor:AccruedExpensesTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RleHRyZWdpb246NDg1ZjVkM2U1OWM3NDQ5N2EzMDU0ZDA1YjMwNmE1YzVfNzA_c05abca8-277a-4809-b17b-d68be26af403">ACCRUED EXPENSES&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</xfor:AccruedExpensesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RleHRyZWdpb246NDg1ZjVkM2U1OWM3NDQ5N2EzMDU0ZDA1YjMwNmE1YzVfNzE_fc846a82-82dd-4e65-9413-1b512aa51427">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfMS0xLTEtMS0zNDQxMQ_f14cfd32-1602-4e78-b4c8-acfb44de2a5a"
      unitRef="usd">3784000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfMS0zLTEtMS0zNDQxMQ_ed08ac24-7bbf-481c-abeb-49161dc15e6c"
      unitRef="usd">5417000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <xfor:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfMi0xLTEtMS0zNDQxMQ_c184af1f-45bd-48d8-981f-e747d418c699"
      unitRef="usd">2013000</xfor:AccruedExternalResearchAndDevelopmentExpenses>
    <xfor:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfMi0zLTEtMS0zNDQxMQ_765ef03e-573d-4606-a78b-fd804f902f2f"
      unitRef="usd">1507000</xfor:AccruedExternalResearchAndDevelopmentExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfMy0xLTEtMS0zNDQxMQ_28be4989-9c61-4870-840d-6b0468dce9ff"
      unitRef="usd">762000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfMy0zLTEtMS0zNDQxMQ_fd7f5537-d588-411d-970c-fa3ccad5a0c7"
      unitRef="usd">632000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfNS0xLTEtMS0zNDQxMQ_d290c3f5-2e31-48d1-894d-1e78130b8765"
      unitRef="usd">318000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfNS0zLTEtMS0zNDQxMQ_171c41c7-d02f-4357-8daa-6966d00e7eff"
      unitRef="usd">314000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfNi0xLTEtMS0zNDQxMQ_c0fea8d7-0517-4102-b7b3-a73d07926c4c"
      unitRef="usd">6877000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81Mi9mcmFnOjQ4NWY1ZDNlNTljNzQ0OTdhMzA1NGQwNWIzMDZhNWM1L3RhYmxlOjg1NjNmYTQ2N2YzNzRiYWI4OTk5NDYyNDQ1NjkzYTljL3RhYmxlcmFuZ2U6ODU2M2ZhNDY3ZjM3NGJhYjg5OTk0NjI0NDU2OTNhOWNfNi0zLTEtMS0zNDQxMQ_53a37e9f-a2cb-46a1-a9d8-fe80d9005fc1"
      unitRef="usd">7870000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzkzOQ_c363ee43-486c-489c-8ae4-ef4ee096f7b4">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt discount, net of accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative accretion of end of term payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hercules Loan Agreement, As Amended&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into a Loan and Security Agreement (the &#x201c;Hercules Loan Agreement&#x201d;), as amended in December 2018, June 2019, March 2020, December 2020 and February 2022, with Hercules, under which the Company has borrowed an aggregate of $32.5 million of term loans to date. The Hercules Loan Agreement provides for maximum borrowings of up to $50.0&#160;million, which include, subject to Hercules investment committee&#x2019;s sole discretion, a right of the Company to request that Hercules make additional term loan advances in an aggregate amount of up to $17.5 million through December 31, 2022.  Borrowings under the Hercules Loan Agreement accrues interest at a variable rate equal to the greater of (i)&#160;8.75% or (ii)&#160;8.75% plus &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wall Street Journal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;prime rate minus 6.0%.&#160;In an event of default and until such event is no longer continuing, the interest rate applicable to borrowings would be increased by 4.0%. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Hercules Loan Agreement are repayable in monthly interest-only payments through January 1, 2023, and in equal monthly payments of principal and accrued interest from February 1, 2023 until the maturity date of the loan, which is July 1, 2024. The Company may prepay all, but not less than all, of the outstanding borrowings, subject to a prepayment premium of up to 1.0% of the principal amount outstanding as of the date of repayment. In addition, the Hercules Loan Agreement provides for payments of $1.3 million and $0.8 million payable on July 1, 2023 and July 1, 2024, respectively, which payments are accelerated upon the prepayment of the borrowings upon the Company&#x2019;s election on upon default of the loan. Borrowings under the Hercules Loan Agreement are collateralized by substantially all of the Company&#x2019;s personal property and other assets except for their intellectual property (but including rights to payment and proceeds from the sale, licensing or disposition of the intellectual property). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As noted above, on February 9, 2022, the Company entered into Amendment No. 3 the Hercules Loan Agreement. The amendment primarily added a financial milestone that if met by June 30, 2022 would modify the minimum cash covenant contained in the Hercules Loan Agreement, which is effective beginning September 1, 2022, as further described below. The Company concluded that the amendment represented a modification to the debt.  Accordingly, fees paid to third parties directly related to the amended debt were expensed as incurred and fees paid to Hercules in conjunction with the amendment were deferred and will be amortized to interest expense over the life of the debt arrangement using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Hercules Loan Agreement, effective as of the earlier of (a) certain specified events impacting the Company&#x2019;s Phase III trial of mavorixafor for the treatment of WHIM syndrome and (b) September 1, 2022, the Company at all times thereafter must maintain cash in an account or accounts in which Hercules has a first priority security interest, in an aggregate amount greater than or equal to the greater of (i) $30.0 million or (ii) 6 multiplied by a metric based on prior months&#x2019; cash expenditures;  provided, however, that from and after the Company&#x2019;s achievement of certain financing milestones through June 30, 2022, the Company must maintain cash in an account or accounts in which Hercules has a first priority security interest in an aggregate amount of $30.0 million. Following the achievement of certain operational performance milestones, the required level shall be reduced to the greater of $20.0&#160;million, or, if the Company had not met the financing milestones noted above, 3 multiplied by the current cash expenditures metric; and provided further, that subject to the achievement of certain milestones, this covenant will be extinguished. The Hercules Loan Agreement also restricts the Company&#x2019;s ability to incur additional indebtedness, pay dividends, encumber its intellectual property, or engage in certain fundamental business transactions, such as mergers or acquisitions of other businesses, with certain exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized interest expense under the Hercules Loan Agreement as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months ended March  31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual effective interest rate of the Hercules Loan Agreement as of March 31, 2022 is 10.7%. There were no principal payments due or paid under the Hercules Loan Agreement during the three months ended March&#160;31, 2022. An end-of-term payment of $0.8 million was paid during the three months ended March 31, 2022 in accordance with the Hercules Loan Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, future principal and end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzk0MA_9e9b15db-6072-4d0f-b66b-9fa2cb855ffa">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt discount, net of accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative accretion of end of term payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfMS0xLTEtMS0zNDQxMQ_1ae5d688-1852-4885-956e-3a664c896f79"
      unitRef="usd">32500000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfMS0zLTEtMS0zNDQxMQ_94b5e359-e7b4-4a41-9c21-3d983f8c935e"
      unitRef="usd">32500000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfMi0xLTEtMS0zNDQxMQ_3dfc7633-4ef1-42c4-9b56-77355c47c005"
      unitRef="usd">-127000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfMi0zLTEtMS0zNDQxMQ_b446d568-be1f-4236-954b-d2fb4101fc97"
      unitRef="usd">-277000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <xfor:AccretionOnLongTermDebt
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfMy0xLTEtMS0zNDQxMQ_991e68a3-9b2e-493e-a1be-f85a8e8257ab"
      unitRef="usd">-597000</xfor:AccretionOnLongTermDebt>
    <xfor:AccretionOnLongTermDebt
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfMy0zLTEtMS0zNDQxMQ_e5fe6f0c-1cc0-441d-9375-2c765e8cd1f2"
      unitRef="usd">-1157000</xfor:AccretionOnLongTermDebt>
    <xfor:LongTermDebtIncludingAccretion
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfNC0xLTEtMS0zNDQxMQ_24607adc-db8a-49f8-a2c8-4ae69c48334a"
      unitRef="usd">33224000</xfor:LongTermDebtIncludingAccretion>
    <xfor:LongTermDebtIncludingAccretion
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfNC0zLTEtMS0zNDQxMQ_da3065a1-50a7-43fc-be16-1f7981a6cb74"
      unitRef="usd">33934000</xfor:LongTermDebtIncludingAccretion>
    <us-gaap:LongTermDebtCurrent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfNS0xLTEtMS0zNDQxMQ_e5c468fd-baae-439e-b959-966058fe7124"
      unitRef="usd">3415000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfNS0zLTEtMS0zNDQxMQ_0e541a4a-8946-4b7c-819c-a24883ac1fc9"
      unitRef="usd">795000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfNi0xLTEtMS0zNDQxMQ_bde32bc1-f520-4708-8949-a9f1108a1929"
      unitRef="usd">29809000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjVjMWQ1MWM4MzZkNzRmNzE5OGIzNDUwMjY1NDg2MTBlL3RhYmxlcmFuZ2U6NWMxZDUxYzgzNmQ3NGY3MTk4YjM0NTAyNjU0ODYxMGVfNi0zLTEtMS0zNDQxMQ_3c14e864-7369-4ac0-a08d-1509f49b027e"
      unitRef="usd">33139000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i1dc0bdf32a5146e0adcea6db6de6615d_D20181001-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzQ2_3cb50d87-966e-45bc-bed7-1a3f42a020c9"
      unitRef="usd">32500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i37a902dab0bd4e4f9e87b18693f5f331_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfNDQx_19c4d6b4-5bba-4942-be9c-318c4bd722e5"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <xfor:LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree
      contextRef="i37a902dab0bd4e4f9e87b18693f5f331_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfODY0_710e6d71-b099-413a-aa81-be19a94ca10c"
      unitRef="usd">17500000</xfor:LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic37a10f994534a07ba477a27d2a2bf64_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTAwNA_befed8c8-5618-4e01-a9b1-550d9de6e007"
      unitRef="number">0.0875</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic37a10f994534a07ba477a27d2a2bf64_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTAxNQ_befed8c8-5618-4e01-a9b1-550d9de6e007"
      unitRef="number">0.0875</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic4206af27e2d487f9f31e058fa7b8c0a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTA2NA_cd6beb81-8c17-4ce9-b317-c96198832344"
      unitRef="number">0.060</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="ic37a10f994534a07ba477a27d2a2bf64_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTIwMg_4102c088-77ba-457c-8a2b-4584319d24aa"
      unitRef="number">0.040</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <xfor:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="icce6cbe45cc4447fbfe3ebb0b1f74930_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTU5OQ_911034df-7b24-48e3-82a8-c9c2a7c51417"
      unitRef="number">0.010</xfor:DebtInstrumentPrepaymentPremiumPercentage>
    <us-gaap:LineOfCreditFacilityPeriodicPayment
      contextRef="i55063b32fb884c81895bd748e6ed4f41_D20220701-20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTc5OA_ebe54f4f-d160-48db-9d95-74e0c2ad0ce5"
      unitRef="usd">1300000</us-gaap:LineOfCreditFacilityPeriodicPayment>
    <us-gaap:LineOfCreditFacilityPeriodicPayment
      contextRef="i26533fb9b8ff4cf98e7fe29b5121aa6d_D20240701-20240701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTgwNg_0ee43ef6-8cf2-42dd-bae5-b7268ac6bd44"
      unitRef="usd">800000</us-gaap:LineOfCreditFacilityPeriodicPayment>
    <xfor:LineOfCreditCovenantMinimumCash
      contextRef="ic45fa2c1cc904680a9c790308256e60f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMjgzMA_a3ca95fb-5947-42a9-be82-fea93c5b5b1b"
      unitRef="usd">30000000</xfor:LineOfCreditCovenantMinimumCash>
    <xfor:LineOfCreditCovenantMinimumCash
      contextRef="ic45fa2c1cc904680a9c790308256e60f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTA5OTUxMTYzMjY3NQ_a3ca95fb-5947-42a9-be82-fea93c5b5b1b"
      unitRef="usd">30000000</xfor:LineOfCreditCovenantMinimumCash>
    <xfor:LineOfCreditCovenantMinimumCash
      contextRef="ia692d84b888a4845bbc1ea6a9ee0dfbd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzA2Nw_45976f3a-f835-435a-a8bc-e614243aaa3f"
      unitRef="usd">20000000</xfor:LineOfCreditCovenantMinimumCash>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzk0MQ_7d081c20-6c75-4b39-b22e-e3b446527a1a">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized interest expense under the Hercules Loan Agreement as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months ended March  31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="ic37a10f994534a07ba477a27d2a2bf64_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOmY2ZjkyZWI4MzVhMDRmYzQ4ZWRjYWVkMDExZjgyYTFjL3RhYmxlcmFuZ2U6ZjZmOTJlYjgzNWEwNGZjNDhlZGNhZWQwMTFmODJhMWNfMi0xLTEtMS0zNDQxMQ_aaea7b4d-d503-4f5e-8911-dd9d420fcfb8"
      unitRef="usd">909000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="id7e48af44af640d5b517c67d3ad4d1f0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOmY2ZjkyZWI4MzVhMDRmYzQ4ZWRjYWVkMDExZjgyYTFjL3RhYmxlcmFuZ2U6ZjZmOTJlYjgzNWEwNGZjNDhlZGNhZWQwMTFmODJhMWNfMi0zLTEtMS0zNDQxMQ_fb03928f-40c7-4596-b020-1993bd449214"
      unitRef="usd">890000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ic37a10f994534a07ba477a27d2a2bf64_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOmY2ZjkyZWI4MzVhMDRmYzQ4ZWRjYWVkMDExZjgyYTFjL3RhYmxlcmFuZ2U6ZjZmOTJlYjgzNWEwNGZjNDhlZGNhZWQwMTFmODJhMWNfMy0xLTEtMS0zNDQxMQ_8e282f00-2e1d-459b-8123-affa19f9096d"
      unitRef="usd">198000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="id7e48af44af640d5b517c67d3ad4d1f0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOmY2ZjkyZWI4MzVhMDRmYzQ4ZWRjYWVkMDExZjgyYTFjL3RhYmxlcmFuZ2U6ZjZmOTJlYjgzNWEwNGZjNDhlZGNhZWQwMTFmODJhMWNfMy0zLTEtMS0zNDQxMQ_60d5d400-1a63-4619-929c-a41cd57e91ac"
      unitRef="usd">178000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i37a902dab0bd4e4f9e87b18693f5f331_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzcxMw_0959810a-1013-4224-97b6-7f37ed3abb3f"
      unitRef="number">0.107</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="ic37a10f994534a07ba477a27d2a2bf64_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzcyOA_a85a5af8-2641-4065-b5f7-63fe1d24d9f2"
      unitRef="usd">0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMTA5OTUxMTYzMzExNg_ad7b76f6-46f1-4e08-85ed-4f864f46cb6b"
      unitRef="usd">800000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RleHRyZWdpb246YzdjZmQ3ZmZhZDQyNGJhNmFjNzlmYjQ1MDE0ZDkxMjdfMzkzNg_f911e494-b53a-4f28-b15b-41b061fe440e">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, future principal and end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjEwNzA1ZDJhZDIzZTQwYjk5NDllMmRkZTI0YWJhOThlL3RhYmxlcmFuZ2U6MTA3MDVkMmFkMjNlNDBiOTk0OWUyZGRlMjRhYmE5OGVfMS0xLTEtMS0zNDQxMQ_e1394ae8-69fa-4843-a092-71baba37700d"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjEwNzA1ZDJhZDIzZTQwYjk5NDllMmRkZTI0YWJhOThlL3RhYmxlcmFuZ2U6MTA3MDVkMmFkMjNlNDBiOTk0OWUyZGRlMjRhYmE5OGVfMy0xLTEtMS0zNDQxMQ_d59d8c85-8342-45e5-9555-5c63324190a9"
      unitRef="usd">19802000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjEwNzA1ZDJhZDIzZTQwYjk5NDllMmRkZTI0YWJhOThlL3RhYmxlcmFuZ2U6MTA3MDVkMmFkMjNlNDBiOTk0OWUyZGRlMjRhYmE5OGVfNC0xLTEtMS0zNDQxMQ_472aedec-b792-4c40-bac1-cf8ecfc667de"
      unitRef="usd">13295000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <xfor:LongTermDebtAndEOTPayment
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81NS9mcmFnOmM3Y2ZkN2ZmYWQ0MjRiYTZhYzc5ZmI0NTAxNGQ5MTI3L3RhYmxlOjEwNzA1ZDJhZDIzZTQwYjk5NDllMmRkZTI0YWJhOThlL3RhYmxlcmFuZ2U6MTA3MDVkMmFkMjNlNDBiOTk0OWUyZGRlMjRhYmE5OGVfNi0xLTEtMS0zNDQxMQ_3a6860e9-d6a1-4c37-bdaf-f79fd2ae41af"
      unitRef="usd">33097000</xfor:LongTermDebtAndEOTPayment>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMzI5MQ_592de9fa-d5a7-480b-84af-75fa1edaa720">LEASES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has lease agreements for its facilities in Boston, Massachusetts, which is the Company&#x2019;s principal executive office; Vienna, Austria, which is the Company&#x2019;s research and development center; and Waltham, Massachusetts, which the Company has sublet to a third party. There are no restrictions or financial covenants associated with any of the lease agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Vienna Austria Leases&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an operating lease for approximately 1,200 square meters of laboratory and office space in Vienna, Austria (&#x201c;Vienna Lease&#x201d;), which commenced in February 2021 for a term of 7 years. The annual base rent for the Vienna Lease is approximately $300 thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Boston Lease&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company leases approximately 28,000 square feet of office space in Boston, Massachusetts (&#x201c;Boston Lease&#x201d;), which serves as the Company&#x2019;s headquarters. Base rental payments are approximately $1.0 million annually, plus certain operating expenses. The term of the Boston Lease will continue until November 2026, unless earlier terminated. The Company has the right to sublease the premises, subject to landlord consent and also has the right to renew the Boston Lease for an additional five years at the then prevailing effective market rental rate. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company is required to maintain a security deposit in the form of a letter of credit for $0.9&#160;million for the benefit of the landlord. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Waltham Lease&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 6,000 square feet of office space in Waltham, Massachusetts (&#x201c;Waltham Lease&#x201d;). The Waltham Lease, as amended, commenced on January&#160;1, 2019, and expires approximately five years from the commencement date. The base rent is approximately $0.3 million annually. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#x2019; right-of-use assets or lease liabilities. The Company is subleasing the space to a third party for the duration of the lease. The right-of-use asset is being amortized to rent expense over the five-year term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As the Company&#x2019;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense for the three months ended March&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(dollars in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March  31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use asset obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities due under lease agreements that have commenced as of March&#160;31, 2022 are as follows (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.220%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remainder of the year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace
      contextRef="icc53f4cff48d40168111b64915f524d7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfNzg3_2c0bacf2-0b5f-42e2-84fc-b8fd43fb14a4"
      unitRef="sqm">1200</xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="i38936b88ef624fe69a0b0bfe09334734_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfOTcz_8a3ef474-3156-457c-b10c-d48653dc2f78">P7Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <xfor:LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent
      contextRef="i38936b88ef624fe69a0b0bfe09334734_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMTMzMQ_32fa8b5b-6f58-45cb-8262-0d49637534e5"
      unitRef="usd">300000</xfor:LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent>
    <xfor:CurrentOfficeSpaceUnderLeaseAgreement
      contextRef="i9f343631aa5f432096c5e6330be2f6e1_D20191111-20191111"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMTM4Mg_0c9f6e74-829f-4096-a761-216054ad95df"
      unitRef="sqft">28000</xfor:CurrentOfficeSpaceUnderLeaseAgreement>
    <xfor:LesseeOperatingLeaseLeaseNotYetCommencedAmount
      contextRef="i9f343631aa5f432096c5e6330be2f6e1_D20191111-20191111"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMTUzOQ_eb5d9943-994a-4ee0-ab19-57e289849715"
      unitRef="usd">1000000</xfor:LesseeOperatingLeaseLeaseNotYetCommencedAmount>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i1fdd127e11e14968982b457103d38af9_I20191111"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMTgyMw_b7b64e5e-ead7-4548-814a-f4ec8b6ac6a6">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <xfor:CurrentOfficeSpaceUnderLeaseAgreement
      contextRef="i829185b9e0084c7584f58e45342583f9_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMjA1OA_c5d60f1e-ead1-46c6-827a-6a8738cba1ad"
      unitRef="sqft">6000</xfor:CurrentOfficeSpaceUnderLeaseAgreement>
    <xfor:OperatingLeaseExpiration
      contextRef="i829185b9e0084c7584f58e45342583f9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMjIwOA_5e1f5126-dc21-4570-baef-74d26178a41e">P5Y</xfor:OperatingLeaseExpiration>
    <xfor:AggregateBaseRent
      contextRef="i829185b9e0084c7584f58e45342583f9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMjI3MA_58f35eea-cce9-4505-8ec5-c14ae7aca86a"
      unitRef="usd">300000</xfor:AggregateBaseRent>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie3e0d04f60ed4d21934cf225abe43d0a_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMzI5Mg_e52a48ca-777a-4a94-87b6-82d83ac0fa08">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMzI5Mw_3b785cb7-1284-455e-8ce8-729ad220b6c5">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense for the three months ended March&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(dollars in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March  31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use asset obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfMi0xLTEtMS0zNDQxMQ_69437ee5-f398-4c38-8b4e-c7e800104d26"
      unitRef="usd">530000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfMi0zLTEtMS0zNDQxMQ_330dfb95-76d0-4e08-b090-b8fc7ad9b961"
      unitRef="usd">476000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfMy0xLTEtMS0zNDQxMQ_0857435c-4d5f-4adb-9386-a4fc8fec93a2"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfMy0zLTEtMS0zNDQxMQ_25ea0679-fcd5-4319-a058-633e933f8964"
      unitRef="usd">42000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfNC0xLTEtMS0zNDQxMQ_74073172-6efa-4ed9-8830-87bfdadc0182"
      unitRef="usd">530000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfNC0zLTEtMS0zNDQxMQ_5e537367-3b4b-4f3b-ac2c-6378cbf6113d"
      unitRef="usd">518000</us-gaap:LeaseCost>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfNi0xLTEtMS0zNDQxMQ_35cee4d9-d033-447e-a709-4192e6f76de0"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfNi0zLTEtMS0zNDQxMQ_8e8e50f8-3537-4a3e-8db1-e8f11e95ea7a"
      unitRef="usd">1343000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfNy0xLTEtMS0zNDQxMQ_c0d36dc7-ca0e-4161-986d-d6784c453c6e"
      unitRef="usd">342000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfNy0zLTEtMS0zNDQxMQ_23d15dbc-3143-45ca-b9ca-3b9ea210e942"
      unitRef="usd">323000</us-gaap:OperatingLeasePayments>
    <us-gaap:SubleaseIncome
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfOC0xLTEtMS0zNDQxMQ_b70b7f16-4e86-45bd-b62b-d1571c232b24"
      unitRef="usd">49000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfOC0zLTEtMS0zNDQxMQ_2118d1ca-0cef-4880-8fb0-fa117b8fc346"
      unitRef="usd">49000</us-gaap:SubleaseIncome>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfOS0xLTEtMS0zNDQxMQ_7cdc0ba7-cd1c-4c92-b63f-c7fa36034aca">P4Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjhjOWMxZTcwODMxZTQ2ZTViM2NhYmZmODcwZTFmMmJlL3RhYmxlcmFuZ2U6OGM5YzFlNzA4MzFlNDZlNWIzY2FiZmY4NzBlMWYyYmVfMTAtMS0xLTEtMzQ0MTE_643a7994-2471-40fd-9641-3889204e2d5b"
      unitRef="number">0.113</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RleHRyZWdpb246ODVkY2I5ZmUyN2I2NGUyYjkzNDllNjQyOTU1NDVlZGFfMzI4OQ_7c23b1f0-919f-472c-aebe-087673bbd29b">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities due under lease agreements that have commenced as of March&#160;31, 2022 are as follows (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.220%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remainder of the year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfMS0xLTEtMS0zNDQxMQ_b9c9e82e-217a-4f2d-aa69-ed9502e89c45"
      unitRef="usd">1194000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfMi0xLTEtMS0zNDQxMQ_89f3ef10-5274-4724-a181-238759339fa7"
      unitRef="usd">1619000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfMy0xLTEtMS0zNDQxMQ_1828069c-4cd7-42b1-9b68-72d065a8bf08"
      unitRef="usd">1384000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfNC0xLTEtMS0zNDQxMQ_c563740f-566b-4d02-9d68-b9600cd0ccf3"
      unitRef="usd">1412000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfNS0xLTEtMS0zNDQxMQ_39ab8e0d-51b4-4ff7-bbaf-519ae84f3614"
      unitRef="usd">1318000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfNi0xLTEtMS0zNDQxMQ_9dc3c725-41d3-4c4f-9ad0-64439aeee956"
      unitRef="usd">363000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfNy0xLTEtMS0zNDQxMQ_95a3d030-50fc-4022-be9a-0aa9ce054429"
      unitRef="usd">7290000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfOC0xLTEtMS0zNDQxMQ_ef8f09d0-486d-4caf-bfef-e70aec1b8e53"
      unitRef="usd">1699000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl81OC9mcmFnOjg1ZGNiOWZlMjdiNjRlMmI5MzQ5ZTY0Mjk1NTQ1ZWRhL3RhYmxlOjE3NGFiZmI2OGUwMjRlYjY5Nzc0NDUxZjBmY2JkOTYyL3RhYmxlcmFuZ2U6MTc0YWJmYjY4ZTAyNGViNjk3NzQ0NTFmMGZjYmQ5NjJfOS0xLTEtMS0zNDQxMQ_7f003983-aea8-4dcb-b065-4a4ac17945b5"
      unitRef="usd">5591000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82MS9mcmFnOmYzMTljODQyZWU1ZTQzOTY4NGUyN2RkYWQ5MWQ2M2E0L3RleHRyZWdpb246ZjMxOWM4NDJlZTVlNDM5Njg0ZTI3ZGRhZDkxZDYzYTRfMjI5OA_e1dd285a-f73f-4458-85b9-cab8b4286351">COMMITMENTS AND CONTINGENCIES The Company has agreements with Contract Research Organizations (&#x201c;CROs&#x201d;) pursuant to which the Company and the CROs are conducting clinical trials of mavorixafor&#160;for the treatment of WHIM syndrome, Waldenstr&#xf6;m&#x2019;s and SCN and chronic &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;neutropenia disorders. The Company may terminate these agreements by providing notice pursuant to the contractual provisions of such agreements and would incur early termination fees. The Company also has agreements with contract manufacturing organizations (&#x201c;CMOs&#x201d;) for the production of mavorixafor for use in clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification Agreements&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company to, among other things, indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of March&#160;31, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to any legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i975809049d0a45c497bb1ac01a475dac_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82MS9mcmFnOmYzMTljODQyZWU1ZTQzOTY4NGUyN2RkYWQ5MWQ2M2E0L3RleHRyZWdpb246ZjMxOWM4NDJlZTVlNDM5Njg0ZTI3ZGRhZDkxZDYzYTRfMTYxNg_465ec98c-b2ab-4735-8723-697f44056949"
      unitRef="usd">0</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i65cb0a8a766640df9a3c2d91519beec5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82MS9mcmFnOmYzMTljODQyZWU1ZTQzOTY4NGUyN2RkYWQ5MWQ2M2E0L3RleHRyZWdpb246ZjMxOWM4NDJlZTVlNDM5Njg0ZTI3ZGRhZDkxZDYzYTRfMTYxNg_fa10300b-24b8-4da3-aff6-b00c7b0ddd2a"
      unitRef="usd">0</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMjgxMg_bed4c37e-28a5-446d-9201-4784c03bd729">COMMON STOCK AND COMMON STOCK WARRANTS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December 31, 2021, the Company&#x2019;s Restated Certificate of Incorporation authorized the Company to issue 125,000,000 shares of common stock, par value $0.001 per share. The voting, dividend and liquidation rights of the holders of the Company&#x2019;s common stock are subject to and qualified by the rights, powers and preferences of the holders of any preferred stock that may be issued. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. No cash dividends have been declared or paid to date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 3, 2022, the Company entered into a securities purchase agreement pursuant to which it agreed to issue and sell to an investor (the &#x201c;Investor&#x201d;), in a private placement (the &#x201c;Q1 2022 Private Placement&#x201d;), 900,000 shares of common stock at a price of $1.80 per share, which represents the volume weighted average price per share of the Company&#x2019;s common stock as quoted on the Nasdaq Stock Market for the thirty (30) consecutive-day trading day period ending on March 2, 2022, and pre-funded warrants to purchase 766,666 shares of common stock at a purchase price of $1.79 per pre-funded warrant (representing the price of  $1.80 per share minus the $0.01 per share exercise price of each such prefunded warrant). The pre-funded warrants are exercisable at any time after their original issuance date and will have no expiration date. The Q1 2022 Private Placement closed on March 7, 2022 and the Company received gross proceeds of 3.0 million, before deducting offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, on March 3, 2022, the Company entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;) with the Investor, pursuant to which the Company agreed to register for resale the shares of common stock purchased by the Investor and the shares of common stock underlying the pre-funded warrants held by the Investor (the &#x201c;Registrable Securities&#x201d;). Pursuant to the Registration Rights Agreement, the Company filed a registration statement covering the resale of the Registrable Securities on April 22, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with its issuance of common stock in a public offering that closed on November 29, 2019, the Company issued 5,416,667 Class B warrants, which are exercisable for shares of the Company&#x2019;s common stock or pre-funded warrants to purchase shares of the Company's common stock. The Class B warrants were immediately exercisable upon issuance, had an initial exercise price of $15.00 per share and expire on a date that is the earlier of (a) the date that is 30 calendar days from the date on which the Company issues a press release announcing top-line data from its Phase 3 clinical trial of mavorixafor for the treatment of patients with WHIM syndrome (or, if such date is not a business day, the next business day) and (b) November 28, 2024. The Class B warrants have a contingent price adjustment feature pursuant to which the exercise price of the Class B warrants is adjusted to the lowest weighted average offering price at which the Company sells its common stock or certain securities convertible into or exercisable for the Company's common stock in one or more subsequent offerings, if the weighted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;average offering price for such offering is below $15.00.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 3, 2022, the exercise price of the Class B warrants was adjusted to $1.80 as a result of the Q1 2022 Private Placement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with previous equity offerings, the Company has issued pre-funded warrants, which are exercisable into one share of the Company's common stock, are immediately exercisable upon issuance, and for which the remaining exercise price  is equal to or less than $0.01 per share.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides a roll forward of outstanding warrants for the three month period ended March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and exercisable warrants to purchase common shares as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,257,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and exercisable warrants to purchase common shares as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,023,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company&#x2019;s outstanding warrants to purchase shares of common stock consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares of&lt;br/&gt;Common&lt;br/&gt;Stock Issuable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 25, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 24, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 28, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 28, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 12, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 19, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 19, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 13, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 12, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 16, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,866,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 15, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,416,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 28, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 23, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 9, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,008,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;766,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,023,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a) In November 2019, the Company received $11.999 per pre-funded warrant, or $21.0 million in aggregate proceeds. Each pre-funded&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;warrant may be exercised for an additional $0.001 per pre-funded warrant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(b) In March 2021, the Company received $8.69 per pre-funded warrant, or $435 thousand in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(c) In November 2021, the Company received $4.97 per pre-funded warrant, or $10.0&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(d) In March 2022, the Company received $1.79 per pre-funded warrant, or $3.0&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0ODc2Nw_fc4131bd-c941-4569-8a17-5a101e4026dd"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0ODgwNQ_823550c1-247b-4a03-a96c-deb6ad0ade91"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0ODgwNQ_87093510-f55e-4f70-a05a-598cc2292937"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DividendsCommonStock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0OTE0Nw_65009448-d33c-4bd3-8cf1-55f4a3198ba4"
      unitRef="usd">0</us-gaap:DividendsCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0ODYzMw_807a74a0-7f08-4d1f-86e0-40bb7bde5261"
      unitRef="shares">900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9987285e8b814bf3a75efbc5d0f415b7_I20210323"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0OTg0Mg_5a18b738-b1dd-4d4e-b435-798ec977e93e"
      unitRef="usdPerShare">1.80</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0ODY0NA_75cfe9f6-756d-4dfa-969e-f1f7884e0be9"
      unitRef="shares">766666</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9987285e8b814bf3a75efbc5d0f415b7_I20210323"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0OTIzMg_5a18b738-b1dd-4d4e-b435-798ec977e93e"
      unitRef="usdPerShare">1.80</us-gaap:SaleOfStockPricePerShare>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i9987285e8b814bf3a75efbc5d0f415b7_I20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0OTI0MQ_d0ea78dd-6af7-4e13-a5e2-508e855118e8"
      unitRef="usdPerShare">0.01</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <xfor:ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses
      contextRef="i5fd283910b0c46c7b76b73ec9c937efa_D20210323-20210323"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0OTI1Ng_fb458331-8599-4b62-a250-aa20d040f076"
      unitRef="usd">3000000</xfor:ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses>
    <xfor:ClassOfWarrantOrRightIssued
      contextRef="i7640c5cc7cdf4a798762f93ad58a800d_D20191129-20191129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMjUw_32218f9b-32ae-49fd-a220-238667d053c9"
      unitRef="shares">5416667</xfor:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i33b0d388662f46dc8e3e78c78b30a392_I20191129"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfNjI1_8c10a180-cfa8-4649-91d2-5d38578b0892"
      unitRef="usdPerShare">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightWarrantsExpirationPeriod
      contextRef="i1c1e0a3da76d47a8892dbba813618c07_D20191126-20191126"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfNzAz_4967130d-d639-4028-9f97-b0e1f40c95a9">P30D</xfor:ClassOfWarrantOrRightWarrantsExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i33b0d388662f46dc8e3e78c78b30a392_I20191129"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTQwNQ_8c10a180-cfa8-4649-91d2-5d38578b0892"
      unitRef="usdPerShare">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY0ODAzMA_e97ba1ca-d668-4627-a841-9179fcc34123"
      unitRef="usdPerShare">1.80</xfor:ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="ib952420c74dc41d0b56c0d7c1ae747af_I20190416"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTk0Ng_fdd4a06b-d0ae-4a78-9919-c2e0120a9f32"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i9987285e8b814bf3a75efbc5d0f415b7_I20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMjE5Mg_d0ea78dd-6af7-4e13-a5e2-508e855118e8"
      unitRef="usdPerShare">0.01</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMjgwOQ_07c04780-bf75-4dab-bc3f-7c7877220bc1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides a roll forward of outstanding warrants for the three month period ended March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and exercisable warrants to purchase common shares as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,257,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and exercisable warrants to purchase common shares as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,023,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company&#x2019;s outstanding warrants to purchase shares of common stock consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares of&lt;br/&gt;Common&lt;br/&gt;Stock Issuable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 25, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 24, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 28, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 28, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 12, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 19, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 19, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 13, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 12, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 16, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,866,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 15, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,416,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 28, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 23, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 9, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,008,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;766,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,023,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a) In November 2019, the Company received $11.999 per pre-funded warrant, or $21.0 million in aggregate proceeds. Each pre-funded&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;warrant may be exercised for an additional $0.001 per pre-funded warrant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(b) In March 2021, the Company received $8.69 per pre-funded warrant, or $435 thousand in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(c) In November 2021, the Company received $4.97 per pre-funded warrant, or $10.0&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(d) In March 2022, the Company received $1.79 per pre-funded warrant, or $3.0&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfMS0yLTEtMS0zNDQxMQ_92fee893-6fef-4b83-b4b3-f56b35d9a577"
      unitRef="shares">13257160</us-gaap:ClassOfWarrantOrRightOutstanding>
    <xfor:ClassOfWarrantOrRightWeightedAverageExercisePrice
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfMS00LTEtMS0zNDQxMQ_203a4a66-c849-4082-a6f8-7481f4d378fd"
      unitRef="usdPerShare">7.96</xfor:ClassOfWarrantOrRightWeightedAverageExercisePrice>
    <xfor:ClassOfWarrantOrRightWeightedAverageContractualTerm
      contextRef="idcbf7212a2a648e0bdba60353fb0018f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfMS02LTEtMS0zNDQxMQ_37a34a82-9b3c-44ae-a578-952193e4700c">P2Y8M19D</xfor:ClassOfWarrantOrRightWeightedAverageContractualTerm>
    <xfor:ClassOfWarrantOrRightIssued
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfMi0yLTEtMS0zNDQxMQ_1d10e30d-a1fc-4c6a-85e2-4cdec0bb7935"
      unitRef="shares">766666</xfor:ClassOfWarrantOrRightIssued>
    <xfor:ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfMi00LTEtMS0zNTE3OQ_f2fd10f4-1b1e-4087-8069-07f5701f9e98"
      unitRef="usdPerShare">1.80</xfor:ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice>
    <xfor:ClassOfWarrantOrRightExercised
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfMy0yLTEtMS0zNDQxMQ_6f990a28-0e3d-4bee-b27f-1d21c96f0851"
      unitRef="shares">100</xfor:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfNS0yLTEtMS0zNDQxMQ_1c1da325-dcd2-4f10-b0e9-474b1c65e6fc"
      unitRef="shares">14023726</us-gaap:ClassOfWarrantOrRightOutstanding>
    <xfor:ClassOfWarrantOrRightWeightedAverageExercisePrice
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfNS00LTEtMS0zNDQxMQ_4a590a24-a460-469c-a119-163bda7c2bc7"
      unitRef="usdPerShare">6.91</xfor:ClassOfWarrantOrRightWeightedAverageExercisePrice>
    <xfor:ClassOfWarrantOrRightWeightedAverageContractualTerm
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjMzZTgzYjUwNjE2NzQxOGZiNzk4ODM2NzBmMTQ0NGIwL3RhYmxlcmFuZ2U6MzNlODNiNTA2MTY3NDE4ZmI3OTg4MzY3MGYxNDQ0YjBfNS02LTEtMS0zNDQxMQ_4e1027af-c6de-4036-ab33-fefc32764eba">P2Y5M19D</xfor:ClassOfWarrantOrRightWeightedAverageContractualTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if11478b9d8ef48469399603eb4700067_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMS0yLTEtMS0zNDQxMQ_a343b8d1-aa7f-4787-af2c-a4e1caf29b0b"
      unitRef="shares">5155</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i53cd7e343ca1417fabb4bb23d6a34e59_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMS00LTEtMS0zNDQxMQ_0376e1e0-0d17-4ae5-801c-2db0b3c9b6c5"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i374920f0a8c246a18acce80fd3f3f518_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMi0yLTEtMS0zNDQxMQ_7da159b4-ab39-440c-a123-91c437cdf693"
      unitRef="shares">115916</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3719e7acfe4d42d793a973477e301657_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMi00LTEtMS0zNDQxMQ_5cb80e1c-7cde-42e5-95cd-5ae55960a5c3"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic2a6dbe35ef24ffeb2d308772056da96_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMy0yLTEtMS0zNDQxMQ_03c1430f-5987-433d-a587-915e329eef4f"
      unitRef="shares">20220</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if852079aba5d4e9ba7bdcc9ca39a389a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMy00LTEtMS0zNDQxMQ_ecb2983f-4d85-46bd-a25c-218edccccbd9"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i82c001a5dabd46658a607c7940a5a634_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNC0yLTEtMS0zNDQxMQ_aff02ce6-65d6-4acc-b121-1d8b22f79aca"
      unitRef="shares">20016</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7762054b7322478e9a88838854405b2f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNC00LTEtMS0zNDQxMQ_4572866a-0783-4fd8-be97-3851e285c007"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if43e448bd5894bd2863d446143e0ff04_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNS0yLTEtMS0zNDQxMQ_6164d91e-c17b-4925-a291-7bb6964f6be0"
      unitRef="shares">5000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3270dde03c414860922ae7af87624181_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNS00LTEtMS0zNDQxMQ_f80934d1-170f-46fd-a0ee-cde75e95a45c"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib1993d79bf6244d0b392f8df783ee312_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNi0yLTEtMS0zNDQxMQ_c86d160c-f3a2-43fc-8826-c8478cd6073e"
      unitRef="shares">3866154</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i4d8975a741104b5296f718b358811082_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNi00LTEtMS0zNDQxMQ_b36feded-b389-46c4-9f07-25c7dd7f13c0"
      unitRef="usdPerShare">13.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1674d766cfaa4621a97b51e4f672d1aa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNy0yLTEtMS0zNDQxMQ_136a33f5-53a9-45bd-b061-13d99e138407"
      unitRef="shares">5416567</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="icfbe308a558a41579f92a9d56f820980_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfNy00LTEtMS0zNDQxMQ_848b10af-3f21-48ca-a36d-3533ba7d17aa"
      unitRef="usdPerShare">1.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i16d2edf8cc33443ea0ffbd013f4b66e0_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfOC0yLTEtMS0zNDQxMQ_91a6e832-0abc-4733-9df0-4b761431cc6f"
      unitRef="shares">1750000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i85b541bd25654094be49307558799aae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfOC00LTEtMS0zNDQxMQ_1d5db741-6875-4b14-84c7-16cca46086f5"
      unitRef="usdPerShare">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i0b51e9aec2ca4554a1cb58776b67a06a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfOS0yLTEtMS0zNDQxMQ_fb4398e4-2681-442d-96e6-aa901dbccee6"
      unitRef="shares">50000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i12273bd7f6f844c29aa5394dbc198547_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfOS00LTEtMS0zNDQxMQ_e5008ed7-daec-4709-a8e4-df15b451330c"
      unitRef="usdPerShare">8.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i31185213cb1d401ab6f9bfaf3eca7163_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMTAtMi0xLTEtMzUwOTQ_bce31ee4-fa5e-4e98-bb3a-6512e9f4c36b"
      unitRef="shares">2008032</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i31185213cb1d401ab6f9bfaf3eca7163_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMTAtNC0xLTEtMzUwOTQ_b9435e91-4d3c-4af3-a923-979b0869a13b"
      unitRef="usdPerShare">4.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="iaadf734ea7f34c549783db6da7a96a56_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMTEtMi0xLTEtMzUwOTQ_17538243-2bb6-4d73-ad36-628d96912ec3"
      unitRef="shares">766666</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iaadf734ea7f34c549783db6da7a96a56_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMTEtNC0xLTEtMzUwOTQ_dd22b6b0-0ac5-45c2-a6b6-a6779c761e8c"
      unitRef="usdPerShare">1.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RhYmxlOjI2ZGU0NTFmMTZhNjRhNzE4M2IzMGI2ZTc4MjI4N2M5L3RhYmxlcmFuZ2U6MjZkZTQ1MWYxNmE2NGE3MTgzYjMwYjZlNzgyMjg3YzlfMTAtMi0xLTEtMzQ0MTE_736116c0-0721-4b0e-8692-8e50e4deffec"
      unitRef="shares">14023726</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i74b9f718ca0e4c5d9b871296a1e02de1_I20191129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjE3Mw_42bbc9d4-ca9f-4f04-a747-d2c892766f13"
      unitRef="usdPerShare">11.999</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued
      contextRef="i0c46977bdcd44c5fbb626a2c7adad70d_I20191129"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjE3Nw_a9be15c0-03fe-4df2-97c2-f61e7a8e688a"
      unitRef="usd">21000000</xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i0c46977bdcd44c5fbb626a2c7adad70d_I20191129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjIyMw_737ce72f-7aa8-47f5-a8d7-460fad71da07"
      unitRef="usdPerShare">0.001</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7a34589fe1b04db8902c62e32428ecf2_I20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjIzMg_09855051-43ed-4729-98d4-7618b54a043a"
      unitRef="usdPerShare">8.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued
      contextRef="i9987285e8b814bf3a75efbc5d0f415b7_I20210323"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMjY5NA_c0febe68-a2d3-46d8-b493-a3395535a976"
      unitRef="usd">435000</xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i9987285e8b814bf3a75efbc5d0f415b7_I20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMjc3OQ_d0ea78dd-6af7-4e13-a5e2-508e855118e8"
      unitRef="usdPerShare">0.01</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i055ed4cd017b4077b80b39c7e53429d5_I20211109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjE5MA_11b82ab2-43a8-445d-8224-7409280db330"
      unitRef="usdPerShare">4.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued
      contextRef="ie946fb34148e40778aa24e30c0fb5174_I20211109"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjIwNw_35db27d2-505e-455f-bd74-7e6d52310398"
      unitRef="usd">10000000</xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i96523b616e2c4aaaa42b757f1dead895_I20201102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjIxOA_1be798ca-b0aa-43c7-953c-9dc821c1147f"
      unitRef="usdPerShare">0.01</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="idb651aa4d13d4e91881e98c2a66705b2_I20220303"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjI0Mg_8acd6475-9dc5-42b0-bf19-aa19287ffddb"
      unitRef="usdPerShare">1.79</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued
      contextRef="i5abc6425ebed4d1098137ddae6cf173b_I20220303"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl82NC9mcmFnOjI1Zjk4OTM5MzNhMDRjNjdiNzRkYjc0NzI5NDZkNWVjL3RleHRyZWdpb246MjVmOTg5MzkzM2EwNGM2N2I3NGRiNzQ3Mjk0NmQ1ZWNfMTA5OTUxMTY1MjI2MA_34ddadbf-7cd1-4d6c-80af-d0216885a9bf"
      unitRef="usd">3000000</xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMzg1NQ_38dcb507-5c9f-4fb1-ab8e-06475d982f35">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Plans&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has the following equity incentive plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The X4 Pharmaceuticals Inc. 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#x201c;2015 Plan&#x201d;);&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The X4 Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;); and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The X4 Pharmaceuticals Inc. 2019 Inducement Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company also has the following employee stock purchase plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;The X4 Pharmaceutical Inc. 2017 Employee Stock Purchase Plan (the &#x201c;2017 ESPP&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These plans are administered by the Board of Directors or by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of the stock option may not be greater than ten years. Incentive stock options granted to employees and restricted stock awards granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over four years. Non-statutory options granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over three or four years. Shares that are expired, terminated, surrendered or canceled under the Plans without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, there are an aggregate of approximately 550,000 shares of common stock available for issuance under the Company&#x2019;s equity incentive plans. Approximately 270,000 shares of common stock remain available for issuance under the 2017 ESPP.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Valuation&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees, directors and non-employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,049,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,798,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no stock options exercised in the three months ended March 31, 2022. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2021 was $13 thousand. The weighted average grant-date fair value per share of stock options granted during the three months ended March&#160;31, 2022 and 2021 was $1.42 and $6.52, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The following table summarizes the Company's restricted stock unit activity for the three months ended March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,242,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,940,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, the Company granted time-based restricted stock units to employees. These restricted stock units vest annually over a two or three year period. Stock-based compensation expense is being recognized for these time-based awards ratably based on the intrinsic value of the awards as of the date of grant, less estimated forfeitures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, total unrecognized compensation expense related to unvested stock options and restricted stock units was $8.5 million, which is expected to be recognized over a weighted average period of 2.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1087c98fdfeb43a5b2b61cf5a5a18780_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMTc4NA_e4aeb9f6-301b-4c69-a677-8ffe7c901c55"
      unitRef="shares">550000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id3f763b38edd403fb65281fd8c0d1e6b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMTg5OA_d3d5b391-b19a-46aa-99f0-a20ce7ada5d4"
      unitRef="shares">270000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMzg1Ng_d974c1bc-6c2e-4ee0-aa9b-2678315dc1b3">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees, directors and non-employees.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfMi0xLTEtMS0zNDQxMQ_a99f6164-eb98-4ffd-bf5a-5f0454a3715d"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfMi0zLTEtMS0zNDQxMQ_ddcd6693-13ca-4c44-8ea2-9bebbe47a134"
      unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfMy0xLTEtMS0zNDQxMQ_473e60d2-7f32-4647-938d-197d454e2c6f">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfMy0zLTEtMS0zNDQxMQ_b59d3c50-1d58-4b32-ba43-c6b5ee871f40">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfNC0xLTEtMS0zNDQxMQ_8d4087ea-d9cd-4007-a5a1-724581039830"
      unitRef="number">0.945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfNC0zLTEtMS0zNDQxMQ_8d35246b-2a9c-42d9-8d64-41980d00855b"
      unitRef="number">1.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfNS0xLTEtMS0zNDQxMQ_dfa3738c-6e81-477f-8f34-2d02d90cb1a2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjQ4NmEzZjdjOGQ4NzRhMDU5MzFhNDhmMDgyMmU0MmFlL3RhYmxlcmFuZ2U6NDg2YTNmN2M4ZDg3NGEwNTkzMWE0OGYwODIyZTQyYWVfNS0zLTEtMS0zNDQxMQ_34027dfb-e241-4c60-85d4-28c02cfd9304"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMzg1MQ_447f7572-a31e-4834-9f81-3a158738002e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,049,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,798,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfMS0xLTEtMS0zNDQxMQ_c50d6d28-999c-4380-a7be-aa4139630bd7"
      unitRef="shares">1916051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfMS0zLTEtMS0zNDQxMQ_8ebc2974-562c-4345-960f-1a19e5ce9f8c"
      unitRef="usdPerShare">10.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia64d3337ee204135be6803aad57e0f54_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfMS01LTEtMS0zNDQxMQ_e9abd500-efa4-41fe-8ebb-8bf78b5deadb">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ied3aba39e79f4b429586d34201372693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfMS03LTEtMS0zNDQxMQ_0fe58058-2bf1-44ad-a7bc-7e8d6c410602"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfMi0xLTEtMS0zNDQxMQ_70ed6a43-e5c7-4d2c-8337-5c6392c71bce"
      unitRef="shares">232850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfMi0zLTEtMS0zNDQxMQ_0a120928-3335-4cbd-a5e4-9c720d4a56ff"
      unitRef="usdPerShare">1.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNC0xLTEtMS0zNDQxMQ_be23db5f-3dc8-4348-9357-404efff6bd72"
      unitRef="shares">99743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNC0zLTEtMS0zNDQxMQ_f0978d29-6b63-4abc-963f-7bd4563719f1"
      unitRef="usdPerShare">23.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNS0xLTEtMS0zNDQxMQ_afd90f96-fec6-433e-b727-1a721ffd86dc"
      unitRef="shares">2049158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNS0zLTEtMS0zNDQxMQ_c1957f2f-f9f5-4a38-abd1-2f5a842f635a"
      unitRef="usdPerShare">8.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNS01LTEtMS0zNDQxMQ_2b981eca-a967-407f-a679-5a59df2b7c90">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNS03LTEtMS0zNDQxMQ_f0e415f3-bbf8-45b1-aba6-9b1a47550ed5"
      unitRef="usd">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNi0xLTEtMS0zNDQxMQ_7a18cdf3-fe13-4e65-921c-c8ddba12db65"
      unitRef="shares">1029146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNi0zLTEtMS0zNDQxMQ_4dfe6f49-7623-4af8-a151-45ef7201744c"
      unitRef="usdPerShare">10.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNi01LTEtMS0zNDQxMQ_496d1185-db3a-434e-b524-61537c357c00">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNi03LTEtMS0zNDQxMQ_b54bc6ab-2023-43c0-9588-3bd3d38612a9"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNy0xLTEtMS0zNDQxMQ_238bace1-540e-4164-abad-da9280994c39"
      unitRef="shares">1798855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNy0zLTEtMS0zNDQxMQ_f23c3ffc-4ba1-46a5-9725-160a9fdf2a18"
      unitRef="usdPerShare">8.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNy01LTEtMS0zNDQxMQ_2d384f98-421d-42df-9239-07e35d00e983">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjYyYjk2YmQxY2Q3ZjRmZDU5ZTMzZGFjOWFkNzgzZjJhL3RhYmxlcmFuZ2U6NjJiOTZiZDFjZDdmNGZkNTllMzNkYWM5YWQ3ODNmMmFfNy03LTEtMS0zNDQxMQ_0253af9f-71d5-4364-aff2-2f393fb877f7"
      unitRef="usd">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMjQ0Ng_5014b585-b584-46f8-989b-77ab3772e55e"
      unitRef="usd">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMjU5Mg_11407a85-f4fc-44b4-a0a9-386f8e8b3fdb"
      unitRef="usdPerShare">1.42</xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue>
    <xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMjU5OQ_dae8be71-88da-4a5d-9043-19fe644c990d"
      unitRef="usdPerShare">6.52</xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMzg1Mg_ab0cae24-1497-4831-a919-b8c959bed7b3">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The following table summarizes the Company's restricted stock unit activity for the three months ended March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,242,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,940,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia735dbcc36df42bd8741cce45232e31a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjM3Y2E0YTlhZDVkNDQ0YzI4MDgwNGQwMjNhZTg4MjViL3RhYmxlcmFuZ2U6MzdjYTRhOWFkNWQ0NDRjMjgwODA0ZDAyM2FlODgyNWJfMS0xLTEtMS0zNDQxMQ_7da31d1f-3316-4822-8089-689e2325afc7"
      unitRef="shares">925101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjM3Y2E0YTlhZDVkNDQ0YzI4MDgwNGQwMjNhZTg4MjViL3RhYmxlcmFuZ2U6MzdjYTRhOWFkNWQ0NDRjMjgwODA0ZDAyM2FlODgyNWJfMi0xLTEtMS0zNDQxMQ_9d7d216b-ec65-46b8-b664-a009d4e528cb"
      unitRef="shares">1242756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjM3Y2E0YTlhZDVkNDQ0YzI4MDgwNGQwMjNhZTg4MjViL3RhYmxlcmFuZ2U6MzdjYTRhOWFkNWQ0NDRjMjgwODA0ZDAyM2FlODgyNWJfMy0xLTEtMS0zNDQxMQ_88511d77-911a-4281-93d5-6c62c5c8a4ea"
      unitRef="shares">192255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjM3Y2E0YTlhZDVkNDQ0YzI4MDgwNGQwMjNhZTg4MjViL3RhYmxlcmFuZ2U6MzdjYTRhOWFkNWQ0NDRjMjgwODA0ZDAyM2FlODgyNWJfNC0xLTEtMS0zNDQxMQ_d3211786-4df2-4eee-bd9d-c0d247d63d98"
      unitRef="shares">34814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i551b03b35a354b9c82567e2c1278da6f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjM3Y2E0YTlhZDVkNDQ0YzI4MDgwNGQwMjNhZTg4MjViL3RhYmxlcmFuZ2U6MzdjYTRhOWFkNWQ0NDRjMjgwODA0ZDAyM2FlODgyNWJfNS0xLTEtMS0zNDQxMQ_0b1c48b0-9177-417b-a4f9-b8f1db8214f0"
      unitRef="shares">1940788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if5ce63ce89fc4d53b2de1b932c6c5971_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMzY1OA_1b6a82da-daa3-48e4-ac79-73bb9707a8b6"
      unitRef="usd">8500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i34f00a49e9164c6f8f5d5aea7638c86e_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMzczMQ_1afda0e6-fecd-4d44-8544-0541a3e58d05">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RleHRyZWdpb246NDZjOTgwZGQxNjFlNDllMGExODE3M2Y0NWFmNzAyYjVfMzg1Mw_e6cc4e20-6aaa-4b67-a365-1e9a4f21991d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f08fbd1d62147b7a24653057a24170f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjUzZDAzNjI1ZDkwMTQyYTU4N2Q1NzU5NTg4NThmZjM5L3RhYmxlcmFuZ2U6NTNkMDM2MjVkOTAxNDJhNTg3ZDU3NTk1ODg1OGZmMzlfMi0xLTEtMS0zNDQxMQ_f883eb5b-5349-4ad4-bb72-8ce96bee5beb"
      unitRef="usd">704000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibe626170d10b4caa80d237bf4ea1bace_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjUzZDAzNjI1ZDkwMTQyYTU4N2Q1NzU5NTg4NThmZjM5L3RhYmxlcmFuZ2U6NTNkMDM2MjVkOTAxNDJhNTg3ZDU3NTk1ODg1OGZmMzlfMi0zLTEtMS0zNDQxMQ_3dafc6af-60ae-4170-8abe-9a652b0d7f5e"
      unitRef="usd">577000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7ce083cdddd2478e9589bcc5c51fb670_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjUzZDAzNjI1ZDkwMTQyYTU4N2Q1NzU5NTg4NThmZjM5L3RhYmxlcmFuZ2U6NTNkMDM2MjVkOTAxNDJhNTg3ZDU3NTk1ODg1OGZmMzlfMy0xLTEtMS0zNDQxMQ_1c648595-a90e-455b-a59d-00b1642574d3"
      unitRef="usd">755000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2610f6c62e848928bf100bd21dc705c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjUzZDAzNjI1ZDkwMTQyYTU4N2Q1NzU5NTg4NThmZjM5L3RhYmxlcmFuZ2U6NTNkMDM2MjVkOTAxNDJhNTg3ZDU3NTk1ODg1OGZmMzlfMy0zLTEtMS0zNDQxMQ_fcaa34e8-ffe6-4d05-ac0d-6ebc6daf8318"
      unitRef="usd">681000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjUzZDAzNjI1ZDkwMTQyYTU4N2Q1NzU5NTg4NThmZjM5L3RhYmxlcmFuZ2U6NTNkMDM2MjVkOTAxNDJhNTg3ZDU3NTk1ODg1OGZmMzlfNC0xLTEtMS0zNDQxMQ_bbdbd58e-6acd-4f98-a240-2fe0482d9a9d"
      unitRef="usd">1459000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83My9mcmFnOjQ2Yzk4MGRkMTYxZTQ5ZTBhMTgxNzNmNDVhZjcwMmI1L3RhYmxlOjUzZDAzNjI1ZDkwMTQyYTU4N2Q1NzU5NTg4NThmZjM5L3RhYmxlcmFuZ2U6NTNkMDM2MjVkOTAxNDJhNTg3ZDU3NTk1ODg1OGZmMzlfNC0zLTEtMS0zNDQxMQ_b0f5ab6d-2154-497a-a700-56c884cda253"
      unitRef="usd">1258000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83Ni9mcmFnOjk1NTYwZTcyMDkzODQ2NDE5NzcwZDIyNzhiMjY3MTA0L3RleHRyZWdpb246OTU1NjBlNzIwOTM4NDY0MTk3NzBkMjI3OGIyNjcxMDRfNDI3_55af8806-736d-4292-b1a9-6cc7e05faa7e">INCOME TAXESThe Company did not record a U.S. federal or state income tax benefit for its losses for the three months ended March&#160;31, 2022 and 2021, due to the conclusion that a full valuation allowance is required against the Company&#x2019;s U.S. federal and state deferred tax assets. For the three months ended March 31, 2022 and March 31, 2021, the Company recorded an immaterial income tax provision related to its Austrian subsidiary.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83Ni9mcmFnOjk1NTYwZTcyMDkzODQ2NDE5NzcwZDIyNzhiMjY3MTA0L3RleHRyZWdpb246OTU1NjBlNzIwOTM4NDY0MTk3NzBkMjI3OGIyNjcxMDRfMzg_9cc60e69-3d27-4903-ba79-a0e14faa0fea"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83Ni9mcmFnOjk1NTYwZTcyMDkzODQ2NDE5NzcwZDIyNzhiMjY3MTA0L3RleHRyZWdpb246OTU1NjBlNzIwOTM4NDY0MTk3NzBkMjI3OGIyNjcxMDRfMzg_a5cd5c6f-5d39-4ca6-ae5f-45c03ec4f467"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83Ni9mcmFnOjk1NTYwZTcyMDkzODQ2NDE5NzcwZDIyNzhiMjY3MTA0L3RleHRyZWdpb246OTU1NjBlNzIwOTM4NDY0MTk3NzBkMjI3OGIyNjcxMDRfMzg_a63305fa-2ccd-4caa-b6e1-829828b765db"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83Ni9mcmFnOjk1NTYwZTcyMDkzODQ2NDE5NzcwZDIyNzhiMjY3MTA0L3RleHRyZWdpb246OTU1NjBlNzIwOTM4NDY0MTk3NzBkMjI3OGIyNjcxMDRfMzg_b53779b2-8a6e-447a-ba66-f6e353a42198"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RleHRyZWdpb246YzVmODcyYWY3Nzc2NGU0ZmJmYjgxY2JmNTk0YWJkMTNfMTY3Mg_2a0c76c5-9258-49f0-8892-0883eb1314d1">NET LOSS PER SHARE&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follow:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deemed dividend as a result of Class B warrant price reset (Note 10)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding&#x2014;basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to common stockholders&#x2014; basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted weighted average shares of common stock outstanding for the three months ended March&#160;31, 2022 and March&#160;31, 2021 include the weighted average effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price is $0.01 or less per share. During the quarters ended March 31, 2022 and March 31, 2021, in accordance with the Class B Warrant agreement, the exercise price of each outstanding Class B Warrant was adjusted to the price of shares of the Company&#x2019;s common stock sold in public or private offerings to the extent such price is lower than the previous Class B warrant price. These price adjustments are accounted for as a deemed dividend that adjusts net loss available to common shareholders for purposes of basic earnings per share. The deemed dividend is calculated using the Black-Scholes pricing model, taking into account historical volatility of the Company&#x2019;s common stock and the estimated remaining life of the outstanding Class B Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s potentially dilutive securities include outstanding stock options, unvested restricted stock units and warrants to purchase shares of common stock for the three months ended March 31, 2022 and 2021. All potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered &#x201c;anti-dilutive.&#x201d; Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,049,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,858,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,940,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase shares of common stock (excluding prefunded warrants, which are included in basic shares outstanding)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,449,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,474,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,438,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,467,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RleHRyZWdpb246YzVmODcyYWY3Nzc2NGU0ZmJmYjgxY2JmNTk0YWJkMTNfMTY3Mw_b8eac8f4-db04-4d03-a920-46f49adcf3d9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follow:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deemed dividend as a result of Class B warrant price reset (Note 10)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding&#x2014;basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to common stockholders&#x2014; basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfMy0xLTEtMS0zNDQxMQ_8d19c9b8-f386-4530-9105-b5210ac5017e"
      unitRef="usd">-21965000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfMy0zLTEtMS0zNDQxMQ_ead8cafe-70e1-4688-892d-405e7c4462e5"
      unitRef="usd">-18676000</us-gaap:NetIncomeLoss>
    <us-gaap:DividendsPaidinkind
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfNC0xLTEtMS0zNDQxMQ_80e76c4b-d1be-4878-bb88-8e8a3a49ab1d"
      unitRef="usd">2259000</us-gaap:DividendsPaidinkind>
    <us-gaap:DividendsPaidinkind
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfNC0zLTEtMS0zNDQxMQ_89d0a6a0-1f3d-49da-9edb-a176562d1cdc"
      unitRef="usd">8239000</us-gaap:DividendsPaidinkind>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfNS0xLTEtMS0zNDQxMQ_1c13f24c-7563-4176-95cc-c85c1e431ecc"
      unitRef="usd">-24224000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfNS0zLTEtMS0zNDQxMQ_bbc3efd3-3892-4df3-b0a4-ee09866aff4c"
      unitRef="usd">-26915000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfNy0xLTEtMS0zNDQxMQ_a38a4990-c996-4377-8924-047e26ff2237"
      unitRef="shares">33737000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfNy0zLTEtMS0zNDQxMQ_0a43d355-8647-4595-b547-0069679c3e55"
      unitRef="shares">20751000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfOC0xLTEtMS0zNDQxMQ_fb0e8ddf-e3f5-4d6d-ad1d-5527da4f82a0"
      unitRef="usdPerShare">-0.72</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOmEyNmQ0ZTVhYzZkODRlODVhNmQ5ODdjYWI1MmE0ZTA3L3RhYmxlcmFuZ2U6YTI2ZDRlNWFjNmQ4NGU4NWE2ZDk4N2NhYjUyYTRlMDdfOC0zLTEtMS0zNDQxMQ_cd63abfc-8b5c-4849-ac9c-731263cb6b6c"
      unitRef="usdPerShare">-1.30</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia0ed061951224fe2b05f82e41a77c8d4_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RleHRyZWdpb246YzVmODcyYWY3Nzc2NGU0ZmJmYjgxY2JmNTk0YWJkMTNfNzM3_7148c239-e708-448a-a7a4-5b0a28ed62b9"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RleHRyZWdpb246YzVmODcyYWY3Nzc2NGU0ZmJmYjgxY2JmNTk0YWJkMTNfMTY3NA_e4676408-fa89-410b-8371-dc1fe7a6f725">The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,049,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,858,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,940,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase shares of common stock (excluding prefunded warrants, which are included in basic shares outstanding)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,449,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,474,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,438,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,467,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1925ffb8b98e470a8755be697908ef08_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfMi0xLTEtMS0zNDQxMQ_e4109aed-fd5b-4dba-9907-842346e4905a"
      unitRef="shares">2049158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i289ea1ad164e40f3bd8d98acc9dd5ec5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfMi0zLTEtMS0zNDQxMQ_00ccf9e2-3137-44df-aa21-dc342c1b4e3e"
      unitRef="shares">1858154</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0c82af5f1bd54ac38a12ea61c79ef148_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfMy0xLTEtMS0zNDQxMQ_3cbca46d-7033-4e7a-93ff-9ac96c034b71"
      unitRef="shares">1940788</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4403e830d3884aac9399f56efc81108c_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfMy0zLTEtMS0zNDQxMQ_5e24f6dc-70dd-4511-819f-0363fe2efefc"
      unitRef="shares">1135419</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9e78ac2b2f9c400db2a88a3ac72a5ab8_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfNC0xLTEtMS0zNDQxMQ_11786537-0858-4607-a8f8-d0385aacf66a"
      unitRef="shares">9449028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifc1e4f78fe354943a530e1e6507b73ea_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfNC0zLTEtMS0zNDQxMQ_fae393d4-0692-4b34-abd6-aa4efb4a26c2"
      unitRef="shares">9474403</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfNS0xLTEtMS0zNDQxMQ_6c564e2f-4d67-42f0-9a3a-fc0f224cf85b"
      unitRef="shares">13438974</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib00aa6fecd42425ea68620951639c543_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA5MjY1M2NjNWI4YzQzYmRhZDM1ODA5NWU1OTNkODFiL3NlYzowOTI2NTNjYzViOGM0M2JkYWQzNTgwOTVlNTkzZDgxYl83OS9mcmFnOmM1Zjg3MmFmNzc3NjRlNGZiZmI4MWNiZjU5NGFiZDEzL3RhYmxlOjcwNTBhYTIwZWQ0OTQ1NzI5NmMwMDUxODMzY2FlZjgwL3RhYmxlcmFuZ2U6NzA1MGFhMjBlZDQ5NDU3Mjk2YzAwNTE4MzNjYWVmODBfNS0zLTEtMS0zNDQxMQ_6f0f6040-a439-40bf-813d-610f23a903f5"
      unitRef="shares">12467976</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "*#K%0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  B@ZQ460&AS>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M3L,P#(=?!>7>.LT8AZCK98@32$A, G&+$F^+:/XH,6KW]J1EZX3@ 3C&_N7S
M9\FMCE*'A,\I1$QD,=^,KO=9ZKAA1Z(H ;(^HE.Y+@E?FON0G*+R3 >(2G^H
M X+@_ X<DC**%$S *BY$UK5&2YU044AGO-$+/GZF?H89#=BC0T\9FKH!UDT3
MXVGL6[@")AAA<OF[@&8ASM4_L7,'V#DY9KNDAF&HA]6<*SLT\/;T^#*O6UF?
M27F-Y5>VDDX1-^PR^76UO=\]L$YP(2J^KAJQ$UR*6[GF[Y/K#[^KL O&[NT_
M-KX(=BW\NHON"U!+ P04    "  B@ZQ4F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M "*#K%0/_S,;4@4  '\6   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9A=<^(V%(:OM[]"PU4[$]:V# G9(<R $[I,DRP;LNUN.[T0M@#/VA*5Y1#^
M?8]LL-F,./:T-XF_SLNCK_?H:+B3ZGNVX5R3US01V4UGH_7V@^-DX8:G+'LO
MMUS FY54*=-PJ]9.ME6<1450FCC4=2^=E,6B,QH6S^9J-)2Y3F+!YXID>9HR
MM9_P1.YN.E[G^. I7F^T>>",AENVY@NNOVSG"NZ<2B6*4RZR6 JB^.JF,_8^
M!'[/!!1?_![S779R34Q3EE)^-S>SZ*;C&B*>\% ;"0;_7GC D\0H <<_!]%.
M]9LF\/3ZJ#XM&@^-6;*,!S+Y(X[TYJ8SZ)"(KUB>Z">Y^\@/#>H;O5 F6?&7
M[,IO>[T."?-,R_00# 1I+,K_[/70$2<!]%P /030-P&>?R; /P3X14-+LJ)9
MMTRST5#)'5'F:U S%T7?%-'0FEB885QH!6]CB-.C0+YP1>8P8J1+L@U3/!LZ
M&H3-:R<\B$Q*$7I&Q"</4NA-1NY$Q*,?XQT JJCHD6I"4<$'IMX3W[L@U*74
MPA,TA>^)>VV+_H'&K_K(+^1\M(_^&B\SK6#:_8U(]BK)7B'9.R-Y*\,<%H,F
MS_LMMW4X'NZYW<\(1;^BZ+>C^)PSI;E*]N2);Z72-B)<2JN<(T27%=%E.Z(Y
M5[&,S(0B,*^M780K':?03^_>-4R#JXKMJN68*08V5KC0^>["M58LR;#^&E1,
M U3G3NA8[\DT3CAYS-,E5S867,-UO:X_H-=]A.>ZXKENP_/$U[%9+-!9CRRU
MCAZN\[5'YA_'3P_CX.[+\RP8WR\NR.PQ0 @]MW8\MPWC3(12P>@Q,Y 79*%A
MFA&I2"!SH=4>_D=6\ ;UVSL,\L26O3:0S^R5S"*8=/$J#@M29)@;).E5U_<&
MWJ4[P AI34C;$(ZC"')&=G&\(/?P'?DD['V'2UYZY!&6TX9,. NAJ? .\AI&
M6UNXY_]WVN>=M-+BDCT G292*@RP3@@>;NEO 0-S!]/Q6>Z$%0Z7FTC8.@B,
MK$X2'F[M;\FJE3)7\B46H7VD<<V',8969PL/-_FW:'-H-4O(G_'V_/+%%5WJ
M^3V,K<X6'F[QQ0".86M]'@47&/2O,) Z17BXO]_+$/IDOI$"RQ$-(GUZW1WX
MKHL1U4G"P]W].=:0K^2*>/3GY2]DP<-<06]9L7"E0*9I810R_([M.^OD0''[
MAMP>Q6)-%OMT*1,;48/ U^FG)XRDS@ 4M^MCKY"[UW##!&S0SZ72!J''\>)V
MC&T7:>WYM)7G![E29B-4[GZ*[@)/R*V50X/BM[?UQH]DM;_35OX^$["-+4M#
MLV]D1U0K&:[80%8;.VUE[&:+!IL+L,ZU5-:IWJ#S*$67A2$4P+!EX5$IB!'6
M!D];&?PB94E")GD&KS/[6/ZO&H#6MDY;V?I=RM7:S*Y?00&2+2SV+1/VOL,%
MF\AJ4Z>X)Q_)7D^+@+)6L6+A:DU8M<735F7 8L-A!+%NPF6:JA):.SQM50><
MVC-L'(KC!?(IUY"EA;%9:VE?*O<+97,*]3+RW0'U^U?^T'FQ4/FUN?NX-X^A
M?(N*$FZ:,-N/3QH$FCK(K]W=QTVY*B:G<6;2\S?.%)G"0^O":Q!K.N>H_=W'
MW?@MU:$*/\^%RWWV,*J3XY=6WAX F *HF8CX*_F-6V=X@Y0+Q6[?]2ZOL:V5
M7WN[CWOR,1&>#B)V9-$@U^UZ%&HT&YIS<L1G;+$X^<Q(:(K5\K2O>EJ=KHZ+
M,T6G_KP\FGU@QE4SDO 5A+KOKV"IJ?*TL[S1<EL<&"ZEUC(M+C><15R9#^#]
M2DI]O#$_4)TYC_X%4$L#!!0    ( "*#K%1[;:Z S04  #L6   8    >&PO
M=V]R:W-H965T<R]S:&5E=#(N>&ULK5AM;]LV$/XKA%<,+6#'(O6>.@;2)%L+
MI&E0I]MG6:)CHI+HBE2<[-?O*#N2+5*,!^Q#(DJ^.SYWY-W#XVS+JY]B3:E$
MST5>BHO16LK-^70JTC4M$G'&-[2$7U:\*A()K]7C5&PJFF2-4I%/B>,$TR)A
MY6@^:[[=5_,9KV7.2GI?(5$715*]?*(YWUZ,\.CUPW?VN);JPW0^VR2/=$'E
MC\U]!6_3UDK&"EH*QDM4T=7%Z!*?7Y%8*302?S&Z%0=CI%Q9<OY3O7S)+D:.
M0D1SFDIE(H''$[VB>:XL 8Y?>Z.C=DZE>#A^M?Y'XSPXLTP$O>+YWRR3ZXM1
M-$(9725U+K_S[6>Z=\A7]E*>B^8_VNYEG1%*:R%YL5<&! 4K=\_D>1^( P7L
M#2B0O0(Y5<'=*[B-HSMDC5O7B4SFLXIO4:6DP9H:-+%IM,$;5JIE7,@*?F6@
M)^=7W^ZN;^X6-]<(1HMOMU^N+Q_@Y=/E[>7=U0U:?+ZY>5B@"?JQN$;OWWU
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M@EH6.-:7[G!S[0 :A$+LF/%AIZOTCA7AMR9)AJ'MU8_B$GC][#!)A<0= '=
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MH$$P98?Q#9W'UG LH1RX,6AEC$5J.,:XP[(U06#W6%":"%0HH]M.@*YMZQ9
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MGU*;221+?)ZY1P#,3G*Q]:TTVPH*U6K$VB=WZ!3Q!V]^40TBTX+K*>AUHHE
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MU3@J&+J:T7@8G>>)N<C3,O"%,]1TG^,4RF*A5C8K>IXI)H_QZ96Z(]\@,$&
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M5\GPT7%NQ]NW :]#.IJG:+Y/H_A=[%-58PG"L;G,WU-7)XJU*Y4F#!BZV7[
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MQRNY%S&_S;VU7^UO_;/FLKO=WOQD@+><TZ1I"=/Q\.WKI!D?W4NP5;SZ+FQ
M9\7' K]<R/$&?%]:M$+[P@[ZWT(G?P-02P,$%     @ (H.L5/@BF+LF!
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M5H#.5U*:P\(:J)ZRHS\!4$L#!!0    ( "*#K%3HL>:&]P(  &X&   9
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M5O1!0.T<:+U4RNXF+D'_B9G]!E!+ P04    "  B@ZQ43)QU]),"  !R!0
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MF1RO"K.9273PSS<#"2>K6<D5M_I=Q*.#(H8/F+H@"N:F&*SL)=<![GP1JY)
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MO<QM8+>CZ.P_>3<!#4BNN4_#3YI]XJ:5).NA0R:5<K$%METW1Y7,FR0CVD+
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M2H-KJ<.&]Y&3B&\'K&OPWS@I3 SILAT9 EI*QK2WOD!++.I^XJN55H\24YU
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M]9[:!6T-:V]^[P6?('V0&.P$UR,:'R)%ZDW'?>@?AH=<-^QB-8-\=Z26=;&
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MWTNW+XYF4S$_G,]WR#L:_'#$\H[ND;?-X/^<+7SG@)O_[CC@>#C@F \XON>
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M%@B9$L1$+G.P_B[!BZ4%+FN.>[(LB<!@Z?A"E2LFMV_?7,:]T7L#65,B[!"
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M6-&P1>T4Z+U4RAXNSD$_OA?_ %!+ P04    "  B@ZQ4="5@*I,"  !V!0
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q]5,ENVS 0_96!T$,"&)$L
MR0L,VX"=I&@/08VDRZ'H@9)&EA N*DG%SM]W2-FR6]0^V.0,Y[U9J,?Y3NE7
M4R%:V LNS2*HK&UF86CR"@4S=ZI!22>ETH)9,O4V-(U&5GB0X&$<1>-0L%H&
MR[GW;?1RKEK+:XD;#:85@NGW-7*U6P3#X.AXKK>5=8YP.6_8%E_0?FLVFJRP
M9REJ@=+42H+&<A&LAK-UZN)]P/<:=^9L#ZZ33*E79WPN%D'D"D*.N74,C)8W
MO$?.'1&5\?O &?0I'?!\?V3_Z'NG7C)F\%[Q'W5AJT4P#:# DK7</JO=)SST
M,W)\N>+&_\.NBTV2 /+66"4.8*I U+);V?XPAS/ -+H B ^ V-?=)?)5/C#+
MEG.M=J!=-+&YC6_5HZFX6KI+>;&:3FO"V>4JSW6+!3SNZ9H-&KCYRC*.YG8>
M6J)W06%^H%IW5/$%J@2>E+25@4=98/$W/J2R^MKB8VWK^"KA$]-WD P'$$=Q
M?(4OZ7M-/%]R@6_#WGUOP&0!OG'&#?Q<9<9J^CI^74F1]BE2GR*]D.*%1%.T
M'$&5\.]H_S?1JVQ.D#/3L!P7 2G.H'[#H+\Q/-Y8KD@BQI*+DMH*H52<M%;+
M[0QN:DDNU1IJV=P"332O_$@?,$>1H?9&3RD:KMX1B5(X<M8)AZ:5H<2RM@8^
M0#*83%,8#=+AY 3<6]22<7!5^AP.5. ;B;XA"=M3M?$@&B8P'(RB$[S1JD3C
M=$X4)5+49!S#.(GA"_7C:IS2+Z7DX\%T,J%U0FL$_[NP\$P+ O76*]X-J96V
MDT7O[1^55:>E4WCW(M&TMK4TP+$D:'0W&06@.Y5WAE6-5U:F+.G4;RMZ&%&[
M #HOE;)'PR7HG]KE'U!+ P04    "  B@ZQ48;3"1[X#   ="0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-BYX;6R-5MMNXS80_96!&A0)X$0WW^3:!IQD
M@PV0+8R-VZ(H^D!+8XM8B51):IWTZSND;,7>.$)?))*:.7,]0TUW4GW3.:*!
ME[(0>N;EQE03W]=ICB73-[)"05\V4I7,T%9M?5TI9)E3*@L_"H*A7S(NO/G4
MG2W5?"IK4W"!2P6Z+DNF7F^QD+N9%WJ'@Z]\FQM[X,^G%=OB,YK?JJ6BG=^B
M9+Q$H;D4H' S\Q;AY'9HY9W [QQW^F@--I*UE-_LYC&;>8%U" M,C45@]/J.
M=U@4%HC<^&>/Z;4FK>+Q^H#^X&*G6-9,XYTL_N"9R6?>V(,,-ZPNS%>Y^XS[
M> 86+Y6%=D_8-;+#@0=IK8TL]\KD0<E%\V8O^SP<*8R##Q2BO4+D_&X,.2_O
MF6'SJ9([4%::T.S"A>JTR3DN;%&>C:*OG/3,_$F*[?4*50GWN#9PN6+K O75
MU#<$;D7\= ]TVP!%'P#%\$4*DVOX)#+,3O5]<JKU+#IX=AMU GYAZ@;BL =1
M$$4=>'$;:>SPX@_P7'SW7*>%U+5"^&NQUD915_S= =YOP?L.O/\!^'/3TR W
M8#,*;4;/);(3RK)PHBN6XLPCFFE4W]%KRF0L:&;#2"6Q0AO,K$&3(VQD0?3B
M8CN!2R[H2-::B4Q? :4QS5T>[S'%<HW*;9:*BY17K !6REH8"U2<&KF ..H-
M@N!MX5*840JM1@\$.C66I@H=Q<)H!-%H!'=U61?,TNWH(TFB:!RV)BKV2MPV
M&@;)",)>.!C!TSO[<2^*^LTBB?OPA%I/B!5*D2944AV WWE^&??ZX>#*KD8)
MO4^A6]=_A+J *.F-@Z0Q&<8)=/3&H.V-06=O/ HRC-K HTAE22FA++1GGUYH
MO&H\:LQS'=-IX'S'K*@K[F19,?%*PS.56\'_I7[A!\.X-UP3797KH<^HTIK(
M3\EB A9;A6@K!$SOVTN_:RX:C$YUE9/P80"@'0!'?6?Y:Q\AK*2AAGOGP@4D
M+N7C)(!?I;A.F<[/287)V#Y'XZZJ#-NJ#+L92]=;1N':-GBHC9T(;YQ8'IK3
MULH&^,#%\?%]?;9,G1;/EVFAK0.GR>K!IG&H>B,I^4%YO9:;ZU/V9/7_*>&.
M4GE4QQ_*.($_D2D[N&F G(Z)IF*N@A?P\T_C*(Q^L=N8BD%$<77M0T@\309G
M^1L0N\]5RS^ZLDI46W<Q:W"3I;F]VM/V[E\T5]Z;>//C0,G;<J&AP VI!C<C
M8HMJ+N-F8V3E+L"U-'2=NF5._R^HK !]WTAI#AMKH/TCFO\'4$L#!!0    (
M "*#K%2R1XU@O ,  -8(   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM
M;(U6;6_C-@S^*X37#2G0QO%+TJ1+ K3=%1MPQ167[N[#L ^*3<?"V5(FR4WZ
M[T=)CINT:7!?'$HB'SZD2#'3C50_=(EH8%M70L^"TICU=1CJK,2:Z;Y<HZ"3
M0JJ:&5JJ5:C7"EGNC.HJC >#45@S+H+YU.T]JOE4-J;B A\5Z*:NF7JYQ4IN
M9D$4[#:^\E5I[$8XGZ[9"A=H_EX_*EJ%'4K.:Q2:2P$*BUEP$UW?#JV^4_C&
M<:/W9+"1+*7\81=_Y;-@8 EAA9FQ"(Q^GO$.J\H"$8W_6LR@<VD-]^4=^KV+
MG6)9,HUWLOK.<U/.@G$ .1:LJ<Q7N?D3VW@<P4Q6VGUAXW73-("LT4;6K3$Q
MJ+GPOVS;YF'/8#SXP"!N#6+'VSMR+/]@ALVG2FY 66U"LX(+U5D3.2[LI2R,
MHE-.=F;^&2DD#;TGMJQ0GT]#0Z#V*,Q:@%L/$'\ D,"#%*;4\$GDF!_:AT2F
M8Q3O&-W&)P$?F.I#$EU /(CC$WA)%V'B\)+3$?YSL]1&41'\>P(S[3!3AYE^
M@+F@WLB;"D$6<"?KM10HC+8KYPT^;:EI-![+YFG@IQ(A.P"L'"!Z0* N!$,Z
MIE2(4/O,H\T\4-ZRLDL<,)%;(8(-*@2FR;2B#M37T,M)8DH#%X0C&TVJ^ASN
M6^@G![U_J7O0/KP[J8WWXCS<\RTIT3NAF.%BU5+.K-(9#),!?=.K$2Q*J<RE
M057O:6CX[9=Q',6_0QK#DS2L>A/Q#F$8C>$+\5-$V[]%MJG=(W(IB\M&VR U
MO6)R:>@M(D(4'FZSDHF5S]M;@A5G2UYQPZDZSCH:9Q!=)&D"7SKMC.D2"IL[
M*)2LW^)8XX3(TS=.8-$L/3H7=(^6?CKQG^_N@<#\DCV3/7%2:!_-5SXV,RV+
M=R[2_A6\H+VT=S YUYELA &RP(_LHZB?P*\G*G_85?[PIRO_@9E&^?QUE?_Y
M-:G'JO\DN!U UWK-,IP%-&$TJF<,YH=>WE]=WB T5*:J/6,KJM_:M8\IF8&2
M$F5[BK8RJ@JF/?7#9CEH$>@==D;+X.6X_]="<5 ]?ZV6#ZG;AK+W=N[J*IJD
M5BDA<11-K)C::AN[W2&):>1::F1WJ=[I-:!!6U!A0#)*#MICS5Y\C%<7\61
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M39JD_O]R.<K8WGIGNF$Y+H+&YHIZP&!Y6Z+CQ<07F\">K:%%7P$4,V@HH<A
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M9..>"!MIZ,'AAB6]\%#9 [2_E93LW<0JZ-^,RZ]02P,$%     @ (H.L5&"
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MWG'-"=I06XZ1K]@\QWW*]G:4[1]2MM^$[?_[+>SO7K'@_37<M8EVN/E;;;)
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M;/A&9+CS1@O4*S^Z#*2JDK9^KNUN.QTG?BB$?]WKT4K]O>+2@, E0;NG9T1
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MKLUE#-(&F/&E$'K7L>=]?;V/_P)02P,$%     @ (H.L5)U1DJF9!   E!,
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MB+(RHBRWUVVPMT#Q"3&"Y$M$7D7WGWL<2^X,)/I?QTS=<J9N/E.O8:8')=)
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M(]7^"FC?,7*37UDLI3$RR9MKX"$H.P#?1U*:EXZ]!2DOXJ8_ 5!+ P04
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M""WKTWX]T*)TY]][H<UIVEWNS!<22#O!/,^%T,\#>Z1NO[E6_P%02P,$%
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M%RFDD'U7[R=:M+:3+H2&OFR'%;P)J30'8'\EA/Z8F.8\OEN+/U!+ P04
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M4'L'=UXK94^&'_;Q;<O_ E!+ P04    "  B@ZQ4-%-/7S$%  ##%   &0
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MP&]\N%YLM\ N%SF0%Q]9+G*@+;YON5@&;.R=]M"U $H3P[5B9UT-O'?:]!=
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M_1]0&^27>+'(E/DE^WJM.R+Q5FF1U\+(($^+ZI^_U(XX$F#!@ "K!=BO OZ
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MN&&*]S<H&X#[<RG-9F()ZG\$@[]02P,$%     @ (H.L5'@*:[CC @  S0@
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M#5/\TV#*&N#WI91F-[$;U/\NH[]02P,$%     @ (H.L5$!6(6$0 P  [0@
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M7) \57=\\QG+@-J&+^*IM+^P*6T]!Z)<*IZ58*T@HZSX)]LR$7L S7,8$)2
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M$HO>2"PF7Z0P6]0I4.0IWL<B=96*]I6ZB08)OU!U1>+P+Q(%4=2C9_'[\'!
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MW)R#!^=1N#FGPNVO0./?4$L#!!0    ( "*#K%27BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ (H.L5 )E)_VG!
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M@O1Q!M+'.4@??(;2"(JH'(54CF(J1T&5HZC*45CE**YR%%@YBJP"15:!(JM
MD56@R"I09!4HL@H4606*K )%5H$BJT215:+(*E%DE2BR2A19)8JL$D56B2*K
M1)%5HLBJ4&15*+(J%%D5BJP*15:%(JM"D56AR*I09%4HLFH4636*K!I%5HTB
MJT:15:/(JE%DU2BRZO^4]<G:]5__V]#?\];4W7L^&WX@N7H%4$L! A0#%
M  @ (H.L5 =!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  B@ZQ460&AS>X    K @  $0
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M=#(N>&UL4$L! A0#%     @ (H.L5"R8LW1> @  &08  !@
M ("!F!,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "*#
MK%2BXMW*\P0  ,X0   8              " @2P6  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    "  B@ZQ4?JS5.7\&  #R&P  &
M        @(%5&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ (H.L5&%=$.$,!P  W!L  !@              ("!"B(  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( "*#K%29#ZZO:P(  .0$   8
M              " @4PI  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    "  B@ZQ47,J,2$X*  !1&0  &               @('M*P  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ (H.L5 VR16FG$
M)B\  !@              ("!<38  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( "*#K%36J &)8P4  !<-   9              " @4Y'
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ (H.L5/@B
MF+LF!   U@H  !D              ("!Z$P  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    "  B@ZQ4Z+'FAO<"  !N!@  &0
M    @(%%40  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M "*#K%1,G'7TDP(  '(%   9              " @7-4  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ (H.L5"#!LX?6"0  ;!D  !D
M             ("!/5<  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    "  B@ZQ4PDSE.5T'   N$@  &0              @(%*80  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "*#K%3WE-H*R04
M $X-   9              " @=YH  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ (H.L5(-Y^8&'"0  11L  !D              ("!
MWFX  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  B@ZQ4
MLS&,I$D(  !F%@  &0              @(&<>   >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( "*#K%24@-28MP(  /8%   9
M      " @1R!  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ (H.L5&67CB(#!@  H0\  !D              ("!"H0  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  B@ZQ4B@/[=DT+  #<'P
M&0              @(%$B@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( "*#K%02>LTV>0,  &X(   9              " @<B5  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ (H.L5.\;-W+
M P  (@H  !D              ("!>)D  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    "  B@ZQ4R%5M%;T"  #*!0  &0
M@(%OG0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "*#
MK%1T)6 JDP(  '8%   9              " @6.@  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ (H.L5&&TPD>^ P  '0D  !D
M         ("!+:,  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    "  B@ZQ4LD>-8+P#  #6"   &0              @($BIP  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "*#K%1YH.2/<P0  .H+
M   9              " @16K  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ (H.L5/%""\SM!   ?PP  !D              ("!OZ\
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  B@ZQ4WTM$
M#TD$   _"@  &0              @('CM   >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( "*#K%1@@+/74P(  $H%   9
M  " @6.Y  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M(H.L5&',%OO@ @    D  !D              ("![;L  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    "  B@ZQ4_/.XE[ "  !C!P  &0
M            @($$OP  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( "*#K%2F,W"5W0(  -H'   9              " @>O!  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ (H.L5.!/=V!0 P
M8PX  !D              ("!_\0  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    "  B@ZQ4_!0WLY@"   _!@  &0              @(&&
MR   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( "*#K%2)
M/2M=2@,  #D-   9              " @57+  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ (H.L5#PNUW)0 @  0@4  !D
M     ("!ULX  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "*#K%31JIXXG ,  '\-   9              "
M@8[>  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ (H.L
M5#,%)W-2 P  ]0D  !D              ("!8>(  'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    "  B@ZQ4/WE[(9,"  !G!P  &0
M        @('JY0  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( "*#K%0$(?B_*@(  .<$   9              " @;3H  !X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ (H.L5#133U\Q!0  PQ0
M !D              ("!%>L  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    "  B@ZQ4LP)P:'(#   E"P  &0              @(%]\
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( "*#K%0L:#KM
MR 8  /(J   9              " @2;T  !X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ (H.L5)2S1$J8 P  C0L  !D
M ("!)?L  'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  B
M@ZQ4F]^3F>P"  !#"   &0              @('T_@  >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( "*#K%0)5\7)500  "(1   9
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M970U-BYX;6Q02P$"% ,4    "  B@ZQ40%8A81 #  #M"   &0
M    @('3$@$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (
M "*#K%0Y#ET..@,  *$+   9              " @1H6 0!X;"]W;W)K<VAE
M971S+W-H965T-3@N>&UL4$L! A0#%     @ (H.L5/S-8O8= P  $A(   T
M             ( !BQD! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  B@ZQ4
MEXJ[',     3 @  "P              @ '3' $ 7W)E;',O+G)E;'-02P$"
M% ,4    "  B@ZQ4 F4G_:<$  "R)@  #P              @ &\'0$ >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ (H.L5!,G[+KO 0  I2(  !H
M         ( !D"(! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ (H.L5&(CYQC8 0  2"(  !,              ( !MR0! %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     $( 0@ %$@  P"8!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>131</ContextCount>
  <ElementCount>264</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1405401 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - License, Collaboration, and Funding Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements</Role>
      <ShortName>License, Collaboration, and Funding Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Fair Value of Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2133110 - Disclosure - Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommonStockWarrants</Role>
      <ShortName>Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2138111 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2145112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2147113 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/AccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/LongTermDebt</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2334307 - Disclosure - Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommonStockWarrantsTables</Role>
      <ShortName>Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/CommonStockWarrants</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2339308 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/StockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2348309 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/NetLossperShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Compensating Balance Arrangements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Compensating Balance Arrangements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - License, Collaboration, and Funding Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail</Role>
      <ShortName>License, Collaboration, and Funding Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PropertyandEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Long-Term Debt - Summary of Long Term Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail</Role>
      <ShortName>Long-Term Debt - Summary of Long Term Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Long Term Debt - Hercules Loan Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail</Role>
      <ShortName>Long Term Debt - Hercules Loan Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Long-Term Debt - Schedule of Future Principal Payments and the Final Payments Due (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail</Role>
      <ShortName>Long-Term Debt - Schedule of Future Principal Payments and the Final Payments Due (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Leases - Schedule of Components of Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail</Role>
      <ShortName>Leases - Schedule of Components of Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Commitment and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitment and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Common Stock Warrants - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail</Role>
      <ShortName>Common Stock Warrants - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Common Stock Warrants - Schedule of Outstanding Warrants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommonStockWarrantsScheduleofOutstandingWarrantsDetail</Role>
      <ShortName>Common Stock Warrants - Schedule of Outstanding Warrants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail</Role>
      <ShortName>Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-date Fair Value of Stock Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-date Fair Value of Stock Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Stock-Based Compensation Summary of Stock-Based Compensation Expense Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails</Role>
      <ShortName>Stock-Based Compensation Summary of Stock-Based Compensation Expense Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2449427 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail</Role>
      <ShortName>Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2450428 - Disclosure - Net Loss per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="xfor-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2451429 - Disclosure - Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail</Role>
      <ShortName>Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="xfor-20220331.htm">xfor-20220331.htm</File>
    <File>ex-311q12022.htm</File>
    <File>ex-312q12022.htm</File>
    <File>ex-321q12022.htm</File>
    <File>xfor-20220331.xsd</File>
    <File>xfor-20220331_cal.xml</File>
    <File>xfor-20220331_def.xml</File>
    <File>xfor-20220331_lab.xml</File>
    <File>xfor-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>xfor-20220331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="459">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xfor-20220331.htm": {
   "axisCustom": 1,
   "axisStandard": 19,
   "contextCount": 131,
   "dts": {
    "calculationLink": {
     "local": [
      "xfor-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "xfor-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "xfor-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xfor-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xfor-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "xfor-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 429,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 37,
   "keyStandard": 227,
   "memberCustom": 32,
   "memberStandard": 22,
   "nsprefix": "xfor",
   "nsuri": "http://www.x4pharma.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.x4pharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - License, Collaboration, and Funding Agreements",
     "role": "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements",
     "shortName": "License, Collaboration, and Funding Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Fair Value of Financial Assets and Liabilities",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities",
     "shortName": "Fair Value of Financial Assets and Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Property and Equipment, Net",
     "role": "http://www.x4pharma.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xfor:AccruedExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Accrued Expenses",
     "role": "http://www.x4pharma.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xfor:AccruedExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - Long-Term Debt",
     "role": "http://www.x4pharma.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Leases",
     "role": "http://www.x4pharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Commitment and Contingencies",
     "role": "http://www.x4pharma.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133110 - Disclosure - Common Stock Warrants",
     "role": "http://www.x4pharma.com/role/CommonStockWarrants",
     "shortName": "Common Stock Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138111 - Disclosure - Stock-Based Compensation",
     "role": "http://www.x4pharma.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145112 - Disclosure - Income Taxes",
     "role": "http://www.x4pharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "xfor:ResearchAndDevelopmentIncentiveReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147113 - Disclosure - Net Loss per Share",
     "role": "http://www.x4pharma.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensatingBalancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensatingBalancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables",
     "shortName": "Fair Value of Financial Assets and Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.x4pharma.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.x4pharma.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Long-Term Debt (Tables)",
     "role": "http://www.x4pharma.com/role/LongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - Leases (Tables)",
     "role": "http://www.x4pharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334307 - Disclosure - Common Stock Warrants (Tables)",
     "role": "http://www.x4pharma.com/role/CommonStockWarrantsTables",
     "shortName": "Common Stock Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339308 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348309 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.x4pharma.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)",
     "role": "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail",
     "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensatingBalancesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Compensating Balance Arrangements (Detail)",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Compensating Balance Arrangements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensatingBalancesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "if34f27299a434668885ee2416dec75fa_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - License, Collaboration, and Funding Agreements - Additional Information (Detail)",
     "role": "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail",
     "shortName": "License, Collaboration, and Funding Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnSaleOfOtherAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "ia42b7fcbe59440f2b41270d5bb32ea91_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value (Detail)",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail",
     "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "ia42b7fcbe59440f2b41270d5bb32ea91_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)",
     "role": "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Property and Equipment, Net - Additional Information (Detail)",
     "role": "http://www.x4pharma.com/role/PropertyandEquipmentNetAdditionalInformationDetail",
     "shortName": "Property and Equipment, Net - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "role": "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Long-Term Debt - Summary of Long Term Debt (Detail)",
     "role": "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail",
     "shortName": "Long-Term Debt - Summary of Long Term Debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Long Term Debt - Hercules Loan Agreement - Additional Information (Detail)",
     "role": "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
     "shortName": "Long Term Debt - Hercules Loan Agreement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Long-Term Debt - Schedule of Future Principal Payments and the Final Payments Due (Detail)",
     "role": "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail",
     "shortName": "Long-Term Debt - Schedule of Future Principal Payments and the Final Payments Due (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i829185b9e0084c7584f58e45342583f9_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "xfor:CurrentOfficeSpaceUnderLeaseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Leases - Schedule of Components of Lease Expense (Detail)",
     "role": "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail",
     "shortName": "Leases - Schedule of Components of Lease Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)",
     "role": "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i975809049d0a45c497bb1ac01a475dac_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Commitment and Contingencies - Additional Information (Detail)",
     "role": "http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail",
     "shortName": "Commitment and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i975809049d0a45c497bb1ac01a475dac_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "xfor:ClassOfWarrantOrRightIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Common Stock Warrants - Additional Information (Detail)",
     "role": "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
     "shortName": "Common Stock Warrants - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i1c1e0a3da76d47a8892dbba813618c07_D20191126-20191126",
      "decimals": null,
      "lang": "en-US",
      "name": "xfor:ClassOfWarrantOrRightWarrantsExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "ied3aba39e79f4b429586d34201372693_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Common Stock Warrants - Schedule of Outstanding Warrants (Detail)",
     "role": "http://www.x4pharma.com/role/CommonStockWarrantsScheduleofOutstandingWarrantsDetail",
     "shortName": "Common Stock Warrants - Schedule of Outstanding Warrants (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "xfor:ClassOfWarrantOrRightExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i551b03b35a354b9c82567e2c1278da6f_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Detail)",
     "role": "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail",
     "shortName": "Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i53cd7e343ca1417fabb4bb23d6a34e59_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i86f8f316e485428cbd4027d61748adf8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "i86f8f316e485428cbd4027d61748adf8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-date Fair Value of Stock Options Granted (Detail)",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail",
     "shortName": "Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-date Fair Value of Stock Options Granted (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "ied3aba39e79f4b429586d34201372693_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "ied3aba39e79f4b429586d34201372693_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Stock-Based Compensation (Details)",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Stock-Based Compensation Summary of Stock-Based Compensation Expense Classification (Details)",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails",
     "shortName": "Stock-Based Compensation Summary of Stock-Based Compensation Expense Classification (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CurrentFederalTaxExpenseBenefit",
       "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CurrentFederalTaxExpenseBenefit",
       "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449427 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Detail)",
     "role": "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail",
     "shortName": "Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DividendsPaidinkind",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450428 - Disclosure - Net Loss per Share - Additional Information (Detail)",
     "role": "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail",
     "shortName": "Net Loss per Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "ia0ed061951224fe2b05f82e41a77c8d4_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451429 - Disclosure - Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail)",
     "role": "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail",
     "shortName": "Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "icb5a551d13c443f58e2de92a4c349fb4_D20211001-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "true"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1405401 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "role": "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "icb5a551d13c443f58e2de92a4c349fb4_D20211001-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "true"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of the Business and Basis of Presentation",
     "role": "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20220331.htm",
      "contextRef": "id169e9f706784f1caa2ff7435bb806f3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 55,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r180",
      "r208",
      "r233",
      "r235",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r400",
      "r401",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r180",
      "r208",
      "r223",
      "r233",
      "r235",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r400",
      "r401",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r180",
      "r208",
      "r223",
      "r233",
      "r235",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r400",
      "r401",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r147",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34",
      "r357"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail",
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r378",
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r38"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r32",
      "r155"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r53",
      "r54",
      "r55",
      "r391",
      "r406",
      "r407"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r52",
      "r55",
      "r58",
      "r59",
      "r60",
      "r95",
      "r96",
      "r97",
      "r302",
      "r402",
      "r403",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r265",
      "r266",
      "r267",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r236",
      "r238",
      "r271",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r213",
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r238",
      "r262",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r68",
      "r77",
      "r193",
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r89",
      "r139",
      "r141",
      "r145",
      "r149",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r299",
      "r303",
      "r321",
      "r355",
      "r357",
      "r374",
      "r388"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r47",
      "r89",
      "r149",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r299",
      "r303",
      "r321",
      "r355",
      "r357"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r239",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Unaudited Interim Financial Statements"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r232",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r232",
      "r234",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r94",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of the Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r81",
      "r82",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Acquisition of property, equipment and right-of-use assets included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Lease Obligation Incurred",
        "terseLabel": "Acquisition of right-of-use asset financed by lease liabilities"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r30",
      "r79"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r79",
      "r84"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r322"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r87",
      "r89",
      "r110",
      "r111",
      "r112",
      "r115",
      "r117",
      "r124",
      "r125",
      "r126",
      "r149",
      "r166",
      "r170",
      "r171",
      "r172",
      "r175",
      "r176",
      "r206",
      "r207",
      "r210",
      "r211",
      "r321",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r222",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (usd per share)",
        "verboseLabel": "Exercise Price (usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of warrants for purchase of convertible preferred shares (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Class of warrant or right, warrants to purchase of common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Number of warrants, Outstanding and exercisable warrants, Ending Balance (in shares)",
        "periodStartLabel": "Outstanding and exercisable warrants to purchase common shares as of December 31, 2021",
        "terseLabel": "Number of Shares of Common Stock Issuable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsScheduleofOutstandingWarrantsDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r222",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r295",
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License, Collaboration, and Funding Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r43",
      "r163",
      "r379",
      "r395"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r164",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitment and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r357"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 125,000,000 shares authorized as of each of March 31, 2022 and December 31, 2021; 30,809,476 and 28,127,657 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r279",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal income tax benefit"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r279",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State income tax benefit"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r88",
      "r93",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r197",
      "r198",
      "r199",
      "r200",
      "r335",
      "r375",
      "r376",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument variable percentage"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r40",
      "r195",
      "r332",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate of loan"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "terseLabel": "Interest rate increase percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r41",
      "r88",
      "r93",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r197",
      "r198",
      "r199",
      "r200",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Principal payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r184",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail": {
       "order": 3.0,
       "parentTag": "xfor_LongTermDebtIncludingAccretion",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "negatedLabel": "Debt discount, net of accretion"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r81",
      "r82",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Issuance costs not yet paid related to sale of shares of common stock, redeemable common stock and pre-funded warrants"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r77",
      "r137"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.x4pharma.com/role/PropertyandEquipmentNetAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r306",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r221",
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends on common stock declared or paid"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPaidinkind": {
     "auth_ref": [
      "r221",
      "r385"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid paid-in-kind dividends (PIK) declared for classes of stock, for example, but not limited to, common and preferred.",
        "label": "Dividends, Paid-in-kind",
        "negatedTerseLabel": "Dividends, Paid-in-kind"
       }
      }
     },
     "localname": "DividendsPaidinkind",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders\u2014basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost of stock based awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost of stock based awards, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r58",
      "r59",
      "r60",
      "r95",
      "r96",
      "r97",
      "r99",
      "r104",
      "r106",
      "r123",
      "r150",
      "r213",
      "r221",
      "r265",
      "r266",
      "r267",
      "r280",
      "r281",
      "r307",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r402",
      "r403",
      "r404",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r186",
      "r197",
      "r198",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r311",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r310",
      "r311",
      "r313",
      "r314",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r186",
      "r224",
      "r225",
      "r230",
      "r231",
      "r311",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r186",
      "r197",
      "r198",
      "r224",
      "r225",
      "r230",
      "r231",
      "r311",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r186",
      "r197",
      "r198",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r311",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r315",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Aggregate Fair Values of Warrant Liability and Derivative Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r186",
      "r197",
      "r198",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r317",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Gain (Loss) on Disposition of Assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "terseLabel": "Gain (Loss) on Disposition of Other Assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r151",
      "r152",
      "r357",
      "r373"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r62",
      "r139",
      "r140",
      "r143",
      "r144",
      "r146",
      "r371",
      "r380",
      "r383",
      "r398"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r157",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r276",
      "r277",
      "r278",
      "r282",
      "r285",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r105",
      "r106",
      "r138",
      "r275",
      "r283",
      "r286",
      "r399"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, other current assets and research and development incentive receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r61",
      "r136",
      "r330",
      "r333",
      "r382"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r68",
      "r191",
      "r196",
      "r199",
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Interest Income and Interest Expense Disclosure"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r66",
      "r135"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r350",
      "r352"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease not yet commenced, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease, renewal term of contract (years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease, term of contract (years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r89",
      "r142",
      "r149",
      "r166",
      "r167",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r300",
      "r303",
      "r304",
      "r321",
      "r355",
      "r356"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r89",
      "r149",
      "r321",
      "r357",
      "r377",
      "r393"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r89",
      "r149",
      "r166",
      "r167",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r300",
      "r303",
      "r304",
      "r321",
      "r355",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "verboseLabel": "Line of credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityPeriodicPayment": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments of both interest and principal.",
        "label": "Line of Credit Facility, Periodic Payment",
        "terseLabel": "Line of credit facility periodic payment"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r17",
      "r185",
      "r194",
      "r197",
      "r198",
      "r376",
      "r389"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail": {
       "order": 1.0,
       "parentTag": "xfor_LongTermDebtIncludingAccretion",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Principal amount of long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.",
        "label": "Long-term Debt and Lease Obligation, Including Current Maturities",
        "terseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Current portion of long-term debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r93",
      "r165",
      "r189"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail": {
       "order": 3.0,
       "parentTag": "xfor_LongTermDebtAndEOTPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r93",
      "r165",
      "r189"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail": {
       "order": 2.0,
       "parentTag": "xfor_LongTermDebtAndEOTPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail": {
       "order": 1.0,
       "parentTag": "xfor_LongTermDebtAndEOTPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r75",
      "r78"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r56",
      "r57",
      "r60",
      "r63",
      "r78",
      "r89",
      "r98",
      "r100",
      "r101",
      "r102",
      "r103",
      "r105",
      "r106",
      "r113",
      "r139",
      "r140",
      "r143",
      "r144",
      "r146",
      "r149",
      "r166",
      "r167",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r308",
      "r321",
      "r381",
      "r397"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r107",
      "r108",
      "r114",
      "r117",
      "r139",
      "r140",
      "r143",
      "r144",
      "r146"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r139",
      "r140",
      "r143",
      "r144",
      "r146"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r343",
      "r352"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Fixed operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r339",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r349",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate-operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r348",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term-operating leases (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r38"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Employee taxes paid related to net share settlement of vested restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r70",
      "r292",
      "r293",
      "r294"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Acquisition of property, equipment and intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r239",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r28",
      "r29"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r71",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r32",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r158",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r31",
      "r154"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r156",
      "r357",
      "r384",
      "r394"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedTerseLabel": "Repayments of Secured Debt"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r274",
      "r369",
      "r424"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r84",
      "r372",
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r14",
      "r84",
      "r408"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash, non-current",
        "verboseLabel": "Total restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings"
       }
      }
     },
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings",
        "terseLabel": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings"
       }
      }
     },
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r221",
      "r268",
      "r357",
      "r392",
      "r405",
      "r407"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r95",
      "r96",
      "r97",
      "r99",
      "r104",
      "r106",
      "r150",
      "r265",
      "r266",
      "r267",
      "r280",
      "r281",
      "r307",
      "r402",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r347",
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensatingBalancesTextBlock": {
     "auth_ref": [
      "r11",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes disclosure of  these arrangements and the amount involved, if determinable, for the most recent audited balance sheet required and for any subsequent unaudited balance sheet required in the notes to the financial statements. Compensating balances that are maintained under an agreement to assure future credit availability are generally disclosed in the notes to the financial statements along with the amount and terms of such agreement.",
        "label": "Schedule of Compensating Balances [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCompensatingBalancesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense Classification"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of Long Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r110",
      "r111",
      "r115",
      "r117",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Principal Payments and the Final Payments Due"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r32",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r239",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r241",
      "r250",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Stock Option Valuation"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r44",
      "r87",
      "r124",
      "r125",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r222",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested ending balance (in shares)",
        "periodStartLabel": "Nonvested beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (in percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (in percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (in percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Number of shares Options, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Exercisable (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, Ending balance",
        "periodStartLabel": "Aggregate intrinsic value, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r243",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in usd per share)",
        "periodStartLabel": "Beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Vested and expected to vest (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Number of shares Options, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r237",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r256",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term outstanding, Exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term outstanding, Vested and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r344",
      "r352"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r85",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r87",
      "r89",
      "r110",
      "r111",
      "r112",
      "r115",
      "r117",
      "r124",
      "r125",
      "r126",
      "r149",
      "r166",
      "r170",
      "r171",
      "r172",
      "r175",
      "r176",
      "r206",
      "r207",
      "r210",
      "r211",
      "r213",
      "r321",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r46",
      "r58",
      "r59",
      "r60",
      "r95",
      "r96",
      "r97",
      "r99",
      "r104",
      "r106",
      "r123",
      "r150",
      "r213",
      "r221",
      "r265",
      "r266",
      "r267",
      "r280",
      "r281",
      "r307",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r402",
      "r403",
      "r404",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "verboseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r123",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r213",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r213",
      "r221",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r213",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r46",
      "r213",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r25",
      "r26",
      "r89",
      "r148",
      "r149",
      "r321",
      "r357"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r345",
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r329",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r329",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r329",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Convertible preferred shares, ending balance, shares",
        "periodStartLabel": "Redeemable common shares, beginning balance, shares"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital": {
     "auth_ref": [
      "r10",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Par Value",
        "terseLabel": "Redeemable Common Shares, Value"
       }
      }
     },
     "localname": "TemporaryEquityValueExcludingAdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount": {
     "auth_ref": [
      "r109",
      "r117",
      "r215"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.",
        "label": "Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount",
        "negatedTerseLabel": "Deemed dividend on Class B Warrant price reset"
       }
      }
     },
     "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average common shares outstanding\u2014basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_AccretionOnLongTermDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail": {
       "order": 2.0,
       "parentTag": "xfor_LongTermDebtIncludingAccretion",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion on long term debt.",
        "label": "Accretion On Long Term Debt",
        "negatedLabel": "Cumulative accretion of end of term payments"
       }
      }
     },
     "localname": "AccretionOnLongTermDebt",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_AccruedExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses.",
        "label": "Accrued Expenses [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedExpensesTextBlock",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xfor_AccruedExternalResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued external research and development expenses.",
        "label": "Accrued External Research And Development Expenses",
        "terseLabel": "Accrued external research and development expenses"
       }
      }
     },
     "localname": "AccruedExternalResearchAndDevelopmentExpenses",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_AggregateBaseRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate base rent.",
        "label": "Aggregate Base Rent",
        "terseLabel": "Current base rent"
       }
      }
     },
     "localname": "AggregateBaseRent",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_AllstonLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allston Lease Agreement",
        "label": "Allston Lease Agreement [Member]",
        "terseLabel": "Allston Lease Agreement"
       }
      }
     },
     "localname": "AllstonLeaseAgreementMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_AllstonLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allston Lease",
        "label": "Allston Lease [Member]",
        "terseLabel": "Allston Lease"
       }
      }
     },
     "localname": "AllstonLeaseMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ClassAWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A Warrant [Member]",
        "label": "Class A Warrant [Member]",
        "terseLabel": "Class A Warrant"
       }
      }
     },
     "localname": "ClassAWarrantMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ClassBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class B Warrants",
        "label": "Class B Warrants [Member]",
        "terseLabel": "Class B Warrants"
       }
      }
     },
     "localname": "ClassBWarrantsMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Additional Exercise Price of Warrants or Rights",
        "label": "Class of Warrant or Right, Additional Exercise Price of Warrants or Rights",
        "terseLabel": "Class of Warrant or Right, Additional Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued",
        "label": "Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued",
        "terseLabel": "Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_ClassOfWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right exercised.",
        "label": "Class Of Warrant Or Right Exercised",
        "negatedLabel": "Exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercised",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsScheduleofOutstandingWarrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right issued.",
        "label": "Class Of Warrant Or Right Issued",
        "terseLabel": "Issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsScheduleofOutstandingWarrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Issued, Weighted Average Exercise Price",
        "label": "Class Of Warrant Or Right Issued, Weighted Average Exercise Price",
        "terseLabel": "Class Of Warrant Or Right Issued, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsScheduleofOutstandingWarrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Warrants Expiration Period",
        "label": "Class Of Warrant Or Right Warrants Expiration Period",
        "terseLabel": "Class of warrants or rights expiration period (in years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWarrantsExpirationPeriod",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right weighted average contractual term.",
        "label": "Class Of Warrant Or Right Weighted Average Contractual Term",
        "terseLabel": "Weighted Average Contractual Term (Years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageContractualTerm",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsScheduleofOutstandingWarrantsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right weighted average exercise price.",
        "label": "Class Of Warrant Or Right Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding and exercisable warrants, Ending Balance (in usd per share)",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding and exercisable warrants, Beginning Balance (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePrice",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsScheduleofOutstandingWarrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "xfor_CollaborationLicenseAndFundingArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration, license and funding arrangements.",
        "label": "Collaboration License And Funding Arrangements [Line Items]",
        "terseLabel": "Collaboration License And Funding Arrangements [Line Items]"
       }
      }
     },
     "localname": "CollaborationLicenseAndFundingArrangementsLineItems",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_CollaborationLicenseAndFundingArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration, license and funding arrangements.",
        "label": "Collaboration License And Funding Arrangements [Table]",
        "terseLabel": "Collaboration License And Funding Arrangements [Table]"
       }
      }
     },
     "localname": "CollaborationLicenseAndFundingArrangementsTable",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_ContingenciesAndCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingencies And Commitments [Line Items]",
        "label": "Contingencies And Commitments [Line Items]",
        "terseLabel": "Contingencies And Commitments [Line Items]"
       }
      }
     },
     "localname": "ContingenciesAndCommitmentsLineItems",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_ContingenciesAndCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingencies And Commitments [Table]",
        "label": "Contingencies And Commitments [Table]",
        "terseLabel": "Contingencies And Commitments [Table]"
       }
      }
     },
     "localname": "ContingenciesAndCommitmentsTable",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_CurrentOfficeSpaceUnderLeaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current office space under lease agreement.",
        "label": "Current Office Space Under Lease Agreement",
        "terseLabel": "Current office space under lease agreement"
       }
      }
     },
     "localname": "CurrentOfficeSpaceUnderLeaseAgreement",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "xfor_DebtInstrumentPrepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Prepayment Premium, Percentage",
        "label": "Debt Instrument Prepayment Premium, Percentage",
        "terseLabel": "Debt instrument prepayment premium, percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentage",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "xfor_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator",
        "label": "Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]",
        "label": "Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Assets And Liabilities Measured On Recurring Basis [Table]",
        "label": "Fair Value Assets And Liabilities Measured On Recurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_FundedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funded",
        "label": "Funded [Member]",
        "terseLabel": "Funded"
       }
      }
     },
     "localname": "FundedMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_GrantAndIncentiveReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant and incentive receivables.",
        "label": "Grant And Incentive Receivables",
        "terseLabel": "Grant receivable"
       }
      }
     },
     "localname": "GrantAndIncentiveReceivables",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_HerculesLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules Loan Agreement [Member]",
        "label": "Hercules Loan Agreement [Member]",
        "terseLabel": "Hercules Loan Agreement"
       }
      }
     },
     "localname": "HerculesLoanAgreementMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_HerculesSecondAmendedLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules Second Amended Loan Agreement",
        "label": "Hercules Second Amended Loan Agreement [Member]",
        "terseLabel": "Hercules Second Amended Loan Agreement"
       }
      }
     },
     "localname": "HerculesSecondAmendedLoanAgreementMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in lease liabilities.",
        "label": "Increase Decrease In Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset, Net Of Non-cash Potion",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset, Non-cash Potion",
        "terseLabel": "Operating lease right-of-use asset, net of non-cash portion"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_IndemnificationAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification Agreements Member.",
        "label": "Indemnification Agreements [Member]",
        "terseLabel": "Indemnification Agreements"
       }
      }
     },
     "localname": "IndemnificationAgreementsMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on april sixteen two thousand nineteen.",
        "label": "Issuance On April Sixteen Two Thousand Nineteen [Member]",
        "terseLabel": "Issuance On April 16, 2019"
       }
      }
     },
     "localname": "IssuanceOnAprilSixteenTwoThousandNineteenMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on december twenty eight two thousand seventeen one.",
        "label": "Issuance On December Twenty Eight Two Thousand Seventeen One [Member]",
        "terseLabel": "Issuance On December 28, 2017 One"
       }
      }
     },
     "localname": "IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnMarch232021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance On March 23, 2021",
        "label": "Issuance On March 23, 2021 [Member]",
        "terseLabel": "Issuance On March 23, 2021"
       }
      }
     },
     "localname": "IssuanceOnMarch232021Member",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnMarch32022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on March 3 2022 [Member]",
        "label": "Issuance on March 3 2022 [Member]",
        "terseLabel": "Issuance on March 3 2022"
       }
      }
     },
     "localname": "IssuanceOnMarch32022Member",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on march thirteen two thousand nineteen.",
        "label": "Issuance On March Thirteen Two Thousand Nineteen [Member]",
        "terseLabel": "Issuance On March 13, 2019"
       }
      }
     },
     "localname": "IssuanceOnMarchThirteenTwoThousandNineteenMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on November Nine Two Thousand Twenty One",
        "label": "Issuance on November Nine Two Thousand Twenty One [Member]",
        "terseLabel": "Issuance on November Nine Two Thousand Twenty One"
       }
      }
     },
     "localname": "IssuanceOnNovemberNineTwoThousandTwentyOneMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on November Twenty Nine Two Thousand Nineteen",
        "label": "Issuance on November Twenty Nine Two Thousand Nineteen [Member]",
        "terseLabel": "Issuance On November 29, 2019"
       }
      }
     },
     "localname": "IssuanceOnNovemberTwentyNineTwoThousandNineteenMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on November Twenty Nine Two Thousand Nineteen One",
        "label": "Issuance on November Twenty Nine Two Thousand Nineteen One [Member]",
        "terseLabel": "Issuance On November 29, 2019 One"
       }
      }
     },
     "localname": "IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on october nineteen two thousand eighteen.",
        "label": "Issuance On October Nineteen Two Thousand Eighteen [Member]",
        "terseLabel": "Issuance On October 19, 2018"
       }
      }
     },
     "localname": "IssuanceOnOctoberNineteenTwoThousandEighteenMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on october twenty five two thousand sixteen.",
        "label": "Issuance On October Twenty Five Two Thousand Sixteen [Member]",
        "terseLabel": "Issuance On October 25, 2016"
       }
      }
     },
     "localname": "IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on september twelve two thousand eighteen one.",
        "label": "Issuance On September Twelve Two Thousand Eighteen One [Member]",
        "terseLabel": "Issuance On September 12, 2018 One"
       }
      }
     },
     "localname": "IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab Equipment [Member]",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_LegacyWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Warrants",
        "label": "Legacy Warrants [Member]",
        "terseLabel": "Legacy Warrants"
       }
      }
     },
     "localname": "LegacyWarrantsMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "terseLabel": "Lease not yet commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAmount",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rent",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rent",
        "terseLabel": "Annual base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Office Space",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Office Space",
        "terseLabel": "Office space"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "xfor_LineOfCreditCovenantMinimumCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit, Covenant, Minimum Cash",
        "label": "Line of Credit, Covenant, Minimum Cash",
        "terseLabel": "Line of Credit, Covenant, Minimum Cash"
       }
      }
     },
     "localname": "LineOfCreditCovenantMinimumCash",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Three",
        "label": "Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Three",
        "terseLabel": "Contingent additional term loan advances, tranche three"
       }
      }
     },
     "localname": "LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LongTermDebtAndEOTPayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt and end of term payments",
        "label": "Long-term debt and EOT payment",
        "totalLabel": "Principal amount of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndEOTPayment",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LongTermDebtIncludingAccretion": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Including Accretion",
        "label": "Long-Term Debt, Including Accretion",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtIncludingAccretion",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LongTermDebtNonCurrentIncludingAccretion": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt non current including accretion.",
        "label": "Long Term Debt Non Current Including Accretion",
        "terseLabel": "Long-term debt, net of discount and current portion"
       }
      }
     },
     "localname": "LongTermDebtNonCurrentIncludingAccretion",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_MinCashTestDate1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Min Cash Test Date 1",
        "label": "Min Cash Test Date 1 [Member]",
        "terseLabel": "Min Cash Test Date 1"
       }
      }
     },
     "localname": "MinCashTestDate1Member",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_MinCashTestDate2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Min Cash Test Date 2",
        "label": "Min Cash Test Date 2 [Member]",
        "terseLabel": "Min Cash Test Date 2"
       }
      }
     },
     "localname": "MinCashTestDate2Member",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash interest expense.",
        "label": "Non Cash Interest Expense",
        "terseLabel": "Accretion of debt discount"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash lease expense.",
        "label": "Non Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator",
        "label": "Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_OperatingLeaseExpiration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease expiration.",
        "label": "Operating Lease Expiration",
        "terseLabel": "Operating lease expiration (years)"
       }
      }
     },
     "localname": "OperatingLeaseExpiration",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "xfor_PreFundedWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre Funded Warrant [Member]",
        "label": "Pre Funded Warrant [Member]",
        "terseLabel": "Pre Funded Warrant"
       }
      }
     },
     "localname": "PreFundedWarrantMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_PrefundedWarrantsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded Warrants",
        "label": "Prefunded Warrants [Axis]",
        "terseLabel": "Prefunded Warrants [Axis]"
       }
      }
     },
     "localname": "PrefundedWarrantsAxis",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_PrefundedWarrantsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded Warrants",
        "label": "Prefunded Warrants [Domain]",
        "terseLabel": "Prefunded Warrants [Domain]"
       }
      }
     },
     "localname": "PrefundedWarrantsDomain",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from borrowings under loan and security agreements, net of issuance costs",
        "label": "Proceeds from borrowings under loan and security agreements, net of issuance costs",
        "negatedTerseLabel": "Proceeds from borrowings under loan and security agreements, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromBorrowingsUnderLoanAndSecurityAgreementsNetOfIssuanceCosts",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_ProceedsFromExerciseOfStockOptionsAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from exercise of stock options and warrants.",
        "label": "Proceeds From Exercise Of Stock Options And Warrants",
        "terseLabel": "Proceeds from exercise of stock options and pre-funded warrants and issuance of shares of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfStockOptionsAndWarrants",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock Before Underwriting Discounts Commissions And Other Expenses",
        "label": "Proceeds From Issuance Of Common Stock Before Underwriting Discounts Commissions And Other Expenses",
        "terseLabel": "Proceeds from issuance of common stock before underwriting discounts commissions and other expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance or Sale of Equity, Net of Issuance Costs",
        "label": "Proceeds from Issuance or Sale of Equity, Net of Issuance Costs",
        "terseLabel": "Proceeds from sale of shares of common stock, redeemable common stock and pre-funded warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_RedeemableCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Common Stock [Member]",
        "label": "Redeemable Common Stock [Member]",
        "terseLabel": "Redeemable Common Stock"
       }
      }
     },
     "localname": "RedeemableCommonStockMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ResearchAndDevelopmentIncentiveProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development incentive program.",
        "label": "Research And Development Incentive Program [Member]",
        "terseLabel": "Research and Development Incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveProgramMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ResearchAndDevelopmentIncentiveReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development incentive receivable.",
        "label": "Research And Development Incentive Receivable",
        "terseLabel": "Research and development incentive receivable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveReceivable",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_ScheduleOfAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accounting Policies [Table]",
        "label": "Schedule Of Accounting Policies [Table]",
        "terseLabel": "Schedule Of Accounting Policies [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountingPoliciesTable",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_ScheduleOfLongTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Long Term Debt [Line Items]",
        "label": "Schedule Of Long Term Debt [Line Items]",
        "terseLabel": "Schedule Of Long Term Debt [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfLongTermDebtLineItems",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_ScheduleOfLongTermDebtTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Long Term Debt [Table]",
        "label": "Schedule Of Long Term Debt [Table]",
        "terseLabel": "Schedule Of Long Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfLongTermDebtTable",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of reconciliation of cash and cash equivalents and restricted cash to cashflows.",
        "label": "Schedule Of Reconciliation Of Cash And Cash Equivalents And Restricted Cash To Cash Flows [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Awards Grant in Period Weighted Average Grant Date Fair Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Awards Grant In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Options granted, weighted average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "xfor_SoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Software [Member]",
        "label": "Software [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Warrants Exercised",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Stock Issued During Period Shares Warrants Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Warrants Exercised",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "terseLabel": "Stock Issued During Period Value Warrants Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_TwoThousandNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_TwoThousandSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Seventeen Equity Incentive Plan",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "Two Thousand Seventeen Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ViennaAustriaLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vienna Austria Lease.",
        "label": "Vienna Austria Lease [Member]",
        "terseLabel": "Vienna Lease"
       }
      }
     },
     "localname": "ViennaAustriaLeaseMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ViennaLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vienna lease agreement.",
        "label": "Vienna Lease Agreement [Member]",
        "terseLabel": "Vienna Austria Lease"
       }
      }
     },
     "localname": "ViennaLeaseAgreementMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_WalthamLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Waltham Lease [Member]",
        "label": "Waltham Lease [Member]",
        "terseLabel": "Waltham Lease"
       }
      }
     },
     "localname": "WalthamLeaseMember",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_WarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants",
        "label": "Warrants [Roll Forward]",
        "terseLabel": "Warrants [Roll Forward]"
       }
      }
     },
     "localname": "WarrantsRollForward",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsScheduleofOutstandingWarrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_WarrantsWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Weighted Average Exercise Price",
        "label": "Warrants, Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Warrants, Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "localname": "WarrantsWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.x4pharma.com/20220331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsScheduleofOutstandingWarrantsDetail"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL109261756-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL109261905-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r425": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r426": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r427": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r428": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r429": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r431": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r432": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.H.3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13728-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001628280-22-014095-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-014095-xbrl.zip
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MB(13*83K5%<"-@&<M0BV 3I%Y%,B[@19@K+6*TS6<' /N@;L1:BQVB11:0@
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MNS/=SJ#&0I@K05CESA2<*)T[X)SJ2@(PMZ(!$^"M^$1IY9>4W[=U2TLKX"Y
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MBJ(+:8HEHIQC7.R.4F]53>Q!ON%V=_7G\8J*2)PVU)BQKMSC'NR3'OA*&JB
M3K^\YV%Q4YK[)0AA)M ?#S?JX E 3AP.Y!K*#,'<!@5MO.NRS;?L1-Y7$"5E
M<YTDE:'0;Z3.'59S;1T^IZ-'M&43-/1[.,UA1X^HI(AAI+ 'TK7CN%\"?V9
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M1W(;[F6VYUT.;N/$V)(7;UK'K4:AAO)D4-ZQJ%G?81X(W0_G)DS+'P\)_Q'
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M9\.*OD@RDBXV#'A+20)C!RZ$TB0DI9 SGI(TX"1^*,2P6O*H B-!!!&3;+H
MI&L>&E1U1'2U=,Z4*0MMQ!4(:0;#QU3,8T9G[.5!J]W=$U2[ ZX,M8Q0BF6O
M%K,0H\34%QNX')V6ZD[-/\Y^?)G8'9R>4RK]]-*[&[!X)T[+P#!9>\QXW3ON
M*OB0$XD1&B]@Q#),%\#P/1,R :]>^V 2R/HN0R4$A2(5+HA$9S>\JEU2K'_G
M$<=/VKBV7W@_(#83\ /1&H,#YQ&39NO2N1&,UU8 #Y9:K((RS&-4+4"E8Q-0
M<ZZC[4Q7)JC6F7=(CDQX>:U#^@V)GM)G&&'^+QEA/,6H20KW!\B%X$QJBK#Q
MQ):?(23<Q%XFF3*NK)IQ)(X!Y^-(+#A(R-"W2#'3PU4A0L[4[J-LW<)1>5Q$
M@L!8M<+55I%R]GHX(7*&^Q0M,C3M";RY>Z4^OX3;\\GE<#R&VW?#T?#J[.=Y
MMW):X)UCD$N%>P#T8$1PD3&K*A(XUF_$7=F2C_E/5F![/F8H)0OS?H'_3(EP
MX&NA[^[:=6@RQ65S.6$J)*I40QABDBG6*7]T*5=93!8=GEIC[*3NDOU4:"V2
MCLG=.U.><$5<"K'R"O)R8WKB.2V+0$_CLJ-I*7BY;74LR=7T,:W9=D[J^\EU
MQ]M+^TYL7:MRH38"HS#LWU0:E:U*UO&S>_ VP399O(U- <O3US9K[, <:>RV
MP(:1YQ>KS2J0EE \<RM?'C1Q$;;/'7N\#6._TK=U8W/ELP M4\CF7(8FBYA3
M*&U]3NA=XN:\")&G V\+'S#_CXN#[:\,U36ND-QL6.QRN>?H\!NRAY =7DN.
M>XT,-QN/D#K:!56I8,G%[HB^'WP;0W]7^F=FY<-*OW7*_@7*_'/)R77%?QH,
MGRE,^[HVIO9/)",JE[^K_=YJ_PBW'=7>M>>+9]HVG9@^3;#1IR%!8$_)1=>.
M/6@!K;H[7.,Q.S:MRJIIZZ1" V4LP9-AR&-\KGHS#[HM)N!6'1<\AR=<J?+,
MON2!_*>F:1 (F0EI+S*F"Y04XLDR#0S%G"_3A9%B[C<^U]ZTQ]5M'=:-GL;#
MCFX5Q*.A7^X"SR.F3><R(=1T-$,AF>%#0KT43-&"\BR\ O$($9/+3H;912#=
M6#1C*9,89FOC#38Q:I 35&*C>:)R=$$!P?Y&QM9-2R:*JZ:.]1L*?G3WLEXK
M[ &YOIY"IKA@Y/KQE"]<URR?Q>61O<8Z_1]02P,$%     @ (H.L5 9IY" $
M>@( 5%,5 !$   !X9F]R+3(P,C(P,S,Q+FAT;>Q]ZU<;N;+O]_-7]&7?>^[,
M6C21U%*W.C.3NQ@>&>9@.P&3;/@R2T]H\(/=M@'SU]^2NFUL PE);+!)SSE[
MQO1#+:D>^E6IJO3[_[MIMX(KD_>R;N>/-;R!UH+_]^[W_Q6&__[S8#_8[JI!
MVW3ZP59N1-_HX#KKGP6?M>E=!#;OMH//W?PBNQ)AZ-_9ZEX.\^STK!\01,C,
MS?PM9H10@]*02&I"&K,H%(BID**4"JP%8Q*MG[Z5#.LTH30T"9,AY5:$:4IQ
MB(B,28PIBQ!=UV]12J %I9CDBD92"QTQCE)F6!IICJ7[[%D?1@<C[/3>9C?]
ML&?4'VMG_?[EVS=OKJ^O-^#OC=/NU9NLT\HZQHWX33\7G9[MYFW1AQEY0Q!F
M(>)AA-?&[4PU<2/SUD8W/W5/1A,-C1[OY?WQ\U;TI'\6+L+S!(:$)UIV366/
M-8Y<X[V^Z"@S>AX^=?&%Q]UM*7KCQP>]\%2(R_N]*6\\TB-]UZ7)]N,WQ<V[
M:>D_W)<OS2U!0-00DU$CVLQ\;$0@N.&[]Q\Z'DT_?W3LZ1NX.Q[#O6FZCOR#
M.$W3-_[N> R]+B4X^1()BB?&;?>RAUJ&1_&;?]?V#]69:8MPEFXW, 73WZ"7
M9P)F94-UVVZ8!$5C&CS><\?;_J&W+=$Y_6/-=,*CPS7@>2/TN]_;IB\"]VIH
M_C/(KOY8V^IV^B#)87-X"3U1Q5]_K/7-3?^-;^K-N__ZK__ZO9_U6^:=ZV(X
MZLGO;XJ+O[\IFI9=/7SWN\ZN@EY_V#)_K.FL=]D2P[>=;L= ![*;M^Y!DQ<_
M,ZU-Q_^$^W50)WFFBN_?] ^,_6,MTSA.36H3%"><6JR$(-8F-&)2<A3;Z)]M
MWQ4,O'DW.QW1=I\VV=M-T%#:::G=ECA="S+MFHP^#>5V]VJ?'%P=1[6!/M^Y
M.GF?GC?.-UGM_!C72/V\_GF/'M]^O#UN'YR=;-=P8WN3U3\?X4:S?M'8WLWV
MHWKK^+9[W6CND7JS?GY\^REKO*^A&OG[XOCSQ]MZ\Q3N?6K5FQ>W)]NG-\<M
MCO;)R?#XLXKKS9/62?ND56M>#(]OCV_K[X^B.MDA=7*$3MJUZ/A6H>/;&FIL
M?[S2[W<S^?XHKKV'?FW#>^>?LEH3WMD^9;5;:/=<P;?.6O ^7-N)3MX?E>]\
M@F^QSDFS>WUR?G1=;W]JPYANZN>NW8M;-X;Z+8P+OGW<A'XW]<7))WZ]W]SI
MUP[1S3Y<@_9N_DD9CBU*XY!K$H->YA@4;B+"B*3&6D*DQG;MG16MGOG]S10=
M%TG6T=JSF_64:!T;D>_"E5Y%X*\1^.8>@1.=1)8!@8E6.J16L%!$1H4RX<*2
MU,;4@. Z(KP8?3] ^UU=4?A)%![>IW#*2(2U#>.$BI":F(?24!E::T2<1!()
MK-;>?<3/2-^=#BP;PRV@<"Y:>QUM;O['#"O:?HVVM_=HBYE**0AP"$B7AI1I
M4-01*&HN4T*EC VQZ=H[!*"#(2!9\HPTWAKD^92*WNGH;3 4*C)_C<SH'IDI
ML4(E+ FE2, Z4C@-N3.18DPL,9$E5D9K[T* RV%T7X[?3$.MW%@#E%&F]P!"
M=)CW;<^#4^""P&/@MWW A7^L];+V9<LA57_M+'=,,@4&-VYZ&IIX,]U&\?V[
MCY9]Z'4'N?_+FS9O2\XK>>,[.&_4D/&J9?17IMW?-C-YX#MD'K3QMO;^9UI(
M9E]^-[HTW?JE7YA&?P&2S_N.P_UJZ:PEA$?OW=T;=U-//!IYLDW?&?T]^LB;
MJ8EZ<-Y Y%'$-$DI2ZDA1N+($)7$*;.@"5+VSYZ?+H;2)9BNPO3IES, EG0Z
M;JB\\[09&'2R8O@],)1,;SRRMA&]00[V2D$ ?W/4Q.C>Z&_7QH,SRAB&*941
M$Q&C,E6<L#B!.<4DX5K$MIS1Y6# Z1F=Y*GOG-&!E^?I*2O-W+='A]O?/)M&
M1T***#5):JFDP)$\UA%U[I&$Q&GD9Q-CLFRSB4>*]4=G$Y#LH6/$\?# 4H9N
M33[JM;;H=_/OG/A[[[N+VZ;3;6>=AYI]JGA,-?%FNO=?H[M$2("P&*4IH80!
M[.0Q0<ZTC%+%:*'/\4B?XR41IRE]CI^NS_$<]3EA FF!6(QIK"A N\0HQ'C"
MTU3'^ 7FK1R^.77F6?&GAH_=7+8RE?5KIBWA$SJ#NX77N'0@OCWLPQRX=W;^
M,W#0O]N^[';@S][F308Z>_38@>F+K&/TCL@[6>>T5S3X^YL'OS.>PW%W5H*J
MDB8XH4C&5FN:&#"S.2S)291(S)72\OFTX(*)"=?;W<YAOZLNYD_'>:GG*=)P
M1E62"(N0U%295%!MM4P%24B4:F5>#6DVM<Z<HUVT/HA,[W6VQ&76%ZT5(5.,
M3$QBC0'@6FI)+!.J.9@(*)8Q%E:_'C(I-6@/6FY[K=$_,[E[+C=GKK4KL]=1
MW;99$9+)F(,5D@J5&D$3RGBD4PM&'3?:)$@^(_1;^15L(?1!6">I3F-+!5 '
M*$4UTUBA6###))8O8'*O\NKT\KX P[5)I:!Q%%$::2FTUI@1336-N: OX4-Y
M+6O:RQ-7$&*T5DA3P2B/N3018L9PK-TOR5X?<9_9,'@1JC(J8B&H!8W+*.)$
M8C /1&1P1#"/$7D^9],JJ]YY><&FET>:))0+PJ3 %.E46@[ZU*26HD@F*GHU
MI'D)PV!^9 )S+07T(HTRAC)$>60B[N*_2!PQ*^/70Z87-@SF1S*#C$H)2R)-
M& 74F1H%"YHRL>8@6O@9/>PKOX(MA#X\MMQ&.#:4,TJXDIHBDN@8.WVH+??T
M02MAN&VU1*_7L'[=*6CCMB^!,-J8MI M\USK$IJ;V:;<9I1-4QY'DEK).>@\
MSE,A> *7R_VIU:#.<D"&.9*&Z<1PE&AB+"5:"R1DI%**+5?"OB+2O 1DF!^9
M(DNEB'',1*RI06 ;)YP LN,)D@#V\.LATPM#ACF23!&,P/C5H/5H0B.A(FL(
M4AI3G1#R>DCVK)!A?O2)8\4YB([$:4HC*H0R3!@+\J12,&[%\]'GQ72_9((Q
MK'&D*(TLX\:I%"*HBFAJ)2TV;C$J-VZ79"IFMD8Q>O+6Z-2\_8 '! D6Q3+A
M$4H$)49))2,2<6TX<4MFLHH;WB^+.E]^N]LR1BA&EF&BJ<54&APG7,62,:JE
ML:M(TV7967B9J)2(<*?)#:&("I(*Q.!W AH?12QAZ/41]&5V%EZ$N#'!,46I
ML$ASRF(K6)RFD0& !8MZ9%&Q3[L2-%T:<Q_/SQFC(B0T30BGE")8'S%FQ,:)
M3)@$S6I7B#K+8>[/CS0Q39$"A:B( = K2:H!L@C ?A(S@8Q^-:1YF="A>9')
MBH09(XUB0"M$98K T$>)!- )*#-Y161Z\="A^9$,\Q1S;0V7U$A8CE)N&8U3
MC2RV9)66I"4R]^=''P9*#@LPT7ABJ"4BU8H@E<9@[Z;(1O+YZ/-B'!K!N!.2
MIH)&-(XYYZ!CP.B)M5$)LV)Y][!Z>1_83K1V>HY%-SMZ0FUL&U 8*O,%&;9-
M3^79I?O9L!_R+DQ.?S@!JCZ+5O],M/>-Z'U-K3Q9:K9R RO-KE!9*QM];'1O
MW_3[)F_8XID5V4I+"$M 3$S,%:(85AZ<L(BG@MM$:B/P\L9 5FSR!&TR-^>A
MP$H:E^\I)4TC+&-!8BJEM53!;_7ZM<FGS'0ZPG/)YFEN_-+YRMAE?EHE33&6
MB'$E.09$&XM($0G<81F)4LOBUZ]5?@)VF6.*B^0JU5)9L%:IT6EJ*4D2%B?8
MZ CXYO5KE\U6J]?O=EXUO\Q/O0 P42*6(C72Q8XSX!T>&VZ-PB8!,^SUJY>?
M@5_FIU]$#*R"6)2ZB"3)#&!=1IBQB#'&#5MB]#*:=E<%K6$W\UQT3CVMIYS'
M/2-R=0;<M&VN3*M[Z1[8ZRCWV2L#W'.:B_:*B'9L!5@A2<K! J$HT1(+82.K
M*%CN-L*KE"*RC#1[^80")$S*991(H"[((I,TTDPRHI 6KL[F"NW4+3V!7V2W
M#J74%2*18!8RRJU.$2<&8V90*K4H=^N66G!W199_$JV!^7-8*ZI.N 9V<_.?
M@>FHF05Q_/#$H[T#HP9YGG5.Y[4D3W1I_/,O&*1CL>&^8[!'>K77N1ST>_X)
MO")+ -%Q0A!-%*.$2K?QBV,L-9@(0DE;[EI5#/3\#$16A($,Q3B!90;%5%&!
MC:3 4H1JE1"&=$I7BH&^FUK1 EAGP=R\+ PD*)&)5=*PE%)D 99@DB" *3(B
M1J1XI1CH9Z%9%!FKA.;46BI<K(,UG(K4I@C(MPK%'%[IJK%8V#$_)X$U*#("
MB]A$,8 /#FA#6\LHM4;%*145 [U*V#$_!B)8(XN$4&#0@N$CA05#EW!-0/V
M"816BH$JV/'\#(032CC"BJ$HH=K(%".PF2V-!2<L+=..5X6!?A*:Z4APE*9
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M:YJ>I^2JY&:(."6:4UB<N*"<,BD5-CZ]TB!MY0KD9JP04ZQ*OH5.#.7"4BK
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M&R<*9A.()J2F<<PX6#Z)2E**!!/Q,L=]?#<FJV<=XXCT -TJ,?\*NR1)#&L
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M%TH[>\)&'S&\L[T=MG3YB8&&NX"YW:.7N5'&(W!,BC9\6G\O^ 5:!OD(>@.
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MQ[=R-Q<# \]>YMUSH(MQBWNO7USH71K?\<N6*$_*Z$KW$*A_/T28$M!CKEM
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M48YTX2$O$?'(M!: *'-3F.'M2^"J0CM. %^_2U"^/#'Z O-..*T<.TZS;1'
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M>=,.K-%3#@_H7%Q7O+9( +<^6S'JWJZZZ3G_I5LDBV",8F=Q1*6I\@3%*0<
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M2?,38$ KE_J13LPIDIRV_E';E_YYI_2/94GR:%(Y5L7/NQMS ,-@6*_#9\;
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M^! 9#5&+BG!O>,WMK#JKDC.8V$WMBKH]O:D'XDDE#BU'Q'N#I(M!TK_FV _
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M'[X3^]N=DX_;OW?W?OS[\]ZK=]_W#G?(K%MZC^Y N_?..J_>B;WM[N?.]JZ
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M:;U42^\I1L')&"R+ 3ER&^ ?Y7(M74X)Z)*4M3G-X'\++KB_RJ#1,+&&B2V
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M9)WE0"2\"KESN: ^:C!WP9_&^K"\DKMX^M!([CU)[@QSX!1S8RE'5(D DAN
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M@$,'84*.K74Z!X*4)!TWDKY*DCYK=<*>*)A=Y)SSB OND%9,(V8M#X1P)X4
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M#8XCE_BS6%OZ/AZ<KTW< *Y2W'7R?/&QGVKU9*.W)DTWJ2HG??5(;O[6L/B
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M:W_G]2*)'TJY4\Y3%#R+.^**(*T%03S3WKD@,(Y)HN6$7WN!D*5%?BJ >J8
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MV4B9Y#!0)!"D2"R9Z+1"!@>.G-&!*!LPE?FJ(F45]E78][2QKPK /5'8FPW
M.9_;C$B*&+$<<1LH4E1F*+>:!<PT=]Q4DA\5[E6X5\7UGCSXS<;U-';:2>>1
MM<#T.(EJ'X)C% AW @?PAK%?55ROTORX!\V/6B7W4;6RDONHY#ZJ&K-K%M!_
MB47$'HC'S,M]2"-S^!]#QM%8>3%()'6D-5HR1;TT0JVNB%A5\+H"HR<68:_
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M7,O^4S2RBC\LMCTK]K>_>>,%='Q #LA+%-@S2#DE4 [N 5B?PS8&V<@6NSH
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M/^24ET]\V^C!0O)S"/LV\.OC5B-!)\JN;HS&<5 ^I!AVZ2E$=+M53@6()HA
MYPQF%:0KYOEP_2Y<W>VN76( 65XKB<RS<[EG<--/>$:6@JX'L:_H DA7-XOJ
MS]@*[0X\K@D/+7\9OJ$XL9U>"Y9&>4.[/-XM?Y3=4J6H=6+W)/I2X#V89A;$
M BSZ7KX#!+G9SZLC/ZZ7ETC1;!QG:(&KX5WM;C<[MSJP*+)P]DO&D=4;K(P9
M*R3+7CXY(+O\F\TX6E0G\-JS?.9<EO'R6A!,VX">'5L8"5BFO<-&)PR;O5[
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M?V*UHQ^X?ISW'NNI=G3PJW;PW<7 /5,146T%XEP&9&",@;IH[C%(IZ)F:F^
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MZO/BJ)=)VGT9ZC/SHU99^:0\[XV8E0_U@8-C.8N<:Q>$-MP%@!(6.)<$/L9
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M:#2)>R;=FW<4J+->PXP^?_?.RO'\JAS/#PM3*_J\8'BJOY^ )\.9B :L^L"
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MO(6EX44P3BM"@0Z3B&F(9<DR8@A\M.+$TU#7C/_Z?+;_-9PXR@&V_C[>V3N
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M@9.',LLF7GFG9)(7B ;7'-![/TBXO>>F>RM$6'EO%H<%D]X;; G%AFH$9KE
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MI(!S+!'AF#JXZA+V#4]^>IIS@29&Y<9CJ)ZBC7N'L1.+T_RCU2[&CR7J%G%
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M/.G#*VPWYGNNZ$2^]/2PX0_+&SKQV#8RQP&>-7AH_!4[O@'/J%)1&MWBO^[
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MS4APB@(4/5L9)N"CFYCLDF\R1Z$H*'FOA<N5=_4)#DT6C4D/C(L\0J62DX9
M7 73-LK-;;!&4M2=60 15_F0=POEW8[5(E"":.TK<9(#18TR*0?C(B+@?U'
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M%C?L2^B#ZZ/1X[2L!0G@!*TX<@V#WPD?)%-4#B8+L?8&*T-E-6$QWHC6$)S
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MNW=X;Q#+^BUO!K%\N#MT/.Q0SW=HYQDA^]ZA_EF2(?3<P0B=;&&$'N(YZ5L
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M+<[SPAS(!>W?;0<=K-,E]C[;J> JYG0E9H>I7=K>L?'5L/%DU#!9EA6=-7K
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M<*YBG"J+7XBFTR1%6H>2SC!1IXR-E5_X%EZU<1X#Y+Q)A4, 7D5=$#EH4_!
M$.7/SL_W3\Y\17&.G 9,H*?/W+@ZTR)81;*J V]-A1V?C$[TR<1)P[=!PAWZ
M_Z)'FCJT+]0OFYP2CKALD-7P23P-:)W>AJ-8FBM2W!@*)HM*Z-2(%6<"=B<F
M$5&*I++=A(':B;T-JVT6,6F ^DT34ZWZ[&UN.ES9/FS'1=&3OR@@@G;^-WSE
M^[,3)X4AB#AR=X#CBF.52<>KC%@6H7FT))X#D$WD<('U?)M?F=D8!-'%K6AO
M8#7F<*LO"<:M(+#?'WF6L29$I5!X=+P942_Q8CX8Q_<?45:AC646GE4IJVU-
MEYS]AN%]F@7OP1[:H/45+%#PVV_/@T?B%/C?LH'(JLS5+G;)1%J@S,0:ZR-8
M/PI3'MB4M'K\8;=!YP0GCVL^P7X<J-#WEY26B)1P)%QI_GD^]H7O>T^P;1BK
MDK;F67>)A#N.&GI.^%I7^)[S-)K0GHZ"X$%(KZ0;;+:!8V]:T6-'I^0<:UC
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MYV"[9F#0*LK+MCQ@N,J^B $%#I6@!S1?8+F\P4?D\8M&]VF0>;_+R[Q8L%M
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M4;>BIL/-L&F>;HOM]]C1JN4-*FM0HZI,YEF&*Z3/G7!HV^^% #><A;9Q%JP
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MT,LKR24L/Q1Y+5?ANM1H8]MP3#1Z@PEV[?Q7VVM#ET0JX*F_W_7V!TYJ22!
M[KD0]6I \VN>Q\&;V@W?XT61GT4"$D?C/OGUS?N!]&@]TN;IPT':#"K@ME1
MDGES5T@_(TV'F=A9*BW-&0T[K( +Y<O7&-8_A&SC"^*-)IOL*_]:*P\]0^VI
MO$0 T7Z"3N$.#PG@.=W2G:K\";XQ&)']H=O=]MM-G*LBYG;H50(7RZO?GMJ@
M/V#6=:%IJ&">SQ7AXY'+R^@$2RV?"3#:I4#LQ%BL_>E<H!806@W0M1&_V:^"
MU2>/@V+;+)0KG6K_-=4ZDXR@3TQXXM&%MC?C^>:;#JYW5O7X*3S%)KV8@)P&
M-M5+0U7;#'!LX1<;3EW;@FX9P^;(;K>0G-?X*KHU0[B.7F7<&+DW-=>FL#5A
MRMO5(T>NTE^S]V'*A6:G]17EH@SGN"!)EQ8Y#V]&(^9*K-80?8?+:3?T,/.>
MU,%G:9I?R_1(F4?!U8NQ2?D*43(K/9@H91W+I*B=PU8L@->+2N_4 JE\15GC
MDH8;@N0L,*]JD7K2N^\.W$3Q%;4EILDSMA-Q7"T\,@D/NX&:0N#:G*'6[F7O
MQS'C9<@@L:X1"H:IG'*G@:SF$?IYDQUPYXR)5S5:#U3!C=OF\TS)_?T!)N14
M_VJR_RPQL?^+@7^]+HO(I,$+$TUR*M:]D=&QS\E#"^'K.2IG!)S\GB4XWR.1
MC,R+*(L.7D4%ELJ>,U#@-4A%LD#*!M?@Q*<8SS,#Z66(FN#O/<+34?!)N/EK
MTY>$85]DULLK^)&"/R:L(L^#?^R]/,LAUCT+5X!<'46BZJH2LA6OWRZO*RUE
MO]Z^">">L+@<L"'_Q;V*!.^+C0P)8D=#%$SLC5'8("2!G5 !?@#8'ID0Y6\C
M54F]#OW2M+TXN2LQCUSPD#4HISA/"YN",6=8)&9!.'M_;IU]!I6FYB/X]M16
MD[9Y,>)@V:W8SKW;;@&K4M$GF^Y(:54X0_E27"D4?/J$[(<M0KL%C-TUBQ5X
MHH 7[?%5@A@ZIS2"S67<[20HXA!8V9T>J-Z-_! K3UT[2R2>!-'%J0P@3"I4
M,1@GK"D;XL6SN&T9L>346),N;IJCS1^:J_<^?=WM :NCI=U2V]JB.^<"83LX
MSA'8R9RYXS,W9R[T/4(WKH/[=RP\50?*P>4.2H&0.'\6(7\T(\5KM"'!*TRI
M2'1W6I7H8Y"9>Y(9<%L1+5'DRRBE]*B=\Y49G78#F[ZR8P[$5VN>L+Z-4SO#
MWM[7WD;.MCNX%P',RTNG(@3\1(B9JM3\ _9SI8G#)&>(+"U<TQEN,4^80DN*
MIE;MC1,!_8LZ463\\3;R@'VWHG420=^=]S#VK9Z]W8(5(ZS!<L,_B>#<99]Q
MC"JB:JU"MT/9+B7.X&8UG1#F+[)W!\L\S9&"[2'H FFW-H*1I^=P5'*;OF^9
MA;S]HX*].CX\.F4*HH3?7@M(S :4XX!/3B]1Z[7).&. &1:;V:6O;NOS6S7)
MHKZM/% _7T9<D%[:<1L/^0+'0V*V88I5)_XU[9@WWP_;-"IFK=SBDA3VX%K%
M!595FFIA 58^,\O2XNZ:2PM?M$-DDVQ>$?%3WESQ[5]QKCO*C+?UWW>O*QX"
M*P,CB -U)_P9KQM\Y%#FO-5EB=Y.WC8U<?UL;B=@Q+QU&Q+FH'_[%)^_Y]<\
MG?NZDZR/P3"X$9B.()NP6'"T%EQ'97"18!)4Y( D2T'A-Q(*'A-NU2-W@$UY
M=V(GBE>RY^MNR$G$39D?[=+N>'U[ \HG-U]HX^LTU 9.Z:;^'4&MVO:V6I@J
M5T!EGD;798,;C$XLX7)=8]85^&@Q1]4L+3Q&A!^N]YK=F[?=&I3SJFR7(<*!
MN!&M!80YTR(G/0QW)/*"J7$I:$E;J =3-X:>C\N=<"U:J"/*7A-(>[5*YB'/
M<6SR5B]FN=TOJ->\,',:!DKE3A0,YE8OKA2,3$Z D.S*Y&?'4$P<YV55H,2-
MMKL]'LBZ=^)60ILTF+%DJ9Y*B4.L"==8N!G 4Y>X\A;*<2VL<8?J-W1X8]Z!
M9X=!'"U+83BTE/77!38J9&C'UN;5!VS&=S^?/'O0V(R^)N5LQOHV\W+-^,3&
MA_9N-TH9'8Z>WBACM'M>*)1)R9C$M^J,;J/7I!#'TLQM5G.3"NX]PXQYJYKS
ME^;FRBSTRT#VUO8V=Z/K'K.NVUK)K>6!ZMV)P?=?6\W1CJ@7KYZ_=OU5^S]<
M>+\;':NVS-(XFGR^*.![\8&L^93^YZ>[V@&JB7_1;LSO3XY=LOC^,F'?_;R3
MVOGJ['2K%MI.V\@CP*%-9M6L7>>(R*Q1-Q#:/$I^H/"+)RQ@(%(42V5(]CI9
MZZ_B.:O^ZSQ*^&I6"67^";"/Y@Y##>+>IJ_HFG!1XBJ0Q!BBYI!G6@DW&HE"
M(O.";;Q**,*A3Z<FS4F-I4)>F3> P/!,$.R%0AE<:)'5=BMY5 G-]\9'O*+7
MEF$6JJ_Q$_Z $YJU;":N:%XM2&M.E_A,M%NH_S/))8!*P/1HN:@I)_[,MB-2
MI*E7+=ORY'C-1U>\,6/FD=9@<7(9I=@-:&S$WKJQM^<@[^P9]\/#>I&4\TI!
M4\P]P OMY6OWC3' 'M*UA@G5?V&C/=0=!'(5OKNY*73>%K*O>I0OF*=H3?8.
MI-9[K[-0>FL"FT.L>/6<@'>4O8S,BM?B_(EZ0\I!(;-2F#)CZ#'9WRY>7QK&
MVVG.E"GTX'!QN035@\71Z* A[331'"GJ_?6'EADH:]"3=9(Q[/A^ZZ/6LZEY
MZVV>DC=0T65DG3QL>= ]+KGF%!5OD"S)H(?9:F8!;1Z=1UJQY\HINDF ^,\K
M[F9R-(PEO%DY13%$4IW6MQ[HG/=O)MP8,/+R+60--_!SEE\?7.;7DI,G^+]R
M>_R9)^CI$: XIU8%$<=V9<-5.0=A\^;9]MU+>SU%3EEVU*A$LT:=:KW-\W6Y
MJ,V^?\L0.1M[K??YD(S%S20@9[V=.*I&9])]L$DM$$6^:9DWM'K>^[Y)KZH"
M;25&4J$-8W7B)X[([!PUJPT+6*VB>D*$K"92A9(K:(\,_RO/+G(\"\_?_??K
M%P='S]""HGY&!+]5B+3<F:MP7L'V*19;QO[Q")^F5;=7Q0?3&_<@$ CK4;7?
MNVHGIY%B=Y!YX0WTNDPLXRK6AB]A_X@S2_>+Q-16+(5Q"X>N.%N3@;AXC39>
M@PRL"7)-P6O#Y3+=AA(KP=*]H"OK7^\J*22O%M'3J:\536R6#%,W^'3NY]3V
M0+UXNC^%/6JP-C@O<E9E/![78XH9!?=_B&Y$Q(9'@;) S8Y&1V#.C4OM#*;<
M/=,7$+^V-[6PDBAOF!"BX^!@GH*Z 4J0%':1V+7Q>BXM448; +W)/:M=9QU3
MLNCB=/X=82S*.\Y10&%UH3I%W_),H<UHK;T3=I,V[X7ONWE(M664(NXK;V@9
MTI0KC,%$.+>UN>!Q;C@ ,9C$DVXGC"]7]\:QWKG9RW)8/0EM_VT^Q:204$H6
MAJ$,IOE;ANZTL6"UO%3;_#5[,3P7BL-;H>OH'M#&TVLPSW59@9R7C4$V:X;7
ME%+1USH.-^>TM?U%+0?4T4:GCCQ:#5=G9V=PGNE/<*8!/ERMWRAL/6)B(AK-
MC-P^-YXE9>D1.=7X3QW\Y-%;IGI$B_7F_/P'_._08V$,FSY6DTQSU1U:PY]O
MAT;KYSH\>@2VT1DB<#*JA=4,*RV'SN*HC#SBVCI/5U?VCQ^LF,]PB,J<4K#H
M^>6%SH^FV4=,[+?4T8>K<GB!^5T<9)YB*SA3/,]A+='AIKWFMA;L-*1[(->B
M;>OS#2R.S<8WPE@@-?%%,R%HT1O([KC:3MH'QW%'F_<"A;-49N@VDT=#.@D%
MJ^*_C0"+[#7&S_]I\CDNIPBA)[4^S7V3/[(AFEO-,^^-!1;R::0)+!**^>/Z
MD@M-26Z9I]<<)_R!$C1N/W&TP<GH+K+' :;L7 Y@G362<7KX<, Z][-"7RNI
MW<-SSU?#WI5 %UX8W)EDXH#%[A#'WBEN/!C3TZ(3X_1>B1WWA>6H,!G"DQ4)
MW:9X;W"LNUZ6'F"K,XLVWGJ^H3<48T%#:(4 -9N"2L<'O\K3*URP#Q68@8@N
M__OG LRG@*AO05DI00'>V5O=-)]$ KSEFX<R)W=QB>&" _9RVS\OMV&F9/EM
M<WXRHH*Q%!RE<"(R)B>KS>+3AW5Y)+D\B0>/,IY159>+O!!*I[FZ'?34V)9'
M7Y#GTZ7T'D6<=K?R2,F X[E6980XO%.B&29G&LXSII\C^AE'ZIVAW+7&1Q@/
M(>.TG_+APC]OLOIGBN%P]MIR]@H).?$(KT@Q:(S)I8FKU(!/UN);C,4:TJS9
MJIRSI^\YUTKX0$D+PYF-58[:OVR/ZU/XWSM-HL?W"2R"P%PD#F-!^@?'B^5&
M'8ZBJ'BRB.I*I4R\HB'(>B+;!I!;(N>ZN#FN:3D\-!]\SKJA80-"7^-SGT&Q
M@%!ESA:BW08,I<?]UH)BS@=S_')I0/%?3E"3@E< NS%!O7J-F0T-,E3CM60&
M6Y+H:[R)NAS5'R,OYQBZ@<4P!1G7J&S3_2A?+,#Z"Y3DZ523<2XO;Y]YD+ [
MES#"DF#;J.SN9]/,"7K%8C>CH,V?G('7ML@+XF,7RB)BEM)VH@RG/(+."G&\
M-V)?R#' D2\YD62"CX>,2\2&5.2+'!:F%,!MS,-EN(03<Q_-U& _,?4+ECC<
MP<N<PH,R[0>B!RUN1AN1,QE_:Y%V:\X!5E$Q]V)*;*<2K+@_J(%F?#AG9&P6
MU_C-57]S$.1]<K]*]E*SK03:130O:J=5W/?._'*4IF51%ZY[GXI/*[W<7#KL
M]!WOM#<1HS8K10=S8CY+=X^(W6HA@D?&"X8H85VE6F>\)*/9(A'UG*M ^PH[
M"0&QR'4=.4C%/HE?94O#H$U $EPW 5]'C3'I4>"QL[JQ2)X+$_+4$?BC*VU'
M*:B7F&)#DUV >VX;;-L(#FWJ?9"!N[8!DZ)*7,63 ARNQB:,VQ&8I33?:,!#
M/XZ&<WL?>W897?$.R<;8Q(VGP@NSJ JFD2%F49><XP3+034?MFV/+,EVTH$-
M\1"G6"X0)HKES-A<)9&'3E0E2#X]]S9*[52#/TZQ4J8BD^JJ(RJH#1YLD.''
M13YG[LI*&H2&4]L/;[L%(&GI!2B[A>EK*TH8844%8NB+BR@3%ZZT39C//[S3
M'LRPSK%>L]0U?A8VUQ-8LOKL8\+WT32TS%SDB\250-"T7V%K;SU3S9"Q.)E.
M:?ID  \C>$QW[T'@[LOI3P0/*?/A>3+I. ?OW-7X_6+ 2GICP0@.W,9A%_>\
MBV43N6ZG[,#VHFZ_RG%GI@GA=FW2^P7RL7_DT4=O;)HI^(5VV39J?WSSBVO4
M1GK6Y;"?>YR0-!LG%U7.U%YV&P5,-2S\/@_2)*%DO)M0&NXRL=-/I0H[/:8Y
M\/APOT+)<'&OPKE:36#:/Z8[P@PLGTV9VBUU<X=-YW+H(!1[38'$H#]QKW"D
ML\5&3J4/*,F&&67WODEI-/E,08INU;3*8A<)(;FX40PG[5X+?G.8 '17$X!J
M2/P&,9X?A_8 4+MVG2TJO+0L@)RE[$2#)QFV$98"Z<E+C+41'A;$V*74WE/B
MBRJ1*:GO+=B$#=A:FZG7*S/+2BNHEH'NENLQGS 6:2*]8_7@;64(1HC>)=89
ML6]"4_Z6V)%@%PV0F>9_"<$332C%P<,,(N(2 7D0 '+81"#7F\X*N_I<;&V#
M,A-+I(/.6V@SU>$1"Y<ROFAE % #7+S5R*<!XOK=SZ='#P?BVG>DO@#)M=.&
M$^Y=-19_Y%&;*N(</"((:1@G]S-R3H>::59Z5EH JOT>7_.Z49@"IR"5?]K%
M62U,;/V:Q(^$W6,3-\!%FK6X60H65RB$V]:?VT9+G>Q%*AB+WG;R:60K+%YY
MI3[)2OK-NN:]" 4TH5&IO\8VGD(@,9M+XSLU\G0^0LMM6]YFEQ>F63:%'6D&
M-L'$G6^^9J/T[7T\,9E&&Q>M-E:T[*)"#6:1US^._,5XM,J&2;%\4;82@MS]
M21Z7/-;,?,&^:D0_?RVZG'>/X81U!S;WOE:'%1(WEN+,)[277FMX)XB,AM'!
MWZ7W1B&,32SX%E=B'+5%\7K/)H@EF?.[)&0T;$CIHY5"03#ANL%5)XZ8@;>S
MX3&Z[]3 _-S= A(!*AR^QV\CKF4=5N#$57O4[,#I6P#C;X6WIV]TPO:)Z]VB
MH^WY$*$@7Y*YW!WG6Q0CEM!X4RY;-HL&)7**71'D??>R>=:#X-@5<;!..[3L
M(K4(D"2)--J3F,M S^M$',[$LY^(0:HR7&V))3??J<'=Y@,^_2M/+O.<Z0)%
MRSJ40[U\XUVU!*%%4L/58:=:H)$MI6][)7K7K""Y>JH#2Z*"#IG-^7>XOWM0
MM/4. +(BI6V/8S_$\:-KW!1KT.3"+N;#LU'7%H_3,0TM#/YU^O[@\/ 8?\S_
M>>+?2(T.\5-IIW(F_: =?L)*IW =::XYOW217Y!X]OTL_E&?)2KP/#V489O7
MLL%'E9;]O+0E::5EE+FCN.<0:F)'2Y' #DRXQYL)115 O5AZP)+0XL\0W;"=
M TP6CT\W$H>&BD!TS3@&CD(5K;@==V,/8&7Q:>#+> JDW*O399T^0%PO&3(V
M&-B27T37](RM7AMHBXM$4@7HSZ(AZ?+AR.9,F7N&;RV=$#D/E? FI9*A44WY
M /(X[U<Z\S#=X&4[)#FAN8>X*J*.3$-(C7*8:;"M8N,EYSDDP3'P0MYE412U
M2(+JI^(9:GZ4M]*GX\Q"\S>+0NQC_<=U<$X-/4&?4UO&3UMQX0S;?+-M=@TT
M!;.:@,OCYE#OUMG3RI/S,+M[0L^8@?%JL0#LE"GE38)L^:P%7;>)ZZH$+PN)
MLHG;Q9^>T_1XAAK7/@N1Z@,7[%MZX03Z VCJ+?JC/3+1W?0S!W7YI@%-$4<(
MC@5L;%@:B@E/0O(#=Y L_M@1\UTE(,1-N:;6:Z*Z'&1DOVS('@\<:R%R&H4D
MU9FL9, -['TKL!Z'JASB/XQ%Z]P$7@ ?/*JIZR8%;E[,,5&'^(.2??L0W<K8
M3"EWA[X+S357MBSNFM=:$URPG$4ND^O=]X=! O8K :T1EL:,#0T)?N:_*SR<
MP\'<>_NW[29;W8=A[??=&-W"5^<UCUDUA;,[T+L9-F2_&X)TP1P-6*X<VR3$
M'(9%/J<VD+%! *1?&'ODQ<R<6;^EKN[!,NV]SRB!:]IYBYGC--*_T6AR+167
M"I5QU">4>:]1J!! DJ,!+B_$W,*2VKYA+AIXR4+X9S1OL.QCM@S9C^ER))C*
M7$TE"4X.HQ$5T$(S9"=7"&N:RB#$:L<RB-9ZS#V'.+OH%KI!RFXTXL%V]- $
M#Y?@4!D3?G"O0$SDL9R:+R'@-5F]R51YTUJX:W?9NWO:IVOE^O(JN([DG*O<
MDN!)BAH_B*/;YZ1_<Y(R?YUH^DU!G*;99$C'[%&ZU4LIS-04!<$Q<;\FDIFY
M7):L88?)'OO7,OZ0"<Y>>C5\@83CC(BJ4&5"4$-7M L]"H*QJ=5N- NVAM)^
M 'M^]_/I\0#V_!I\BT\1K,6GI4>LL GJZ35B=I0Q?()_D7.7T:5R62AUW5J#
MDE8[\$SQ%;;'25KDD@\K74M8OH&(G)/;D0]2WP65W5=T[VOE!%6B]B"G6@]-
MUD!OYT:  MBQ3GP9TI)B3I"<!U@"=(8SA38QCLXY^H*DD4W@/=B(@?"@_1:V
MH.J5D6K8 *Z*5EU$.R^5^@TJ; SO#::87X9RNOF:#9.2L3?D:!'A')I:!+)A
M_:];<38*>@&1GR+-"A\B.C!%?KVXI"FCD1M#T\2J.*!GQ)RZCMRCJ->2&D2\
M9#$)U+#Z.^E#].$I?BPW+Q*:Z4US8G+,6*,*0Z)^FQ?8'AXSX4$]^L-NAN?;
M!V12)[M +E>!-YI/?Q"SNVMH965:NXZX/I%G*![!%&[%10,7JSN/%T<N%+B%
M* "-M1;D>8''V^-=Q1A[9B=-^"ATQ$#*AYPBBF.<LD"WK(NAM\[!+U0))?JX
M<9%'^)\$?2RKXLHLZRXXU21!%?.('D$(8F]#E)+!;3R;F_YBN3-0*X$-+A8(
M".)</0Y&T[G,;.68\3&_H+0#"%8$1S3B27$T]I@.^LFA'=,-=\NSY0QV+O;6
M%AE:)$.!PH'V]N@P6,)SU*=3RZPAVD%__0K>4)Y<?A*"P0$1CRXRHEWCF6#N
MW[2^M;X"V(#?,Y+NCXNH0=*%P#)#D$ISA9M*$ZWLQ4;!;F9LHPX4Q.[8\' 7
MU*1NIW3@F2<L+64U2A?A0HR)33POB#=83);?05WN:O-NR93US!5=M'6V>-X:
MVAEZ01G4K98H-3:G5IO*MPK77K4N8:M:7J>,1\$[=C?_--(I(-+@^<4FGV.F
MY3)GI5V7O$=H#)$XF@?^V$WO-E8_W(;3A>=R[/26QVHNT*0Z@,A-G6LH*%!-
MR]+8\UI24$#C1U.L,$8\C5UY=UK/P"B0,8+ARIPY;\(<]V)*XZY__AP R"I1
MZY!;;T^\PI5@Q0=(XU$BTRJ_$EPJ3U;UH,5.@,C9M!Y((HP),G2+&+VM#9*>
M@0C;6#D#((/VVI^KE)PR$6OI#9C5'V?TY669C)'+_MP:"!S M(46(F53%34'
M4/2'NA*B4=3A@UNKT^<>A8Y.#;!.T +8/OL"?-6)#$] U0:BA)D/#2EK:PHW
MI8%'$8\TPRY;/UYKZC9Z!V^(&$X#C;Q.'4_G/<#Y?RMAN)B]R!<4D8&6(E<+
M W([+,\JFY:)2=S';(=U6:Q=5W0M<F5P0!:Z'[F,SB2F:#=Y5N"1VC_B3[8(
MI=7"=6)X?9]@TWOBLJ[.48)-,04ZEJM;P6D^'N)90[>%[1C(CJ;7ANG3N52;
MMZUKQMJ _'YXD.!O! X\%((&LO][(_N_3:[_09#O@'UV(_V!A!7P9U/C&<3P
M@F?T.L(ZZXUS\^<$O$]A2I-.4[Z<-B)495@CE>P<Q4OF72:]KF%U&E3?GE5?
M2QCE426T]M.OD2H,B3!;WIX2JD- .-QLH_I!6EHF0UB]"GD%7G,BRZ4BW&P4
MV\;+1V/<*=F],&U7'L!P#U&(J4+C)5NT!48UDW+N^!,M.HBS*8PW1B>EZY40
ME9./4VFZH'1TU<["@SH-!"T=0,A[W'!G><(U',<E&S2FKJ'N8!"2";'"@#>V
M,**P*,$DTU%H +G-]?BMH?6)*<UAIL5:#N6HQNOM/,5N$1GP*-_]?'KRH/$H
MP]&^T=&^7C-O6YGT2<M>U_G4Z+.PDV._<2A5K[>PO'HQUPHE_T!J?Y<RH(-X
MMV)=[G9*T875&G;+[-E(&=4YE<C=?9YS224? L2#3%((3EZA)UN<CZ(FC)(C
M9:(]X2$Z$"SIE--!9!Z(1Z"1K!9$6QV"]5)I<0<;I ^)I]$K33:.=.&I?+<I
MJX,\[C>N1J*KM@STQOCY @N&K:'OL&5[;O>NYA@APE$COM'%<LUF6?R)\O>5
M06:P#(OX R\!MO/V(T#( H5Y*J,@X(=.A/TG$CKVA9R1+LON9*'*[!#Q!N=9
M2)381+/1'F*&P:T9L2ZGJ86Z[D'@'=]Y^^)GB(E*L,'+GJR \5?X_PBJT:P!
MEX2];3*Y^NSP+:4>QSW%X^B5O[7)1J94D^\O\1%/5O('TP;*=R.6UUWL:+SS
MU3K137#A+8&V.Q111\%'CX=M7IC:I(UE2P3&:UYSTNOW<[PVA&GF\G]YF1<+
MP[!MX?75?B'+ONK""L0H?;&%#H((:8IG,PB WGC)L%MI:.7,']+SR&0 9@*5
MU-&XD&H>7HO^P@*H_=CP:''.TP)G\R@IFM"%&B1ONX=T[5 K-/]THU88T(/0
M!C5F8R\_?Y'F8R0-_HHTO8C2"FYJ&YHQ+/#OL-)(5YFB4GYEQD6%/L/QX?%Q
M* ^5(<0X6>"?J<6GA.]6V>02._N]TV2_%'$I-T(T&'B=\CJCX+S(*Z0*1M\F
MFG%?;MB&$?;^]$^0U3B?\=]>5GCZX7G@0V*I036'_$2H:,CD919!EL&])H2<
M9D WPI3(@T*$&T'622? !2#:$=9;#%2*A3;#2JU1_"K0YT@S;=_*VR\I9'L0
M"O[0H?WABOF,M(M=)&E51H0BH@ZW%8IF8[L;T];]'LXCL%S75T9VJ:QUQ'OS
MM%>V!9_B;_9*()L9@?9#UF$3"A-BE?O23"IBC<(*KBFR&C;*$?'2T&ZIQ^J[
MVQ5%#F7;(Q&QM71LU/:'U+ BIXW6.6'&^J4H06_$)".SDA*A%<*R3RXV>$?"
M&M(*4JR-/Y%S)P8&?R/8[AW:V-P6^G:XU6!N0P@K;V>Y9?GRIK2C>(5=4L2)
ML/"442A,DT2J=*0=:%"(90VQ^']HISD3L^/NXE=2<.<RKM?[,$!FC%($N^/F
M13SW ATDAL%J3@TIW/%Q$,$O3YK2%VQ?%(N&]QA@H+!4XMYY;%)J9FK!/%EJ
M<GJE^M09EB=I8Q2 []B--[C6S$9.2B:U\C?EQ[5"2V[?V"A->HO$M*GHFG;&
M24;4J)CVQ?#M"GG% D4R@Y>>'U#S#,_J,8@WRE#E80M+-Y^@9=$0U4V5]6J<
M)N6E8.EPB!U"F/'_H\)B*#G:56J(44^7;B.P9==N1*>[J V8C> ,LKY!BKNI
M@*EY$%),RKY5:5F*?&\&%8T<HC$!>/>^X%Q?-9?-M@+JPB;-/6/$ZG9;AFX#
M_]Q]K6M7:;_LB/#Z/M19@W)^"MK2)J-67BUP6SD*UGU(?4EH"7=TX 6?N<VB
M,@K>>RN ^E<7A[Y.7GYAD%_J!L+$*5T5I;K82+K4>R\WR]BB25=VY[K6024;
MBSI[[5O,(FLG0FZ;T!8^^MC-MXB4[0_I>XB?I]MDD$6O2X X:>C_KCPY!$EX
MLD3G8E(!;0IND]?;$+)JGU)[ 4,4C63#I=^F[3'HA@T[0#I:FUX5O6[]X<)+
M8WL/6AOHP:_AXE?6^<HTAFM>&Q^BAZM5#\K+NQ>G<'@2498%(HD%EA+KXD$A
MGI/2%R(<Z)"KPSBO[WGBGT_R5=S5)%!=/X3-S5JS#4#</L<^2:1-N=RQ(\'F
M+$=-ET\^$P]/6B%D9=&PO/WI76LW9A^H@/8!(0[&SG5[XQ(UL!C/VWHK,#OT
M7ER^Y];E&[ 5Z[ 5IP\:6]&KMJ/S@)8(7/N\NK@4/K2E$%3:UIU7$$T%GPJ<
M<NI_XN84VQZSC@0TJFP=> B&'RZ'LW"\9*B/R%UJQAB#@L:T26TZ2TB5NZ8_
M]U2ES:9R^B1-/H.*N\SS6(Q ^U.2<NYNLNF+AZ997N8MP<@;C%K['N)"M6\<
MQUN;*31B]#I:DKD>HGI>%27-MLV;N^!:G%M66\:<@?UK?_:D9'9AL>_V$K2#
M26FIAC&'*OX?3S :ZZP;;H'S74.>OX0<QJ%M;$1OQ7!]&X=])E-S@%$N/"./
M6] QHN&*3;:^ HAJ3*EZ<4'4<?,)ZAE[#F:.&.S)E\4N">K#@P@1<["\Z,BF
M9KXD=M(/DQ-2E.B]BMX[K<U$!7\FGN<)#CRAB7!=@Y!(?L9H_'6_>)5;-D*(
M$;&I=V+K!&BPJTS]574D5!%$FK";P]OF>D05N00'YM*D<]<#BI_-L-1L;-$0
M!.ZR#MWV%053V.$T@%GR'^T^:@&!S]-HPJX=2)&.2[*T=9@,@LN5G0+HJ[D(
M,V]Q*?23V(*9:'55Z9%882%"'%PM?2I<#@)WD3*C5)\TBZ,.JNF8U"TGI=1!
M0&9)J<U:D1<)N>^*3')/Z#+47C/5GBT]L'U,A^/;$=$F$ODG<->+9.)-'_;.
M>H>2VNX \R069J)7$:7;>L=2=U@[9-%6<6<UN-<S \<8N[?A@\R8N'0TVDY)
M^()/,W\I6SCMM*!]Z%->NSTO_&-04FY\)TM#(0BJ8AU=E""IIC_# PX)',()
MTHY0KWA()1 IA&J2;IWA5L![G=\\WNK!.S<FM >85'=2$C23:UP@+>C)Q(9+
MTX:<&RJ*?38<\=5V^#47]:BPPY<E+V-.TJM^3,%VG.3Y*QPR)MY?G>&M+IB?
M2&]QPJR/U>)_H0:*"@YM;"D0*;)!E6NOC?TRSWJ 3_&E.>N.:^GE-G EXQS^
M@P#L)99*['!L=QWG8#9&@JJ,-'(_'2(BXW>[C9Q2LFPC#&G$RX:=9"N6'M\G
M (_DPA2>8*J"8)W!3R-*_*&F;LD+LWP$?M*N01HF!'ND$(5@W1LGT91KK6JC
M&=.0@KZW6ASF=(0_"<[1J/C\9+T?%OW!FWG)G1S*X59BFO'/JDC*.-%27;VG
M>Z7@)B7/4%Q.\>]D=$>+ ;5\ SIFN#;G3UI#1'@%X+EQJ@>Y]_[,D!$\9\P\
MP<$[_OL+W-1SKHP</7MZPF?L$0&K#G]J?(G^^O_9>]?F-HXL6_2O(.;$G>B.
M*/)8'D]/>QPQ$1K9[O:<5EM7<H]OW&]%H$"6!51QZD$*\^MO[K4?N3.K"B3M
MI@3=P9=NBP#JD8^=^['V6B^^^7UFE>WMHLGC9*!?8,%(U,S3(O]6;\*% /ZE
MDW<V:JT\')F2K(3WV%;6\O?E%U\48=4@)@CQP2BJCY,I VQ'HL[-XL:P7*Y&
MVD\K^-&=?UP/+;G(7W[QXH_L.-I%OWO]DK[Q'^..JOC$- NG3(<4LUXN[UJ*
M9:K_&KFJ)J_22R:RZX<YPHHI)[JC4Z\I0NDG!VF1!%0U96^'>MA5DE*@JGYS
M031E I_ANJC>VMD5G5-@>5#UM)$%N2<>DE-VBI"<<]3U'0!,P* D?W&O)C >
M/BJHMB(/B('%%@]/)T3W%(^8SBX]!T( 63DIFH'Q.GW"SN;-9_@1_X YC>S'
M_COR)!267=$ZI(YJ#&A??Y"KUN:@IR=;/_6YCMCUVA'T4]76(*(@13(2K[[5
MHL?,Q-$/XS/\,O;$.44Y]!_=??WWM:&7PLLP&O"PCAE-=5NDEMO7E(9FJ^OQ
M.%% 1%S8FW:WL634XBB8WU1Y*MW@#- ZKC,1 W(GU7W@:".76V-/<LEPJ4-C
MTNF#XYH[@53ZKR)'8CEL=2RJGM8,U23[<J>U.ELWZ_*69ZFN/&*- 4"$\5@"
MGADY<;R3T0$S?@:,?*?B/'P7@Z72N=!T.AOJ#OC-ITAL/^)((6]?[*,OO<&[
MPU$_'?)<Q)NF8#%!6#<^,F&TA<.KT!D.:.)8[YCR4'6]<=7[AA=%X8UW RC/
MT-577#+S<+:7N^!X44C F9FF9&#**D1Z>QQ'6C'UV%PVX&09!)N%,ZJKU)XV
M+4<VZ(Y1%UF+@.GTX#W$J:.M[)%V1]>^@NL?\;Y^2RQ1_"XQ7ULQC[^?D2_"
MB^%J*=6ZKRI%D!)ZE5GC&J[FETUM* F;3H$M#\0<=E=)=GFWN]B.@K>;;N]L
M@!S9\5RR.4&ZSNUP?MR,/%*!>SPE"#%MW(&]D]?Y_,SICZ-G#-.W7C$HOU^-
MM^1=#&HP$LBF[&GNR6K61Z)N((WCL)?[<&Y'VJG"\>,63BV!<*B1(>NV/+3=
MR01JSM9*5#MG2]F\'5N//EHVLT7Z*:J%R][SR#R:>1V!=B!H$Z=S<72,I7G.
MC6LV[DC%2X93<OS#X5)JV-F4'W_!Z,S?6W03!TB7&4A(8^;^*?KDYRKX/_S;
M5__\65?!STU>O[K/#Z6R<LUY][[<*HDO8Z;F:JVNR+&94:\Z-V8^<R^M#K=G
MX(U&TEOXI/*EI^=Y?IYO?MRY=D4I@U\HD0'OLN6<RNQQF@@6+LK1<[*0=B@K
MR%D9V@D_)<++:/>)R84G14Q)6!"^M ]!UUTEW6[4PT*(@TW9(3.V+J.C$:.\
M\"SEIK[>/RA:"-3'4;W"\\+\>Q@.)W9)ZXT0M4@4I]*72RW>!";Q'1<VT5@4
MOJ#'54GVG:0O=6E-"P?\[&7/R^&9ET.DN[=.-C$5Y) G3=T3#?<'6XN<M3E/
MY$<3#&P)DXWI,W59JR63&:;LQPI-)=R36T. B70>SY/TO+MM(*C?=:PC4=J1
M9V9*BV^(1K6L<:KX\_-D/3?Q1;T&N9IF,J3OP7RI-3KRKJ6O2[.F757OKX(S
MP]E>P$WJ;K-B)D[.DG"_J+%2^QK]>5*?DQ/+W!%"$=5VZE6B:55N" 2*H#;L
MQS.YS$?).W#\@D8?,8!SV7E5U>:]V/8Q2YSK6T61D-D\[_S\?:)Y^0FU':D=
M1&:5ZVH8M#/[P2QX.#A,1P&8=2T/D?X1!8$"1LLH]]5XI<WWL5=5(CDG0M2S
MS<L;CLBC"+'@SGD;@M!Y4A5E=34.1EZI'7)/S$?'Z+F;S4UKK6RI0N7+$JK/
MF@H("16 M=]*K[ZL8VV]ULZU(K:N%6A[:]9"MBDE]2?PCIQZ >C-#(S6.O46
M>:*.J=4,8)R>8GT*A]!S)2?4#G=22HC+*JQF4I9H.X=4]?-L9/\$/ 7H:(UR
M R%A.(29WK_&PDX#'?T6!4F;KKP_G?Z>ORT-/N8&1!N_J;C$TR<3;1IIA'YR
MG!^S>$12[E*9D2(N@)MRMR#YC%:1K!.^9=D;XQ3!A-MCV$4WQ-BT2R%<,Z#@
M!Y]Y.2M^N7KKMO+,X^NCWU5D.4"]+_*5CI#2(G#I#IJ(T=D#^KD$EID118WB
MPL$"[^\,B !8T*J4!VUC+JZ, "=R\#S4.Q*VR])P\)49H#$R*SB\J2UK\:4-
M>5N9B!0F<J3BYQA46'$8M09+(&8(;OHV'3T7G;3,IJN=F8S84#MQTFZL#;B:
M)4NMFSO5))>^F=B#E!B7!#2,E]K5>DT6.+U<O?1RW^V:<0MK8];+&J"7SX[8
M&7VBC<T+G! JU)CO$-Z'-3B4 -\?:G!Z4<:;1MU2B'&,IX+%JY\!+S4APFDG
M5\$H-TMXY>2%1PDI(2<,J =<*.V:+[,V=M'\F&DC<U2TL^E0.$X+#W!$LDTZ
M*-4\]+$A;O'TC0? 4J'O=[H)Q>(PC!3^W>]7J/Z*U;&S,147E&G*N@KGSUQO
MV<_"<A^7)3HUZK3,U8^QT$%VIK?<"ZOFG,/X)#,66;HK.Q1IEN 0 75%Z&21
M05/T<;F2_HBK]D.UD:Z(U7W9-4(,6HHV0#QVS]/[[$S_0,Z+XA2Y'.@^I;BS
MLA: ZY$L>3L..X;4*8%1]% 34[_E9M4(W23LN)Q(YPG]Z!/*7%$T9_?E\NDK
M4'R>-/;9-45)CD?Q2$TY=S>S!8NUV/-B^*3&NUP1Z\_JNW#"CI%'^74]B-36
MZAT@5]<'8B/ +M[S9[+[TU9&8=>:V V?-\O(%^BRK,-<[81)<6BUG1:XD^ S
MQO-#(^\J0X;OJ_!^FYB3 SU"#[9.QV@*QC4A7M"6EO8,'OLX!LD1Q[F%&2G8
M30;=5:JJ!NR[7+7B_M'S9#W[9&EG.#C_VKMJ\<"P!DR.#T%8(F':D!-TG\76
MCD*A_W"&0O^/W&\N52IYT9L*I ":#0T6\I>Q.VCR!#GLV)'MDCN43RS?+]?Q
MSO7EY\=P=-7MR$5/&%+JDJVZ4T^/_IRQU)0^6RQL_KQ,M50VBNGGNJE)>C Y
M1JQ/91TW2!080_8\*E,8.B.Y&'-[L[3(<..@G;XR_.CB-5*P,VS8OUGO@1T7
M+>QJ,?<$9OZ)955M$'L@'SS3-5;PD8]E#\+S+3D# I+P91DN0MOOB>^7T..#
MNNKS0,+8=&I>9.RW##8P'&.:*5P0<#N5^N@/CVJ_FXY^0;P2]_&XF!D'I>A/
M=.M<L5&X[QY9:V,_7),]X;U':G!#1Y^J<PD973%7?RLL^J>H;/V^O,9_]N$^
MP8TIDOBMT":@$/;=56&JR684T&;H!A5W*!C^,-0]7S-8H)9_')9EVVW>5]6M
MM@T'0RRZ%)2>XFO'.!#KQ2"1!%R14LY/-Y5^6^O[TO; [4H"4X[$(KN=<6VC
MF;MB9G\2I&X;DI^)RA)/GP#VI(V_D^HTOZIHJFS?]R5S3*&5@M_2O7UVNP=[
M) LY(1Z19; TD-+'NZ*]_YYU?T1JO#P],9>::&.IJ)>_%:+KD6%LI&POF"3;
M9*9:H@28&\HZ](E0E5UQ=I/1GO7E)SJFB!@D,4RDMR3H*+\"_9HG"O/V&H1]
MO(0Y*V?)O!)\&UV8*"$1Z.X 2Z*RX@&<)V'=#3=B2<G8-B.ZMN2;TKH*&33J
MD>8CE71-#D7DBM]V1H<3S@)E)S3P$;L$J".?"OG7XP6+G!WC[B@FEA)$0MW1
MN:6L&QEIO^STJ <G+2UU&U8-(>&@4TR+*]OR1Q$>6]G+7H-T_:?7;_3[D2(@
MN4)P-M;@]4-9.-([[*@ ^[XA HFP[()UV/=:,9;5[JHQV8QN"1MB8I>^/:/3
M-;$^% R:\I=&LS</V\&45A*J(S?JY(;-O G8^7F'Y?L47JD]?'H8T4JV6[<$
M"O$X*=XW_%]K".-T#C&59Z6S= ;L"@ LRF*:W%9X+8HC^I2+CZKSOH1%$5PB
MEL4A+@F?RQ0F)S+_"PY/PC6F] 7\8V*SO.[/I>[GBP;KGDBEM;"YJX9@@,^Y
MRV<M=@3S1&1MP1AO8\MG&_W$<N>D8H&A8J]CU*\1#7;8<UTG/:[>.0K?\*P>
M8).F#\ZS^NRS&N<(*4IR9EK&"?00M*G6714EP:"DPF4H'">&2U 5<")!!$&L
MZYOI)=.F)SBG&8KH=VU&B,B(V::OT2(S03EV!,(*,\N>"(N?5\CSK9"^JMZS
M?,XO8[,VMC[V)-;U78U#?]V!]7[G9@FDNTW%&H^T)LZS](RS%.60#>DUD_LX
M3\'S3P&">HEASRPJ'_$DVT)$JM7DYDH#<<?)VG/,$?[@L!#^8TI)(:,TGB?K
MXYBKA9@T]D[Y>%/2/I1@2^,^'Y=]$RY[GKMG= A0IJ%<-%+L6D(@;TZWX"VU
MHG!+%^>811X9_[5U/YF$"<%>#G7*V,VIA5,I+U *.[9X:!:7ZW:4N('_ ^KQ
MX!-=44KQJKVK1!SQIKZJ9P2 %^I?\U6O4TD)/K'R]=+E]2/]4<(#*#6;F6:(
M]4Q9)GXMM1U)!BI+.15>F"J]7'1<F;]Q+D>TD @2^NK[RE._IIF^-)_GY_A4
MUO5OFI^9ZJ%/YOJAVDK]" G>)^1Q43SJJ_1J&HE&,:3^H8(4/7=2E;%J%BS8
MM?$%X).="&VE>3])'_L_:<4NTOER+:HC@IVVD:Y2T!)KO9ZK:BITLA[WQK.9
MO&/431UNJHR?>"N-5)QA2;G'DJ+=Y4HKSS.SUVYG)6'J?G4-;=0-9SKM^]/-
MDS6C.V(P+?7,<]G)E?B9I(NQS151VJTK@C.%N=1VLP*1+PK%UQRJWMB.?2D(
M-H2+B$+*SS2)75*.-,K3L&&X?DF+58N0LE0K4_YRU:B49_F,SCN&SON7SP>=
M]VE&R)*LL:*&?!U@W"HQQ(#0N)D:41:+FS?MMQ6Q*H(1!4L1JV.R0UE:PGC>
MTA9\V)03\40>7YP4928IZAW8%WV@KN</ZTEYL\OBD%O6QZK8M24? A/T*#>B
M2)6\SQ6ECYU 2"-0#\I^PL2?TP8?;XI\"U3AH22IET15ZRKQ<LZ3].PE)<NO
M:5-;ZAV=,Z,?#P4?NW]'5<0Z%\R??]B7<#"3OI[S+#QS64"4>I]<%V!_-_F>
MDB<AXW">N6>=.4:4Q73Q>;2?;[0-M=&'$\+\IN!'7;>=*%WQ3&SK0= ]R$:?
MY^2YJV2]S$5ZGDS3>.?M\7&.D0=J6SY=<)Z1YYL132%3.3+$Y.?NRV?&VQK\
MRY#7*?SO"!3L,ZU8_K M<J6UWR(QRK6-OMHQ^G5W2."6UUTEKJ>D8)5D7(@U
MH8\9K_Z0.JE0XJ82DH]KZ60ZU WU&313FH%3*5?^7*TV+5Y3.'QY_'U'$97Y
MNK(?NA%9.V[^IB\WK2_4RA33[[TX9DZP1-X/43F6ZRK\81WY(*DR&2F.9T03
ME?DR;[K,1?!84GAF&7$)L:]3:<ZQ'U95[;L";10R)<SNNFR4D 5-$4,?IAZ*
MHQ6X/75C4Y>[9IOC\@,M9[8+P 5\T[8,]Q"-U?!":S31SSU%-AFZI*%NO<S0
M^*O6XDG5'Y@3'$UFH/.JF[MV!X)L$IO&9C<CHIO2U&F/V1.,"WY.9H2'F"Q)
MUU$/X#%;$I8^U;]E^L-[W9%8R.7J>S@R*"@72J6J]4M0QN$?\F0@CH'*^H=;
M)\L*^7*"CH][_:GG@_;=G;LR++P;:[MT.X<_6:I+Y]J1])C98Z&IU$SSP@#6
M/3\4UYTW;=7#G@#<8YN6!;&9:SQ2AM]VU1Z4ICMNBFJ:BK9ZV=7<3T_HH(V,
M[Y1BG4>,(0UUKT5PKEX7)N/%S#V(O*PKF87* 34)XT%/*V8# 5D\CA=8]\/$
MAY=IJD4PU4GMG.]9[C,2VGO\E H(',-/)=UBC>TL 8V<:VG/R]41?,"(<;-M
M"F *EJPIK##!+.K,4?_NZ/(]QU7/*^,1IPX((YH)&WLX"0P$*]F_2:%'=(:$
MS0<(Y\P,^V^R5W%5-14GE5",!VR2CXZ#TEM8/'T.\IYU[D?"Q84SJY(&+3Y'
MY;0B:%N[K@'IXHY9HC'EF2)4"1K?Z;1ZR ?]+ X?9A'Q$=KC_2H,0)$!P))@
M0GVNM+E94JH:7W.RU>U$]B?R;X<;C^9$[-I[N.^ERI#?5^QL*V,0.-(12AYB
M/4J+&J8&07U[) V:,?(?"RZ?[(4^+J+EB$X8VC7J#I%?W\)^5-U>'I\\["WI
M$^J7QO#T/U="P4]"$O4P["JE5&'M2V \DB<KC".'!WR/"R@8. Q0*U(!ZO$!
ML8-P2DDAP%+!+:U'WK&/A]WN(+WN&M(^(:O@F90*C0>=LX.V2R>B1 \VG8^)
MELZO21R<RKY^8IKGYXJIE!PI5M3GPZI'K)%@LY237Y%D##KAW2/)@WS,;-JO
M*C*RW![952D5%C8NUL$RM=49,/H/__;5'\^ T8?;5')6L&DD*F1%!"B-"S2$
MI*1EP\QL*E,)6XI]XO;&K(0LM\8,L]E)SEDH>=FQ*Y5S[0BI=A$ZD]DHJX91
M&@IFR5N@+EB^.\OD@>JI@1U$ZSDZ>):^@Y>XJL,YL+YIPFQ>']QG]VVWVX3E
MPUAQ2?QX#0WHB.37/G9%EM3B,27:J^P<MUFC?(73W1:UI$2M)U&-376](?C=
MK$G$1<EKUNNWKUY=KMY)@LZ2&1/A4N7VZ<I;)?6Y*GL D%?]NH9J"?7R4]:N
M7-]4[L#FQ.L>,NB.94I6DOXB-G)D5Z=+(P=#)'<55EV\R^7JC<G*Z&-#K'/7
MM]8X4JY#D+)G=B$M?(=5X,4\B3XGI;F^'</AO!;%GOJ.>[/ZJNPH9^4<7=-#
M:\1AX^\4O'*I,8BWR2"D"&G6RIW9E%OS#M66%8KD:@DG7(I*G=WUIW).'[5?
M/X;YWU7E#)%EX66H"[)6Y*$HG- O^=EE_O.??WB]Z@_-)EB#<*WU3=>&7P8S
M. :W\)94Q588MI_+78AF@L_^C__KRZ_^\,U>.<P*M5+BN/TL>US)WWB)9/NW
MC!R--"VO_I]7;[_2=):EN.A+%%4[LC52HR7 OS?D??;^UAS[[W7[ES".;S\4
MJ[^V'SZ0Z_*WVSX\S<6[?;"N1=@/N\/M#1*;F]6?=H?PD&'*@@GB$@9M.0+
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MKW-.)4$O_FF8PJG3F0ABUMUZW%.$C-R&DFISP,):9IS;IP!9MGBFZ G271@
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MK!,8=2R@SGB+K[KP:XH<^/RG?U8;QSG(-]6[5)OHI21RSGQ;5;>0'PE9<J)
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M85>>==&B_H:Z*AKW-OE\6G*^F5!^D6FYY8X9YOH,^UZBYIF7UP/<'4'.MBJ
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M.$WM3;<7XS03YYR*[_FSJ<O"2G>6=Y<EHN7KXW.<4AI.EBP7N5/UVK FH4B
M,WJL=PR4I8<XNJ;3"0D3;'+?V4V <A8..@0 F.BVJ>;7KSRS=1EGRS>LRK_C
M:HPE?Q(,""=@%7'/^3HTRDRVY&3M17F! \%$ 'G4Y)[%9#BXH>6-4,""-.<=
MZTG;"F_4I'#\F)@*@C9PX.GN*949TE$ZJ?Q%)8<"K>.N#OX._2<?T1HPRR7#
M];[\XLLO:1[J7F'N2JUWQ0A25, IHU$19.C4DWS!&E?5H-;]%P[=2#R+MUHZ
M5-)R0/]-^58X#W%X%5GO_4(CE$OH M.=DUNWL"(2CLEL'V$-JKQ79%4!G"G,
M%N(Q<:YYFU(YSNVHSM*7>I&P138>XD &9"=Y[[OTR7C#B-&@Z&Y@QF)RZ.4G
ME8Y59ZEM33O8NV1O6ZW"9H&G!&BJ8J,P,V'5 \I(=8>M2V:D1XAP[Z7'R!YG
M#3QR^RS$XZ*F+.G0>#MIUV7\FWM_+]60FKP^K("U:'2GU^(A;:;7D7,;QI+G
MACBY:78TTVM%F/1>C"R7Z4MO%@Z-$(6U7E(<[GG9M_(=4DD1H=HL0V296P$]
MZ34UKYW$QD>(%(T97A1F5/\9TW#B1B!XMYP(!Y!J;K)I+1/BI][U*'&[PAMM
M)K;%;5)B8YY<=XG-H@M)6.'=7945E?PSI8MGVR91ELODT[H.!IL%'7NCB>/4
M!0&:+)RCZNSZ1H^;<\W[6,W[GS^?FO=I;:S4@D7:9RF,^C6MO98Q41K^=&C5
M8Y$ZR.]<^1/H+U"P!_-W:,A=TU@[<8X7-EVW2J3IM:Y'IA#'%3>1IYA;N%-K
M4CVTLAG\+='.Y&CB]Z:2E>\Y,L-U8ST=3=N$L["Z9X9:SJ8NCU 1Z4[IK"?G
MW#&U:[LSP8?%Q$NC80_H,NN;@V&\9FGD,8<F3#-]WI%QI::H.E$.2\,+]_S)
MXWN5&4P>;'G@]9]>OV$76C#=2DA,)/B;LMN$%_IV*IH27\<(6(1 W\#V?KDD
M/ !:S],<I; ' H^!,=AP8> :%7]M.NTIV1MBCD0!((ZMTZV):4.,5PJOXZ[;
M>DT'?8A/1G"<U0U:M)G)NYU6EC%(*;#UE:"$)86=[DE-W)4"J5T/\!PP[]+"
MS82NIJZ#GF1Z%RM#SBP3Y_E>$12^DNJ5:\BY%%RT!QI0,EEOE%95V7]&3.&*
MK"3L*6E %+%LB0A7:.2TQ[2VZS%B^I,[C[?A+V-<MLM>@%_'F[#M&:0>+-<E
MU).Q6JGRD+OTPFWF8T?6S\%>+40!'%!":$SHVBS)C<M<>'_*JV4D=YF:C* ,
M0L,05P:W5JBU#):%]NR1-TSQM+@8Q='.VB*L&&_GUU+JQY3NUA!WAD9R6.>
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M0A:V]N&B'/@N+(21VL[(_"Z]&82]&X4 N#*! 'I9$4J.U"U46Q1[']D&;$#
M-"]KT1+W"3&59&JQ3<;F?2.MIF/#Q?^-]+> $['O#<(EA5#\2MRHA DW@>LZ
M;DHE9VS9#HX4,9*3#*897"8!\E]5<]Q4*H[8K]KDZ&&V Y6/T5NQJ1%]L# Q
M1'O9,V^GZ_M*2T1TUTVU%2BB=>2@Q!-&@4'$6+:H$Q?*H9-03XHSX\/I>>XI
M+75-"QQY IT!B1H7^RMOM2B5L69]?G[LSW,G<BDLH7U5O0?FN(J\<A&TE['E
MIQRBJH&PG7;,Q2M0?]J#K7,&:<)S4F*%DBF,]_/4,0DV3T VW%E]*I[KC[,0
M17_P<-^*9E6FKW,D*<$B EQO=V"LI-I>TIBWS,&C]&W,UZ+@P@< G!%T'V>[
M4G75.0F/8+9N&A+R$,>J\6WT^?0]\.:\ZY]28CB-1JR?P2%0)09DG>H$T48S
M O;@WM"HQA&&,L+/4LN_IQP2 ;%*5K"MF=/?FI>01TDW(R\.YK.8%W<"X V1
M.9TZO?:;LB,2'\,*;!$I4,I20D:5#U1N>)7(2IG?Y6JF.I4^H*W]Z<?NKM5=
MN1LCT9_+#$O7&KF7M$:TB8W)E#GFX@5'<\#GF-G_B7\%MJ+Z?;6K;UK.0,5^
MFH./C[)X+$? M./0UW)G81)]-\248USMTKNKVT*=\\E*UU1EK[R@R-M^L/:-
M:0Y(\C<(PJ03.\LCDULOI=7\L22T9)\ZYH^L39HI:+8D9\00P\$09?VM<KTR
ME84P\*$-3PV".;+(^E$*D'-RS/OIA271]4\I6;L0W8;P)&'D25]%NZO"FT8!
MS?A[)/,M_&E4T\<O3Z,:9TYRO_QBQ=X$#GTZ?\86;]W:(,U*[:M()&<\PL<;
M4]D-"MUAYRK;+E:6@!I#.0!-PUWN92/NLICE\1@RXP0LY]/=%3Z'T+U%65]H
M<:3TY4OGRQ/.4P%JDS')N=$G[NMB%W_DH$I$0M(M=BZ;_XJR^;^<R^:/@KQ[
M5SZZ\'#K,^\]1;L[S^/OLYO(]<69.G=U"B(S?R#-9?$)SD1?>*%Z@]'(G4YS
M,0'58Z>7OF\<XDO?/^:N&F<6S3CEPUH7]?KG9*RN-K!&^BQM,I+W1Q@CA>:(
MU%>:1*DCE]R;*EQ;#IBI&>YT%#?0YQHL6Y+PAG1/GZHCE4LK7%($GKZ^.9D:
M<B</*6[<RGJXY%R/Z"K'Y^1X;X-+:KIY"!AYY6:W/X&C[.B&?)6>(K'0N!#/
MH85ZCSJC4IZ,68*B'/[UD81_J=K[UU^H*:_!;_>O%Q^%XG!^7$!Q]X=O]$4^
M_B.D8_/BJ\M_IK%(MQ>V;(9"6G>51F_(BXHH-;QC-)%;HLEO78"2L5-818?7
M],3+^.8\L1]E8M5K$T'9WW#$K210P#'+:'O76(:($VR\#QEF2P<9X4A6;Y?(
MM3 !.BL8S$3,T*P-)^$ZG+/KD3.J%G@8Y7.'(E#'U4B.G#6W32Q:Z_\::TF#
M<K\-A92#3P+0FZ!UMD\B1N5%.:_FC[>:!=&5YS2TZDN:]-;XX8GXRWR=R4(L
MF.UX\C']Y"JL?F #9S(577 $2EGC7!2CY3_3B:0YRQ)?H/-_W+D<SS1CD?1E
M"QSMO,(^S@I3&(-QXP)#"),&5)7\]XQ<F"$(Y2!D.T$@***5X<HXY4KD7T;O
M]"A*DLP;5B)-=Z/:YVHXB$?N1'QR+GXESFBJ]<#R IGD@RB9(=W)RGAZ6=7]
M04$CS\]0@>N\8#_.@A4TBD<&)*!!Z3RE3&6#8QK3]\"B4Z\!D(+!M](E'70Q
MXS-[:Q62!:_5>3U\9(=/B>*-MPG6:UM) QK!7B"F-?)12 6.@_4ILZL'% >;
MJ%L2&B'DN8=TU(UF;^\I@]PS-\<=]4=1 "SD6F*DR*[^4K7!6FZ0,*1'N MV
MAL'>1^XBW#J]==E:<C'>Y+RZGFMUA1U].ZJ0,]/;7E7#/6'/I^<2F8!1CHH(
MW.%\C6@R)RR%?+8IY43Q&[(ZB?E"/B]Y!"$I=*N2W+ONJAZZ<NKW.T*+<+0)
M%U02ZY[7VW.M-ZDT #RHQ!ZHBE) )^:)W9*T7S2VX%C+99:00HX3/[UNN?HF
M:#M)49[G]/E/*(-!7E59-SAW5=B?"@5+R@8N(V55@O=@A11NI*$$QY:E7!YE
M2:;,+9E1^88>[+PJ/L:J\+0/ZL(HO>)CYG+F1-"^$6*.J\R!C<IU%,[L=AG/
M6DTAN9#7)35R/GD(0.F@A)'HM?2,4?LK.>$4S\!)L@TOTII3;]7^]@;$C5)*
MT#=X; )-K."T/#RA#R 8\5Y[-A,:AA.H*?RZ\KCK8."Y<CD\P91>A L"_Y6"
M,KP[*OU)F7 G,T5OZMVH'0-,!]6NW]^TNXVR_EKC[8R$I>]L O<E,IJG@M(S
M/8ZI3HMQYIA@"P:V$_[#!#5>90.-KSCCG+AC'A2#*2SR^BR(&O-I='-82,A0
M]8-630M?#YV]75U%3EU-FH#<U26.4S; ;=B>EIM1IJ@%HCC;\HJ3A71$2WW,
M8?:I;V)LHJZ.]#NL24EQ+:@U$R2:KE][41VQ<RWLN4XBYLK%#I?5(N:!L".3
MW:]EWK"]"211LA-IT*VS&_E<TR2,U@3R/0_RL^V%9@W<^=6@[;CCGM(Y!FHX
M.\7//_SEGHCEQ=]3'#O3?R@#;@A[K]'#1(#F0<X,^FT$$=5[B)L3?KVKA^HB
M'$RGXX,(,:7$@IFT$3G)3,[G2K/1'<C/X0<TAI:=BN ^$@N(;\6@ $ # V0,
M-OY*S<(3>6XZYF9<'=J1#Q,X%+O=BGKI]]PD&9R/X,&&DU\S%:Z"T\:+)S^7
MMQ-]6R?-1BV=TNZ7R,ZKMJAY$\"/GV&7QV"7?SS#+H^/D$GEDNO^N@JFI@.2
M2[K?%J(QVW&N;Y1^55"'0]51\Z8+' P/EFK9.FS8V15^KO/'E.R8;I;C5W1-
M"%'-QLWGQD7-2^'7V5-[1E=!&/]EJZBC<![Q9QKQC$X521-TZ-]5':,EA/9@
MXQUF2S6OA9[:;R!X;T9%T1S.V^7Y"IG$_5*KZJ]6^"*EIE7Z%/]=$[O%(8SX
MQ::<DJN?9^JY9LKS.$R2J* BGF9<S[/Q7+-!;2$0^N3.$(TJZB8JE"8-'Z#B
M%B&WR 5VSAH\J]<6(3%MCP.'B 0]1Y0G+N&NO_Q4@G[AX00J0@_E#8Z%^A[C
ME@<AQE,"[A;V;KEWV<<8WH\EYC[*UN]6UTQ=HW()CA0D9@.T9??1?&/%8NEH
MEKSC<5/S,?;&?&GN+<*VMS%)17U6/WB8V1N!F3W2#IQ,T?%M16&YXW0:B=^F
MI\S+WR[?78+*"'7K]Z24'EQ"JC83<($II39$]W33WE,?>FPDHP(RU1U@,8V?
M2[ KVLQ]*NFZ5[$50_A\$1/B?8PZAS95%]YW2! 6_DM2\DNX AP?%:BN.M76
M>)#OQO7P"7\0:T_&6J^C/GL0]'CJEN\G$ =@4,#\:IF3CE?G.A5B]<..7DMA
M$1QW,2))Y^$-_X*^_%-7;BHZZ5<_TE)F:9^_O7OSTX^%TT+[V!,$'I?J0TFV
MGA-0?ZG*F\/%NSW545\2.<*Z#!;G#IOL);%VA1^\_.&E48*6_4I:+>'+A,&A
M)?GE%R]>:'*)UB/17#5BU(5#"N=^F-VZZP<*"&K<!']]\8T0L[(2:/[-;;VK
MTN^)KI!.%S&'$8L'VP(U$52D-GZ'S>7JE4#AY&>1FPLT3D)');ONF;V31>,Y
MOVYA%>" Q,S$I]@_U-Y;ATM!1[;:,"T,-S7L=L$X3Z6QC%ZCJ>YW^0P13F0O
M/G$\WM]5MV&&B;/EQ1\*6EA?,MW&U=AM*@4JH=]9O"[T^LB-6'=<-J[U +OG
M!8$WA";09D&-F;6P">((<OA67F2ZFL3N7M5(RJW9(J2MXGTD$(DV)I6&L.6X
M&GM)"_88'/ /7T D-GYK3@ <I^6[\9;(6E>O\,C$9$U&B;DNJCLP8\H8K)'=
M E<>3-RA*JG$(2=04W9=>Z_YR7X=C(4(; ED8Q"816P(), Z(URH,SW!C[9$
M/!0.<.MQ322[ ,9"A3^]1K 2HY+%?5NIUFS;@$>JA^<IC#IX]5=M<]W!\T,J
M27A V7V(NNYB:(4N7YFN[BIOXJ-Y]XS)QA0?C!Y,M,(A^=46M$$P@[)2F+[3
MFV0PUZ#=44V36UBF5TV#95I$*; 'LK_;C)<W%RTX<1)P7_N@X*+P9ZS6O2)7
M;<,:;-=@/#0$_"-:;X_O4$C&^4C.B(F"E;EO;;]HY_VF+J^;L#7K-0F6WK0D
MJUC60ETE!Q6Q'^ATZCDE6I)KQH;!$C OVD97<[*'+U<_-JO7$(W\\@NV>L7T
M6VH_2]L;-#*G=5:]+@_MRA$9A&%X5W5W1.RZNKND^(7&L0I.EZD9 GOV0[.^
M_)1G&QR=^'0%P=M)5" N!;6H//_<A<A1VKXJ10*SI%42WFM'^#]!O ':JK)&
M9#)NB;2#])"%Z*_M"0 EI![*I"(_<*+UZG\F2X)7B1X1,!+!^[L L+4?VG93
MK(*'.]0<U(<0^<Y(I96DU/P@6<[E!DC7 91@NI[#C^5C1V1@3ME0W?9P#2FI
M4#4(\.EIR0ED.;_&H?OL>*YV-0,P5*CD]B;\.&QO+.QHHNU[RGJVITQSATWS
M'V/87__DMPQLOVZ5Z['>2.:-.;94IQ0^ 4&-I]-9XDP(0XG'(O,[]X L15!>
M]2SZ&K9V*2TPK&ZGC#2N*EOMHA8<CQG#$Y),BMV*.<EWXB !!4W/"G,HL\A3
M9ZJ9,S_ME5>9NTRA*K*)(FUT05EY3+42 Q'J>VL[1Q<V<_6!.)U7_8VBI;M*
M5*++=$3#>%T03??(U,-SLQ@6Z N>QG\Z8OF(NNUT;=]+<2,0]80Y?MV&.(S.
M&0H,;SA<"S;P]:&KR\WJ3^'8"!-S*K:/G^I!NW=3[7"$S;Z$R"M%6T40CQZ@
MWS6 ]CW)6-;B/M&YV:_^_>VKER^P(NF_OK3AP8UX?_0M)\3ZZEKVSU97(S6%
M$W,ZK.^W?WV91G7A#R#DX]!.O-+LAOP8A?);'S<Y17"WAM@SSON9NBUQ:_;/
M:F;$Z"!/+(G)8"0@C./(_9@,8\/A\=OPH+"6ZZZ^Y1>4QY)O9X_U63A[/R_B
MN> 4"P$.J(.K]S-!AW(29LD.2R][3)<#<W$")3I:ZO)O*AK=*[).5RW1G@G2
M1E.1TUB0G4$.+S5W9P<*=TNNJPV$&<0^::1"1Q"KB/$ "'>5)#+OL:HYSS,Q
M=59-C?&/98J$(E#CC[!*=O6V8C7L=>4<YQB9Q,RH11S9)JU=VR<.!H_\3P*1
MSV+5O0Z'%J$)*&H2&;'I<4(A,PQ,>#^Q-T\V-<;RR.-ZL6@RM <S38\HCFM7
M70L+A==VT*"06LC)EP/C?-ULZ>:5Y'K)0EPHHE6VSQF;> R;^/49FWA\A/B0
M+SPDF.2^J203E?/03Z@L"$+#KQS^0E3&OL+5P7'SDP^H"U@C^/\=*0S(GED6
M  [);>DS+*4AER,=&N[".;+&!)Y)D(5E(%@70=CW+<OD/!O/9WDL;9Y2U"]I
M$N@0R,O'K)=_:Z?R=85G78ML"HUTN2^O^<"Y,BLB(0EYN[\(W:%OL%'9"95\
M"&[.KOYO0QSB <B<92[W.U ECT,X,:IE&<P3,?=/+#7^,",GX&LGQV=Z$4R^
M3@6J3Z6L^'.5\6DN5(P\-4ATJ."CJ+[I0"6K</(1:V$A:X?Z V\/&!QV#JRL
M166Q0AG<M\P=4+)V*._43.8GTZ0W9(4$HPD-5)+OE&; !N03#)")3B)3D<J6
ME)& U\(]''3%F8%1FP+>6^%VF?J?CRZUSA&:SX]WXL""K[^K#/YC*7-8V. 6
MM]*@W(ZQ;R..(TR)JF\L3;4MWV"+M_7.Q7/2MJ\V<>%5RZNN+3>^;X;NT 0'
M:Y<ZBHEG;D17I([24>Y=?[EL6TZN5#R;FT[Y?Z<99N>#&UT\1N(F7-RGFPM3
M?1*&_I5(Q;'>+(S3?XW$7*<:3:R E%9R.+/L!0$(F0DQ'JMC)4KNG%NA:(6"
MF()K/L5*C^!"@P7=+&F:'30B40-$RWB><+:-"3XI_QA0%_2T'"*ENWUF>#Z'
M]2%I3]V]* ^!7(G>6#?$[*Z4D?$PK$WU7Z-J+8091NIP7_=1["/E[EFB>4H\
M+/GZ\0,O^/<DTP,5"ABW)44*+L/*HY>[X"!O#BM4+(WF3MPPU_<]*?J*N6_[
M*LF&I->1R#S[I>/E D_EZ'2=$YL737B;'N;EYJY$NW&,L*!TQ\HJVJZ6N@Z/
M.RL>R%5X.5DKL_KZEWMD$WGK14- B3=2YR12+2JA8EX2JQ8S)RH\T4)-M@+0
ME VT'.G9>9D6L9-;'$O0J(R%"<B6J/*?!&G&<:<J.] 3@U9(2R--#JFSF0R'
M"T*TC#UWUBJ;_8,Z39[\2RUV#"MZJV/,H8(<EQ?6GJ!WZ,(>Q*GA SP:"2'\
M_$(AW&V@Q2.?_3!][>1])05&,G<*T8O1HL^(2*5"@Q?/LV^%#TGO^NN/S4X5
MVU1N7@,OLA_R5I/?7:Z21CP"12FIFM:&F#^)R3N8&#EZ8K3]J+(!!$4LIO0>
MW05W]2%HA;>"NO?#D:VYJUG?C^W>GZKFOP\ T!CL*JH=9;;3/++J0_ARS[.?
MGLS%9*&Y@10NRT9^K$R% ,;0"FI!W##Q)USZ4<Q),?MDI/3.,H<"A)<'DSX2
MOTHT?1ZA-$X-4T#'@C8!\.Y!YU:BX8BZR7BSZ+>*"9],7R&E,<710"L*\;^N
M5?.2I+#K\AU0=<P<+F7\M)]YT <OJ-PX$_>RW\ ,+<J(CR#O%,T^QVO,CKQ\
M8L4%O!F[.4CJXT] E/Y5H-)EBU)Y6Q$]C=YEM4F(;RS\]('841[.L'2YJ:^F
ME'_$%8OF"3AT(&R'9'^A_ICJFR*[Y#^O;;/&:[4=RT":(JKH@GKEU]0QZQ9]
MN^/.&EEKC@%V)L:<[*>5S^#!41(E>BRJY"'D-7!)5'KMA4[@>'XZI]4Z%J$%
M& B2!^)S\/!:HX)P)9('AUW2H7*2A=^/766&"X>J7&I?E02,H-S@\@YYC)+3
MIX]ZN^"BK\?D//1[2=5GJ@M(H^\A:;O,)$$87EV3N&Z%)$],*H-:MZ^92&+.
M;:+SR^M^$A^II'A+/ B(>HF9+N>CP_FE#?.R1_W<43]JHF/,MV?V#/B L/T*
M!#3T!1T4H,NWXR=:KX>A:J[:<U5M&6E1<:[@=KP*[TW\XMH,"VXOVLIDCEN"
M70\^.)F)(O!0>^?D7-=WDBH0I!%9\C!L*9 V@]D52I[OA;@)PR%(8*J.,2!X
MH@:JY[O3)6:BO>CG,N0Q+"ERL&00*"0)I\& :&$P=C['5M+E'.M(8M+"9&<=
M*3%1+)>LC8P/L[#?(^DFG&%=E6);66;*$GN:GRN9\)MW1 1R4DA<]]$!F_4T
MA &>X @$]WK347;@E=/VI*&5SH&?PA.NWH)HA%?)2T[IO/CZCU^I*W!+\"L*
MI/UKQ1>&VN(M[[FP335-=&@%\X/A]N()<A'&--PQ-Y^H659V?L=1X_M#)-U6
MC,L013+SUC3,)4!G-!PC,P#NEU=AC:O%*Q3"HA2<,%J'_/NNVI<BID-OGWHE
MF[82*-H'PGVO7GS%PW"Y^G-[7]VIR^^(2YTD9R[P3#J><_,JCQ76"^V?X-,A
M0IRJ?!YB$<H65A3_ADL?V?)2:=5$W]&MZ&351OFVKMJ.7!]C'+G[A2:EG2]*
MO^#OB<@!I];]CPCY=<\&(BQ)D3LDNDTJ@_?3=(3&^V+S4;.VE$MT<)26C\MG
MF9W,Q#^N\%IAZ35K%<*RK_!Q4MF_@WTH\<==.3; Q3ELP[DR?NS@_\,7Y\KX
M\1$*]F-7:]N(8/4-T7K%EI%"A,O5IVCT4W9:_&0N28^>\IBKL'Q$_$I25"-'
MD!]UBX(Z*2*G=Y1$K.6>HD@&KD^-/3 E@UILO=R"(>7S6.^%+YNF;JR&2U-1
M&-\03\)+*JTTHS0B#K8$8!1P>%0/H2Y@<MS;L';I%M?APC>U'(M2<G$7\?T_
MCZR6\=3\,G9U3T O,];#X580N"PD!F7[2O-5+_X83' SW/3B\4B=CGW;&'OR
M>2'$:C_1<;Q%&T4,3*XJAS62K$J>L[K78YQ/8- 1O*\T,Z&.K4NXJ3IS2KKB
MEM617&=A%&R/>Q1$"=MV9DE:7B0^Y E$J4<MQ@^QHT,QS>F*B3V2BCOWG8\Z
M'EF'I)%&Q('3#%R,LV;FPCJF05*P,ZE,^2H\69=E@XM!37W\Q;#]*!/$E!14
M4[_5FL%BSM!#(<U%N:H(<9+0?KO&-PTJ*'SJ@DL5@T]IWD/J/,FEU]+V1A]@
M\_"02^O@/Q5L:-F!J!YS+0E#\LN<%M"\^L#=H)^X&=3ES+'33VN03JUKUO>H
MNF,WZ@4Y#R!V3G)B]W+ULC$J#.W ,04AR^]AFR(T*]Q:9\-MLBV<* L!_[BN
M$F= Z<%%4:B8/F6:C<[K>LO8J1P@DV3T3\"./S';^".R+IH5T:IP-J_N[%)8
M$@9_'TP.C"4&Y:X,AG3L#4I>[HH0OJY'Z2LH5MN*%L7! B1V,21G(RSNE'MF
M\/DU^2X-?FP9R."TA^"I<I7=Z1.ZY"DM"R;4H)"0Q46V8"1J+O*G9Z?-/\RI
M9#+?4%%[0UV;-#M5@V?>5LQ82_LES9K3<;<9597BMJSM>)1.8L!RQ#G-QA5>
MFG1=]PPN,*5N@N<CR98X^.Q?QY-1%X'>X-@L6D$RGPM?_/LMJVG#G8S.&'DO
M0E+!!%WCC&YX>]@!"5QNF5J8Q@3"U.RY7D$H@9>HWAZ^ O*8]%"$>55U!$JB
M8U1+M#XFR\TG;4#$ <>J$QR'!_F*J0K+UHT4/9I3Q&%Q4BW)\-.GH5CT1=TH
M%'(-)&0;MF,L=VHL2EG!4(M1C22O=A5E19)(X7+UUW2'57>Q/JHV^Z$G+X\^
MMR8JN8M)VQ<T\S.TA:=F9+(^AOQMI9.IE)B&9H->O+.6&BQR7 DUM.;"3?-6
M49[NZJ:M!]0;NF%!6@TW$XBFG:W<7H$YDPA",_<&S(DSUR]&;QS?+:JJSZ2U
M$.V[Q!92%;@7YRJ-'$5PU.!T>22#U>=W^KWQR71)^9$1\ "VF!>8)^9NEJ O
M6VFKU:NEM8J3.5UDB<E4ZPXB:T^/@P+43)Z#B-%WN^F1A!0!5[#HZ%%, ;?;
M+N3K:P\P_?(+R?.C_D_% 4Y7A> 0I!G8D%0,[KD163(,-.27J_^4T\=E?C61
M&W/,W/;(!YI_CDBYX8'3 WF$P71S6Z4,S^7J.U2O(X#I@9V(<5%(3-B6C?BK
MFB6C1Z%&+BX@;53D!4":6\9BKEV91<%-$Z5?G_''F!)Y!!U(=2N(B6"!_O3_
MX_)9@@^.^1ZDTM.$SXK@W-MV5[>+:$RO=&LY0:".-M51G-D<.M'!5!B>^/F9
MRY^KI<P')3G'F@?(3&;W,)E7&H5=51[@@B5I%7D!Q47XYJD84%>@MSP4:O.N
ML=4"5M^OFB!8E(H%/68.5E@/SA9@V$M!X= J@H]I-L3N$MWAA-XJFH9S=N/1
MG&#3G%[R\4)V;U.%">VR+FKV"\4B)$1>S;0R08[Y=<EL*4=187,=.ZI4UAK^
M/$&[MK-'E,/9<E0'6 IW.M QV1QFEIIJG;GW46C7%@*Y:B&@C4?R*D7<[,9F
M5>XN5^_:O95QCE1B^[$W]Y@>L+=T>OI4?GQ9H]YAA;4<S#KW+/''P5+=^:?:
M45V9N T\R[3)_EXJU.&AK1?+/U15[:X2%)>3%X9?&#PMJ7P,'"-K>*9$Y&$T
MP_WB[410,HI?/F:2%'!/K?MUE^,P>?P-#\2AP>VN7,^XK:=5J7B5K9S89^Y%
M^>YJ],8?.Y>BL4S0O7LE9\160W=KE+\X0-4O<4&B'^>Q?"AM1'!M&":FD# ,
M;-K.F\(M<Y0I)50E:2J77$L_;7O7OE=XD*,RY$.&34WP6N3DD0-G3 X*_9!:
M^XUOZ-ZU[PLP(9;0'L:Q"M*(]QY]>!/.2MF8[OA/J,T02ZDJ@EH)6A?%(GA/
MC9 VQICC4+ TY7TPKF@Q:QONM7$]RYI+VE>;@TXA]:J1J^T0@='M"X^HLM0Y
M9*_AS)*;0V\J2^'GX/;T-7<K":V(.0/SHRE(=N2XX6#V'H*]JPP:$\$TLK8J
M\QSH.@YHG?4JE-)WH&0=UUU8,IL^/F'R8&=4RC%4RHO/!Y5R6A;=UKM!X1!K
M(S7@N[\?JBJEYR&X#C(^53&;X['>^G* (!7Z9ROVS;3(M$G ,*3*!I#*3CM/
M_<474,%Z:9"NA9U'G7PG?N#^P#EF6K0;0OYU)F>787(>=3:0$2,K'TQ2+>I2
MPPT\,.1-:DT?+Y'T'NOG<_XM_7?,0/-LI^[/(]L"E>5?[/M3F#B2IJV9KJ -
MH @;[1QRHM[A)G#ZQU-((3P0&SO$PC(6X@HZ"AG.HN4MG@1&86N57>S&S'A<
M>--+8HU '1)_.S#0++W!'-C'P?\%MS7)><Q$V$K8UE47DR8\_4Y$R#_\HI>K
M;T=EB?%Q29(,U%I!VKP?IGLMQ+2QF,;M6%E@HLIAZI=)(^ZN/&@RU+HG=$<?
M:0GE!B*E [/^,$?M[MK#R"Y+@#KA$ ZWYX1IYE 90L#36T>T0!K[1>=;(M%8
MZ.? -CQ7C%>]CY@VSJ5CWTM)!AQKY5I3/S0T,9H[];V9\!>G07#RNC%'K(#"
M0XQEZJF"^;S-\Y/%5<X:81(=>)CR/@G_(PM+P@I@F0-_1EQ9<\F(TK?4? F=
M?V!DJ">0B)QJ"P]:WD^H'[=UM=ND(D<LQ(*WZ >T(BL3$U84Q2($-2?6@,+V
MR0-M?I&=(]/]D  F@XTR:-] H([]V<GB4%<T519K3RP%(O':QVN.P7"^"SL6
M1^;#) #M**3",8V=73PB5/HV5NACT]'"W.G"L47 O44K HS2RQO)'=>E33/G
MIBH[-KW[UFQ4G(>NWB<FL4TZGKA@2P:06RK"W<K=H<^$=%G]O;[38%OOSA@,
M)70L7#*%#JAU97UT-#S$@0O1^9@?2RALE\B:3KUJP 5OK6\#%7"(;2)MF,/K
M%(SL^)6XX<AVG7:/'W4A9QJMD^1/E"$CN]&-MX/O*]%BMO6E4C-X'Y_7*O:.
M_HSZVHX_TZ]A$?IT4MQ=4F500-"4MLFPL$TEA$I",!)YHDWK%[,B-3/*05$O
MC52&PFZI@%'%F>J[:&)?(>5_Q.=/BWY)Q['FO><*L-+AY/T+ZY*$3Q_,SV@I
M3V$)!15$Y'^9&0)&K)G#J+U[=!?Q;&9^! "S_E(A4TFQ=1-\)())5<7T;0MW
MDOCM$\9A9 [!_K8>[#05VUYD@!,NN3(/PB:VD0('H( /XOL/ON&: /[Y9N6M
M*9[8_,I@ C"%]Z\T**^D_#YE <-WT2>UYW9O;=S7RKH+TI:I8N8I8 \K56;E
M,*.?>P1I#*NPGR]L\9;^Z3>> 0>CL#OX/+%:.JTF<\H^?+9!3QK33H ^PI<Y
M[$R:!H/76N_8AL?<M'OK#/4M>FAR).365HYJ%6=T(G:3$K0/<[(4]9I"@D?V
M_R[2OW!J>L)FN7X"N&@.=%,<%\WKB]6L9)XQ"7 C] F<I(]D_PW'U.TXR&H(
MU@(>QO'BH/,6E6Z4V2IDI9_ETS^20K2UIXDGD+*#S1K"+%"(O77&D,QL0&>5
MV^><.&GY"QM(N#L7();3U"#E$("EUM)CL[!)Q3#JF;P2WF[A2K,-'+^3;.'S
M]#_KOD5P*6,>J^H.:<[[.=*:KA.E(']J)J'$>=J>:]K@K*C?/..K+AO;^XRS
MO@^_Z[>JC3Q[S?,T/N?N\TQLO.<@MT?_2A/Z]!DQ%UZ0HNX,5N:7X' .+% B
MR6%)<\Y;9&K<2*(DH Y[UV[4#?0@9P'SYUX!LP6<:(@3,K53]^0GRI?+&:YI
MKF'!=4AJDC,IKU+[JJH/0FTN[?0&GH^\?NYQ)!(T>2,&W>UI6XE^E_-'E4>W
M BA#8?V@'6I$2BSEA@B!3#2\AJ?BB(:#0B%VN)=LQ%6UJZL[;6:;T#VD3 W6
MB_2((9,&4:Y\+=P.D$4++RU GS]8[.8NQ!+.C(G<Y5.::F8CW$<&N+[8L8U1
M),,G9L<HR0)%P+Q2JW8+>$%K6O))N#,>Z!@>Z,LS'NC7C9R+A+JN%$R=-B3'
M&E.Y)@/&J&%J[_)0S,B(G;!!'R&?)ILMA,^S0>#?>7]_/AFL)]:"OL=!18T=
M9+/#_]NT: E!%3PL]RH=EA,!BCJ.^QR+:61W3 3$Y&ZHV.B):+=:N!J>:@']
M_,F*-#-EEV3(7.>H 55RTGX50)S@J&0G4 6W&2'AT%52[$'Q<BG;.T<Z+]V
M\HQ)XGVZ:QTI)C=E)ESUZ8^+&=1ZO-+1)XV]GL >,]!,3CETW_V&[;RP<6=V
M.1N:LK]9;7?M_6>XFW^:E"JD-:$2!1!?5Y]@R%$.];@Y0I(?)Z\%=)FEGJ)7
M=:_E<D- .,#EP[/'R1X6W1&W\M1JLC^.G@![(A$TWDYE@>9V<*&; GU(%5']
M+N0TI8 T2@5HR?[.PQ^K.5/#L ['E+)*FPFUVERDD$_<P>0M>?)*3&0&V4AZ
M['YUW]1"Y=!W1"0D3)[Q@AK%A(4RP39F<#^F%$ K<WMK7>0)0I"N^J=@_<)"
M:X)C CFY^'E.;X4(BCLZ9CL*K:]C=57VS#!5?:A[S_T:*19<EXM3,GE .?.T
M_$/7?J/AZ)0P7*G%F?BKO&OK,*#M() SDS_@);J^:<E=X&X?U"-W0CJ&*NP2
MX,T#'[*U_U-Z"GJ2:6/P!:]R[L,2#$)H\[Y+^UMRC1>]>I&D/>^%>_\]'\D(
M9-'O++I]^CVFEPD!=GLH=PK ('F=B /+ZED,IY0KFTD.:]U4&E)J"6)&B8TD
MOA(.O"U;[QG'9E!*QMEAOUS]+3PN67O"W7E]0CO=YSNVRZD=S'(L//U1YI +
MY( M,K-V?GJXXS_,4T&XX&1A\I.GYFYVD4Y<*B;M@)9Z]*2VC\J!3!>5PZ'+
M:AJ&:G_+?(KM!O"8QPR.AV3LPI4;KH/LJW!$;)+NTA58_XF2A;N2YLS6@QM3
MVA>9%#]'YY+VE^"H&<F,>QIO<S/P?QE@F;YH0##*BI4[VJ9^+3%QL< DU]'E
M.-:0?EJ&\8T=&.]]:U\\'R+D>J4*G7>Q<1+<T+QN.DJ3;5,WV;?77NT(QIAY
M),HYOQQE+_CJ<XBMR]6WTL!CB%9=&WS\[\2=8Z\RW 2-]+)F6*S.KQKG/HBJ
M M>%=)[+Y-MA:H,?(OE.57^,?<&"=?..I+*H2!YMBPN:]BH>G1/=7E36=63*
MZ[,Z&YOJY($8DYOP?7<5396B=0%_&X)];:I#+[K<;.4)@DIX-!:!]?*N=!<[
M &A@2=7@6J')YO'YIAH-M!NL&V'C7CP(L_C="8^TQN25O"<R!P@)M6D3LQ7"
MJ<_ ,7G4_GNHTUT5%J=-WH]J<A](EP&K:+[+W?6V?ZK^ /@X&W! #U)+3[SC
MY^P>F&DU&7]C-W[6>NBBT@<R"LYT=B452!RJ=HLVW 35_,QIBL\XY_C#0PN.
MYX07.+O"/52(_2J/QMTW_D@W5-?3&M_9FJB)8A*\;^+F,!G,+$'HI[%%?YDA
MAYBF;%*VFKE1-(>LYMY/30C(@8N6].!Y$R\@BU.$P8M<7U,%GHSOI[:(@KQ+
M.G6'A#MCYLA=DQF,RSP>B-:L)5!B>*\FON!8.)XTGY_,3'[B-JJ\I/W1^W)X
M??S]6G.LM5@,:3)WLTE#[N")C#6Q@8<>3:],JK'<#_DHHRX*?LM<-OR0Z>EM
M=6Q@]-F:A\DCXDXQ6(XBV5DRRS5LV^Y8XT7LTD1@I'E$ >AC8]57# "(OSR!
M@^)1-91V4(?(R-YFBOYQU-"\PI2.4)!M$*\<9R Z(7:C<U7^6%7^G\Y5^5\W
M<D=HLB1@Z^#Q:B%1K,TBN8V1,U(/";B3PUJG/$R(0;FYR7<VS0OU*6PE+6\R
MKV@,7[EZDJM8LFE3N5VG&)TQWQ]G>/BH5%Z/BP ^%Y:OI_+8DT='BJKD$'35
MP "XI(:OC<WB.$RRJOHYV][H.@D(L<WO4*397LEGS2@&J%^TU,#[R4&)6LI(
MNMB(R<4=6DMRV2D,IN+LO8(XLO&*SGB("A3&J>C=22?%%+;@?-AB"CN;&7M4
M&5&D2>>7,B'YH\% %.0&PP1+K:]%N<XYQK)-D]61='8.-V9J[F]:V95<L.7R
MQ3[RA,"(2?ZPIW[ [K8%K4#L)6A9G6[HJ970B4!EWS#$I:OWRM_)Z)1HKPP6
MH394\TRW(88+$^@J#-G+%J:>(/PC_(=PX ?G:7#]J1&T6_84LTE.,QVI9 !T
M;/6!I3RD52H:.J&OHRRD\G<</!S<'RL35@%R?^[;[CW6]N@E%*/NU/58HJ"5
M-<16'R#TJMI>^6M0BZR6L+5^BM^UH@)^4V[<(IB8$M.6RL#!D]NC<5@;2XU9
M_-;)G7TKYR,_J)V0"?E#PC2$_M[\QI+D@&+K! *0;,.XIV<,I&LOS<YFZQ27
M5S 2"=@=VA[2>+Q,J!A+<5?=3$(URS0KY]=&OZ?C?9"?^W1[0B>4M!XH4IBK
M#+J'%VJ1K]N&O'PV>(ZTT9F3$%ZG0M[AVIL6HT6&T70S!58!*0Q7$\'J"'Z2
MJ5NISX,A]&:+";55.4O'_7+U'4AYN 3*=0CF*E"M[QW20E[ =^(L$:U.,O/)
M6Q6/$%KVN)X\9Y3E&EA$CC@3J5('J\C-&6PAAXDTF:P6%(3H]<6U&QO]AS\:
M_/(%G"WNFZS<Z?,I.AOF8?39]F9Y.&0<=N4]>Y+*!L\78RP/(_^C$;LZ".LE
MAXM8_4Z9H6G9TTR=W6 E$TI'6N;+CQ[=0.44<Z\]-53N3>*"$-C.\EL4V6LL
MJRL]Y"N=NA]JJ*:$K\=9G/3$PS3>=RUTUG?$'\L+(HXM8',TQNEYH><9S61E
M5YPCE?]TD#7GV<138E\1&9E![?JJJ5M/FU7P$J/E3+ JRA+S9:A^*4[+5=UF
MO'XI]QGSQ&8"R'GFA7X6@07Q@W#>['8*&0KC5V^"44^NA .3W^/(:]B9/47#
M%7-.9>96)1PCT_2P,+GQ(,D0@74L/#VEX*_1330P-5ZPON  GZX_.6JD-+AT
MRM-869.=";F)BY4Z5?Z 7M@!K'XC_DFZ$Z;+_T%VYHD?]4#8X"%A>G>IA_?Y
M;F)_6+2%B-VJTI\[R$X;^?#D+;5+G]W]'GF/H>(E1WPK5=<H4G+.'YY92U?
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M1^]B,'0L/:SWW@1H).!."W>)%*4^G-JTU>"=\AH7URW>S:;8N0?X=P@+R@K
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M(:I"T0C\45B7%SBVPY-L+XF4.F )0D^1"YL>J0DFOY-U7[3J@&*Q]X=@"Y'
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M=QE'3.-+DM<!3J[@:[FW7>&0"$1E;W=?)L*EB?_))+.G? /XW-OX1@R_N%*
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MO=C [@:PGR&?S&#UYIDN8LRZ&.QQ@)482&?TM=<??-_=6)IPE'NU<_BWD9$
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M+,1+ 4,FXKKC2T"3.^98W/5G!FZTO.<%4"/W _STF^L$"Y!;%.<^FY^0\&K
MY?W'EZ8SI]R^@V?(*+E%-*>WR+<'TVC1=> .\=[IQ$MV7YEK< ]?>#+8LI@7
ME?/2#3&EEK=LB6W9KF^:\)I<OW++Q+U>H6TZLYG+9M1GU^(>1JRL1-V"DE7
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MT_AAY940K=(+)%J=K*%@X76;(S$4>-1!ZVCWT)T-$0N@HKC//%>\KH%\,CQ
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M C6*2C0>(#"J O$Y*>*DL""E]*)1<?@PKH'F3#7X4=$@]:+DE>3_$@C/7)B
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M_J] @'HFJ-N]="[:E;89;JW( 0D:N2ZY$P7B; !"P0JN>0)0H5WCTDTXR[!
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MH^[(?_EC/#\N778H\INN/SSV/;S" B658\%A.ENH<L0C#59CMJ)5::@05)!
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MVZ:Z@OL2Z$#M'(E(,3L!P!AA6>+*'%PFUN=(O),B@Z-&V3:IL*,1Z)Y=F<?
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MY=IO0ZPL9TQYM$ZWN<]A-Z:!"RD&6ZGV%_AC*:C8SOXN5Y(CC](J D!EN6X
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M= *=4U!M,G%#S?"?[]-1WJ<#:':,].*#Y_GW3A]7\[0>0&:%=J+T+99)>N+
M<\(A1'#6.IS_=_8ZW9SA/U^GH[Q.!]"L0<%GNWFB%C*,KT\U8KR/CC@C/F6T
M' DM!\[>EBNSC-=<.DB/+!;=?Y+_?*F.\E(=1K86-:&#N;?"F\C*\2"37;E\
M6Z%"$OZ8N$[6"\79YF5NC_ZMNC...F9]KO$0I3&<2*WP2X)0Z*5),EPQGY(V
MH5&.YP>LSSTH:7,4E3^6^MR;NV0\:6&E!L*BL.40841+F!P!Y6.4'!CX-E>8
MGUB%QEY,N+-"8Q^-?"][VWWF],\*C0=4:.Q%EB$VN1^BZ>^&Q1)=1EG<Q.B
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M$E?5J46I@(@[/RG*_ZMJ65JS:VWQ:Y)!-V1]%\F5X")&_PFQN%7%L;^",;P
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M<=CZ=]PHL<.1!.CUVWYH>L@N(M8B'\1B6I*NJ1^S-AKK/WS S,3TBJ>^R;%
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M6T**=.UK2RP@V5^HK?V 746X8._;$;Z0@-7/".9C.-\P8W7YG*TA7P#,1=]
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M0_AFDW!(G8CN4/G9?PDOTPP]M9XTUL5]$VPR3\VX)DCVZ?( AQ('%SPK4TD
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M0*0R'OGOB"HVQQ,_6MM*>_$&!^XB 7R:$CNJ*3%U1GH=H:KBFW<3>,#=/X5
M2ZR>UR,:!>\(;0@>4Y. ;JV%R567+BUR7'\'D1O3GU3QSRYHYLE"W=^ZQM;
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M7$22DL_L]3^&[&OKE+L03/[R:S&9'Q4&"Q%S)_NG==0J_28%,P[,?R%[W"]
M3Y,2?&"L1+5Z0/?I2A.R.G'CT93"M2?I:/9^FTU[7<D-%Z7T3PK<CP7OLZXL
M;4^C!:.HL+!CBP)BGM55"H<ZEEKID])>Y7@SD)-9WX>J>[$5EO@J>J;SWZ"-
MNJE?VE.XZZYZ[A%?(*8M&<?/?O)Q!:.%@G0)SCIJ &Y+9ZKY[Q)ZSLS;0%KB
M3RVV][]'6Y0-V0=(I$M\(\X,"DCTS>&5L-%OP.[,YAW&<_JNJ*#;MQ6V$A0Y
M[7DMC8,_/N8?^*1+'W[V<5C\J:NW?M8$:!>YI$FJ6HD%OX3R:H=\_M7&2A:
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M=CL\U_(K%/YO7WSV[VUR!4BBB+F@[,9V!;&!F[#[74*G'O)&\%+S3>PGKR]
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MO+^/G@#V"RAJ3VNW]ZPR4LM*70K7%JU&6T0!.0-PR ^B\J<=!ORPU9ZJA9]
M!#3^3' 5A"YDM U$/(U-PAL ]LL4$!, ,1R'VA6^R#R]YQ_.Z%$WS=8OZ:";
MZ=YV=?W93P<A/CLN=G"OP0@;5)-4KV9G)]AA#4NL%6 9>^FZ+7\;\KAZ?-N;
M JHNSI)"IK[ZFMH$3_55ATC2CNF!"$M=(=?&FNT+.DH!F'G%M'=I_'OWZKEW
M]>'W^/@K+XL''"@40_C(_8*L9!%_F15DO _O2(0QD0?P0C@_&#H1A;]Y><AK
M.GGE[;5T+I1P_Q+;-_M'C(2\$0V(+M0+IT !A9// 03(CSF'HJ)?2M.U(_&8
M=%4_;[>"/!#Y$LT \14IWULP.N04$"$33=1'M^@B<[C'W'P4L ='8X,JU0]V
M!5P;]409!C:*Z5[)V4"BU:\Z]V.3NEKE<6Y?B@#?6<+=ZM:FQJ9Z:VL]6XNT
M/E;AI^:2GNEB\]/=@=/;2.P,#)6YNUR$);W!07,N"%Q)[>&EQ[^K2]%:[Q/8
MV*U4]HW/<RU4O&FU=*EPM%E;9OLP5P-[9 *,K<2!Z;6^S  \P3JS(UJ)"V4K
M"0BW(5QETZJKMI@[?:C>/ V^.(HLX2_1:Z6 1^3Z=]V9EL\Z[=C4-NYS2UJH
MSIB13>1-CS&(05DXU&48;$\!S<+T2/E/<*]Z/CL9?/ZMLH;Y6/OQTR:#V@]G
MG$JA^<N\2C--?1:0R=LS@? /Z@S^2I;8)<R"<Q&0A%Z*4.>S\H]NSX X8^&1
MW/:UF?./3PNZW"EE:[@<9>IQ9T-!J<.&$SW=U39CAX_$"2 <%MDKD[I/\,E>
M7_VM?IQ5,*TB:(J8I>^]4]5P>*0-%D\?&9P !1<[X[K0W_.688 .!@I#!\$O
M!.08X?]0&:ZR.8X U-X2CH+L%.;,5Z>125%DH7$*R#[8X&$E*1/*B87?&=O>
MWHCN/LDI/CW]YOD#24WEBP;^4QIR'#:=9COMB>%M)LV"/E)'K[T-8E:='3-[
M&422&R1[%43@7W*9 _]W5AK>"Q:?ETE=A0[YNBU,QGP//B$KW#:O,$Y'G7T>
MZF97:<ZTY+^?G</Z8$13Q;MXU,;@T@/MRY'_4(+^/]($+\(Z;&5"^@G7M 3Q
M&3_5)Y<9;T'APD,$]WZ)8]6VM1S%@":JVTY<6LG/HQIM^PM.#DAEV6OC1:0S
M_U*,E%".DF;O&IU)WY7'UV?G"O1E[\;_T>6K9R:>T_>F#'(X?K(3W*5]Z5'Z
M?^B/[F:P-]X6:KJY+ZP,?T37MM:F3)D^?6LZ^F6E[4RK+.D-U(\".C>'=N\I
M$S9WL&R^[*- K*@3>J9H9KI!F-H@GQSELM8Y(89V?RX]G((R$C0!B/%4HA!N
M'>X]-F2M[O#[^>6LI&;[.F*VP.$V[)P&D$8(A&K@.%84,J(PSZLB3TXG:\ZM
M+!6NAZI_SV]EISYT"%$'"P^'RJTXJ6DO!_-J9 8_$+AV:*@IX9"L>?YN]-/D
MG.6R):! !P<C7C+IF(V*+/VYY2LX,RPX6[WUKC[.HZ9A8$=31T=7X( &3V+'
M%7=20,=ZB&YWPADE<EPUXH-\F=E6![C:\4VS#XV=*WJ)4\XF/_&;@8^X\G=_
MK@$JHNL!A50]@/Q9<5/K\'>S(=4%(\.K9_S.8J2)^GYU:7OY,=V.B0W=^2UL
M9 9J0+RZ0<4?3R40I+/&]#_>F5_&^2U?$CQ'Y@&B>TR0&\R*DX6);.TI#S5[
MHT<Y[043H(<X.[0-.8X@^JER9QR8N]]4ATL[W*H;$<5KW>].'(@? +6?4D#>
M!9W\B,6YSS(N5_Z"5*F7+7]4,<S@J<VZ9,8%OAF46](4W/YJ"<N#;GM. 3&,
M8)60.2* G9]:2ER">%>WXEQ?1W+!^04,?O\1S3;],LTA._M^5%B)I7\!_A-5
MY?@:B:*X.UB6)(%4]J%F+:9RICI6N"G-.P+/:".I6DW,U:FQF'@EYU9&YY _
M3N67M/Q"9.WN/G>$ZPA!&3\,"B*QKY/52+EJE[%'7>J\.(X\'X7OT8B[%;,0
M2QV1>_*&XDVGM)Z4H$Z?KKS3X^^'')EU?]B(-8J^.M9\&4?;!7&>+DL/D*Y&
M5,F/%I3*<U]D:S0>8/=?I&7YD,M:[H00Q^EBN',!K:Y6OK8);Z.+TA7+IQV^
M89NMG@9;XDG8)\R1XC>SZP+KL,B5Q4B<JG7+Z+C!M)K<LH3>Z8E,I1CY?4?O
M)U+5=TM3SJV&=>Q<H_WQ.;^9<26:F!W=#CXYF6P[^'"-=LFIY"2:Z/^8 IJ^
M2M9I=2!]4!=Q;F.BNI>1Z.G,FIK5=*NH4L4L?-QS'0/'=+R];H;7*;9;=*%Z
M?<NAZGGY#49O!"_*CT3?_ 6;/6^S,%+VXNUO1=\I/83PL+2'GH/Q)9 !'_:T
M1X@(J53M.M7$7,CL-L+=5B,QWC$%T00)W?&>R9Y%H#L2K0U]IRWL&5P_PIW+
MZIA?#XX$\T"5<>$CQL&"F'3SDY?A_%KZDU+#+6NIV>CG\:GQJ#T&O@O9$8]U
M"@A/ '7>K;4?WD;L0+'^M^2"YNEJ?OX=><*SMB#O!FY:NAUC#;YP;5#01_8^
MF9Z1L^ NKY7)::FYSF?S\]28[U7GI.I9QUNW<^QKY[N;P;W<_&D?/X]U2"TP
M+-E<Y,,EQCT9.T[GY$E/6M4M83JH?46PP!RW/FO@5Z8.0&0^%8M3X36?F@)V
M27_,K09<]WAQRY_'+;78JF88,\?.9"ILB[KQ78\O+#O90H"65*RFM&+$K8$V
M&&;K;F7&,4^X2A5%QWIW.1S=I1%![M^X!3KL]?#,!!V>2"#5# @F_N9=(7(X
M^M=ME<U:I?ZI>DZ/G#/OYT@7M^P+[\N=$EXMD5:2PX"2^X>-_SQ!*$.WF?FX
MS/D3D++1[7E_:@3-Y?TIV-Y2Q^+]I;>76+Y:TW[RZ@$%I;%OM)UK5?;W6SZ,
M*I-.X\@K7OI],< J*K74.CAG;_*-"/V]Y.]3O0R_ LWA5B%S BR3S:H<%87^
M+KTJF,;2EDWGP#O9OTN^#F:E6RI>U>0 W535$V$:I1_U-H_:A-1RAMN-/YN0
MYU?JSE&HW.-8WZ$"6)/'R.+24W?JGSW2::=-$Q/FB]U9!B91O]4Y$=UR7Y&"
MKV=9P9CO"<G[+V>J>.MVCWW#LG%W^%O840D$>_^'O4'*"@A&_^DN*]&5KQY
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M.;X4(ZO>"N R*E@5?;!(']>%!4<Z^"8?;,6(?#"0VY5J^/E-M8%.@/6>,?T
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M8/KFKR0L&Z3#O<B<DG():&QA;[4/@IB/4*'Y*UG@^+-U]:28:#\!E1:+)W3
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MAKJLK:M+VLC[Z9DF%T:P86X.,: #CA#I@-21<N@X D1[A;%:\@L-I /^;B'
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MH6MP:.*B**421.)K7^?#AO;2 >S4<\=2$$@MLYE,N37XY$/16\C=E^L*59]
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MFK?OZ>2*$>%K7/A^SL#!D:O8B:SI\N$L^[Q.(3SOVN&RLPV ]5V?83_17E(
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M+?&,Q/?5@G05#9*F(O46ZE%]B4DS"=J 2VY;/B-3G> ?-*/.8!85<4CPLTM
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M]^>=0!&!R.V.8@/Y]CHEX=+NBJU%YJ0JVB>_Z\\!)IWZ%"NY715ON^GT'R#
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M%?B^(>/Z]15WXBWO\+!K"-=OH4IFR\/;.2AP..Q>(\X,OQ2CY(,FQH)_)#)
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M /5%Q#D@5/H<@).!MU.@$T_9CN DBO1S0/3?;3#HUBZ8)%R$&$<M B<ST+/
M1VI+S@'+-$B2'A ;"LDE1S2#SP$ AW, VAG_89>ONV ?6=?ZK?8<\.]OX *^
MKE'%@-:M?E\@WU4P62C1A0[U?U;^/RO__V[EA(/_7!"RA0_$ME1^(XSA0[1T
M6GY$5!VK"?ZN[,YK^C5$\?)AJU(PURE;BQO/>.FLRI9P; +K71'7]I@[""5\
M^S^,3-@':I.@U>EODE:1"QX*0'L=-V"J&_6U9$ A52IP05]E?=GKK@=[2%-)
MY4!?4N6#A9ZG^._58/%)UGU262%5>M8.)C\8G:,>E#RJP1+S/S4Y0_A<2W;3
MO""6JWWFBA@I:)R\!&_@W%RD$E[NWHV/I-XRJ]X#_R=6_MM_F_E.[TUQG /<
ME(N^2@?=^?:A_7^0U*BGO**_5PO-BB2*6Z.^=]N=F'O:T"MA:FD"2V1M=D'2
MND8K@7.""XVP)8E5V\:E<JF]'=.[R;5.(C@CZXFF^]B]"_666 B!Z_P6$^.S
M"MYCU1_9\*I;GQ+_+MVM^,$EB:2#Q2?:%VB@@2P$_Q[33%VNK,*&..]N;#$B
MTYO!?_XE#>QD^9*TVS#(?>]$!AZSA*>H(ZNW0' !'6!ZDO'911PX\0*[N'RY
MNN/90P6:TO4;K+$O9%SSV!ZO;P+=W%^JS4K3WDZL(=W"(&FA:F-#>2A/A@T;
MP?'PCX-_$H-9YV]%F2QQ,^:\G@ Q-GDZ8:=:83=Q)J3[\S/KD_?!.IZNC7E_
MW6:;#F^4XN!;,1L 75;B_@H5.6MIN0MQ:E?0*XAJ A5"M/1_.X[+$-[);7E5
M<G0(N$6H17H NG6.$*5^@_"GV)9TE8+23;D,_<RK-+7IXZ62/<F ^6U53@$Z
M@^=W* ]J>LC4RCA$.WZ1BQ"-N4!;2X]$K%&GV3G H:JE,FGPE-]C=L9%'\W*
M&[ENSW3E1/N7[!']C@/19CVGDO[=H=O[P]XF,S2"H7_%.8@V,S4X'R-N+L(0
MVD!'X>AD2/5<)> "E6.<%1+R4'!ZJ&-FMZ59I\0[2[D\^P#ZT,=VBHJC0OSW
M!;?IGJ[&OKK*;:)KSW^K NYLP.624;LS0Q2%8$PB;+$>U;ESPW:U7RY'!EJJ
MO\.%]HU;\34QT/,Z4[J9G2&0;LA(!1!)*%N%</U;(D7[M^#J<2&'YC#FH;6N
M@4&^T>/8=L!>3<L800('[UCB4^%:;Y''=NZ)IQ9K-&E)SHDR4=9H?^?]S,'Z
M0(#G%=,UX8^$9MP!RC/R%@X<3C)!+_#UFT0]RMC?TVZI,U])GL%X1]!V5 )@
M:FDKWF'W#Z9(C.0A\A+><B*O@:XF@$^@(;D_@'3 J%JJQ1._>0YX+T.Q2)X&
M5O=$PZX3<MMM  1OU#62 XZ[B]---[B]??)R+S68IC&6-25^G45S0%\DZRP+
M^3KQ_>Q:CQ-!%H=L-;6AP35W98(W#ESH;!9?F4A4)<H]ZROYL'6+4_T[)5B5
M!"6<H"1F>E"K:[%-UA#;ZK@3TQJOY7FPOIH(S3T#4:^0T,O) *$6][-T,@U)
ME5"$VS(Z^]XBLJ&+BMTJH;1')=[PL)>-+[EK>.!TQ<I><E95,,__WD>3+W1.
M/<A:1+<!"V&N)P>;2^;8@(E@A=\*0?SB[9\[N0A+K0TXJV:HJ.A(%O^LH#!_
M^T%DHMI@;D^M\BQAN^6!U;J/M;4-L$+KB^A\&<'1+/H[M3?7NX!%S2<4K<*L
MF!RL[J>OXQ?;!QG/Z/JT8L%RJS8>*K2:JE&\4K\KC3CA6D<N_Z70A7@'MX]W
MLYKRO#UV:&7]YG17=Z[WTB.6NS2*\Q7+=^XM)7VA@_7@"00<%F&.C43@D"CQ
MU"]099S&@)>EJ^4CR?I0G4B:3:=T48;=_1E[.]:*<=8-<%7.3C2.N0/.+4IF
M@#)C60OB2*ZONXY63BNE+=OS'FU3#KQ_Q<_/[@+@LXMC<AOTTU;2/0=<D204
MH3*)RD+NE'@(-J%P2J<(7*+EC>8<K:F(?G"+CIJRNW6,23='#)9_5@!RI:<C
M#Y!9J^J::C)M</IEPC.^0!H7TH*KV>4(ZB^73"@<KOP("J64HE95.L:KGR&4
M]'"9W8OB!#><2#LC1!YM%LGHU%CST]'-)5?0)"9L^$<8+NF@[N5R.-C$K!=4
M8;"]A3&X3JCL7N*$B81D ]^3'[RT>EK]4$]ZZM:[QROQ/:_M/:Q<.W.]!2N.
MJO]]F;!--^.5.C5/WL+YGOY8[D [GY$W/BF[>N:%HO;[9>TG*EH#/8X["^99
M:TL(C,&7AI31_^6V5:_ ,Z8=L *A[$&TKH;V,_-8S*H^-)(_] NEN%5<:R[G
M/36C?]B&]O[#-C1]6N7W/VQ#^0>(GKTB)XK(U6RYP,9SP$;"$N9;T?;[A+W3
MC;. ,_J:]6\QR?\C\/C_TJ!97P$3M OTS@&2U7';\PJ>,&\D*&'D ;'GRV@I
M8>4<$!/F.P^ICJ_9>T#<&UJ8YE78 1K%T5(7,?)]U6 Q3OMGGKI9K6$M^^-'
M L%93+O+I3GW]G.%*6LD'U[&9&6RVBRHUC7<$GK^@FGLX;VE>_OA%U\!_L4C
M])^Q ^5Z6G3"@,I,"%UY2;Z=_-M_MOVR)\,UJG1^#P?,UX</0=&G8_,^GC?O
M;<OEI-V/5/*EXJ?"?:^F<+>E>*7V _JSPHG'UTZG][CWGW >*70INQZI(]>G
M_<KK\@6)&)"6?M@M&?C2NULC!O'F:WZ5H)"=H #'?#'BO['WWE%-?MNZ<! $
M$232.U&Z(J!4I05$*2*"J/0B@O2B(#TF%.E5$%!Z1Z1$>B?TCDCO+?2>4$(@
M(?GX[3.^<?;>YYQ=SKUWW''OW7^L?S*2N=::ZYEMY7V?V3U;TSW;^-.UYT64
M&!O]WV7\T:W7'C:,HR[;3;R9_2X+'-]D=1JDZN#:P_'^LU6AR7=;85>.P5 7
M:I&7HKVS35=Z<1P'JAR6!GE/YE+ 7< @&*H62HN%MX"FS2:)@)DJ.H./]=V'
M^,BV?2^?1'=Y:6"Q"Q.B/'T**G;AE-;QO+*()3I4?QHG81#'I##6('C8,"B^
MTKE07UEWOH7QOL7@916-DL8)8&(G"'=@CJ>(Z6DR-F:,ZM2]52^7TS3G5,3:
MH&8]N;Q]*39XD9,>F>COEDZ)C>HWLTEJ+#><4ZHIN.U3P%%(ZG]E0U%RZ+DB
M"&!KAE)/MFH:J8BFA;Q%JX8TL6U6JZR-M!RH#*FR]MQ?6!>[]>!U_^>;-Z.N
MIMEO[D<CRO)]$3;105474>=:@('!IA^LS%EBKG0PGU'3]Y$:C]5ODH=78RA8
M7_%,VF0 ?Z5:$"C9"["M]FIX S2NW91WY .6ZYK,^*&6+=N VBDCFT8^"0E5
M_"MCO^C$[V<(C"96=5G4#T;IV$"/W/5119-Y/QTDCU.(>^/H/A6E_42&E?*.
M.NG6+W4[C+<@Z4KZ]#Z&90)F9Q;2Q(F61W381Y,K91C=ML5(G2FE%N_)M>Z^
MBRWN?VO\&:3T>37*SLQWH72P?>$3@KYBD!X;C8E!6[<+<P_Q&T# /X1_^R\V
M.(09?=P)/TB@%@N.YY29&)?0IF@W8X(M?I.:OXOU0WZ$M8 8CHF H#.]<%Y;
MB'+&Y*.#F87R>]:@.VA\D:%R:;LO\WT I'(.\NH\R*'!"'=W T0&84=N-M N
MS<EXKM77QG;M#F^1:,A24B0S43UMU5'J? G(> W\OI$!],-+$P%D\UCXDI&)
M5)?F>1'^K77.Y)7E@&>55?5!5Y!/WT@^'I7ZL6@!>$TS-@3]#4)IF3'B';!H
M<#L.&,46''#,DA6V\#1::QCT:R1+#1,?]:$^LNG-\+T;P.-/>M.CVA0#B'+I
MG6HTZ:)SA*2P14<ZEYP&^EGG5OMT1^ZVQCMN?V5NZ92FMZ-M[@SPJS0LAY/G
M?/_AX6]&2B= D!KYFBS?NX&3Z <]B\<<1SSY3TI?[;P4KB'ACW!R3O"XL^!Y
M&*O%E8*Z>W]3*U->XY]BR?WK2XM@Q.)/ML".Q)U"<P;ITFE5#Z2&FD#D[]):
M)8:#*XE7W:LVAI_&9M/>G8ME# ,O_F3:E]XI?+WYWOI2!U)#]4/]3)/YZK/Z
M&]T"_3W7XEL.ADW?Z=_3/.*7JE=8R@J[Q?"/>DRIQU:1_E6=/"2E*3[C((Q"
M+1&@#"2H"V#'CQF?/).E%;SE?%KQF@BPV$X_NDL$K,3"(D&39^OGU.!3WO1E
MH]%7K@C16MJ=[+GS?7P_:.>C*R$(A(_50F?C0,9$0&8P$< ;A[?W#GNPD#@;
M,*5:CULX_0K^=P&J?S$CPQ_"*,JB/4X0AW=AI<>#9RRP W5P9_2_RRW>$ER'
MFKD WW+M[\/6_L;"GO_"-ZUP]<HOS!,!_2V$K@GPACD1T,/[QS/F_RZY^GMV
MZNG';ODO/HA&(N!;P'ET">QW&Q$0JTZ0@/V9:.?GJK('N!@?P1.8#Q$@3O'G
MN[/Y"^'S65$>JR<W,,_W""<$*^"?[6_HSX1+-C[FV._;4_J7XOZEN'\I[G^E
MXKYH"I@0IK["G*44?@5[3(Z O+"=WD1 I,E?S-/( 4-K/\-I2966[ :#/F+G
MJBG@FET;XG&9F@,7DWX=CJK[>[-J_+$Z^+]0\G\D2I("U,;[)\!H\!?SKK,^
MWFGH\Q.OS7/7%W^Q''NCG]+,BG+]RKZZCV[JK9I>7[3TZ!:(5?%L+M4<( +4
M*77^]D9O_:$-X/\U.OO? [:4HS.%JIMQA-ODX%M$@)YE<IW[>C%?571QLF<T
MGI=&0:D]0;T^'^H]?MS2T?"I_/LTU*93__TH-4=Z:^QH4.6GH,^=+8=/<HW1
M8WZD%#.7TF6K\62B;]G_M%#I_WJA(A?[N8G[EYG]3X2,'54DCQ&]$:R=\.(;
M\*R>=UI!!3=[1*BWS_UQ<H?)7M'T+;\.())*"!+9EL)9N"# $<BZ?KD L7E3
MYM^4J_6OT_KOG=: B2W;9.P,0>"0HR=ZSH"?HA=Z O8X0^;_Q>_'ZE^7&:ZI
MQXDM7M'^Z1Q? R$-/+F_0N/54JZ5^B=G%SD/_]N+T_EC#Z#_TV#Y_PY"_ ?5
MQJ<!*HC;^('V<?7Z?1 T+6VR)*%P\J?].^6!&[,+$ANOFM#+9#3R]U=>'X[_
MA:O\E_']"Y/_<Q2'C2-<C2G,)O0ETFWOOD6R6(XN!8U351FI!BUE?5&5N_PR
M,9Y2>'750X6OI_EVA_(?U^HUGK"W1F0:/@_&S>@,>1KGYU#1M]T7R-44K!2-
M1;02#M"^'4_X!'C]4QB,BT\7,D^N,3PW2/Y'&4S^=P\.1$C#\QQ/:9TX[;%U
M' >=,@.5=(R9<)TN57Q$M6)7 L^DM8 0@3G?CPC8D+XXZ3@B ,W8#1W^2N@(
M6#4^SUI8:QZ<JUF6/.SPT8=PRHR.KDP=U,P.5S&5YY,5K\,.%:J(@,#-1=C9
MM8N3R2$"\(]!J$8Y(!&@A,!_22<"0N"Q-B7I.],F"TL$50K,FL"IQ0GX'_I5
M-DXJT0,+BX$YO8$E@%TO0+SMC#5-HR ",A8(3[2(@/;G1 #52#,1<,1^ 65U
M(@ ;=LH?!BZW]8 %G_YKJO]WIKI/N._)QQL?'6*JN!NO6YY\Y2XY.0\%*^NZ
M "^F&?C7(B%QCT%3H_6(-GP SI4>7XJ']9_-_)4%,,!:CU#@<W(BX$ '1N!N
M4L^*_C<(*YW7AA+TSP?Q@\6()6]/$"$ =GH+3 30JN)%M4B)@-_.1 "? !&
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MZ_BS$GOG>7EIZW?>N W!2T*X]I$=)Y$<ZJ$6]B<MWC$9<=%0H3BL--I(';N
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M0O,9R2GPC,E#U\HS[Z!7]O(ITDHY_JJG %QNK=$]#'  _L1%,7&T'V;&A+=
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M+0$2$=ZKS!E]TLZ5&QG 5 4Y:#^!&^W1[BB-!+=%TRLOF;$9MF&\##?5_=T
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MX1):U/-;,4KP;0WQS3.OGH0E<Y.#GX!W/^[%OGM 6G"ING )%,7%BB8"(H@
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MJU*D!H\>E4M]!$S:]X+M!BD'"B'>AT>!U^W2V%%BVTFVS]M=IA=8 :1SC*-
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M/4^D)O^T)OBY[5M1AF&[LBIS8XO;))WBD?V*YXQ9OF I!1#^-C8P#_KKHBJ
M2!=B50T)\R@BH+/>IUC)?'A]!O,V3<]GK/>28]DIW:*([,2F/(,V11<10.<&
M9"0,(BHQI6AN8+#"+6S DB@3UF5&PQH5^+6QKKS!_^'#'B8]!X<:V1[2-'%_
MH8X&@TSL],(B?#<5CIUHU3.EJT63C.P7[Z[J>3YA^;*C'A;X+?OR\RFQS#:
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M5%9R_*$6A>?1@ ^V-$"2!AS<!?_C\TC&[/C"61J02H O@,=_8!;)O'O".S2
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M1<52!OC,R.SE_=+B L?QH/ /Q0I:64$NS@F]_EWUM[XNTU^_Z\\8V31SKP2
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MO<RG+/F&]SX4[,P%P55Z#385HN2@J[)Q&%5T:(?541:F7^22^@6IT2-LEAI
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M;C^K@TZ.V=A2K(&B7)II@&T0V&!$ZQ3IT"^95%;5C_I8!=XR]/[*4+H9\#+
MU'TYZV^:ISHW;,SC'STSDG!P,=I0['H]02]$?%@WXU'V^*15)[%^0ZDL4CPY
MU'6+3HVA@ G8?L^!TZ,@@T$KZ=L6F@6QJ]^VD?,%[QCP;=]^!)2&:,&G2\V(
M(90")708Y*0&^^R2S\Z@]+?6!Z0PK7;QC]7YBG.S(2J,6Z_3H+\YT*MM8L9K
M+$A)160&M/%Q$GVK,!M^OGY"^I9!$>N7'QE?;T5#YPMU'BJ #@3*K1$$_6CR
M3<I;_DA[%3^&I*%#39(!GNF@:F<;#7 2Z0\)UF4^Q4A04!&(H[BG#E8=*ZO3
M?R4#-OFN5EH W#J=37IQH$]6(ME\C)5L0\E4E@V1,$Z"GI/Z/-IB7SFE7+M.
MDW_,A#ZPST&0W#55A."SC$E@$I\+A"A:5M%(@B)=S)Y>E8NJ8O<EN?B=  ;3
M7B*6)S.U@=":@J_&SP!B8; 8R7ZEF8O4,G&_N@$_Q+-II5\X?B&-P?&8UTN&
MQ,]JMQ28Q?A+C^*(:)*F2\ C%\DXUY<UY9W2YN&/HTKI;"Z$N+V:B8DXK_=4
MJKTR.M -;$CYZ.W&?D^.U:)MT[(5.,)7FCE@7)D-/)7O>?]B$'CXN)["VW)*
M)G[U_$B"4TKV-/1H%3ER7E9XMH0M_W:G#'IA:O3%DK;P*!;SREH +Q=N_,IG
MS7G0L+\L#RJ>=$YB-OE83*JXYY&YA >]K?!QJ=G>]L8;5I=:,L_6#.TP]]56
M^3^I2?[-Y_RG[!1ZU"2V 4(][J0E'OP=PG"BM]W"* R[IB8#];8,\D@NV5B(
MTV".<4AI&O<L:F,C?-?=B6CKY?>WQ)J]E-&2@UT\I!@3T VCM%S_SFL)9XY_
M$TTH-]F]\2*"8=U:L7D1 -_L_\]G;,N'E#_<2X4XUNQY*NZZJ[7#"#97J0.)
M<D3I8^@%7IY%^]E!MTY5#*+343 (UW=X]_8+*@M$ZQMZ^HV)SLEI_ZQ_C'@M
MM(2&T64:E_.7@\T0Q$MOUC5*)OQ6'_[XSJ$8][DHQ3<1,]7L=B0@Z>N*H,MK
MA;89MDSU]#Z"2EB5,=-R2?XR$6W7>-?L0D 4F?.U9V[\2-[8 ?)#[IU$8J1C
M768DN!,IUT8]-P(IJZ#4N@C5)!'1.P*V8_5^J5L.I?)2D%ED1S$Z@@H>V@Z0
MAE2NKG]Z?-MC?H_M3KC8O&MH<Z>0YLKK/AC_1__,SML-@]+40;?\]D4K='KD
M?#[?(MME#2GOWAO*O4==A 4&O1NOFE0<:.87@#.<)--C%V2Y%UGT!15V.BT6
MB'<@$4NCU9@7D^5\5<X]^S:63L6C>367D$?(SN5X9"A7:UU\F SYLFM%)0U8
MNEW:HM^U=^HBOW 5*!:EJH^5X]!ZD?WS7C#?@+W;8*M#B-VB:M==X,11_^[.
M!Q[6CW1LAI>VO":LOE+K;<8.M-QDW%*FD"Z'T;05$[/)?[(H^7'+SD^!^9NP
MQDUZM"^L-T'78R+_PEKFCJ99S:T:WFM7Q0/?GEB?^8@XOYDC25\MK\: >YO!
M_>.UR;](3_WKTGM:OS9OE6E_)S:M8UW=H>I,T9YO&3)UWDU;HV$1*J2(X:ZA
M]VD(M=5/AH@**GK\2I?79FI1.F&N'8NE S;GW+XV>$M*2A(@%G\Z:PCK&W)W
MB67WEN\-2]_5 +@8^X^-43X:X*)9] SIF95?*<$O/G%.)*&)DQRC(M_5M<C7
M//^BDY_]V.^RX/Z'U<ZG.A?TG6'QE^SJ:Z 3O[+E!>YT:%**VN_5WQJP2&+[
MM)8JDO,T&Y*,LM\+UW/UZA;T2+!/D_(-*%A3++9QA%2@VQH-;C9^'JP2,.;
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MF!(A/DZ#?A;-7)I!>2M+!C_R' \C&_#K1-V6Y[P2N[EQ042549>NY!S\"5C
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MT!1M55$:V-VD28LSV(I15WEGZ5K1<B+/JW%+\<?M1(FY=-.0,^]D 4[)GRD
M1\.(VJ6F0/)Y:81?_A20/;#/",<)QT-209G@*PGG]!JXV)ABA.Q]6W@C\8\)
M?*40SEK"A_,U ?F6,G$0FQ TH\SZ@:B/0#W*O^CU@">&7CB Q4<+*$F@VZ8"
M/U(2R UTK.>SM>N$;H0?$_C&H.CP>?ENSJQKVSI?\?=. ;?X'WM9@L)!CRF
M4X0E/!C;%U]EZ6/]&IW7R%O=,%1O55N/T_MPI=HD@ON<Z<-1[G8NO@#6KYNT
M\^Z!0[,>#5@PWH]4HLCDNG6G-J9M7[6]X7$UV\T-?K;K*!/+SJ\PHP\Q#0X0
M6<*U(SW7F8JEJ'J>N9G8[#-5A)"B0.B(J<6PI(=Y*Z][4?]%YW,/SO$H27#H
MVA8G>.<=!Z@?H<')1.VCZ]!.4#F^ O;9\"/AM0EN\6V^?I$Y)[M8J[>%>6A!
MH)#*Q47?=LQ@+7)"!A^*S5]_C99Y"F1MY-,O=IX6;\!]A.>N<=UWXU+6?8B
M![WXF^="9H_M"%[AQL,%H9V#+#$@&B+7K-MK-4N)N?TXA2G'@!$'O]1%1N^-
MR]*=/WG>OJD^:=RE'K>"_-,NRW%L7E )6P2KRM](QH"BR7+#57)8U+=@Q1>E
M<X6,75(V(]*;86D]7YU_7KZ4,\$E0GO\9+>'(2-!4V:<"_^-$#HK0[O*FP!C
M:A1RR5R%R(3 Q(9YW1>*H&#XL?17_:IS-_M45,09N :@,N0^395D#!O1@J"&
M=A>YBDMO?U-K4IQ+2)W6\VTPXW@\4!DMLGAC+<'#2 \ ,%V<G(E"5O0ERVC*
MZ^# &)EGE>[@MFI52)9CXGN"X_3#RH9+*J?D.Q,O[HBF-$EDT ">ZT/JM-09
M\6ZD3'61(VTW:P$G0MAA=LW<$3AVHOYLMF#RW>S!7I7]&WW>W8PBZE$<=VMB
MC?)I1+.*CRY">\S$.]R5T;I/H6)KJOL)]>RSAAS3!)^6K!.CA>JR9KI\FSL6
MK9V#C3S& 64,- "ZP,-2O#U!H@3"E8RV70LP"QW *2?LL; ^HH*(+I$#_YW8
M9M'7 UY"/[WI=&_+?0(YLE#5T61>&G?/+3/8;Y"0W\[5*%1.[DO5E4/U(%R[
M&KB89;VY//<5CJ%AY1XYGYV1=!2 ,\MQ6'.(<LRO.Q69#P8JP1QN'M)WDAT_
M'5<#V]/J1MMD -A_>EDK$R@  ](K^)Q2V>? J^!8."OYDLL$)"TY-NL!;UG:
M1EF!G8_$]S4.+WIZ+\#&[>=Z!\FCHZ R_ZI"B!KI/42LU"U#R0MR$R?06_'1
M<J54M-@U84WTJI_#G6OG-HU%65-J/UE CI'RR$)$F:\$%PR0/Y"^!<IJJ7QT
MQ9*@V;Q0Q4C(D(_G^/CXW%.^A6G;JYX,"31:_. V/4UQXF-2+/34FK]2[5:B
MY((YXPRO2S#3D/9G5_RY<P)W,Q=#6YF^OZM@RR\[E[^>4P+M"0:U]TCW?:/O
M -(1G=>DBLC'<;0(5NW/%<(=V6FO7M1BO$]D*'4N!W&NGP56@%M)XG@?@O5<
M*0N!#*2':&-5A=A<AOHTDS]?.MZH\\/^AGUBIDVW\*6 Q_R+!>/$8X0A7 C:
M.KQ>!U=A@94J29YMN'9D;CA8S^3F:[6Y+,WZ,6MI4>=^9)4\'[=(#@!H^O<?
MH([AQ(F<Z/UU>'F4' 7@$AJY8254$=.UK=Y734Q%IM61'V&<7B/)+S?(JI>
M!$FZ'"^'HTL_=9C6_5.F"*F#IS"^DAY&.NH18LUOBVL5TD0_M=Y6MG]J6[ >
M&S=" 5B"2I8F%05^&'B!)?4NH^IR[BK8! B+\$7/WM"UTA9LSWN?5]&E>9K\
MHY&=(%+B9C:=[O/9C7>TN*T]M]B0?RCL8<53AT3-'9O7*J*?EN*<$D".0,;
M.G3[:QRO&LE:&Z>1DEB_<<XY5V_\"IUQX(R_Z;QZ0BE=0W <(&YS"BSEB/"^
M>BN1CW,M0JXM:.D;->(<TG\#,<TL9P/KATNE9*03)Y,+]/F^>L>]/,%*)YM;
M%4P5R"*<5A- ")D5?%LX'@C=N5\??_^K^:ND#Y(>W[_9,98K?#M<;)#^Q=-Q
M@E!VQ$E4(32@"R ZG\Y_R%O-I%4<SC)HOH&0I%-6K;W22R_F:7B_3W'K@1&]
MW"PL.IN/$##[$R*1LY*"<O;*S377>Z4^=3!M+Y7:5NX#S[_-@),A!(PU6Q-N
M@:K(/86AF3]V0&7D"<T.\M;4CMS&HNG@"R/Z5(@'Z17Q,@[==ZUB=(_)^G;9
M0$N\FZ7@0]OD10;Y)C0T',#=?DRS:B%C!FO0%^V/8+V=M13/>&/NFUO=$WM^
M"J"O(=12!W"N9 3@S_WAOV+@ZX&*0OO(9PGIA6W%/R8R8X@&#$%W"9$M8XE.
MD +2X-KS%M*L%XISA;JK5((,W@E;&D74<4,+W*  K'"(6$D* #-T'^>8-S8X
ML0.?BCA>L!*)$.%GM;1^ILF] KV VX\B6OIY!0E^F"NM)"5=L*25#\(=@!>/
MY[UA?BF275/2& ? 0&RPI7HX1*(Z$!VR%O^SE"BCL/-(UV/Y7,H'8Q.VXWG/
MCR>X2Q#&%'%<U$"YU KD +*U?29$-FN>2V5U]_H<:&VD=-_R^A7&BQ--7P \
M[9Z 7@#-R/([9N5OR),0">Q6DSSAOMX0:V5\LNRTV,Q6-BZ/.^6CX]%"#+WZ
MXV/? *99\)_(IBM*$L6$&O5+UD'8K+5R"L AVR=9A@]' =#T-80L<!QK(0S-
M;H9CW-E;5*\WA\H88C=SW0H>-GU\D6A<W,3:KFTB:,4L*QO(?:X 8D1-BTKC
MQO"\'W9K,^+1 AJG_;/P3P-',[_DJ%SBMV=-#7SLE99@OS3@_([E"L$:R]5B
MS; GL6$UZ'[? B>P?;+$;R,85[+ED, ?-:UUS)M^BN8*3R^=IAU."8EM!,8*
MBL/;*PBHV8YG)3*6,@K%Q[>7UAN%$O@EQ^..<^MU7D&EMLZG&H1VZ  @?4>R
MXQ.0<P0;#)QG+>L!^32VBERL],'!QLM=.&O,T/C!LVS%TP="ODWJ'O/\(UOC
M+2V' 0F:XI"KA+K\GWUN']R&BK.3=G(,-6D?L%M\ECUQO?Q&_G.6;FN=NUHG
M@MKA6'&M(8@:9H-7K4&O&.(2X!?T24U?D) ]Y_\U:KTY3-6#:=,@6(/C6%<+
M%G4[9LZ5<,*I3O7*(*@,LKV&3Q;OVD9XH!#0:1\$S\9$F0?Y&$'W 4'_(U%M
M>"-_1$%*E1M=G8'6DK9S;CIUJ3/<_VO7/(#YIE"$]J[K!9HF"F N"7+13^QI
M>S':D"LP^>Z7NNC5(:/1JKM^&K7M3:URF\FN[3_HUJ4QX3L,NZ\:N5=\(":1
M:!H+*R9' ='E-8#O$2C50=Y# N%/S*XK2QH9&] 2E,&PC.LV9U_"G2\H-G,3
M%,/FU=9,?9X@^-Q7RCA\MNF8[$*OOL3=J[>J5Y)F0:"9+?:9<T>V+ TV=LW5
M&45/J.DQZ-/&!9PR/E#;9]/GGR_K]78;N/".Y40M*1$B7+P\YB\H@F.)K[?:
MOMH_,;5VV%2;:4C/X^9I:HOXKG+)K900CN6Z3DB<FV%:04R4U-B$S*$3\]>"
M+6<1R&<1M%+UYR>_T%RYNQ&W6WN!YND0](Q+,*R52:;=H, ULW84GE,241H@
MK]IS,I3\!"[D^"*[^#ESL*D$>F;<J9DL@E/**77)ZGM6S_G)U1UY3_/LB%F/
MS,L]^8^CM-D$&M%4;SW%=>J) W<!'2>*S\T\/2P-VXW7J^SA>A#A[+$0;3DF
M7UE8K6>FRU33N:E- [ #,(S$S%6_8FD>P3+T^?MZY<%L#Q;&-@0-TQ8\IA >
MI/HEC\NH*C_JE"]=X16E48I]3P^YPDL'\4N&_8-R^=:DW.X&1,HQ1JIFM:"A
MLJ$2H"98!3"F7@)="&1=M1+"&296A:H%X"'D2R,&L^62LNUB$^_8-+3;CW&?
M:X#^.7[1?S5PAA/W# DIJ(^8MIXZ]VFO?0\55!U-OF7NJE?X3D,H^]&M+7(3
MXFC:>L(=M_(V$UAZZV"B,9>&R $-?4T!-,B^CY/H_XT#AV:2S$\$5M438/2Q
M^=CU;&EDXXLBU>#5XSW"L7+W%K;EO?.3@I-4LP)BR4PKJL#6/GK4:Y7W WO5
M)/QK];8L>B-&W44)^^27WJ>6@Q2["0%HY9BM>AJ6*(BE#4SQ;=YBB'Z/5%KO
M53VQFS[):(^@V5V,@AY.0BL9K11>Z#+!L*(JF/K@9+%-@L4=0%. R+&7N.%L
MXK;;CX72/O& ,3*]=?\A,T2\/*+\2!.!; @%*7MTA.0' N<6\W&73;#W OTW
MQ)*4?(<U9\0W?UX0,[[<3S,2;X]O\P:>;A1\Z&H:?&A)"*8 6BL>WNF_<7;!
M7;)]4-M%;))/ _MNUG\IJI\LY<(+;D_4;=M&62N]]N87U>/EB3;6ZIQ)FJZL
M96D#,7?-(=D"?5K/FJ4,[DGL-\2%7GGW*N#*$UD[1&+N6 &F0=ILP,1T1!H)
MN]?PD=?;8/Q1]WO4^HP^9,+I%Z=(#"_7TTUUEF+GT2[;_:PH.0-W<."8D9.G
MRB.^M(B3NWC.?H@>F'8&\KAZH*J';<VH<?@>MQG!LM+-XX=2.R<77TV[ON#E
M_MT2]C;0V7KEPL"0YBR/M_FN9R_FS'1<2#)(I7]Z:LE_-B E,L%.=&>Z:J\T
M'L[BM\5O'IB]IC/:0XK+'V]^&>4C/U^0$N#Y8%<H.U(DP<0BW=?;T&EM'KSA
M2=Z.C#-H6ZU$64H=BE@W03D$3\9@F.-2%;Z@'B9?G-GB<'9TZ&L\612?' WE
MTR-S?%[YRCL?4L4RTWV$66B?F3X(LMOW&BU3@"6:-#JU,KXU&<5L6(E$?D>8
M&YO<+../S7GVV)-&1D@P)BX;G! LF0:YXN4&2V;JJ-[:=]F!2W'MPT#J!6M)
M(Y#T%Z_)C<"=R_BOC^[?'>QVPR\AYWT/ \+)@JXP=D7P"?$8C\&'&">#:QO;
MT(V("./[&@"-A]6&3TQ%9L$QM4S),41SM"%;DU*!W?M)Q3<F*3<'3N71GLZP
MTI5\R\*CTJ-\C5"5YX+D501R=;M#)MP[/5-$G1UYC&E$H&K!HS/-/?<PK6:F
MB>L.6!*^9BY^91IM7)8A[$,C)\G0WLO(QFG(LZ V(':/U1WAIELZ8Z/=7ZR0
MRQG2.VIEM3%HEJMFC45&[K%$[&M*#/@^JSQ:;'A8;>"[?0"4/<&12B.M0INP
MLV&E;'V5,#'==XV4/5\6H]_0CTZ[:UR-& FL?7V:NR[A-'LTAKLY[F"U]LN@
M=T+#HR4[=,X5T53(9[S),-7;U]5;_C=8IB10G[BXKHM^UX\PTQ4S7[ RLI_U
M_T;S_(Y*5YF1.0506DO%ON0OL*(CI!=T";'7\R=O(](&\*,Z&>J8\A<2YI(%
MCG4V$5VDM,P?:CTZ\P0H6?2H0X [U3MTV\4#A)FV1NX;'B(;AA -8J7$X!9R
MQ2;+'A*6CPOY;_!6/5 8C<K[<3TODB_=^( ODX<OLYHYZ))7NTY<Q!+)K_1P
M:R^?9#UUE+C_B_6ZSB5'/OB/>OB/N?+J6W1<1EM$,J8S;B-D(N0;.]13.GC.
MNC;,''9;[\VLP1:2#6MG8"3X6MPOJEOY^D=S[C(=@MPC$(WB"1)"=T3*OJ*^
M>D<0I,3#45@R+QRM+2(4N>SV<ECS! 'X %L:J:[L]SZH5B:RI&C+5\VZJE>S
M2_']!L*]:5_OBU>,) N.QG*!(^Z"V\19.#J1C0+0'2E"#RO4$01'5T?])M.N
MKQJGQ.30QNTL4S5M'5T&80='N<W50S2>1.:2:I?JJ7DI576+0<@U*!BY,12W
MQW"!9M&<A7 >N3[U<?J:'U?+3:N;K[V+VTL_&?" -D0F.6W6M3EW'6-R5AIY
M!J44BD4,JP8KZZZT*N%-C(IDFR/?O[]P3&OW>"D5'GDJS1R',#GA(M;0+U0%
M^P2FS$(C+,TW?-[V/S4>7^#:CCE9']4GX-;X/NR*=3R(1OT$;NA&LCYNYFF1
MNJ[;J?-G:^Y57+US>>%[E'K0M]Y1G@Y%C%D,D=T0[U^+G<(GN\\*?XQ_SVV-
M6C4U#* !> YT22:9EDXM&/+0'V^$OP^3(P+G0L"T!%.]?LE-&>EB7]3##3NX
MT5>W^&><'(#!FQV2'3SB![ZE]-2,D+T0'X(+B/73\#$E0,&*EK=6];OKHD?W
M..5[1+C\FR<!\JUO ( -ZYMWM01ML.9X)X+[D3IJ[2P%P$)44N#V\^%IN!;B
MXWO^)[?XX0&0FWE*[LV.Q4P,!6 S$P[E)(1S)?J6QJ@ZP&-MWEA>D^^2B^#1
M/F&EYKW((12F_8!;1(2NH9<:CF$)UF7(9I;DQHOQK5!U;,I8U<OBC!YIYH(@
MC[.<C@Y&SW_$C_Q<XEFL:.2#-B-IR&<(U:A6,BM6;U"Q.W A3J*L<.:VL?V-
MQ/9Q<8>%1]%>*6\2>/>S+M L+%( $0[DGB>M\.@#\=0[=044P+9!B&[35H0F
M X%^S@6B,JO!=<1X(V.A5!"U<7_2T<38Q'U(#2',E8!)2I\<^,>N*T;5L[19
M<C6-CR8K0C&]>NK!/M^^83X\_"0)PTS"2HYZR,BM4,QA<(@M7-M/_+^Z'; S
MDP"JH*:FFJ"'*TI03>PZ5+AZL,1@*L_;PN!DTE59O>VI@..JA0Z&'P*J_9^[
MX+],H*X)-%1>*&L[?8N3]<'C"S1A (#MA[_]^4&NWF&6)(*FC]H#,[GAX> !
M13<7R2TI2$=RS[/V4<O.:]+:JWG X+*Y/I85,AN6_"IG18D"L!_<13FO;SR>
M[EMHXXW2F6PM:PZ3UQ.O*>;]US1]<UL$R1-U/4>7?JI://I6%I@Z,"6-WWH9
M=+^D4_[4COPU!T](9>:;LZ<?S/P1>P&GH?WU -C8M?\^7>:_<="T@5QN4@!H
M78\C0V6EM3J;CJFO&/])P09EX+O>7W>C,C=.O+=:,WLBMS(1VD;JS*)SJ$+(
M*_4C^-\6O#FN:R)D[WDY;0Z.#0O,)3]ML*8   Z_2'M6OMR+>Y_FU.18N21Y
MWRO>\00G\A?S3!QHV?Q70U ZZ[^Q MW]Q7I32C4<>0H ISBS(3R)(R4:+L"\
MPG7 O\AHT,F'9_=@Q&.9?R>CX8#U(WXUO3V-)!H(#@JT_!PFF^YS<YA0 $0A
MP0N_N&=,*8!O/+#?>(%PNB3&8"09T/V+]X8ZM<;_23-S!NB/5C$QS_9]G+%8
MV4FI[':[?/WG[O?G;OJ_>P7X.]&Z^#0M3_!^,)%>E=ETA!:7KF;M/CN?_VEJ
M55ZHN6IRX^+=94;VN!QJ_/[=>[_Q!+4!=Z5^M<FCH8(#]JMOSCY[Y[O:-=5&
M^O'M/8*:>?[SQGZO,'AEC%<(+_P[&5-/HF*,>0A5I5^>P ^5+AW:-@:3LB$R
M1<N-"@WPNX/@(F%WC7X]OR>X K#\Y;"'S)XL@NV-3TNS.A36E))KN]"8I[=N
M35!=1*)/XY>C'&^HH_'RI?G1>N6$_55.J/$<,YTN)")(U"F!D=-J*M+"\IA"
MJKLG@RJ@C%C8_.9TTD'7?$JVK.1]6^T_Z#+PVZ^# DUM]5$5GR:@SNT/O89/
M\\.;4X>CJZ*B4]J;=FY]L,"-A-/0HXYGS%6C.@,J ^_OO.N6$=!JZB(RB15Z
M5$7%!&EK0;JXW)0%;GYK(M(/PJ\&IP[H<,3]JRJ>WT:I-]7Z3RS><Q ZV5^.
MZ)Q4:9IHV/;JO)OM^<0X)(-1\=UE/<&5FPRQ)]/F[:J2F.EY>G4OT04U_8EF
M7&8;$5UNK\[?[@X3OMK4:#*'9>::Q#Q76:+K,:GS+#>+5"CSR#QFI]5LF-YH
M<G"''H+KY-^)_%4EQ'%7YUS$GVVB4/CSBYOGM1ZAR1F%9>-&'(:66>/*_..=
MT2+CD+,L'B>S]-H7^1:TBO>3N;_-^O+[TI3^*I_Z=7>,XW\69UE9XHXP^#0L
M2TNMY=1HYJ? 9(O1TK3; _6@O'<AQ5=7PH4YV !W1UY_$8FX24LS[%SZTI<%
M1=,F",2-1=>KX6)FR;G8CRSL4XQ,P(?D"<1(T4(MR)LGF]-:[/7[R%3#=[1)
M^?@H4J[Z-2R\O?$4%AQ!!L*:.W%.<6S;@95MH^@A]9?N(SQOZC]U1W[%B$%7
M5@/?L?B]KW>:G6D#QD\KXC3:DI.A)ZE>BQ@8'/@8;TSUD?(^XYWSS.$VVSE&
M+9<L$8)T/P(XU\<[Q,.U3G!NAXYMU*"3V301140%@D@)\1HAY+V%@7L .M;/
M/.2:YP";F)N:X^G]F[*>#R(,N3G7_"F RKYP:9 3DF#1<C<%PD7*!D]<C>RE
M56JAF\3T[(#\$%=FVKUZ ,'%G-MFT$G-"]B)Y>ESA*=8D!56O$7*=I%;JOZ1
MUV?49$/MCV\Z8@OO ?A.;_F';YQHQ &',QT4P 3?'0+7QV79MO<SA+HVJ&BM
MDBI7C,+;QM#=G  YR4G16PR;:?0>LUY:@A4ZD#TL O]IM*HOS@3.K'F>J-!(
MN(\FW1G4GSK'LW=344U#3V3Q>A):B*O'^"#N\>QQ/7Z:79'J$<>U\"R F40W
MR-$ZR1H[ #NIT,=/ =C"FC7PXYN/C^@GR$,57:_0?:_*+K]]=53OQ+_WD:A-
M6*$>'^(=+$\I &8*H$QSB@(XA< G$V\WCBV0XM>_G(*-K&LZKF.VI%5W!L,T
M3.(DJ(#F+'DT"Y^#*3U#T)_C:DXT13?FSG61NXJLI0O 'UQ&Q[B[PCW.=Z;J
M+'F'-W58?0/>O&O%B,W%?\QLLV85(?A0$^OCKDC&1J$^Y['1+ ?2#]/J3&SI
MC-*^%Z1<?C;U*S<-\LI^QB1G=9@Y_W'/4X?]QP>LY7LPR8($/K136*6&.9HI
M.4[='2UU.]'N6W!H0UG%D&\[6TTMPN&I=(H-Z_L#!'/WQ>GC= ZG=D?^1_4A
M1(,".!'V-1#F8$ZK'Z(R:LUF)M(P/85-ON0_0W=3TU'+0MHP8QL7UG8+-/N%
M-[1M:[W01E+I[E2'"UI?;REELJ#Z&@?NF>EI9:45-O4S+6QEJ.<\M\ Y<E7C
M^TQ_9T+[=V.$/X4C5-5AS3I>VR70;F!/.+R1Z%CIIJH,Q*;<J1N&E[?[@WF
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M# ,.@RKHXMCG7C#AV%L")EQ7#DM;2/H61VRZ\M7W5@<6SE]XF4"'>2/(7?V
M1F(NN;4OSIH!YFP@,T??%@IMZ1AM%!LJ402R!-;V&1AH!J0R.U9_122L<UN_
ME#],R)B*V@<G9&;RPIIE^*8>99A_]55;$;[XMJF5^4&"SQO,AT!8,_(IDATJ
M!H%4$#IP;GI#1!Y2S,>>CP1P4S57-TRLX/6S36EI]I.]I@O'Z$Z*J-TB3N?,
MPI]1$?N91F'(;:QTS9QPKAG!%Z7#-(./LTB\,[$@*B&L<W<>&S,O:7[Z5 </
M8![Y^*W2T&U2,I1+QS&V3"_OV8SM!IV>:,!S>.B/R?W29S*YNJ14=9VY/KD\
M[!911FEPXGQW>S7,U60\?"3 )RD*;G;(_JU1@)0'<[2FMR!*89U:2.QHKIAB
MAZ_63(1:C'5<WY'FM![/ %CJ#7WZ\S+Q;B'6=@,_(V@;+;3=%'CRPZCM+_2Q
MDE2F5/\94CUZNAG3<U0C%\,HZ+_T>"7[ DTMJ7KWR'QK'(@N4K[4>,N9B^W3
M+&"YCAKT.M+=FM1/>,D\ [DFCZ>ZF]VH#0$_=8>!1;_5*,M??R82V2]WK6OM
MT 21K "<L,;'81]8,ZB;SPJP?)N06G^.(B2WXVMW35U"79.*Q<>E."&=60:Y
M@HZZH@(UG;NP"<99ZSA3,X(+9BLJX] ML'3NL-N)+N93]SQJ5?5)V<GY:C:[
M>4]6?[EO/"H*QR*/GIRH(*0<*;H:==H,VQ$BW=WX<FWJ7]G97"*=-*;_>30V
M<AGV&;9O /DPAP00'Y'>::H$RK13 )P0SGRB$K8TG+C6(-/BM<;JBC#-BHH[
M8RA:=D$K5M.!AE96P*=CE./8-H+(?EX'-L[8HOU0SO+:/:;(?E+Y_<B#./#&
MB7,40(LWM'OE*QB%9D>H8]9%LMJP^1'0*] NU?QGNZ 8,LT05 :B-N+W:,_]
MTM 15.K<T4V7U[[/5=[>4K=IW)P.3DN8]9UAA'(2#0AI.'P'!MCV5L8 Z]F_
MVU4YPQRH9MC(M6VF,&FHT=8<EK  -6*/.+ELN@@XA#9J#FLR$@-(V<0 C'O
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MXN/!$K"Z1H"(OI-,2HA- &OTZJ#AICZ?-PM]RG-/SSO, #6S"R6PCD:E<D+
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M96LJ-FH"/7&OMT!RUFL7H#K\0@I=K_)%OPI(XSM(6M9;/075A9P^"JG./+I
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M-=(3$!W6]/7'X:>=".9H?>H9_-# 1R"C ,Q& =C?%DV??R1:*WXR-ZCS6!(
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M!!DT3^[OX0L94!&L/1?.G9AU<V\.GN)Y.:]^/'9< '4=':F#:, )T'FIF)A
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MA_VV<-D[2<TSIN=OJ>VC=MVIG#/-%,XVN?3@O$GFY'X4[5JP5[>^4&CQ_S)
MR-?RKU,X6!__ U!+ P04    "  B@ZQ4E0C,S_G'  "N<0@ %0   'AF;W(M
M,C R,C S,S%?;&%B+GAM;-R]>W/<.)8G^O]\"MR:C;M5$4(5'R (],[,AOSJ
M<83+\K557=M1L9&!IY3;J4QU,F5;^^DOP$>^DPDP08HU,=,N62:!<WX@?C@
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M6@@;$EE\8L_E>DQ91K1-GZV)=7',T@QR(3.8ISI5)*:""Z^8LK,]CHVA&O'
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M4:R*B<:*TE2G,$MI#I%($&09SV 21W'*:(;C3#51R[>.2T@8T9RFX&Z(\^T
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M*!'B*8M91OQ*!;AU.[[5BCW)J26B\GAF^@#>3>=L+FRL5UF?OLRTY;<6.0Z
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M;<],NA[6FX-AO:F&M0Q>W1_9\I=[ PMN%]5_2XW!'Z7.3IY9@XZ\1R3L.+Z
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M2<&WNVM A>!_K.LH1_U O?^<_Y!?)9?S'R;HH9QIJT+F"@F A?X?"',)2)Y
MO07,"Z1MD"155@GW5T>:&GU4LD;KG8 .%6A[ >TG#J\P!>:,&B$M9[03-.I(
MZ@LPA_J\OH ;J1AO#:!Q^,UW .Y?N-)7\5T;5'HK[?8^8+RRNC9Z'-30M;K!
MC3#+]6;V*_TY?]H^-9[J.!=80L2!4 D%,*&%)D@:@TS()-4&&&1V)>9.GCPU
M0FR$L_NL3W'JY[V;M _,<XU<'L.I+FK;9_/HFSKVCO[7L:US^M11OLV+RK3?
MXN4+ANUZ]E4Z]#:J$V_]52[HQH1@EYNRBLBNXN2;,/EREUZD",_BJGM)S&-M
MT3 )F,@P$$G*6<(@4VZ'?K>),[6OO%/7QK@+NOD8C4)1I=%=="87H1R<%7;C
MG-KMQL:;J<",="4-)$A&F1_PO&[J;A1IU$V?'_B.-X6>GCJP.F\GV(AP5.0Y
M58!#TRR@B 6@N. @R9G>/Q:B*'#JTBQ@:.C6"$T"'LT8N\*.?9%&5U&SHZUI
M1F(%";4*'5'U:H%3%O%1MX=!59L>XU]NW<L?**_J-)JRL>4^$MW\\].*+N_%
M#]-BI-QOBTSP ?\N'S7H<B:I8FG.S%;&'/PG. 5$%1DH)"6H*'@>9U:I*'[%
MFIK!]':U--ZX*G1GGXI157->:&7T+VMM[J)-K46T,6HX>$?\S:B%[^E5YBDX
M52UE]- >?D6M6G=1I=A=U$FA,;^)C')1JUW'I747-0I&CZ\VA0[>L%>9RI%<
M9V-/J9O'S3ORO>XY?Z.-Y\OSCM"!X\__TV^M_GD:ZER5[=M7T8T%%C*#'(BX
M$"8460)*. %48)FE(N&I6V-5^Z&GMJ!V"U:V<?WO!Z5).,!O9XF' 36TL^ ,
MGAVYF]*?49 BQNZ !2H%>G7X5ZH':@O+Y:*@UD\8F%)ABND]ZGNK%L9,[^F3
M0N8@S4T/:)CF@"19!A*%()8IS5A!G1(FND^?&A%5PD5&.L=<AP/([)AE,!"!
MR6./@?=^SV=5]IM+<##"N)D"YY0[R0,X>Y'/DE+=3(,W+_MK&D]@)<##<Y5K
M4!V6EA^77^1ZOA+_DB:,58K['W)-O\GW/^6:STOY93WG<I;R-&;:( &*Y43;
M*I(")C'6MHJ*,ZQB2=W*T(PH^]0XII)<+\@F"V!;BNA9KNML ,=D@#&GW])6
MFN:DCG@R<W!X=I!;QU[.G9Y%E?9W4:/_750C8/);:PSNHA:%J($A:G&(*B!"
ME_L*.GLCU! +(_\$"I,%G1B[:F=A11BV*'Z6&U/NX,MZ]6,N3)K&[UJ@C\L/
M\Z7>XL^7W^[Y9OZCLIEW)\F(H)@*JD"&I3G((@Q@13!0.1("Q46*W&HPNHLP
MM26J*O>A%JL_FUP"U8H>T9WL_^6V6@V8%[M%)RS:@=<.+7Q=6Z45WZP3OQ@-
M]!+PMVBG1+37(LA)_W 0O5+X #%&9>+A,!T3Z@U/"K19N$+@#]M-N:%5B[&/
MR\UZOBSGO"Y]I!1,>8QSP G56P.)3(W\3 $IBKQ DF8)R6;/%>__MJ'KC:<-
MPE!Y7;[^8ZD#;KJ_?5O+;Z:^X[R5-OIAQ+V+WLAO\^72D "C"^.X]KQ-&#SQ
M<9XEJ60*8)HQO2>$!< %1B!/3?0'*13.:3/Q[Y?B+S?MK<RO,NGOZV9^$YMQ
M3]O ,>9P IL^VSU?1U_3\[E]$SQ750L^*^-NY@9+.ZVMVZV@.V_4;A[P=<R/
M?\K2[!>7PAP+<OWCX\K\JMDYFM./7O]5!CF3*6<@E2:EC4"]Q:,I!WF..$R0
M8 F,QUZJ;E-IBNO9SE5%&U>5;%U5ST;DNZA6N4I_DHW2IE#*#_WK\.[0L&_8
M.$OC>._,7VC][+Q5[SMOE?GU7=2!9DJ^U%'F>5(K\HTJ_:66;3_3YWMM]R35
MP,P!69927F@J_RO=F.(Z+T<1.A02E@BE0)(5.8"YB8VB<0Y2A?(XDU!O-KF+
M8W: #%/SS'8C>QJ)YW69ETH;JVJHWN;';LT+C'K@A:J6WJPV;9&,2H&['=(O
M=^U$O 2-J[H!1K_Y% /D&#?O8CA0)_D9-SQJ&$W^JH?8KBLV_[A\WFYV,46(
MDB(5N0 \97H'H[#05I&>'15G19%(4?#<J:3_I8&F1G@=.:-*T '161=!M2,P
M'U %9JGS*'F/W[J&A%>BN3C8J&QR3>5CRKAZ_4#_R4GCXQE*"@:)0B#AD@.8
MIBG *4? G%FG.<DABZ5+_N7I$$Y<,%H:9MF1\W_\!TZ3XG]5W3TV+XX.@U-(
MX[B BJ,8Y-51%L,<8*X$4!(1EN4<(AX/.,JZ"=CQSJ!N/6@ZQ9,Q(G.L&$AS
ME&D\H<8S%@P(A@H$L3;?1>'L=O. 9GA7V$WG-Z= 6GJ7;H(FM,>G(]S_C&KQ
MHOO-9CUGVTUE-F]6T1>]?5UZK%5Y&1&_OI'38<;U5UQ4\\2'</G*@:7&J\+6
MU6,KYT/YL2RW4LP@1PA3$0/SH0,H\Q301.8@*Y*<R)@JQ#.G$N+GQYF:N?JV
M4^?[KBGR'<TK41U+?5_ U8X)/* 5F X:H'ZK@:J%O(L^]B/E7FJ['P>_);0O
MC#5N:>Q^A4]*7E^YW(T3A)S/WFI*N5]+^G8EY(SK)1Z2% )HJJ5!5J2 0)B!
M(H-ZVYK&+"7$A@2.'SRYK[Y:R[1PD9'.[D,_ :O_R[X%@M"?LIWVUA_O)57/
M?*VEY'__MOKQG_J6ZD/]-S0_@OK'ZNL\>=@HG^,E%=KO[^+?;SA=9]=/!MB%
MDX'.$<#AJ7\R4[$D2,4Y8)CJ[SB)":!*K^,,YD2)HL@SZM0*))RH4R.%GN@N
MN5=BP"%WF(EV.,!^]>G["QU.'YP_APWN"CHM_L^2PX@[_CEQ4-C/G@&''7%
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MD@%*DMP$0K*4*U(DRFK[>^'Y4R.>IA9&)6/4"NE:)N00P7XN\8!+8-9P@V1
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M'$:F7]8K;4-N7K[H-W5SOZR"G)_-:O^HG_=N]43GRYF2*9%,;]UX(7, (5<
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MPI$F::SJA;=,EOZB'I3UG#E6-?2 <W]EPUL&&+&ZH0<<#BL<^GC@R 7IFVK
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MOZ'F5\8<-^C<#H"3\'/+VP8XN/XYE\LEO=\:UQFM-A1-=P N-=% EH(L8PF
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M1M^?5>\DT/[\5<.^USK@JHJWJH[TROOMYOMJ/?]O*6:8<(Q33("2IH=!3%.
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M$!LCI/7<\%,(:>V!Q3*DM>\) RS)SZMJ/_MQJ0TSO:=M:PJ:1H*"$0$X5@K
ME*2 0L2 D)@KD<(LB96U_7A^C*E9C?><KV55D$'OFX0)CA'SLLK <K!U+L!I
M82#>#E)HEEDUOJ-61+?3SSYX' S VV$:R>S3@H)JQ9NW<,E:5E_1G/U(]%IX
M%VX=SZ[KE_W FKMRZ3 ;[LVVG"]E6=[S?V_G=5?SZL>U;)N\%2Q!2A449+$J
M "1Z\<$:18!,4B0MH&9#JY,&ZQ&G1H>MP%%'XKNHE=G-3+L.MYUUYA7$P'39
MCU^ WGO6X'BUOZZ/.JK990W"L;5E?^.M,=R5\X\=E_/YJKEM/><;*2I/H=ZV
M'OWF]^5\4S8VW\MQ=!9EA520 4H$,6F3>I^9Y 0HP?*$%HBD*AX6 ^Y?V*GQ
MW-ER6_O:2J9T8:M:[4VO(A-.?FDTOFLW6(Y)XD'?#<LCC8G,>.ACD1"3/5(0
M?;B)"12$'T#@5PKB#P?]Y22 @&,.6\'^H1=!T[WE85F?:#ULOLOU?5G*33EC
M@B<Q@SF #)IZG0B9VL$YR"'G!6%49L)I >H9:VKKAQ&U;5^D=\COYN7SJK8?
MC!^A$CRJ)7=;%/K@MN-T3R &IF0/^#F3J@4R7CFQ;[Q1*<U"\6-&LKGEQBI$
M>L[Y8F5*CW1*=$&4<\0@ 3$K((!89H!*KO\I$5.IQ#!.G2BE=[2ID8H1-JJD
M-1]!X_*EB^9#J(R23W/*YHL!9R;]L-M1BS<P Y-+!\>.I('JH%F!$J8.T=D1
M7Z<"49_R%VL/]=XTC%V:ZFFE-O.-%?1VNUYK"W^6,I$I)BA(BCP%4&498+ 0
M0"F<9!@SE!16!QO]PTR-3UHIH^=:3#?&N "E'57<#E!@CMAATTAX%S4R^F.&
M?@R\4L*%H4;E@GYUCTG@RM7#OOYW\GDM]9)I[$C]\Z(ZV-.[I?NGU7HS_^_Z
MH G*7&2,(<"1MBY@JB3 7&]=4IIJDB 20;>D1IM!I\8,79DKNX)VA&V/K-SH
MP@I[J@0C)"L H0G1YEW, $UY#.(\Q[(0!*LTF_V0:[9Z+?2[@__?A[\=>?O&
M-#"5=\6]BW8"5[AV1?;'["X >>5YJX%'97T7*([7 *=[!ZX(IL&Z7(JRTW)8
MKP!)EBF: :+R D D,:!Y2H"$*(T3)9G"3KU)SPTR.<9O933NEFY/\TA(OJ!K
M*32NVE"<"T?:.0>P)<W<"%MH6FG%NSOH2>Z117KT]\L:YP8:ER5Z5#UAA;YK
M;_0YU9Z4IN*M>%A^E5P;GO/E-]-\K^,/22"*$=-;16*JXE0,07*8@#S+64)S
MKAAWRL!R%6!J[-&MB''>&Q6U.D5T$^T=, .=5+;SY.BW"H#^:*ZLNQ;X'=":
MD78*5)U$RZ!GDD-1#./[LA7B==QACA!=])"Y/F>PTVS[M%W0C1["^/G-T>-:
M?M=[D/D/^7&IK86V>&=*A1 Q%" C)K4!2P(P+30YIAE',:$HH\C1CV8W\M0(
ML2-X<UIU('IDSDZ<W6V6DV#M@?,/;6BGW,/;C]']9K.>L^VF8K+-*OI"UU;M
MHX;XY]P0\NVRLQQ];"^>&RAG''N.#QA8D6AO'59!$^7#=E-NM%6BV7&FS;2"
M"\U3@IC6\$*;;IBH K DS5/$,(NSU*D<4<]@4Z.FMYW-W5V=**\W?7MY':L0
M]<%LQT2^P M,/MU-WEV=,:^W?@\6P+F7'K) Q&_=H;X!QRTZ9*'Z2<4AFWN&
ML8@FI+4IF/9.UO_]N'R43\^K-5V_F.)&FY>OJ\7BPVIM&FO.M)&3H)3E "5(
M :B*!%#"!2 )PAG*4HK=>J6[##XUEFEECWYII?^;Z5>R4R"J-8C^,#I$C1*.
M%="<)L>.BT)!'IB;/*/M3%A#8/-*8$X"C$IH0Z Y)KA!SQB>]EF5B&RS\#()
M:4(H!ZG(8@ 1C@%+:0X@YPAF+$8YM3H.O33 U(AKEZ&WJ#XHI[.VBR#VDX\/
M: (3S"[-<T"%VXNHN"=X#D5G[.S.@W?'<VKG.0QL\CH/[AL]J?.<U.<R.L]>
M-S T?;42?\X7B_NE^*BG?OEMSA:-QZS]4]5"\V66LYPD7,5 *6.X\9@"RC(,
M,E[$F$C.D' Z\+,>>6KDUTKG&)1N#;2=$18$OL $V0I6G7OLI6Z<\G=1^_>[
MNN^N-L6:_P;QQ3LCZ#>PW7KT<</<74$Y"7IW?L  &^Q?U&2>;<I_U;V>Q/T/
MN:;?-"7*-9^7LBH6U]W7((YYG.9"[S=-\5L2*T A,?ZL)"="_Y$GA;5]YCCX
MU.BK%?\N:A6(&@VB5H6FZ.&0;>>@Z;&P_ *"'ICT)HBW@TT9$/>1[$UK_#U9
MH ,1Z[5.79\YGN4Z4-L#JW;H,]P6#B'GLW?-*_=%KN<K\7XI3"'B&<:2H]3T
M@1.FRVC,<[TPY E@/"\H5RR5R"I0Y>((4UL"6B&C6LI(BUE5M+:CG,M ]O.X
M%W@"D[4S,M;<<%7[,]9E*?G?OZU^_*>^MS(L_PW-CZ#^L6*'RT\=A0*N*M5^
MY]<O=/^8WR\W\\W+6_W$-5U\7 KY\_^1+]K4BY'&)P,(J0S !*> DB0%N4IB
MR'(1)\SZ8SX[PM0^YEK(J)$RJL2,M)SV'_-Y(*]_S#?#$_AC=D;&Z6/NU7[P
MQWS^J:-]S+U*=3_F_@L'AE#I9XKY8KN9_Y"_F2"M*BCR_4^^V HI/FA!31S$
MMC88']1[NE[.E]_*MBKXIUU7G\04C44T,ZT8-0?$*@<4ZZ4]@;EDJ4A83+!3
MA)4GP:9&'5V]HKUB4:M99%Z.J*.;"5UMM=O7Q+^A/Y.W*;=SFKW&1 8FN5'G
MT#T\S#/@?J/'? DW;G"99TA/8L]\/W](DX8%+<L'U6P,']9?S<;0] ^78D:8
MT+NU) :,R01 Q!/33Y,")8GD69% FMG[\GH&FAI9UU*Y- _H ='"X^8)FL#T
M5TD9/:BHD3-Z6$>5I)%7O%SZ+/C!;:P6"Q5^>DGXL\%OM8[6%7[S2F1?Y[(6
MJ/1W5NBY?\2F"M>U..RG8'']P**8AFO?'-<XZQ3D>_.ROZ2IUW=OO&</S^;"
M;O1?US-<* 85Q@(D/*5Z]QQ+0*G>3!N:-;8S(XE;.<P@8DZ-FC]O32QVU32J
M"JUTK&$99BKM+.+7GZ# "T2W;F57Q6[Q2M/TX6Q]2Z/+7=2H>A#''"Q*,.R$
M^*U7&4;4<2M5!H7[I$9EV-%N;%P_HY@R3%(.BAQC "F" *N4 *)9GR6LR!5B
M+DUW=D]V(NP1>NH\FC&&!"^>8F9'LX.0",R,G6;S 3K+!V&<_=-?IWO\I>_Z
M]()AG^*7]>I9KC<O7_1$;>Z7P@0N/QL2V&=KDS23.1,$) PA #/$ $WT'IBF
M>88A5T)!IZRLZT-.S=KJYM&WTE<193O1W;YE"]#M/G*_4 ;^^EMA[Z)*W$,
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M&QF-LY1*/1/$.%QH@@&E- 92TCA%C-",."5A3;I^BU/=EO-XV9'25"NV^*]
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M]+5#VX[W_&,8F.=:^#Y9P.=>[M<)#;_U?^V&'K<@L!,<)Q6"W>X>FLE#-U5
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M<WS-:V@RM95L)V8T;^6,?AA![]H3%!-&+W=!.JOJUP."<U[EM;'; /PE7H;
MJZR'T)Z'-I;GG_L7YWWGQ3&_OCML<KA_^W; U,%!GB. 7G-R_0<(O8HVX\</
MO>:DG0TO>E6!!NSNOJQEW4&^,0>:K"]*,"0J$2#.<N.SDE6]'@PX5!#F*<UC
M;A6KVC/&U%8Y+654B]D:KPX[A LP6FRY;@<G]+G]"2[74^.L 7+8*]T.U$B;
MHB& N>U]^J'HW>1<N'6\W4R_[ ?;EBN7NF?C-+%<'^8EIXO_+>GZ_5*\TW0Z
MDU@213,39444@(EB *=I"F(&8Y))I&)I%0O0-\C4^*Z1,ZH%C8RDT7O32EK+
M:I^A<Q'2?NKS!51HO](0C)RR=JZ!,#AWY^*#1\O@N:9:-X_GZK7#G!&F6M?'
M9;E95[QO>@LUL2M"*97!G(/_K[EKZXW;QL+O_15Z=  3$"5*E/:A@#?- @&Z
MCI%U4!1Y&/ :3^M(KC7CU/WU2THCS5U#4J*LER"V->0Y'X='ASR7#PF6 H1H
MJ/T; ;B$$.:QS*/8JA;GW$1SV_1:SF KZ'6@1;4[J9_%U.P@/092GG?]29 \
M) ==@F+44^'9R28]M%U2^?!,=?'Y@833]X0^BD6:,!%F/ ,0(=GU6)< "RPQ
MCG,D,R.VF-/#S\T&;#FHO];R69)A'F!G>'WFC(CO.RUC,-SYM_=T]L.XW4SQ
M-AS;>^J=9=7>?VJT.+30_PI^\R*>R3?QOBSJ[D1K\JCKLA9"(@AC @&I4V\T
M@T(&$PY0B%,D)$4XY@.CT;T"S&WKM](&&W&#'7F;WKI7OX\3A.Y?%^=0]&AH
MOUU ^M(2>(9^<'1ZM"68-$:]S</HTC""'^U2D,U2L)VET*7F8W5,'@"D0\2Z
M?]RWCEL;:6T0O38;Q[5KYX\;QLIUH7O?W3V7A?HOJ]]B5=,:YK!942RDS'F>
M $%B]7;1R9Y$YB'(F4PA1)'$E-GU[+038&[OF<^"*5D?-2]-^50;NTZ;8%\=
MV[:=E@MCYIWZA-OSBT:)?A[<:3I-N:(W<J].2R$F[M3I!M%QGT['<1S\[8]5
MM=:%(9^*V_*EOGF__Z$F>KU=%N+^1WG_4*XK4G#]XTJ(H@WH9"C,4H( 1X0!
MQ"D$E$D$L*021CQ.$HZ-/6XG$>9F"ULE-(=%JT80Y==!%,+<PMES6P\#3]L[
MRIY-8 =PN0-PHT)PNZ%!"UHM@E8-ER"FXY8P][B]+\5$/K?;DHSD;0\"L=??
M=AMY.H][D.9[/O>PD=R\[K:)P__$\\N2B=/I-+=ET>0<UIDS5=TT9O?O[\MJ
M=5NN?A<KY8.6WXKE/X(O4DDAY4( B9,(((%20#&) $SS,$2,)3"RJ@'U)NG<
MWEU?BN=.-G4ZWDGY8TIZ?:AN&F8TN7ZD5M3.H_>WZ&:N_RR6TO<==W]_C>N@
MTZ]-T]0*J=^N@E>Q"K8Z76O^E?68'3F\PS_J(<.?M).>1KR#?GAL\3_A&.D!
MGP4737.WIA"B314@-!:)>F_D&.M\ 8@!P4@"*)(L3U >ISAV3Q4X/>G<W@-'
M$?&MV->;LI[+\7'W)7#)+!@.[-19!BZ8#LPYZ ?)8_[!F8G?,!>A'XK^O(0+
MG[4S3M7S:O%9OYMO_EY6"QK2E&0Q5N8&ZRY%, 4$I11DB*.$I3C)8J-NX7NC
MSLV\U(*9V8U]=/H-@[/.$^0<+*O54J<4_E>0:OV\R4#0<HZPUT_JW;>9U0=V
M-K+ZZ7 3[X\XR2X]J42[#4__<0PGX$NQH8$4_)=E55^UWJGE6:Z_WXK5(F8R
M)XQ@(!G.E"_ "<@(@P#R,(>0IDF20SO&38O9C;[!DY)JUJ\POA'TNFZSJ(Z$
M';WQ$$^@?QU<'(+AV+Z17[ C>-!*'EQM9'^G3F]BQ .9 V8>W83^^=_06S "
MIM]I,!O",;]Q32OQUUK-\N%%=,4V6!FM#(8,9"(2 *$(*>M%B2YU2 F)8LJ$
M79KCJ5GFYEMLA0QJ*2V3'4\":69^!L/CVPTY0,8#XUDO!.-F0IZ<:=J$R#YE
MC_(B>Q]V)%4L2_YC^:B^F3S*8:Z."H@)M=%9J X-0OV8Q1GD6$899D9ICX<#
MSVUOMW)9\AZV,)EM8Q?E/>_<BWK;4Q,>*#DN^V [^+0$@P<J'7$('O[=(4?B
MU[+XIO/-])O]MBPV54P?"_:XKNNU6T]XD5"6Q'F8 TDUJ3-& I!<G>IYGG+"
M4YYEF7DBLNFL<]NN6FY04_AP)7EW7F@/$'4SB);_X4F[1J9'"+NUZ-_VWA#V
M;!.TR$T*=WV 4%*W/!%!)W=P8W<TL\/5(L_!![X3I3;4.'=?XJ#0L= -SLL.
MY^X(/%8&L2U@O6D,QH--E[E@J]]>LH+UAQTL_6_D<?5 OM?]9#>G@#A-PX33
M2).^Y@!E6  :\QB0$#,8)3%+N5'2[YGQYV:]-Q(&M8@6]N,$<@86>!@>GFWM
M'A0NB60G,+&PGL.PF<A.6F)D9P[/(]!K^$Y\;#H3=U[F/6/6\YA#'$F0QP^5
M+L'35-E,+?RZIMWX13P]"[9LXNYJ$3_)N^?R23RO7C<15RPRF$<X!HR(#* 8
M$>6O8@(8EPCRA.5):M008X@0<S. =16X\E=;*2TCWH/6PR#0-0'*GLVJ/<!V
M(;&!" V/H+D*,%W ;2!$>_&YH6.Y78+=\#_6U:HNB;@O=:90P9:/XE9H?[#\
M+GXM*_7[]Z1Z4+.^++G@_W[]4@G^L?BD9""KVE]<+5]J]HL;6M5590LB<PDS
MY=MI4B#='TA7-20)H%+JU%*).;'* ?(AY-S,Y8Z.NK/C<ZME?>Q_5!JVS&Q,
MZ1FL=7+BL@C*5D%UAFHU_)?=_9Z7;X#97>%;KZMG WVPI)V".@09-"H&5UK)
M=_K/6L^@553W!;WZTBSRNZ!3-]CJ&WQM-1XQ .%S04:](_4BZ*3WK3ZA/KR[
M]3K7*"'7>S5*G:*41B3!/.6 ITAYTCE- )$,ZD12!'&>1PQ;Q6+.S#,WZW\4
M7-2"#HJ]=H@Z15]=<)HZ_JIE'"T)S! 'GT'8;JZW#,,>*GPA$'OTN)LUZ.Q,
M?8[7J>N+B&>Q@@V#F"(*4!)1D.=8.9(A8@E!"<2IE0]Y/,7<;,!_EG^K]_W6
MHVO8Y73ED)TA. &FF0T8!I'G[;_U@6KIFJ*;\?;]>=U'W?(GIIETMY]7\W"C
M]SSIR#Q9?G]:JWWTX:_U\NG[-CL(TI@C%&&0H02KC2X(R+ 0@$G!, MQBA.C
ME.T+\\QMM[=B!J*5TY(\\@R<9EM]!) \[_<.GTY$#PE7%V 8ER;RS%S3TD/V
M*WQ$"WGA<1]U9+73BD2(4$PED%*WF"3:*"!=5,9I)I6-4/;"*O?R\I1SLP]&
M]4[]SJ\K^&8F9%Q(/5N3$= <N7;,VZG"8-H9U8WUG34L/NEX"<$>!%\_BD_R
M---(5XBKJ_;OU'?Q03UQI[Y8FD>DH2NIJG4C5%5W[-RVTF*44QQS"BA6IQ9E
MS+ ZO\02)"2$(9)9BNR:*'B4=6ZFKV&7;VA>@DY\R]L0CTMK>*,RCP7S?2NS
MT5('(GN(K%IE@V9M6W4#K>_U=HV#'94W'8;]-&&;8''&O2KR*.^TUTW^@3^Z
MLII@2D=>])U,O*UYB<*<8\8(P)$F9I0D!7F240 %@S&)0D9#JROPD[/,S>;7
MR<Y=/JXE@?E)&,VL]&!P/-O7;1)X[<)^]6(->T$8EV/\Y$S3DHGW*7O$&M[[
ML$L)Q X-^?OR112:J&E9:!IR'8!;I'$H\BC+0"JDVOR,<) 3!27#29)+)+ D
MR+SRH7^RV=D W>I.^1&-P/J&MQ'Y.M@(7<?(;7+Q+X#=;R+&AM"WI9@:/9L"
MAO%0G*IN81B:EN4*9O#T5RE<&&/"X@0S;?9K$@P_,X!DFUZF&J7.5*,'_=4_
M"YV:IWY_T&@=+B+=XCQ-$Y!#AI1S%S&0$<% 3!)(TTS];!?6G(]J<WN;_':)
MKB H=WF3=QB6#ZFY@ZME$;Q:$'W,;W%L:+MG(?",7JQOP^-]1'S2065.@>+&
M[#VK]1^?ZGL>ZDW/_3T/O<_=T<Q/PG.NQNYN4V[+GS__U/Y&_:/E^_FG_P-0
M2P,$%     @ (H.L5( M0<;M=0  [T\% !4   !X9F]R+3(P,C(P,S,Q7W!R
M92YX;6S<O6EWFSF2)OI]?D7>FJ\W*K$O?;I[CM-+E<\X+8_MJIJ^7WBP!&S>
MED@W23GM^?43H*A]H\@7?*'JQ2E+,A'+@T!$(!#QK__CQ\GQ+]]QL9S.9__V
M)_YG]J=?<);F>3K[\F]_^MOG-^#^]#_^_;_]MW_]?P#^]V\?W_WR:IY.3W"V
M^N7E L,*\R]_3%=??_E'QN5__E(6\Y-?_C%?_.?T>P#X]_4_>CG_]G,Q_?)U
M]8M@0MS\Z>)?N!9"(?,@HD)01DL(3"=0S*O <] ZLO_WR[]$S;.W2@%:'4&Y
M$L![Q8&):(3A2DNFUA]Z/)W]Y[_4/V)8XB_$W&RY_NN__>GK:O7M7W[]]8\_
M_OCSC[@X_O-\\>57P9C\]?RW_[3Y]1^W?O\/N?YM[KW_=?W3BU]=3N_Z1?I8
M_NO__OW=I_053P),9\M5F*6ZP'+Z+\OU-]_-4UBM9?XH7;_<^QOU;W#^:U"_
M!5R Y'_^L<Q_^O?_]LLO9^)8S(_Q(Y9?ZG__]O'M]275MZ]A<1+^G.8GO]9?
M^/7EG.#P(7RIY*[_^>KG-_RW/RVG)]^.+[[W=8'EW_[TH\P74/7*Y-FB__WR
M'_]ZN?ZW!2X),FM^W]$W-I]15]N-%ORQPEG&,Q[/5SF>IVN_=%PE/%^<_\OC
M$/%X_=U)QNED_<DOXG*U"&DU(9B9)*0"B\6"LMJ "Z4 ?1^%STS%Z*ZS7LE>
M$MUKA2PQ_?G+_/NO],&D&,'_2]4OX>S+M5QN+7DFG]UH/]^#G^EW)\YE;:01
M@*0'VD!>@J,M0?1S+YG7G!6]-^E75[Q.^57=OEBD7^:+C LR).=+AD6ZK>=K
M(-[\QJ_?PH(^"-+7Z7$^_]?5H@RAL]5\ .F=J8;(_=,OQ'7!Q0+SNS/-W,O<
MFK,5F5=<_^806O]?IV%!GWC\\R-^FR]6D^0*-XJX-X4Q4.@3N%0,**&UEL&S
MR/-@ +BQ^%98$/UC81^9=@*+#[B8SO/K67Y%Q_*$H1,\L@PL!Q*(00_>R01)
MV""U+1E1# :*:TMO!0G9/R1VEV<G@/B\"+/EM I^ ^J<4#J4''3BY&IAMA (
MR^ M][98+[S&X4Z*&ZMO!0O5/RSVDNK(R'@]6TU7/]],C_']Z4G$Q<1I'PF\
M"APZ3\*(#KSD!0P/0B2KG G[^PXW5]T*";I?).PEQ2X0\!&_3*L09JOWX00G
MT9:8N0J00Z'#+B@-P=,?QJJ(C@>-F0^$@NLK;X4$TSL2]I!F%VAX2^'^@DS9
M6O"?2/[X<GXZ6RU^OIQGG!BG+3)$2-(74"4'DHTS4(J4VFL7C+<#@>-!0K;"
MBNT=*\/)N@OH? X_WF82W[1,S[(9&XLH90@L2 E9V03*J4Q1%0597KB4K8T:
MXU 6Y1X2MH*+ZQTN0\BW"Z"\R)E4L-S\Y]UTAGRB(N<^H *54B8FR)N.@804
MK2;_FAOZGS(02.Y8?BN ^-X!LJ]<.P6'F&!A$HUPX)03Y%6340PE2?!<*,N<
M],*89N 0VZ6XV/-#Q],$VQ,Z7M*71XO/\S]FDYQY\LX3K#T%6RHJ1A&758#"
M9/*N,&J^?QQ[S^+;(:/C[.<00NT)%VLGZFCQ83'_/ITEG COO24_"4J6 133
MGJR?M9!9=-&G+%A.PX+C!@7;(:3CG.A@XNT))A_FRU4X_O^FW]:.=JP.M8B"
M](IT1(HBP DCH7"49/_0)[/_=<_]ZV\'D8YSI .)=F2 5.OW8H%A33<F"L_)
MV(%=Y_D5RQ"$)"/(2U22<>-P_UN4JRMN!X*.,Z([BV]DM=>;]^,/7^>S\_P=
M+T&SY!@8KZM+1."-W!."><94DG*8]C\R;JZZG?H[3H/N)<:1(? )T^F"X,M%
M_#Q='>/$DE>L,D=@@AA0.24(J .0HYQ9,2&A4WM#X.:JVT&@X_SG7F(<&0*?
M%Z'6.'WZ>1+GQ^3]&J8DV2NG.)U:VE;+A04P*!^SECK)_1-6UY;<3OD=)S1W
M%V GF__UC_0US+[@.FM/40Z7A8ZNXJT&Y4.$F$H&&ZT0BFOM^?X N&OE[7#0
M<:9R;W%V$2:\/%U4<9W=Z598DPY.EQ/CN/6\>$C)D%!0*/""[%LNK*2H- LE
M#!0HW$W!=O#H/D\Y@'B[@,G;&7T:B6/Z'5^%5=BP-0G..Z-EA((,04DNP2NN
MH!@7<N8ZZ '*!Q^B8+LZK.X3E@.(MPN8U.* Q<NPPB_SQ<\).;])6HJ&"=6*
M0N*DP''D$'Q6!8-&YX:Z#;NV\':@Z#Y7N;LPN\#"IY-P?/S;Z7(ZP^5R$GE1
M 06#F%FB.)DB)1=Y *&"\0JYY';_0...A;?#0O=9R=V%V0467I_@X@L=?W]9
MS/]8?7TY/_D69C\GWAIM(],0;.2@BG*$9FOKE8QU)C#-!L/$G01LAXWNTY'[
M"[</C/RX+#$\JT&=)",5#PH!LZO)-1\A!"- %S)YBMOH]5 U.+=7WPX='><I
M!Q%K%]#X]!6/C\^!G;6UF#*OA%.(I12%6"$A\&*)J^0E=VRHD^3*NMO!H>.\
MY9ZB[ ((1/A)K1^;I__\])7DMCPZ7=4G9C4A,T'D(D6*O6,HCF)O1<9.J 2)
M.2M##)&SH8#Q$!W; :7C[.; HAX9."].<)9K ?N;X_!EXDU1++F:J2N19)(X
M.)8R&!Z3YIA4TON7UUQ;<CLX=)SOW%V G;P'>3-=IG#\'Q@6;^@[RXE,*:=(
M)U_FF;SGS"L+Q)'VSFGK6<2P/P;N67P[-'2<]1Q"J%WAXLPG.F,"54J.6P.)
M_*'ZI(7D44N#E!?1H"%'6@_W>.S6\MMAH^.4YS""[</1(#86X?CM+../_XD_
M)U9;S8TDVNM[%\6(%<=0@(R>6/"BEHD-Y5M<7WJ[9X7=9SCW$>C8Y3)GV=A+
MBW?^-C)P1Z&T1(CD =6"XUS?/U7#QW(,4I +O;^YN&_U[7#1<9)S$+$.!HU_
M_?66'-_1-W;N)7'T_M7K]Y]>OZ(O/AV]>_OJQ>?7KWY[\>[%^Y>O/_WU]>O/
MGZYSL&63B<<_=9CN$T^D?L^V%*=+^!+"M\FZYK(>($?ES7069FE*I\C\+'5Q
M ;?"9#264^B1C2<OU"EPA<#"E53"(5,R/W3E5,(RKJ&P672]\W[%X]7R_#OK
M#0B,;]J)_/>G4+>KF3E?X\5RB:OE!:^986!::6".HG*E>00G2B+B&)V<V><2
M'XIH=^?U.AWC-+YHAHIS(S2 T$<\F:Y3OS&F%TQP*9B-ZSLB%T!QF\#%2-:4
M>,O2FJ!2FUUR)SGC F@?_=X)E7V$W0%B7H;EUQ>S7/_S^K].I]_#,3&S?+%Z
M&1:+G]/9E[^'XU.<T+%;9! UNT/[2$6T$(T6D(5D$K40PCY4%[P[@K8BKP=$
M[06#>6N=C BTZKA,/I)*:/7*U2O\CL?S;]6&OYTE^G/ZG5RIA,1F/,8)FJ2+
MB1*X])RXLHSD1K@H'+G.:+)-YC'/Z&E+CM.]9WCT-!1T!W;JPP*_A6E^_>,;
MSI9([!VMOE+<<55Z$\=4,36=D%FJL:0($**L?Z3H#:-@\O(YR:!6:@OBQFD(
MU,Y&#:V/#B!VG7@B4I6:P^3.D'"0O@HV)R@L6#2*(TFHO=,T3L.@=K#97<:[
M V2^"L<#V:#Y-URL?GXX#B2.6:Z'\]J^OL?5Q&HZ=W-$,+4!I5(I0E0Y@+2U
M-D^&VCFMD?&YGZH>SK9!?.W!1-^!G?G+?)[_F!X?3Y#3_Q0=P:="1[#C 9R+
M-1O.DT>RE\ZU,3'G%/1P* T"CYU$V@$4C@C4H9:"O\.PQ(^U0_!1^1N=IU4T
MDUA,L$5G$(E%,K3,@6,F@171:^^16?O0D[S=\?$@63T<28. 9CCA]X"D2_?K
M_7R6-@=L1.YMO6H+<=W8U6KP2C,(Y'T9)I7*#UY*[(&@N\@9I^=="^3L+>P.
M$'-&_T0IQD6I+?MX)A].!P].&@=1DA/&4LXQ/=2 :%\_=YSN=\VR@4\29P<N
M[;MIB-/CZ6J*2_*JU@5>7^?')/1E];!6/R]$(P1'-$62-I4#):O3[UV&&&+F
M-FJC'^Q3M3M,MJ5P7%>W^;U$$T5U8(6N\'4SSO2AMM&(M'<RT@D<LR4FR+)R
MD[7*.AMT#ST[' 1R7=U=M,' _4#;1R$=0.M%2K6MY/)#^%DSGA=9J1R]30%!
M!E:?6SI-PA%T3"=;LU5!Q <;9^UQX-U)3S>0VDO;-P_#_47?!X 6I[3J+1E-
MF-4V)I]!2DF,>%[ 6320G3'>Z*B8\:TP=#=)XQY_[6 T@ (Z0-+U4/.<G_,'
MX9.B(Z8J%"UJD9,(!KQV$30R[I5C03_8KFVH0/\F7>.FAQIA:D!5= "L=_/9
ME\^X.'F%<77.@A2>8W*"9,(J"R92")H*!37<AU0L":A-T'\',>,FBQI!:%^A
M]X";VR95%&E\J2W;4TU?.!8I:$4'Q7+N,_W=NG@@=WO<1%$KU.PG\A&3!>O*
M@JN@?S^?;5AX.TO'I_456#VJL6IHPF6)Q2$)9=WZWSN$:&L/5<8LSXSDYVY4
MF]U3P;'MBMVX/L,'9>TDWX$-NN<DOI)1#2FK4A2'P&(!Q9.&J&O0H$(*B@>?
M<IL+LD=)Z\8U:I<(&%8]/>"M9NVOB.X*)T()G8PF3DK.H,CR4C@A'.AL([/!
MH7YP?.">]R1WTM2-Y]008<,HI -H76%B8D,6,I4"!E&"(JM+$DD",M-<!86%
MV39&ZPH1W3A0!\E3/DGD'5RZU-?TT]7)NJAWEE_.9]7*XBQ55BAZ$%S8.F*O
M/J#"*,$;4YO[%&[1.RU#FU<>#Q U[AW=0= TE$HZL$4/2$AB\3Q&#;ZVK%=H
M/83:KE2HZ!EYCB69-@6R>U[;#=X0X:#8&D@A'4#K2AN0LS<(1FAEK0M@4AV$
M8%2!X"D <8E;H1AY@:Y-XO(F)6._2AM&PW<8I9W%W0%<7N2\O@ /QQ_"-+^=
MO0S?IG2&7F%KPJ(G*QH#."X2*"LC>,^((U8\_44[@XV>ICU*V]@%!4T@-;!*
M>@!92J<GI\=AA6=/$&H[JP5^Q=ER^AWKI,$3?#=?+M_CZJA\#C_H-.<2:V3A
M6+TYDI[D6 M]=+%.)<:2:V2RGDCHN!F&5O!KJ*P.L/@15V$ZP_PZ+&;D/RZO
ML/L*RS1-Z_V2)(\Q>Y!,URZ^FCCRWD'"$GDDP0;>YN;X<=K&S3@T0MS *ND
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MM^'97_!C=_;&</QZN:I-26?Y14JG)Z?'=>K@*R1JTG2S*2_XJZFA.1G;38>
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M(F-W0-@(AQ!>!"YCK90TY+=Q2QX<+X!)*B.E85[L9@\\\((1;R0'8-JC&#B
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M#<_ZA=\FX<-G,O)D[9[(,QF 49+3(YP&@\J5>GG.&YU(CRYK7 @.QOS=0'4
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MV@EPNI6AM^$+;BX<!#?<<9] <V;)K+0"7-(.I!)6%Z_)LG4G%(0?*QL7S=U
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M2P$"% ,4    "  B@ZQ4%]:"A=0'   <)   $               @ $
M97@M,S$Q<3$R,#(R+FAT;5!+ 0(4 Q0    ( "*#K%3T!/3!T0<  !0D   0
M              "  0((  !E>"TS,3)Q,3(P,C(N:'1M4$L! A0#%     @
M(H.L5,S[=H,1!@  (1L  !               ( ! 1   &5X+3,R,7$Q,C R
M,BYH=&U02P$"% ,4    "  B@ZQ4!FGD( 1Z @!44Q4 $0
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E,#(R,#,S,5]P<F4N>&UL4$L%!@     *  H A@(  #@;!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
